FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Khan, ZU Kortom, M Marouf, R Chandy, R Rinaldi, MG Sutton, DA AF Khan, ZU Kortom, M Marouf, R Chandy, R Rinaldi, MG Sutton, DA TI Bilateral pulmonary aspergilloma caused by an atypical isolate of Aspergillus terreus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; IMMUNOCOMPROMISED HOSTS; EXPERIENCE; INFECTION; DIAGNOSIS AB A case of bilateral pulmonary aspergilloma caused by an atypical isolate of Aspergillus terreus is described. The diagnosis was established by the presence of septate, dichotomously branched fungal elements in freshly collected bronchoalveolar lavage and sputum specimens and by repeated isolation of the fungus in culture. Specific precipitating antibodies against the A. terreus isolate were demonstrated in the patient's serum. The isolate was atypical as it failed to produce fruiting structures on routine mycological media, but it did so on extended incubation on potato Rake agar and produced globose, relatively heavy-walled, hyaline accessory conidia (formerly termed aleurioconidia) on both vegetative and aerial mycelia. Also, it produced an intense yellow diffusing pigment in the medium. The report underscores the increasing importance of A. terreus in the etiology of pulmonary aspergillosis. It is suggested that A. terreus antigen be included in the battery of serodiagnostic reagents to facilitate the early diagnosis of infections caused by this species. C1 Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait. Minist Publ Hlth, Mubarak Al Kabeer Hosp, Dept Med, Kuwait, Kuwait. Minist Publ Hlth, Mubarak Al Kabeer Hosp, Dept Hematol, Kuwait, Kuwait. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. RP Khan, ZU (reprint author), Kuwait Univ, Fac Med, Dept Microbiol, POB 24923, Safat 13110, Kuwait. NR 31 TC 7 Z9 7 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2000 VL 38 IS 5 BP 2010 EP 2014 PG 5 WC Microbiology SC Microbiology GA 311TU UT WOS:000086902400060 PM 10790144 ER PT J AU Hendrick, V Altshuler, LL Gitlin, MJ Delrahim, S Hammen, C AF Hendrick, V Altshuler, LL Gitlin, MJ Delrahim, S Hammen, C TI Gender and bipolar illness SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID CYCLING AFFECTIVE-DISORDER; COMORBIDITY; FAMILY AB Background: For major depression and schizophrenia, gender differences have been reported in symptom expression and course of illness. Gender differences in bipolar disorder are becoming increasingly apparent, but have been less studied. Research data on these differences will help determine whether gender is important in influencing illness variables such as course, symptom expression, and likelihood of comorbidity. Method: Charts of 131 patients (63 women and 68 men) with a DSM-IV diagnosis of bipolar disorder admitted to the University of California Los Angeles Mood Disorders Program over a 3-year period were reviewed to gather data on demographic variables and course of illness and to assess differences in the illness across genders. Results: No significant gender differences were found in the rate of bipolar I or bipolar II diagnoses, although women were overrepresented in the latter category. Also, no significant gender differences emerged in age at onset, number of depressive or manic episodes, and number of hospitalizations for depression. Women, however, had been hospitalized significantly more often than men for mania. Further, whereas bipolar men were significantly more likely than bipolar women to have a comorbid substance use disorder, women with bipolar disorder had 4 times the rate of alcohol use disorders and 7 times the rate of other substance use disorders than reported in women from community-derived samples. Conclusion: For bipolar disorder, course of illness variables such as age at onset and number of affective episodes of each polarity do not seem to differ across genders. Women, however, may be more likely than men to be hospitalized for manic episodes. While both men and women with the illness have high rates of comorbidity with alcohol and other substance use disorders, women with bipolar disorder are at a particularly high risk for comorbidity with these conditions. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Hendrick, V (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. NR 15 TC 114 Z9 117 U1 2 U2 17 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2000 VL 61 IS 5 BP 393 EP 396 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 321FP UT WOS:000087445700018 PM 10847318 ER PT J AU McKay, JR Alterman, AI Cacciola, JS Mulvaney, FD O'Brien, CP AF McKay, JR Alterman, AI Cacciola, JS Mulvaney, FD O'Brien, CP TI Prognostic significance of antisocial personality disorder in cocaine-dependent patients entering continuing care SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article ID ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSERS; RELIABILITY; ALCOHOL; DRINKING; RELAPSE; REHABILITATION; PSYCHOTHERAPY; INTERVIEW; VALIDITY AB This study examined the relationship of antisocial personality disorder (APD) to response to continuing care treatments in a sample of cocaine-dependent patients. Patients (N = 127) were randomly assigned to 20-week standard group or individualized relapse prevention continuing care interventions after the completion of an initial treatment episode and followed up at 3, 6, and 12 months. APD and non-APE patients did not differ on retention in continuing care, substance use outcomes, social function outcomes, or experiences before or during cocaine relapse episodes. A diagnosis of APD was also not a predictor of differential response to the two continuing care interventions in the study. However, APD patients had worse medical and psychiatric problem severity than non-APE patients at entrance to continuing care and during follow-up. These results suggest that cocaine patients with APD who are in the continuing care phase of outpatient rehabilitation might benefit from additional medical and psychiatric treatment services. C1 Univ Penn, Treatment Res Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP McKay, JR (reprint author), Univ Penn, Treatment Res Ctr, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [DA00361, DA05186, DA08399] NR 39 TC 39 Z9 39 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAY PY 2000 VL 188 IS 5 BP 287 EP 296 DI 10.1097/00005053-200005000-00006 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 313YZ UT WOS:000087028500006 PM 10830566 ER PT J AU Agostini, HT Ryschkewitsch, CF Baumhefner, RW Tourtellotte, WW Singer, EJ Komoly, S Stoner, GL AF Agostini, HT Ryschkewitsch, CF Baumhefner, RW Tourtellotte, WW Singer, EJ Komoly, S Stoner, GL TI Influence of TC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy SO JOURNAL OF NEUROVIROLOGY LA English DT Article; Proceedings Paper CT Symposium on An Update on Multiple Sclerosis Research and Care CY MAY 03-05, 1999 CL MILAN, ITALY SP Dompe Biotec, Farmades s p a, Serono Pharma, Teva Pharm, Beckman Coulter, Int Lab, Celbio, Space Inport Export, Dasit, PBI Int DE polyomavirus; genotype; demyelination; nuclear factor-1 site ID POLYOMAVIRUS JC-VIRUS; BRAIN-TISSUE; CEREBROSPINAL-FLUID; REGULATORY REGIONS; TRANSGENIC MICE; SEQUENCES; DNA; INFECTION; PROTEIN; URINE AB Two features of the biology of JC virus make it a particularly suitable candidate for an agent in MS-like disease: its neurotropic capability targeting glial cells as evidenced in progressive multifocal leukoencephalopathy lesions, and its capacity for latency and persistence as illustrated by its behaviour in the kidney. TC virus is chronically or intermittently excreted in the urine by some 40% of the population. The existence of TC virus in multiple coding-region genotypes provides a unique approach to the study of JC virus-induced neurological disease. We have previously shown that a genotype originating in Asia but also present in Europe and the US, called Type 2B, is more frequently found in PML brain than expected based on its prevalence in urine samples from a control population. In contrast, we find that the excretion of JCV in MS patients is similar in both genotype and frequency to that of control individuals, and appears to be regulated by factors unrelated to those that control CNS disease activity. C1 NINDS, Neurotoxicol Sect, NIH, Bethesda, MD 20892 USA. W Los Angeles Vet Affairs Med Ctr, Serv Neurol, Los Angeles, CA 90073 USA. John Ferenc Del Pesti Teaching Hosp, Budapest, Hungary. RP Stoner, GL (reprint author), NINDS, Neurotoxicol Sect, NIH, Bldg 36,Room 4A-27,MSC-4126, Bethesda, MD 20892 USA. NR 41 TC 14 Z9 14 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD MAY PY 2000 VL 6 SU 2 BP S101 EP S108 PG 8 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 326RN UT WOS:000087748700023 PM 10871796 ER PT J AU Jacobson, AF Haseley, DR AF Jacobson, AF Haseley, DR TI Reliability of left ventricular ejection fraction (LVEF) determinations from gated myocardial spect imaging (GMSI) with Tl-201. SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2000 VL 41 IS 5 SU S MA 492 BP 125P EP 125P PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 364KW UT WOS:000089892400493 ER PT J AU Jacobson, AF Maisey, RN Fogelman, I Kuhn, D AF Jacobson, AF Maisey, RN Fogelman, I Kuhn, D TI Yield of FDG-PET scanning as a routine follow-up exam in patients with malignancy. SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Guys & St Thomas Hosp, London SE1 9RT, England. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD MAY PY 2000 VL 41 IS 5 SU S MA 1325 BP 304P EP 304P PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 364KW UT WOS:000089892401219 ER PT J AU Cooper, RA AF Cooper, RA TI Wheelchairs and related technology for the millennium - Guest editorial SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Engn Mech, Pittsburgh, PA 15213 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. NR 11 TC 5 Z9 5 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2000 VL 37 IS 3 BP XIII EP XVI PG 4 WC Rehabilitation SC Rehabilitation GA 370YB UT WOS:000165149900002 PM 10917256 ER PT J AU Cooper, RA Dvorznak, MJ Rentschler, AJ Boninger, ML AF Cooper, RA Dvorznak, MJ Rentschler, AJ Boninger, ML TI Displacement between the seating surface and hybrid test dummy during transitions with a variable configuration wheelchair: A technical note SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article ID SHEAR AB Changing seating posture can extend the amount of time a person can safely remain seated without damaging tissue or becoming fatigued. The Excelsior is an electrically powered wheelchair that utilizes sit-to-stand (STS) and sit-to-recline (STR) motions to aid in pressure relief. The motion of the wheelchair seating system must closely follow anatomical paths or ulcers may develop from the resulting shear forces. Displacement between the person and the wheelchair seating surface is one measure of these shear forces. The displacement between a Hybrid II 50th percentile anthropometric test dummy (ATD) and the seating surface of the Excelsior wheelchair was examined during STS and STR with two cushions, a Jay Active and a low-profile Roho cushion. The difference between the backrest and ATD back angles were 4.29 degrees +/- 2.13 degrees and 1.78 degrees +/- 1.73 degrees for the Roho and Jay cushions respectively during STS and 3.32 degrees +/- 4.21 degrees and 10.71 degrees + 6.20 degrees during STR. These were statistically significant at p<.05. During STS, shear displacement between the Hybrid II back and Excelsior backrest did not exceed 1.5 cm for either cushion. ATD thigh-to-seat displacements were 2.5 cm for the Jay and 3.0 cm for the Roho cushion. STR produced dummy thigh-to-seat displacements of 1.5 cm and 3.5 cm for the Jay and Roho cushions respectively. Shear displacement in the ATD back was about 3.5 cm for the Roho and 6 cm for the Jay. The latter displacement should be reduced; however, the other conditions are marginal or acceptable. Hysteresis was acceptable or better for all cushion/motion combinations, with the highest net displacement of about 2.5 cm. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 13 TC 3 Z9 3 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2000 VL 37 IS 3 BP 297 EP 303 PG 7 WC Rehabilitation SC Rehabilitation GA 370YB UT WOS:000165149900007 PM 10917261 ER PT J AU Shireman, PK Greisler, HP AF Shireman, PK Greisler, HP TI Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 23rd Annual Meeting of the Midwestern-Vascular-Surgical-Society CY SEP 23-25, 1999 CL CHICAGO, ILLINOIS SP Midwestern Vascular Surg Soc ID INTIMAL HYPERPLASIA; CELL-PROLIFERATION; FACTOR TYPE-1; GRAFTS; SUSPENSIONS; INHIBITION AB Purpose: Fibrin glue (FG) has been used for local cytokine delivery on both vascular grafts and angioplasty sites. We measured the diffusive release of vascular endothelial growth factor (VEGF) and heparin from FG and the mitogenic activity of VEGF with and without heparin in FG on canine endothelial cells (ECs) and smooth muscle cells (SMCs). Methods: Release of VEGF labeled with iodine 125 and tritiated heparin from FG into the overlying media was serially measured over 96 hours, and the data are reported as the mean percent released +/- SD. Proliferation assays measuring tritiated thymidine incorporation were performed for ECs and SMCs plated in media with 10% serum on FG containing various concentrations of VEGF and heparin. Media was placed on the FG for 24 hours and removed before plating cells to minimize the effect of the released, soluble VEGF and heparin. Results: At 24 hams, 54% +/- 1% and 58% +/- 1% of the radioactive VEGF and heparin were released, respectively, with minimal release thereafter (58% +/- 1% and 66% +/- 1% at 96 hours). The ECs, SMCs, or media only (no cells) was plated an FG containing radioactive VEGF in an immediate or 24-hour delayed fashion for 72 hours to determine the percent release of VEGF into the media with the two different methods of plating. Cell type and the presence or absence of cells did not affect VEGF release, but there was three times more VEGF in the media for the immediate versus delayed plating (P < .001). Without heparin, VEGF at 100 ng/mL, or more in the FG was needed to induce EC proliferation. Heparin at 5 U/mL, enhanced EC proliferation at the VEGF dose of 100 ng/mL, as compared with no heparin (P < .001), but not at the VEGF dose of 1000 ng/mL, which Likely represents a maximal response. With heparin at 500 U/mL, the ECs died. In contrast, VEGF, in the presence or absence of heparin, did not affect SMC proliferation. Conclusions: We conclude that FG with VEGF at 1000 ng/mL, and heparin at 5 U/mL is the optimal concentration for in vivo use because this may encourage EC, but not SMC, proliferation. The VEGF at 1000 ng/mL, should leave mitogenic concentrations of VEGF intact after the initial, diffusive loss, and the addition of heparin at 5 U/mL may enhance VEGF mitogenic activity. C1 Loyola Univ, Med Ctr, Dept Surg, Div Peripheral Vasc Surg, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Dept Cell Biol, Maywood, IL 60153 USA. Edward Hines Vet Adm Hosp, Dept Surg, Hines, IL 60141 USA. Univ Texas, Hlth Sci Ctr, Dept Surg, Vasc Surg Sect, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Dept Surg, San Antonio, TX 78284 USA. RP Greisler, HP (reprint author), Loyola Univ, Med Ctr, Dept Surg, Div Peripheral Vasc Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. FU NHLBI NIH HHS [R01 HL41272] NR 12 TC 20 Z9 22 U1 0 U2 2 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2000 VL 31 IS 5 BP 936 EP 943 DI 10.1067/mva.2000.106420 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 315JG UT WOS:000087109900012 PM 10805884 ER PT J AU Yang, L Embree, LJ Hickstein, DD AF Yang, L Embree, LJ Hickstein, DD TI TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID CARBOXY-TERMINAL DOMAIN; HUMAN MYELOID-LEUKEMIA; POLYMERASE-II; BINDING PROTEIN; IN-VIVO; CHROMOSOMAL TRANSLOCATION; LARGEST SUBUNIT; NUCLEAR MATRIX; TRANSCRIPTION; GENE AB The translocation liposarcoma (TLS) gene is fused to the ETS-related gene (ERG) in human myeloid leukemia, resulting in the generation of a TLS-ERG protein. We demonstrate that both TLS and the TLS-ERG leukemia fusion protein bind to RNA polymerase II through the TLS N-terminal domain, which is retained in the fusion protein; however, TLS recruits members of the serine-arginine (SR) family of splicing factors through its C-terminal domain, whereas the TLS-ERG fusion protein lacks the ability to recruit SR proteins due to replacement of the C-terminal domain by the fusion partner ERG. In transient-transfection assays, the TLS-ERG fusion protein inhibits E1A pre-mRNA splicing mediated by these TLS-associated SR proteins (TASR), and stable expression of the TLS-ERG fusion protein in K562 cells alters the splicing profile of CD44 mRNA. These results suggest that TLS fusion proteins may lead to cellular abnormalities by interfering with the splicing of important cellular regulators. C1 Univ Washington, Sch Med, Div Oncol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Mol Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Hickstein, DD (reprint author), Univ Washington, Sch Med, Dept Med Oncol, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. NR 52 TC 97 Z9 103 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAY PY 2000 VL 20 IS 10 BP 3345 EP 3354 DI 10.1128/MCB.20.10.3345-3354.2000 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 308ET UT WOS:000086698100002 PM 10779324 ER PT J AU Gangolli, EA Belyamani, M Muchinsky, S Narula, A Burton, KA McKnight, GS Uhler, MD Idzerda, RL AF Gangolli, EA Belyamani, M Muchinsky, S Narula, A Burton, KA McKnight, GS Uhler, MD Idzerda, RL TI Deficient gene expression in protein kinase inhibitor alpha null mutant mice SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID PHOSPHOENOLPYRUVATE CARBOXYKINASE; CATALYTIC SUBUNIT; REGULATORY SUBUNITS; SOMATOSTATIN GENE; BETA-ISOFORMS; PKI-ALPHA; LOCALIZATION; TRANSCRIPTION; CREB; PHOSPHORYLATION AB Protein kinase inhibitor (PKI) is a potent endogenous inhibitor of the cyclic AMP (cAMP)-dependent protein kinase (PKA). It functions by binding the free catalytic (C) subunit with a high affinity and is also known to export nuclear C subunit to the cytoplasm. The significance of these actions with respect to PKI's physiological role is not well understood. To address this, we have generated by homologous recombination mutant mice that are deficient in PKI alpha, one of the three isoforms of PKI. The mice completely lack PKI activity in skeletal muscle and, surprisingly, shelf decreased basal and isoproterenol-induced gene expression in muscle, Further examination revealed reduced levels of the phosphorylated (active) form of the transcription factor CREB (cAMP response element binding protein) in the knockouts. This phenomenon sterns, at least in part, from lower basal PKA activity levels in the mutants, arising from a compensatory increase in the level of the RI alpha subunit of PKA. The deficit in gene induction, however, is not easily explained by current models of PKI function and suggests that PKI may play an as yet undescribed role in PKA signaling. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA. RP Idzerda, RL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NICHD NIH HHS [HD 33057]; NIDDK NIH HHS [T32 DK07247, T32 DK007247]; NIGMS NIH HHS [R01 GM032875, GM 32875] NR 34 TC 18 Z9 18 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAY PY 2000 VL 20 IS 10 BP 3442 EP 3448 DI 10.1128/MCB.20.10.3442-3448.2000 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 308ET UT WOS:000086698100012 PM 10779334 ER PT J AU McGinty, D Szymusiak, R AF McGinty, D Szymusiak, R TI The sleep-wake switch: A neuronal alarm clock SO NATURE MEDICINE LA English DT Editorial Material ID WAKING DISCHARGE; RATS; HYPOTHALAMUS; WAKEFULNESS AB A 70-year-old hypothesis that a rostral hypothalamic area is essential for maintaining sleep is re-awakened by the demonstration that the sleep-active ventrolateral preoptic neurons interact with wake-promoting systems in the upper brainstem. C1 Vet Adm Greater Los Angeles Healthcare Syst, Neurophysiol & Sleep Physiol Res Sepulveda Ctr, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Psychol, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Sepulveda, CA 91343 USA. RP McGinty, D (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Neurophysiol & Sleep Physiol Res Sepulveda Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 16 TC 56 Z9 56 U1 1 U2 6 PU NATURE AMERICA INC PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAY PY 2000 VL 6 IS 5 BP 510 EP 511 DI 10.1038/74988 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 309YB UT WOS:000086796200028 PM 10802704 ER PT J AU Rao, VLR Rao, AM Dogan, A Bowen, KK Hatcher, J Rothstein, JD Dempsey, RJ AF Rao, VLR Rao, AM Dogan, A Bowen, KK Hatcher, J Rothstein, JD Dempsey, RJ TI Glial glutamate transporter GLT-1 down-regulation precedes delayed neuronal death in gerbil hippocampus following transient global cerebral ischemia SO NEUROCHEMISTRY INTERNATIONAL LA English DT Article DE delayed neuronal death; gerbil; global cerebral ischemia; glutamate transporters; hippocampus; immunoblotting ID FOREBRAIN ISCHEMIA; SELECTIVE VULNERABILITY; MESSENGER-RNA; BRAIN INJURY; CA1 NEURONS; DAMAGE; EXPRESSION; EXCITOTOXICITY; MODEL; GABA AB Glial (GLT-1 and GLAST) and neuronal (EAAC1) high-affinity transporters mediate the sodium dependent glutamate reuptake in mammalian brain, Their dysfunction leads to neuronal damage by allowing glutamate to remain in the synaptic cleft for a longer duration. The purpose of the present study is to understand their contribution to the ischemic delayed neuronal death seen in gerbil hippocampus following transient global cerebral ischemia. The protein levels of these three transporters were studied by immunoblotting as a function of reperfusion time (6 h to 7 days) following a 10 min occlusion of bilateral common carotid arteries in gerbils. In the vulnerable hippocampus, there was a significant decrease in the protein levels of GLT-1 (by 36-46%, P < 0.05; between 1 and 3 days of reperfusion) and EAAC1 (by 42-68%, P < 0.05; between 1 and 7 days of reperfusion). Histopathological evaluation showed no neuronal loss up to 2 days of reperfusion but an extensive neuronal loss (by similar to 84%, P < 0.01) at 7 days of reperfusion in the hippocampal CA1 region. The time frame of GLT-1 dysfunction (1-3 days of reperfusion) precedes the initiation of delayed neuronal death (2-3 days of reperfusion). This suggests GLT-1 dysfunction as a contributing factor for the hippocampal neuronal death following transient global cerebral ischemia. Furthermore, decreased EAAC1 levels may contribute to GABAergic dysfunction and excitatory/inhibitory imbalance following transient global ischemia. (C) 2000 Published by Elsevier Science Ltd, All rights reserved. C1 Univ Wisconsin, Dept Neurol Surg, Clin Sci Ctr F4 309, Madison, WI 53792 USA. Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI USA. William S Middleton Mem Vet Adm Hosp, Madison, WI USA. Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. RP Rao, VLR (reprint author), Univ Wisconsin, Dept Neurol Surg, Clin Sci Ctr F4 309, 600 Highland Ave, Madison, WI 53792 USA. RI rothstein, jeffrey/C-9470-2013 NR 41 TC 61 Z9 62 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0197-0186 J9 NEUROCHEM INT JI Neurochem. Int. PD MAY PY 2000 VL 36 IS 6 BP 531 EP 537 PG 7 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 296YK UT WOS:000086054200007 ER PT J AU Rocco, MV Frankenfield, DL Frederick, PR Pugh, J McClellan, WM Owen, WF AF Rocco, MV Frankenfield, DL Frederick, PR Pugh, J McClellan, WM Owen, WF CA Natl ESRD Core Indicators Workgrou TI Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: Results from the 1997 ESRD Core Indicators project SO PERITONEAL DIALYSIS INTERNATIONAL LA English DT Article DE demographics; race; ethnicity; outcome; Health Care Financing Administration; Medicare, Hispanics ID NON-HISPANIC WHITES; MEXICAN-AMERICANS; HEMODIALYSIS-PATIENTS; HYPERTENSION; PREVALENCE; DISEASE; COHORT; HEALTH; RISK AB Background: Hispanics are the fastest growing minority group in the United States, and approximately 10% of all end-stage renal disease (ESRD) patients are Hispanic. Few data are available, however, regarding dialysis adequacy and anemia management in Hispanic patients receiving peritoneal dialysis in the U.S. Methods: Data from the Health Care Financing Administration (HCFA) ESRD Core Indicators Project were used to assess racial and ethnic differences in selected intermediate outcomes for peritoneal dialysis patients. Results: Of the 1219 patients for whom data were available from the 1997 sample, 9% were Hispanic, 24% were non-Hispanic blacks, and 59% were non-Hispanic whites. Hispanics were more likely to have diabetes mellitus as a cause of ESRD compared to blacks or whites, and both Hispanics and blacks were younger than white patients (both p < 0.001). Although whites had higher weekly Kt/V and creatinine clearance values compared to blacks or Hispanics (p < 0.05), blacks had been dialyzing longer (p < 0.01) and were more likely to be anuric compared to the other two groups (p < 0.001). Blacks had significantly lower mean hematocrit values (p < 0.001) and a greater proportion of patients who had a hematocrit level less than 28% (p < 0.05) compared to Hispanics or whites, despite receiving significantly larger weekly mean epoetin alfa doses (p < 0.05) and having significantly higher mean serum ferritin concentrations (p < 0.01). Multivariate logistic regression analysis revealed significant differences by race/ethnicity for experiencing a weekly Kt/V urea < 2.0 and hypertension, but not for other intermediate outcomes examined (weekly creatinine clearance < 60 L/week/1.73 m(2), Hct < 30%, and serum albumin < 3.5/3.2 g/dL). Conclusion: Hispanics had adequacy values similar to blacks and anemia parameters similar to whites. Additional studies are needed to determine the etiologies of the differences in intermediate outcomes by racial and ethnic groupings in peritoneal dialysis patients. C1 Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Nephrol Sect, Winston Salem, NC 27157 USA. US Hlth Care Financing Adm, Off Clin Stand & Qual, Baltimore, MD 21207 USA. S Texas Vet Hlth Care Syst, Disseminat & Implementat Ctr, San Antonio, TX USA. Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA. Emory Univ, Sch Med, Program Hypertens & Renal Dis Hlth Serv Res, Atlanta, GA USA. Duke Univ, Inst Renal Outcomes Res & Hlth Policy, Durham, NC USA. RP Rocco, MV (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Nephrol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA. NR 33 TC 11 Z9 12 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 0896-8608 J9 PERITON DIALYSIS INT JI Perit. Dial. Int. PD MAY-JUN PY 2000 VL 20 IS 3 BP 328 EP 335 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 330KM UT WOS:000087961300010 PM 10898051 ER PT J AU Friedl, L Bernardini, J Piraino, B AF Friedl, L Bernardini, J Piraino, B TI Latrogenic peritonitis: the need for prophylaxis SO PERITONEAL DIALYSIS INTERNATIONAL LA English DT Article ID DIALYSIS PATIENTS; ANTIBIOTIC-PROPHYLAXIS; COLONOSCOPY; ENDOCARDITIS; POLYPECTOMY; PREVENTION C1 Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Friedl, L (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. NR 19 TC 13 Z9 14 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 0896-8608 J9 PERITON DIALYSIS INT JI Perit. Dial. Int. PD MAY-JUN PY 2000 VL 20 IS 3 BP 343 EP 345 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 330KM UT WOS:000087961300014 PM 10898055 ER PT J AU Davis, JM Caroff, SN Mann, SC AF Davis, JM Caroff, SN Mann, SC TI Treatment of neuroleptic malignant syndrome SO PSYCHIATRIC ANNALS LA English DT Article ID ELECTROCONVULSIVE-THERAPY; LETHAL CATATONIA; RISK-FACTORS; DANTROLENE; SUCCINYLCHOLINE; PROGRESSION C1 Univ Illinois, Illinois State Psychiat Inst, Chicago, IL USA. Univ Penn, Dept Psychiat, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Davis, JM (reprint author), UIC, Dept Psychiat, 1601 W Taylor St, Chicago, IL 60612 USA. NR 36 TC 19 Z9 20 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD MAY PY 2000 VL 30 IS 5 BP 325 EP 331 PG 7 WC Psychiatry SC Psychiatry GA 313TJ UT WOS:000087015100008 ER PT J AU Fricchione, G Mann, SC Caroff, SN AF Fricchione, G Mann, SC Caroff, SN TI Catatonia, lethal catatonia, and neuroleptic malignant syndrome SO PSYCHIATRIC ANNALS LA English DT Article ID ELECTROCONVULSIVE-THERAPY; PREFRONTAL CORTEX; SERUM IRON; LORAZEPAM; DOPAMINE; METABOLISM; DIAZEPAM; SCHIZOPHRENIA; BROMOCRIPTINE; APOMORPHINE C1 Carter Ctr, Atlanta, GA 30307 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Fricchione, G (reprint author), Carter Ctr, 1 Copenhill,453 Freedom Pkwy, Atlanta, GA 30307 USA. NR 61 TC 24 Z9 25 U1 2 U2 3 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD MAY PY 2000 VL 30 IS 5 BP 347 EP 355 PG 9 WC Psychiatry SC Psychiatry GA 313TJ UT WOS:000087015100010 ER PT J AU Mann, SC Caroff, SN Fricchione, G Campbell, EC AF Mann, SC Caroff, SN Fricchione, G Campbell, EC TI Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome SO PSYCHIATRIC ANNALS LA English DT Article ID GANGLIA-THALAMOCORTICAL CIRCUITS; CONDITIONED AVOIDANCE-RESPONSE; FRONTAL-SUBCORTICAL CIRCUITS; PREFRONTAL CORTEX; BASAL GANGLIA; PARKINSONS-DISEASE; NUCLEUS ACCUMBENS; CAUDATE-NUCLEUS; SCHIZOPHRENIA; CATATONIA C1 Vet Adm Med Ctr 116A, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Carter Ctr, Atlanta, GA USA. RP Mann, SC (reprint author), Vet Adm Med Ctr 116A, Univ Ave, Philadelphia, PA 19104 USA. NR 47 TC 26 Z9 29 U1 1 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD MAY PY 2000 VL 30 IS 5 BP 363 EP 374 PG 12 WC Psychiatry SC Psychiatry GA 313TJ UT WOS:000087015100012 ER PT J AU Cohen, LM Steinberg, MD Hails, KC Dobscha, SK Fischel, SV AF Cohen, LM Steinberg, MD Hails, KC Dobscha, SK Fischel, SV TI Psychiatric evaluation of death-hastening requests - Lessons from dialysis discontinuation SO PSYCHOSOMATICS LA English DT Review ID PHYSICIAN-ASSISTED SUICIDE; OF-LIFE CARE; TERMINALLY ILL; ADVANCE DIRECTIVES; MEDICAL-TREATMENT; PATIENT REQUESTS; CRITICALLY ILL; DYING PATIENTS; UNITED-STATES; EUTHANASIA AB The authors aim to facilitate the psychiatric evaluation of death-hastening decisions, such as cessation of life-support treatment or physician-assisted suicide, by deriving principles for evaluating patients from a literature review and a recently completed prospective study on dialysis discontinuation conducted by consultation psychiatrists. Factors are delineated and suggestions are provided for the evaluation of requests to accelerate dying. Included are the authors' method for determining major depression in the context of terminal illness and their "vector analysis " in assessing patient requests to stop dialysis. As our society heatedly examines the care provided to the terminally ill, psychiatry also needs to reconsider whether actions that foreshorten life can be normative and permissible. Familiarity with competency, psychiatric diagnosis, and ease in communication and negotiation between patient, family, and staff are resources that psychiatrists can bring to these complicated assessments. Challenging areas include diagnosing depression, establishing the adequacy of palliative care, and appreciating issues related to personality features, family dynamics, and ethnic differences. C1 Baystate Med Ctr, Dept Psychiat, Springfield, MA 01199 USA. Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA. Albert Einstein Med Ctr, Philadelphia, PA 19141 USA. Portland VA Med Ctr, Portland, OR USA. RP Cohen, LM (reprint author), Baystate Med Ctr, Dept Psychiat, Springfield, MA 01199 USA. NR 111 TC 18 Z9 18 U1 1 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2000 VL 41 IS 3 BP 195 EP 203 DI 10.1176/appi.psy.41.3.195 PG 9 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 318GR UT WOS:000087276000002 PM 10849450 ER PT J AU Tanielian, TL Pincus, HA Dietrich, AJ Williams, JW Oxman, TE Nutting, P Marcus, SC AF Tanielian, TL Pincus, HA Dietrich, AJ Williams, JW Oxman, TE Nutting, P Marcus, SC TI Referrals to psychiatrists - Assessing the communication interface between psychiatry and primary care SO PSYCHOSOMATICS LA English DT Article ID MANAGED CARE; DEPRESSION; PHYSICIANS AB The Study of Outpatient Referral Patterns was conducted in 1998 to examine the nature of the communication relationship between psychiatrists and primary care physicians regarding outpatient referrals. Nationally representative psychiatrists were surveyed (N = 542) regarding their aggregate experience with outpatient referrals from non-psychiatric physicians in the previous 60 clays. Data regarding frequency and type of information and mode of communication were gathered. Results indicate that primary care physicians represent a significant source of referrals to psychiatrists and that psychiatrists are generally satisfied with the communication interface with the referring physicians. Psychiatrists' level of satisfaction was related to the quantity and quality of information provided by referring physicians. C1 RAND Corp, Arlington, VA 22202 USA. Amer Psychiat Assoc, Washington, DC 20005 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA. S Texas Vet Healthcare Syst, Div Gen Internal Med, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Ctr Res Strategies, Denver, CO USA. RP Tanielian, TL (reprint author), RAND Corp, 1200 S Hayes St, Arlington, VA 22202 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 12 TC 26 Z9 27 U1 0 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2000 VL 41 IS 3 BP 245 EP 252 DI 10.1176/appi.psy.41.3.245 PG 8 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 318GR UT WOS:000087276000009 PM 10849457 ER PT J AU Basile, JN AF Basile, JN TI Combination agents as a means of improving adherence and other aspects of the Sixth Joint National Committee report SO SOUTHERN MEDICAL JOURNAL LA English DT Article; Proceedings Paper CT 3rd Annual Conference on Hypertension - Improving Outcomes in Primary Care CY JUN 11-13, 1999 CL KIAWAH ISL, SOUTH CAROLINA SP SO Med Assoc C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Basile, JN (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. NR 9 TC 1 Z9 2 U1 0 U2 0 PU SOUTHERN MEDICAL ASSN PI BIRMINGHAM PA 35 LAKESHORE DR PO BOX 190088, BIRMINGHAM, AL 35219 USA SN 0038-4348 J9 SOUTHERN MED J JI South.Med.J. PD MAY PY 2000 VL 93 IS 5 BP 534 EP 536 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 316YA UT WOS:000087194700023 PM 10832960 ER PT J AU Page, CW Barnes, SA Fisher, WE AF Page, CW Barnes, SA Fisher, WE TI Ulcer necessitans: A forgotten entity SO SURGERY LA English DT Article C1 Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. RP Fisher, WE (reprint author), Houston VAMC, Surg Serv 112, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2000 VL 127 IS 5 BP 593 EP 594 DI 10.1067/msy.2000.104405 PG 2 WC Surgery SC Surgery GA 312HQ UT WOS:000086938000021 PM 10819071 ER PT J AU Arterburn, DE Richardson, WS AF Arterburn, DE Richardson, WS TI Evidence-based case review - Should we look further for cancer in a patient with venous thromboembolism? SO WESTERN JOURNAL OF MEDICINE LA English DT Review ID DEEP-VEIN THROMBOSIS; OCCULT CANCER; PULMONARY-EMBOLISM; CLINICAL COURSE; MALIGNANCY; SEARCH; SIGN; RISK AB A 71-year-old woman with venous thromboembolism was referred to us to determine whether a workup for cancer was indicated. She had been hospitalized because of deep venous thrombosis of her left leg and pulmonary embolism; she had no history of venous thromboembolism or cancer. For the past few months, she had the feeling of being "full" before she had eaten much but had no other constitutional or gastrointestinal symptoms. On physical examination, she was found to be obese (body mass index*=33), and there was fibrocystic nodularity in both breasts. She also had a trace of symmetric edema in her ankles. Laboratory test values showed mild normocytic anemia, but routine chemistry test results were normal, as were those of her liver function tests, urinalysis, activated protein C resistance, proteins C and S and antithrombin III concentrations, antiphospholipid antibody, and a chest film. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Off Educ Programs, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Arterburn, DE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Off Educ Programs, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 28 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING INC PI SAN FRANCISCO PA 221 MAIN ST, PO BOX 7690, SAN FRANCISCO, CA 94120-7690 USA SN 0093-0415 J9 WESTERN J MED JI West. J. Med. PD MAY PY 2000 VL 172 IS 5 BP 325 EP 328 DI 10.1136/ewjm.172.5.325 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 313VR UT WOS:000087020300021 PM 10832425 ER PT J AU Cook, JW Yin, Q De La Melena, VT Malinow, MR Orloff, SL AF Cook, JW Yin, Q De La Melena, VT Malinow, MR Orloff, SL TI Diet-induced hyperhomocyst(e)inemia accelerates transplant vascular sclerosis in a rat cardiac transplant chronic rejection model. SO TRANSPLANTATION LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Oregon Reg Primate Res Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR 27 PY 2000 VL 69 IS 8 SU S MA 924 BP S351 EP S351 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 311XQ UT WOS:000086911800922 ER PT J AU De La Melena, VT Yin, Q Cook, JW Kreklywich, CN Streblow, DN Nelson, JA Orloff, SL AF De La Melena, VT Yin, Q Cook, JW Kreklywich, CN Streblow, DN Nelson, JA Orloff, SL TI The kinetics and development of CMV-accelerated transplant vascular sclerosis in rat cardiac allografts is linked to early presence of virus in the graft. SO TRANSPLANTATION LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR 27 PY 2000 VL 69 IS 8 SU S MA 909 BP S347 EP S347 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 311XQ UT WOS:000086911800907 ER PT J AU Odorico, JS Jacobson, LM Lumelsky, N Hullett, DA Thomson, JA Kahan, BW AF Odorico, JS Jacobson, LM Lumelsky, N Hullett, DA Thomson, JA Kahan, BW TI Pancreatic gene expression in differentiating embryonic stem cells. SO TRANSPLANTATION LA English DT Meeting Abstract C1 Univ Wisconsin, Sch Med, Dept Surg, Madison, WI USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR 27 PY 2000 VL 69 IS 8 SU S MA 707 BP S296 EP S296 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 311XQ UT WOS:000086911800705 ER PT J AU Ivanov, IP Rohrwasser, A Terreros, DA Gesteland, RF Atkins, JF AF Ivanov, IP Rohrwasser, A Terreros, DA Gesteland, RF Atkins, JF TI Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: Antizyme 3 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID CELL-SPECIFIC EXPRESSION; POLYAMINE HOMEOSTASIS; GENE; RAT; TISSUES; TRANSPORT; CLONING; GROWTH; LINE; CDNA AB Previous studies with mice overproducing ornithine decarboxylase have demonstrated the importance of polyamine homeostasis for normal mammalian spermatogenesis. The present study introduces a likely key player in the maintenance of proper polyamine homeostasis during spermatogenesis. Antizyme 3 is a paralog of mammalian ornithine decarboxylase antizymes. Like its previously described counterparts, antizymes 1 and 2, it inhibits ornithine decarboxylase, which catalyzes the synthesis of putrescine. Earlier work has shown that the coding sequences for antizymes 1 and 2 are in two different, partially overlapping reading frames. Ribosomes translate the first reading frame, and just before the stop codon for that frame, they shift to the second reading frame to synthesize a trans-frame product. The efficiency of this frameshifting depends on polyamine concentration, creating an autoregulatory circuit. Antizyme 3 cDNA has the same arrangement of reading frames and a potential shift site with definite, although limited, homology to its evolutionarily distant antizyme 1 and 3 counterparts. In contrast to antizymes 1 and 2, which are widely expressed throughout the body, antizyme 3 transcription is restricted to testis germ cells. Expression starts early in spermiogenesis and finishes in the late spermatid phase. The potential significance of antizyme 3 expression during spermatogenesis is discussed in this paper. C1 Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA. US Dept Vet Affairs, Salt Lake City, UT 84148 USA. RP Atkins, JF (reprint author), Univ Utah, Dept Human Genet, 15 North 2030 East, Salt Lake City, UT 84112 USA. FU NIGMS NIH HHS [R01 GM048152, R01-GM48152] NR 45 TC 98 Z9 105 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 25 PY 2000 VL 97 IS 9 BP 4808 EP 4813 DI 10.1073/pnas.070055897 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 308GW UT WOS:000086703000075 PM 10781085 ER PT J AU Li, X Martin, F Kearney, JF Carte, RH AF Li, X Martin, F Kearney, JF Carte, RH TI Differences in BCR signaling in mature splenic B cells SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Alabama, Birmingham, AL USA. Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR 20 PY 2000 VL 14 IS 6 SU S BP A970 EP A970 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 307FQ UT WOS:000086643100345 ER PT J AU Melby, PC Chandrasekar, B Zhao, W AF Melby, PC Chandrasekar, B Zhao, W TI Susceptibility of hamsters to an intracellular pathogen is associated with a defect in IFN-gamma-mediated macrophage activation SO FASEB JOURNAL LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR 20 PY 2000 VL 14 IS 6 SU S BP A1031 EP A1031 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 307FQ UT WOS:000086643100702 ER PT J AU Quinones, M Melby, PC Ahuja, SK Ahuja, SS AF Quinones, M Melby, PC Ahuja, SK Ahuja, SS TI Microbe-induced mobilization of preformed, membrane-associated IL-12 from dendritic cells is a determinant for the rapid induction of TH1 responses SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR 20 PY 2000 VL 14 IS 6 SU S BP A1180 EP A1180 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 307FQ UT WOS:000086643101581 ER PT J AU Weisbart, RH Baldwin, R Huh, B Zack, DJ Nishimura, R AF Weisbart, RH Baldwin, R Huh, B Zack, DJ Nishimura, R TI Novel protein transfection of primary rat cortical neurons utilizing an antibody that penetrates living cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Rheumatol, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR 20 PY 2000 VL 14 IS 6 SU S BP A1135 EP A1135 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 307FQ UT WOS:000086643101314 ER PT J AU Jain, M McCall, A Riddle, M AF Jain, M McCall, A Riddle, M TI Standardization of hemoglobin A(1c) values SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Providence Portland Med Ctr, Portland, OR 97213 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Jain, M (reprint author), Providence Portland Med Ctr, Portland, OR 97213 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 18 PY 2000 VL 132 IS 8 BP 676 EP 676 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 304RG UT WOS:000086497500014 PM 10766691 ER PT J AU Eliaz, Y Johnson, J Westwood, Z Schuff, N Deicken, RF AF Eliaz, Y Johnson, J Westwood, Z Schuff, N Deicken, RF TI Abnormal cortico-thalamic-cerebellar circuitry in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 San Francisco Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, Magnet Resonance Unit, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 70 BP 21S EP 21S DI 10.1016/S0006-3223(00)00332-2 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200068 ER PT J AU Grunhaus, L Lisanby, SH George, MS Maeda, F AF Grunhaus, L Lisanby, SH George, MS Maeda, F TI Magnetic stimulation of the brain: Correlates of antidepressant response SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Chaim Sheba Med Ctr, Div Psychiat, IL-52621 Tel Hashomer, Israel. Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Biol Psychiat, New York, NY 10032 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Hosp, Charleston, SC USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 185 BP 56S EP 56S DI 10.1016/S0006-3223(00)00448-0 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200183 ER PT J AU Yao, JK Reddy, RD Pettegrew, JW van Kammen, DP Horrobin, DF Mahadik, SP AF Yao, JK Reddy, RD Pettegrew, JW van Kammen, DP Horrobin, DF Mahadik, SP TI Membrane deficits in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Med Coll Georgia, Augusta, GA 30912 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 190 BP 58S EP 58S DI 10.1016/S0006-3223(00)00453-4 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200188 ER PT J AU Lorberbaum, JP Emmanuel, NP Mintzer, O Kapp, R Crawford, M Morton, A Johnson, MR Book, SW Hamner, MB Nahas, Z Arana, GW Ballenger, JC Lydiard, RB George, MS AF Lorberbaum, JP Emmanuel, NP Mintzer, O Kapp, R Crawford, M Morton, A Johnson, MR Book, SW Hamner, MB Nahas, Z Arana, GW Ballenger, JC Lydiard, RB George, MS TI Chances in anxiety after prefrontal rTMS in patients with GAD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 269 BP 81S EP 82S DI 10.1016/S0006-3223(00)00533-3 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200266 ER PT J AU Lorberbaum, JP Newman, JD Horwitz, AR Dubno, JR Hamner, MB Bohning, DE Shastri, A Ballenger, JC Lydiard, RB George, MS AF Lorberbaum, JP Newman, JD Horwitz, AR Dubno, JR Hamner, MB Bohning, DE Shastri, A Ballenger, JC Lydiard, RB George, MS TI Activating brain regions involved in social attachment SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 324 BP 97S EP 98S DI 10.1016/S0006-3223(00)00588-6 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200320 ER PT J AU Pegues, M Eliaz, Y Chosiad, L Schuff, N Amend, D Deicken, RF AF Pegues, M Eliaz, Y Chosiad, L Schuff, N Amend, D Deicken, RF TI Tissue volume corrected hippocampal NAA is reduced in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 San Francisco Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Magnet Resonance Unit, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 354 BP 107S EP 107S DI 10.1016/S0006-3223(00)00618-1 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200350 ER PT J AU Arciniegas, DB Topkoff, JL Rojas, DC Sheeder, JL Teale, PD Reite, ML Adler, LE AF Arciniegas, DB Topkoff, JL Rojas, DC Sheeder, JL Teale, PD Reite, ML Adler, LE TI Reduced hippocampal volume in association with P50 nonsuppression following traumatic brain injury SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. RI Arciniegas, David/A-3792-2009; Rojas, Don/F-4296-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 359 BP 108S EP 109S DI 10.1016/S0006-3223(00)00623-5 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200355 ER PT J AU Deicken, RF Eliaz, Y Chosiad, L Johnson, C Schuff, N AF Deicken, RF Eliaz, Y Chosiad, L Johnson, C Schuff, N TI Altered prefrontal-thalamic neuronal integrity in bipolar I disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 San Francisco Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, Magnet Resonance Unit, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 407 BP 124S EP 125S DI 10.1016/S0006-3223(00)00677-6 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200403 ER PT J AU Nahas, Z Oliver, NC Johnson, MR Molloy, M Hughes, PL Ballenger, JC Risch, SC George, MS AF Nahas, Z Oliver, NC Johnson, MR Molloy, M Hughes, PL Ballenger, JC Risch, SC George, MS TI Feasibility and efficacy of left prefrontal rTMS as a maintenance antidepressant SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Hosp, Charleston, SC USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 515 BP 156S EP 157S DI 10.1016/S0006-3223(00)00785-X PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200511 ER PT J AU Hamner, MB Ulmer, HG Faldowski, RA Frueh, BC Twomey, TJ Tyson, C Lorberbaum, JP Teneback, CC Huber, MG Arana, GW AF Hamner, MB Ulmer, HG Faldowski, RA Frueh, BC Twomey, TJ Tyson, C Lorberbaum, JP Teneback, CC Huber, MG Arana, GW TI A randomized, controlled trial of risperidone for psychotic features in PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2000 VL 47 IS 8 SU S MA 521 BP 158S EP 159S DI 10.1016/S0006-3223(00)00791-5 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304ZW UT WOS:000086515200517 ER PT J AU Marten, NW Stohlman, SA Atkinson, RD Hinton, DR Fleming, JO Bergmann, CC AF Marten, NW Stohlman, SA Atkinson, RD Hinton, DR Fleming, JO Bergmann, CC TI Contributions of CD8(+) T cells and viral spread to demyelinating disease SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MOUSE HEPATITIS-VIRUS; CENTRAL-NERVOUS-SYSTEM; MURINE CORONAVIRUS JHM; MONOCLONAL-ANTIBODIES; NUCLEOCAPSID PROTEIN; MULTIPLE-SCLEROSIS; STRAIN MHV-4; IN-VIVO; MICE; INFECTION AB Acute and chronic demyelination are hallmarks of CNS infection by the neurotropic JHM strain of mouse hepatitis virus. Although infectious virus is cleared by CD8(+) T cells, both viral RNA and activated CD8(+) T cells remain in the CNS during persistence potentially contributing to pathology, To dissociate immune from virus-mediated determinants initiating and maintaining demyelinating disease, mice were infected with two attenuated viral variants differing in a hypervariable region of the spike protein. Despite similar viral replication and tropism, one infection was marked by extensive demyelination and paralysis, whereas the other resulted in no clinical symptoms and minimal neuropathology, Mononuclear cells from either infected brain exhibited virus specific ex vivo cytolytic activity, which was rapidly lost during viral clearance. As revealed by class I tetramer technology the paralytic variant was superior in inducing specific CD8(+) T cells during the acute disease. However, after infectious virus was cleared, twice as many virus-specific IFN-gamma-secreting CD8(+) T cells were recovered from the brains of asymptomatic mice compared with mice undergoing demyelination, suggesting that IFN-gamma ameliorates rather than perpetuates JHM strain of mouse hepatitis virus-induced demyelination. The present data thus indicate that in immunocompetent mice, effector CD8(+) T cells control infection without mediating either clinical disease or demyelination. In contrast, demyelination correlated with early and sustained infection of the spinal cord. Rapid viral spread, attributed to determinants within the spike protein and possibly perpetuated by suboptimal CD8(+) T cell effector function, thus ultimately leads to the process of immune-mediated demyelination. C1 Univ So Calif, Dept Neurol, Keck Sch Med, Los Angeles, CA 90033 USA. Univ So Calif, Dept Mol Microbiol & Immunol, Keck Sch Med, Los Angeles, CA 90033 USA. Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA. Univ Wisconsin, Madison, WI 53792 USA. William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. RP Bergmann, CC (reprint author), 1333 San Pablo St,MCH 142, Los Angeles, CA 90033 USA. FU NIAID NIH HHS [AI33314]; NINDS NIH HHS [NS07149, NS18146] NR 63 TC 37 Z9 40 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 15 PY 2000 VL 164 IS 8 BP 4080 EP 4088 PG 9 WC Immunology SC Immunology GA 303GZ UT WOS:000086415300020 PM 10754301 ER PT J AU van Royen, M Carbo, N Busquets, S Alvarez, B Quinn, LS Lopez-Soriano, FJ Argiles, JM AF van Royen, M Carbo, N Busquets, S Alvarez, B Quinn, LS Lopez-Soriano, FJ Argiles, JM TI DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE DNA fragmentation; skeletal muscle; cancer cachexia ID NECROSIS-FACTOR-ALPHA; UBIQUITIN GENE-EXPRESSION; TISSUE PROTEIN-TURNOVER; NF-KAPPA-B; CELL-DEATH; INDUCED APOPTOSIS; TNF RECEPTOR-1; BEARING RATS; MALNUTRITION; THERAPY AB In two different experimental models of cancer cachexia, the rat Yoshida AH-130 ascites hepatoma and the mouse Lewis lung carcinoma, the implantation of the tumor caused a loss of body weight which was associated with a reduction in the weight of different skeletal muscles, as well as with their protein content. The decrease in protein content was accompanied by a reduction in DNA content. Interestingly, the protein/DNA ratio was unchanged in the skeletal muscle of the tumor-bearing animals as compared with the nontumor-bearing controls. Analysis of DNA fragmentation in skeletal muscle clearly showed enhanced laddering in the skeletal muscle of tumor-bearing animals, suggesting an apoptotic phenomenon. Interestingly, the degree of laddering (total DNA fragmented) increased with tumor burden. These results suggest that DNA fragmentation may be a primary event in cancer-associated cachexia. (C) 2000 Academic Press. C1 Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain. VA Puget Sound Hlth Care Syst, Amer Lake Div, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. RP van Royen, M (reprint author), Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain. NR 37 TC 77 Z9 80 U1 0 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 13 PY 2000 VL 270 IS 2 BP 533 EP 537 DI 10.1006/bbrc.2000.2462 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 305DY UT WOS:000086525200034 PM 10753659 ER PT J AU Marshall, MN Shekelle, PG Leatherman, S Brook, RH AF Marshall, MN Shekelle, PG Leatherman, S Brook, RH TI The public release of performance data - What do we expect to gain? A review of the evidence SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CARDIAC-SURGERY; QUALITY IMPROVEMENT; OUTCOMES DATA; HEALTH-CARE; MORTALITY; INFORMATION; INDICATORS; CONSUMERS AB Context information about the performance of hospitals, health professionals, and health care organizations has been made public in the United States for more than a decade. The expected gains of public disclosure have not been made clear, and both the benefits and potential risks have received minimal empirical investigation. Objective To summarize the empirical evidence concerning public disclosure of performance data, relate the results to the potential gains, and identify areas requiring further research. Data Sources A literature search was conducted on MEDLINE and EMBASE databases for articles published between January 1986 and October 1999 in peer-reviewed journals. Review of citations, public documents, and expert advice was conducted to identify studies not found in the electronic databases. Study Selection Descriptive, observational, or experimental evaluations of CIS reporting systems were selected for inclusion. Data Extraction Included studies were organized based on use of public data by consumers, purchasers, physicians, and hospitals; impact on quality of care outcomes; and costs. Data Synthesis Seven US reporting systems have been the subject of published empirical evaluations. Descriptive and observational methods predominate, Consumers and purchasers rarely search out the information and do not understand or trust it; it has a small, although increasing, impact on their decision making. Physicians are skeptical about such data and only a small proportion makes use of it, Hospitals appear to be most responsive to the data. In a limited number of studies, the publication of performance data has been associated with an improvement in health outcomes. Conclusions There are several potential gains from the public disclosure of performance data, but use of the information by provider organizations for quality improvement may be the most productive area for further research. C1 Univ Exeter, Sch Postgrad Med & Hlth Sci, Exeter, Devon, England. RAND Hlth Program, Santa Monica, CA USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Ctr Hlth Care Policy & Evaluat, United Hlth Grp, Minnetonka, MN USA. Univ Cambridge, Judge Inst Management, Cambridge, England. Univ Calif Los Angeles, Ctr Hlth Serv, Los Angeles, CA USA. RP Marshall, MN (reprint author), Univ Manchester, Natl Primary Care Res & Dev Ctr, 5th Floor,Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England. NR 50 TC 495 Z9 497 U1 2 U2 28 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 12 PY 2000 VL 283 IS 14 BP 1866 EP 1874 DI 10.1001/jama.283.14.1866 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 300HY UT WOS:000086248600033 PM 10770149 ER PT J AU Heydari, AR You, SH Takahashi, R Gutsmann-Conrad, A Sarge, KD Richardson, A AF Heydari, AR You, SH Takahashi, R Gutsmann-Conrad, A Sarge, KD Richardson, A TI Age-related alterations in the activation of heat shock transcription factor 1 in rat hepatocytes SO EXPERIMENTAL CELL RESEARCH LA English DT Article ID PROTEIN-70 MESSENGER-RNA; DECREASED EXPRESSION; DIPLOID FIBROBLASTS; GENE-TRANSCRIPTION; STRESS; CELLS; HSP70; LIVER; OLIGOMERIZATION; PHOSPHORYLATION AB The induction of hsp70 transcription by heat shock is significantly reduced in hepatocytes isolated from old rats compared to hepatocytes isolated from young! adult rats, and the decline in hsp70 transcription is correlated with a decrease in the induction of heat shock transcription factor 1 (HSF1) binding to the heat shock element. However, the decreased HSF1 binding activity to DNA is not due to reduced levels of HSF1 that are available for activation by heat shock. In fact, the levels of HSF1 are two- to threefold higher in hepatocytes from old rats, and the age-related increase in the levels of HSF1 protein in hepatocytes appears to arise from a decrease in the degradation of the HSF1 because HSF1 mRNA levels do not change and the synthesis of HSF1 decreases approximately 50% with age. No evidence was found for an impairment in HSF1 oligomerization in hepatocytes from old rats, e.g., the level of HSF1 trimers, the nuclear translocation of HSF1, and the phosphorylation of HSF1 after heat shock are similar in hepatocytes isolated from young/adult and old rats. However, the thermostability of the DNA binding activity of HSF1 was significantly reduced with age in a cell-free system as well as in isolated hepatocytes. (C) 2000 Academic Press. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, GRECC 182, San Antonio, TX 78284 USA. Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48202 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA. RP Richardson, A (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, GRECC 182, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG01548, AG01188] NR 52 TC 79 Z9 84 U1 0 U2 7 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD APR 10 PY 2000 VL 256 IS 1 BP 83 EP 93 DI 10.1006/excr.2000.4808 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 304HB UT WOS:000086476700011 PM 10739655 ER PT J AU Bartzokis, G Beckson, M Lu, PH Edwards, N Rapoport, R Wiseman, E Bridge, P AF Bartzokis, G Beckson, M Lu, PH Edwards, N Rapoport, R Wiseman, E Bridge, P TI Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE aging; psychostimulant addiction; gray matter; white matter; frontal lobe; temporal lobe ID MAGNETIC-RESONANCE; GRAY-MATTER; IN-VIVO; MRI; ABUSERS; LOBE; HIPPOCAMPUS; DEPENDENCE; METABOLISM; ACTIVATION AB The study evaluated the relationship between age and frontal and temporal lobe volumes in young cohorts of cocaine-dependent (CD), amphetamine-dependent (Am), and normal control subjects. Ten CD, nine Am, and 16 age- and gender-matched control subjects underwent magnetic resonance imaging (MRI). The volume of the frontal and temporal lobes was measured from an identically positioned slab of seven contiguous 3-mm-thick coronal images. Follow-up measures of the gray and white matter subcomponents of these volumes were also obtained. Both CD and Am groups had a significantly smaller temporal lobe volumes, but only the CD group demonstrated a significantly greater decline in temporal lobe volume with age (intracranial volume, education, and race were controlled for in all statistical analyses). Segmenting the brain regions into gray and white matter revealed that the negative correlation between age and temporal lobe volume of CD patients was mostly due to a significant age-related decline in the gray matter subcomponent. Negative trends between age and gray matter volumes were also observed in the Am and normal groups. In the frontal lobes, age was negatively correlated with gray matter volume in the control, CD, and Am groups. Unlike the consistent decreases in gray matter volumes, white matter showed non-significant increases in volume with age. The data suggest that CD patients may have an accelerated age-related decline in temporal lobe gray matter volume and a smaller temporal lobe volume compared to normal controls. In the frontal lobe, age-related gray matter volume reductions occur in all three groups. These age-related cortical gray matter volume reductions may be a biological marker for the risk of addictive behavior, which also decreases with age. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved. C1 Cent Arkansas Vet Healthcare Syst, Mental Hlth Serv Line, N Little Rock, AR 72114 USA. Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. Greater Los Angeles VA Healthcare Syst, W Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90074 USA. NIDA, Medicat Dev Div, Rockville, MD 20857 USA. RP Bartzokis, G (reprint author), Cent Arkansas Vet Healthcare Syst, Mental Hlth Serv Line, 2200 Ft Roots Dr,Bldg 170 116A-NLR, N Little Rock, AR 72114 USA. RI Bartzokis, George/K-2409-2013 FU NIDA NIH HHS [1YO1 DA 50038] NR 32 TC 77 Z9 81 U1 2 U2 4 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD APR 10 PY 2000 VL 98 IS 2 BP 93 EP 102 DI 10.1016/S0925-4927(99)00052-9 PG 10 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 310BN UT WOS:000086806800002 PM 10762735 ER PT J AU Foo, NC Yen, TSB AF Foo, NC Yen, TSB TI Activation of promoters for cellular lipogenic genes by hepatitis B virus large surface protein SO VIROLOGY LA English DT Article DE hepatitis B virus; large surface protein; ground glass cells; farnesyl diphosphate synthase; fatty acid synthase; NF-Y ID ENDOPLASMIC-RETICULUM; NF-Y; TRANSCRIPTION FACTOR; REGULATORY ELEMENT; SYNTHASE PROMOTER; RESPONSE PATHWAY; EXPRESSION; STRESS; SECRETION; ANTIGEN AB Hepatitis B virus large surface protein has the unusual property of accumulating in a particulate form within a preGolgi compartment, leading to marked proliferation of intracellular membranes. We show here that large surface protein activates the promoters for two lipogenic genes that code for farnesyl diphosphate synthase and fatty acid synthase. This activation is transduced, in part, by the transcription factor NF-Y. Although NF-Y Is also necessary for the transcriptional induction of chaperone proteins residing in the endoplasmic reticulum by unfolded proteins, other inducers of chaperone synthesis do not activate the promoters for farnesyl diphosphate synthase and fatty acid synthase. Our results suggest the presence of a novel signaling pathway from the endoplasmic reticulum to the nucleus that causes the intracellular membrane proliferation seen in the hepatocytes of persons with accumulated large surface protein particles. (C) 2000 Academic Press. C1 Univ Calif San Francisco, Dept Pathol, Pathol Serv 113B, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94121 USA. RP Yen, TSB (reprint author), Univ Calif San Francisco, Dept Pathol, Pathol Serv 113B, 4150 Clement St, San Francisco, CA 94143 USA. FU NCI NIH HHS [R01-CA-55578] NR 32 TC 5 Z9 5 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 10 PY 2000 VL 269 IS 2 BP 420 EP 425 DI 10.1006/viro.1999.0148 PG 6 WC Virology SC Virology GA 304MK UT WOS:000086487800019 PM 10753720 ER PT J AU Schwartz, MW Woods, SC Porte, D Seeley, RJ Baskin, DG AF Schwartz, MW Woods, SC Porte, D Seeley, RJ Baskin, DG TI Central nervous system control of food intake SO NATURE LA English DT Review ID PROOPIOMELANOCORTIN MESSENGER-RNA; HYPOTHALAMIC NEUROPEPTIDE-Y; AGOUTI-RELATED PROTEIN; LEPTIN RECEPTOR; BODY-WEIGHT; MELANOCORTIN RECEPTORS; GENE-EXPRESSION; OB/OB MICE; IN-VIVO; PARAVENTRICULAR NUCLEUS AB New information regarding neuronal circuits that control food intake and their hormonal regulation has extended our understanding of energy homeostasis, the process whereby energy intake is matched to energy expenditure over time. The profound obesity that results in rodents (and in the rare human case as well) from mutation of key signalling molecules involved in this regulatory system highlights its Importance to human health, Although each new signalling pathway discovered in the hypothalamus is a potential target for drug development in the treatment of obesity the growing number of such signalling molecules indicates that food intake is controlled by a highly complex process. Se better understand how energy homeostasis can be achieved, we describe a model that delineates the roles of individual hormonal and neuropeptide signalling pathways in the control of food Intake and the means by which obesity can arise from Inherited or acquired defects in their function. C1 Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. Univ Washington, Harborview Med Ctr, Dept Biol Struct, Seattle, WA 98104 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98104 USA. Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45267 USA. RP Schwartz, MW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. RI sheng, jian/E-9474-2012; Schwartz, Michael/H-9950-2012 NR 121 TC 3458 Z9 3548 U1 37 U2 360 PU MACMILLAN MAGAZINES LTD PI LONDON PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD APR 6 PY 2000 VL 404 IS 6778 BP 661 EP 671 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 303BC UT WOS:000086400100066 PM 10766253 ER PT J AU Peabody, JW Luck, J Glassman, P Dresselhaus, TR Lee, M AF Peabody, JW Luck, J Glassman, P Dresselhaus, TR Lee, M TI Comparison of vignettes, standardized patients, and chart abstraction - A prospective validation study of 3 methods for measuring quality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CLINICAL DECISION-MAKING; SIMULATED PATIENTS; GENERAL-PRACTICE; PHYSICIAN JUDGMENTS; CONTROLLED TRIAL; CARE; PERFORMANCE; OUTCOMES; CONSULTATION; ASSOCIATION AB Context Better health care quality is a universal goal, yet measuring quality has proven to be difficult and problematic. A central problem has been isolating physician practices from other effects of the health care system, Objective To validate clinical vignettes as a method for measuring the competence of physicians and the quality of their actual practice. Design Prospective trial conducted in 1997 comparing 3 methods for measuring the quality of care for 4 common outpatient conditions: (1) structured reports by standardized patients (SPs), trained actors who presented unannounced to physicians' clinics (the gold standard); (2) abstraction of medical records for those same visits; and (3) physicians' responses to clinical vignettes that exactly corresponded to the SPs' presentations. Setting Outpatient primary care clinics at 2 Veterans Affairs medical centers. Participants Ninety-eight (97%) of 101 general internal medicine staff physicians, faculty, and second- and third-year residents consented to be randomized for the study. From this group, 10 physicians at each site were randomly selected for inclusion. Main Outcome Measures A total of 160 quality scores (8 cases x 20 physicians) were generated for each method using identical explicit criteria based on national guidelines and local expert panels, Scores were defined as the percentage of process criteria correctly met and were compared among the 3 methods. Results The quality of care, as measured by all 3 methods, ranged from 76.2% (SPs) to 71.0% (vignettes) to 65.6% (chart abstraction). Measuring quality using vignettes consistently produced scores closer to the gold standard of SP scores than using chart abstraction, This pattern was robust when the scores were disaggregated by the 4 conditions (P<.001 to <.05), by case complexity (P<.001), by site (P<.001), and by level of physician training (P values from <.001 to <.05). The pattern persisted, although less dominantly, when we assessed the component domains of the clinical encounter-history, physical examination, diagnosis, and treatment, Vignettes were responsive to expected directions of variation in quality between sites and levels of training. The vignette responses did not appear to be sensitive to physicians' having seen an SP presenting with the same case. Conclusions Our data indicate that quality of health care can be measured in an outpatient setting by using clinical vignettes. Vignettes appear to be a valid and comprehensive method that directly focuses on the process of care provided in actual clinical practice. Vignettes show promise as an inexpensive case-mix adjusted method for measuring the quality of care provided by a group of physicians. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, San Francisco, CA 94105 USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif San Diego, San Diego Vet Affairs Med Ctr, Sch Med, La Jolla, CA 92093 USA. RP Peabody, JW (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, Suite 508,74 New Montgomery St, San Francisco, CA 94105 USA. NR 61 TC 599 Z9 600 U1 2 U2 32 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 5 PY 2000 VL 283 IS 13 BP 1715 EP 1722 DI 10.1001/jama.283.13.1715 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 298BK UT WOS:000086119300032 PM 10755498 ER PT J AU Fihn, SD AF Fihn, SD TI The quest to quantify quality SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA USA. RP Fihn, SD (reprint author), Vet Affairs Puget Sound Healthcare Syst, 1660 S Columbian Way,HSR&D 152, Seattle, WA 98108 USA. NR 21 TC 17 Z9 17 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 5 PY 2000 VL 283 IS 13 BP 1740 EP 1742 DI 10.1001/jama.283.13.1740 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 298BK UT WOS:000086119300036 PM 10755502 ER PT J AU Pahlavani, MA Vargas, DM Guo, ZM Richardson, A AF Pahlavani, MA Vargas, DM Guo, ZM Richardson, A TI Normal immune function in young and old DNA polymerase-beta deficient mice SO IMMUNOLOGY LETTERS LA English DT Article DE DNA polymerase-beta; DNA repair; knockout mice; immune function; aging ID BASE-EXCISION-REPAIR; DAMAGE; CELLS AB The effect of the DNA polymerase-beta (beta-pol) deficiency on mitogenic response and cytokine production was studied in spleen lymphocytes from 4-5- and 20-22-month-old beta-pol(-/+) mice and their age-matched wild-type littermates. The proliferative response of lymphocytes to Concanavalin A (Con A) and lipopolysaccharide (LPS) was measured by [H-3]thymidine incorporation. and the induction of cytokine production (interleukin (IL)-2, IL-4, and interferon necrosis factor (IFN)-gamma) was assessed by enzyme-linked immunosorbent assay. There was no significant difference in Con A- or LPS-induced proliferation or cytokine production in young beta-pol(-/+) mice compared with young wild-type littermates or in old beta-pol(-/+) mice compared with old wild-type littermates. However, mitogen-induced proliferation and cytokine production changed significantly with age. The proliferative response to Con A and to LPS, and the IL-2 production was significantly lower, and IL-4 and IFN-gamma levels were significantly higher in lymphocytes from old beta-pol(-/+) mice and old wild-type mice than in lymphocytes from young beta-pol(-/+) mice and young wild-type littermates. In addition, flow cytometric analysis showed no significant differences between young beta-pol(-/+) mice and young wild-type littermates or between old beta-pol(-/+) mice and old wild-type littermates in the proportion of B- and T-cell populations, and T-cell subsets. However, the number of lymphocytes expressing CD4(+) phenotype slightly decreased and the proportion of lymphocytes expressing CD44/Pgp-1 (memory) phenotype increased with age. Thus, we found no evidence for alteration in immune function in DNA polymerase-beta deficient mice, although they exhibit a decline in immunologic function with age. (C) 2000 Published by Elsevier Science S.A. All rights reserved. C1 Audie L Murphy Mem Vet Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. RP Pahlavani, MA (reprint author), Audie L Murphy Mem Vet Hosp, S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [P01-AG14674, AG00677, AG14088] NR 22 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-2478 J9 IMMUNOL LETT JI Immunol. Lett. PD APR 3 PY 2000 VL 72 IS 1 BP 17 EP 21 DI 10.1016/S0165-2478(00)00159-0 PG 5 WC Immunology SC Immunology GA 304QP UT WOS:000086495200003 PM 10789676 ER PT J AU Rex, DK Johnson, DA Lieberman, DA Burt, RW Sonnenberg, A AF Rex, DK Johnson, DA Lieberman, DA Burt, RW Sonnenberg, A TI Colorectal cancer prevention 2000: Screening recommendations of the American College of Gastroenterology SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID FECAL-OCCULT-BLOOD; CONTRAST BARIUM ENEMA; FLEXIBLE FIBEROPTIC SIGMOIDOSCOPY; AVERAGE-RISK PERSONS; ADENOMA FOLLOW-UP; ASYMPTOMATIC PATIENTS; FAMILY HISTORY; COLON-CANCER; COST-EFFECTIVENESS; TRANSPARENT CAP AB In conjunction with ACG Consumer Brochure: "ACG Recommendations on Colorectal Cancer Screening for Average and Higher Risk Patients in Clinical Practice". C1 Indiana Univ Hosp, Indianapolis, IN 46202 USA. Eastern Virginia Med Sch, Norfolk, VA 23501 USA. Portland VA Med Ctr, Portland, OR USA. Univ Utah, Salt Lake City, UT USA. VA Med Ctr, Albuquerque, NM USA. RP Rex, DK (reprint author), Indiana Univ Hosp, Suite 2300,550 N Univ Blvd, Indianapolis, IN 46202 USA. NR 142 TC 408 Z9 417 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2000 VL 95 IS 4 BP 868 EP 877 DI 10.1111/j.1572-0241.2000.02059.x PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 301HU UT WOS:000086305400005 PM 10763931 ER PT J AU El-Zimaity, HMT Graham, DY Genta, RM Lechago, J AF El-Zimaity, HMT Graham, DY Genta, RM Lechago, J TI Sustained increase in gastric antral epithelial cell proliferation despite cure of Helicobacter pylori infection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID ANTIGASTRIC AUTOANTIBODIES; NUCLEAR ANTIGEN; MUCOSA; ERADICATION; ANTIBODIES; MIMICRY; CANCER; CAGA AB OBJECTIVE: Studies of the effect of Helicobacter pylori treatment on gastric mucosa proliferation have yielded inconsistent results. We compared gastric mucosa cell proliferation posttherapy and in uninfected controls. METHODS: Biopsies were obtained from patients with H. pylori infection before treatment and at intervals for up to 33 months. Epithelial cell proliferation was determined using Ki-67 immunostaining. The labeling index (LI) is the proportion of positively labeled cells with respect to the total number of cells. The proliferative index was calculated by multiplying the labeling index (LI) and the proliferation zone PZ (PZ = length of the area between the uppermost and lowest labeled cells). RESULTS: The study included 27 patients with H. pylori gastritis and 35 controls. Epithelial cell proliferation (LI) was greater with H. pylori infection than without in both the antrum and corpus (65 +/- 5 vs 91 +/- 8 in the antrum and 44 +/- 3 vs 72 +/- 8 in the corpus, for uninfected controls vs H. pylori gastritis, respectively) (p = 0.0001). In the antrum there was no significant decrease in epithelial cell proliferation after cure of the H. pylori infection despite follow-up for >2 yr (labeling index = 83 +/- 10). In contrast, epithelial cell proliferation decreased in the corpus and became similar to that in controls after 7-13 months. CONCLUSIONS: Patients with H, pylori infection have sustained high epithelial cell proliferation in the antrum compared to that in uninfected subjects. A continued increase in proliferation in the antrum after cure of H. pylori infection suggests continuing damage. (C) 2000 by Am. Cell. of Gastroenterology. C1 Methodist Hosp, Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA. Methodist Hosp, Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Zimaity, HMT (reprint author), VA Med Ctr, Gastrointestinal Mucosa Pathol Lab, Dept Pathol, Rm 3A352,111-D,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 31 TC 9 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2000 VL 95 IS 4 BP 930 EP 935 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 301HU UT WOS:000086305400014 PM 10763940 ER PT J AU Goodfriend, TL AF Goodfriend, TL TI Angiotensin receptors: History and mysteries SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article; Proceedings Paper CT Symposium to Commemorate the 100th Anniversary of the Discovery of Renin CY APR 24, 1998 CL HELSINKI, FINLAND DE angiotensin; receptors; hypertension; cardiovascular diseases ID II TYPE-1 RECEPTOR; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; RAT-BRAIN; EXPRESSION; ANTAGONISTS; MODULATION; ESTROGEN; MEDIATE; CLONING AB Angiotensin receptors became relatively easy to study when radioactive derivatives of the peptide were synthesized for radioimmunoassays. Binding assays in vitro led to the discovery of receptors in many tissues different from those involved in the classic actions of angiotensin. The physiologic significance of receptors in sites such as the gonads, other endocrine organs, peripheral blood cells, and many regions of the brain is still uncertain. Kinetics of the binding reaction are susceptible to intracellular guanine nucleotides, and extracellular cations, fatty acids, steroids, and eicosanoids. Synthesis of receptors is under equally complex control. Receptor binding assays simplified screening for angiotensin antagonists. Nonpeptide antagonists proved so specific they revealed the existence of receptor subtypes. The two principal subtypes are found in different tissues and trigger different postreceptor cascades. Studies of receptors, the genes that code for them, and the drugs that block them have led to a growing awareness of angiotensin's effects on the structure of the heart, vessels, and kidneys, some of which are pathologic. The existence of receptor subtypes, the different signal transduction cascades they stimulate, the widespread location of receptors, and the range of effects they mediate suggest that the angiotensins are of broad relevance in biology and pathology. This multidimensional matrix also indicates that receptor antagonists may have effects not yet described. (C) 2000 American Journal of Hypertension, Ltd. C1 William S Middleton Mem Vet Hosp, Med Res Serv, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA. RP Goodfriend, TL (reprint author), William S Middleton Mem Vet Hosp, Med Res Serv, Room C-3127,2500 Overlook Terr, Madison, WI 53705 USA. NR 56 TC 15 Z9 15 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD APR PY 2000 VL 13 IS 4 BP 442 EP 449 DI 10.1016/S0895-7061(99)00212-5 PN 1 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 312QR UT WOS:000086954400021 PM 10821350 ER PT J AU Greene, EL Houghton, O Collinsworth, G Garnovskaya, MN Nagai, T Sajjad, T Bheemanathini V Grewal, JS Paul, RV Raymond Jr AF Greene, EL Houghton, O Collinsworth, G Garnovskaya, MN Nagai, T Sajjad, T Bheemanathini, V Grewal, JS Paul, RV Raymond, JR TI 5-HT(2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE serotonin receptor; kidney; signal transduction; reactive oxygen species; NADP(H) oxidase ID ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; OXIDASE ACTIVATION; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; NADPH OXIDASE; SEROTONIN; SUPEROXIDE; PATHWAY; INHIBITION AB Serotonin (5-HT) stimulates mitogenesis in rat renal mesangial cells through a G protein-coupled 5-HT(2A) receptor. We tested the hypothesis that oxidants might be involved in the signal transduction pathway Linking the receptor to extracellular signal-regulated protein kinase (ERK). 5-HT rapidly increased the activity and phosphorylation of ERK. These effects were blocked by the 5-HT(2A) receptor antagonist ketanserin. The peak effect was noted at 5-10 min, and half-maximal stimulation was achieved at 10-30 nM 5-HT. Chemical inhibitor and activator studies supported the involvement of phospholipase CI protein kinase C (PKC), and reactive oxygen species (ROS, i.e., H(2)O(2) and superoxide) generated by an NAD(P)H oxidase-like enzyme in the ERK activation cascade. Mapping studies supported a location for the NAD(P)H oxidase enzyme and the ROS downstream from PKC. Our studies are most consistent with an ERK activation pathway as follows: 5-HT(2A) receptor --> G protein --> phospholipase C --> diacylglycerol - classical PKC - NAD(P)H oxidase - superoxide --> superoxide dismutase -->, H(2)O(2) --> mitogen-activated extracellular signal-regulated kinase - ERK. These studies demonstrate a role for the 5-HT(2A) receptor in rapid, potent, and efficacious activation of ERK in rat renal mesangial cells. They support a role for oxidants in cont eying the stimulatory signal from 5-HT. because I) chemical antioxidants attenuate the 5-HT signal, 2) oxidants and 5-HT selectively activate ERK to a similar degree, 3) 5-HT produces superoxide and H(2)O(2) in these cells, and 4) a specific enzyme [NAD(P)H oxidase] has been implicated as the source of the ROS, which react selectively downstream of classical PKC. C1 Med Univ S Carolina, Dept Internal Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Greene, EL (reprint author), Med Univ S Carolina, Dept Internal Med, Div Nephrol, Rm 829C CSB,171 Ashley Ave, Charleston, SC 29425 USA. EM greeneel@musc.edu FU NHLBI NIH HHS [HL-03710]; NIDDK NIH HHS [DK-52448] NR 43 TC 64 Z9 68 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2000 VL 278 IS 4 BP F650 EP F658 PG 9 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 303ZJ UT WOS:000086457800017 PM 10751227 ER PT J AU Huang, MS Adebanjo, OA Awumey, E Biswas, G Koval, A Sodam, BR Sun, L Moonga, BS Epstein, J Goldstein, S Lai, FA Lipschitz, D Zaidi, M AF Huang, MS Adebanjo, OA Awumey, E Biswas, G Koval, A Sodam, BR Sun, L Moonga, BS Epstein, J Goldstein, S Lai, FA Lipschitz, D Zaidi, M TI IP(3), IP(3) receptor, and cellular senescence SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE inositol 1,4,5-trisphosphate; fibroblasts; cytosolic calcium; growth factors ID CALCIUM-BINDING PROTEIN; CYTOSOLIC-FREE CALCIUM; GROWTH-FACTOR BINDING; HUMAN-FIBROBLASTS; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; ALZHEIMER DONORS; BRADYKININ STIMULATION; REPLICATIVE SENESCENCE; SIGNAL-TRANSDUCTION AB Herein we demonstrate that replicative cellular senescence in vitro results in sharply reduced inositol 1,4,5-trisphosphate (IP(3)) receptor levels, reduced mitogen-evoked IP(3) formation and Ca(2+) release, and Ca(2+) store depletion. Human diploid fibroblasts (HDFs) underwent either 30 mean population doublings [mean population doublings (hTPDs) thymidine labeling index (TI) >92% ("young" or between 53 and 58 MPDs (TI < 28); "senescent")]. We found that the cytosolic Ca(2+) release triggered by either ionomycin or by several IP(3)-generating mitogens, namely bradykinin, thrombin, platelet-derived growth factor PDGF, and epidermal growth factor (EGF), was attenuated markedly in senescent HDFs. Notably, the triggered cytosolic Ca(2+) transients were of a smaller magnitude in senescent HDFs. However, the response latency seen with both PDGF and EGF was greater for senescent cells. Finally a smaller proportion of senescent HDFs showed oscillations. In parallel, IP(3) formation in response to bradykinin or EGF was also attenuated in senescent HDFs. Furthermore, senescent HDFs displayed a sharply diminished Ca(2+) release response to intracellularly applied IP(3) Finally to compare IP(3) receptor protein levels directly in young and senescent HDFs, their microsomal membranes were probed in Western blots with a highly specific anti-IP(3) receptor antiserum, Ab(40). A similar to 260-kDa band corresponding to the IP(3) receptor protein was noted; its intensity was reduced by similar to 50% in senescent cells. Thus, we suggest that reduced IP3 receptor expression, lowered IP(3) formation, and Ca(2+) release, as well as Ca(2+) store depletion, all contribute to the deficient Ca(2+) signaling seen in HDFs undergoing replicative senescence. C1 CUNY Mt Sinai Sch Med, Dept Med, Div Endocrinol, New York, NY 10029 USA. Vet Affairs Geriatr Res Educ & Clin Ctr, Little Rock, AR 72205 USA. Vet Affairs Med Ctr, Ctr Skeletal Aging, Philadelphia, PA 19104 USA. Coll Med, Sch Med, Dept Med, Philadelphia, PA 19104 USA. CUNY Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Bronx Vet Affairs Geriatr Res Educ & Clin Ctr, New York, NY 10029 USA. Univ Penn, Sch Vet, Biochem Labs, Philadelphia, PA 19104 USA. Univ Wales Coll Cardiff, Dept Med, Cardiff CF4 4XN, S Glam, Wales. RP Zaidi, M (reprint author), CUNY Mt Sinai Sch Med, Dept Med, Div Endocrinol, Annenberg 5,POB 1050,1 Gustave Levy Pl, New York, NY 10029 USA. FU NIA NIH HHS [R01-AG 14702] NR 34 TC 12 Z9 13 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2000 VL 278 IS 4 BP F576 EP F584 PG 9 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 303ZJ UT WOS:000086457800008 PM 10751218 ER PT J AU Ganzini, L Leong, GB Fenn, DS Silva, JA Weinstock, R AF Ganzini, L Leong, GB Fenn, DS Silva, JA Weinstock, R TI Evaluation of competence to consent to assisted suicide: Views of forensic psychiatrists SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID WASHINGTON-STATE; UNITED-STATES; EUTHANASIA; PHYSICIANS; ATTITUDES; OREGON AB Objective: Mental health evaluation of competence to consent has been proposed as an important safeguard for patients requesting assisted suicide, yet mental health professionals have not developed guidelines or standards to aid in such evaluations. The authors surveyed a national sample of forensic psychiatrists in the United States regarding the process, thresholds, and standards that should be used to determine competence to consent to assisted suicide. Method: An anonymous questionnaire was sent to board-certified forensic psychiatrists between August and October 1997. Results: Of the 456 forensic psychiatrists who were sent the questionnaire, 290 (64%) responded. Sixty-six percent believed that assisted suicide was ethical in at least some circumstances, and 63% thought that it should be legalized for some competent persons. Twenty-four percent indicated that it was unethical for psychiatrists to determine competence; however, 61% thought such an evaluation should be required in some or all cases. Seventy-eight percent recommended a very stringent standard of competence. Seventy-three percent believed that at least two independent examiners were needed to determine competence, and 44% favored requiring judicial review of a decision. Fifty-eight percent believed that the presence of major depressive disorder should result in an automatic finding of incompetence. Psychiatrists with ethical objections to assisted suicide advocated a higher threshold for competence and more extensive review of a decision. Conclusions: The ethical views of psychiatrists may influence their clinical opinions regarding patient competence to consent to assisted suicide. The extensive evaluation recommended by forensic psychiatrists would likely both minimize this bias and assure that only competent patients have access to assisted suicide, but the process might burden terminally ill patients. C1 Portland Vet Affairs Med Ctr, Mental Hlth Div P7 1DMH, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Psychiat, Ctr Eth Hlth Care, Portland, OR 97201 USA. Western State Hosp, Ctr Forens Serv, Tacoma, WA USA. Vet Affairs Outpatient Clin, San Jose, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Ganzini, L (reprint author), Portland Vet Affairs Med Ctr, Mental Hlth Div P7 1DMH, POB 1034, Portland, OR 97207 USA. NR 14 TC 39 Z9 39 U1 2 U2 5 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2000 VL 157 IS 4 BP 595 EP 600 DI 10.1176/appi.ajp.157.4.595 PG 6 WC Psychiatry SC Psychiatry GA 300BE UT WOS:000086232300015 PM 10739419 ER PT J AU Arozullah, AM Yarnold, PR Weinstein, RA Nwadiaro, N McIlraith, TB Chmiel, JS Sipler, AM Chan, CL Goetz, MB Schwartz, DN Bennett, CL AF Arozullah, AM Yarnold, PR Weinstein, RA Nwadiaro, N McIlraith, TB Chmiel, JS Sipler, AM Chan, CL Goetz, MB Schwartz, DN Bennett, CL TI A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IN-HOSPITAL MORTALITY; CLASSIFICATION TREE ANALYSIS; SERUM LACTATE-DEHYDROGENASE; AIDS PATIENTS; EXAMPLE; LONDON; CARE; PCP AB A common severe complication of human immunodeficiency virus (HIV) infection has been Pneumocystis carinii pneumonia (PCP). Recently, with increasing use of PCP prophylaxis and multidrug antiretroviral therapy, the clinical manifestations of HIV infection have changed dramatically and the predictors of inpatient mortality for PCP may have also changed. We developed a new staging system for predicting inpatient mortality for patients with HIV-associated PCP admitted between 1995 and 1997. Trained abstractors per formed chart reviews of 1,660 patients hospitalized with HIV-associated PCP between 1995 and 1997 at 78 hospitals in seven metropolitan areas in the United States. The overall inpatient mortality rate was 11.3%. Hierarchically optimal classification tree analysis identified an ordered five-category staging system based on three predictors: wasting, alveolar-arterial oxygen gradient (AaPo(2)), and serum albumin level. The mortality rate increased with stage: 3.7% for Stage 1, 8.5% for Stage 2, 16.1% for Stage 3, 23.3% for Stage 4, and 49.1% for Stage 5. This new staging system may be useful for severity of illness adjustment in the current era while exploring current variation in HIV-associated PCP inpatient mortality rates among hospitals and across cities. C1 VA Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA. Brockton W Roxbury Vet Affairs Med Ctr, W Roxbury, MA USA. Edward Hines Vet Adm Med Ctr, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA. Univ Illinois, Coll Med, Dept Med, Chicago, IL USA. Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA. Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA. Univ Illinois, Dept Psychol, Chicago, IL 60680 USA. Cook Cty Hosp, Chicago, IL 60612 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Bennett, CL (reprint author), VA Chicago Hlth Care Syst, Lakeside Div, 400 E Ontario St, Chicago, IL 60611 USA. RI Bennett, Charles/C-2050-2008 OI Goetz, Matthew/0000-0003-4542-992X FU NIDA NIH HHS [5R01DA10628-02] NR 23 TC 35 Z9 35 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR PY 2000 VL 161 IS 4 BP 1081 EP 1086 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 306AF UT WOS:000086573400005 PM 10764294 ER PT J AU Littner, MR Ilowite, JS Tashkin, DP Friedman, M Serby, CW Menjoge, SS Witek, TJ AF Littner, MR Ilowite, JS Tashkin, DP Friedman, M Serby, CW Menjoge, SS Witek, TJ TI Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID ANTIMUSCARINIC BRONCHODILATOR; COPD; MANAGEMENT; BA-679-BR; BROMIDE AB Tiotropium (Spiriva; Ba679BR) is a new-generation, long-acting anticholinergic bronchodilator that has muscarinic M-1 and M-3 receptor subtype selectivity. A multicenter, randomized, double-blind, parallel group, placebo-controlled study was conducted to evaluate the dose-response characteristics of tiotropium inhalation powder given once daily to stable patients with chronic obstructive pulmonary disease (COPD). Patients (mean FEV1 = 1.08 L [42% predicted]) were randomized to receive 0, 4.5, 9, 18, or 36 mu g tiotropium once daily at noon for 4 wk, with spirometry done before and hourly for 6 h after dosing. Patients measured and recorded their peak expiratory flow rates (PEFRs) three times each day. Significant dose-related improvement in FEV1 and significant improvement in FVC occurred within 1 h after the first dose of tiotropium as compared with placebo. Over the 29 d of the study, all doses of tiotropium produced significant increases over placebo in trough (i.e, as measured spirometrically at 20 to 24 h after the previous dose and just before the next dose of tiotropium), peak, and 6-h postdose average FEV1 and FVC, and in PEFR, without a significant difference among the different doses investigated. PEFR gradually returned to pretreatment baseline levels over a 3-wk evaluation period following the discontinuation of tiotropium. The overall safety profile far the tiotropium doses was, similar to that for placebo. In summary, tiotropium was shown to be safe and effective in doses ranging from 4.5 to 36 mu g delivered once daily. The improvements in spirometry with once-daily dosing confirm the long duration of action of tiotropium reported in single-dose studies, and its sustained improvement of spirometric measures over the 1 mo of testing in the study points to utility of tiotropium as a maintenance bronchodilator for patients with COPD. On the basis of the comparable bronchodilator response at doses from 9 to 36 mu g, and advantages suggested by the safely profile at doses below 36 mu g In this study, a dose of 18 mu g once daily was selected for use in long-term studies of the safety and efficacy of tiotropium. C1 Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care & Nursing Home, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Med, Div Pulm, Los Angeles, CA USA. Winthrop Univ Hosp, Div Pulm, Mineola, NY 11501 USA. Tulane Univ, Med Ctr, Sect Pulm Dis Crit Care & Environm Med, New Orleans, LA USA. Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. RP Littner, MR (reprint author), Vet Adm Med Ctr, 111P,16111 Plummer St, Sepulveda, CA 91343 USA. NR 18 TC 146 Z9 159 U1 0 U2 3 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR PY 2000 VL 161 IS 4 BP 1136 EP 1142 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 306AF UT WOS:000086573400013 PM 10764302 ER PT J AU Talke, P Chen, R Thomas, B Aggarwall, A Gottlieb, A Thorborg, P Heard, S Cheung, A Son, SL Kallio, A AF Talke, P Chen, R Thomas, B Aggarwall, A Gottlieb, A Thorborg, P Heard, S Cheung, A Son, SL Kallio, A TI The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery SO ANESTHESIA AND ANALGESIA LA English DT Article ID SELECTIVE ALPHA-2-ADRENOCEPTOR AGONIST; ADMINISTERED DEXMEDETOMIDINE; INTRAVENOUS DEXMEDETOMIDINE; ISOFLURANE REQUIREMENTS; ABDOMINAL HYSTERECTOMY; BYPASS-SURGERY; CLONIDINE; ANESTHESIA; MEDETOMIDINE; HUMANS AB We tested dexmedetomidine, an alpha(2) agonist that decreases heart rate, brood pressure, and plasma norepinephrine concentration, for its ability to attenuate stress responses during emergence from anesthesia after major vascular operations. Patients scheduled for vascular surgery received either dexmedetomidine (n = 22) or placebo (n = 19) IV beginning 20 min before the induction of anesthesia and continuing until 48 h after the end of surgery. All patients received standardized anesthesia. Heart rate and arterial blood pressure were kept within predetermined limits by varying anesthetic level and using vasoactive medications. Heart rate, arterial blood pressure, and inhaled anesthetic concentration were monitored continuously; additional measurements included plasma and urine catecholamines. During emergence from anesthesia, heart rate was slower with dexmedetomidine (73 +/- 11 bpm) than placebo (83 +/- 20 bpm) (P = 0.006), and the percentage of time the heart rate was within the predetermined hemodynamic limits was more frequent with dexmedetomidine (P < 0.05). Plasma norepinephrine levels increased only in the placebo group and were significantly lower for the dexmedetomidine group during the immediate postoperative period (P = 0.0002). We conclude that dexmedetomidine attenuates increases in heart rate and plasma norepinephrine concentrations during emergence hum anesthesia. Implications: The alpha(2) agonist, dexmedetomidine, attenuates increases in heart rate and plasma norepinephrine concentrations during emergence from anesthesia in vascular surgery patients. C1 Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA. Piedmont Anesthesia Associates, Atlanta, GA USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Univ Massachusetts, Med Ctr, Worcester, MA USA. Univ Penn, Philadelphia, PA 19104 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RP Talke, P (reprint author), Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. NR 15 TC 121 Z9 173 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD APR PY 2000 VL 90 IS 4 BP 834 EP 839 PG 6 WC Anesthesiology SC Anesthesiology GA 299GZ UT WOS:000086191800011 PM 10735784 ER PT J AU Wallace, AW Tom, WL AF Wallace, AW Tom, WL TI Interaction of L-arginine and phosphodiesterase inhibitors in vasodilation of the porcine internal mammary artery SO ANESTHESIA AND ANALGESIA LA English DT Article ID MYOCARDIAL-ISCHEMIA; ENDOTHELIAL DYSFUNCTION; CORONARY-ARTERIES; NITRIC-OXIDE; RABBIT AORTA; IN-VITRO; RELAXATION; NITROGLYCERIN; REPERFUSION; RESISTANCE AB We tested the hypothesis that L-arginine (the substrate for nitric oxide production)-combined with amrinone, milrinone (Type III phosphodiesterase [PDE] inhibitors), zaprinast, or sildenafil (Type V PDE inhibitors)-would vasodilate synergistically. Internal mammary artery segments were excised from anesthetized swine, divided into rings, and suspended in a tissue bath at 37 degrees C. Force of contraction was measured during dose-response testing of combinations of L-arginine and amrinone, milrinone, zaprinast, or sildenafil. Amrinone and milrinone were additive to L-arginine. N-G-methyl-L-arginine (L-NMA) inhibited the effects of milrinone but not amrinone. The effective concentration of amrinone eliciting 50% relaxation (EC50) was 3.8E-05M (n = 6) when given alone and 4.4E-05M (n = 6) with L-NMA. Milrinone had EC50 = 6.0E-06M alone(n = 6) and 2.8E-05M(n = 6) with L-NMA. Zaprinast (EC50 = 6.5E-05M, n = 6) and sildenafil (EC30 = 1.8E-05M, n = 6) were synergistic with L-arginine. L-NMA blocked their effects, increasing the EC50 for zaprinast to 9.9E-03M and the EC30 for sildenafil to 6.1E + 02M. In conclusion, L-arginine is additive to the vasodilation of the type III PDE inhibitors, amrinone and milrinone, but synergistic with the type V PDE inhibitors, zaprinast and sildenafil. Implications: Amrinone and milrinone, Type III cAMP-dependent phosphodiesterase inhibitors, are additive to L-arginine-dependent vasodilation. Zaprinast and sildenafil, Type V cGMP-dependent phosphodiesterase inhibitors, are synergistic with L-arginine. C1 San Francisco Vet Adm Med Ctr, Dept Anesthesiol, San Francisco, CA USA. Univ Calif San Francisco, Dept Anesthesiol, San Francisco, CA 94143 USA. RP Wallace, AW (reprint author), VAMC Anesthesia 129, 4150 Clement St, San Francisco, CA 94121 USA. NR 35 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD APR PY 2000 VL 90 IS 4 BP 840 EP 846 PG 7 WC Anesthesiology SC Anesthesiology GA 299GZ UT WOS:000086191800012 PM 10735785 ER PT J AU Yasuda, M Takamatsu, J D'Souza, I Crowther, RA Kawamata, T Hasegawa, M Hasegawa, H Spillantini, MG Tanimukai, S Poorkaj, P Varani, L Varani, G Iwatsubo, T Goedert, M Schellenberg, GD Tanaka, C AF Yasuda, M Takamatsu, J D'Souza, I Crowther, RA Kawamata, T Hasegawa, M Hasegawa, H Spillantini, MG Tanimukai, S Poorkaj, P Varani, L Varani, G Iwatsubo, T Goedert, M Schellenberg, GD Tanaka, C TI A novel mutation at position+12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) SO ANNALS OF NEUROLOGY LA English DT Article; Proceedings Paper CT International Symposium on Dementia CY SEP 11-13, 1999 CL KOBE, JAPAN ID PAIRED HELICAL FILAMENTS; MULTIPLE SYSTEM TAUOPATHY; PRESENILE-DEMENTIA; PROTEIN-TAU; MONOCLONAL-ANTIBODY; MICROTUBULE-BINDING; ALZHEIMERS-DISEASE; ISOFORMS; PHOSPHORYLATION; EXPRESSION AB Exonic and intronic mutations in the tau gene cause familiar frontotemporal dementia and parkinsonism linked to chromosome 17. Here, we describe a new mutation, consisting of a C-to-T transition at position +12 of the intron following exon 10 of the tau gene in the Kumamoto pedigree, showing frontotemporal dementia. The mutation caused a marked reduction in melting temperature of the tau exon 10-splicing regulatory element RNA and a targe increase in exon 10-containing transcripts. Brain tissue from affected individuals showed an abnormal preponderance of exon 10-containing transcripts that was reflected at the protein level by an overproduction of tau isoforms with four microtubule-binding repeats. Immunostaining revealed the presence of tau aggregates in degenerating neurons and glial cells. isolated tau filaments had a twisted ribbon-like morphology and were made of hyperphosphorylated four-repeat tau isoforms. The additional mutation located close to the splice-donor site of the intron following exon 10 of the tau gene supports the view that intronic mutations exercize their pathogenic effect by destabilizing RNA secondary structure. C1 Inst Aging Brain & Cognit Disorders, Himeji, Hyogo 6700981, Japan. Kikuchi Natl Hosp, Div Clin Res, Kumamoto, Japan. Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo, Japan. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol & Neurol, Seattle, WA USA. MRC, Mol Biol Lab, Cambridge CB2 2QH, England. Univ Cambridge, Dept Neurol, Cambridge, England. RP Yasuda, M (reprint author), Inst Aging Brain & Cognit Disorders, 520 Saisho Ko, Himeji, Hyogo 6700981, Japan. OI varani, luca/0000-0002-0963-0987 FU NIA NIH HHS [R01 AG11762] NR 46 TC 72 Z9 73 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2000 VL 47 IS 4 BP 422 EP 429 DI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 300XF UT WOS:000086278500004 PM 10762152 ER PT J AU Finkelstein, JA Metlay, JP Davis, RL Rifas-Shiman, SL Dowell, SF Platt, R AF Finkelstein, JA Metlay, JP Davis, RL Rifas-Shiman, SL Dowell, SF Platt, R TI Antimicrobial use in defined populations of infants and young children SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ACUTE OTITIS-MEDIA; ANTIBIOTIC-RESISTANCE; PENICILLIN; PREVALENCE; CARE; PNEUMOCOCCI; STRATEGY; COLDS AB Background: Antimicrobial overprescribing contributes to bacterial resistance, but data on use in infants and young children are limited. Objectives: To assess antimicrobial use in a defined population of infants and young children and to determine diagnosis-specific prescribing rates for common infections. Design and Setting: Retrospective cohort study of children served by 44 practices affiliated with 2 managed care organizations. Patients: Children aged 3 months to 72 months enrolled in either health plan between September 1, 1994, and August 31, 1996. Analysis: Rates of antimicrobial use were calculated as the number of pharmacy dispensings divided by the number of person-years of observation contributed to the cohort in 2 age groups (3 to <36 months and 36 to <72 months). Other outcomes included the distribution of diagnoses associated with antimicrobial dispensing and population-based rates of diagnosis of common acute respiratory tract illnesses. Results: A total of 46 477 children contributed 59 710 person-years of observation across the 2 health plans. Rates of antimicrobial dispensing for children aged 3 to 36 months were 3.2 and 2.1 dispensings per person-year in the 2 populations. A substantial fraction of younger children (35% in population A and 23% in population B) received 4 or more antimicrobial prescriptions in a single year. For children aged 36 to 72 months, the dispensing rates for the 2 populations were 2.0 and 1.5 antimicrobials per person-year. We found significant differences in rates between the populations studied and a decrease in use at all sites from 1995 to 1996. The diagnosis of otitis media accounted for 56% of antimicrobial drugs dispensed to children aged 3 to 36 months and 40% of those dispensed to children aged 36 to 72 months. Antimicrobial prescribing for colds and upper respiratory tract infections, bronchitis, and sinusitis was less frequent than previously reported but accounted for 10% to 14% of antimicrobial drugs dispensed. Conclusions: In these populations, otitis media accounted for the largest number of antimicrobial agents dispensed to children younger than 6 years. Clearly inappropriate indications such as cold, upper respiratory tract infection, and bronchitis accounted for smaller fractions of antimicrobial use but may be most amenable to change. However, interventions that encourage use of strict criteria for diagnosis and treatment of otitis media will likely have the greatest impact on overall antimicrobial exposure. Monitoring defined populations longitudinally will allow assessment of the effectiveness of such national and local initiatives. C1 Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA. Harvard Pilgrim Hlth Care, Boston, MA USA. Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. RP Finkelstein, JA (reprint author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA. NR 25 TC 98 Z9 99 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2000 VL 154 IS 4 BP 395 EP 400 PG 6 WC Pediatrics SC Pediatrics GA 302LK UT WOS:000086366400014 PM 10768680 ER PT J AU Garber, SL Rintala, DH Hart, KA Fuhrer, MJ AF Garber, SL Rintala, DH Hart, KA Fuhrer, MJ TI Pressure ulcer risk in spinal cord injury: Predictors of ulcer status over 3 years SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 73rd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine CY OCT 15, 1996 CL CHICAGO, ILLINOIS SP Amer Congress Rehabil Med DE pressure ulcers; spinal cord injury ID SORES; COMMUNITY; MANAGEMENT AB Objective: To identify predictors of pressure ulcers in men with spinal cord injury over a 3-year period. Design: Longitudinal, two-panel, cohort. Setting: Community. Participants: One hundred eighteen men with spinal cord injury. Measures: Interviews, questionnaires, and physical examinations were completed in two phases, 3 years apart. Information obtained included demographic and spinal cord injury characteristics; ulcer history; health beliefs and practices; measures of impairment, disability, and handicap; and skin integrity. Results: Thirty-one percent of the participants reported having a pressure ulcer in the 12 months before Phase 2. Some Phase 1 predictors of self-reported ulcers in the year before Phase 2 were a younger age at onset of spinal cord injury, previous pressure ulcer surgery, and the presence of a pressure ulcer in the year before Phase 1. On examination at Phase 2, 59% presented with an ulcer. Phase 1 predictors of ulcer presence at Phase 2 examination were similar to predictors for self-reported ulcers. Conclusion: Individuals with the identified predictive characteristics are at greater risk for developing pressure ulcers. These individuals should receive additional interventions to reduce that risk. Potential interventions include more systematic and frequent follow-up, frequent review of pressure ulcer prevention and management strategies, and provision of needed personal assistance and relevant equipment. C1 Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Inst Rehabil & Res, Houston, TX USA. Vet Affairs Med Ctr, Ctr Excellence Hlth Aging Disabil, Houston, TX 77030 USA. NIH, Bethesda, MD 20892 USA. RP Garber, SL (reprint author), Houston VA Med Ctr, 580-128,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 36 TC 69 Z9 70 U1 0 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2000 VL 81 IS 4 BP 465 EP 471 DI 10.1053/mr.2000.3889 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 300WW UT WOS:000086277600014 PM 10768537 ER PT J AU DiGiovine, MM Cooper, RA Boninger, ML Lawrence, BM VanSickle, DP Rentschler, AJ AF DiGiovine, MM Cooper, RA Boninger, ML Lawrence, BM VanSickle, DP Rentschler, AJ TI User assessment of manual wheelchair ride comfort and ergonomics SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE wheelchair; ride comfort; ergonomics; pain ID WHOLE-BODY VIBRATION; DISCOMFORT; SEAT AB Objective: To examine wheelchair-user perceived ride comfort during propulsion and to compare the ride comfort of ultralight and lightweight manual wheelchairs, An ultralight wheelchair is defined as having a high degree of adjustability, whereas a lightweight wheelchair has minimal adjustability. Design and Participants: Repeated measures design of a sample of 30 community-dwelling manual wheelchair users evaluating 7 different manual wheelchairs over an activities of daily living course. Setting: A rehabilitation engineering center. Main Outcome Measures: Subject ratings of perceived ride comfort and basic ergonomics while propelling over the activities of daily Living course. Ratings were recorded for each wheelchair on individual tasks and for the course overall. Results: The Invacare Action XT wheelchair was ranked best for both ride comfort and basic ergonomics. The ride-comfort scores (p <.05) and wheelchair ergonomics ratings (p <.05) for the ultralight wheelchair group were significantly different from those for lightweight wheelchair group. Conclusion: There are differences in perceived ride comfort and basic ergonomics between the designs of the wheelchairs (lightweight vs ultralight). Subjects perceived that ultralight wheelchairs were more comfortable and had better basic ergonomics than lightweight wheelchairs. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Orthopaed Surg, Div Phys Med & Rehabil, Pittsburgh, PA 15260 USA. UPMC Hlth Syst, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, 7180 Highland Dr, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 13 TC 39 Z9 40 U1 1 U2 8 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2000 VL 81 IS 4 BP 490 EP 494 DI 10.1053/mr.2000.3845 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 300WW UT WOS:000086277600018 PM 10768541 ER PT J AU Harte, RA Hulten, LM Lindmark, H Reue, K Schotz, MC Khoo, J Rosenfeld, ME AF Harte, RA Hulten, LM Lindmark, H Reue, K Schotz, MC Khoo, J Rosenfeld, ME TI Low level expression of hormone-sensitive lipase in arterial macrophage-derived foam cells: potential explanation for low rates of cholesteryl ester hydrolysis SO ATHEROSCLEROSIS LA English DT Article DE atherosclerosis; hormone-sensitive lipase; macrophage-derived foam cells; neutral cholesteryl ester hydrolase ID DEPENDENT PROTEIN-KINASE; LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; PHOSPHORYLATION; MOBILIZATION; DIFFERENCE; HYDROLASE; EFFLUX; HDL AB Conversion of arterial macrophages into foam cells is a key process involved in both the initiation and progression of atherosclerotic lesions. Foam cell formation involves the progressive accumulation and storage of lipoprotein-derived cholesteryl esters. The resulting imbalance in cholesterol metabolism in arterial foam cells may be due in part to an inadequately low level of cytoplasmic neutral cholesteryl ester hydrolase (NCEH) activity. In this study, we have demonstrated that hormone-sensitive lipase (HSL) mRNA is expressed at very low levels in macrophage-derived foam cells, using the unique approach of extracting mRNA from macrophage-derived foam cells purified from human and rabbit atherosclerotic plaques coupled with reverse transcriptase polymerase chain reaction (RT-PCR). We also demonstrate that macrophage-derived foam cells isolated from rabbit atherosclerotic lesions exhibit a resistance to high density lipoprotein (HDL)-mediated cholesterol efflux along with reduced levels of NCEH activity compared to lipid-loaded mouse peritoneal macrophages. Thus, low level expression of HSL may partially account for the reduced NCEH activity observed in arterial foam cells isolated from atherosclerosis-susceptible species. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved. C1 Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA. Univ Washington, Interdisciplinary Program Nutr Sci, Seattle, WA 98195 USA. Sahlgrenska Univ Hosp, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden. Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. W Los Angeles VA Med Ctr, Lipid Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. RP Rosenfeld, ME (reprint author), Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA. FU NIDDK NIH HHS [DK35816] NR 29 TC 16 Z9 17 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD APR PY 2000 VL 149 IS 2 BP 343 EP 350 DI 10.1016/S0021-9150(99)00345-7 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 302BK UT WOS:000086344900010 PM 10729384 ER PT J AU Mukhin, YV Garnovskaya, MN Collinsworth, G Pendergrass, D Magai, T Pinckney, S Greene, EL Raymond, JR AF Mukhin, YV Garnovskaya, MN Collinsworth, G Pendergrass, D Magai, T Pinckney, S Greene, EL Raymond, JR TI 5-Hydroxytryptamine(1A) receptor/G(i)beta gamma stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of Src in Chinese hamster ovary fibroblasts SO BIOCHEMICAL JOURNAL LA English DT Article DE G protein; phosphorylation; proliferation; serotonin receptor; tyrosine kinase ID SMOOTH-MUSCLE CELLS; TYROSINE-PHOSPHATASE CATALYSIS; HYDROGEN-PEROXIDE; 5-HT1A RECEPTOR; MESANGIAL CELLS; NADPH OXIDASE; REDOX REGULATION; ANGIOTENSIN-II; C-JUN; DIFFERENTIAL ACTIVATION AB The hypothesis of this work is that the 'serotonin' or 5-hydroxytryptamine (5-HT)(1A) receptor, which activates the extracellular signal-regulated kinase (ERK) through a G(1)beta gamma-mediated pathway, does so through the intermediate actions of reactive oxygen species (ROS). Five criteria were shown to support a key role for ROS in the activation of ERK by the 5-HT1A receptor. (1) Antioxidants inhibit activation of ERK by 5-HT. (2) Application of cysteine-reactive oxidant molecules activates ERK. (3) The 5-HT1A receptor alters cellular redox properties, and generates both superoxide and hydrogen peroxide. (4) A specific ROS-producing enzyme [NAD(P)H oxidase] is involved in the activation of ERK. (5) There is specificity both in the effects of various chemical oxidizers, and in the putative location of the ROS in the ERK activation pathway. We propose that NAD(P)H oxidase is located in the ERK activation pathway stimulated by the transfected 5-HT1A receptor in Chinese hamster ovary (CHO) cells downstream of G(1)beta gamma subunits and upstream of or at the level of the non-receptor tyrosine kinase, Src. Moreover, these experiments provide cofirmation that the transfected human 5-HT1A receptor induces the production of ROS (superoxide and hydrogen peroxide) in CHO cells, and support the possibility that an NAD(P)H oxidase-like enzyme might be involved in the 5-HT-mediated generation of both superoxide and hydrogen peroxide. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Raymond Jr (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St, Charleston, SC 29425 USA. FU NHLBI NIH HHS [HL03710]; NIDDK NIH HHS [DK52448] NR 51 TC 49 Z9 53 U1 0 U2 0 PU PORTLAND PRESS PI LONDON PA 59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD APR 1 PY 2000 VL 347 BP 61 EP 67 DI 10.1042/0264-6021:3470061 PN 1 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 309WQ UT WOS:000086792600008 PM 10727402 ER PT J AU Stock, W Tsai, T Golden, C Rankin, C Sher, D Slovak, ML Pallavicini, MG Radich, JP Boldt, DH AF Stock, W Tsai, T Golden, C Rankin, C Sher, D Slovak, ML Pallavicini, MG Radich, JP Boldt, DH TI Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia SO BLOOD LA English DT Article ID SOUTHWEST-ONCOLOGY-GROUP; CYTOGENETICALLY ABERRANT CELLS; HEMATOPOIETIC PROGENITOR CELLS; CLINICAL-SIGNIFICANCE; GROUP EXPERIENCE; STEM-CELLS; MARROW; P53; COMPARTMENT; EXPRESSION AB To test the hypothesis that cell cycle regulatory gene abnormalities are determinants of clinical outcome in adult acute lymphoblastic leukemia (ALL), we screened lymphoblasts from patients on a Southwest Oncology Group protocol for abnormalities of the genes, retinoblastoma (Rb), p53, p15(INK4B), and p16(INK4A), Aberrant expression occurred in 33 (85%) patients in the following frequencies: Rb, 51%; p16(INK4A), 41%; p53, 26%, Thirteen patients (33%) had abnormalities in 2 or more genes. Outcomes were compared in patients with 0 to 1 abnormality versus patients with multiple abnormalities. The 2 groups did not differ in a large number of clinical and laboratory characteristics. The CR rates for patients with 0 to 1 and multiple abnormalities were similar (69% and 54%, respectively). Patients with 0 to 1 abnormality had a median survival time of 25 months(n = 26; 95% CI, 13-46 months) versus 8 months (n = 13; 95% CI, 4-12 months) for those with multiple abnormalities (P <.01). Stem cells (CD34+lin-) were isolated from adult ALL bone marrows and tested for p16(INK4A) expression by immunocytochemistry, In 3 of 5 patients lymphoblasts and sorted stem cells lacked p16(INK4A) expression. In 2 other patients only 50% of sorted stem cells expressed p16(INK4A), By contrast, pig expression was present in the CD34+lin- compartment In 95% (median) of 9 patients whose lymphoblasts expressed p16(INK4A), Therefore, cell cycle regulatory gene abnormalities are frequently present in adult ALL lymphoblasts, and they may be important determinants of disease outcome. The presence of these abnormalities In the stem compartment suggests that they contribute to leukemogenesis. Eradication of the stem cell subset harboring these abnormalities may be important to achieve cure, (Blood, 2000;95:2364-2371) (C) 2000 by The American Society of Hematology. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78229 USA. Univ Illinois, Dept Med, Chicago, IL USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. SW Oncol Grp, Leukemia Biol Program, San Antonio, TX USA. SW Oncol Grp, Cytogenet Program, San Antonio, TX USA. Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA. Childrens Hosp, Dept Hematol Oncol, Oakland, CA 94609 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Div Clin Res, Genet Program, Seattle, WA 98104 USA. City Hope Natl Med Ctr, Dept Cytogenet, Duarte, CA 91010 USA. RP Boldt, DH (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, Mail Code 7880,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. FU NCI NIH HHS [CA6032, CA32102, CA3333572] NR 37 TC 22 Z9 23 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1200 19TH ST, NW, STE 300, WASHINGTON, DC 20036-2422 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 2000 VL 95 IS 7 BP 2364 EP 2371 PG 8 WC Hematology SC Hematology GA 298GC UT WOS:000086130100028 PM 10733508 ER PT J AU Prochazka, AV AF Prochazka, AV TI New developments in smoking cessation SO CHEST LA English DT Article; Proceedings Paper CT Symposium on the Multimodality Approach to Lung Cancer - Update CY FEB, 1998 CL UNIV COLORADO, CTR CANC, VAIL, COLORADO SP Univ Colorado, Ctr Canc, Univ Colorado, Sch Med, Off Continuning Educ HO UNIV COLORADO, CTR CANC DE bupropion; drug therapy; nicotine; smoking cessation; therapy; tobacco ID DOUBLE-BLIND TRIAL; NICOTINE NASAL SPRAY; TRANSDERMAL NICOTINE; COST-EFFECTIVENESS; RANDOMIZED TRIAL; GENERAL-PRACTICE; PATCH; INTERVENTIONS; REPLACEMENT; WITHDRAWAL AB Research on smoking has increased in the past several years, and many new therapeutic modalities have been developed. Primary intervention for smoking cessation begins with systematic identification of smokers and a formal diagnosis of nicotine dependence. Providing self-help brochures without clinical advice has marginal efficacy, but these can be useful as an adjunct to clinician intervention. Several large studies have shown that physician advice alone can lead to quit rates of up to 10%, and follow-up for patients trying to quit can double cessation rates. Behavioral therapy alone has demonstrated cessation rates of approximately 20% for those willing to participate. Drug therapy remains the most attractive method of smoking cessation for many patients. The standard approach has been nicotine substitution using one of the four forms of nicotine replacement (gum, patches, nasal spray, inhaler) currently available. The efficacy of nicotine replacement products is similar, with each agent providing a doubling of the cessation rate. Thus, the choice of agent depends on patient factors and preference. Bupropion is the first nonnicotine-containing agent approved for smoking cessation, with cessation rates ranging from 10.5 to 24.4%, depending on dose. One-year follow-up suggests a continued benefit with this agent, The combination of bupropion and transdermal nicotine has also been shown to be effective for smoking cessation in clinical trials. Effective approaches to smoking cessation should combine identification of smokers, provision of advice at each visit, and widespread availability of treatment. C1 Denver VA Med Ctr, Ambulatory Care Sect, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA. RP Prochazka, AV (reprint author), Denver VA Med Ctr, Ambulatory Care Sect, 1055 Clermont, Denver, CO 80220 USA. NR 52 TC 26 Z9 26 U1 1 U2 3 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2000 VL 117 IS 4 SU 1 BP 169S EP 175S DI 10.1378/chest.117.4_suppl_1.169S PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 308CA UT WOS:000086690000018 PM 10777474 ER PT J AU Gross, PA Asch, S Kitahata, MM Freedberg, KA Barr, D Melnick, DA Bozette, SA AF Gross, PA Asch, S Kitahata, MM Freedberg, KA Barr, D Melnick, DA Bozette, SA TI Performance measures for guidelines on preventing opportunistic infections in patients infected with human immunodeficiency virus SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PNEUMOCYSTIS-CARINII PNEUMONIA; ACTIVE ANTIRETROVIRAL THERAPY; SOCIETY USA PANEL; HIV-INFECTION; UPDATED RECOMMENDATIONS; UNITED-STATES; AIDS; DISCONTINUATION; PROPHYLAXIS; MANAGEMENT AB This article serves as a complement to the 1999 US Public Health Service/Infectious Diseases Society of America guidelines on the prevention of opportunistic infections in persons infected with HIV, published in this issue of Clinical Infectious Diseases [1], A number of performance measures to assess compliance with the guidelines and to aid in their implementation are proposed. C1 Hackensack Univ, Med Ctr, Dept Internal Med, Hackensack, NJ 07601 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Vet Adm San Diego Healthcare Syst, San Diego, CA USA. Univ Calif San Diego, La Jolla, CA 92093 USA. Rand Hlth, Santa Monica, CA USA. Univ Washington, Ctr AIDS & STD, Harborview Med Ctr, Seattle, WA 98195 USA. Boston Univ, Harvard Boston Med Ctr, Boston, MA 02215 USA. George Washington Univ, Ctr Hlth Policy Res, Forum Collaborat HIV Res, Washington, DC USA. Kaiser Permanente, Springfield, VA USA. RP Gross, PA (reprint author), Hackensack Univ, Med Ctr, Dept Internal Med, 30 Prospect Ave, Hackensack, NJ 07601 USA. FU NIAID NIH HHS [R01 AI058736] NR 32 TC 5 Z9 5 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR PY 2000 VL 30 SU 1 BP S85 EP S93 DI 10.1086/313845 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 314QQ UT WOS:000087067600008 PM 10770917 ER PT J AU Boyko, EJ Fujimoto, WY Leonetti, DL Newell-Morris, L AF Boyko, EJ Fujimoto, WY Leonetti, DL Newell-Morris, L TI Visceral adiposity and risk of type 2 diabetes - A prospective study among Japanese Americans SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; BODY-FAT DISTRIBUTION; FASTING PLASMA-INSULIN; ANTHROPOMETRIC MEASUREMENTS; ABDOMINAL OBESITY; COMPUTED-TOMOGRAPHY; TISSUE DISTRIBUTION; MASS INDEX; FOLLOW-UP; MEN AB OBJECTIVE - We conducted a prospective study among Japanese Americans of diabetes incidence in relation to visceral and regional adiposity, fasting insulin and C-peptide, and a measure of insulin secretion, because little prospective data exist on these associations. RESEARCH DESIGN AND METHODS - Baseline variables included plasma glucose, C-peptide, and insulin measured after an overnight fast and 30 and 120 min after a 75-g oral glucose tolerance test; abdominal, thoracic, and thigh fat areas by computed tomography (CT); BMI (kg/m(2)); and insulin secretion (incremental insulin response [IIR]). RESULTS - Study subjects included 290 second-generation (nisei) and 230 third-generation (sansei) Japanese Americans without diabetes, of whom 65 and 13, respectively, developed diabetes. Among nisei, significant predictors of diabetes risk for a 1 SD increase in continuous variables included intra-abdominal fat area (IAFA) (odds ratio, 95% CI) (1.6, 1.1-2.3), fasting plasma C-peptide (1.4, 1.1-1.8), and the IIR (0.5, 0.3-0.9) after adjusting for age, sex, impaired glucose tolerance, family diabetes history, and CT-measured fat areas other than intraabdominal. Intra-abdominal fat area remained a significant predictor of diabetes incidence even after adjustment for BMI, total body fat area, and subcutaneous fat area, although no measure of regional or total adiposity was related to development of diabetes. Among sansei, all adiposity measures were related to diabetes incidence, but, in adjusted models, only IAFA remained significantly associated with higher risk (2.7, 1.4-5.4, BMI-adjusted). CONCLUSIONS - Greater visceral adiposity precedes the development of type 2 diabetes in Japanese Americans and demonstrates an effect independent of fasting insulin, insulin secretion, glycemia, total and regional adiposity, and family history of diabetes. C1 Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), Vet Affairs Puget Sound, Epidemiol Res & Informat Ctr, 1660 S Columbian Way,S111GIMC, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X FU NHLBI NIH HHS [HL-49293]; NIDDK NIH HHS [DK-17047, DK-31170] NR 45 TC 320 Z9 327 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2000 VL 23 IS 4 BP 465 EP 471 DI 10.2337/diacare.23.4.465 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 298YG UT WOS:000086167900007 PM 10857936 ER PT J AU Moreno, MJ Clayburne, G Schumacher, HR AF Moreno, MJ Clayburne, G Schumacher, HR TI Processing of noninflammatory synovial fluids with hyaluronidase for cytospin preparations improves the accuracy of differential counts SO DIAGNOSTIC CYTOPATHOLOGY LA English DT Article DE neutrophils; monocytes; joint fluid; crystals AB Differential leukocyte counts on noninflammatory synovial fluids (NISF) are not widely reported or used in research, apparently dire to technical, difficulties related to either high viscosity or low numbers of cells. We describe an evaluation of a technique using hyaluronidase and cytospin preparations to study NISF: Twenty-three consecutive synovial fluids (SF) with less than 2,000 white blood cells (WBC)/mm(3) were studied either by the usual smear of a single drop or by adding two drops of hyaluronidase (150 USP units/ml) to 0.25 cc of SF and cytocentrifuging at 800 rpm for 10 min. Both preparations were stained with Wright's stain. Cytospin preparations gave better morphology, and in 22/23 specimens we could count 100 cells on one slide. Smeared preparations gave dark cells and required 2-3 slides to count 100 cells. Differential counts on the cytospin preparations consistently showed higher percentages of monocytes, suggesting that these cells wt l-e underdetected and misinterpreted as lymphocytes on the routine smears. Polymorphonuclear leukocytes (PMN) were significantly less frequent (P 0.005) in osteoarthritis (OA) fluids than in the other diseases with NISF Relatively more PMN may suggest consideration of a diagnosis other than OA. Cytospin preparations of hyaluronicdase-treated NISF may open up an important area for investigation of the role of SF cells in less inflammatory diseases. Published 2000 Wiley-Liss, Inc. C1 Dept Vet Affairs Med Ctr, Arthrit & Immunol Ctr, Philadelphia, PA 19104 USA. RP Schumacher, HR (reprint author), Vet Affairs Med Ctr, Arthrit Immunol Ctr, 151K,Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 13 TC 13 Z9 14 U1 0 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 8755-1039 J9 DIAGN CYTOPATHOL JI Diagn. Cytopathol. PD APR PY 2000 VL 22 IS 4 BP 256 EP 258 DI 10.1002/(SICI)1097-0339(200004)22:4<256::AID-DC13>3.0.CO;2-G PG 3 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA 299HP UT WOS:000086193200013 PM 10787150 ER PT J AU Robbins, SJ Ehrman, RN Childress, AR Cornish, JW O'Brien, CP AF Robbins, SJ Ehrman, RN Childress, AR Cornish, JW O'Brien, CP TI Mood state and recent cocaine use are not associated with levels of cocaine cue reactivity SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE cue reactivity; cocaine dependence; mood state; craving; cocaine use ID ABUSE PATIENTS; SMOKING URGES; ABSTINENCE; HUMANS; RESPONSES; ALCOHOL; IMAGERY; AVAILABILITY; INPATIENT; SMOKERS AB Eighty-one cocaine-dependent outpatients were assessed for their reactions to cocaine-related cues in a laboratory setting. All subjects contributed a urine sample prior to the session. Compared with non-drug control cues, the cocaine stimuli produced increases in physiological arousal, self-reports of high, craving, and withdrawal, and self-reports of negative mood. Subjects who tested cocaine-positive on the day of testing differed only in skin resistance responding from those who tested cocaine-negative. Changes in cue-induced physiological and self-report measures were also not associated with between-subject variations in mood as measured by the Profile of Mood States (POMS) questionnaire administered prior to cue assessment. Thus, variations in baseline mood and recent cocaine use history do not introduce an additional source of variability in cue reactivity measurements. However, negative mood states at the start of a session were associated with higher levels of self-reported craving, high, and withdrawal both before and after cue exposure. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved. C1 Beaver Coll, Dept Psychol, Glenside, PA 19038 USA. Univ Penn, Treatment Res Ctr, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Robbins, SJ (reprint author), Beaver Coll, Dept Psychol, 450 S Easton Rd, Glenside, PA 19038 USA. FU NIDA NIH HHS [P50DA09252-02, DA03008] NR 49 TC 25 Z9 25 U1 4 U2 5 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2000 VL 59 IS 1 BP 33 EP 42 DI 10.1016/S0376-8716(99)00103-9 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 294VQ UT WOS:000085931400003 PM 10706973 ER PT J AU Yildiran, ST Saracli, MA Fothergill, AW Rinaldi, MG AF Yildiran, ST Saracli, MA Fothergill, AW Rinaldi, MG TI In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID IN-VITRO; PIGEON DROPPINGS; VAR. NEOFORMANS; SEROTYPE-A; ITRACONAZOLE; FLUCONAZOLE; YEASTS AB The in vitro antifungal susceptibility of 27 environmental (pigeon droppings) isolates of Cryptococcus neoformans var. neoformans, isolated from throughout Turkey, to six antifungal agents (amphotericin B, flucytosine, fluconazole, voriconazole, itraconazole, and SCH56592) was studied. Voriconazole, itraconazole, and SCH56592 all showed comparable activity and were more active than the remaining three antifungal agents tested. Overall, SCH56592 was the most active agent (MIC90, 0.015 mu g/ml, at both 48 and 72 h), followed by itraconazole (MIC90, 0.03 mu g/ml, at both 48 and 72 h) and voriconazole (MIC90, 0.25 mu g/ml, at both 48 and 72 h), respectively. Antifungal susceptibility data for environmental isolates may reflect patterns for the clinical isolates recovered from patients from the same geographic area. C1 Gulhane Mil Med Acad & Sch Med, Dept Microbiol & Clin Microbiol, Div Med Mycol, TR-06018 Ankara, Turkey. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA. RP Yildiran, ST (reprint author), Gulhane Mil Med Acad & Sch Med, Dept Microbiol & Clin Microbiol, Div Med Mycol, TR-06018 Ankara, Turkey. NR 18 TC 13 Z9 13 U1 0 U2 3 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD APR PY 2000 VL 19 IS 4 BP 317 EP 319 DI 10.1007/s100960050484 PG 3 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 316WC UT WOS:000087190200015 PM 10834825 ER PT J AU Lew, EA Pisegna, JR Starr, JA Soffer, EF Forsmark, C Modlin, IM Walsh, JH Beg, M Bochenek, W Metz, DC AF Lew, EA Pisegna, JR Starr, JA Soffer, EF Forsmark, C Modlin, IM Walsh, JH Beg, M Bochenek, W Metz, DC TI Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome SO GASTROENTEROLOGY LA English DT Article ID PROTON PUMP INHIBITORS; SUBSTITUTED BENZIMIDAZOLES; OMEPRAZOLE; PHARMACOKINETICS; MANAGEMENT; SECRETION; EFFICACY; SURGERY; SAFETY AB Background Be Aims: Parenteral control of gastric acid hypersecretion in conditions such as Zollinger-Ellison syndrome (ZES) or idiopathic gastric acid hypersecretion is necessary perioperatively or when oral medications cannot be taken for other reasons (e.g., during chemotherapy, acute upper gastrointestinal bleeding, or in intensive care unit settings). Methods: We evaluated the efficacy and safety of 15-minute infusions of the proton pump inhibitor pantoprazole (80-120 mg every 8-12 hours) in controlling acid output for up to 7 days. Effective control was defined as acid output > 10 milliequivalents per hour (mEq/h) (<5 mEq/h in patients with prior acid-reducing surgery) for 24 hours. Results: The 21 patients enrolled had a mean age of 51.9 years (range, 29-75) and a mean disease duration of 8.1 years (range, <0.5-21); 13 were male, 7 had multiple endocrine neoplasia syndrome type 1, 4 had undergone acid-reducing surgery, 2 had received chemotherapy, and 13 had undergone gastrinoma resections without cure. Basal acid output (mean +/- SD) was 40.2 +/- 27.9 mEq/h (range, 11.2-117.9), In all patients, acid output was controlled within the first hour (mean onset of effective control, 41 minutes) after an initial 80-mg intravenous pantoprazole dose. Pantoprazole, 80 mg every 12 hours, was effective in 17 of 21 patients (81%) for up to 7 days. Four patients required upward dose titration, 2 required 120 mg pantoprazole every 12 hours, and 2 required 80 mg every 8 hours. At study end, acid output remained controlled for 6 hours beyond the next expected dose in 71% of patients (n = 15); mean acid output increased to 4.0 mEq/h (range, 0-9.7), No serious or unexpected adverse events were observed. Conclusions: Intravenous pantoprazole, 160-240 mg/day administered in divided doses by 15-minute infusion, rapidly and effectively controlled acid output within 1 hour and maintained control for up to 7 days in all ZES patients. C1 Univ Penn, Med Ctr, Dept Med, Div Gastroenterol,GI Physiol Lab, Philadelphia, PA 19104 USA. W Los Angeles Vet Affairs Med Ctr, Dept Med, Div Digest Dis, CURE UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Florida, Dept Gastroenterol, Gainesville, FL USA. Yale Univ, Sch Med, GI Surg Pathol Res Grp, New Haven, CT USA. Wyeth Ayerst Res, Clin Res & Dev, Radnor, PA USA. RP Metz, DC (reprint author), Univ Penn, Med Ctr, Dept Med, Div Gastroenterol,GI Physiol Lab, 3 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA. FU NCRR NIH HHS [MO1-RR00040, MO1-RR09758, MO1-RR00082] NR 35 TC 52 Z9 55 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 BP 696 EP 704 DI 10.1016/S0016-5085(00)70139-9 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 298BH UT WOS:000086119100010 PM 10734021 ER PT J AU Abreu, MT Palladino, AA Arnold, ET Kwon, RS McRoberts, JA AF Abreu, MT Palladino, AA Arnold, ET Kwon, RS McRoberts, JA TI Resiliency of a model human intestinal epithelium to Fas-mediated apoptotic injury, evidence for junctional restructuring in its repair. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 4264 BP A802 EP A803 PN 1 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783703277 ER PT J AU Dominitz, JA Koepsell, TD Boyko, EJ AF Dominitz, JA Koepsell, TD Boyko, EJ TI Association between analgesic use and inflammatory bowel disease (IBD) flares: A retrospective cohort study. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 7 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3024 BP A581 EP A581 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702388 ER PT J AU El-Serag, HB Mason, AC AF El-Serag, HB Mason, AC TI Risk factors for the rising rates of hepatocellular carcinoma in the United States. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Houston VAMC, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ New Mexico, Albuquerque, NM 87131 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3792 BP A693 EP A693 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702829 ER PT J AU El-Serag, HB Everhart, JE AF El-Serag, HB Everhart, JE TI Improved survival following esophageal variceal hemorrhage in the department of veterans affairs (VA). SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Houston VAMC, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NIDDKD, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 1220 BP A192 EP A192 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700770 ER PT J AU Gopal, DV Rabkin, J Berk, BS Corless, CL Olyaei, A Orloff, SL Rosen, HR AF Gopal, DV Rabkin, J Berk, BS Corless, CL Olyaei, A Orloff, SL Rosen, HR TI Treatment of progressive HCV recurrence post liver transplantation with combination interferon plus ribavirin. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 1157 BP A996 EP A996 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783704054 ER PT J AU Gukovskaya, AS Mouria, M Jung, Y Zaninovic, V Pandol, SJ AF Gukovskaya, AS Mouria, M Jung, Y Zaninovic, V Pandol, SJ TI Intracellular mechanisms of CCK-induced apoptosis in pancreatic acinar cells. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 898 BP A156 EP A156 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700630 ER PT J AU Gukovsky, I Blinman, TA Mouria, M Zaninovic, V Livingston, E Pandol, SJ Gukovskaya, AS AF Gukovsky, I Blinman, TA Mouria, M Zaninovic, V Livingston, E Pandol, SJ Gukovskaya, AS TI p38 map kinase is a key regulator of cytokine and chemokine expression in pancreatic acinar cells. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 899 BP A157 EP A157 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700631 ER PT J AU Jensen, DM Ho, S Hamamah, S Frankl, H Faigel, D DeMarco, D Chitayat, R Jensen, ME Alofaituli, G Fontana, L Cheng, S Lam, F AF Jensen, DM Ho, S Hamamah, S Frankl, H Faigel, D DeMarco, D Chitayat, R Jensen, ME Alofaituli, G Fontana, L Cheng, S Lam, F TI A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDs. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Med Ctr, Minneapolis, MN USA. Kaiser Permanente, Panorama City, CA USA. Kaiser Permanente, Los Angeles, CA USA. VA Med Ctr, Portland, OR USA. Baylor Univ, Med Ctr, Dallas, TX USA. Columbia W Hills Med Ctr, W Hills, CA USA. Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 4931 BP A892 EP A892 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783703627 ER PT J AU Kearney, DJ Brousal, A AF Kearney, DJ Brousal, A TI Retreatment of Helicobacter pylori non-responders. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 5745 BP A1255 EP A1255 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RY UT WOS:000086784100819 ER PT J AU Kuldau, JG Corless, C Wildes, JW Magilner, M Lieberman, DA Fennerty, MB Faigel, DO AF Kuldau, JG Corless, C Wildes, JW Magilner, M Lieberman, DA Fennerty, MB Faigel, DO TI Comparison of gastritis grading scales for the diagnosis of Helicobacter pylori (HP) infection. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. OHSU, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3825 BP A698 EP A698 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702849 ER PT J AU Kuratani, K Tache, Y AF Kuratani, K Tache, Y TI Vagal stimulation of gastric secretion by intracisternal RX77368: Modulation by central NMDA or AMPA/kainate receptors in anesthetized rats. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 VA Greater LA Heathcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, DDRC, CURE, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 2360 BP A431 EP A431 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783701763 ER PT J AU Lembo, T Robson, K Zaman, MS Gralnek, IM AF Lembo, T Robson, K Zaman, MS Gralnek, IM TI The long-term clinical outcome and impact of nonspecific esophageal motility disorders. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Beth Israel Med Ctr, Boston, MA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 5448 BP A1185 EP A1185 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RY UT WOS:000086784100522 ER PT J AU McDonald, MJ Longnecker, DS Moonka, R Robinson, L Bell, RH AF McDonald, MJ Longnecker, DS Moonka, R Robinson, L Bell, RH TI Hypergastrinemia induced by proton pump inhibitor (PPI) causes pancreatic growth but does not promote pancreatic carcinogenesis. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Madigan Army Med Ctr, Tacoma, WA 98431 USA. Dartmouth Med Sch, Lebanon, NH USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 2296 BP A1042 EP A1042 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783704240 ER PT J AU Mouria, M Gukovskaya, AS Pandol, SJ AF Mouria, M Gukovskaya, AS Pandol, SJ TI Mechanisms of the effects of food polyphenolic compounds on apoptosis in pancreatic cancer cells. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 2843 BP A538 EP A538 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702207 ER PT J AU Okolo, CN Bronner, MP Nguyen, TD AF Okolo, CN Bronner, MP Nguyen, TD TI Mast cell recruitment in chronic pancreatitis. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3312 BP A652 EP A652 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702675 ER PT J AU Provenzale, D Gralnek, I Ofman, J Rabeneck, L Koff, R AF Provenzale, D Gralnek, I Ofman, J Rabeneck, L Koff, R TI Gastroenterologist specialist care is effective and cost-effective compared to care provided by generalists. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Duke Univ, Med Ctr, Durham VA Med Ctr, Durham, NC USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. ZYNX Hlth Inc, Beverly Hills, CA USA. VA Med Ctr, Houston, TX USA. Columbia Metrowest Med Ctr, Framingham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 5061 BP A1093 EP A1093 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RY UT WOS:000086784100126 ER PT J AU Rabeneck, L Wristers, K Campbell, CJ Souchek, J Menke, T Wray, N AF Rabeneck, L Wristers, K Campbell, CJ Souchek, J Menke, T Wray, N TI Dyspepsia patients are not all the same: Differences between VA and private practice settings. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3919 BP A719 EP A719 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702932 ER PT J AU Sampliner, RE Faigel, DO Lieberman, DA Fennerty, MB Ippoliti, AF Lewin, KJ Weinstein, WM AF Sampliner, RE Faigel, DO Lieberman, DA Fennerty, MB Ippoliti, AF Lewin, KJ Weinstein, WM TI Reversal of Barrett's esophagus with high dose omeprazole and electrocoagulation 6 month follow-up. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 So Arizona VA Hlth Care Syst, Tucson, AZ USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 1370 BP A228 EP A228 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700918 ER PT J AU Tamori, K Yuan, PQ Yang, H Miampamba, M Kuratani, K Tache, Y AF Tamori, K Yuan, PQ Yang, H Miampamba, M Kuratani, K Tache, Y TI Peripheral CRF inhibits cold restraint-induced activation of Fos expression in the gastric duodenal myenteric plexus in rats. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, DDRC, CURE, Los Angeles, CA USA. VA Greater LA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 598 BP A81 EP A81 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700332 ER PT J AU Targownik, L Gralnek, IM Dulai, GS Oei, T Chang, D Alofaituli, G Bernstein, CN AF Targownik, L Gralnek, IM Dulai, GS Oei, T Chang, D Alofaituli, G Bernstein, CN TI Do persons with acute, non-variceal upper gi hem hemorrhage (UGIH) require admission to an icu/monitored bed? Comparison of a Canadian and US center. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Manitoba, Winnipeg, MB, Canada. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 4935 BP A893 EP A893 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783703631 ER PT J AU Vaquero, E Gukovsky, I Zaninovic, V Gukovskaya, AS Pandol, SJ AF Vaquero, E Gukovsky, I Zaninovic, V Gukovskaya, AS Pandol, SJ TI Upregulation of transcription factors and cytokine mRNA expression in taurocholate-induced pancreatitis. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 3316 BP A653 EP A653 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783702679 ER PT J AU Vaquero, E Gukovskaya, AS Brennan, ML Lusis, AJ Holland, SM Pandol, SJ AF Vaquero, E Gukovskaya, AS Brennan, ML Lusis, AJ Holland, SM Pandol, SJ TI Leukocyte NADPH oxidase but not myeloperoxidase regulates pancreatic trypsin activation in cerulein induced pancreatitis. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NIAID, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 956 BP A170 EP A170 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783700688 ER PT J AU Yen, TW Zhou, W Bell, RH AF Yen, TW Zhou, W Bell, RH TI The gastrin receptor promotes pancreatic growth: Initial studies in a novel transgenic mouse. SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2000 VL 118 IS 4 SU 2 MA 2386 BP A1053 EP A1053 PN 1 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 309RU UT WOS:000086783704284 ER PT J AU Ayub, K Qureshi, W Brown, R Cole, RA Graham, DY AF Ayub, K Qureshi, W Brown, R Cole, RA Graham, DY TI Pulsed irrigation evacuation: A better technique for colon cleansing? SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 VA Med Ctr, Houston, TX USA. NR 0 TC 1 Z9 1 U1 2 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 3423 BP AB88 EP AB88 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300117 ER PT J AU Bjorkman, DJ Zaman, A Fennerty, MB Lieberman, DA DiSario, JA AF Bjorkman, DJ Zaman, A Fennerty, MB Lieberman, DA DiSario, JA TI Preliminary results of a multicenter randomized trial of urgent vs. elective endoscopy in acute nonvariceal upper GI bleeding (UGIB). SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Utah, Salt Lake City, UT USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 3571 BP AB129 EP AB129 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300265 ER PT J AU Chang, KJ Angelov, FA Coleman, JA Wiersema, MJ Gress, FG Faigel, DO Das, A Kochman, ML Catalano, MF Gerdes, H Bhutani, MS Carrougher, JG AF Chang, KJ Angelov, FA Coleman, JA Wiersema, MJ Gress, FG Faigel, DO Das, A Kochman, ML Catalano, MF Gerdes, H Bhutani, MS Carrougher, JG TI A prospective, multi-center comparison between the relative work of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) - An American endosonography committee study. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Calif Irvine, Med Ctr, Orange, CA USA. Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. Winthrop Univ Hosp, Mineola, NY 11501 USA. Portland VA Med Ctr, Portland, OR USA. Univ Hosp Cleveland, Cleveland, OH 44106 USA. Univ Penn, Hlth Syst, Philadelphia, PA 19104 USA. St Lukes Med Ctr, Milwaukee, WI USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Florida, Gainesville, FL USA. Tacoma Digest Dis Ctr, Tacoma, WA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 4592 BP AB177 EP AB177 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300433 ER PT J AU Dulai, GS T, OT Dong, C Alofaituli, G Gralnek, IM AF Dulai, GS T, OT Dong, C Alofaituli, G Gralnek, IM TI Over utilization of healthcare resources for low-risk patients with acute, non-variceal upper GI hemorrhage (UGIH): A retrospective cohort study. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 3572 BP AB129 EP AB129 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300266 ER PT J AU Faigel, DO Lieberman, DA Weinstein, WM Fanning, S Sampliner, RE Fennerty, MB AF Faigel, DO Lieberman, DA Weinstein, WM Fanning, S Sampliner, RE Fennerty, MB TI Squamous overgrowth of Barrett's metaplasia after multipolar electrocoagulation (MPEC) is not a widespread phenomenon: An endoscopic ultrasound study. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. Univ Calif Los Angeles, Hlth Sci Ctr, Los Angeles, CA USA. Univ Arizona, Tucson, AZ USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 6947 BP AB227 EP AB227 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300612 ER PT J AU Gopal, DV Faigel, DO de Garmo, P AF Gopal, DV Faigel, DO de Garmo, P TI Physician resource utilization for endoscopic ultrasound vs. ERCP. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Cori Res Grp, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 4577 BP AB172 EP AB172 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300418 ER PT J AU Jensen, DM Kovacs, TO Jutabha, R Machicado, GA Gralnek, IM Savides, TJ Smith, J Lam, F Fontana, L Cheng, S Jensen, ME Alofaituli, G AF Jensen, DM Kovacs, TO Jutabha, R Machicado, GA Gralnek, IM Savides, TJ Smith, J Lam, F Fontana, L Cheng, S Jensen, ME Alofaituli, G TI Randomized, controlled trial of medical therapy compared with endoscopic therapy for prevention of recurrent ulcer hemorrhage in patients with non-bleeding adherent clots. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. Oschner Fdn, New Orleans, LA USA. RI smith, james/C-9922-2016 NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 4461 BP AB141 EP AB141 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300302 ER PT J AU Jensen, DM Kovacs, TO Jutabha, P Gralnek, IM Machicado, GA Savides, TJ Smith, J Cheng, S Fontana, L Lam, F Jensen, ME Gornbein, J AF Jensen, DM Kovacs, TO Jutabha, P Gralnek, IM Machicado, GA Savides, TJ Smith, J Cheng, S Fontana, L Lam, F Jensen, ME Gornbein, J TI Randomized, prospective study of bipolar coagulation alone compared to combination epinephrine injection and bipolar coagulation for prevention of rebleeding from ulcers with non-bleeding visible vessels. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. USCD Med Ctr, San Diego, CA USA. Oschner Clin, New Orleans, LA USA. Univ Calif Los Angeles, Hlth Sci Ctr, Los Angeles, CA USA. RI smith, james/C-9922-2016 NR 0 TC 5 Z9 5 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 3576 BP AB130 EP AB130 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300270 ER PT J AU Machicado, GA Jensen, DM Hirabayashi, K AF Machicado, GA Jensen, DM Hirabayashi, K TI Randomized double blind study of efficacy and safety of ethanolamine-alcohol mixtures or morrhuate for hemostasis of bleeding canine gastric varices. SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2000 VL 51 IS 4 MA 3544 BP AB122 EP AB122 PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 313PD UT WOS:000087007300238 ER PT J AU Kaufman, KM Farris, AD Gross, JK Kirby, MY Harley, JB AF Kaufman, KM Farris, AD Gross, JK Kirby, MY Harley, JB TI Characterization and genomic sequence of the murine 60 kD Ro gene SO GENES AND IMMUNITY LA English DT Article DE 60 kD Ro; lupus; SSA; Sjogren's syndrome; chromosome 1; mapping; chromosomal assignment ID SYSTEMIC LUPUS-ERYTHEMATOSUS; 60-KDA RO; SS-A/RO; MICE; AUTOIMMUNITY; MOUSE; AUTOANTIGEN; SPECIFICITY; LOCI; DNA AB Autoantibodies binding 60 kD Ro (or SS-A) are commonly found in patients with systemic lupus erythematosus and Sjogren's syndrome. While many studies have examined the autoimmune response directed against this RNA-protein, its function is still uncertain. As part of a broad effort to better understand animal models of anti-Ro autoimmunity we have characterized the murine 60 kD Ro gene. Southern blot analysis of mouse genomic DNA suggests that the 60 kD Ro gene is a single copy gene. The complete sequence of the gene was determined from three overlapping genomic lambda phage clones (GenBank accession number AF065398). The murine 60 kD Ro gene spans similar to 23 kb and consists of 8 or 9 exons. DNA sequence analysis revealed the presence of multiple B1 repetitive units. It maps in synteny with the human 60 kD Ro gene. Therefore, the isolation and characterization of the 60 kD Ro gene will be instrumental for future studies on protein function and the role this protein plays in the development of autoimmune responses. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. RP Kaufman, KM (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NIAID NIH HHS [AI31584, AI24717]; NIAMS NIH HHS [AR42460, AR42474]; NIGMS NIH HHS [GM08237] NR 28 TC 2 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD APR PY 2000 VL 1 IS 4 BP 265 EP 270 DI 10.1038/sj.gene.6363675 PG 6 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 342UA UT WOS:000088662500004 PM 11196703 ER PT J AU Kerr, EA Mittman, BS Hays, RD Zemencuk, JK Pitts, J Brook, RH AF Kerr, EA Mittman, BS Hays, RD Zemencuk, JK Pitts, J Brook, RH TI Associations between primary care physician satisfaction and self-reported aspects of utilization management SO HEALTH SERVICES RESEARCH LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the Association-for-Health-Services-Research CY JUN 27-29, 1999 CL CHICAGO, ILLINOIS SP Assoc Hltht Serv Res DE utilization management; utilization review; physician satisfaction; capitation ID QUALITY AB Objective. To evaluate the association between physician-reported utilization management (UM) techniques in capitated physician groups and physician satisfaction with capitated care. Study Setting. 1,138 primary care physicians from 89 California capitated physician groups in 1995. Study Design. Eighty percent of physicians (N = 910) responded to a mail survey regarding the UM policies in their groups and their satisfaction with the care they deliver. Physician-reported UM strategies measured included group-mandated preauthorization (number of referrals requiring preauthorization, referral denial rate, and referral turnaround time), group-provided explicit practice guidelines, and group-delivered educational programs regarding capitated care. We also measured two key dimensions of satisfaction with capitated care (multi- item scales): (1) satisfaction with capitated care autonomy and quality, and (2) satisfaction with administrative burden for capitated patients. Extraction Methods. We constructed two multivariate linear regression models to examine associations between physician-reported UM strategies and physician satisfaction, controlling for demographic and practice characteristics and adjusting for clustering. Principal Findings. Physician-reported denial rate and turnaround time were significantly negatively associated with capitated care satisfaction. Physicians who reported that their groups provided more guidelines were more satisfied on both dimensions, while physicians who reported that their groups sponsored more educational programs were more satisfied with administrative burden. The number of clinical decisions requiring preauthorization was not significantly associated with either dimension of satisfaction. Conclusions. Physicians who reported that their groups used UM methods that directly affected their autonomy (high denial rates and long turnaround times) were less satisfied with care for capitated patients. However, a preauthorization policy for referrals or tests was not, in and of itself, associated with satisfaction. Indirect control mechanisms such as guidelines and education were positively associated with satisfaction. C1 VA Ctr Practice Management & Outcomes Res, Ann Arbor, MI 48113 USA. Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. VA Greater Los Angeles Healthcare Syst, VA Ctr Hlth Care Provider Behav, Sepulveda, CA USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Pfizer Hlth Solut, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Kerr, EA (reprint author), VA Ctr Practice Management & Outcomes Res, POB 130170, Ann Arbor, MI 48113 USA. RI Hays, Ronald/D-5629-2013 NR 23 TC 17 Z9 17 U1 0 U2 3 PU HEALTH ADMINISTRATION PRESS PI MELROSE PARK PA C/O FOUNDATION AMER COLL HEALTHCARE EXECUTIVES 1951 CORNELL AVE, MELROSE PARK, IL 60160 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2000 VL 35 IS 1 BP 333 EP 349 PN 2 PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 302RC UT WOS:000086378200013 PM 10778819 ER PT J AU Haake, DA Chao, G Zuerner, RL Barnett, JK Barnett, D Mazel, M Matsunaga, J Levett, PN Bolin, CA AF Haake, DA Chao, G Zuerner, RL Barnett, JK Barnett, D Mazel, M Matsunaga, J Levett, PN Bolin, CA TI The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection SO INFECTION AND IMMUNITY LA English DT Article ID INTERROGANS SEROVAR HARDJO; TREPONEMA-PALLIDUM; SEQUENCE-ANALYSIS; PATHOGENIC LEPTOSPIRA; MOLECULAR-CLONING; BOVIS INFECTION; BORRELIA-BURGDORFERI; GENE; VACCINATION; IMMUNOGEN AB We report the cloning of the gene encoding the 32-kDa lipoprotein, designated LipL32, the most prominent protein in the leptospiral protein profile. We obtained the N-terminal amino acid sequence of a staphylococcal V8 proteolytic-digest fragment to design an oligonucleotide probe. A Lambda-Zap II library containing EcoRI fragments of Leptospira kirschneri DNA was screened, and a 5.0-kb DNA fragment which contained the entire structural lipL32 gene was identified. Several lines of evidence indicate that LipL32 is lipid modified in a manner similar to that of other procaryotic lipoproteins. The deduced amino acid sequence of LipL32 would encode a 272-amino-acid poly-peptide with a 19-amino-acid signal peptide, followed by a lipoprotein signal peptidase cleavage site. LipL32 is intrinsically labeled during incubation of L. kirschneri in media containing [H-3]palmitate. The linkage of palmitate and the amino-terminal cysteine of LipL32 is acid labile, LipL32 is completely solubilized by Triton X-114 extraction of L. kirschneri; phase separation results in partitioning of LipL32 exclusively into the hydrophobic, detergent phase, indicating that it is a component of the leptospiral outer membrane. CaCl2 (20 mM) must be present during phase separation for recovery of LipL32. LipL32 is expressed not only during cultivation but also during mammalian infection. Immunohistochemistry demonstrated intense LipL32 reactivity with L. kirshneri infecting proximal tubules of hamster kidneys. LipL32 is also a prominent immunogen during human leptospirosis. The sequence and expression of LipL32 is highly conserved among pathogenic Leptospira species. These findings indicate that LipL32 my be important in the pathogenesis, diagnosis, and prevention of Leptospirosis. C1 VA Greater LA Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA. ARS, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA. Univ So Indiana, Dept Biol, Evansville, IN 47712 USA. Univ W Indies, Sch Clin Med & Res, Bridgetown, Barbados. RP VA Greater LA Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [AI-34431, R01 AI034431, R21 AI034431, R29 AI034431, R29 AI034431-04] NR 42 TC 258 Z9 321 U1 3 U2 14 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD APR PY 2000 VL 68 IS 4 BP 2276 EP 2285 DI 10.1128/IAI.68.4.2276-2285.2000 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 296EP UT WOS:000086010300071 PM 10722630 ER PT J AU Tsai, EC Boyko, EJ Leonetti, DL Fujimoto, WY AF Tsai, EC Boyko, EJ Leonetti, DL Fujimoto, WY TI Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE testosterone; visceral adiposity; body fat distribution; diabetes mellitus; insulin resistance; Japanese Americans; computed tomography ID HORMONE-BINDING-GLOBULIN; DEPENDENT DIABETES-MELLITUS; FASTING PLASMA-INSULIN; C-PEPTIDE LEVELS; ADIPOSE-TISSUE; OBESE MEN; COMPUTED-TOMOGRAPHY; GLUCOSE-TOLERANCE; SEX-HORMONES; RISK-FACTORS AB OBJECTIVE: To examine the association between baseline testosterone levels and changes in visceral adiposity in Japanese-American men. DESIGN: Prospective observational study. SUBJECTS: Second-generation Japanese-American males enrolled in a community-based population study. MEASUREMENTS: At baseline, 110 men received a 75 g oral glucose tolerance test (OGTT), and an assessment of body mass index (BMI); visceral adiposity measured as intra-abdominal fat area (IAF) using computed tomography (CT); fasting insulin and C-peptide levels; and total testosterone levels. IAF was re-measured after 7.5 y. Subcutaneous fat areas were also measured by CT in the abdomen, thorax and thigh. The total fat (TF) was calculated as the sum of IAF and total subcutanous fat areas (SCF). RESULTS: After 7.5 y, IAF increased by a mean of 8.0 cm(2) (95% CI: 0.8, 15.3). Baseline total testosterone was significantly correlated with change in IAF (r = -0.26, P = 0.006), but not to any appreciable degree with change in BMI, TF, or SCF. In a linear regression model with change in IAF as the dependent variable, baseline testosterone was significantly related to this outcome while adjusting for baseline IAF, SCF:, BMI, age, diabetes mellitus status (OGTT by the WHO diagnostic criteria) and fasting C-peptide (regression coefficient for baseline testosterone [nmol/l] = -107.13, P = 0.003). CONCLUSIONS: In this Japanese-American male cohort, lower baseline total testosterone independently predicts an increase in IAF. This would suggest that by predisposing to an increase in visceral adiposity, low levels of testosterone may increase the risk of type 2 diabetes mellitus. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. Seattle Epidemiol Res & Informat Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Tsai, EC (reprint author), VAMC, HSR&D 152,1660 S Columbian Way, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [RR 00037]; NHLBI NIH HHS [HL 49293]; NIDDK NIH HHS [DK 31170] NR 51 TC 107 Z9 127 U1 0 U2 6 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD APR PY 2000 VL 24 IS 4 BP 485 EP 491 DI 10.1038/sj.ijo.0801183 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 300RR UT WOS:000086266400013 PM 10805506 ER PT J AU Nguyen, T Shrager, J Kaiser, L Mei, LJ Daood, M Watchko, J Rubinstein, N Levine, S AF Nguyen, T Shrager, J Kaiser, L Mei, LJ Daood, M Watchko, J Rubinstein, N Levine, S TI Developmental myosin heavy chains in the adult human diaphragm: coexpression patterns and effect of COPD SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE human diaphragmatic muscle; embryonic myosin heavy chain; neonatal myosin heavy chain; fiber types; immunocytochemistry ID RAT SKELETAL-MUSCLE; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN MASSETER MUSCLE; ELECTROPHORETIC SEPARATION; CONTRACTILE PROPERTIES; CELLULAR ADAPTATIONS; RESPIRATORY MUSCLES; NORMAL MEN; FATIGUE; ISOFORMS AB In preliminary experiments we noted developmental (i.e., embryonic and neonatal) myosin heavy chains (MHCs) in the diaphragms of patients with severe chronic obstructive pulmonary disease (COPD). We hypothesized that this finding represented new fiber formation secondary to injury associated with the mechanical stress of COPD or previously undescribed MHCs in the human diaphragm. To distinguish between these possibilities, me analyzed diaphragmatic biopsies obtained from 9 patients with severe COPD (forced expiratory volume in 1 s = 21 +/- 2% predicted, residual volume = 283 +/- 22% predicted) and 10 age-matched controls. First, using immunocytochemistry with specific monoclonal antibodies, we noted that control diaphragms had greater proportions of fibers expressing embryonic (50 +/- 2 vs. 28 +/- 3%, P < 0.0001) and neonatal (52 +/- 2 vs. 32 +/- 3%, P < 0.001) MHCs than COPD diaphragms. Second, SDS-PAGE demonstrated that these developmental MHCs represented only a very small fraction of the diaphragmatic MHC content. Third, the RT-PCR demonstrated mRNA coding for embryonic and neonatal MHCs in COPD and control diaphragms. Last, COPD and control diaphragms exhibited normal histology on light microscopy. We conclude that the presence of developmental MHC isoforms does not indicate new fiber formation in diaphragms of patients with severe COPD. Although these results represent the first systematic description of embryonic and neonatal MHCs in normal adult human diaphragms, their function remains to be elucidated. C1 Philadelphia Vet Affairs Med Ctr, Med Serv, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Pediat, Pittsburgh, PA 15213 USA. Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Res Serv, Philadelphia, PA 19104 USA. RP Levine, S (reprint author), VA Med Ctr, Pulm & Crit Care Sect 111P, Univ & Woodland Ave, Philadelphia, PA 19004 USA. NR 53 TC 26 Z9 28 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD APR PY 2000 VL 88 IS 4 BP 1446 EP 1456 PG 11 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 301MA UT WOS:000086312900040 PM 10749841 ER PT J AU Attorri, S Dunbar, S Clarridge, JE AF Attorri, S Dunbar, S Clarridge, JE TI Assessment of morphology for rapid presumptive identification of Mycobacterium tuberculosis and Mycobacterium kansasii SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CORD FORMATION; COMPLEX; CULTURES; PROBES AB Mycobacterium tuberculosis often exhibits serpentine cording when grown in liquid medium, whereas Mycobacterium kansasii can be larger and cross-barred, We assessed the use of these morphologic characteristics as a cost-effective method for rapid presumptive identification of isolates from BACTEC bottles. Without specific training, using the Kinyoun acid-fast stain, definitive cording was found in 237 of 373 specimens positive for M. tuberculosis (64%) and cross-barring was recognized within 63 of 76 (83%) of the specimens positive for M. kansasii, giving sensitivities specificities, positive predictive values, and negative predictive values of 63.5, 96, 92, and 79%, respectively, for M. tuberculosis and 83, 95, 59, and 98%, respectively, for M kansasii. With training and experience, these results improved to 74.5, 98, 96, and 84% and 93, 98, 79, and 98%, respectively. The major improvements were in distinguishing the pseudocording or loose aggregation of Mycobacterium avium complex from M. tubereculosis and the long bended forms of Mycobacterium gordonae from M. kansasii. Mycobacterium asiaticum and Mycobacterium szulgai, which rarely occur, are genetically related to M kansasii and morphologically difficult to distinguish. In defined circumstances, serpentine cording and cross-barring can be used for rapid presumptive identification of M. tuberculosis and M. kansasii, respectively, and as guides for initial probe selection to reduce costs. C1 VA Med Ctr, Pathol & Lab Med Serv 113, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA. RP Clarridge, JE (reprint author), VA Med Ctr, Pathol & Lab Med Serv 113, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 8 TC 17 Z9 17 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2000 VL 38 IS 4 BP 1426 EP 1429 PG 4 WC Microbiology SC Microbiology GA 301GN UT WOS:000086302500020 PM 10747119 ER PT J AU Caroff, SN Mann, SC Keck, PE Francis, A AF Caroff, SN Mann, SC Keck, PE Francis, A TI Residual catatonic state following neuroleptic malignant syndrome SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article AB Neuroleptic malignant syndrome (NMS) is usually a self-limited disorder, with most cases resolving within 2 weeks after antipsychotic drug discontinuation. However, the course of NMS may not always be short-lived. In this report, the authors describe five patients who developed a residual catatonic state that persisted after acute hyperthermic symptoms of NMS had subsided and compare them with 27 similar cases in the literature. Two of our patients recovered gradually with supportive treatment. Three patients were treated with electroconvulsive therapy (ECT). Of these, two showed a positive response, although one died later of intercurrent pneumonia. A third patient did not respond to ECT, but recovered gradually thereafter. Although dopamine agonists or benzodiazepines have been advocated for the treatment of residual symptoms in previous case reports, ECT was the treatment most often associated with a. rapid response and no mortality, even in patients refractory to pharmacotherapy. In conclusion, catatonic and parkinsonian symptoms of NMS may persist as a residual state lasting for weeks to months after more fulminant acute symptoms abate. These residual symptoms may be more Likely to develop in patients with preexisting structural brain disorders. Although patients may improve gradually with supportive care or pharmacotherapy, ECT can often be highly effective in treating the residual catatonic state that follows NMS. C1 Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Cincinnati, Coll Med, Dept Psychiat, Biol Psychiat Program, Cincinnati, OH USA. SUNY Stony Brook, Sch Med, Dept Psychiat, Stony Brook, NY 11794 USA. RP Caroff, SN (reprint author), Dept Vet Affairs Med Ctr, 116A Univ Ave, Philadelphia, PA 19104 USA. NR 26 TC 39 Z9 40 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2000 VL 20 IS 2 BP 257 EP 259 DI 10.1097/00004714-200004000-00021 PG 3 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 301GR UT WOS:000086302800021 PM 10770467 ER PT J AU Faber, RA Benzick, JM AF Faber, RA Benzick, JM TI Nefazodone-induced palinopsia SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Letter ID LSD C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. USAF, Med Ctr, Lackland AFB, TX 78236 USA. RP Faber, RA (reprint author), Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 9 TC 12 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2000 VL 20 IS 2 BP 275 EP 276 DI 10.1097/00004714-200004000-00030 PG 2 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 301GR UT WOS:000086302800030 PM 10770476 ER PT J AU Clever, SL Edwards, KA Feudtner, C Braddock, CH AF Clever, SL Edwards, KA Feudtner, C Braddock, CH TI Defining the "hidden curriculum": Does medical students' ethical experience on clinical rotations vary by specialty? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, RWJ Clin Scholars, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 28 EP 28 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400022 ER PT J AU Taneda, K Boyko, EJ Martin, DC Fihn, SD Itoh, H Ohbu, S Fukui, T Matsui, Y AF Taneda, K Boyko, EJ Martin, DC Fihn, SD Itoh, H Ohbu, S Fukui, T Matsui, Y TI The impact of autopsies on clinical education of residents. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Kyoto Univ Hosp, Kyoto 606, Japan. St Lukes Int Hosp, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 46 EP 46 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400102 ER PT J AU Burman, ML McDonell, MB Fihn, SD Bradley, KA AF Burman, ML McDonell, MB Fihn, SD Bradley, KA TI Determinants of alcohol advice or treatment among at-risk drinkers in the outpatient setting. Results from the ACQUIP study. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Ctr Excellence, HSR&D, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 56 EP 56 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400143 ER PT J AU Herndon, B Kilbourne, AM Wang, M Lee, M Asch, S Andersen, R Gelberg, L AF Herndon, B Kilbourne, AM Wang, M Lee, M Asch, S Andersen, R Gelberg, L TI HIV testing among high-risk homeless women - Good news from Los Angeles County. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 70 EP 70 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400203 ER PT J AU Kolbusz, KM Elicler, IA Kaur, J Mak, EB Collins, D AF Kolbusz, KM Elicler, IA Kaur, J Mak, EB Collins, D TI Effectiveness of exercise demonstration for arthritis patients. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 LUMC, Maywood, IL USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 77 EP 78 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400234 ER PT J AU Lawrence, VA Hilsenbeck, SG Noveck, H Poses, RM Carson, JL AF Lawrence, VA Hilsenbeck, SG Noveck, H Poses, RM Carson, JL TI Medical complications after hip fracture repair. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. Brown Univ, Providence, RI 02912 USA. Vet Adm Med Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 79 EP 79 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400241 ER PT J AU Micek, MA Braddock, CH Bradley, KA Martin, D McDonell, MB Fihn, SD AF Micek, MA Braddock, CH Bradley, KA Martin, D McDonell, MB Fihn, SD TI The relationship between patient satisfaction and health related beliefs. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Dept Med, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Ctr Excellence, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 83 EP 84 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400260 ER PT J AU Natarajan, S Bradford, WD Kleckley, TV Silverstein, MD AF Natarajan, S Bradford, WD Kleckley, TV Silverstein, MD TI Independent effects of cardiovascular disease and diabetes on acute health care utilization and health status. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Ralph H Johnson VAMC, Charleston, SC USA. Med Univ S Carolina, Div Gen Internal Med, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 87 EP 87 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400275 ER PT J AU Natarajan, S Nietert, PJ Kleckley, TV Silverstein, MD AF Natarajan, S Nietert, PJ Kleckley, TV Silverstein, MD TI Impact of multiple cardiovascular risk factors on acute health care utilization and health status. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Ralph H Johnson VAMC, Charleston, SC USA. Med Univ S Carolina, Div Gen Internal Med, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 87 EP 87 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400276 ER PT J AU Badgett, RG Mulrow, CD Levy, LS Arterburn, J AF Badgett, RG Mulrow, CD Levy, LS Arterburn, J TI Observations on how clincians use SUMsearch. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 99 EP 99 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400327 ER PT J AU Braddock, CH Edwards, KA Micek, M Levinson, W AF Braddock, CH Edwards, KA Micek, M Levinson, W TI What factors predict physician involvement of patients in clinical decisions? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA. Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. VA Puget Sound, Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 104 EP 104 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400345 ER PT J AU Geraci, JM Johnson, ML Gordon, HS Petersen, NJ Daley, J Hur, K Henderson, WG Khurl, SF Wray, NP AF Geraci, JM Johnson, ML Gordon, HS Petersen, NJ Daley, J Hur, K Henderson, WG Khurl, SF Wray, NP TI Mortality after non-cardiac surgery: Prediction from administrative versus clinical data. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Houston VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. MGH Partners HealthCare Syst, Inst Hlth Policy, Boston, MA USA. Hines VA Med Ctr, VA Cooperat Studies Program, Hines, IL USA. W Roxbury VA Med Ctr, Surg Serv, W Roxbury, MA USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 116 EP 116 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400399 ER PT J AU Groeneveld, PW AF Groeneveld, PW TI A cost-effectiveness comparison of the cyclooxygenase-1-sparing agents celecoxib and rofecoxib with three other strategies for high-dose nonsteroidal anti-inflammatory drug therapy. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 120 EP 120 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400413 ER PT J AU Hickam, DH Joos, SK AF Hickam, DH Joos, SK TI Effect of a primary care delivery model on satisfaction with medical care among young adult patients. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Portland VA Med Ctr, HSR&D Program, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 121 EP 121 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400419 ER PT J AU Jacobs, BP Lee, M Patterson, M Avins, A AF Jacobs, BP Lee, M Patterson, M Avins, A TI Personal use and prescribing patterns of complementary and alternative medicine among university physicians. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 123 EP 123 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400427 ER PT J AU Jacobs, BP Lee, M Patterson, M Avins, A AF Jacobs, BP Lee, M Patterson, M Avins, A TI Personal use and prescribing patterns of alternative medicine among university physicians. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 123 EP 123 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400426 ER PT J AU Weisbord, S Whittle, J Brooks, R AF Weisbord, S Whittle, J Brooks, R TI Why don't patients with atrial fibrillation receive warfarin? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 154 EP 154 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400552 ER PT J AU Winterbottom, LM Noel, GL Jackson, JA Borrego, C Snodgrass, LS Smith, DC AF Winterbottom, LM Noel, GL Jackson, JA Borrego, C Snodgrass, LS Smith, DC TI Evaluation of employee attitudes on budget-driven medical service reductions. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 155 EP 155 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400556 ER PT J AU Rosenfeld, KE Steckart, J Patterson, R AF Rosenfeld, KE Steckart, J Patterson, R TI Conceptualizing spiritual well-being: A focus group study of older adults with chronic illness. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 167 EP 167 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400608 ER PT J AU Haidet, P El Farra, R AF Haidet, P El Farra, R TI The lure of the unifying diagnosis. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 181 EP 181 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400666 ER PT J AU Lu, HD Haidet, P AF Lu, HD Haidet, P TI Conjunctivitis as a manifestation of gonococcal infection. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 189 EP 190 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400703 ER PT J AU Sutton, PR Johnson, TJ AF Sutton, PR Johnson, TJ TI Fever and delirium in a hospitalized man with Diffuse Lewy Body Dementia. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 200 EP 200 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400749 ER PT J AU Edwards, KA Braddock, CH Back, A Marshall, S AF Edwards, KA Braddock, CH Back, A Marshall, S TI Ward ethics: Building survival skills for third-year students. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Sch Med, Deans Off, Seattle, WA USA. VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 211 EP 211 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400796 ER PT J AU Haidet, P Pierrel, S Moran, B Yeoman, L AF Haidet, P Pierrel, S Moran, B Yeoman, L TI Faculty development for problem-based learning tutors through peer observation and feedback. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 213 EP 213 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400806 ER PT J AU Wade, BJ Garcia, D AF Wade, BJ Garcia, D TI Should generalists biopsy? Preliminary evaluation of a flexible sigmoidoscopy screening program. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Los Angeles VA Hlth Care Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2000 VL 15 SU 1 BP 232 EP 233 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 308CE UT WOS:000086690400885 ER PT J AU Hamner, MB Frueh, BC Ulmer, HG Huber, MG Twomey, TJ Tyson, C Arana, GW AF Hamner, MB Frueh, BC Ulmer, HG Huber, MG Twomey, TJ Tyson, C Arana, GW TI Psychotic features in chronic posttraumatic stress disorder and schizophrenia - Comparative severity SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article; Proceedings Paper CT Annual Meeting of the Anxiety-Disorders-Association-of-America CY MAR, 1999 CL SAN DIEGO, CALIFORNIA SP Anixety Disorders Assoc Amer ID AUDITORY HALLUCINATIONS; NEGATIVE SYMPTOMS; DEPRESSION; SUBTYPES AB Psychotic features are frequent in combat veterans with chronic posttraumatic stress disorder (PTSD), may correlate with severity of PTSD symptoms,;and may reflect a distinct subtype of the disorder. These psychotic features include auditory and visual hallucinations and delusional thinking that is usually paranoid in nature. Psychotic features may be under-recognized in chronic PTSD because patients are reluctant to report these symptoms and because they may not have overt changes in affect or bizarre delusions characteristic of other psychoses, e.g., schizophrenia. To further assess these phenomena, we compared clinical ratings on the Positive and Negative Syndrome Scale (PANSS) and other assessments, including the Clinical Global Impression Scale and the Structured Clinical Interview with Psychotic Screen, in veterans meeting DSM-nt criteria for chronic PTSD with well-defined comorbid psychotic features (N = 40) or chronic sckizophrenia (N = 40). The patients with schizophrenia had modestly higher composite PANSS scores and positive symptom scores although average scores in both groups were moderate to severe in intensity. Negative symptom and general psychopathology subscale scores were comparable in both groups. Regarding specific positive symptoms, hallucinations were comparable between groups in severity; however, schizophrenia patients had slightly more intense delusions and conceptual disorganization. These data further validate the occurrence of positive as well as negative symptoms of psychosis in chronic PTSD in a range of severity that may approach that of patients with schizophrenia. Although meeting DSM-IV criteria for two different major psychiatric disorders, these two patient populations were remarkably similar with respect to not only positive but also negative symptoms. C1 Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 116 Mental Hlth,109 Bee St, Charleston, SC 29401 USA. NR 26 TC 56 Z9 58 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2000 VL 188 IS 4 BP 217 EP 221 DI 10.1097/00005053-200004000-00004 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 304DQ UT WOS:000086467900004 PM 10789998 ER PT J AU Brand, JG AF Brand, JG TI Receptor and transduction processes for umami taste SO JOURNAL OF NUTRITION LA English DT Article; Proceedings Paper CT International Symposium on Glutamate CY OCT 12-14, 1998 CL BERGAMO, ITALY SP Baylor Coll Med, Univ Pittsburgh Sch Med, Ctr Nutrit, Int Glutamate Tech Comm, Monell Chem Senses Ctr, Int Union Food Sci & Technol, Mario Negri Inst Pharmacol Res DE umami; glutamate; taste; nucleotides; calcium imaging; glutamate receptor ID BEHAVIORAL DISCRIMINATION; MONOSODIUM GLUTAMATE; AMINO-ACIDS; SUBSTANCES; MICE; RESPONSES; CELLS AB The unique taste of umami argues for a specific receptor at the taste cell level. The taste synergism between monosodium glutamate (MSG) and certain 5'-ribonucleotides provides a pharmacologic test for hypothetical mechanisms of umami taste. Early neurophysiologic and biochemical studies demonstrated specific recognition of L-glutamate by taste tissue and suggested that the synergism found with certain 5'-ribonucleotides was due to a peripheral event. The search fdr a receptor for umami relies at present on the data in the literature on central nervous system (CNS) glutamate receptors. These data distinguish several classes of receptors on the bases of pharmacologic properties and mode of action. Two hypotheses now seek to explain umami taste transduction. One states that umami is transduced by an N-methyl-D-aspartate (NMDA)-type glutamate ion channel receptor, the other that this taste is transduced via a metabotropic-type glutamate receptor. Evidence for the first hypothesis derives from earlier reconstitution studies, revealing a glutamate-stimulated ion channel conductance whose kinetics were affected by 5'-ribonucleotides. Additional evidence is provided from more recent calcium-imaging and patch-clamp studies, both showing that an ionotropic-type receptor on rodent taste cells mediates glutamate-induced depolarization. Evidence for the second mechanism derives from studies that located the message for an metabotropic-type (mGluR4) receptor to rat taste buds, and from whole-cell patch-clamp recordings that revealed sustained cellular conductances to glutamate and an mGluR4 agonist. It appears likely that both mechanisms are involved in umami taste transduction, suggesting the possibility that reception and transduction of the umami signal constitute a collective property of a number of cells within the taste bud. C1 Univ Penn, Sch Dent Med, Dept Biochem, Monell Chem Senses Ctr,Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Brand, JG (reprint author), Univ Penn, Sch Dent Med, Dept Biochem, Monell Chem Senses Ctr,Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. FU NIDCD NIH HHS [DC-00356] NR 27 TC 25 Z9 26 U1 0 U2 4 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD APR PY 2000 VL 130 IS 4 SU S BP 942S EP 945S PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 300VQ UT WOS:000086274200010 PM 10736357 ER PT J AU Oslin, DW Streim, J Katz, IR Edell, WS TenHave, T AF Oslin, DW Streim, J Katz, IR Edell, WS TenHave, T TI Change in disability follows inpatient treatment for late life depression SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE depression; disability; geriatrics ID FUNCTIONAL STATUS; PRIMARY-CARE; MORTALITY; PERFORMANCE; OUTCOMES; SYMPTOMS; IMPACT; TESTS AB OBJECTIVES: The objective of this study was to examine the relationship between functional disability and improvement in late life depression after acute inpatient treatment. DESIGN: The study was a longitudinal assessment of depression and disability. Patients were assessed during an initial inpatient hospitalization and then 3 months postdischarge. SETTING: All patients were evaluated initially after admission to one of 71 inpatient psychiatric treatment facilities. PARTICIPANTS: The study comprised of 2572 patients older than age 60 who were relatively cognitively intact and experiencing significant depressive symptoms. MEASUREMENTS: Depressive symptoms were measured using the Geriatric Depression Scale. Disability was measured using the Instrumental Activities of Daily Living Scale and the Medical Outcomes SF-36. RESULTS: Depressive symptoms improved in the majority of patients. Moreover, improvement in depressive symptomatology was significantly related to improvement in instrumental activities of daily living (IADLs) and to health-related quality of life as measured by the SF-36. This relationship was strongest among those who initially presented with some disability in IADLs. CONCLUSIONS: This work underscores further the disabling nature of depression. Moreover, findings from this study suggest that treatment focused on depression can lead to significant improvements in both depressive symptoms and functional abilities. However, the results also suggest that the relationship between depression and disability is complex and that the effect of treating depression is not the only factor in the reversal of disability. C1 Univ Penn, Sect Geriat Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Study Addict, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Mental Hlth Outcomes, Lewisville, TX USA. Univ Penn, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Oslin, DW (reprint author), Univ Penn, Sect Geriat Psychiat, 3600 Market St,Room 790, Philadelphia, PA 19104 USA. FU NIMH NIH HHS [2P30 MH 52129-05] NR 24 TC 34 Z9 37 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2000 VL 48 IS 4 BP 357 EP 362 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 302LJ UT WOS:000086366300001 PM 10798459 ER PT J AU Sloss, EM Solomon, DH Shekelle, PG Young, RT Saliba, D MacLean, CH Rubenstein, LZ Schnelle, JF Kamberg, CJ Wenger, NS AF Sloss, EM Solomon, DH Shekelle, PG Young, RT Saliba, D MacLean, CH Rubenstein, LZ Schnelle, JF Kamberg, CJ Wenger, NS TI Selecting target conditions for quality of care improvement in vulnerable older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE vulnerable elders; quality of care; quality improvement ID RESIDENT ASSESSMENT INSTRUMENT; NURSING-HOME; HEALTH-CARE; POPULATION; SERVICES; DISEASE; IMPACT; FALLS; PAIN AB OBJECTIVE: To identify a set of geriatric conditions as optimal targets for quality improvement to be used in a quality measurement system for vulnerable older adults. DESIGN: Discussion and two rounds of ranking of conditions by a panel of geriatric clinical experts informed by literature reviews. METHODS: A list of 78 conditions common among vulnerable older people was reduced to 35 on the basis of their (1) prevalence, (2) impact on health and quality of life, (3) effectiveness of interventions in improving mortality and quality of life, (4) disparity in the quality of care across providers and geographic areas, and (5) feasibility of obtaining the data needed to test compliance with quality indicators. A panel of 12 experts in geriatric care discussed and then ranked the 35 conditions on the basis of the same five criteria. We then selected 21 conditions, based on panelists' iterative rankings. Using available national data, we compiled information about prevalence of the selected conditions for community-dwelling older people and older nursing home residents and estimated the proportion of inpatient and outpatient care attributable to the selected conditions. RESULTS: The 21 conditions selected as targets for quality improvement among vulnerable older adults include (in rank order): pharmacologic management; depression; dementia; heart failure; stroke (and atrial fibrillation); hospitalization and surgery; falls and mobility disorders; diabetes mellitus; end-of-life care; ischemic heart disease; hypertension; pressure ulcers; osteoporosis; urinary incontinence; pain management; preventive services; hearing impairment; pneumonia and influenza; vision impairment; malnutrition; and osteoarthritis. The selected conditions had mean rank scores from 1.2 to 3.8, and those excluded from 4.6 to 6.9, on a scale from 1 (highest ranking) to 7 (lowest ranking). Prevalence of the selected conditions ranges from 10 to 50% among community-dwelling older adults and from 25 to 80% in nursing home residents for the six most common selected conditions. The 21 target conditions account for at least 43% of all acute hospital discharges and 33% of physician office visits among persons 65 years of age and older. Actual figures must be higher because several of the selected conditions (e.g., end-of-life care) are not recorded as diagnoses. CONCLUSIONS: Twenty-one conditions were selected as targets for quality improvement in vulnerable older people for use in a quality measurement system. The 21 geriatric conditions selected are highly prevalent in this group and likely account for more than half of the care provided to this group in hospital and ambulatory settings. C1 RAND, Washington, DC 20005 USA. RAND, Santa Monica, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. RP Sloss, EM (reprint author), RAND, 1333 H St NW,Suite 800, Washington, DC 20005 USA. NR 38 TC 64 Z9 65 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2000 VL 48 IS 4 BP 363 EP 369 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 302LJ UT WOS:000086366300002 PM 10798460 ER PT J AU Liao, S Ferrell, BA AF Liao, S Ferrell, BA TI Fatigue in an older population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE fatigue; long-term care; quality of life ID SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; PRIMARY-CARE; HEALTHY-INDIVIDUALS; COMMUNITY ONCOLOGY; CANCER; CHEMOTHERAPY; PREVALENCE; EPIDEMIOLOGY; THERAPY AB OBJECTIVES: Fatigue is a common symptom that has not been studied well in the older populations. The purpose of this pilot study was to ex-amine the epidemiology of fatigue symptoms in relation to demographic and medical characteristics of older patients in a long-term care setting. DESIGN: A cross-sectional interviewer-assisted survey. PARTICIPANTS/SETTING: A total of 199 ambulatory older residents of a single residential care facility. MEASUREMENTS: Along with medical and demographic characteristics, the survey included mental status (Folstein), activities of daily living (Katz and Lawton), depression (Yesavage GDS), a 3-minute walk, a 7-item pain scale, and the modified Piper Fatigue Scale. RESULTS: One-hundred ninety-nine (65%) of 308 potential subjects completed the study (mean age 88 pears, 82% female). Of these 199 subjects, 195 (98%) reported some fatigue symptoms (median duration 44 weeks). Significant (P < .0005) relationships were found between fatigue and GDS (r = 0.57), S-minute walk (r = -0.29), Lawton IADLs (r = 0.31), pain (r = 0.36), and number of medications (r = 0.26). No significant relationships were found between fatigue and age, sex, Folstein score, or number of medical diagnoses. Multivariate regression analysis identified GDS, pain, number of medications and 3-minute walk as significant predictors of fatigue intensity (multiple R = 0.68, r(2) = 0.46, P < .02). CONCLUSIONS: Fatigue is a symptom often found among older residents of a residential facility and has important implications fur quality of life. Fatigue is poorly recognized and probably undertreated in older people. C1 Univ California, Med Ctr,Irvine Sch Med, Primary Care Med Grp, Dept Internal Med, Orange, CA 92868 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, VA Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. Ctr Geriatr Res Educ & Clin, Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. RP Liao, S (reprint author), Univ California, Med Ctr,Irvine Sch Med, Primary Care Med Grp, Dept Internal Med, 101 City Dr S,Pavil 3,2nd Floor, Orange, CA 92868 USA. NR 49 TC 80 Z9 82 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2000 VL 48 IS 4 BP 426 EP 430 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 302LJ UT WOS:000086366300013 PM 10798471 ER PT J AU Zhu, WH Guo, XD Villaschi, S Nicosia, RF AF Zhu, WH Guo, XD Villaschi, S Nicosia, RF TI Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis SO LABORATORY INVESTIGATION LA English DT Article ID MICROVASCULAR ENDOTHELIAL-CELLS; IN-VITRO; EXPRESSION; INVITRO; LOCALIZATION; PROLIFERATION; ORGANIZATION; MICROVESSELS; PROGRESSION; COLLAGENASE AB Matrix metalloproteinases (MMPs) have been implicated in the formation of microvessels during angiogenesis, but their role in vascular regression is poorly understood. The rat aorta model of angiogenesis was used to study the function of MMPs at different stages of the angiogenic process. Gelatin zymography and Western analysis demonstrated production of MMP-2 and MMP-9 by aortic outgrowths in serum-free collagen gel culture. MMP-2 was found in both culture medium and collagen gel, whereas MMP-9 was predominantly associated with the gel. MMP expression increased gradually during the angiogenic growth phase and stayed high when vessels regressed and collagen lysed around the aortic rings. The MMP inhibitors, batimastat and marimastat, blocked formation of microvessels when added to the culture medium at the beginning of the experiment. They, however, stabilized the microvessels and prevented vascular regression after the angiogenic growth phase. This effect was observed also under conditions of angiogenic stimulation by basic fibroblast growth factor. MMP inhibitor-mediated stabilization of microvessels was associated with inhibition of collagen lysis and accumulation of collagen fibrils in the subendothelial space. This study demonstrates that MMPs promote microvessel formation during the early stages of angiogenesis, but also contribute to the reabsorption of the neovasculature in the later stages of this process. The time-dependent divergent effects of MMPs on microvessel growth and survival may influence the in vivo activity of MMP inhibitors used to treat angiogenesis-dependent disorders. C1 VA Puget Sound Hlth Care Syst, Pathol & Lab Med S113 Lab, Seattle, WA 98108 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. NCI, Dept Pathol, Bethesda, MD 20892 USA. Univ Roma Tor Vergata, Dipartimento Biopatol, Rome, Italy. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol & Lab Med S113 Lab, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NHLBI NIH HHS [HL52585] NR 41 TC 78 Z9 83 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD APR PY 2000 VL 80 IS 4 BP 545 EP 555 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 307DP UT WOS:000086638200011 PM 10780671 ER PT J AU Lee, NJ Wang, SJ Durairaj, KK Srivatsan, ES Wang, MB AF Lee, NJ Wang, SJ Durairaj, KK Srivatsan, ES Wang, MB TI Increased expression of transforming growth factor-beta 1, acidic fibroblast growth factor, and basic fibroblast growth factor in fetal versus adult fibroblast cell lines SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT Meeting of the Western Section of the American-Laryngological-Rhinological-and-Otological-Society CY JAN 08-09, 2000 CL SAN FRANCISCO, CALIFORNIA SP Amer Laryngol Rhinol & Otolog Soc, Western Sect DE fibroblasts; fetal; wound-healing; growth factors; Western blot ID SKIN WOUNDS AB Objectives: Fetal wound healing occurs without scar tissue formation. Differences in growth factor expression between fetal and adult fibroblasts have been explored. Recently we used RNA expression studies to demonstrate that transforming growth fan tor (TGF)-beta 1, acidic fibroblast growth factor (alpha-FGF), and basic fibroblast growth factor (beta-FGF) could be detected in both fetal and adult fibroblast cell lines. In addition, adult fibroblasts showed greater relative expression of these growth factors than fetal fibroblasts. The aim of this study was to identify the level of protein expression in fetal and adult fibroblasts. Study Design/Methods: Fetal. and adult fibroblasts were grown in culture using standard and serum-free media. After protein extraction, Western blot studies were performed to detect the presence and amount of TGF beta-1, alpha-FGF, and beta-FGF growth factor proteins. beta-Tubulin was used as a control Results: TGF beta-1, alpha-FGF, and beta-FGF proteins were detected in fetal and adult fibroblasts grown in standard and serum-free media The fetal fibroblasts showed higher levels of all three growth factor proteins compared with the adult fibroblasts. Conclusions: Western blot studies suggest higher levels of TGF beta-1, alpha-FGF, and beta-FGF expression in fetal fibroblasts. It is clear that significant differences exist in the expression/production of these growth factors and it seems likely that further study. of these differences will help elucidate the unique healing capabilities of fetal fibroblasts. C1 Univ Calif Los Angeles, Div Head & Neck Surg, Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90024 USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, Div Head & Neck Surg, Sch Med, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA. NR 14 TC 4 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD APR PY 2000 VL 110 IS 4 BP 616 EP 619 DI 10.1097/00005537-200004000-00015 PG 4 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 301UF UT WOS:000086328100015 PM 10764007 ER PT J AU Ubel, PA Baron, J Nash, B Asch, DA AF Ubel, PA Baron, J Nash, B Asch, DA TI Are preferences for equity over efficiency in health care allocation "all or nothing"? SO MEDICAL CARE LA English DT Article DE ethics; allocation; rationing; cost-effectiveness analysis; physician survey; general public survey ID COST-EFFECTIVENESS ANALYSIS; LIVERS AB BACKGROUND. In a previous study we showed that within a budget constraint, most people would rather offer a less effective screening test to 100% of a Medicaid population, thereby saving 1,000 lives, than a more effective test to 50% of the population, thereby saving 1,100 lives. We present here a study exploring whether this preference for equity over efficiency persists when neither test can be offered to the entire population. METHODS. Members of Physicians' Online and prospective jurors at the Philadelphia County Courthouse randomly received I of 3 questionnaires (41, 42, or 43) describing a limited budget to screen Medicaid enrollees for colon cancer, In all questionnaires, test I was said to save 1,000 lives, and test 2, a more effective and more expensive test, was said to save 1;100. In 41,test I was offered to 100% and test:! to 50% of the population In 42, the 2 tests could be offered to 50% and 25%, respectively; in 43,to 90% and 40%, respectively. Respondents indicated which test they recommended and provided justification. RESULTS. The majority of physicians (59%) and the general public (56%) receiving Q1 favored the less effective screening test However, of those receiving Q2,only 26% of physicians and 27% of the general public recommended the less effective screening test And of: those receiving Q3, only 38% of physicians and 28% of the general public recommended the less effective test. Justifications for these recommendations were based largely on concerns for equality of: treatment among those who chose the less effective test and concerns for saving the most lives among those who preferred the more effective test. CONCLUSIONS, Although most: respondents show a preference for equity over efficiency when equity means that 100% of a population can receive a service, many fewer;respondents maintain this preference when equity is no longer absolute. This result suggests that the preference for equity is sometimes "all or none." C1 Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. Physicians Online, Tarrytown, NY USA. RP Ubel, PA (reprint author), Univ Penn, Div Gen Internal Med, Sch Med, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. FU NCI NIH HHS [R01 CA78052-01] NR 20 TC 30 Z9 30 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2000 VL 38 IS 4 BP 366 EP 373 DI 10.1097/00005650-200004000-00003 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 296XN UT WOS:000086052200003 PM 10752968 ER PT J AU Rektorschek, M Buhmann, A Weeks, D Schwan, D Bensch, KW Eskandari, S Scott, D Sachs, G Melchers, K AF Rektorschek, M Buhmann, A Weeks, D Schwan, D Bensch, KW Eskandari, S Scott, D Sachs, G Melchers, K TI Acid resistance of Helicobacter pylori depends on the UreI membrane protein and an inner membrane proton barrier SO MOLECULAR MICROBIOLOGY LA English DT Article ID ALLELIC EXCHANGE; UREASE ACTIVITY; METABOLISM; PH; LOCALIZATION; TRANSPORTER; GASTRITIS; SURVIVAL; STRAINS; BIOLOGY AB ureI encodes an inner membrane protein of Helicobacter pylori. The role of the bacterial inner membrane and UreI in acid protection and regulation of cytoplasmic urease activity in the gastric microorganism was studied. The irreversible inhibition of urease when the organism was exposed to a protonophore (3,3',4',5-tetrachlorsalicylanide; TCS) at acidic pH showed that the inner membrane protected urease from acid. Isogenic ureI knockout mutants of several H. pylori strains were constructed by replacing the ureI gene of the urease gene cluster with a promoterless kanamycin resistance marker gene (kan(R)). Mutants carrying the modified ureAB-kan(R)-EFGH operon all showed wild-type levels of urease activity at neutral pH in vitro. The mutants resisted media of pH > 4.0 but not of pH < 4.0. Whereas wild-type bacteria showed high levels of urease activity below pH 4.0, this ability was not retained in the ureI mutants, resulting in inhibition of metabolism and cell death. Gene complementation experiments with plasmid-derived H. pylori ureI restored wild-type properties. The activation of urease activity found in structurally intact but permeabilized bacteria treated with 0.01% detergent (polyoxy-ethylene-8-laurylether; C12E8), suggested a membrane-limited access of urea to internal urease at neutral pH. Measurement of C-14-urea uptake into Xenopus oocytes injected with ureI cRNA showed acid activation of uptake only in injected oocytes. Acceleration of urea uptake by UreI therefore mediates the increase of intracellular urease activity seen under acidic conditions. This increase of urea permeability is essential for H. pylori survival in environments below pH 4.0. ureI-independent urease activity may be sufficient for maintenance of bacterial viability above pH 4.0. C1 Byk Gulden Pharmaceut Konstanz, Dept Biol Mol, Constance, Germany. W LA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Melchers, K (reprint author), Byk Gulden Pharmaceut Konstanz, Dept Biol Mol, Constance, Germany. NR 41 TC 51 Z9 56 U1 0 U2 5 PU BLACKWELL SCIENCE LTD PI OXFORD PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND SN 0950-382X J9 MOL MICROBIOL JI Mol. Microbiol. PD APR PY 2000 VL 36 IS 1 BP 141 EP 152 DI 10.1046/j.1365-2958.2000.01835.x PG 12 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 301YM UT WOS:000086338200014 PM 10760171 ER PT J AU Harwood, DG Sultzer, DL Wheatley, MV AF Harwood, DG Sultzer, DL Wheatley, MV TI Impaired insight in Alzheimer disease: Association with cognitive deficits, psychiatric symptoms, and behavioral disturbances SO NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY LA English DT Article ID NEUROBEHAVIORAL RATING-SCALE; MINI-MENTAL-STATE; MEMORY DEFICIT; DEPRESSION; ANOSOGNOSIA; DEMENTIA; UNAWARENESS; AWARENESS; PREVALENCE; CLINICIAN AB Objective: The purpose of this study was to evaluate symptoms associated with impaired insight in patients with Alzheimer disease (AD). Background: Although unawareness of deficits is common in AD. the relation of awareness to psychiatric and behavioral disturbances has not been extensively studied. Method: We conducted a cross-sectional investigation of 91 patients with probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. Awareness of cognitive and functional deficits was measured with the Inaccurate Insight item from the Neurobehavioral Rating Scale. Psychiatric and behavioral symptoms were measured using factor scores and individual items from the Neurobehavioral Rating Scale. Global cognitive deficits were measured using the Mini-Mental State Examination (MMSE). Results: Stepwise regression analysis showed that insight was associated with MMSE score, depression/anxiety factor score, and agitation/disinhibition factor score. Variables not associated with awareness of deficits included patient age, behavioral retardation factor score, verbal output disturbance factor score, and psychosis factor score. Post hoc analyses showed a positive relation (i,e., greater insight. more symptomatology) between deficit awareness and symptoms of depressed mood and anxiety. There was a negative relation (i.e.. greater insight, less symptomatology) between insight and symptoms of hostility, agitation, inattention, and tension. In a follow-up stepwise regression analysis, increased deficit awareness was associated with a higher MMSE score, greater depressed mood, and decreased agitation. Conclusions: These findings suggest that patients with AD may experience symptoms of depressed mood in relation to increased awareness of decrements in functioning. The data also indicate that patients with poor insight demonstrate greater agitated behavior. Consistent with previous research, impaired insight was higher in the later stages of the illness. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Vet Affairs Med Ctr Greater Los Angeles Healthcar, Mental Hlth Serv, Los Angeles, CA USA. RP Sultzer, DL (reprint author), W Los Angeles Vet Affairs Med Ctr, 3 South,116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIMH NIH HHS [MH00910, MH56031] NR 42 TC 94 Z9 98 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-878X J9 NEUROPSY NEUROPSY BE JI Neuropsychiatr. Neuropsychol. Behav. Neurol. PD APR PY 2000 VL 13 IS 2 BP 83 EP 88 PG 6 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 408AL UT WOS:000167304300002 PM 10780626 ER PT J AU Friedlander, AH Maeder, LA AF Friedlander, AH Maeder, LA TI The prevalence of calcified carotid artery atheromas on the panoramic radiographs of patients with type 2 diabetes mellitus SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS LA English DT Article ID RISK-FACTORS; COMPLICATIONS; STROKE; LIPOPROTEIN; PREDICTORS; MORTALITY; DISEASE AB Objective. Type 2 diabetes mellitus, which afflicts 15 million Americans, is associated with accelerated cervical carotid artery atherosclerosis and a heightened risk of stroke. This study attempted to determine the prevalence of calcified atherosclerotic lesions in a group of patients with type 2 diabetes mellitus. Study design. The panoramic radiographs of 49 men (age range, 55 to 81; mean age, 66.2 years) receiving routine dental treatment and insulin for diabetes at a Department of Affairs Veterans clinic were evaluated for calcified atheromas. Age-match controls, free of diabetes, were assessed in a like manner. Statistical comparison of the atheroma prevalence rates was by means of the Fisher exact test and statistical comparison of atherogenic risk factors was by means of t test with Bonferroni adjustment and, where necessary, the Mann-Whitney U test. Results. The radiographs of the diabetics (mean age, 66.9 years) revealed that 20.4% had atheromas whereas those of the controls (mean age, 68.1 years) demonstrated that 4% had atheromas (a statistically significant difference; P = .0275). Also statistically significant was the prevalence of atherogenic risk factors (plasma glucose, low density lipoproteins, and serum triglycerides) identified in the diabetic group. The radiographic appearance of the atheromas manifested by both groups of individuals, however was similar, with the lesions located 1.5-2.5 cm inferior-posterior to angle of the mandible. Conclusions. People with type 2 diabetes have a greater prevalence of calcified atheromas on their panoramic radiographs than do nondiabetics. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90094 USA. Univ So Calif, Sch Dent, Los Angeles, CA 90089 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 25 TC 29 Z9 30 U1 0 U2 1 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD APR PY 2000 VL 89 IS 4 BP 420 EP 424 DI 10.1016/S1079-2104(00)70122-3 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 306CD UT WOS:000086577900008 PM 10760724 ER PT J AU Chen, FH Sun, W Ding, SL Wetzel, GT Sarma, JSM Singh, BN Klitzner, TS AF Chen, FH Sun, W Ding, SL Wetzel, GT Sarma, JSM Singh, BN Klitzner, TS TI Dronedarone alters calcium current kinetics in isolated mouse ventricular myocytes SO PEDIATRIC RESEARCH LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Cardiovasc Res Labs, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD APR PY 2000 VL 47 IS 4 SU S MA 227 BP 39A EP 39A PN 2 PG 1 WC Pediatrics SC Pediatrics GA 298TM UT WOS:000086155300228 ER PT J AU Duerinckx, AJ Takahashi, M AF Duerinckx, AJ Takahashi, M TI Coronary magnetic resonance angiography in patients with Kawasaki disease. SO PEDIATRIC RESEARCH LA English DT Meeting Abstract C1 W Los Angeles Vet Affairs Med Ctr, Dept Radiol, Los Angeles, CA 90073 USA. Childrens Hosp, Cardiol Sect, Los Angeles, CA 90027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD APR PY 2000 VL 47 IS 4 MA 38 BP 555 EP 555 PN 1 PG 1 WC Pediatrics SC Pediatrics GA 298QQ UT WOS:000086151000063 ER PT J AU Ellis, SL Billups, SJ Malone, DC Carter, BL Covey, D Mason, B Jue, S Carmichael, J Guthrie, K Sintek, CD Dombrowski, R Geraets, DR Amato, M AF Ellis, SL Billups, SJ Malone, DC Carter, BL Covey, D Mason, B Jue, S Carmichael, J Guthrie, K Sintek, CD Dombrowski, R Geraets, DR Amato, M TI Types of interventions made by clinical pharmacists in the IMPROVE study SO PHARMACOTHERAPY LA English DT Article ID ELDERLY OUTPATIENTS; VETERANS-AFFAIRS; CONTROLLED TRIAL; CARE CLINICS; MANAGEMENT; SERVICES AB The purpose of this study was to describe and evaluate the activities and interventions provided by ambulatory care clinical pharmacists during the IMPROVE (Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers) study. A total of 523 patients were randomized into the intervention arm at nine Veterans Affairs medical centers if they were considered to be at high risk for drug-related problems. Patients randomized to the control group had no interventions and they are not reported. Using a standard form, pharmacists were asked to document the length of visit, method of contact, medical conditions addressed, and drug-related problems addressed and resolved during each contact. Seventy-eight ambulatory care clinical pharmacists documented 1855 contacts over 12 months, an average of 3.54 +/- 2.31/patient. The length of visits was 15 minutes or more for 73% of contacts. In-person contacts accounted for 1421 visits (76.6%), with the remainder being telephone contacts. During each contact the average number of drug-related problems addressed and resolved were 1.64 +/- 1.16 and 1.14 +/- 0.98, respectively. More drug-related problems were addressed and resolved when visits were 15 minutes or longer (p=0.001) and when the contact was in person (p=0.001). These data may provide information to clinical pharmacists developing pharmacy-managed clinics for patients at high risk for drug-related problems. The information may be a benchmark for types of interventions that can be made, as well as the time commitments required to make them. C1 Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Denver, CO 80262 USA. Kaiser Permanente, Denver, CO USA. Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. James A Haley Vet Hosp, Tampa Bay, FL USA. Boise VAMC, Boise, ID USA. Reno Vet Affairs Med Ctr, Reno, NV USA. John L McClellan Mem Vet Hosp, Little Rock, AR USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Baltimore VAMC, Baltimore, MD USA. Iowa City Vet Affairs Med Ctr, Iowa City, IA USA. STVHCS, Audie Murphy Div, San Antonio, TX USA. RP Carter, BL (reprint author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, 4200 E 9th Ave,C238, Denver, CO 80262 USA. NR 25 TC 38 Z9 39 U1 0 U2 6 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER BOX 806 171 HARRISON AVE, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD APR PY 2000 VL 20 IS 4 BP 429 EP 435 DI 10.1592/phco.20.5.429.35055 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 300XE UT WOS:000086278400010 PM 10772374 ER PT J AU Kanofsky, JR Sima, PD AF Kanofsky, JR Sima, PD TI Structural and environmental requirements for quenching of singlet oxygen by cyanine dyes SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article; Proceedings Paper CT 26th Meeting of the American-Society-for-Photobiology CY JUL 11-15, 1998 CL SNOWBIRD, UTAH SP Amer Soc Photobiol ID MOLECULAR-OXYGEN; SOLVENT; PHOTOSENSITIZATION; PHENOLS; AMINES; PI AB Singlet-oxygen quenching constants were measured for 19 cyanine dyes in acetonitrile, The most efficient quenchers were 1-butyl-2-[2-[3-[(1-butyl-6-chlorobenz[cd]indol-2(1H)-ylidene)ethylidene]-2-chloro-1-cyclohexen-1-yl]ethenyl]-6-chlorobenz[cd]indolium and 6-chloro-2-[2-[3-(6-chloro-1-ethylbenz[cd]indol-2(1H)-ylidene)ethylidene]-2-phenyl-1-cyclopenten-1-yl]ethenyl]-1-ethyl-benz[cd]indolium, having quenching constants with diffusion-controlled values of 2.0 +/- 0.1 x 10(10) and 1.5 +/- 0.1 x 10(10) M-1 s(-1), respectively. There was a trend toward increased quenching constants for cyanine dyes with the absorption band maxima at longer wavelengths. However, the quenching constants correlated better with the oxidation potentials of the cyanine dyes, suggesting that quenching proceeds by charge transfer rather than energy transfer. The quenching constants for 1,1',3,3,3',3'-hexamethylindotricarbocyanine perchlorate and 1,1'-diethyl-4,4'-carbocyanine iodide were measured in several solvents as well as in aqueous solutions of detergent micelles. In different solvents, the quenching constants varied by as much as a factor of 50, The quenching constants were largest in solvents with the highest values on the pi* scale of Kamlet, Abboud, Abraham and Taft, This was consistent with quenching occurring by charge transfer. Within cells, cyanine dyes concentrate in membrane-bound organelles. The quenching constants were substantial within detergent micelles, To the extent that micelles are models for biological membranes, cyanine dyes may be effective biological singlet-oxygen quenchers. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Med Serv, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA. RP Kanofsky, JR (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Med Serv, POB 278, Hines, IL 60141 USA. NR 25 TC 27 Z9 29 U1 3 U2 9 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 USA SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD APR PY 2000 VL 71 IS 4 BP 361 EP 368 DI 10.1562/0031-8655(2000)071<0361:SAERFQ>2.0.CO;2 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 305LA UT WOS:000086540500002 ER PT J AU Sima, PD Kanofsky, JR AF Sima, PD Kanofsky, JR TI Cyanine dyes as protectors of K562 cells from photosensitized cell damage SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article; Proceedings Paper CT 26th Meeting of the American-Society-for-Photobiology CY JUL 11-15, 1998 CL SNOWBIRD, UTAH SP Amer Soc Photobiol ID SINGLET OXYGEN; LEUKEMIA-CELLS; INACTIVATION; MECHANISM; INVITRO AB Several cyanine dyes were found to protect K562 leukemia cells against toxicity mediated by cis -di(4-sulfonatophenyl)diphenylporphine (TPPS2) and light. Most cyanine dyes derived from dimethylindole were better photoprotectors than cyanine dyes with other structures. This correlated with the fact that cyanine dyes derived from dimethylindole were predominately monomeric at millimolar concentrations within K562 cells, while other cyanine dyes formed aggregates. For cyanine dyes that are derived from dimethylindole and have absorption band wavelengths greater than 700 nm, fluorescence-energy transfer from TPPS2 to the cyanine dye was the most important mechanism for photoprotection, There was no spectroscopic evidence for complex formation between the cyanine dyes and TPPS2, The dimethylindole derivative, 1,1',3,3,3',3'-hexamethylindodicarbocyanine, was an excellent photoprotector, but a poor quencher of TPPS2 fluorescence and a relatively poor singlet-oxygen quencher. This cyanine dye may act by quenching excited triplet TPPS2. Singlet-oxygen quenching may contribute to the photoprotection provided by cyanine dyes not derived from dimethylindole. Differences in the subcellular distribution of the various cyanine dyes studied may have contributed to the different apparent mechanisms of photoprotection. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Med Serv, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Mol & Cellular Biochem, Maywood, IL 60153 USA. RP Kanofsky, JR (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, POB 278, Hines, IL 60141 USA. NR 21 TC 21 Z9 22 U1 0 U2 5 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 USA SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD APR PY 2000 VL 71 IS 4 BP 413 EP 421 DI 10.1562/0031-8655(2000)071<0413:CDAPOK>2.0.CO;2 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 305LA UT WOS:000086540500008 PM 10824591 ER PT J AU Netscher, DT Meade, RA Goodman, CM Alford, EL Stewart, MG AF Netscher, DT Meade, RA Goodman, CM Alford, EL Stewart, MG TI Quality of life and disease-specific functional status following microvascular reconstruction for advanced (T3 and T4) oropharyngeal cancers SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; OF-LIFE; NECK-CANCER; OROMANDIBULAR RECONSTRUCTION; PERFORMANCE STATUS; RADIATION-THERAPY; LARYNGEAL-CANCER; ORAL-CANCER; HEAD; RADIOTHERAPY AB In an effort to evaluate quality-of-life benefits of ablative head and neck cancer surgery and microvascular reconstruction, a longitudinal study was under-taken in which patients with T3 or T4 oropharyngeal cancers without systemic metastases at presentation were administered both general and disease-specific quality-of-life instruments preoperatively and postoperatively. In an initial prospective pilot study, 17 cancer patients were evaluated both preoperatively and postoperatively using the Medical Outcomes Short-Form Wealth Survey questionnaire (SF-36) and the Performance Status Scale Tor Head and Neck Cancer Patients. In the second part of the study, the need was recognized for a different disease-specific measure, for more frequent intervals of longitudinal follow-up (rather than be limited by a single data collection point), and for a noncancer control group. Since then, 17 more cancer patients were evaluated in the second part of the study and were compared with patients who had similar reconstructions after suffering head and neck trauma and also with age-matched controls. Instead of the performance status scale, the University of Washington Head and Neck Quality of Life questionnaire was substituted. Interval assessments were done at 1, 3, 6, and 12 months and preoperatively. Whereas many of the general and disease-specific quality of life subclasses initially worsened following extensive surgery and radiation therapy, most returned to the preoperative baseline by 6 months following conclusion of treatment and surpassed pretreatment values at 1 year. It can be concluded, based on this study, that large resections and reconstructions for head and neck cancer patients are justified in terms of outcome; the resection controls the local disease, and the microvascular reconstruction restores quality of life and functional status. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Baylor Coll Med, Dept Otolaryngol & Commun Sci, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. RP Netscher, DT (reprint author), Suite 800,6560 Fannin, Houston, TX 77030 USA. NR 30 TC 34 Z9 35 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR PY 2000 VL 105 IS 5 BP 1628 EP 1634 DI 10.1097/00006534-200004050-00005 PG 7 WC Surgery SC Surgery GA 299QF UT WOS:000086208800005 PM 10809090 ER PT J AU Reiner, BI Siegel, EL Flagle, C Hooper, FJ Cox, RE Scanlon, M AF Reiner, BI Siegel, EL Flagle, C Hooper, FJ Cox, RE Scanlon, M TI Effect of filmless imaging on the utilization of radiologic services SO RADIOLOGY LA English DT Article DE economics, medical; picture archiving and communication system (PACS); radiology and radiologists, socioeconomic issues ID COST; SYSTEMS; TRENDS AB PURPOSE: To determine the effect of a large-scale picture archiving and communication system (PACS) on in- and outpatient utilization of radiologic services. MATERIALS AND METHODS: Data were collected at the Baltimore Veterans Affairs (VA) Medical Center (BVAMC) before and after implementation of an enterprise-wide PACS; the numbers and types of imaging examinations performed for fiscal years 1993 and 1996 were evaluated. These data were compared with those from a similar academic medical center, the Philadelphia VA Medical Center (PVAMC), and with aggregate data obtained nationally for all VA hospitals over comparable periods. RESULTS: Inpatient utilization, defined as the number of examinations per inpatient day, increased by 82% (from 0.265 to 0.483 examinations per patient day) after a transition to filmless operation at BVAMC. This is substantially greater than the increases of 38% (from 0.263 to 0.362 examinations per patient day) and 11%(from 0.190 to 0.211 examinations per patient day) at the film-based PVAMC and nationally, respectively. Outpatient utilization, defined as the number of examinations per visit, increased by 21% (from 0.108 to 0.131 examinations per visit) at BVAMC, compared with a 1% increase (from 0.087 to 0.088 examinations per visit) at PVAMC and a net decrease of 19% (from 0.148 to 0.120 examinations per visit) nationally. CONCLUSION: The transition to filmless operation was associated with increases in inpatient and outpatient utilization of radiologic services, which substantially exceeded changes at PVAMC and nationally over the same interval. C1 Vet Affairs Maryland Hlth Care Syst, Dept Radiol, Baltimore, MD 21201 USA. Univ Maryland, Sch Med, Dept Radiol, Baltimore, MD 21201 USA. Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. Amer Radiol Serv, Baltimore, MD USA. Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA. Philadelphia Vet Affairs Med Ctr, Dept Radiol, Philadelphia, PA USA. RP Siegel, EL (reprint author), Vet Affairs Maryland Hlth Care Syst, Dept Radiol, 10 N Greene St, Baltimore, MD 21201 USA. NR 13 TC 59 Z9 62 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD APR PY 2000 VL 215 IS 1 BP 163 EP 167 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 298UC UT WOS:000086156700024 PM 10751482 ER PT J AU Krieger, JN AF Krieger, JN TI Consider diagnosis and treatment of trichomoniasis in men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED DISEASES; VAGINALIS; PROSTATITIS; POPULATION; URETHRITIS C1 Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. RP Krieger, JN (reprint author), VA Puget Sound Hlth Care Syst, Dept Urol, 112UR,1660 S Columbian Way, Seattle, WA 98109 USA. NR 16 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2000 VL 27 IS 4 BP 241 EP 242 DI 10.1097/00007435-200004000-00011 PG 2 WC Infectious Diseases SC Infectious Diseases GA 303CY UT WOS:000086404300011 PM 10782748 ER PT J AU Taub, E AF Taub, E TI Constraint-induced movement therapy and massed practice SO STROKE LA English DT Letter ID STROKE; REHABILITATION C1 Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. RP Taub, E (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. NR 17 TC 39 Z9 41 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2000 VL 31 IS 4 BP 986 EP 988 PG 3 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 300WR UT WOS:000086277200041 PM 10754013 ER PT J AU Munshi, HG Montgomery, RB AF Munshi, HG Montgomery, RB TI Severe neutropenia: a diagnostic approach SO WESTERN JOURNAL OF MEDICINE LA English DT Review ID COLONY-STIMULATING FACTOR; DRUG-INDUCED AGRANULOCYTOSIS; AUTOIMMUNE NEUTROPENIA; GRANULOCYTE; SARCOIDOSIS; PATIENT C1 Univ Washington, Sch Med, Div Oncol,Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Montgomery, RB (reprint author), Univ Washington, Sch Med, Div Oncol,Dept Med, Vet Affairs Puget Sound Hlth Care Syst, 111-ONC,1660 S Columbian Way, Seattle, WA 98108 USA. NR 35 TC 11 Z9 15 U1 0 U2 1 PU B M J PUBLISHING INC PI SAN FRANCISCO PA 221 MAIN ST, PO BOX 7690, SAN FRANCISCO, CA 94120-7690 USA SN 0093-0415 J9 WESTERN J MED JI West. J. Med. PD APR PY 2000 VL 172 IS 4 BP 248 EP 252 DI 10.1136/ewjm.172.4.248 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 301AW UT WOS:000086286800025 PM 10778379 ER PT J AU Moll, J de Oliveira-Souza, R Passman, LJ Cunha, FC Souza-Lima, F Andreiuolo, PA AF Moll, J de Oliveira-Souza, R Passman, LJ Cunha, FC Souza-Lima, F Andreiuolo, PA TI Functional MRI correlates of real and imagined tool-use pantomimes SO NEUROLOGY LA English DT Article DE tool-use pantomimes; hemispheric specialization; functional MRI ID CONCEPTUAL APRAXIA; FMRI; ACTIVATION; AREAS AB Objective: To study the pattern of cerebral activation related to the performance of tool-use pantomimes with functional MRI (fMRI) using a task-subtraction design. Background: Tool use comprises a particular category of transitive actions. Inability to pantomime the use of tools has been classically associated with retrorolandic dominant hemisphere damage. However, where in the left hemisphere these transitive representations are generated is unclear. Methods: Echoplanar images were acquired in eight alternating task and control periods. Sixteen right-handed normal adults pantomimed the use of common tools and utensils with each hand. The control condition consisted of a sequence of nonsymbolic complex movements of forearm, hand, and fingers at a self-paced rate. Eight individuals also imagined the execution of the real task and control actions. A repeated measures ANOVA compared activations in five regions of interest in each hemisphere. Results: Regardless of which hand was used, the left hemisphere was more active than the right in both real (p < 0.02) and imagined (p < 0.04) tasks. Activations clustered in the left intraparietal cortex and posterior dorsolateral frontal cortex. Conclusions: Pantomiming the use of tools is associated with activation of the left intraparietal cortex and dorsolateral frontal cortex. The left intraparietal cortex may store the representations of tool-use formulae, whereas the dorsolateral frontal cortex activation may reflect the switching between innervatory motor programs. C1 Hosp Barra Or & LABS, Funct MRI Ctr, Neuroimaging Div, Rio De Janeiro, Brazil. Univ Fed Rio de Janeiro, Hosp Gaffree & Guinle, Rio De Janeiro, Brazil. Philippe Pinel Inst, Rio De Janeiro, Brazil. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Moll, J (reprint author), Rua Pinheiro Guimaraes,22-5 Andar, BR-22281080 Rio De Janeiro, Brazil. RI Moll, Jorge/B-2654-2013 NR 27 TC 120 Z9 121 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR 28 PY 2000 VL 54 IS 6 BP 1331 EP 1336 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 297XY UT WOS:000086109300023 PM 10746606 ER PT J AU Sheng, SH Li, JQ McNulty, KA Avery, D Kleyman, TR AF Sheng, SH Li, JQ McNulty, KA Avery, D Kleyman, TR TI Characterization of the selectivity filter of the epithelial sodium channel SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN SECONDARY STRUCTURE; SENSITIVE NA+ CHANNEL; CATION-PI INTERACTIONS; TOAD URINARY-BLADDER; POTASSIUM CHANNEL; ION SELECTIVITY; STRUCTURE PREDICTION; K+ CHANNEL; MEMBRANE TOPOLOGY; WEAVER MUTATION AB The epithelial sodium channel (ENaC) is composed of three homologous subunits termed alpha, beta, and gamma. Previous studies suggest that selected residues within a hydrophobic region immediately preceding the second membrane-spanning domain of each subunit contribute to the conducting pore of ENaC. We probed the pore of mouse ENaC by systematically mutating all 24 amino acids within this putative pore region of the alpha-subunit to cysteine and co-expressing these mutants with wild type beta- and gamma-subunits of mouse ENaC in Xenopus laevis oocytes, Functional characteristics of these mutants were examined by two-electrode voltage clamp and single channel recording techniques. Two distinct domains were identified based on the functional changes associated with point mutations. An amino-terminal domain (alpha-Val(569)-alpha-Gly(579)) showed minimal changes in cation selectivity or amiloride sensitivity following cysteine substitution. In contrast, cysteine substitutions within the carboxyl-terminal domain (alpha-Ser(580)-alpha-Ser(592)) resulted in significant changes in cation selectivity and moderately altered amiloride sensitivity. The mutant channels containing alpha G587C or alpha S589C were permeable to K+, and mutation of a GSS tract (positions alpha 587-alpha 589) to GYG resulted in a moderately K+-selective channel. Our results suggest that the C-terminal portion of the pore region within the alpha-subunit contributes to the selectivity filter of ENaC. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Kleyman, TR (reprint author), Div Renal, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA. OI Sheng, Shaohu/0000-0002-7198-1702 FU NIDDK NIH HHS [DK54354] NR 51 TC 68 Z9 70 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 24 PY 2000 VL 275 IS 12 BP 8572 EP 8581 DI 10.1074/jbc.275.12.8572 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 304WU UT WOS:000086507700046 PM 10722696 ER PT J AU Munson, KB Lambrecht, N Sachs, G AF Munson, KB Lambrecht, N Sachs, G TI Effects of mutations in M4 of the gastric H+,K+-ATPase on inhibition kinetics of SCH28080 SO BIOCHEMISTRY LA English DT Article ID MUSCLE SARCOPLASMIC-RETICULUM; AMINO-ACID-SEQUENCE; MEMBRANE TOPOLOGY; H+/K+-ATPASE; CDNA CLONING; BINDING-SITE; BETA-SUBUNIT; PUMP; H+; EXPRESSION AB The effects of site-directed mutagenesis were used to explore the role of residues in M4 on the apparent K-i of a selective, K+-competitive inhibitor of the gastric H+,K+ ATPase, SCH28080, A double transfection expression system is described, utilizing HEK293 cells and separate plasmids encoding the alpha and beta subunits of the H+,K+-ATPase. The wild-type enzyme gave specific activity (micromoles of Pi per hour per milligram of expressed H+,K+-ATPase protein), apparent K-m for ammonium (a KC surrogate), and apparent K-i for SCH28080 equal to the H+,K+-ATPase purified from hog gastric mucosa. Amino acids in the M4 transmembrane segment of the a subunit were selected from, and substituted with, the nonconserved residues in M4 of the Na+,Ki-ATPase, which is insensitive to SCH28080. Most of the mutations produced competent enzyme with similar K-m,K-app values for NH4+ and K-i,K-app for SCH28080, SCH28080 affinity was decreased 2-fold in M330V and 9-fold in both M334I and V337I without significant effect on K-m,K-app. Hence methionine 334 and valine 337 participate in binding but are not part of the NH4+ site. Methionine 330 may be at the periphery of the inhibitor sire, which must have minimum dimensions of similar to 16 x 8 x 5 Angstrom and be accessible from the lumen in the E2-P conformation. Multiple sequence alignments place the membrane surface near arginine 328, suggesting that the side chains of methionine 334 and valine 337, on one side of the M4 helix, project into a binding cavity within the membrane domain. C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90024 USA. RP Wadsworth VA Hosp, CURE, 11301 Wilshire Blvd,Bldg 113,Room 324, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK 41301, DK 40615] NR 44 TC 21 Z9 21 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD MAR 21 PY 2000 VL 39 IS 11 BP 2997 EP 3004 DI 10.1021/bi991837d PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 296KL UT WOS:000086023500020 PM 10715120 ER PT J AU Yao, JK Leonard, S Reddy, RD AF Yao, JK Leonard, S Reddy, RD TI Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients SO SCHIZOPHRENIA RESEARCH LA English DT Article DE arachidonic acid; caudate; phospholipids; polyunsaturated fatty acids; postmortem changes ID MAGNETIC-RESONANCE SPECTROSCOPY; ESSENTIAL FATTY-ACIDS; PERFORMANCE LIQUID-CHROMATOGRAPHY; LIGHT-SCATTERING DETECTION; DRUG-FREE PATIENTS; ARACHIDONIC-ACID; PHOSPHOINOSITIDE HYDROLYSIS; SIGNAL-TRANSDUCTION; TARDIVE-DYSKINESIA; RAPID METHOD AB Previous studies in schizophrenia have shown alterations in membrane phospholipids and polyunsaturated fatty acids. However, these studies have primarily examined peripheral (non-neuronal) cell types. The purpose of the present study was to examine whether the membrane deficits seen in peripheral tissues are also observed in the brain. The caudate was the primary region of interest for this study. Using high-pressure liquid chromatography in conjunction with an evaporative light-scattering detector, we first measured the level of various membrane phospholipids (PL) in schizophrenic (n = 11) and control groups with (n = 7) and without (n = 14) other mental disorders. Polyunsaturated fatty acids (PUFAs) were then determined by capillary gas chromatography. Within groups, there are no significant correlations between membrane PL levels and other collection and demographic parameters including age, postmortem interval, storage time and brain weight. Significantly lower amounts of phosphatidylcholine and phosphatidylethanolamine were found in postmortem brain tissue from schizophrenic patients than in those from control groups, even after accounting for potential confounds. In addition, strong reductions of total PUFAs and saturated fatty acids were found in schizophrenic brains, relative to control brains. Specifically, the reduced PUFAs were largely attributable to decreases in arachidonic acid (AA) and, to a lesser extent, its precursors, linoleic and eicosadienoic acids. There are no significant differences between the control groups with and without other mental disorders. The present findings suggest that deficits identified in peripheral membranes may also be present in the brain from schizophrenic patients. Such a deficit in membrane AA may contribute to the many biological, physiological, and clinical phenomena observed in schizophrenia. (C) 2000 Elsevier Science B.V. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. NR 62 TC 170 Z9 175 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR 16 PY 2000 VL 42 IS 1 BP 7 EP 17 DI 10.1016/S0920-9964(99)00095-X PG 11 WC Psychiatry SC Psychiatry GA 295KM UT WOS:000085965300002 PM 10706981 ER PT J AU Akiba, Y Engel, E Guth, PH Nastaskin, I Kaunitz, JD AF Akiba, Y Engel, E Guth, PH Nastaskin, I Kaunitz, JD TI How important is duodenal bicarbonate secretion in mucosal defense? SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A361 EP A361 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918102087 ER PT J AU Durante, W Liao, L Reyna, SV Peyton, KJ Schafer, AI AF Durante, W Liao, L Reyna, SV Peyton, KJ Schafer, AI TI Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. Houston VAMC, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A450 EP A450 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918102604 ER PT J AU Garnovskaya, M Mukhin, Y Collinsworth, G Ullian, M Raymond, J AF Garnovskaya, M Mukhin, Y Collinsworth, G Ullian, M Raymond, J TI The role of the Na+/H+ exchanger in the mitogen-induced activation of extracellular signal regulated protein kinase in vascular smooth muscle cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A592 EP A592 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918103422 ER PT J AU Keith, RL Miller, YE Malkinson, AM Moore, MD Geraci, MW AF Keith, RL Miller, YE Malkinson, AM Moore, MD Geraci, MW TI Pulmonary prostacyclin synthase overexpression chemoprevents lung tumorigenesis SO FASEB JOURNAL LA English DT Meeting Abstract C1 Denver VAMC, Denver, CO USA. CU, Sch Pharm, Denver, CO USA. UCHSC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A474 EP A474 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918102741 ER PT J AU Knowlton, AA Sun, LM AF Knowlton, AA Sun, LM TI Differential effects of hormones on heat shock protein expression SO FASEB JOURNAL LA English DT Meeting Abstract C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A424 EP A424 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918102451 ER PT J AU Livingston, EH Lee, S AF Livingston, EH Lee, S TI Fractal modeling provides for precise estimation of body surface area in normal weight and obese humans SO FASEB JOURNAL LA English DT Meeting Abstract C1 VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A432 EP A432 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918102502 ER PT J AU Mukhin, Y Garnovskaya, M Collinsworth, G Fitzgibbon, W Raymond, J Ploth, D AF Mukhin, Y Garnovskaya, M Collinsworth, G Fitzgibbon, W Raymond, J Ploth, D TI Bradykinin stimulates a formation of complex between calmodulin and Janus Kinase in mIMCD-3 cells. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A589 EP A589 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918103408 ER PT J AU Rosenthal, MJ Song, MK AF Rosenthal, MJ Song, MK TI Anti-diabetic effects of cyclo (his-pro) are mediated via regulation of zinc metabolism in rats. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Dept Med & Pediat, Los Angeles, CA 90024 USA. VA Greater Los Angles Hlth Care Syst, N Hills, CA 91343 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A737 EP A737 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918104265 ER PT J AU Schutzer, WE Xue, H Reed, JF Roullet, JB Mader, SL AF Schutzer, WE Xue, H Reed, JF Roullet, JB Mader, SL TI Angiotensin II enhances isoproterenol-induced vasorelaxation in aorta from young but not old rats SO FASEB JOURNAL LA English DT Meeting Abstract C1 Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A674 EP A674 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918103899 ER PT J AU Wolden-Hanson, T Matsumoto, AM AF Wolden-Hanson, T Matsumoto, AM TI Neuroendocrinology of energy balance in the aging male Brown Norway rat. SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Washington, Sch Med, GRECC, Seattle, WA USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA USA. Univ Washington, Sch Med, Populat Ctr Res Reprod, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A776 EP A776 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918104488 ER PT J AU Zhu, WH Nicosia, RF Yancopoulos, G AF Zhu, WH Nicosia, RF Yancopoulos, G TI Phosphorylation of MAP and AKT kinases is not sufficient for the induction of angiogenesis ex vivo SO FASEB JOURNAL LA English DT Meeting Abstract C1 Univ Washington, Dept Pathol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 15 PY 2000 VL 14 IS 4 BP A707 EP A707 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 294NV UT WOS:000085918104094 ER PT J AU Fuhr, PSW Elliott, JL Kuyk, TK AF Fuhr, PSW Elliott, JL Kuyk, TK TI Mask spatial frequency and the human periphery effect. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 Birmingham VAMC, Birmingham, AL USA. Univ Alabama, Sch Optometry, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 2000 VL 41 IS 4 SU S MA 4274B221 BP S806 EP S806 PG 1 WC Ophthalmology SC Ophthalmology GA 300HF UT WOS:000086246704343 ER PT J AU Wen, Y Sachs, G AF Wen, Y Sachs, G TI A novel lens epithelial gene product, LEP503: Protein identification, genomic organization, promoter analysis and chromosomal localization. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Membrane Biol Lab, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 2000 VL 41 IS 4 SU S MA 3324B422 BP S626 EP S626 PG 1 WC Ophthalmology SC Ophthalmology GA 300HF UT WOS:000086246703394 ER PT J AU Scull, GS Martin, JS Weaver, WD Every, NR AF Scull, GS Martin, JS Weaver, WD Every, NR CA MITI Investigators TI Early angiography versus conservative treatment in patients with non-ST elevation acute myocardial infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID THROMBOLYTIC THERAPY; TRIAGE AB OBJECTIVES To compare short- and long-term outcome after early invasive or conservative strategies in the treatment of non-ST segment elevation acute myocardial infarction (AMI). BACKGROUND It is uncertain whether or not there is benefit from emergent invasive diagnosis and treatment of AMI in patients without ST segment elevation on the admission electrocardiogram (ECG). METHODS In a cohort of 1,635 consecutive patients with AMI who presented to hospitals without ST segment elevation on their admission EGG, we compared treatments, hospital course and outcome in 308 patients who presented to hospitals whose initial strategy favored early angiography and appropriate intervention when indicated versus 1,327 similar patients who presented to hospitals that favor a more conservative initial approach. RESULTS At baseline, patients admitted to hospitals favoring an early invasive strategy were younger, more predominately Caucasian and had less comorbidity. Early coronary angiography occurred in 58.8% versus 8% (p < 0.001), and early angioplasty was performed in 44.8% versus 6.1% (p < 0.001) in the two different cohorts. Patients treated in hospitals favoring the early invasive strategy had a lower 30-day (5.5% vs. 9.5%, p = 0.026) and four-year mortality (20% vs. 37%, p < 0.001). Multivariate analysis showed a trend towards lower hospital mortality (OR = 0.56, 95% CI: 0.29 to 1.09) and a significant lower long-term mortality (hazard ratio = 0.61, 95% CI: 0.47 to 0.80) in patients admitted to hospitals favoring an early invasive strategy. CONCLUSIONS These data suggested that an early invasive strategy in patients with AMI and nondiagnostic ECG changes is associated with lower long-term mortality. (C) 2000 by the American College of Cardiology. C1 VA Puget Sound Healthcare Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Henry Ford Hlth Syst, Inst Heart & Vasc, Detroit, MI USA. Univ Washington, Div Cardiol, Seattle, WA 98195 USA. RP Every, NR (reprint author), COR Ctr, 1910 Fairview Ave E,205, Seattle, WA USA. FU AHRQ HHS [R01-HS08362-03] NR 13 TC 33 Z9 36 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 15 PY 2000 VL 35 IS 4 BP 895 EP 902 DI 10.1016/S0735-1097(99)00643-9 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 294NK UT WOS:000085917200008 PM 10732885 ER PT J AU Griffith, HR Perlman, SB Woodard, AR Rutecki, PA Jones, JC Ramirez, LF DeLaPena, R Seidenberg, M Hermann, BP AF Griffith, HR Perlman, SB Woodard, AR Rutecki, PA Jones, JC Ramirez, LF DeLaPena, R Seidenberg, M Hermann, BP TI Preoperative FDG-PET temporal lobe hypometabolism and verbal memory after temporal lobectomy SO NEUROLOGY LA English DT Article DE PET; epilepsy surgery; neuropsychology; memory; anterior temporal lobectomy ID INTERICTAL GLUCOSE HYPOMETABOLISM; POSITRON EMISSION TOMOGRAPHY; PARTIAL EPILEPSY; METABOLISM; PERFORMANCE; TOPOGRAPHY; SCALE AB Objective: To examine the relationship of preoperative fluorodeoxyglucose (FDG)-PET asymmetry in temporal lobe metabolism and memory outcome after anterior temporal lobectomy (ATL). Methods: In a university-based epilepsy surgery center, 60 ATL patients (27 left, 33 right) were divided into two groups: no/mild (n = 21) or moderate/ severe (n = 39) asymmetry in temporal lobe hypometabolism as determined by FDG-PET. All patients were nonretarded, at least 18 years of age, left-hemisphere speech dominant, without MRI abnormalities other than hippocampal atrophy, and with unilateral temporal lobe origin of intractable complex partial seizures. Neuropsychological measures of intelligence and verbal and visual memory function were assessed preoperatively and 6 months postoperatively. Results: Left ATL patients with no/mild asymmetry in FDG-PET temporal lobe metabolism exhibited significantly greater verbal memory decline compared with left ATL patients with moderate/severe hypometabolism. There was no significant relationship between PET asymmetry and pre- to postsurgical IQ change. No significant relationship was observed between extent of PET hypometabolism and memory outcome for right ATL patients. Conclusions: FDG-PET asymmetry can be added to the preoperative clinical markers that appear useful in predicting verbal memory decline after left ATL. C1 Univ Wisconsin, Dept Neurol, Madison, WI 53792 USA. Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA. Univ Wisconsin, Dept Neurosurg, Madison, WI 53792 USA. Chicago Med Sch, Dept Psychol, Chicago, IL USA. William S Middleton Mem Vet Adm Hosp, Dept Neurol, Madison, WI USA. William S Middleton Mem Vet Adm Hosp, Dept Neurosurg, Madison, WI USA. RP Hermann, BP (reprint author), Univ Wisconsin, Dept Neurol, 600 N Highland, Madison, WI 53792 USA. FU NINDS NIH HHS [NS 37738] NR 21 TC 37 Z9 37 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAR 14 PY 2000 VL 54 IS 5 BP 1161 EP 1165 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 292GK UT WOS:000085785700027 PM 10720291 ER PT J AU Mao, CG Xu, RJ Bielawska, A Obeid, LM AF Mao, CG Xu, RJ Bielawska, A Obeid, LM TI Cloning of an alkaline ceramidase from Saccharomyces cerevisiae - An enzyme with reverse (CoA-independent) ceramide synthase activity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROGRAMMED CELL-DEATH; HUMAN ACID CERAMIDASE; FARBER-DISEASE; SERINE PALMITOYLTRANSFERASE; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; PURIFICATION; BIOSYNTHESIS; YEAST; DNA AB Ceramide is not only a core intermediate of sphingolipids but also an important modulator of many cellular events including apoptosis, cell cycle arrest, senescence, differentiation, and stress responses. Its turnover may be tightly regulated. However, little is known about the regulation of its metabolism because most enzymes responsible for its synthesis and breakdown have yet to be cloned. Here we report the cloning and characterization of the yeast gene YPC1 (YBR183w) by screening Saccharomyces cerevisiae genes whose overexpression bestows resistance to fumonisin B1. We demonstrate that the yeast gene YPC1 encodes an alkaline ceramidase activity responsible for the breakdown of dihydroceramide and phytoceramide but not unsaturated ceramide. YPC1 ceramidase activity was confirmed by in vitro studies using an Escherichia coli expression system. Importantly, YPC1p also has reverse activity, catalyzing synthesis of phytoceramide from palmitic acid and phytosphingosine. This ceramide synthase activity is CoA-independent and is resistant to fumonisin B1, thus explaining why YPC1 was cloned as a fumonisin B1-resistant gene. C1 Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. RP Div Gen Internal Med, 114 Doughty St,Rm 602 STB,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIA NIH HHS [AG12467, AG16583] NR 40 TC 128 Z9 132 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 10 PY 2000 VL 275 IS 10 BP 6876 EP 6884 DI 10.1074/jbc.275.10.6876 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 292RV UT WOS:000085809600027 PM 10702247 ER PT J AU Armstrong, K Asch, DA AF Armstrong, K Asch, DA TI Direct sale of sildenafil (Viagra) to consumers over the Internet. Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Armstrong, K (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 9 PY 2000 VL 342 IS 10 BP 742 EP 742 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 290ZW UT WOS:000085708800025 ER PT J AU Sees, KL Delucchi, KL Masson, C Rosen, A Clark, HW Robillard, H Banys, P Hall, SM AF Sees, KL Delucchi, KL Masson, C Rosen, A Clark, HW Robillard, H Banys, P Hall, SM TI Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID DIAGNOSTIC INTERVIEW SCHEDULE; SUBSTANCE-ABUSE TREATMENT; ADDICTION SEVERITY INDEX; FOLLOW-UP; COCAINE ABUSERS; VALIDITY; PHARMACOTHERAPY; PSYCHOTHERAPY; RELIABILITY; SERVICES AB Context Despite evidence that methadone maintenance treatment (MMT) is effective for opioid dependence, it remains a controversial therapy because of its indefinite provision of a dependence-producing medication. Objective To compare outcomes of patients with opioid dependence treated with MMT vs an alternative treatment, psychosocially enriched 180-day methadone-assisted detoxification. Design Randomized controlled trial conducted from May 1995 to April 1999. Setting Research clinic In an established drug treatment service. Patients Of 858 volunteers screened, 179 adults with diagnosed opioid depen dence were randomized into the study, 154 completed 12 weeks of follow-up. Interventions Patients were randomized to MMT (n = 91), which required 2 hours of psychosocial therapy per week during the first 6 months; or detoxification (n = 88), which required 3 hours of psychosocial therapy per week, 14 education sessions, and 1 hour of cocaine group therapy, if appropriate, for 6 months, and 6 months of (non-methadone) aftercare services. Main Outcome Measures Treatment retention, heroin and cocaine abstinence (by self-report and monthly urinalysis), human immunodeficiency virus (HIV) risk behaviors (Risk of AIDS Behavior scale store), and function in 5 problem areas: employment, family, psychiatric, legal,:and alcohol use (Addiction Severity Index), compared by intervention group. Results Methadone maintenance therapy resulted in greater treatment retention (median, 438.5 vs 174.0 days) and lower heroin use rates than did detoxification, Cocaine use was more closely related to study dropout in detoxification than in MMT, Methadone maintenance therapy resulted in a lower rate of drug-related (mean [SD] at 12 months, 2.17 [3.88] vs 3.73 [6.86]) but not sex-related HIV risk behaviors and in a lower severity score for legal status (mean [SD] at 12 months, 0.05 [0.13] vs 0.13 [0.19]). There were no differences between groups in employment or family functioning or alcohol use. In both groups, monthly heroin use rates were 50% or greater, but days of use per month dropped markedly from baseline. Conclusions Our results confirm the usefulness of MMT in reducing heroin use and HIV risk behaviors. Illicit opioid use continued in both groups, but frequency was reduced. Results do not provide support for diverting resources from MMT into longterm detoxification. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Hall, SM (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box 0984-TRC, San Francisco, CA 94143 USA. FU NIDA NIH HHS [2P50 DA09253] NR 27 TC 206 Z9 213 U1 2 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 8 PY 2000 VL 283 IS 10 BP 1303 EP 1310 DI 10.1001/jama.283.10.1303 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 289ND UT WOS:000085628100026 PM 10714729 ER PT J AU Metz, DC Pratha, V Martin, P Paul, J Maton, PN Lew, E Pisegna, JR AF Metz, DC Pratha, V Martin, P Paul, J Maton, PN Lew, E Pisegna, JR TI Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID ATPASE-INHIBITOR PANTOPRAZOLE; PHARMACOKINETICS; SINGLE AB OBJECTIVE: The aim of this study was to assess the ability of pantoprazole to maintain gastric acid suppression in patients with gastroesophageal reflux; disease who are switched from an oral (p.o.) to an intravenous (i.v.) dosage form. METHODS: A total of 65 patients with gastroesophageal reflux disease were administered either 40 or 20 mg of p.o. pantoprazole daily for 10 days, then were switched to either a matching dose of i.v. pantoprazole or to placebo for 7 days. Acid output (basal and maximal) was measured at the end of the p.o. treatment period and on the first and last days of i.v. therapy. In the primary efficacy analysis: the acid output Values at the end of the p.o. pantoprazole treatment were compared with those at the end of the i.v. treatment. Safety was monitored by periodic vital sign measurements, clinical laboratory evaluations, ophthalmic examinations, electrocardiograms, and reports of adverse events. The data were tested by an analysis of covariance and by Wilcoxon signed rank and t tests. RESULTS: Maximal acid output (mean +/- SD) in the 40 mg and 20 mg pantoprazole group after p.o. treatment was 6.5 +/- 5.6 mEq/h and 14.5 +/- 15.5 mEq/h, respectively; whereas, at the end of the i.v. treatment period, the Values were 6.6 +/- 6.3 mEq/h and 11.1 +/- 10.2 mEq/h. respectively. In patients given i.v. placebo, acid output was significantly (p < 0.05) increased to 29.2 +/- 13.0 mEq/h by day 7. Both p.o. and i.v. pantoprazole dosage forms had similar favorable safety and tolerability profiles. CONCLUSIONS: The p.o. and i.v. formulations of pantoprazole (40 and 20 mg) are equivalent in their ability to suppress gastric acid output. The i.v. form of pantoprazole offers an alternative for gastroesophageal reflux disease patients who are unable to take the p.o. formulation. (Am J Gastroenterol 2000;95:626-633. (C) 2000 by Am. Coll. of Gastroenterology). C1 Univ Penn, Sch Med, Div Gastroenterol, Med Ctr,Dept Med,Gastrointestinal Physiol Lab, Philadelphia, PA 19104 USA. Clin Applicat Labs, San Diego, CA USA. Wyeth Ayerst Res, Dept Clin Pharmacol, Radnor, PA USA. Digest Dis Res Inst, Oklahoma City, OK USA. Univ Calif Los Angeles, CURE, W Los Angeles Vet Affairs Med Ctr, Dept Med,Div Digest Dis,Digest Dis Res Ctr, Los Angeles, CA USA. RP Metz, DC (reprint author), Univ Penn, Sch Med, Div Gastroenterol, Med Ctr,Dept Med,Gastrointestinal Physiol Lab, 3400 Spruce St, Philadelphia, PA 19104 USA. NR 12 TC 36 Z9 36 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2000 VL 95 IS 3 BP 626 EP 633 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 289DL UT WOS:000085605200011 PM 10710049 ER PT J AU Streim, JE Oslin, DW Katz, IR Smith, BD DiFilippo, S Cooper, TB Ten Have, T AF Streim, JE Oslin, DW Katz, IR Smith, BD DiFilippo, S Cooper, TB Ten Have, T TI Drug treatment of depression in frail elderly nursing home residents SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MAJOR DEPRESSION; OLD-AGE; NORTRIPTYLINE; DISEASE; PLASMA; PROGNOSIS; STATE; CARE AB The authors conducted a randomized, double-blind, 10-week clinical trial of two doses of nortriptyline in eight nursing homes. Sixty-nine patients, average 79.5 years, were randomized to receive regular doses (60 mg-80 mg/day) vs. low noses (10 mg-13 mg/day) of nortriptyline. Among the more cognitively intact patients, there was a significant quadratic relationship defining a "therapeutic window" for nortriptyline plasma levels and clinical improvement. There were also significant differences in plasma level-response relationships between depressed patients who were cognitively impaired and those who were more cognitively intact. Depression remains a syndrome that, responds to specific treatment, even in frail nursing home patients, and those depressions that occur in patients with significant dementia may represent a treatment-relevant condition with a different plasma level-response relationship than in depression alone. C1 Univ Penn, Dept Psychiat, Ralston Penn Ctr, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA USA. Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. RP Streim, JE (reprint author), Univ Penn, Dept Psychiat, Ralston Penn Ctr, Sect Geriatr Psychiat, 3615 Chestnut St,Room 237, Philadelphia, PA 19104 USA. FU NIMH NIH HHS [MH-01300, MH-52129, MH-51247] NR 33 TC 35 Z9 36 U1 0 U2 3 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD SPR PY 2000 VL 8 IS 2 BP 150 EP 159 DI 10.1176/appi.ajgp.8.2.150 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 306GR UT WOS:000086589400010 PM 10804076 ER PT J AU Freedman, R Adams, CE Adler, LE Bickford, PC Gault, J Harris, JG Nagamoto, HT Olincy, A Ross, RG Stevens, KE Waldo, M Leonard, S AF Freedman, R Adams, CE Adler, LE Bickford, PC Gault, J Harris, JG Nagamoto, HT Olincy, A Ross, RG Stevens, KE Waldo, M Leonard, S TI Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Article DE schizophrenia; genetics; nicotinic receptors; inhibition; auditory evoked potential ID ALPHA-BUNGAROTOXIN-BINDING; SENSORY GATING DEFICITS; REPEATED AUDITORY-STIMULI; RAT HIPPOCAMPUS; EVOKED-RESPONSE; P50 SUPPRESSION; CHROMOSOME-15 LOCUS; ONSET SCHIZOPHRENIA; CIGARETTE-SMOKING; LINKAGE ANALYSIS AB Many investigators have proposed that biological endophenotypes might facilitate the genetic analysis of schizophrenia. A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia. This deficit is linked to a candidate gene locus, the locus of the alpha 7-nicotinic cholinergic receptor subunit gene on chromosome 15q14. Supportive evidence has been found by other investigators, including: 1) linkage of schizophrenia to the same locus, 2) linkage of bipolar disorder to the locus; and 3) replication of the existence of this neurobiological deficit and its relation to broader neuropsychological deficits in schizophrenia. It is certain that there are many genetic factors in schizophrenia and bipolar disorder; what is needed is a complete and precise description of the contribution of each individual factor to the pathophysiology of these illnesses. (C) 2000 Wiley-Liss, Inc. C1 Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Denver VA Med Ctr Schizophrenia Res Ctr, Denver, CO USA. RP Freedman, R (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Campus Box C-268-71,4200 E 9th Ave, Denver, CO 80262 USA. RI Bickford, Paula/J-5970-2012 OI Bickford, Paula/0000-0001-9657-7725 NR 71 TC 65 Z9 66 U1 2 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD SPR PY 2000 VL 97 IS 1 BP 58 EP 64 DI 10.1002/(SICI)1096-8628(200021)97:1<58::AID-AJMG8>3.0.CO;2-Y PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 309UM UT WOS:000086787700008 PM 10813805 ER PT J AU Mundinger, TO Taborsky, GJ AF Mundinger, TO Taborsky, GJ TI Differential action of hepatic sympathetic neuropeptides: metabolic action of galanin, vascular action of NPY SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE hepatic glucose production; hepatic arterial conductance; neurotransmitter; blood flow ID NERVE-STIMULATION; ANESTHETIZED DOGS; CELIAC GANGLION; LIVER; INNERVATION; NOREPINEPHRINE; NORADRENALINE; RESPONSES; SECRETION; PANCREAS AB Activation of hepatic nerves increases both hepatic glucose production (HGP) and hepatic arterial vasoconstriction, the latter best described by a decrease of hepatic arterial conductance (HAC). Because activation of canine hepatic nerves releases the neuropeptides galanin and neuropeptide Y (NPY) as well as the classical neurotransmitter norepinephrine (NE), we sought to determine the relative role of these neuropeptides vs, norepinephrine in mediating metabolic and vascular responses of the liver. We studied the effects of local exogenous infusions of galanin and NPY on HGP and HAC to predict the metabolic and vascular function of endogenously released neuropeptide. Galanin (n = 8) or NPY (n = 4) was infused with and without NE directly into the common hepatic artery of halothane-anesthetized dogs, and we measured changes in HGP and HAC. A low dose of exogenous galanin infused directly into the hepatic artery potentiated the HGP response to NE yet had little effect on HGP when infused alone. The same dose of galanin infused into a peripheral vein (n = 8) did not potentiate the HGP response to NE, suggesting that the locally infused galanin acted directly on the liver to modulate NE's metabolic action. In contrast, a large dose of exogenous NPY failed to influence HGP when infused either alone or in combination with NE. Finally, NPY, but not galanin, tended to decrease HAC when infused alone; neither neuropeptide potentiated the HAC response to NE. Therefore, both hepatic neuropeptides may contribute to the action of sympathetic nerves on liver metabolism and blood flow It is likely that endogenous hepatic galanin acts directly on the liver to selectively modulate norepinephrine's metabolic action, whereas endogenous hepatic NPY acts independently of NE to cause vasoconstriction. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Dept Med, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Mundinger, TO (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK-12829, DK-17047, DK-50154] NR 44 TC 10 Z9 10 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAR PY 2000 VL 278 IS 3 BP E390 EP E397 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 292XD UT WOS:000085819900004 PM 10710492 ER PT J AU Chapman, GB Durante, W Hellums, JD Schafer, AI AF Chapman, GB Durante, W Hellums, JD Schafer, AI TI Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE apoptosis; cyclic strain; cyclin-dependent kinase inhibitors; proliferation; retinoblastoma ID MECHANICAL STRAIN; GROWTH-FACTOR; ENDOTHELIAL-CELLS; PULSATILE STRETCH; ANGIOTENSIN-II; APOPTOSIS; PROLIFERATION; PHOSPHATIDYLSERINE; ACTIVATION; EXPRESSION AB Smooth muscle cells (SMC) are the major cellular component of the blood vessel wall and are continuously exposed to cyclic stretch due to pulsatile blood flow This study examined the effects of a physiologically relevant level of cyclic stretch on rat aortic vascular SMC proliferation. Treatment of static SMC with serum, platelet-derived growth factor, or thrombin stimulated SMC proliferation, whereas exposure of SMC to cyclic stretch blocked the proliferative effect of these growth factors. The stretch-mediated inhibition in SMC growth was not due to cell detachment or increased cell death. Flow cytometry analysis revealed that cyclic stretch increased the fraction of SMC in the G(0)/G(1) phase of the cell cycle. Stretch-inhibited G(1)/S phase transition was associated with a decrease in retinoblastoma protein phosphorylation and with a selective increase in the cyclin-dependent kinase inhibitor p21, but not p27. These results demonstrate that cyclic stretch inhibits SMC growth by blocking cell cycle progression and suggest that physiological levels of cyclic stretch contribute to vascular homeostasis by inhibiting the proliferative pathway of SMC. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. Rice Univ, Dept Bioengn, Houston, TX 77005 USA. Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Schafer, AI (reprint author), Baylor Coll Med, Dept Med, 6550 Fannin,SM MS 1423, Houston, TX 77030 USA. FU NHLBI NIH HHS [HL-18584, HL-36045, HL-59976] NR 41 TC 65 Z9 66 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 2000 VL 278 IS 3 BP H748 EP H754 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 293FB UT WOS:000085839900009 PM 10710342 ER PT J AU Prabhu, SD Freeman, GL AF Prabhu, SD Freeman, GL TI Altered LV inotropic reserve and mechanoenergetics early in the development of heart failure SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE ventricular function; myocardial energetics; length-dependent activation; dog; pacing ID CLOSED-CHEST DOGS; FRANK-STARLING MECHANISM; END-SYSTOLIC PRESSURE; LEFT-VENTRICULAR FUNCTION; FAILING HUMAN HEART; CONSCIOUS DOGS; CARDIAC-MUSCLE; CONTRACTILE FUNCTION; HUMAN MYOCARDIUM; VOLUME RELATION AB To test the hypothesis that alterations In left ventricular (LV) mechanoenergetics and the LV inotropic response to afterload manifest early in the evolution of heart failure, we examined six anesthetized dogs instrumented with LV micromanometers, piezoelectric crystals, and coronary sinus catheters before and after 24 h of rapid ventricular pacing (RVP). After autonomic blockade, the end-systolic pressure-volume relation (ESPVR), myocardial O(2) consumption (M(V) over dotO(2)), and LV pressure-volume area (PVA) were defined at several different afterloads produced by graded infusions of phenylephrine. Short-term RVP resulted in reduced preload with proportionate reductions in stroke work and the maximum first derivative of LV pressure but with no significant reduction in baseline LV contractile state. In response to increased afterload, the baseline ESPVR shifted to the left with maintained end-systolic elastance (E(es)). In contrast, after short-term RVP,in response to comparable increases in afterload, the ESPVR displayed reduced E(es) (P < 0.05) and significantly less leftward shift compared with control (P < 0.05). Compared with the control M(V) over dotO(2)-PVA relation, short-term RVP significantly increased the M(V) over dotO(2) intercept (P ( 0.05) with no change in slope. These results indicate that short-term RVP produces attenuation of after-load-induced enhancement of LV performance and increases energy consumption for nonmechanical processes with maintenance of contractile efficiency, suggesting that early in the development of tachycardia heart failure, there is blunting of length-dependent activation and increased O(2) requirements for excitation-contraction coupling, basal metabolism, or both. Rather than being adaptive mechanisms, these abnormalities may be primary defects involved in the progression of the heart failure phenotype. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S TExas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. RP Prabhu, SD (reprint author), Univ Louisville, ACB, Div Cardiol, 3rd Floor,550 S Jackson St, Louisville, KY 40292 USA. RI Prabhu, Sumanth/D-5223-2009 NR 40 TC 11 Z9 11 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 2000 VL 278 IS 3 BP H698 EP H705 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 293FB UT WOS:000085839900003 PM 10710336 ER PT J AU Cutaia, M Tollefson, K Kroczynski, J Parks, N Rounds, S AF Cutaia, M Tollefson, K Kroczynski, J Parks, N Rounds, S TI Role of the Na/H antiport in pH-dependent cell death in pulmonary artery endothelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article; Proceedings Paper CT Meeting of the American-Thoracic-Society CY MAY, 1998 CL SAN FRANCISCO, CALIFORNIA SP Amer Thorac Soc DE sodium/hydrogen exchange; intracellular pH; intracellular cytosolic calcium ID INTRACELLULAR PH; RAT HEPATOCYTES; HYDROGEN-PEROXIDE; CHEMICAL HYPOXIA; OXIDANT STRESS; ACIDOSIS; INJURY; EXCHANGE; ATP; MYOCARDIUM AB We investigated the role of intracellular pH (pH(i)) and Na/H exchange in cell death in human pulmonary artery endothelial cells (HPAEC) following a metabolic insult (inhibition-oxidative phosphorylation, glycolysis). Metabolic inhibition in medium at pH 7.4 decreased viability (0-15% live cells) over 6 h. Cell death was attenuated by maneuvers that decreased pHi and inhibited Na/H exchange (acidosis, Na/H antiport inhibitors). In contrast, cell death was potentiated by maneuvers that elevated pHi or increased Na/H exchange (monensin, phorbol ester treatment) before the insult. HPAEC demonstrated a biphasic pHi response following a metabolic insult. An initial decrease in pHi was followed by a return to baseline over 60 min. Maneuvers that protected HPAEC and inhibited Na/H exchange (acidosis, Na+-free medium, antiport inhibitors) altered this pattern. pHi decreased, but no recovery was observed, suggesting that the return of pHi to normal was mediated by antiport activation. Although Na/H antiport activity was reduced (55-60% of control) following a metabolic insult, the cells still demonstrated active Na/H exchange despite significant ATP depletion. Phorbol ester pretreatment, which potentiated cell death, increased Na/H antiport activity above the level observed in monolayers subjected to a metabolic insult alone. These results demonstrate that HPAEC undergo a pH-dependent loss of viability linked to active Na/H exchange following a metabolic insult. Potentiation of cell death with phorbol ester treatment suggests that this cell death pathway involves protein kinase C-mediated phosphorylation events. C1 Univ Penn, Sch Med, Vet Affairs Med Ctr, Div Pulm Dis,Res Serv,Dept Med, Philadelphia, PA 19104 USA. Brown Univ, Sch Med, Vet Affairs Med Ctr, Dept Med,Pulm Crit Care Sect, Providence, RI 02908 USA. RP Cutaia, M (reprint author), Univ Penn, Sch Med, Vet Affairs Med Ctr, Div Pulm Dis,Res Serv,Dept Med, 3900 Univ & Woodland Aves, Philadelphia, PA 19104 USA. NR 43 TC 15 Z9 15 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD MAR PY 2000 VL 278 IS 3 BP L536 EP L544 PG 9 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 292AD UT WOS:000085771200015 PM 10710526 ER PT J AU Raff, H Bruder, ED Jankowski, BM Goodfriend, TL AF Raff, H Bruder, ED Jankowski, BM Goodfriend, TL TI Neonatal hypoxic hyperlipidemia in the rat: effects on aldosterone and corticosterone synthesis in vitro SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE adrenal cortex; steroidogenesis; fatty acids; cholesterol; triglycerides ID FATTY-ACIDS; CONSCIOUS RATS; RESPONSES; SECRETION; STEROIDOGENESIS; ACTH AB Neonatal hypoxia increases aldosterone production and plasma lipids. Because fatty acids can inhibit aldosterone synthesis, we hypothesized that increases in plasma lipids restrain aldosteronogenesis in the hypoxic neonate. We exposed rats to 7 days of hypoxia from birth to 7 days of age (suckling) or from 28 to 35 days of age (weaned at day 21). Plasma was analyzed for lipid content, and steroidogenesis was studied in dispersed whole adrenal glands untreated and treated to wash away lipids. Hypoxia increased plasma cholesterol, triglycerides, and nonesterified fatty acids in the suckling neonatal rat only. Washing away lipids increased aldosterone production in cells from 7-day-old rats exposed to hypoxia, but not in cells from normoxic 7-day-old rats or from normoxic or hypoxic 35-day-old rats. Addition of oleic or linolenic acid to washed cells inhibited both aldosterone and corticosterone production, although cells from hypoxic 7-day-old rats were less sensitive. We conclude that hypoxia induces hyperlipidemia in the suckling neonate and that elevated nonesterified fatty acids inhibit aldosteronogenesis. C1 St Lukes Med Ctr, Endocrine Res Lab, Milwaukee, WI 53215 USA. Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Raff, H (reprint author), St Lukes Phys Off Bldg,2801 W KK River Pkwy Suite, Milwaukee, WI 53215 USA. FU NIDDK NIH HHS [DK-54685] NR 27 TC 17 Z9 17 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR PY 2000 VL 278 IS 3 BP R663 EP R668 PG 6 WC Physiology SC Physiology GA 292RC UT WOS:000085808000016 PM 10712286 ER PT J AU Haenel, LC Mayfield, RK AF Haenel, LC Mayfield, RK TI Primary hyperparathyroidism in a twin pregnancy and review of fetal/maternal calcium homeostasis SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE hyperparathyroidism; pregnancy; calcium; parathyroid hormone-related peptide (PTHrP) ID HORMONE-RELATED PROTEIN; FETAL PARATHYROID-GLANDS; PLACENTAL TRANSPORT; INORGANIC-PHOSPHATE; LACTATION; SERUM; STIMULATION; MAGNESIUM; SHEEP AB Background: Hyperparathyroidism occurs rarely in pregnancy; this is the first reported case in a twin gestation. Management of this unusual case is described and an overview of fetal/maternal calcium homeostasis is discussed. Methods: The patient presented at 33 weeks' gestation with hypertension and premature labor. Serum calcium and phosphorus were 14.6 and 1.7 mg/dL, respectively. An intact parathyroid hormone (PTH) level was 243 pg/mL (normal, 10-65). Results: The patient was treated with parenteral saline hydration and oral phosphate supplementation that was continued through week 37. Although the calcium remained elevated between 12.6 and 13.3 mg/dL, medical therapy was continued because of the risks of surgery in the third trimester. Alternative medical treatments (bisphosphonates, calcitonin) were considered ill advised in pregnancy. The patient remained asymptomatic without further labor, and at week37, fraternal twins were delivered by cesarean section. The infants were monitored closely and experienced no hypocalcemic symptoms after delivery. Postpartum, the mother's parathyroid scan and ultrasound were negative. She underwent neck exploration and a single 700-mg adenoma was removed. Transient asymptomatic hypocalcemia (7.5 mg/dL) occurred postoperatively, and she was placed on oral calcium (1500 mg/day) and calcitriol (0.25 mg/day). These were stopped at 8 weeks, when both PTH and parathyroid hormone-related peptide levels were normal. Conclusion: Mother and infants continue to do well after 18 months. This case provides an interesting setting to consider the interrelationships between elevated maternal PTH and the fetal/placental factors that regulate calcium metabolism in pregnancy. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Mayfield, RK (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 323,POB 250624, Charleston, SC 29425 USA. NR 35 TC 20 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAR PY 2000 VL 319 IS 3 BP 191 EP 194 DI 10.1097/00000441-200003000-00011 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 295YT UT WOS:000085996800011 PM 10746832 ER PT J AU Tolcher, AW Aylesworth, C Rizzo, J Izbicka, E Campbell, E Kuhn, J Weiss, G Von Hoff, DD Rowinsky, EK AF Tolcher, AW Aylesworth, C Rizzo, J Izbicka, E Campbell, E Kuhn, J Weiss, G Von Hoff, DD Rowinsky, EK TI A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors SO ANNALS OF ONCOLOGY LA English DT Article DE antimicrotubule; cancer; phase I; rhizoxin ID BREAST-CANCER; LUNG-CANCER; I/II TRIAL; PACLITAXEL; AGENT; CELLS AB Background: Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. In preclinical evaluations, rhizoxin demonstrated broad antitumor activity in vitro and in vivo including both vincristine- and vindesine-resistant human lung cancers. Prolonged exposure schedules in xenograft models demonstrated optimal efficacy indicating schedule-dependent antitumor activity. The early phase I and II evaluations a five-minute bolus infusion schedule was studied, however, only modest anti-tumor activity was noted, possibly due to rapid systemic clearance. To overcome these limitations and to exploit the potential for schedule-dependent behavior of rhizoxin, the feasibility of administering rhizoxin as a 72-hour continuous intravenous (i.v.) infusion was evaluated. Patients and methods: Patients with advanced solid malignancies were entered into this phase I study, in which both the infusion duration and dose of rhizoxin were increased. The starting dose was 0.2 mg/m(2) over 12 hours administered every 3 weeks. In each successive dose level, the dose and infusion duration were incrementally increased in a stepwise fashion. Once a 72-hour i.v. infusion duration was reached, rhizoxin dose-escalations alone continued until a maximum tolerated dose (MTD) was determined. Results: Nineteen patients were entered into the study. Rhizoxin was administered at doses ranging from 0.2 mg/m(2) i.v. over 12 hours to 2.4 mg/m(2) i.v. over 72 hours every 3 weeks. The principal dose-limiting toxicities (DLT) were severe neutropenia and mucositis, and the incidence of DLT was unacceptably high at rhizoxin doses above 1.2 mg/m(2), which was determined to be the MTD and dose recommended for phase II studies. At these dose levels, rhizoxin could not be detected in the plasma by a previously validated and sensitive high-performance liquid chromatography assay with a lower limit of detection of 1 ng/ml. No antitumor responses were observed. Conclusions: Rhizoxin can be safely administered using a 72-hour i.v. infusion schedule. The toxicity profile is similar to that observed previously using brief infusion schedules. Using this protracted i.v. infusion schedule the maximum tolerated dose is 1.2 mg/m(2)/72 hours. C1 Univ Texas, Hlth Sci Ctr, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. Brooke Army Med Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Tolcher, AW (reprint author), Univ Texas, Hlth Sci Ctr, Inst Drug Dev, Canc Therapy & Res Ctr, 250-8122 Datapoint Dr, San Antonio, TX 78229 USA. FU NCI NIH HHS [UO1 CA69853, 5P30 CA54174]; NCRR NIH HHS [5 MOI RR01346] NR 19 TC 12 Z9 13 U1 0 U2 2 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD MAR PY 2000 VL 11 IS 3 BP 333 EP 338 DI 10.1023/A:1008398725442 PG 6 WC Oncology SC Oncology GA 297UE UT WOS:000086100400020 PM 10811501 ER PT J AU Kirkpatrick, WR McAtee, RK Fothergill, AW Loebenberg, D Rinaldi, MG Patterson, TF AF Kirkpatrick, WR McAtee, RK Fothergill, AW Loebenberg, D Rinaldi, MG Patterson, TF TI Efficacy of SCH56592 in a rabbit model of invasive aspergillosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID IN-VITRO; AMPHOTERICIN-B; ITRACONAZOLE; FUMIGATUS; INFECTION; SCH-56592; FUNGI AB SCH56592 (SCH) was evaluated in an immunosuppressed rabbit model of invasive aspergillosis. SCH was more effective than similar doses of itraconazole and as effective as amphotericin B in the clearance of Aspergillus spp. from tissues. Compared with controls, SCH regimens reduced mortality, improved survival, and significantly reduced tissue colony counts. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA. RP Kirkpatrick, WR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 17 TC 52 Z9 53 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2000 VL 44 IS 3 BP 780 EP 782 DI 10.1128/AAC.44.3.780-782.2000 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 285QF UT WOS:000085399200054 PM 10681359 ER PT J AU Weymuller, EA Yueh, B Deleyiannis, FWB Kuntz, AL Alsarraf, R Coltrera, MD AF Weymuller, EA Yueh, B Deleyiannis, FWB Kuntz, AL Alsarraf, R Coltrera, MD TI Quality of life in patients with head and neck cancer - Lessons learned from 549 prospectively evaluated patients SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT Spring Meeting of the American-Head-and-Neck-Society CY APR 24-27, 1999 CL PALM DESERT, CALIFORNIA SP Amer Head & Neck Soc ID OF-LIFE AB Objectives: To summarize our quality-of-life (QOL) research findings for patients with head and neck cancer, to suggest areas for future productive QOL research, and to discuss how to undertake QOL studies in a cost-effective manner. Design: Review of previously published analyses of advanced larynx cancer, advanced oropharynx cancer, and neck-dissection cases and current data from the complete:set of patients. Patients: From January 1, 1993, through December 31, 1998, data on 549 patients were entered in our head and neck database. Of these patients, 364 met additional criteria for histologic findings (squamous cell carcinoma) and the restriction of their cancer to 4 major anatomical sites (oral, oropharynx, hypopharynx, or larynx). Of these, 339 patients were more than 1 year beyond initial treatment. Complete baseline TNM staging and QOL data were obtained for 260 of these patients, of whom 210 presented with an untreated first primary tumor (index cases) to the University of Washington, Seattle, Intervention: Pretreatment QOL was assessed with an interviewer-supervised self-administered questionnaire. Subsequent self-administered tests were completed at 3, 6, 12, 24, and 36 months. Other data collected:on each patient included cancer site, stage, treatment, histologic findings, type of surgical reconstruction, and current disease and vital status. Results/Conclusions: It is difficult to achieve "statistically significant" results in a single-institution setting. The "composite" QOL score may not be a sufficiently sensitive tool. Analysis of separate domains may be more effective. C1 Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Surg Serv, Seattle, WA USA. RP Weymuller, EA (reprint author), Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Box 356515, Seattle, WA 98195 USA. OI Yueh, Bevan/0000-0003-1380-1053 NR 7 TC 116 Z9 121 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD MAR PY 2000 VL 126 IS 3 BP 329 EP 335 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 292RH UT WOS:000085808500011 PM 10722005 ER PT J AU Saffold, SH Wax, MK Nguyen, A Caro, JE Andersen, PE Everts, EC Cohen, JI AF Saffold, SH Wax, MK Nguyen, A Caro, JE Andersen, PE Everts, EC Cohen, JI TI Sensory changes associated with selective neck dissection SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT Spring Meeting of the American-Head-and-Neck-Society CY APR 24-27, 1999 CL PALM DESERT, CALIFORNIA SP Amer Head & Neck Soc ID CLINICALLY NEGATIVE NECK; SQUAMOUS CARCINOMA; NO NECK; MANAGEMENT; METASTASES; LARYNX AB Objective: To evaluate sensory changes in the head and neck region associated with selective neck dissection with or without preservation of cervical root branches. Design: Retrospective cohort study. Setting: University tertiary referral hospital and a Veterans Affairs hospital. Patients: Fifty-seven patients who had undergone 84 neck dissections with or without preservation of the sensory cervical root branches 3 or more months before evaluation. Interventions: Questionnaire combined with head and neck sensory examination. Main Outcome Measures: Neck and facial sensory function. Results: Neck dissections with preservation of the cervical rootlets were most likely to be associated with a small area of anesthesia in the upper neck below the body of the mandible and anterior to the mid-body of the mandible (P=.03). Neck dissections without rootlet-preserving technique increased the area of anesthesia to include all other areas of the neck (P=.02). Conclusions: Preservation of the cervical root branches resulted in a small, limited, and uniform area of the neck rendered permanently anesthetic. Conversely, sacrifice of the nerve branches led to a pattern of anesthesia involving-the entire neck. C1 Oregon Hlth Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. SUNY Buffalo, Dept Otolaryngol Head & Neck Surg, Buffalo, NY 14260 USA. Portland Vet Affairs Med Ctr, Dept Otolaryngol, Portland, OR USA. RP Cohen, JI (reprint author), Oregon Hlth Sci Univ, Dept Otolaryngol Head & Neck Surg, PV-01,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. NR 18 TC 15 Z9 18 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD MAR PY 2000 VL 126 IS 3 BP 425 EP 428 PG 4 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 292RH UT WOS:000085808500030 PM 10722022 ER PT J AU Le, HN Norton, JA AF Le, HN Norton, JA TI Perspective on RET proto-oncogene and thyroid cancer SO CANCER JOURNAL LA English DT Article ID ENDOCRINE NEOPLASIA TYPE-2A; TYROSINE KINASE; HIRSCHSPRUNG-DISEASE; SOMATIC MUTATIONS; PROTOONCOGENE; MEDULLARY; CARCINOMA; 2A; GERMLINE; CHROMOSOME-10 C1 San Francisco Vet Affairs Med Ctr, Surg Serv 112, Dept Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Norton, JA (reprint author), San Francisco Vet Affairs Med Ctr, Surg Serv 112, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. NR 34 TC 10 Z9 10 U1 0 U2 0 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PONE DR, SUDBURY, MA 01776 USA SN 1528-9117 J9 CANCER J JI Cancer J. Sci. Am. PD MAR-APR PY 2000 VL 6 IS 2 BP 50 EP 57 PG 8 WC Oncology SC Oncology GA 342YZ UT WOS:000088676100002 PM 11069217 ER PT J AU Prabhu, SD AF Prabhu, SD TI Nonlinear biphasic relationship between the time constant tan and load SO CARDIOVASCULAR RESEARCH LA English DT Letter ID LEFT-VENTRICULAR CONTRACTILITY; SYSTOLIC PRESSURE; RELAXATION C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. RP Prabhu, SD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. RI Prabhu, Sumanth/D-5223-2009 NR 9 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD MAR PY 2000 VL 45 IS 4 BP 1066 EP 1067 DI 10.1016/S0008-6363(99)00380-6 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 288MN UT WOS:000085566800031 ER PT J AU Delen, FM Sippel, JM Osborne, ML Law, S Thukkani, N Holden, WE AF Delen, FM Sippel, JM Osborne, ML Law, S Thukkani, N Holden, WE TI Increased exhaled nitric oxide in chronic bronchitis - Comparison with asthma and COPD SO CHEST LA English DT Article DE asthma; chronic bronchitis; COPD; nitric oxide ID OBSTRUCTIVE PULMONARY-DISEASE; AIR; GAS AB Study objectives: To test the hypothesis that exhaled nitric oxide (NO) is increased in patients with chronic bronchitis, and to compare the results with exhaled NO in patients with asthma and COPD. Study design: Cross-sectional survey, Setting and patients: Veterans Administration pulmonary function laboratory. Patients (n = 179) were recruited from 234 consecutive patients. Two nonsmoking control groups of similar age, with normal spirometry measurements and no lung disease, were used (18 patient control subjects and 20 volunteers), Measurements: Participants completed questionnaires and spirometry testing. Exhaled NO was measured by chemiluminescence using a single-breath exhalation technique. Results: Current smoking status was associated with reduced le, els of exhaled NO (smokers, 9.2 +/- 0.9 parts per billion [ppb]; never and ex-smokers, 14.3 +/- 0.6 ppb; p < 0.0001). Current smokers (n = 97) were excluded from further analysis. Among nonsmokers, the levels of exhaled NO were significantly higher in patients with chronic bronchitis (17.0 +/- 1.1 ppb; p = 0.035) and asthma (16.4 +/- 1.3 ppb; p = 0.05) but not in those with COPD (14.7 +/- 1.0 ppb; p = 0.17) when compared with either control group (patient control subjects, 11.1 +/- 1.6 ppb; outside control subjects, 11.5 +/- 1.5 ppb), The highest mean exhaled NO concentration occurred in patients with both chronic bronchitis and asthma (20.2 +/- 1.6 ppb; p = 0.005 vs control subjects). Conclusions: Exhaled NO is increased in patients with chronic bronchitis. The increase of exhaled NO in patients with chronic bronchitis was similar to that seen in patients with asthma, The highest mean exhaled NO occurred in patients with both chronic bronchitis and asthma, Exhaled NO was not increased in patients with COPD, Although chronic bronchitis and asthma have distinct histopathologic features, increased exhaled NO in patients with both diseases suggests common features of inflammation. C1 Portland VA Med Ctr, Pulm & Crit Care Med Sect, Portland, OR 97201 USA. RP Holden, WE (reprint author), Portland VA Med Ctr, Pulm & Crit Care Med Sect, P3-Pulm,3710 SW US Vet Rd, Portland, OR 97201 USA. NR 25 TC 53 Z9 59 U1 0 U2 5 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2000 VL 117 IS 3 BP 695 EP 701 DI 10.1378/chest.117.3.695 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 293YZ UT WOS:000085884000016 PM 10712993 ER PT J AU Ganly, I Kirn, D Eckhardt, SG Rodriguez, GI Soutar, DS Otto, R Robertson, AG Park, O Gulley, ML Heise, C Von Hoff, DD Kaye, SB AF Ganly, I Kirn, D Eckhardt, SG Rodriguez, GI Soutar, DS Otto, R Robertson, AG Park, O Gulley, ML Heise, C Von Hoff, DD Kaye, SB TI A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; RECOMBINANT ADENOVIRUS; GENE-TRANSFER; SOLID TUMORS; P53; EXPRESSION; INFECTION; CHEMOTHERAPY; ONCOPROTEIN; CISPLATIN AB An E1B 55 kDa gene-deleted adenovirus, Onyx-015, which reportedly selectively replicates in and lyses p53-deficient cells, was administered by a single intratumoral injection to a total of 22 patients with recurrent head and neck cancer. The objectives of this Phase I study were to determine the safety, feasibility, and efficacy of this therapy and determine any correlation to p53 status. Six cohorts were investigated with a dose escalation from 10(7)-10(11) plaque-forming units. Toxicity was assessed using NCIC criteria. Tumor response was assessed by clinical and radiological measurement. Blood samples were taken to detect adenovirus DNA and neutralizing antibody to adenovirus, Tumor biopsies were taken to detect adenovirus by iii situ hybridization. Treatment was well tolerated, with the main toxicity being grade 1/2 flu-like symptoms. Dose-limiting toxicity was not reached at the highest dose of 10(11) plaque-forming units. Twenty-one of the 22 patients treated showed an increase in neutralizing antibody to adenovirus, In situ hybridization showed viral replication in 4 of 22 patients treated, all of whom had mutant p53 tumors, Using conventional response criteria, no objective responses were observed. However, magnetic resonance imaging scans were suggestive of tumor necrosis at the site of viral injection in five patients, three of whom were classified using nonconventional criteria as partial responders, and two of whom were classified using nonconventional criteria as minor responders. Of these five cases, four had mutant p53 tumors. The response duration for the three partial responders was 4, 8, and 12 weeks. An additional eight patients had stable disease in the injected tumors lasting from 4-8 weeks, These preliminary results show that intratumoral administration of Onyx-015 is feasible, well tolerated, and associated with biological activity. Further investigation of Onyx-015, particularly with a more frequent injection protocol and in combination with systemic chemotherapy, is warranted. C1 CRC Beatson Labs, Crc Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland. Canniesburn Hosp, Dept Plast & Reconstruct Surg, Glasgow, Lanark, Scotland. Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. ONYX Pharmaceut, Richmond, CA 94806 USA. RP Ganly, I (reprint author), CRC Beatson Labs, Crc Dept Med Oncol, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland. NR 32 TC 312 Z9 325 U1 2 U2 6 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAR PY 2000 VL 6 IS 3 BP 798 EP 806 PG 9 WC Oncology SC Oncology GA 294KF UT WOS:000085909900007 PM 10741699 ER PT J AU Metlay, JP Hofmann, J Cetron, MS Fine, MJ Farley, MM Whitney, C Breiman, RF AF Metlay, JP Hofmann, J Cetron, MS Fine, MJ Farley, MM Whitney, C Breiman, RF TI Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIMICROBIAL RESISTANCE; INVASIVE DISEASE; UNITED-STATES; SURVEILLANCE; THERAPY; GUIDELINES; MANAGEMENT AB The impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia was evaluated in a retrospective cohort study conducted during population-based surveillance for invasive pneumococcal disease in the greater Atlanta region during 1994. Of the 192 study patients, 44 (23%) were infected with pneumococcal strains that demonstrated some degree of penicillin nonsusceptibility. Compared with patients infected with penicillin-susceptible pneumococcal strains, patients whose isolates were nonsusceptible had a significantly greater risk of in-hospital death due to pneumonia (relative risk [RR], 2.1; 95% confidence interval [CI] 1-4.3) and suppurative complications of infection (RR, 4.5; 95% CI, 1-19.3), although only risk of suppurative complications remained statistically significant after adjustment for baseline differences in severity of illness, Among adults with bacteremic pneumococcal pneumonia, infection with penicillin-nonsusceptible pneumococci is associated with an increased risk of adverse outcome. C1 Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Pittsburgh, Vet Affairs Hlth Care Syst, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Vet Affairs Hlth Care Syst, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Childhood & Resp Dis Branch, Atlanta, GA USA. Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. Vet Affairs Med Ctr, Atlanta, GA 30033 USA. RP Metlay, JP (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. NR 37 TC 197 Z9 202 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR PY 2000 VL 30 IS 3 BP 520 EP 528 DI 10.1086/313716 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 302BR UT WOS:000086345500023 PM 10722438 ER PT J AU Dai, MS Heinrich, MC Broxmeyer, HE Lu, L AF Dai, MS Heinrich, MC Broxmeyer, HE Lu, L TI Enhancing effects of co-transduction of both human erythropoietin receptor and c-kit cDNAs into hematopoietic stem/progenitor cells from cord blood on proliferation and differentiation of erythroid progenitors SO CYTOKINES CELLULAR & MOLECULAR THERAPY LA English DT Article DE EpoR; c-kit; hematopoietic stem/progenitor cells; gene transfer ID MEDIATED GENE TRANSDUCTION; COLONY FORMATION; TYROSINE KINASE; SIGNAL-TRANSDUCTION; HUMAN CD34(+); MUTANT MICE; SI-LOCUS; GM-CSF; BFU-E; CFU-E AB Steel factor (SLF) and erythropoietin (Epo) play critical roles in erythropoiesis. To evaluate Interactive effects of Epo and SLF receptors (R) in erythropoiesis, CD34(+) and CD34(+++) cord blood cells were transduced with human EpoR and c-kit cDNAs by retroviral mediated gene transfer. Erythroid (BFU-E) colonies derived from CD34(+) or CD34(+++) cells transduced with either the EpoR or c-kit gene were significantly increased in the presence of interleukin (IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), Epo, and different concentrations of SLF compared with that from mock transduced cells. This number was further enhanced by co-transduction of both genes. Enhancement was move apparent in the absence of SLF. Cell numbers in individual erythroid colonies were also significantly increased in cells transduced with both genes compared with cells transduced with a single gene. Short-term liquid culture showed that ex vivo expansion for five days and numbers of CD34(+)CD71(+) cells in expanded cells from single CD34(+++) cells co-transduced with both EpoR and c-kit genes were increased compared with those of EpoR or c-kit-transduced cells. These results demonstrate that co-transduction of both c-kit and EpoR enhances the proliferative capacity of erythroid progenitors under cytokine stimulation above that of single-gene transduced cells. C1 Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA. Walther Canc Inst, Indianapolis, IN USA. Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Lu, L (reprint author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St,R4,Room 302, Indianapolis, IN 46202 USA. FU NHLBI NIH HHS [R01 HL 54037, R01 HL 56416]; NIDDK NIH HHS [R01 DK 53674] NR 50 TC 3 Z9 4 U1 0 U2 0 PU MARTIN DUNITZ LTD PI LONDON PA LIVERY HOUSE, 7-9 PRATT ST, LONDON, ENGLAND NW1 0AE SN 1368-4736 J9 CYTOKINES CELL MOL T JI Cytokines Cell. Mol. Ther. PD MAR PY 2000 VL 6 IS 1 BP 1 EP 8 DI 10.1080/13684730050515859 PG 8 WC Biotechnology & Applied Microbiology; Cell Biology; Immunology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Cell Biology; Immunology; Research & Experimental Medicine GA 349DT UT WOS:000089029000001 PM 10976533 ER PT J AU Ubel, PA Richardson, J Menzel, P AF Ubel, PA Richardson, J Menzel, P TI Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis SO HEALTH ECONOMICS LA English DT Article DE cost-utility analysis; ethics; person trade-off; QALYs ID HEALTH-CARE; STATE; PREFERENCES; UTILITIES; ILLNESS; OREGON AB In a previous paper, it was argued that Societal Value measurement through person trade-off(PTO) elicitation offers a way to include the values of both general public and patients into cost-effectiveness analysis (CEA). It was said that patients' values could be used to estimate the effect that various health care dimensions have on health-related utility and that public values could be used to estimate the Societal Value of these changes in utility. However, this previous proposal still creates opportunities for the public to misvalue the benefit of health care interventions because of bias or misunderstanding about what the health-related utility really is of various illnesses or disabilities. A procedure that combines patient and public values into CEA to partially correct for this bias is suggested in this paper. In addition, it is pointed out that, although Societal Value measurement offers a role for distinctly public preferences in CEA, it still does not answer the question of whose utilities ought to be included in CEA. Copyright (C) 2000 John Wiley & Sons, Ltd. C1 Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Pacific Lutheran Univ, Tacoma, WA 98447 USA. RP Ubel, PA (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. NR 32 TC 46 Z9 47 U1 1 U2 10 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD MAR PY 2000 VL 9 IS 2 BP 127 EP 136 DI 10.1002/(SICI)1099-1050(200003)9:2<127::AID-HEC500>3.0.CO;2-Y PG 10 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 295UZ UT WOS:000085987400004 PM 10721014 ER PT J AU Shekelle, PG Kravitz, RL Beart, J Marger, M Wang, MM Lee, M AF Shekelle, PG Kravitz, RL Beart, J Marger, M Wang, MM Lee, M TI Are nonspecific practice guidelines potentially harmful? A randomized comparison of the effect of nonspecific versus specific guidelines on physician decision making SO HEALTH SERVICES RESEARCH LA English DT Article DE practice guidelines : nonspecific; specific; physician decision making ID LOW-BACK-PAIN; CLINICAL GUIDELINES; MEDICAL-PRACTICE AB Objective. To test the ability of two different clinical practice guideline formats to influence physician ordering of electrodiagnostic tests in low back pain. Data Sources/Study Design. Randomized controlled trial of the effect of practice guidelines on self-reported physician test ordering behavior in response to a series of 12 clinical vignettes. Data came from a national random sample of 900 U.S. neurologists, physical medicine physicians, and general internists. Intervention. Two different versions of a practice guideline for the use of electrodiagnostic tests (EDT) were developed by the U.S. Agency for Health Care Policy and Research Low Back Problems Panel. The two guidelines were similar in content but varied in the specificity of their recommendations. Data Collection. The proportion of clinical vignettes for which EDTs were ordered for appropriate and inappropriate clinical indications in each of three physician groups were randomly assigned to receive vignettes alone, vignettes plus the nonspecific version of the guideline, or vignettes plus the specific version of the guideline. Principal Findings. The response rate to the survey was 71 percent. The proportion of appropriate vignettes for which EDTs were ordered averaged 77 percent for the no guideline group, 71 percent for the nonspecific guideline group, and 79 percent for the specific guideline group (P = .002). The corresponding values for the number of EDTs ordered for inappropriate vignettes were 32 percent, 32 percent, and 26 percent, respectively (P = .08). Pairwise comparisons showed that physicians receiving the nonspecific guidelines ordered fewer EDTs for appropriate clinical vignettes than did physicians receiving no guidelines (P = .02). Furthermore, compared to physicians receiving nonspecific guidelines, physicians receiving specific guidelines ordered significantly more EDTs for appropriate vignettes (p = .0007) and significantly fewer EDTs for inappropriate vignettes (P = .04). Conclusions. The clarity and clinical applicability of a guideline may be important attributes that contribute to the effects of practice guidelines. C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Davis, Div Gen Med, Davis, CA 95616 USA. Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Davis, CA 95616 USA. RP Shekelle, PG (reprint author), W Los Angeles Vet Affairs Med Ctr, Vet Affairs Hlth Serv Res & Dev Serv, 11G,1301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI Kravitz, Richard/0000-0001-5575-529X NR 22 TC 76 Z9 76 U1 0 U2 1 PU HEALTH ADMINISTRATION PRESS PI MELROSE PARK PA C/O FOUNDATION AMER COLL HEALTHCARE EXECUTIVES 1951 CORNELL AVE, MELROSE PARK, IL 60160 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD MAR PY 2000 VL 34 IS 7 BP 1429 EP 1448 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 291GF UT WOS:000085725200003 PM 10737446 ER PT J AU Yen, TSB AF Yen, TSB TI Nuclear factor kappa B and hepatitis C - Is there a connection? SO HEPATOLOGY LA English DT Editorial Material ID VIRUS CORE PROTEIN; TUMOR-NECROSIS-FACTOR; MICE LACKING; TRANSCRIPTION; RECEPTOR C1 Univ Calif San Francisco, Dept Pathol, San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA 94143 USA. RP Yen, TSB (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco VA Med Ctr, Pathol Serv, 4150 Clement St,113B, San Francisco, CA 94143 USA. NR 14 TC 10 Z9 11 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAR PY 2000 VL 31 IS 3 BP 785 EP 787 DI 10.1002/hep.510310334 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 289JY UT WOS:000085618500033 PM 10706574 ER PT J AU Ayala, G Liu, C Nicosia, R Horowitz, S Lackman, R AF Ayala, G Liu, C Nicosia, R Horowitz, S Lackman, R TI Microvasculature and VEGF expression in cartilaginous tumors SO HUMAN PATHOLOGY LA English DT Article DE chondrosarcoma; angiogenesis; VEGF; immunoperoxidase ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-BETA; CELL-LINE; ANGIOGENESIS; INHIBITOR; NEOVASCULARIZATION; CHONDROCYTES; VASCULARIZATION; INVOLVEMENT; BONE AB We examined the microvasculature and VEGF expression in 26 cartilaginous lesions (CL) including 5 enchondromas, 9 grade 1 chondrosarcoma (CS), 6 grade 2 CS, 4 grade 3 CS, 1 mesenchymal, and 1 myxoid chondrosarcoma. The degree of neovascularization was measured by counting microvessels on H&E and factor VIII related antigen immunostained slides. Vessels were divided into pericartilage vessels (PCV) and intracartilage vessels (ICV). PVC comprised vessels around the lobules or invading the lobules but themselves surrounded by noncartilaginous stroma (ie, fibrous stroma); ICV consisted of those vessels present inside the tumoral nodules and in direct apposition with malignant cells or tumoral stroma. A direct correlation was seen between histological type and grade of CS and pericartilage vessels. In contrast, ICV were found only in higher-grade CS, No enchondromas and only 1 of 9 grade 1 CS had ICV. This patient had Oilier's disease. All but 2 of the grade 2 CS showed ICV (average, 20.5). The exceptions were predominantly grade 1 CS with focal grade 2 areas and extensive areas of necrosis. All but 1 grade 3 CS had ICV, the exception being a case of metastatic CS to the lung. Malignant chondrocytes of high-grade lesions stained strongly for vascular endothelial growth factor (VEGF), a potent angiogenic factor. The only high-grade tumors that did not express VEGF did not show ICV either. Enchondromas and grade 1 CS, most without ICV, did not express VEGF. In summary, PCV are present in all categories of tumoral cartilage and the number increases with histological grade; ICV are found in high-grade lesions, and the exceptions show extensive necrosis; VEGF expression by malignant chondrocytes is seen in high-grade lesions almost exclusively and among these in those lesions that showed intracartilage vessels. It is possible that PCV are involved in supporting tumor growth, whereas ICV might be involved in the acquisition of metastatic potential by cartilage tumors. VEGF expression is strongly associated with the presence of ICV. Copyright (C) 2000 by W.B. Saunders Company. C1 Baylor Coll Med, Dept Pathol & Lab Med, Houston, TX 77040 USA. Univ Texas, MD Anderson Canc Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA. Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Washington, Dept Pathol & Lab Med, Seattle, WA 98195 USA. MCPHU, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA. MCPHU, Sch Med, Dept Orthoped Surg, Philadelphia, PA USA. RP Ayala, G (reprint author), Baylor Coll Med, Dept Pathol & Lab Med, Mail Stop 205,1 Baylor Plaza, Houston, TX 77040 USA. FU NHLBI NIH HHS [HL52585] NR 24 TC 42 Z9 45 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD MAR PY 2000 VL 31 IS 3 BP 341 EP 346 DI 10.1016/S0046-8177(00)80248-8 PG 6 WC Pathology SC Pathology GA 296QP UT WOS:000086035800012 PM 10746677 ER PT J AU Lipsky, BA Baker, PD Ahroni, JH AF Lipsky, BA Baker, PD Ahroni, JH TI Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder SO INTERNATIONAL JOURNAL OF DERMATOLOGY LA English DT Article ID BULLOSIS DIABETICORUM; MELLITUS; MANIFESTATIONS; ERUPTION AB Background Spontaneous bullae are a characteristic type of skin lesion occurring in patients with diabetes mellitus. These diabetic bullae are considered to be a rare phenomenon; only about 100 cases have been described in the literature since the disorder was first reported 70 years ago. Methods We collected a series of patients with diabetic bullae who were referred to us at a Veterans Affairs Medical Center Clinic specializing in diabetic foot problems. We then reviewed the medical literature for similar cases and summarized the available information. Results We saw 12 patients with typical diabetic bullae over an 8-year period in our clinic. The clinical presentation and outcome of the lesions in these patients were similar to those in previously reported cases. The patients were mostly elderly, all but one had lesions located on the lower extremities, all had peripheral neuropathy, two had secondary staphylococcal infection of their bullae, and in all patients the lesions healed without scarring. Although most of the patients had had previous similar lesions, the diagnosis of diabetic bullae had not been previously reported in any of them. Conclusions We have reviewed the clinical syndrome of diabetic bullae and presented brief clinical details of these cases; we offer several vignettes and photographs of these lesions to remind clinicians of what we believe is a not so rare cutaneous disorder. C1 Vet Affairs Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Lipsky, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gen Internal Med Clin, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 34 TC 22 Z9 23 U1 0 U2 2 PU BLACKWELL SCIENCE LTD PI OXFORD PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND SN 0011-9059 J9 INT J DERMATOL JI Int. J. Dermatol. PD MAR PY 2000 VL 39 IS 3 BP 196 EP 200 DI 10.1046/j.1365-4362.2000.00947.x PG 5 WC Dermatology SC Dermatology GA 303PH UT WOS:000086430900008 PM 10759959 ER PT J AU Sreenivasan, S Kirkish, P Shoptaw, S Welsh, RK Ling, W AF Sreenivasan, S Kirkish, P Shoptaw, S Welsh, RK Ling, W TI Neuropsychological and diagnostic differences between recidivistically violent not criminally responsible and mentally ill prisoners SO INTERNATIONAL JOURNAL OF LAW AND PSYCHIATRY LA English DT Article ID PSYCHIATRIC-INPATIENTS; SUBSTANCE-ABUSE; JUSTICE SYSTEM; DISORDER; BEHAVIOR; SCHIZOPHRENIA; PREDICTORS; OFFENDERS; PSYCHOSIS; EEG C1 W Los Angeles Vet Adm Med Ctr, Forens Outreach Serv, Dept 691B116, Los Angeles, CA 90073 USA. Calif Dept Mental Hlth, Sacramento, CA USA. Los Angeles Addict Treatment Res Ctr, Los Angeles, CA USA. Friends Res Inst Inc, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Sreenivasan, S (reprint author), W Los Angeles Vet Adm Med Ctr, Forens Outreach Serv, Dept 691B116, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 52 TC 5 Z9 6 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-2527 J9 INT J LAW PSYCHIAT JI Int. J. Law Psychiatr. PD MAR-APR PY 2000 VL 23 IS 2 BP 161 EP 172 DI 10.1016/S0160-2527(99)00040-0 PG 12 WC Law; Psychiatry SC Government & Law; Psychiatry GA 310PT UT WOS:000086837100004 PM 10813114 ER PT J AU Wong, M Germanson, T Taylor, WR Cohen, IS Perry, G Baruch, L Deedwania, P Lopez, B Cohn, JN AF Wong, M Germanson, T Taylor, WR Cohen, IS Perry, G Baruch, L Deedwania, P Lopez, B Cohn, JN TI Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE V-HeFT III; left ventricular emptying; echocardiography; reproducibility ID DIASTOLIC FUNCTION; ENALAPRIL; THERAPY; VARIABILITY; VALIDATION; MASS AB Background: The echocardiographic substudy of the Vasodilator-Heart Failure Trial III (V-HeFT III) aimed to determine if felodipine treatment in patients with heart failure who were taking an angiotensin-converting enzyme inhibitor had a favorable effect on left ventricular (LV) structure and function. Earlier V-HeFT trials showed that hydralazine isosorbide dinitrate improved ejection fraction (EF) and survival, whereas enalapril achieved greater survival with smaller increases in EF. Would the combination of a potent vasodilator and enalapril produce greater improvements in function and survival? Methods and Results: Doppler-echocardiographic data were collected from 260 males with heart failure who were randomized to felodipine or a placebo. Mean intrasubject differences between baseline, at 3 months, and at 12 months were compared. Intersite and intrareader reproducibilities were measured from duplicate recordings and readings. At 3 months, no changes in ultrasound variables from baseline occurred in either group. At 12 months, felodipine patients achieved greater increases in EF, shortening of LV end-systolic length, and increases in stroke volume index. Reproducibility coefficients of variation were 7.4% (EF), 6.0% (end-diastolic length), and 13.0% (stroke volume index). Conclusions: The echocardiographic substudy showed that felodipine, added to heart failure therapy, increased EF, shortened end-systolic length, and increased stroke volume index. The changes were small and confirmed that reproducibility from multiple laboratories can be coordinated into a useful research tool. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles Div, Los Angeles, CA 90073 USA. Pharmaceut Res Associates, Charlottesville, VA USA. Emory Univ, Dept Med, Atlanta, GA 30322 USA. Vet Adm Med Ctr, Cardiol Sect, W Haven, CT 06516 USA. Vet Adm Med Ctr, Cardiol Sect, Birmingham, AL USA. Vet Adm Med Ctr, Cardiol Sect, Bronx, NY 10468 USA. Vet Adm Med Ctr, Cardiol Sect, Fresno, CA USA. Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA. RP Wong, M (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles Div, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 27 TC 9 Z9 11 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD MAR PY 2000 VL 6 IS 1 BP 19 EP 28 DI 10.1016/S1071-9164(00)00008-7 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 295EP UT WOS:000085954000005 PM 10746815 ER PT J AU Kurihara, N Reddy, SV Menaa, C Anderson, D Roodman, GD AF Kurihara, N Reddy, SV Menaa, C Anderson, D Roodman, GD TI Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MARROW CULTURES; BONE TISSUE; DISEASE; CELLS; IDENTIFICATION; ANTIGENS AB Osteoclasts (OCLs) in Paget's disease are markedly increased in number and size, have increased numbers of nuclei per multinucleated cell, and demonstrate increased resorption capacity and increased sensitivity to 1,25-(OH)(2)D-3, the active form of vitamin D. These cells also contain nuclear inclusions, reminiscent of those seen in paramyxovirus-infected cells, which cross-react with antibodies to measles virus nucleocapsid (MVNP) antigen. To elucidate the role of MV in the abnormal OCL phenotype of Paget's disease, we transduced normal OCL precursors with retroviral vectors expressing MVNP and the MV matrix (MVM) genes. The transduced cells were then cultured with 1,25-(OH)(2)D-3 for 14 or 21 days to induce formation of OCL-like multinucleated cells. The MVNP-transduced cells formed increased numbers of multinucleated cells, which contained many more nuclei and had increased resorption capacity compared with multinucleated cells derived from empty vector-transduced (EV-transduced) and MVM-transduced or normal bone marrow cells. Furthermore, MVNP-transduced cells showed increased sensitivity to 1,25-(OH)(2)D-3, and formed OCLs at concentrations of 1,25-(OH)(2)D-3 that were 1 log lower than that required for normal, EV-transduced, or MVM-transduced cells. These results demonstrate that expression of the MVNP gene in normal OCL precursors stimulates OCL formation and induces OCLs that express a phenotype similar to that of pagetic OCLs. These results support a potential pathophysiologic role for MV infection in the abnormal OCL activity and morphology that are characteristic of pagetic OCLs. C1 Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78229 USA. Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Roodman, GD (reprint author), Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NCI NIH HHS [P01 CA040035]; NIA NIH HHS [AG13625, R01 AG013625]; NIAMS NIH HHS [AR41336, R01 AR044603, R01 AR041336]; NIDCR NIH HHS [R01 DE012603, DE12603] NR 20 TC 73 Z9 75 U1 1 U2 1 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2000 VL 105 IS 5 BP 607 EP 614 DI 10.1172/JCI8489 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 291QD UT WOS:000085746800012 PM 10712432 ER PT J AU von Pawel, J von Roemeling, R Gatzemeier, U Boyer, M Elisson, LO Clark, P Talbot, D Rey, A Butler, TW Hirsh, V Olver, I Bergman, B Ayoub, J Richrdson, G Dunlop, D Arcenas, A Vescio, R Viallet, J Treat, J AF von Pawel, J von Roemeling, R Gatzemeier, U Boyer, M Elisson, LO Clark, P Talbot, D Rey, A Butler, TW Hirsh, V Olver, I Bergman, B Ayoub, J Richrdson, G Dunlop, D Arcenas, A Vescio, R Viallet, J Treat, J TI Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID COMPARING CISPLATIN; BIOREDUCTIVE AGENT; SOLID TUMORS; PHASE-II; SR-4233; CHEMOTHERAPY AB Purpose: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors (CATAPULT I), wets designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with previously untreated NSCLC were randomized to receive either tirapazamine (390 mg/m(2) infused over 2 hours) followed 1 hour later by cisplatin (75 mg/m(2) over 1 hour) or 75 mg/m(2) of cisplatin alone, every 3 weeks for a maximum of eight cycles. Results: A total of 446 patients with NSCLC (17% with stage IIIB disease and pleural effusions: 83% with stage IV disease) were entered onto the study. Karnofsky performance status (KPS) was greater than or equal to 60 for all patients (for 10%, KPS = 60; for 90%, KPS = 70 to 100). Sixty patients (14%) had clinically stable brain metastases. The median survival was significantly longer (34.6 v 27.7 weeks; P = .0078) and the response rate was significantly greater (27.5% v 13.7%; P < .001) for patients who received tirapazamine plus cisplatin (n = 218) than for those who received cisplatin alone in = 219). The tirapazamine-plus-cisplatin regimen was associated with mild to moderate adverse events, including acute, reversible hearing loss, reversible, intermittent muscle cramping, diarrhea, skin rash, nausea, and vomiting. There were no incremental increases in my elosuppression, peripheral neuropathy, or renal, hepatic, or cardiac toxicity and no deaths related to tirapazamine. Conclusion: The CATAPULT 1 study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies. (C) 2000 by American Society of Clinical Oncology. C1 Asklepios Klin, Leiter Abt Onkol, D-82121 Gauting, Germany. Hosp Grosshansdorf, Hamburg, Germany. Sanofi Res, Malvern, PA USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. Royal Prince Alfred Hosp, Camperdown, NSW, Australia. Royal Adelaide Hosp, Adelaide, SA 5000, Australia. Monash Med Ctr, Clayton, Vic 3168, Australia. Univ Hosp, Malmo, Sweden. Sahlgrenska Univ Hosp, Gothenburg, Sweden. Clatterbridge Ctr Oncol, Clatterbridge, Merseyside, England. Churchill Hosp, Oxford OX3 7LJ, England. Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland. Sanofi Rech, Gentilly, France. Clarksville Reg Hematol Oncol Grp, Clarksville, TN USA. Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada. Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada. Washington DC Vet Affairs Med Ctr, Washington, DC USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP von Pawel, J (reprint author), Asklepios Klin, Leiter Abt Onkol, Robert Koch Allee 2, D-82121 Gauting, Germany. RI Olver, Ian/I-1518-2015 OI Olver, Ian/0000-0001-5478-1576 NR 28 TC 214 Z9 216 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR PY 2000 VL 18 IS 6 BP 1351 EP 1359 PG 9 WC Oncology SC Oncology GA 296JE UT WOS:000086020600026 PM 10715308 ER PT J AU Zimmerman, P Lu, DSK Yang, LY Chen, SA Sayre, J Kadell, B AF Zimmerman, P Lu, DSK Yang, LY Chen, SA Sayre, J Kadell, B TI Hepatic metastases from breast carcinoma: Comparison of noncontrast, arterial-dominant, and portal-dominant phase spiral CT SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE computed tomography, spiral; breast, neoplasms; metastases; liver, neoplasms ID HELICAL CT; HEPATOCELLULAR CARCINOMAS; LIVER METASTASES; VENOUS PHASE; NEOPLASMS; LESIONS; IMAGES; SCANS AB Purpose: The purpose of this work was to determine the relative value of noncontrast (NC), arterial-dominant (AD), and portal-dominant (PD) phase images in spiral CT of the liver for breast cancer metastases. Method: Forty-four spiral CT scans in 18 patients with hepatic metastases from breast cancer were retrospectively reviewed by three radiologists. Subjective evaluation!; of overall lesion conspicuity and margination were graded on a 5 point scale for NC, AD, and PD phase images, and the three phases were also ranked for demonstration of overall tumor volume. Those scans with hypervascular lesions were separately analyzed, resulting in three groups (all, hypervascular, hypovascular). Results: For lesion conspicuity and margination for the entire study group, AD phase images showed the lowest grades (1.97 and 1.83), whereas the PD phase showed the highest grade (3.34 and 3.14; p < 0.0001) followed by NC (2.36 and 2.42; p < 0.0001). For the hypervascular subgroup, the AD phase also showed the lowest grades (2.39 and 2.24). In no case did the AD phase show more lesions than the combination of NC and PD phases. For depiction of overall tumor volume, the AD phase had the lowest ranking (2.51) compared with the NC and PD phases (1.71 and 1.78; p < 0.001). For the hypervascular subgroup, the AD phase had the lowest ranking (2.33) compared with the NC and PD phases (1.39 and 2.27; p < 0.0001). Conclusion: The AD phase is not required for lesion detection in spiral CT for hepatic metastases from breast carcinoma. The NC phase depicts the maximal tumor volume. C1 Univ Calif Los Angeles, Med Ctr, Dept Radiol Sci, Los Angeles, CA 90024 USA. RP Zimmerman, P (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 21 TC 7 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD MAR-APR PY 2000 VL 24 IS 2 BP 197 EP 203 DI 10.1097/00004728-200003000-00003 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 296LX UT WOS:000086026800003 PM 10752878 ER PT J AU Sattin, A AF Sattin, A TI Obstructive sleep apnea as a risk factor for treatment-resistant depression. SO JOURNAL OF ECT LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, ECT Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1095-0680 J9 J ECT JI J. ECT PD MAR PY 2000 VL 16 IS 1 MA 5 BP 78 EP 79 PG 2 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA 293XM UT WOS:000085880600026 ER PT J AU Covinsky, KE Chren, MM Harper, DL Way, LE Rosenthal, GE AF Covinsky, KE Chren, MM Harper, DL Way, LE Rosenthal, GE TI Differences in patient-reported processes and outcomes between men and women with myocardial infarction SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE myocardial infarction; gender; patient-reported processes; outcomes; health status; patient satisfaction ID CORONARY-ARTERY DISEASE; SEX-DIFFERENCES; INTERVENTION REGISTRY; THROMBOLYTIC THERAPY; GENDER DIFFERENCES; MORTALITY; MANAGEMENT; PROGNOSIS; SURVIVAL; TRIAGE AB OBJECTIVE: Previous research measuring differences in the care between men and women with myocardial infarction has focused on differences in procedure use and mortality. How ever, little is known about differences in processes and outcomes that are reported by patients, such as interpersonal processes of care and health status. Our goal was to measure differences in patient-reported measures for men and women who recently were hospitalized with myocardial infarction. PARTICIPANTS AND SETTING: We surveyed by mail patients with myocardial infarction discharged to home from one of 27 Cleveland area hospitals 3 months following discharge; 502 (64%) of 783 patients responded. The mean age of subjects was 65 years and 40% were women. MEASUREMENTS: Process measures included the quality of communication during the hospitalization and at time of discharge and reports of health education discussions during hospitalization. Outcome measures included physical and mental health component scores of the Medical Outcomes Study 36-Item Short-Form Health Survey, change in work status, and days spent in bed because of ill health. We compared processes and outcomes in men and women using multivariate analyses that adjusted for age, other demographic characteristics, comorbid conditions, severity of the myocardial infarction, and premorbid global health status. MAIN RESULTS: In multivariate analyses, women were as likely as men to report at least one problem with communication during the hospitalization (odds ratio [OR] 0.86; 95% confidence interval [95% CI] 0.56 to 1.33) or at time of discharge (OR 1.24; 95% CI, 0.82 to 1.89) and to report that they were given dietary advice before discharge (OR 0.60; 95% CI, 0.36 to 1.01), were told what to do if they developed chest pain (OR 1.21; 95% CI, 0.66 to 2.23), or, if they smoked cigarettes, given advice about how to stop smoking (OR 0.64; 95% CI, 0.26 to 1.58). However, 3 months after discharge, women reported worse physical health (P < .05) and mental health (P < .05), were more likely to report spending time in bed because of ill health (OR 1.80; 95% CI, 1.06, 3.05), and were more likely to report working less than before their myocardial infarction (OR 4.02; 95% CI, 1.58 to 10.20). CONCLUSIONS: In terms of processes of care measured with patient reports, women with myocardial infarction reported their quality of care to be similar to that of men. However, 3 months following myocardial infarction, women reported worse health status and were less likely to return to work than men. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Covinsky, KE (reprint author), San Francisco VA Med Ctr, 111G,4150 Clement St,Bldg 1, San Francisco, CA 94121 USA. FU NIA NIH HHS [Z01 AG000714, 1K08AG00714]; NIAMS NIH HHS [K08AR01962] NR 30 TC 22 Z9 22 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2000 VL 15 IS 3 BP 169 EP 174 DI 10.1046/j.1525-1497.2000.01269.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 292ZY UT WOS:000085828100004 PM 10718897 ER PT J AU Soler-Rodriguez, AM Zhang, HW Lichenstein, HS Qureshi, N Niesel, DW Crowe, SE Peterson, JW Klimpel, GR AF Soler-Rodriguez, AM Zhang, HW Lichenstein, HS Qureshi, N Niesel, DW Crowe, SE Peterson, JW Klimpel, GR TI Neutrophil activation by bacterial lipoprotein versus lipopolysaccharide: Differential requirements for serum and CD14 SO JOURNAL OF IMMUNOLOGY LA English DT Article ID BORRELIA-BURGDORFERI LIPOPROTEINS; SYNTHETIC LIPOPEPTIDE ANALOGS; OUTER SURFACE LIPOPROTEINS; NF-KAPPA-B; TREPONEMA-PALLIDUM; CYTOKINE PRODUCTION; HUMAN-MONOCYTES; L-SELECTIN; PROTEIN-A; LIPID-A AB Neutrophil activation plays an important role in the inflammatory response to Gram-negative bacterial infections. LPS has been shown to be a major mediator of neutrophil activation which is accompanied by an early down-regulation of L-selectin and up-regulation of CD11b/CD18, In this study, we investigated whether lipoprotein (LP), the most abundant protein in the outer membrane of bacteria from the family Enterobacteriaceae, can activate neutrophils and whether this activation is mediated by mechanisms that differ from those used by LPS or Escherichia coli diphosphoryl lipid A (EcDPLA), Neutrophil activation was assessed by measuring down-regulation of L-selectin and up-regulation of CD11b/CD18, When comparing molar concentrations of LP vs EcDPLA, LP was more potent (four times) at activating neutrophils, In contrast to LPS/EcDPLA, LP activation of neutrophils was serum independent, However, LP activation of neutrophils was enhanced by the addition of soluble CD14 and/or LPS-binding protein. In the presence of serum, LP activation of neutrophils was inhibited by different mAbs to CD14. This inhibition was significantly reduced or absent when performed in the absence of serum, Diphosphoryl lipid A from Rhodobacter spheroides (RaDPLA) completely inhibited LPS/EcDPLA activation of neutrophils but only slightly inhibited LP activation of neutrophils, These results suggest that LP activation of human neutrophils can be mediated by a mechanism that is different from LPS activation and that LP is a potentially important component in the development of diseases caused by Gram-negative bacteria of the family Enterobacteriaceae. C1 Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA. Curagen Corp, Branford, CT 06405 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Dept Bacteriol, Madison, WI 53705 USA. RP Klimpel, GR (reprint author), Univ Texas, Med Branch, Dept Microbiol & Immunol, Route 1070,301 Univ Blvd, Galveston, TX 77555 USA. NR 70 TC 48 Z9 53 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAR 1 PY 2000 VL 164 IS 5 BP 2674 EP 2683 PG 10 WC Immunology SC Immunology GA 286YU UT WOS:000085477100050 PM 10679108 ER PT J AU Knowlton, AA Sun, LM AF Knowlton, AA Sun, LM TI Differential effects of hormones on heat shock protein expression SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2000 VL 48 IS 2 MA 68 BP 193A EP 193A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CE UT WOS:000086346700084 ER PT J AU Livingston, EH Lee, S AF Livingston, EH Lee, S TI Fractal modeling provides for precise estimation of body surface area in normal weight and obese humans SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2000 VL 48 IS 2 MA 89 BP 196A EP 196A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CE UT WOS:000086346700101 ER PT J AU Wolden-Hanson, T Matsumoto, AM AF Wolden-Hanson, T Matsumoto, AM TI Neuroendocrinology of energy balance in the aging male Brown Norway rat. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Sch Med, Dept Med, Seattle, WA USA. Univ Washington, Sch Med, Div Geriatr, Seattle, WA USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. Univ Washington, Sch Med, Populat Ctr Res Reprod, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2000 VL 48 IS 2 MA 142 BP 205A EP 205A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CE UT WOS:000086346700154 ER PT J AU Clever, SL Edwards, KA Feudtner, C Braddock, CH AF Clever, SL Edwards, KA Feudtner, C Braddock, CH TI Defining the "hidden curriculum": Does medical students' ethical experience on clinical rotations vary by specialty? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2000 VL 48 IS 2 MA 229 BP 225A EP 225A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CE UT WOS:000086346700242 ER PT J AU Geraci, JM Johnson, ML Gordon, HS Peterson, NJ Daley, J Hur, K Henderson, WG Khuri, SF Wray, NP AF Geraci, JM Johnson, ML Gordon, HS Peterson, NJ Daley, J Hur, K Henderson, WG Khuri, SF Wray, NP TI Mortality after non-cardiac surgery: Prediction from administrative versus clinical data SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Houston VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Inst Hlth Policy, Boston, MA USA. Edward Hines Vet Adm Med Ctr, Cooperat Studies Program, Hines, IL 60141 USA. Vet Adm Med Ctr W Roxbury, Surg Serv, W Roxbury, MA USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAR PY 2000 VL 48 IS 2 MA 240 BP 227A EP 227A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CE UT WOS:000086346700253 ER PT J AU Morganelli, PM Kenedy, SM Mitchell, TI AF Morganelli, PM Kenedy, SM Mitchell, TI TI Differential effects of interferon-gamma on metabolism of lipoprotein immune complexes mediated by specific human macrophage Fc gamma receptors SO JOURNAL OF LIPID RESEARCH LA English DT Article DE Fc receptors; scavenger receptors; bispecific antibodies; gamma interferon; human macrophages; lipoproteins; lipoprotein metabolism; cholesterol metabolism; cholesterol linoleate; cholesterol trafficking ID LOW-DENSITY-LIPOPROTEIN; HUMAN MONOCYTE-MACROPHAGES; ACYL-COENZYME-A; CHOLESTERYL ESTER ACCUMULATION; FOAM CELL-FORMATION; OXIDIZED LDL; SCAVENGER RECEPTOR; SELECTIVE UPTAKE; HYPERCHOLESTEROLEMIC RABBITS; MONONUCLEAR PHAGOCYTES AB The objectives were to determine whether there are differences in the mechanisms of lipoprotein metabolism associated with different Fc gamma Rs and how metabolism associated with Fc gamma Rs compares to that mediated by scavenger receptors (SRA). To analyze lipoprotein metabolism in a receptor-specific manner, bispecific antibodies were used to target low density lipoproteins (LDL) labeled with I-125 or. [H-3]cholesterol linoleate to Fc gamma RI or Fc gamma RIIA in human macrophages, Interferon-gamma (IFN-gamma), which stimulates expression of Fc gamma RI while inhibiting expression of SRA, was used to help delineate differences in metabolism between each receptor. For each receptor, the total amount of lipoprotein degradation paralleled changes in receptor expression induced by IFN-gamma, In particular, while SPA-mediated degradation typically exceeded degradation mediated by Fc gamma RI, in IFN-gamma-treated cells degradation associated with Fc gamma RI and SRA was similar. Assay of [H-3]cholesterol linoleate-labeled lipoproteins indicated that total uptake and hydrolysis of [H-3]cholesterol linoleate was similar for each class of receptor, and inhibited by IFN-gamma, For Fc gamma RI versus Fc gamma RIIA, in the presence or absence of IFN-gamma, the [H-3]cholesterol derived from Fc gamma RIIA-mediated uptake was preferentially targeted for reesterification to [H-3]cholesterol oleate, in comparison to that resulting from hydrolysis of [H-3]cholesterol linoleate incorporated by selective uptake. For SRA, the formation of [3H]cholesterol oleate, which was substantial in control cells, was significantly inhibited in the presence of IFN-gamma. We conclude that there may be differences in cholesterol trafficking with respect to lipoprotein immune complex metabolism mediated by different classes of Fc gamma Rs. C1 US Dept Vet Affairs, White River Junction, VT 05009 USA. Dartmouth Med Sch, Dept Microbiol, Lebanon, NH 03756 USA. RP Morganelli, PM (reprint author), US Dept Vet Affairs, White River Junction, VT 05009 USA. FU NIA NIH HHS [AG14405-01] NR 65 TC 6 Z9 8 U1 0 U2 0 PU LIPID RESEARCH INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAR PY 2000 VL 41 IS 3 BP 405 EP 415 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 299XZ UT WOS:000086224900010 PM 10706588 ER PT J AU Mendez, MF AF Mendez, MF TI Corticobasal ganglionic degeneration with Balint's syndrome SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article AB Corticobasal ganglionic degeneration (CBGD) is a neurodegenerative dementia characterized by asymmetric parkinsonism, ideomotor apraxia, myoclonus, dystonia, and the alien hand syndrome. This report describes a patient with CBGD who developed Balint's syndrome with simultanagnosia, oculomotor apraxia, and optic ataxia. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 11 TC 23 Z9 25 U1 0 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2000 VL 12 IS 2 BP 273 EP 275 DI 10.1176/appi.neuropsych.12.2.273 PG 3 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 314UH UT WOS:000087075600015 PM 11001609 ER PT J AU Korostoff, JM Wang, JF Sarment, DP Stewart, JCB Feldman, RS Billings, PC AF Korostoff, JM Wang, JF Sarment, DP Stewart, JCB Feldman, RS Billings, PC TI Analysis of in situ protease activity in chronic adult periodontitis patients: Expression of activated MMP-2 and a 40 kDa serine protease SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE periodontitis/pathogenesis; proteases, matrix metallo; proteases, serine; periodontitis/drug therapy; tetracycline/therapeutic use ID MATRIX METALLOPROTEINASES; COLLAGENASE ACTIVITY; TISSUE DESTRUCTION; GINGIVAL; INHIBITORS; NEUTROPHIL; TETRACYCLINES; DISEASES; PROTEINASES; BREAKDOWN AB Background: Periodontitis is characterized by extensive destruction of the gingival tissues and associated supporting structures of the teeth. Although the pathogenesis of the various forms of this disease is not completely understood, host-derived proteases are believed to have an important role. In this study, we analyzed human tissue samples from chronic adult periodontitis patients to assess the levels of specific proteases and determine the effect of pH and tetracyclines on their activity. Methods: Gingival tissue samples were obtained from patients with chronic adult periodontitis (probing depths ranged from 5 to 9 mm) and periodontally healthy controls. Tissue extracts were prepared and analyzed for protease activity by zymography and Western blotting. Results: Maximal protease activity from clinically normal and diseased tissues was observed at pH 8. Latent matrix metalloproteinase (MMP)-9 and MMP-2 were expressed in all samples examined, while active MMP-2 was detected only in tissues obtained from patients with clinical disease. The MMP activities were differentially inhibited by derivatives of tetracycline. At pH 6, a protease with a mass of approximately 40 kDa was observed in diseased samples. The enzymatic activity was inhibited by phenylmethylsulfonyl fluoride, suggesting it is a serine protease. Conclusions: The results of the current study substantiate the proposed role of host-derived proteases in the pathogenesis of chronic adult periodontitis. Specifically, they indicate that activated MMP-2 and a 40 kDa serine protease are involved in tissue destruction associated with this form of periodontal disease and also suggest that tissue pH influences protease activity in situ. C1 Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Dent Med, Dept Pathol, Philadelphia, PA 19104 USA. Univ Penn, Sch Dent Med, Dept Periodont, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Dent Serv, Philadelphia, PA USA. Univ Penn, Sch Dent Med, Dept Anat & Histol, Philadelphia, PA 19104 USA. RP Korostoff, JM (reprint author), Univ Penn, Sch Dent Med, Dept Microbiol, 4010 Locust St, Philadelphia, PA 19104 USA. NR 33 TC 44 Z9 50 U1 0 U2 1 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD MAR PY 2000 VL 71 IS 3 BP 353 EP 360 DI 10.1902/jop.2000.71.3.353 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 411GD UT WOS:000167489100003 PM 10776921 ER PT J AU Minghetti, PP Blackburn, WD AF Minghetti, PP Blackburn, WD TI Effects of sulfasalazine and its metabolites on steady state messenger RNA concentrations for inflammatory cytokines, matrix metalloproteinases, and tissue inhibitors of metalloproteinase in rheumatoid synovial fibroblasts SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE sulfasalazine; mRNA concentration; rheumatoid synovial fibroblasts ID NF-KAPPA-B; EXPRESSION; PROTEINS AB Objective. To determine the effects of sulfasalazine (SASP) and its metabolites sulfapyridine (SP) and 5-amino salicylic acid (5ASA) on steady state mRNA levels of inflammatory cytokines [interleukin 1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha)], matrix metalloproteinases [collagenase (MMP1), stromelysin (MMP3), gelatinase 72 kDa (MMP2)], tissue inhibitors of metalloproteinase (TIMP 1 and TIMP 2), and the TNF-alpha receptor in rheumatoid synovial fibroblasts. Methods, Cells were dosed with each compound for 24 h in the presence or absence of PMA inducer and messenger RNA (mRNA) extracted and subjected to Northern blot analysis. Messenger RNA levels were quantitated by densitometry and normalized to GAPDH or 18S rRNA. Results. We observed some modest effects of sulfasalazine and its metabolites on steady state mRNA levels including: (1) repressed mRNA levels for TNF-alpha [approximate to 40% with 3x (drug median serum concentration) all 3 drugs], stromelysin (approximate to 24% with 3x all 3 drugs and approximate to 31% with 3x 5ASA), and collagenase (approximate to 27% with 3x 5ASA); (2) elevated mRNA levels for TIMP 2 (3.5 kb transcript) (51% with 3x SP and 44% with 3x 5ASA), gelatinase (approximate to 20% with 3x SP and 3x 5ASA), stromelysin (approximate to 40% with 3x and 1x SASP), IL-1 beta (approximate to 31% with 0.1x 5ASA); and (3) no effect on mRNA levels for TNF-alpha receptor and TIMP 1. Conclusion. (1) SASP and its metabolites showed varied effects on steady state mRNA concentrations for gene transcripts that fell into 3 categories: (a) repressed, (b) elevated, (c) no effect on mRNA levels. (2) No apparent linear dose response effect was observed for SASP or its metabolites, although a generalized suppression of mRNA levels at all doses was seen in some cases. (3) No predominant suppressive effect (greater than or equal to 50%) of mRNA levels by any of the drugs was observed for any of the genes studied; however, TIMP 2 mRNA levels increased 51% with 3x SP and 44% with 3x 5ASA. C1 Birmingham VA Med Ctr, Dept Rheumatol, Birmingham, AL 35233 USA. RP Blackburn, WD (reprint author), Birmingham VA Med Ctr, Dept Rheumatol, Res Wing,Room 2R28,700 S 19th St, Birmingham, AL 35233 USA. NR 13 TC 6 Z9 6 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2000 VL 27 IS 3 BP 653 EP 660 PG 8 WC Rheumatology SC Rheumatology GA 290WG UT WOS:000085700400017 PM 10743803 ER PT J AU Lehmann, KG Popma, JJ Werner, JA Lansky, AJ Wilensky, RL AF Lehmann, KG Popma, JJ Werner, JA Lansky, AJ Wilensky, RL TI Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article; Proceedings Paper CT 70th Scientific Session of the American-Heart-Association Meeting CY NOV 09-13, 1997 CL ORLANDO, FLORIDA SP Amer Heart Assoc ID PLATELET-DEPENDENT THROMBOSIS; MUSCLE CELL-PROLIFERATION; DRUG-DELIVERY; BALLOON ANGIOPLASTY; INJURY MODEL; IN-VITRO; RESTENOSIS; ARTERY; DISSECTION; ATHERECTOMY AB Objectives. This study sought to determine the safety,: feasibility and outcome of local delivery of cytochalasin B at the site of coronary angioplasty. Background. Previous failures in the pharmacologic prevention of restenosis may have been related to inadequate dosing at the angioplasty site as a result of systemic drug administration. Alternatively, although previous experimental protocols have typically targeted control of excess tissue growth (intimal hyperplasia), it now appears that overall arterial constriction (vascular remodeling) is the major contributor to late lumen loss. Cytochalasin B inhibits the polymerization of actin and has proved to be a potent inhibitor of vascular remodeling in animal models. Methods. In this phase I, multicenter, randomized, controlled trial, cytochalasin B (or matching placebo) was administered to the site of a successful balloon angioplasty using a microporous local delivery infusion balloon. Results. The rate of drug delivery at a constant infusion-pressure varied significantly from patient to patient (range 1.7 to 20.2 ml/min), perhaps related to a variable constricting effect of the atherosclerotic plaque on the infusion balloon. The minimal stenosis diameter after the procedure was slightly better in the active drug-group (1.86 +/- 0.44 vs. 1.49 +/- 0.63 mm, p < 0.03), but this difference was not seen: at Four to six weeks. Although the study was not powered for clinical outcomes (n = 43), the combined end point (death, nonfatal infarction or repeat revascularization) was encountered in 20% of the patients receiving cytochalasin B and in 38% of the patients receiving placebo. Clinical restenosis occurred in 18% of the treatment group and 22% of the placebo-group. There were no significant differences between groups in biochemical or electrocardiographic variables. Conclusions. Cytochalasin B can be safely administered by local delivery after successful coronary angioplasty and warrants further study of its efficacy in reducing restenosis. (C) 2000 by the American College of Cardiology. C1 Univ Washington, Sect Cardiol 111C, Vet Affairs Puget Sound Hlth Care Syst, Sch Med,Div Cardiol, Seattle, WA 98108 USA. Providence Hlth Grp, Seattle, WA USA. Washington Hosp Ctr, Washington, DC 20010 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Lehmann, KG (reprint author), Univ Washington, Sect Cardiol 111C, Vet Affairs Puget Sound Hlth Care Syst, Sch Med,Div Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 40 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 1 PY 2000 VL 35 IS 3 BP 583 EP 591 DI 10.1016/S0735-1097(99)00603-8 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 292CD UT WOS:000085775800006 PM 10716458 ER PT J AU Knight, RA Remington, PL AF Knight, RA Remington, PL TI Training internal medicine residents to screen for domestic violence SO JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE LA English DT Article ID BATTERED WOMEN; PREVALENCE; EMERGENCY AB Internal medicine residency programs will need to train residents about domestic violence to comply with the Residency Review Commission standards. To assess the effectiveness of an educational intervention intended to increase screening of patients for domestic violence by internal medicine resident physicians and identify characteristics associated with increased screening, we used a quasi-experimental, pretest/posttest trial. This was conducted in an internal medicine residency program and its affiliated primary care clinic with categorical internal medicine and combined medicine/pediatrics resident physicians. Exit interview surveys of patients were conducted at baseline and following the educational program. Patients were questioned about demographics and if they were asked about domestic violence during the current visit. Physicians were questioned about demographics and attitudes and beliefs related to domestic violence. Prior to the intervention, only 0.8% (1 of 122) of patients reported being asked about domestic violence. After the intervention, the percentage asked rose to 17% (20 of 116). The odds ratio (OR) for being asked about domestic violence after training was 25.2 (6.1-104). Patients who were younger than 50 years were more likely to be asked (OR 2.5, 1.5-4.6). Caucasian physicians were more likely to ask (OR 2.8, 1.1-7.6). Patients reporting they were taught breast self-examination at that day's visit were also more likely to be screened (OR 2.9, 1.1-7.9). We found evidence that moderately intense training and focusing on results can increase resident physician screening rates for domestic violence. To do so effectively, we recommend a training session similar to this one and continued monitoring of outcome in the clinical setting. C1 Univ Wisconsin, Madison, WI USA. William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. RP Knight, RA (reprint author), 5401 N Knoxville Ave,Suite 47, Peoria, IL 61614 USA. NR 19 TC 13 Z9 13 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1524-6094 J9 J WOMEN HEALTH GEN-B JI J. WOMENS HEALTH GENDER-BASED MED. PD MAR PY 2000 VL 9 IS 2 BP 167 EP 174 DI 10.1089/152460900318669 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 295EG UT WOS:000085953300012 PM 10746520 ER PT J AU Petrie, EC Peskind, ER Dobie, DJ Veith, RC Raskind, MA AF Petrie, EC Peskind, ER Dobie, DJ Veith, RC Raskind, MA TI Increased plasma norepinephrine response to yohimbine in elderly men SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID CEREBROSPINAL-FLUID NOREPINEPHRINE; NERVOUS-SYSTEM ACTIVITY; ALZHEIMERS-DISEASE; BLOOD-PRESSURE; SYMPATHETIC ACTIVITY; HEART-FAILURE; AGE; HUMANS; KINETICS; CLONIDINE AB Background. The effects of aging on sympathetic nervous system and adrenomedullary outflow were estimated by the measurement of plasma norepinephrine (NE) and epinephrine (EPI) responses to yohimbine and clonidine in healthy young and healthy older subjects. Methods. Yohimbine (0.65 mg/kg), clonidine (5 mu g/kg), and placebo were administered on separate days in random order to 5 healthy older men (age 74 +/- 1 years) and 18 healthy young men (age 26 +/- 1 years). NE and EPI were measured by radioenzymatic assay in plasma samples obtained before and 30, 60, and 90 minutes after drug administration. Results. Plasma NE increases after yohimbine were greater in older men than in young men, but plasma NE decreases following clonidine did not differ between groups. Plasma NE and systolic blood pressure were higher in older men than in young men at baseline but no longer differed 90 minutes after clonidine. Plasma EPI increases after yohimbine and decreases after clonidine did not differ between groups. Conclusions. These results suggest increased sympathetic nervous system outflow in human aging that is not a function of reduced responsiveness of alpha-2 adrenoreceptor-mediated feedback inhibition. C1 Univ Washington, Sch Med, Vet Affairs NW Network Mental Illness Res, Educ & Clin Ctr, Seattle, WA 98195 USA. Univ Washington, Sch Med, Mental Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Petrie, EC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Med Hlth Serv S 116, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [AG08419, AG05136] NR 34 TC 6 Z9 6 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2000 VL 55 IS 3 BP M155 EP M159 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 331XR UT WOS:000088044400016 PM 10795728 ER PT J AU Choudhury, GG Grandaliano, G Jin, DC Katz, MS Abboud, HE AF Choudhury, GG Grandaliano, G Jin, DC Katz, MS Abboud, HE TI Activation of PLC and PI 3 kinase by PDGF receptor alpha is not sufficient for mitogenesis and migration in mesangial cells SO KIDNEY INTERNATIONAL LA English DT Article DE PDGF receptors; cell signaling; DNA synthesis; tyrosine kinase; enzymatic pathway; chemotactic response ID GROWTH-FACTOR RECEPTORS; PHOSPHOLIPASE-C-GAMMA; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; MEDIATED ACTIVATION; TYROSINE KINASES; CHEMOTAXIS; BETA; ISOFORMS; PHOSPHORYLATION AB Background. Platelet-derived growth factor (PDGF) isoforms act through two distinct cell surface alpha and beta receptors. Glomerular mesangial cells express both receptors. PDGF BE and AB are potent mitogens for glomerular mesangial cells, and PDGF BE stimulates cell migration in a phosphatidylinositol 3 (PI 3) kinase-dependent manner. In this study, we investigated the effect of PDGF AA on cell migration, PI 3 kinase and phospholipase C (PLC) activation. and the role of these two enzymes in mediating biological responses in these cells in response to all three isoforms. Methods. H-3-thymidine incorporation and modified Boyden chamber assay were used to determine DNA synthesis and directed migration, respectively.. in response to all three PDGF isoforms. Differential activation of alpha and beta receptors was studied by immunecomplex tyrosine kinase assay of corresponding receptor immunoprecipitates. PLC gamma 1 activity was determined by measuring total inositol phosphates in response to different PDGF isoforms. PI 3 kinase activity was determined in anti-phosphotyrosine or PDGF receptor immunoprecipitates. Results. Both PDGF BE and AB resulted in stimulation of DNA synthesis and directed migration of mesangial cells. AA a was neither chemotactic nor mitogenic, However, all three isoforms increased tyrosine phosphorylation of a 180 kD protein in antiphosphotyrosine immunoprecipitates. suggesting activation of respective receptors. Direct immunecomplex tyrosine kinase assay of alpha and beta receptors demonstrated significant activation of both of these receptors when cells are treated with PDGF BE or AB. PDGF AA increased tyrosine kinase activity of the alpha receptor but not the beta receptor. All three isoforms significantly stimulated the production of inositol phosphates with order of potency being BE > AB > AA. PDGF AA also dose dependently stimulated PI 3 kinase activity measured in antiphosphotyrosine immunoprecipitates of treated cells. A comparison of PI 3 kinase activity in antiphosphotyrosine immunoprecipitates from mesangial cells stimulated with three different PDGF isoforms showed significant activation of this enzyme with a decreasing order of activity: BE > AB > AA. Conclusion. Taken together, these data demonstrate that all three isoforms of PDGF significantly stimulate: PLC gamma 1 and PI 3 kinase, two enzymes necessary for both DNA synthesis and directed migration. However, activation of alpha receptor bg PDGF AA with a subsequent increase in PLC and PI 3 kinase activities is not sufficient to induce these biological responses in mesangial cells. These data indicate that the extent of activation of signal transduction pathways may be a major determinant of the biological activity of different PDGF isoforms in mesangial cells. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. RI Grandaliano, Giuseppe/G-2963-2012 FU NIDDK NIH HHS [DK 43988, DK-50190] NR 45 TC 24 Z9 25 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2000 VL 57 IS 3 BP 908 EP 917 DI 10.1046/j.1523-1755.2000.00907.x PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 286TJ UT WOS:000085461500019 PM 10720944 ER PT J AU Freymiller, EG Sung, EC Friedlander, AH AF Freymiller, EG Sung, EC Friedlander, AH TI Detection of radiation-induced cervical atheromas by panoramic radiography SO ORAL ONCOLOGY LA English DT Article DE radiation therapy; atherosclerosis; carotid artery disease; panoramic radiography ID CAROTID-ARTERY DISEASE; THERAPEUTIC RADIATION; ORAL CAVITY; IRRADIATION; NECK; RISK; ATHEROSCLEROSIS; ANGIOPATHY; DIAGNOSIS; STENOSIS AB Therapeutic irradiation of the neck is frequently used to treat patients with head and neck carcinoma. The irradiation: however, has been implicated as the cause of cervical carotid artery atherosclerotic lesions and subsequent stroke. Panoramic radiography previously shown capable of demonstrating isolated lesions was used to assess their development over time. Individuals with a pre irradiation radiograph free of atheromas were enrolled for study. The prevalence rate of atheroma formation on post-irradiation (bilateral portals at greater than or equal to 45 Gy) radiographs obtained at an interval of greater than or equal to 36 months was determined. A control group of non irradiated patients having similar risk factors for head and neck carcinoma and atherosclerosis and having an initial radiograph free of atheroma formation were likewise enrolled for study. The prevalence rate of atheroma formation on a second radiograph obtained from these individuals at an interval of greater than or equal to 36 months was determined. The study population consisted of 17 patients, with a mean age of 56.5 (range 21.5-77.8) years who received a mean therapeutic irradiation dose of 53.2 Gy (range 45-71) to each side of their neck. The prevalence rate of atheromas manifested on the post-irradiation radiographs was 53%. These radiographs were obtained, on average. 69.7 (range 37-133) months after completion of radiation therapy. The prevalence rate of atheromas manifested on the second radiograph of patients in the control group was 5.9%. These radiographs were obtained, on average, 53.5 (range 52-55) months after the first. The difference in prevalence rates was statistically significant (p = 0.0003). Individuals who have received therapeutic irradiation to the neck are more likely to develop carotid artery atheromas after treatment than are risk-matched control patients who have not been irradiated. These lesions can be detected by panoramic radiography. (C) 2000 Elsevier Science Ltd. All lights reserved. C1 Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Med, Dent Serv, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Freymiller, EG (reprint author), Univ Calif Los Angeles, Sch Dent, CHS 53-076,10833 Le Conte Ave, Los Angeles, CA 90095 USA. NR 35 TC 20 Z9 20 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0964-1955 J9 ORAL ONCOL JI Oral Oncol. PD MAR PY 2000 VL 36 IS 2 BP 175 EP 179 DI 10.1016/S1368-8375(99)00072-X PG 5 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA 289YR UT WOS:000085650000004 PM 10745169 ER PT J AU Jones, AC Gulley, ML Freedman, PD AF Jones, AC Gulley, ML Freedman, PD TI Necrotizing ulcerative stomatitis in human immunodeficiency virus-seropositive individuals: A review of the histopathologic, immunohistochemical, and virologic characteristics of 18 cases SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Oral-and-Maxillofacial-Pathology CY JUN, 1999 CL KOHALA COAST, HAWAII SP Amer Acad Oral & Maxillofacial Pathol ID EPSTEIN-BARR-VIRUS; RECURRENT APHTHOUS ULCERS; HIV-INFECTED PATIENTS; DISEASE; CELLS; PERIODONTITIS; ASSOCIATION AB Objective. The purpose of this retrospective study was to delineate the histopathologic, immunohistochemical, and virologic characteristics of 18 cases of necrotizing ulcerative stomatitis. Study design. Eighteen examples or oral ulcerations in human immunodeficiency virus-seropositive individuals were identified that displayed unique histopathologic features. Immunohistochemic staining for CD1a, CD3, CD23, CD68, HLA-DR, p24, cytomegalovirus, HSV-1, and HSV-2 was performed, along with in situ hybridization for Epstein-Barr virus RNA and special staining for bacteria and fungi. Results. The lesions demonstrated ulceration, extensive necrosis, leukocytoclasia, histiocytic vasculitis with luminal fibrin clots, and a prominent infiltrate of large atypical cells with amphophilic cytoplasm, vesicular nuclei, and prominent nucleoli, interspersed with crescentic histiocytes, a histologic picture resembling extranodal Kikuchi's disease. Immunohistochemical findings suggested that the large atypical cells were histiocytes. Fifty-six percent (10/18) of the cases were immunoreactive for human immunodeficiency virus p24 within focal histiocytes, whereas Epstein-Barr virus RNA was identified in 1 (6%) of 17 cases. Conclusions. Necrotizing ulcerative stomatitis is an inflammatory disease characterized by specific, reproducible microscopic features. We postulate that the histopathologic resemblance of necrotizing ulcerative stomatitis to extranodal Kikuchi's disease reflects a similar immune response to differing pathogens. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX USA. New York Hosp, Queens Med Ctr, Sect Oral Pathol, Flushing, NY USA. RP Jones, AC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 22 TC 12 Z9 13 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD MAR PY 2000 VL 89 IS 3 BP 323 EP 332 DI 10.1016/S1079-2104(00)70097-7 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 293BQ UT WOS:000085832000014 PM 10710458 ER PT J AU Miller, TA Rudkin, G Honig, M Elahi, M Adams, J AF Miller, TA Rudkin, G Honig, M Elahi, M Adams, J TI Lateral subcutaneous brow lift and interbrow muscle resection: Clinical experience and anatomic studies SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID FOREHEAD LIFT AB The authors report consistent improvement in 65 patients with lateral brow ptosis by using a lateral subcutaneous brow lift at the temporal hairline. In 48 of these patients, vertical glabellar wrinkles were improved by the direct excision of procerus, corrugator, and orbicularis muscles through 3-mm medial brow incisions. Anatomic dissections in 10 cadavers and examinations of 50 skulls were used to study the location of the supraorbital and supratrochlear nerves. Dissections revealed that the supratrochlear nerve was never closer than 1.6 cm to the midline at the level of the supraorbital ridge. In no dissection was a supratrochlear foremen noted. Lateral subcutaneous brow lift was consistently successful in elevating the lateral brow. In no patient was nerve damage to the supraorbital nerve noted. In most patients, the temporal hairline was improved by excising a triangle of balding scalp. Through 3-mm medial brow incisions, the interbrow musculature can be excised by using a small rongeur in an area 3.2 cm nide without risk of nerve damage, improving vertical glabellar wrinkles. C1 Univ Calif Los Angeles, Med Ctr, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Plast Surg Sect, Los Angeles, CA 90073 USA. RP Miller, TA (reprint author), Univ Calif Los Angeles, Med Ctr, Div Plast & Reconstruct Surg, 200 Med Plaza,Suite 669, Los Angeles, CA 90095 USA. NR 20 TC 23 Z9 24 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD MAR PY 2000 VL 105 IS 3 BP 1120 EP 1127 DI 10.1097/00006534-200003000-00044 PG 8 WC Surgery SC Surgery GA 292HB UT WOS:000085787600043 PM 10724274 ER PT J AU Lawrence, VA Streiner, D Hazuda, HP Naylor, R Levine, M Gafni, A AF Lawrence, VA Streiner, D Hazuda, HP Naylor, R Levine, M Gafni, A TI A cross-cultural consumer-based decision aid for screening mammography SO PREVENTIVE MEDICINE LA English DT Article DE mammography; cross-cultural comparison; decision-making; mass screening; prevention and control ID CARCINOMA IN-SITU; BREAST-CANCER RISK; PATIENTS PREFERENCE; CONSERVING SURGERY; INFORMED CONSENT; WOMEN; AGE; INSTRUMENT; MANAGEMENT; BENEFITS AB Background. "Women should have mammograms" is the usual perspective of educational interventions about screening. The perspective that ''women should be informed'' about potential risks and benefits so they can make value- and evidence-integrated personal decisions has recently been advocated. However, this perspective has not previously been operationalized. we developed an evidence-based cross-cultural mammography decision aid (MDA), for European American and Mexican American women who are 50-70 years old at average risk of breast cancer, of varying educational levels, and English- or Spanish-speaking. Methods. MDA development included: (1) content development by a multidisciplinary team and lay women and (2) testing for validity and reliability, Four parts include: (1) introduction; (2) information about logistics (cost, time, discomfort) and risks (sequelae of false-positive or negative results; (3) probability of developing breast cancer; and (4) benefit of mammography regarding breast cancer outcomes (e.g., death and recurrence). We assessed reliability (stability of decisions with the same information) after 1-2 weeks. We assessed validity (comprehension of information) quantitatively (probabilities were changed to see whether preferences changed predictably) and qualitatively (focus groups, standardized probes for comprehension). Subjects were a convenience sample of 49 European American (50-81 years old) and 54 Mexican American (49-89 years old) women from administrative staff at a medical school, the waiting room of an indigent primary care clinic, and a community center. Results. Reliability was 100%. In quantitative validity testing, 22 of 28 women (89%) changed preference as predicted with changed probabilities, Comprehension was confirmed qualitatively in all phases of testing with both Spanish and English versions. Conclusion, The decision aid is valid and reliable in English and Spanish for southwestern Mexican American and European American women at average risk of breast cancer, including those of low educational levels. (C) 2000 American Health Foundation and Academic Press. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Gen Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Div Clin Epidemiol, San Antonio, TX 78284 USA. McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. RP Lawrence, VA (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Gen Med, San Antonio, TX 78284 USA. FU AHRQ HHS [1-UO1-HS07397]; NCI NIH HHS [P50CA58183, P30CA54174] NR 67 TC 21 Z9 21 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2000 VL 30 IS 3 BP 200 EP 208 DI 10.1006/pmed.1999.0620 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 294QC UT WOS:000085921000004 PM 10684743 ER PT J AU Thompson, NJ Boyko, EJ Dominitz, JA Belcher, DW Chesebro, BB Stephens, LM Chapko, MK AF Thompson, NJ Boyko, EJ Dominitz, JA Belcher, DW Chesebro, BB Stephens, LM Chapko, MK TI A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering SO PREVENTIVE MEDICINE LA English DT Article DE allied health personnel; colorectal neoplasms; mass screening; occult blood; practice guidelines; preventive medicine; randomized controlled trials; reminder systems ID COLORECTAL-CANCER; PREVENTIVE CARE; REMINDERS; PHYSICIANS AB Background. Colorectal cancer is the second most common fatal malignancy in the United States. Early detection using fecal occult blood tests has been shown to reduce mortality, but these tests are underutilized among those eligible for this screening, Attempts to increase use of fecal occult blood tests in eligible populations have focused on the provider, patient, or system, But none have examined whether a support-staff intervention is effective in achieving this aim. We therefore conducted a randomized controlled trial to test the impact of authorizing support staff to order fecal occult blood tests in a general internal medicine clinic organized into four teams. Methods. A total of 1,109 patients were included in the study, 545 of whom were in the two teams randomized to treatment, Univariate and multivariate regression analyses were used to evaluate the impact of the intervention. Results. The intervention resulted in significantly more fecal occult blood test ordering in the treatment group than in the control group for all patients (52% vs 15%, P < 0.001), Treatment fecal occult blood test cards were returned as frequently as the control cards for all patients (44% vs 48%, P = 0.571). Conclusion. Delegation of selected screening tasks to support staff can enhance patient access to preventive care. (C) 2000 American Health Foundation and Academic Press. C1 Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA 52242 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Med Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Gastroenterol Sect, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Gen Internal Med Sect, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle Div, Hlth Serv Res & Dev Serv, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. RP Thompson, NJ (reprint author), Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA 52242 USA. OI Dominitz, Jason/0000-0002-8070-7086; Boyko, Edward/0000-0002-3695-192X NR 29 TC 25 Z9 25 U1 1 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2000 VL 30 IS 3 BP 244 EP 251 DI 10.1006/pmed.1999.0624 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 294QC UT WOS:000085921000009 PM 10684748 ER PT J AU Gurvits, IG Koenigsberg, HW Siever, LJ AF Gurvits, IG Koenigsberg, HW Siever, LJ TI Neurotransmitter dysfunction in patients with borderline personality disorder SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article ID IMPULSIVE AGGRESSIVE-BEHAVIOR; RECEPTOR-BINDING-SITES; CEREBROSPINAL-FLUID; DEPRESSED-PATIENTS; D-FENFLURAMINE; SEROTONERGIC FUNCTION; PSYCHIATRIC-PATIENTS; PROLACTIN RESPONSE; HEALTHY-VOLUNTEERS; CHALLENGE AB Neurotransmitter system dysfunction may contribute to the borderline personality disorder traits of impulsive aggression and affective instability. This article reviews evidence from neurochemical assays, receptor-density studies, neuroendocrine-challenge paradigms, functional neuroimaging studies, and candidate-gene research, which converge to identify particular neurotransmitter systems that seem to be dysregulated in patients with borderline personality disorder. C1 Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY USA. RP Koenigsberg, HW (reprint author), Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. NR 88 TC 59 Z9 59 U1 4 U2 11 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD MAR PY 2000 VL 23 IS 1 BP 27 EP + DI 10.1016/S0193-953X(05)70141-6 PG 15 WC Psychiatry SC Psychiatry GA 290MX UT WOS:000085680900004 PM 10729929 ER PT J AU Workman, RH McCullough, LB Molinari, V Kunik, ME Orengo, C Khalsa, DK Rezabek, P AF Workman, RH McCullough, LB Molinari, V Kunik, ME Orengo, C Khalsa, DK Rezabek, P TI Clinical and ethical implications of impaired executive control functions for patient autonomy SO PSYCHIATRIC SERVICES LA English DT Article ID MACARTHUR TREATMENT COMPETENCE; CONSENT; BEHAVIOR; DEMENTIA AB The authors identify the clinical and ethical implications of impaired executive control functions for patient autonomy. Executive control functions are processes that orchestrate relatively simple ideas, movements, or actions into complex goal-directed behavior, and impairments in these functions are becoming more common as the population ages, The authors examine difficulties that individuals with impair ed executive control functions may have in making treatment decisions and describe a practical, ethically justified framework for making treatment decisions for patients with impairments in these functions. Three components of autonomy are identified-intentionality, understanding, and voluntariness. Intentionality and voluntariness are especially affected by impaired executive control functions, Impairments of these aspects of autonomy may often be overlooked when only traditional mental status examinations are employed, with adverse consequences for the health of patients wrongly thought to possess intact ability to make, and carry put plans of care. Two case vignettes illustrate the:complexities faced by clinicians intervening with patients who have deficits in:decision-making capacity caused by impaired executive control functions. C1 Dept Vet Affairs Med Ctr, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. RP Workman, RH (reprint author), Dept Vet Affairs Med Ctr, Dept Psychiat & Behav Sci, 2002 Holcombe Blvd 580-116A, Houston, TX 77030 USA. NR 23 TC 18 Z9 18 U1 1 U2 3 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD MAR PY 2000 VL 51 IS 3 BP 359 EP 363 DI 10.1176/appi.ps.51.3.359 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 291AH UT WOS:000085710100013 PM 10686244 ER PT J AU McFall, M Malte, C Fontana, A Rosenheck, RA AF McFall, M Malte, C Fontana, A Rosenheck, RA TI Effects of an outreach intervention on use of mental health services by veterans with posttraumatic stress disorder SO PSYCHIATRIC SERVICES LA English DT Article ID ALCOHOLISM-TREATMENT; MAMMOGRAPHY USE; BARRIERS; REASONS; CARE AB Objective: The study examined the effectiveness of an outreach intervention designed to increase access to mental health treatment among veterans disabled by chronic posttraumatic stress disorder (PTSD) and identified patient-reported barriers to care associated with failure to seek. the treatment offered, Methods: Participants were 594 male Vietnam veterans who were not enrolled in mental health care at a Department of Veterans Affairs (VA) medical center but who were-receiving VA disability benefits for PTSD, Half the sample was randomly assigned to an outreach intervention, and the other half was assigned to-a control group. Veterans in the intervention group received a mailing that included a brochure describing PTSD treatment available at an urban VA medical center, along with a letter informing them about how to access care. Participants in the intervention group were subsequently telephoned by a; study coordinator who encouraged them to enroll in PTSD treatment and who administered a survey assessing barriers to care. Results: Veterans in the intervention group were significantly more likely than those in the control group to schedule an intake appointment (28 percent versus 7 percent), attend the intake (23 percent versus 7 percent), and enroll in treatment (19 percent versus 6 percent). Several patient-identified barriers were associated with failure to seek VA mental health care, such as personal obligations that prevented clinic attendance, inconvenient clinic hours, and current receipt of mental health treatment from a non-VA provider. Conclusions: Utilization of-mental health services among underserved veterans with PTSD can be increased by an inexpensive outreach intervention, which may be useful with other chronically mentally ill populations. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. Vet Affairs Connecticut Healthcare Syst, NE Program Evaluat Ctr, W Haven, CT USA. Yale Univ, Sch Med, New Haven, CT USA. RP McFall, M (reprint author), VA Puget Sound Hlth Care Syst, PTSD Program 1116PTSD, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 18 TC 17 Z9 17 U1 2 U2 6 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD MAR PY 2000 VL 51 IS 3 BP 369 EP 374 DI 10.1176/appi.ps.51.3.369 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 291AH UT WOS:000085710100015 PM 10686246 ER PT J AU Alterman, AI Renner, BJ Cacciola, JS Mulvaney, FD Rutherford, MJ AF Alterman, AI Renner, BJ Cacciola, JS Mulvaney, FD Rutherford, MJ TI Familial risk for alcoholism and self-reported psychopathology SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article ID PERSONALITY-ASSESSMENT INVENTORY; PARENTAL ALCOHOLISM; ANXIETY DISORDERS; ADOLESCENT SONS; MEN; CHILDREN; PREDICTORS; VALIDITY; VALIDATION; BEHAVIOR AB Three groups of young men varying in familial alcoholism risk thigh density, high risk [HDHR]; low density, high risk [LDHR]; and low risk [LR]) were compared on the 11 clinical scales of the Personality Assessment Inventory. Significant group differences were found on 9 scales, with scores of the HDHR group exceeding those of the other 2 groups. No differences were found between the LDHR and LR groups. When the proportion with pathological scores per scale was examined, significant group differences were still revealed on 7 scales. The HDHR group exceeded the other 2 groups, but the LDHR group also exceeded the LR group on several scales. These findings support the need to more finely characterize familial alcoholism risk than is provided by the typical high-risk-low-risk dichotomy. Finally, statistically controlling for normal variations in response style reduced the number of group differences, although the same patterns persisted. C1 Univ Penn, Sch Med, Treatment Res Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. Dept Publ Hlth & Human Serv, Helena, MT USA. Vet Affairs Med Ctr, Dept Vet Affairs, Philadelphia, PA USA. Univ Washington, Inst Alcohol & Drug Abuse, Seattle, WA 98195 USA. RP Alterman, AI (reprint author), Univ Penn, Sch Med, Treatment Res Ctr, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. NR 38 TC 2 Z9 2 U1 3 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD MAR PY 2000 VL 14 IS 1 BP 19 EP 28 PG 10 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 327NN UT WOS:000087800100003 PM 10822742 ER PT J AU Lavrovsky, Y Song, CS Chatterjee, B Roy, AK AF Lavrovsky, Y Song, CS Chatterjee, B Roy, AK TI Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NF kappa B SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE aging; nuclear factor kappa B; heme oxygenase-1; reactive oxidative species; transcriptional regulation ID ANDROGEN RECEPTOR GENE; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; PROTEIN OXIDATION; PROMOTER REGION; BINDING; IDENTIFICATION; TOXICITY; ELEMENTS; CELLS AB Heme, the iron-porphyrin coordination complex, released from the degradation of hemoproteins, is a strong prooxidant. It is enzymatically degraded by heme oxygenase to free iron, carbon monoxide and biliverdin. Biliverdin and its reduced metabolite bilirubin are two potent physiological antioxidants. Here we show a progressive increase of steady-state levels of the mRNA encoding the inducible isoform of this enzyme (heme oxygenase-1) in the rat liver during aging. We had previously reported that aging is associated with increased activation of the nuclear factor kappa B (NF kappa B). We now provide evidence to establish that overexpression of NF kappa B in transfected liver-derived HepG2 cells can cause a marked induction of the endogenous heme oxygenase-1 (HO-1) mRNA and activation of the cotransfected HO-1 gene promoter. Taken together, these results support the conclusion that enhanced oxidative stress during aging is accompanied by compensatory induction of the antioxidant enzyme HO-1 through activation of the NF kappa B pathway. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM lavrosky@uthscsa.edu FU NIA NIH HHS [R37AG10486] NR 43 TC 57 Z9 58 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD FEB 22 PY 2000 VL 114 IS 1 BP 49 EP 60 DI 10.1016/S0047-6374(00)00087-7 PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 304GR UT WOS:000086475800006 PM 10731581 ER PT J AU Higgins, JJ Mendez, MF AF Higgins, JJ Mendez, MF TI Roll over Pick and tell Alzheimer the news! SO NEUROLOGY LA English DT Editorial Material ID FRONTOTEMPORAL DEMENTIA; TAU-GENE; CHROMOSOME-17; PARKINSONISM; MUTATIONS; MISSENSE C1 New York State Dept Hlth, Wadsworth Ctr Labs & Res, Lab Clin Neurogenet, Albany, NY 12201 USA. Calif State Univ Los Angeles, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90032 USA. RP Higgins, JJ (reprint author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Lab Clin Neurogenet, Empire State Plaza,POB 509, Albany, NY 12201 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD FEB 22 PY 2000 VL 54 IS 4 BP 784 EP 785 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 284ZL UT WOS:000085362700002 PM 10690961 ER PT J AU Ballou, LM Cross, ME Huang, S McReynolds, EM Zhang, BX Lin, RZ AF Ballou, LM Cross, ME Huang, S McReynolds, EM Zhang, BX Lin, RZ TI Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; B C-AKT; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; GROWTH-FACTOR; IN-VIVO; ACTIVATION; PHOSPHORYLATION; P70(S6K); INHIBITION AB Phosphatidylinositol (PI) 3-kinase and its downstream effector Akt are thought to be signaling intermediates that link cell surface receptors to p70 S6 kinase. We examined the effect of a G(q)-coupled receptor on PI 3-kinase/Akt signaling and p70 S6 kinase activation using Rat-1 fibroblasts stably expressing the human su,adrenergic receptor. Treatment of the cells with phenylephrine, a specific alpha(1)-adrenergic receptor agonist, activated p70 S6 kinase but did not activate PI 3-kinase or any of the three known isoforms of Akt. Furthermore, phenylephrine blocked the insulin-like growth factor-I (IGF-I)-induced activation of PI 3-kinase and the phosphorylation and activation of Akt-1. The effect of phenylephrine was not confined to signaling pathways that include insulin receptor substrate-1, as the alpha(1)-adrenergic receptor agonist also inhibited the platelet-derived growth factor-induced activation of PI 3-kinase and Akt-1. Although increasing the intracellular Ca2+ concentration with the ionophore A23187 inhibited the activation of Akt-1 by IGF-I, Ca2+ does not appear to play a role in the phenylephrine-mediated inhibition of the PI 3-kinase/Akt pathway. The differential ability of phenylephrine and IGF-I to activate Akt-1 resulted in a differential ability to protect cells from UV-induced apoptosis. These results demonstrate that activation of p70 S6 kinase by the alpha(1A)-adrenergic receptor in Rat-1 fibroblasts occurs in the absence of PI 3-kinase/Akt signaling. Furthermore, this receptor negatively regulates the PI 3-kinase/Akt pathway, resulting in enhanced cell death following apoptotic insult. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Res Serv, San Antonio, TX 78284 USA. RP Lin, RZ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Mail Code 7764,7703 Floyd Curl Dr, San Antonio, TX 78284 USA. RI Lin, Richard/J-1754-2014 OI Lin, Richard/0000-0002-3473-7276 NR 55 TC 55 Z9 56 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 18 PY 2000 VL 275 IS 7 BP 4803 EP 4809 DI 10.1074/jbc.275.7.4803 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 285FC UT WOS:000085378200040 PM 10671514 ER PT J AU Rush, AJ George, MS Sackeim, HA Marangell, LB Husain, MM Giller, C Nahas, Z Haines, S Simpson, RK Goodman, R AF Rush, AJ George, MS Sackeim, HA Marangell, LB Husain, MM Giller, C Nahas, Z Haines, S Simpson, RK Goodman, R TI Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-College-of-Neuropsychopharmacology CY DEC 13, 1999 CL ACAPULO, MEXICO SP Amer Coll Neuropsychopharmacol DE Vagus Nerve Stimulation (VNS); treatment-resistant depression; bipolar disorder; electrical stimulation ID ELECTROCONVULSIVE-THERAPY; MAJOR DEPRESSION; MEDICATION RESISTANCE; CONTINUATION THERAPY; CLINICAL-RESPONSE; RELAPSE; PREVENTION; PLACEBO; ECT; LITHIUM AB Background: Vagus nerve simulation (VNS) delivered by the Neurocybernetic Prosthesis (NCP) System was examined for its potential antidepressant effects. Methods: Adult outpatients (n = 30) with nonpsychotic, treatment-resistant major depressive (n = 21) or bipolar I (n = 4) or II (n = 5; depressed phase) disorders who had failed at least two robust medication trials in the current major depressive episode (MDE) while on stable medication regimens completed a baseline period followed by NCP System implantation. A 2-week, single-blind recovery period (no stimulation) was followed by 10 weeks of VNS. Results: In the current MDE (median length = 4.7 years), patients had not adequately responded to two (n = 9), three (n = 2), four (n = 6), or five or more (n = 13) robust antidepressant medication trials or electroconvulsive therapy (n = 17). Baseline 28-item Hamilton Depression Rating Scale (HDRS28) scores averaged 38.0. Response rates (greater than or equal to 50% reduction in baseline scores) were 40% for both the HDRS28 and the Clinical Global Impressions- Improvement index (score of 1 or 2) and 50% for the Montgomery-Asberg Depression Rating Scale. Symptomatic responses (accompanied by substantial functional improvement) have been largely sustained during long-term follow-up to date. Conclusions: These open trial results suggest that VNS has antidepressant effects in treatment-resistant depressions. Biol Psychiatry 2000;47:276-286 (C) 2000 Society of Biological Psychiatry. C1 Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA. Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. Ralph H Johnson Vet Hosp, Charleston, SC USA. Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA. New York State Psychiat Inst, New York, NY 10032 USA. Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA. RP Rush, AJ (reprint author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA. RI Haines, Stephen/L-3209-2013 OI Haines, Stephen/0000-0002-4263-0268; Rush, Augustus/0000-0003-2004-2382 FU NIDA NIH HHS [DA011434-01A1]; NIMH NIH HHS [MH 41115, MH 46673] NR 49 TC 304 Z9 309 U1 8 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2000 VL 47 IS 4 BP 276 EP 286 DI 10.1016/S0006-3223(99)00304-2 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 285VV UT WOS:000085409700002 PM 10686262 ER PT J AU George, MS Sackeim, HA Rush, AJ Marangell, LB Nahas, Z Husain, MM Lisanby, S Burt, T Goldman, J Ballenger, JC AF George, MS Sackeim, HA Rush, AJ Marangell, LB Nahas, Z Husain, MM Lisanby, S Burt, T Goldman, J Ballenger, JC TI Vagus nerve stimulation: A new tool for brain research and therapy SO BIOLOGICAL PSYCHIATRY LA English DT Article DE vagus nerve; locus ceruleus; antidepressant; brain stimulation; depression ID ELECTROCONVULSIVE-THERAPY; ELECTRODE PLACEMENT; TREATMENT RESPONSE; SLEEP-DEPRIVATION; MAJOR DEPRESSION; PARTIAL SEIZURES; BLOOD-FLOW; ECT; EPILEPSY; EFFICACY AB Biological psychiatry has a long history! of using somatic therapies to tl ent neuropsychiatric illnesses and to understand brain function, These methods have included neurosurgery, electroconvulsive therapy, and most recently, transcranial magnetic stimulation, Fourteen years ago researchers discovered that intermittent electrical stimulation of the vagus nerve produces inhibition of neural processes, which can alter brain electrical activity and terminate seizures in dogs. Since then, approximately 6000 people worldwide have received vagus nerve stimulation for treatment-resistant epilepsy. We review the neurobiology, and anatomy of the vagus nerve and provide an overview of the vagus nerve stimulation technique. We also describe the safety and potential utility of vagus nerve stimulation as a neuroscience research tool and as a putative treatment for psychiatric conditions. Vagus nerve stimulation appears to be a promising new somatic intervention that may improve our understanding of brain function and has promise in the treatment of neuropsychiatric disorders. Biol Psychiatry 2000;47:287-295 (C) 2000 Society, of Biological Psychiatry. C1 Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Ralph H Johnson Vet Hosp, Charleston, SC USA. New York State Psychiat Inst, Dept Biol Psychiat, New York, NY 10032 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. Columbia Univ, Coll Phys & Surg, Dept Radiol, New York, NY USA. Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA. Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Radiol, 171 Ashley Ave, Charleston, SC 29425 USA. RI Burt, Tal/O-1951-2013 OI Burt, Tal/0000-0002-5853-6110; Rush, Augustus/0000-0003-2004-2382 NR 60 TC 209 Z9 215 U1 4 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2000 VL 47 IS 4 BP 287 EP 295 DI 10.1016/S0006-3223(99)00308-X PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 285VV UT WOS:000085409700003 PM 10686263 ER PT J AU Nagatsu, M Spinale, FG Koide, M Tagawa, H DeFreitas, G Cooper, G Carabello, BA AF Nagatsu, M Spinale, FG Koide, M Tagawa, H DeFreitas, G Cooper, G Carabello, BA TI Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction SO CIRCULATION LA English DT Article DE contractility; heart failure; receptors, adrenergic, beta ID IDIOPATHIC DILATED CARDIOMYOPATHY; CANINE MITRAL REGURGITATION; SYSTOLIC PRESSURE-VOLUME; CHRONIC HEART-FAILURE; MYOCARDIAL STIFFNESS; CONTRACTILE FUNCTION; ADRENERGIC-BLOCKADE; METOPROLOL; BUCINDOLOL; CARDIOCYTE AB Background-It is clear that beta-blockers are effective for treatment of congestive heart failure, but their mechanism of action remains controversial. Hypothesized mechanisms include normalization of beta-receptor function and myocardial protection from the effects of catecholamines, possibly by the institution of bradycardia. We hypothesized that beta-blockade-induced bradycardia was an important mechanism by which these agents were effective for correction of LV dysfunction, Methods and Results-In 2 groups of dogs with mitral regurgitation and LV dysfunction, beta-blockers were instituted. In I group that received beta-blockers and pacing (group beta+P), a pacemaker prevented the natural bradycardia that beta-blockers cause. In both groups, substantial LV dysfunction developed. Before beta-blockade, the end-systolic stiffness constant decreased from 3.5+/-0.1 to 2.7+/-0.2 (P<0.01) at 3 months in group beta+P. A similar reduction occurred in the group that eventually received only beta-blockers (group beta B). In group PB, end-systolic stiffness improved after 3 months of beta-blockade from 2.9+/-0.2 to 3.5+/-0.4 and was not different from baseline. However, in group beta+P, end-systolic stiffness failed to improve (2.7+/-0.2) after 3 months of mitral regurgitation, and was 2.9+/-0.2 at the end of the studies. The contractile function of cardiocytes isolated from the ventricles at the end of the studies confirmed these in vivo estimates of contractility. Conclusions-We conclude that institution of bradycardia is a major mechanism by which beta-blockers are effective for restoration of contractile function in a model of LV dysfunction. C1 Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs, Charleston, SC USA. RP Carabello, BA (reprint author), Vet Affairs Med Ctr, Med Serv 111, 2002 Holcombe Blvd, Houston, TX 77030 USA. FU NHLBI NIH HHS [R01 HL38185] NR 31 TC 74 Z9 76 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 15 PY 2000 VL 101 IS 6 BP 653 EP 659 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 284NZ UT WOS:000085339600014 PM 10673258 ER PT J AU Whitsel, EA Boyko, EJ Rautaharju, PM Raghunathan, TE Pearce, RM Siscovick, DS AF Whitsel, EA Boyko, EJ Rautaharju, PM Raghunathan, TE Pearce, RM Siscovick, DS TI QT interval prolongation and risk of primary cardiac arrest in diabetic patients without clinically recognized heart disease SO CIRCULATION LA English DT Meeting Abstract C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. Univ Michigan, Ann Arbor, MI 48109 USA. CV Hlth Res Unit, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 15 PY 2000 VL 101 IS 6 MA 25 BP 716 EP 716 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 284NZ UT WOS:000085339600047 ER PT J AU Allen, DN Anastasiou, A Goldstein, G Gilbertson, M van Kammen, DP AF Allen, DN Anastasiou, A Goldstein, G Gilbertson, M van Kammen, DP TI Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes SO PSYCHIATRY RESEARCH LA English DT Article DE schizophrenia; frontal lobes; neuropsychology ID CEREBRAL BLOOD-FLOW; SCHIZOPHRENIC SYNDROMES; PERFORMANCE AB The aim of the study was to examine effects of haloperidol on the relationships between neuropsychological measures of frontal lobe functioning and the schizophrenia syndromes of psychomotor poverty and disorganization. Twenty-one participants with schizophrenia were initially evaluated when clinically stable and chronically treated with haloperidol, and 19 were evaluated again after a 3-week haloperidol-free period. Participants were evaluated with the Trail Making Test, the Wisconsin Card Sorting Test, the Purdue Pegboard, and psychiatric rating scales at each evaluation. There were significant correlations between schizophrenia syndromes and the tests sensitive to frontal lobe function when participants were medicated but not when drug-free. No significant changes in symptom severity or motor function occurred from the medication to the medication-free evaluation. The results indicate that haloperidol mediates the relationship between tests sensitive to frontal lobe function and the schizophrenia syndromes of psychomotor poverty and disorganization. This mediation effect was not attributable to changes in overall symptom severity or motor function. (C) 2000 Elsevier Science ireland Ltd. All rights reserved. C1 Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. VA Pittsburgh Healthcare Syst, Highland Dr Div, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Med Ctr, Manchester, NH USA. Robert Wood Johnson Pharmaceut Res Inst, Raritan, NJ USA. RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy,Box 455030, Las Vegas, NV 89154 USA. FU NIMH NIH HHS [MH44841] NR 22 TC 15 Z9 15 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD FEB 14 PY 2000 VL 93 IS 1 BP 33 EP 39 DI 10.1016/S0165-1781(00)00112-8 PG 7 WC Psychiatry SC Psychiatry GA 301AF UT WOS:000086285400004 PM 10699226 ER PT J AU Lambrecht, N Munson, K Vagin, O Sachs, G AF Lambrecht, N Munson, K Vagin, O Sachs, G TI Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID COMPETITIVE PHOTOAFFINITY INHIBITOR; H+/K+-ATPASE; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; MEMBRANE TOPOLOGY; H+,K+-ATPASE; OMEPRAZOLE; PUMP; IDENTIFICATION AB The gastric H,K-ATPase is covalently inhibited by substituted pyridyl-methylsulfinyl-benzimidazoles, such as omeprazole, that convert to thiophilic probes of luminally accessible cysteines in the acid space. The K+ competitive inhibitor, SCH28080, prevented inhibition of acid transport by omeprazole. In stably expressing HEK293 cells, the benzimidazole-reactive cysteines, Cys-321 (transmembrane helix (TM) 3), Cys-813 and Cys-822 (TM5/6), and Cys-892 (TM7/8) were mutated to the amino acids found in the SCH28080-resistant Na,K-ATPase and kinetic parameters of H,K-ATPase activity analyzed. Mutations of Cys-822 and Cys-892 had insignificant effects:an the K-i(app), K-m(app) or V-max, but mutations of Cys-813 to threonine and Cys-321 to alanine decreased the affinity for SCH28080, Mutation of Cys-321 to alanine produced mixed kinetics of inhibition, still with higher affinity for the cation-free form of phosphoenzyme. Since the phenylmethoxy ring of the imidazo-pyridine inhibitors binds to TM1/2, as shown by earlier photoaffinity studies, and the mutations in TM6 (Cys-813 --> Thr) as well as the end of TM3 (Cys-321 --> Ala) decrease the affinity for SCH28080, the TM1/2, TM3, and TM6 helices lie within: similar to 16 Angstrom of each other based on the size of the active, extended conformation of SCH28080. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. RP Vet Affairs Greater Los Angeles Hlth Care Syst, Bldg 113,Rm 326, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK17294, DK40615, DK41301] NR 34 TC 37 Z9 37 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 11 PY 2000 VL 275 IS 6 BP 4041 EP 4048 DI 10.1074/jbc.275.6.4041 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 283RJ UT WOS:000085288800045 PM 10660561 ER PT J AU Berger, AK Schulman, KA Gersh, BJ Every, NR AF Berger, AK Schulman, KA Gersh, BJ Every, NR TI Primary angioplasty vs thrombolysis in elderly patients - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Yale Univ, New Haven, CT 06520 USA. Duke Univ, Durham, NC USA. Mayo Clin, Minneapolis, MN USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Berger, AK (reprint author), Yale Univ, New Haven, CT 06520 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 2 PY 2000 VL 283 IS 5 BP 601 EP 602 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 277WL UT WOS:000084956500013 ER PT J AU Sachdev, GP Ohlrogge, KD Johnson, CL AF Sachdev, GP Ohlrogge, KD Johnson, CL TI Aspirin and dipyridamole for stroke prevention SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Letter ID SECONDARY PREVENTION C1 William S Middleton Mem Vet Hosp, Rockford Vet Affairs Primary Care Clin, Madison, WI 53705 USA. Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53295 USA. Good Samaritan Hosp, Dayton, OH 45406 USA. RP Sachdev, GP (reprint author), William S Middleton Mem Vet Hosp, Rockford Vet Affairs Primary Care Clin, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD FEB 1 PY 2000 VL 57 IS 3 BP 223 EP 223 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 281AC UT WOS:000085135100014 ER PT J AU Schuna, AA Megeff, C AF Schuna, AA Megeff, C TI New drugs for the treatment of rheumatoid arthritis SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Review DE anakinra; anti-inflammatory agents; arthritis; celecoxib; CGP-28238; drugs; etanercept; infliximab; leflunomide; mechanism of action; meroxicam; nimesulide; rofecoxib; toxicity ID COX-2 INHIBITION; FUSION PROTEIN; DOUBLE-BLIND; LEFLUNOMIDE; PLACEBO; EFFICACY; METHOTREXATE; COMPLICATIONS; IMPROVEMENT; MELOXICAM AB New pharmacologic treatment options for rheumatoid arthritis (RA) are described Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for RA but are limited by the risk of adverse effects, especially gastrointestinal and renal toxicity. The therapeutic effects of these agents are mediated primarily through inhibition of cyclooxygenase (COX) and prevention of subsequent formation of prostaglandins and related inflammatory mediators. Nonspecific COX inhibition appears to be responsible for much of the toxicity of NSAIDs. Agents have been developed that can selectively inhibit the COX-2 isoforms, while sparing COX-1. Celecoxib and other COX-2 inhibitors appear to be no more efficacious than conventional NSAIDs, but offer superior safety. COX-2 inhibitors should be considered for patients who are candidates for NSAID therapy but at risk for GI bleeding. Unlike disease-modifying antirheumatic drugs (DMARDs), these agents do not alter underlying disease progression. Leflunomide is a newer DMARD that reduces pyrimidine synthesis, thus decreasing rheumatoid inflammation. Leflunomide appears to be as effective as methotrexate but, unlike that drug, does not necessitate monitoring for bone marrow toxicity. Etanercept, the first biological agent with FDA-approved labeling for use in RA, has shown efficacy and minimal toxicity, except for injection-site reactions. Other biologicals that have been investigated for use in RA include infliximab and interleukin-1-receptor antagonist. COX-2 inhibitors, leflunomide, and etanercept are promising new drugs available for treating RA. Other agents are underdevelopment. C1 Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. St Louis Univ, Coll Pharm, St Louis, MO 63103 USA. St Louis Univ, Dept Community & Family Med, St Louis, MO 63103 USA. RP Schuna, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 48 TC 48 Z9 50 U1 2 U2 3 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD FEB 1 PY 2000 VL 57 IS 3 BP 225 EP 234 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 281AC UT WOS:000085135100015 PM 10674776 ER PT J AU Gukovskaya, AS Gukovsky, S Pandol, SJ AF Gukovskaya, AS Gukovsky, S Pandol, SJ TI Endoplasmic reticulum Ca2+-ATPase inhibitors stimulate membrane guanylate cyclase in pancreatic acinar cells SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE calcium transport; cyclopiazonic acid; 2,5-di-(t-butyl)-1,4-hydroquinone; guanosine 3 ',5 '-cyclic monophosphate ID NATRIURETIC-PEPTIDE RECEPTOR; CA2+ TRANSPORT ATPASES; NITRIC-OXIDE; CYCLIC-GMP; SARCOPLASMIC-RETICULUM; PROTEIN; CALCIUM; BINDING; ATRIAL; FAMILY AB In this study, we show that particulate guanylate cyclase (GC) is present in rat pancreatic acinar cells and is located both on plasma membrane and membranes of endoplasmic reticulum (ER). Western blot analysis indicates that the enzyme isoform GC-A is present in the acinar cell membranes. The specific inhibitors of ER Ca2+-ATPase thapsigargin, 2,5-di-(t-butyl)-1,4-hydroquinone (BHQ), and cyclopiazonic acid all activated particulate GC in pancreatic acini, both in membrane fractions and intact cells. These inhibitors also induced dephosphorylation of GC. Dose dependencies of Ca2+-ATPase inhibition and GC activation by BHQ are very similar, and those for thapsigargin partially overlap. ER Ca2+-ATPase and GC are coimmunoprecipitated both by antisera against membrane CC and by antisera against ER Ca2+-ATPase, suggesting a physical association between the two enzymes. The results suggest that thapsigargin and the other inhibitors act through ER Ca2+-ATPase to activate membrane GC in pancreatic acinar cells, although their direct effect, on GC cannot be excluded. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Gukovskaya, AS (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-33010] NR 42 TC 3 Z9 3 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD FEB PY 2000 VL 278 IS 2 BP C363 EP C371 PG 9 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 282RD UT WOS:000085231400015 PM 10666032 ER PT J AU Henke, KG Frantz, DE Kuna, ST AF Henke, KG Frantz, DE Kuna, ST TI An oval elastic mandibular advancement device for obstructive sleep apnea SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID ORAL APPLIANCES; AIRWAY-PATENCY; SITE; UVULOPALATOPHARYNGOPLASTY; EFFICACY AB Oral mandibular advancement devices are becoming an increasingly important treatment alternative for obstructive sleep apnea (OSA). The first aim of the study was to determine whether a new oral elastic mandibular advancement device (EMA) prevents pharyngeal air-way closure during sleep in patients with OSA. The second aim of the study was to determine if the polysomnographic response to the oral mandibular advancement device: was dependent on the site of airway closure. Overnight polysomnograms were performed in 28 untreated OSA subjects with and without EMA. A third polysomnogram was performed in 12 of the subjects to determine the site of airway closure without the device. Site of airway closure above or below the oropharynx was determined by measuring the respective presence or absence of respiratory fluctuations in oropharyngeal pressure during induced occlusions in non-rapid eye movement (NREM) sleep, Mean apnea-hypopnea: index (AHI) was 52.6 +/- 28.2 (SD) events/h without the device and 21.2 +/- 19.3 events/h with the device, Nineteen subjects (68%) had at least a 50% reduction in AHI with the device. The change in AHI with the, device (AHI without device - AHI with device) was directly related to the AHI without the device. All three subjects with airway closure in the lower pharyngeal airway had a greater than 80% reduction in AHI with the device. Two of the nine subjects with airway closure in the velopharynx had a similar therapeutic response. The results show the effectiveness of EMA in the treatment of OSA, The results also indicate that polysomnographic severity of OSA and the site of airway closure should not be used to exclude patients from this oral device treatment. C1 Sleep Disorders Ctr Virginia, Richmond, VA USA. Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77550 USA. RP Kuna, ST (reprint author), Philadelphia Vet Affairs Med Ctr 111P, Pulm Crit Care & Sleep Sect, Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NCRR NIH HHS [RR-73]; NHLBI NIH HHS [HL-61272] NR 23 TC 58 Z9 62 U1 0 U2 1 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB PY 2000 VL 161 IS 2 BP 420 EP 425 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 285ED UT WOS:000085376000016 PM 10673180 ER PT J AU Burns, SP AF Burns, SP TI Duplex ultrasound screening SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Letter C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Burns, SP (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2000 VL 81 IS 2 BP 242 EP 242 DI 10.1016/S0003-9993(00)90153-9 PG 1 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 281NF UT WOS:000085166700024 PM 10668785 ER PT J AU Kwiatkowski, BA Zielinska-Kwiatkowska, AG Bauer, TR Hickstein, DD AF Kwiatkowski, BA Zielinska-Kwiatkowska, AG Bauer, TR Hickstein, DD TI The ETS family member Tel antagonizes the Fli-1 phenotype in hematopoietic cells SO BLOOD CELLS MOLECULES AND DISEASES LA English DT Article DE Tel; Fli-1; K562 cells; GPIIb; GPIX; GPIb alpha ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MYELOGENOUS LEUKEMIA; LINE; EXPRESSION; FUSION; GENE; PROTEIN; DNA; DIFFERENTIATION; TRANSLOCATION AB The ETS family member Tel is rearranged in human leukemia of both myeloid and lymphoid origin while the ETS member Fli-1 is insertionally activated in Friend erythroleukemia in mice and is translocated to the EWS locus in Ewing's sarcoma. In previous studies we demonstrated that Tel binds to Fli-1 and blocks transactivation of megakaryocytic promoters by Fli-1. In this study we demonstrate that expression of Fli-1 in the leukemia cell line K562 induces a megakaryocytic phenotype and the expression of the platelet markers GPIX, GP1b alpha, and GPIIb. Introduction of Tel blocked the megakaryocytic phenotype induced by Fli-1, suggesting a biological correlation to the biochemical interaction of Tel and Fli-1 reported previously. (C) 2000 Academic Press. C1 VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Hickstein, DD (reprint author), VA Puget Sound Hlth Care Syst, Med Res Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 26 TC 9 Z9 10 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1079-9796 J9 BLOOD CELL MOL DIS JI Blood Cells Mol. Dis. PD FEB PY 2000 VL 26 IS 1 BP 84 EP 90 DI 10.1006/bcmd.2000.0282 PG 7 WC Hematology SC Hematology GA 331GM UT WOS:000088010000024 PM 10772879 ER PT J AU Kao, GD Devine, P AF Kao, GD Devine, P TI Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy SO CANCER LA English DT Article DE prostate carcinoma; complementary health practices; complementary medicine; radiation therapy ID ALTERNATIVE MEDICINE; CANCER MEDICINE; UNITED-STATES; PREVALENCE AB BACKGROUND. There has been increasing interest in complementary health practices among patients, popular media, and even institutional health care providers. However, there is still surprisingly little information on the use of alternative medicine by patients undergoing treatment for prostate carcinoma. METHODS. A prospective study of 50 consecutive patients undergoing radiation treatment for prostate carcinoma at a tertiary care referral center was conducted. Patients were surveyed after the initiation of radiation therapy whether they had used complementary health practices at any time. RESULTS. The authors found that a surprisingly high proportion of patients (37%) relied on complementary health practices not prescribed by physicians. In contrast, according to a separate survey of the treating physicians, the physicians believed that on average only 4% of their patients resorted to such practices. The use of complementary health practices usually continued even after the initiation of definitive treatment for prostate carcinoma. Patients who used complementary health practices tended to have higher levels of education and income, whereas there were no differences in age, religion, perception of health status, stage of prostate carcinoma, or prostate specific antigen level. Herbal remedies were the most frequently utilized, by 60% of those using complementary health practices, followed by old-lime remedies (47%), high dose vitamins (41%), chiropractic/ massage therapy and relaxation techniques (18% each), and special diets (12%). CONCLUSIONS. Patients undergoing radiation therapy for prostate carcinoma frequently rely on complementary health practices not prescribed by their treating physicians. Patients who do so tend to have higher education and income levels and continue their complementary practices during the conventional treatment. As the health implications of these practices are unclear, further research is clearly needed. (C) 2000 American Cancer Society. C1 Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. RP Kao, GD (reprint author), Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St,2 Donner, Philadelphia, PA 19104 USA. NR 14 TC 84 Z9 85 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0008-543X J9 CANCER JI Cancer PD FEB 1 PY 2000 VL 88 IS 3 BP 615 EP 619 DI 10.1002/(SICI)1097-0142(20000201)88:3<615::AID-CNCR18>3.0.CO;2-P PG 5 WC Oncology SC Oncology GA 276JQ UT WOS:000084874900018 PM 10649255 ER PT J AU Malin, JL Asch, SM Kerr, EA McGlynn, EA AF Malin, JL Asch, SM Kerr, EA McGlynn, EA TI Evaluating the quality of cancer care - Development of cancer quality indicators for a global quality assessment tool SO CANCER LA English DT Article DE cancer; oncology; health services research; quality of care; quality assessment; quality methods ID PERFORMANCE AB BACKGROUND. The rise of managed care has increased interest in measuring, reporting, and improving quality of care. To date, quality assessment has relied on a leading indicator approach, which may miss important variations in care. The authors developed cancer specific indicators using a novel case-based approach for a quality measurement tool designed to compare different managed care organizations. METHODS. Based on a review of the literature, quality indicators were developed for 6 types of cancer and the human immunodeficiency virus (HIV) as well as 39 general adult conditions (GAC). The validity and feasibility of these candidate indicators were evaluated using three modified Delphi expert panels. The strength of evidence, type of care (preventive, acute, or chronic), function (screening, diagnosis, treatment, and follow-up), and modality (history, physical examination, laboratory, medication, or other intervention) of the cancer/HIV quality indicators were compared with indicators developed for GAG. RESULTS. The final system included 117 of the 145 proposed cancer/HIV quality indicators (81%) and 569 of the 705 proposed GAC indicators (81%). A greater percentage of the cancer/HIV indicators were based on evidence from clinical trials compared with the GAC indicators (59% vs. 31%; P = 0.001). Cancer/HIV had significantly more indicators pertaining to chronic care than did GAC (74% vs. 56%; P = 0.001) as well as more indicators for treatment (53% vs. 39%; P = 0.004). CONCLUSIONS. Using the case-based approach, it is feasible to develop quality indicators for cancer that cover the continuum of care. Future studies will evaluate the reliability and validity of measurements made using these indicators in three managed care plans. (C) 1999 American Cancer Society. C1 Univ Calif Los Angeles, Div Canc Prevent & Control Res, Dept Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Vet Adm Ann Arbor Healthcare Syst, Vet Adm Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA. Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Malin, JL (reprint author), Univ Calif Los Angeles, Div Canc Prevent & Control Res, Dept Med, A2-125 CHS Box 956900, Los Angeles, CA 90095 USA. NR 12 TC 51 Z9 52 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0008-543X J9 CANCER JI Cancer PD FEB 1 PY 2000 VL 88 IS 3 BP 701 EP 707 DI 10.1002/(SICI)1097-0142(20000201)88:3<701::AID-CNCR29>3.0.CO;2-V PG 7 WC Oncology SC Oncology GA 276JQ UT WOS:000084874900029 PM 10649266 ER PT J AU Miller, LG Asch, SM Yu, EI Knowles, L Gelberg, L Davidson, P AF Miller, LG Asch, SM Yu, EI Knowles, L Gelberg, L Davidson, P TI A population-based survey of tuberculosis symptoms: How atypical are atypical presentations? SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PULMONARY TUBERCULOSIS; CLINICAL-FEATURES; DIAGNOSIS; EXPERIENCE; PNEUMONIA; INFECTION; ADULTS; YOUNG AB There is scant information on tuberculosis symptoms from a population-based perspective. We prospectively identified 526 tuberculosis cases reported in Los Angeles County over a 6-month period. Of 313 persons who completed our questionnaire, 72.7% had cough, 48.2% for >2 weeks, and 52.3% had fever, 29.4% for >2 weeks. Among those with pulmonary disease, only 52.4% had cough for >2 weeks, In a multivariate model, persons with significant symptoms typical of tuberculosis disease (defined as cough or fever for >2 weeks, weight loss, or hemoptysis) were associated with lack of medical insurance, negative tuberculin skin test, diagnosis during a process other than screening, and non-Asian race, In summary, classic symptoms of prolonged cough and fever are insensitive predictors of tuberculosis. Our data suggest that Asians may need to be added to the list of persons who present with tuberculosis atypically. We believe that the Infectious Diseases Society of America guidelines for community-acquired pneumonia should emphasize demographic features in addition to clinical symptoms when suggesting which patients require evaluation for Mycobacterium tuberculosis. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Div Infect Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Med Ctr, Dept Family Med, Los Angeles, CA 90024 USA. Los Angeles Cty Dept Hlth, Los Angeles Cty TB Control, Los Angeles, CA USA. RP Miller, LG (reprint author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Div Infect Dis, 1124 W Carson St,Box 466, Torrance, CA 90502 USA. NR 40 TC 36 Z9 37 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2000 VL 30 IS 2 BP 293 EP 299 DI 10.1086/313651 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 293JX UT WOS:000085849400013 PM 10671331 ER PT J AU Kilzieh, N AF Kilzieh, N TI The eclipse of the state mental hospital: Policy, stigma and organization SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Book Review C1 VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA 98493 USA. RP Kilzieh, N (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div, 116 MHC,Bldg 85B, Tacoma, WA 98493 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD FEB PY 2000 VL 36 IS 1 BP 126 EP 127 PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 284NL UT WOS:000085338400010 ER PT J AU Rogers, PL Jacob, H Thomas, EA Harwell, M Willenkin, RL Pinsky, MR AF Rogers, PL Jacob, H Thomas, EA Harwell, M Willenkin, RL Pinsky, MR TI Medical students can learn the basic application, analytic, evaluative, and psychomotor skills of critical care medicine SO CRITICAL CARE MEDICINE LA English DT Article DE education, medical; students, medical; critical care; teaching; educational measurement; clinical clerkship; intensive care unit; learning; clinical competence ID STRUCTURED CLINICAL EXAMINATION; RELIABILITY; COMPETENCE AB Objective: To determine whether fourth-year medical students can learn the basic analytic, evaluative, and psychomotor skills needed to initially manage a critically ill patient, Design: Student learning was evaluated using a performance examination, the objective structured clinical examination (OSCE). Students were randomly assigned to one of two clinical scenarios before the elective. After the elective, students completed the other scenario, using a crossover design. Setting: Five surgical intensive care units in a tertiary care university teaching hospital, Participants: Forty fourth-year medical students enrolled in the critical care medicine (CCM) elective. Interventions: AII students evaluated a live "simulated critically ill" patient, requested physiologic data from a nurse, ordered laboratory tests, received data in real time, and intervened as they deemed appropriate. Measurements and Main Results: Student performance of specific behavioral objectives was evaluated at five stations. They were expected to a) assess airway, breathing, and circulation in appropriate sequence; b) prepare a manikin for intubation, obtain an acceptable airway on the manikin, demonstrate bag-mouth ventilation, and perform acceptable laryngoscopy and intubation; c) provide appropriate mechanical ventilator settings; d) manage hypotension; and e) request and interpret pulmonary artery data and initiate appropriate therapy. OSCEs were videotaped and reviewed by two faculty members masked to time of examination, A checklist of key behaviors was used to evaluate performance. The primary outcome measure was the difference in examination score before and after the rotation. Secondary outcomes included the difference in scores at each rotation, The mean preelective score was 57.0% +/- 8.3% compared with 85.9% +/- 7.4% (p < .0001) after the elective. Significant improvement was demonstrated at each station except station I. Conclusion: Fourth-year medical students without a CCM elective do not possess the basic cognitive and psychomotor skills necessary to initially manage critically ill patients. After an appropriate I-month CGM elective, students' thinking and application skills required to initially manage critically ill patients improved markedly, as demonstrated by an OSCE using a live simulated "patient" and manikin. C1 Univ Pittsburgh, Med Ctr, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Educ Psychol, Pittsburgh, PA USA. RP Rogers, PL (reprint author), VA Pittsburgh Hlth Care Syst, Crit Care Serv 124U, Univ Dr, Pittsburgh, PA 15240 USA. NR 10 TC 22 Z9 23 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2000 VL 28 IS 2 BP 550 EP 554 DI 10.1097/00003246-200002000-00043 PG 5 WC Critical Care Medicine SC General & Internal Medicine GA 288CB UT WOS:000085543300043 PM 10708198 ER PT J AU Elbein, SC Wegner, K Kahn, SE AF Elbein, SC Wegner, K Kahn, SE TI Reduced beta-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; POLYCYSTIC-OVARY-SYNDROME; PIMA-INDIANS; INTRAVENOUS GLUCOSE; SENSITIVITY; SECRETION; MELLITUS; LEPTIN; NIDDM; HYPERINSULINEMIA AB OBJECTIVE - Both obesity and a family history of diabetes reduce insulin sensitivity but the impact of obesity on insulin secretion among individuals predisposed to diabetes is uncertain. We used a pedigree-based approach to test the hypothesis that p-cell compensation to the insulin resistance associated with obesity is defective among individuals predisposed to diabetes by virtue of a strong family history of type 2 diabetes before the development of diabetes or glucose intolerance. RESEARCH DESIGN AND METHODS - A total of 126 members of 26 families ascertained for at least a sib pair with type 2 diabetes with onset before age 65 years underwent a tolbutamide-modified frequently sampled intravenous glucose tolerance rest (FSIGT). Family members included 26 individuals with impaired glucose tolerance and 100 individuals with normal glucose tolerance (NGT). The acute insulin response to glucose (AIR(glucose)) was determined and insulin sensitivity (S-I) estimated by minimal model analysis of FSIGT data. The beta-cell compensation for insulin sensitivity was estimated from the disposition index (DI), calculated as the product of SI and AIR(glucose). Obesity was measured by BMI. RESULTS - Among all individuals, BMI was a significant predictor of both SI and AIR(glucose), as expected. However, BMI also significantly predicted DI (P = 0.002) after correcting for age, sex, family membership, and glucose tolerance status. The relationship of BMI and DI was confirmed in 85 individuals with NGT who were aged <45 (P = 0.002) but not in 91 unrelated control individuals without a family history of diabetes. When normoglycemic individuals aged <45 were separated into three classes by BMI (less than or equal to 27, 27-30, >30), S-I decreased progressively and significantly with obesity, whereas AIR(glucose) rose significantly from lean to most obese classes. In contrast to the expectation of complete beta-cell compensation with obesity DI fell significantly (P = 0.004) among obese family members. This relationship was not observed in control subjects CONCLUSIONS - Individuals with a genetic predisposition to diabetes show a reduced beta-cell compensatory response to the reduced insulin sensitivity associated with obesity We propose that this impaired compensation may be one manifestation of the underlying genetic defect in susceptible individuals. This finding helps explain the multiplicative effects of family history and obesity on risk of type 2 diabetes. C1 Cent Arkansas Vet Hlthcare Syst, Endocrinol Sect, Little Rock, AR USA. Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Elbein, SC (reprint author), John L McClellan Mem Vet Hosp, 4700 W 7th St, Little Rock, AR 72205 USA. FU NIDDK NIH HHS [DK17047, DK39311] NR 32 TC 74 Z9 78 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2000 VL 23 IS 2 BP 221 EP 227 DI 10.2337/diacare.23.2.221 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 279HA UT WOS:000085037300017 PM 10868835 ER PT J AU Whitsel, EA Boyko, EJ Siscovick, DS AF Whitsel, EA Boyko, EJ Siscovick, DS TI Reassessing the role of QT(c) in the diagnosis of autonomic failure among patients with diabetes - A meta-analysis SO DIABETES CARE LA English DT Article ID QT INTERVAL PROLONGATION; Q-T INTERVAL; NERVOUS-SYSTEM; NEUROPATHY; MELLITUS; TESTS; ELECTROCARDIOGRAM; METAANALYSIS; ASSOCIATION; PROPRANOLOL AB OBJECTIVE- A 1992 consensus statement on autonomic testing portrayed Bazett's heart race-corrected QT interval (QT(c)) prolongation as a specific yet insensitive indicator of diabetic autonomic failure. At that time, only a few small studies had evaluated the accuracy of QT(c). To date, even fewer studies have evaluated whether its accuracy is influenced by patient characteristics. RESEARCH DESIGN AND METHODS - We critically appraised 17 studies reporting the sensitivity and specificity of QT(c) for diabetic autonomic failure. The studies represented 4,584 patients with diabetes (mean age 34.9 years, 46% female, 92% with type 1 diabetes, mean duration of diabetes 14.5 years). We summarized the accuracy of QT(c) prolongation for diabetic autonomic failure as an odds ratio (OR) (95% CI) and determined whether patient and study design characteristics influenced the accuracy of QT(c) prolongation by comparing summary receiver operating characteristic curves. RESULTS - Autonomic failure, defined as greater than or equal to 1.2 +/- 0.4 (mean +/- SD) abnormal of 2.0 +/- 1.6 administered cardiovascular reflex tests, was found in 26% (25-28) of patients. The pooled sensitivity and specificity of QT(c) > 441 +/- 8 ms for autonomic failure were 28% (26-29) and 86% (85-87), respectively. Autonomic failure was 2.26 times (1.90-2.70) more likely to be present in patients with than in patients without QT(c) prolongation. At 86% specificity the sensitivity of QT(c) prolongation was 46 vs. 12% for men versus women (P = 0.0077), respectively, and, after adjustment for sex, 66 vs. 17% among patients aged 25 vs. 55 years (P = 0.1902) and 61 vs. 27% at thresholds of >420 vs. >460 ms, respectively (P = 0.2964). CONCLUSIONS - QT(c) prolongation is a specific albeit insensitive indicator of autonomic failure. Although QT(c) prolongation is relatively accurate for men, accuracy may be even greater for young men at low QT(c) thresholds. C1 Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. Univ Washington, Dept Med & Epidemiol, Seattle, WA 98195 USA. RP Whitsel, EA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, 1660 S Columbian Way, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X NR 48 TC 57 Z9 60 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2000 VL 23 IS 2 BP 241 EP 247 DI 10.2337/diacare.23.2.241 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 279HA UT WOS:000085037300020 PM 10868838 ER PT J AU Kearney, DJ Brousal, A AF Kearney, DJ Brousal, A TI Treatment of Helicobacter pylori infection in clinical practice in the United States - Results from 224 patients SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Helicobacter pylori; peptic ulcer; dyspepsia ID LANSOPRAZOLE TRIPLE THERAPY; METRONIDAZOLE RESISTANCE; TREATMENT REGIMENS; PEPTIC-ULCER; ERADICATION; CLARITHROMYCIN; OMEPRAZOLE; EFFICACY; TRIAL; CURE AB Our objectives were to define treatment success, compliance, and side effects for treatment of Helicobacter pylori in clinical practice. In all, 224 consecutive patients received Helicobacter pylori treatment: 97 received two weeks of bismuth subsalicylate, metronidazole, tetracycline four times a day with a H-2-receptor antagonist twice a day (BMT); 89 received one week of metronidazole, lansoprazole, and clarithromycin twice a day (MLC); and 38 received one week of BMT with lansoprazole twice a day (BMT-PPI). Cure rates were: BMT 81% (95% CI 74-89%), MLC 90% (95% CI 84-96%) BMT-PPI 87% (95% CI 81-92%). More patients prescribed a bismuth-based regimen discontinued medications due to side effects compared to MLC (P = 0.049). Nausea was more common for BMT compared to MLC (P = 0.04). In conclusion, treatment of Helicobacter pylori infection with a one-week course of MLC achieves a high rate of cure in clinical practice. Significantly fewer patients prescribed PPI-based therapy discontinue medications due to side effects as compared to bismuth-based triple therapy. C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Kearney, DJ (reprint author), Vet Adm Med Ctr, 1660 S Columbian Way,111GI, Seattle, WA 98108 USA. NR 40 TC 26 Z9 29 U1 0 U2 0 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2000 VL 45 IS 2 BP 265 EP 271 DI 10.1023/A:1005444006042 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 290YJ UT WOS:000085705200009 PM 10711436 ER PT J AU Singh, B AF Singh, B TI Azimilide - Viewpoint SO DRUGS LA English DT Editorial Material C1 W Los Angeles Vet Affairs Med Ctr, Div Cardiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Singh, B (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Cardiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ADIS INTERNATIONAL LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PD FEB PY 2000 VL 59 IS 2 BP 278 EP 278 DI 10.2165/00003495-200059020-00017 PG 1 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 292CY UT WOS:000085777600020 ER PT J AU Mazarati, AM Baldwin, RA Sofia, D Wasterain, CG AF Mazarati, AM Baldwin, RA Sofia, D Wasterain, CG TI Felbamate in experimental model of status epilepticus SO EPILEPSIA LA English DT Article DE self-sustaining status epilepticus; seizures; felbamate; anticonvulsant ID INSENSITIVE GLYCINE RECEPTORS; HUMAN POSTMORTEM BRAIN; PARTIAL SEIZURES; RAT; ANTICONVULSANT; ISCHEMIA AB Purpose: To examine the putative seizure protective properties of felbarnate in an animal model of self-sustaining status epilepticus (SSSE). Methods: SSSE was induced by 30-min stimulation of the perforant path (PPS) through permanently implanted electrodes in free-running male adult Wistar rats. Felbarnate (FBM; 50, 100, and 200 mg/kg), dizepam (DZP; 10 mg/kg), or phenytoin (PHT; 50 mg/kg) were injected i.v. 10 min after SSSE induction. Electrographic manifestations of SSSE and the severity of SSSE-induced neuronal injury were analyzed. Results: Felbamate injected during the early stages of SSSE (10 min after the end of PPS), shortened the duration of seizures in a dose-dependent manner. Total time spent in seizures after FBM and 290 +/- 251 min (50 mg/kg), 15.3 +/- 9 min (100 mg/kg), and 7 +/- 1 min (200 mg/kg), whereas control animals spent 410 +/- 133 min seizing. This effect of FBM was stronger than that of DZP (10 mg/kg, 95 +/- 22 min) and comparable to that of PHT (50 mg/kg, 6.3 +/- 2.5 min). In the applied doses, FBM (200 mg/kg) was more effective than PHT (50 mg/kg) or DZP (10 mg/kg) in shortening seizure duration and decreasing spike frequency, when administered on the pleateau of SSSE (injection 40 min after the end of PPS). Anticonvulsant action of FBM was confirmed by milder neuronal injury compared with control animals. Conclusions: Felbamate, a clinically available AED with a moderate affinity for the glycine site of the NMDA receptor, displayed a potent seizure-protective effect in an animal model of SSSE. These results suggest that FBM might be useful when standard AEDs fail in the treatment of refractory cases of SE. C1 Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90024 USA. Wallace Labs, Cranbury, NJ USA. RP Mazarati, AM (reprint author), VA GLAHCS, 111N1 Epilepsy Res,16111 Plummer St, Sepulveda, CA 91343 USA. FU NINDS NIH HHS [NS11315] NR 19 TC 19 Z9 19 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD FEB PY 2000 VL 41 IS 2 BP 123 EP 127 DI 10.1111/j.1528-1157.2000.tb00130.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 282RH UT WOS:000085231900001 PM 10691107 ER PT J AU Krahl, SE Senanayake, SS Handforth, A AF Krahl, SE Senanayake, SS Handforth, A TI Seizure suppression by systemic epinephrine is mediated by the vagus nerve SO EPILEPSY RESEARCH LA English DT Article DE adrenaline; anticonvulsant; epilepsy; pentylenetetrazol; vagus nerve ID STIMULATION AB The present study investigated the seizure-suppressing effects of systemic epinephrine. Rats were injected with epinephrine, and seizures induced with pentylenetetrazol. Seizure severities were significantly reduced 15 min after 1 mg/kg of epinephrine. Severing the subdiaphragmatic vagus nerves abolished this effect, demonstrating that epinephrine-induced seizure suppression is mediated by subdiaphragmatic vagal afferents. The development of novel anti-epileptic drugs that exploit this peripheral pathway may yield new seizure treatments. (C) 2000 Elsevier Science B.V. All rights reserved. C1 W Los Angeles VA Med Ctr, Neurol Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA. RP Krahl, SE (reprint author), W Los Angeles VA Med Ctr, Neurol Serv, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM scott.krahl@med.va.gov NR 14 TC 21 Z9 23 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2000 VL 38 IS 2-3 BP 171 EP 175 DI 10.1016/S0920-1211(99)00089-3 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 273PU UT WOS:000084716700009 PM 10642045 ER PT J AU Wetter, DW Carmack, CL Anderson, CB Moore, CA De Moor, CA Cinciripini, PM Hirshkowitz, M AF Wetter, DW Carmack, CL Anderson, CB Moore, CA De Moor, CA Cinciripini, PM Hirshkowitz, M TI Tobacco withdrawal signs and symptoms among women with and without a history of depression SO EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; SMOKING-CESSATION; DAYTIME SLEEPINESS; TRANSDERMAL NICOTINE; DISORDERS; RELAPSE; FRAGMENTATION; INSOMNIA; LATENCY AB A past history of depression is associated with a decreased likelihood of quitting smoking. Tobacco withdrawal may be a mechanism through which depression history impedes smoking cessation. This research examined the influence of depression history on unmedicated tobacco withdrawal signs (polysomnographic measures of sleep) and symptoms (self-reported urge, negative affect, hunger, and sleep) among women (N = 13). Depression history was associated with differential withdrawal-induced changes in several REM sleep parameters. Self-report and other polysomnography (sleep fragmentation, slow-wave sleep) measures displayed statistically significant withdrawal effects but did not discriminate between depression history groups. These results suggest that REM sleep parameters may be sensitive to differential tobacco withdrawal responses that are not readily apparent through self-reported symptoms. C1 Univ Washington, Sch Publ Hlth & Community Med, Ctr Hlth Sci, Grp Hlth Cooperat, Seattle, WA 98101 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Sci, Seattle, WA 98101 USA. Univ Texas, MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Houston Vet Affairs Hosp, Sleep Disorders & Res Ctr, Houston, TX USA. RP Wetter, DW (reprint author), Univ Washington, Sch Publ Hlth & Community Med, Ctr Hlth Sci, Grp Hlth Cooperat, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. RI Cinciripini, Paul/I-5773-2012 OI Cinciripini, Paul/0000-0003-2877-9928; Wetter, David/0000-0002-6366-0108 FU NIDA NIH HHS [R03 DA10969] NR 52 TC 21 Z9 22 U1 6 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1064-1297 J9 EXP CLIN PSYCHOPHARM JI Exp. Clin. Psychopharmacol. PD FEB PY 2000 VL 8 IS 1 BP 88 EP 96 DI 10.1037//1064-1297.8.1.88 PG 9 WC Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry SC Psychology; Pharmacology & Pharmacy; Psychiatry GA 293GQ UT WOS:000085844000010 PM 10743908 ER PT J AU Wen, Y Sachs, G Athmann, C AF Wen, Y Sachs, G Athmann, C TI A novel lens epithelium gene, LEP503, is highly conserved in different vertebrate species and is developmentally regulated in postnatal rat lens SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE lens epithelial cell; mRNA expression; genome organization; lens protein; confocal microscopy; postnatal development ID FIBROBLAST GROWTH-FACTOR; CELL MESSENGER-RNA; CRYSTALLIN GENES; FIBER DIFFERENTIATION; MOLECULAR-FEATURES; CATARACT FORMATION; FACTOR FGF; EXPLANTS; AGE; EXPRESSION AB The development of the lens is dependent on the proliferation of lens epithelial cells and their differentiation into fiber cells near the lens bow/equator. Identification of genes specifically expressed in the lens epithelial cells and their functions may provide insight into molecular events that regulate the processes of lens epithelial cell differentiation. In this study, a novel lens epithelium gene product. LEP503, identified from rat by a subtractive cDNA cloning strategy was investigated in the genome organization, mRNA expression and protein localization. The genomic sequences for LEP503 isolated from rat, mouse and human span 1754 bp, 1694 bp and 1895 bp regions encompassing the 5'-flanking region, two exons, one intron and 3'-flanking region. All exon-intron junction sequences conform to the GT/AG rule, Both mouse and human LEP503 genes show very high identity (93% for mouse and 79% for human) to rat LEP503 gene in the exon 1 that contains an open reading frame coding for a protein of 61 amino acid residues with a leucine-rich domain. The deduced protein sequences also show high identity (91% between mouse and rat and 77% between human and rat). Western blot shows that LEP503 is present as a specific similar to 6.9 kDa band in the water-insoluble-urea-soluble fraction of lens cortex where lens epithelium is included. Immune-staining shows that LEP503 is localized in the epithelial cells along the entire anterior surface of rat lens. Developmentally, LEP503 is expressed at a low level at newborn, and then the expression level increases by about ten-fold around postnatal day 14 and remains at this high level for about 25 days before it drops back to the low level by postnatal day 84. These data suggest that the LEP 503 may be an important lens epithelial cell gene involving the processes of epithelial cell differentiation. (C) 2000 Academic Press. C1 W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Wen, Y (reprint author), W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK53462, DK41301, DK46917] NR 34 TC 6 Z9 10 U1 0 U2 0 PU ACADEMIC PRESS LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 J9 EXP EYE RES JI Exp. Eye Res. PD FEB PY 2000 VL 70 IS 2 BP 159 EP 168 DI 10.1006/exer.1999.0770 PG 10 WC Ophthalmology SC Ophthalmology GA 284UZ UT WOS:000085352400004 PM 10655141 ER PT J AU Conrad, CC Grabowski, DT Walter, CA Sabia, M Richardson, A AF Conrad, CC Grabowski, DT Walter, CA Sabia, M Richardson, A TI Using MT-/(-) mice to study metallothionein and oxidative stress SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE metallothionein; knockout mice; liver; DNA oxidation; lipid peroxidation; protein oxidation; free radicals ID MANGANESE SUPEROXIDE-DISMUTASE; I-TRANSGENIC MICE; X-IRRADIATION; IONIZING-RADIATION; RAT-LIVER; GLUTAMINE-SYNTHETASE; LIPID-PEROXIDATION; DNA-DAMAGE; ANTIOXIDANT ENZYMES; RENDERED RESISTANT AB Mice with null mutations for metallothionein genes MT-1 and MT-2 were used to study the role that metallothionein plays in protecting cellular targets in vivo from oxidative stress. Wild-type (MT+/+) and MT-null (MT-/-) mice were treated with either saline or zinc and exposed to two types of oxidative stress: gamma-irradiation or 2-nitropropane. There was no alteration in the antioxidant defense system (superoxide dismutase, catalase, or glutathione peroxidase and glutathione levels) to compensate for the lack of the metallothionein in the MT-/- mice. The amount of oxidative damage to liver DNA, lipids, and proteins were similar for the MT-/- and MT+/+ mice even though the levels of metallothionein in the livers of the saline- or zinc-pretreated MT+/+ mice were 5- to 100-fold greater than found in the MT-/- mice. To determine if metallothionein can protect mice from the lethal effects of ionizing radiation, the mean survivals of MT-/- and MT+/+ mice exposed to whole body gamma-irradiation were measured and found to be similar. However, the mean survival increased significantly after zinc pretreatment for both the MT-/- and MT+/+ mice. These results demonstrate that tissue levels of metallothionein do not protect mice in vivo against oxidative stress. (C) 2000 Elsevier Science Inc. C1 S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA. Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78285 USA. RP Richardson, A (reprint author), S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, GRECC 182,7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG14674, AG15908]; NIEHS NIH HHS [ES06277] NR 97 TC 38 Z9 39 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB 1 PY 2000 VL 28 IS 3 BP 447 EP 462 DI 10.1016/S0891-5849(99)00263-4 PG 16 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 289KD UT WOS:000085619000017 PM 10699757 ER PT J AU Graham, DY AF Graham, DY TI Therapy of Helicobacter pylori: Current status and issues SO GASTROENTEROLOGY LA English DT Article ID PEPTIC-ULCER DISEASE; TRIPLE THERAPY; DUODENAL-ULCER; REFLUX ESOPHAGITIS; H-2-RECEPTOR ANTAGONISTS; GASTRIC-CANCER; INFECTION; ERADICATION; OMEPRAZOLE; METRONIDAZOLE C1 Vet Affairs Med Ctr 111D, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA. RP Graham, DY (reprint author), Vet Affairs Med Ctr 111D, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 51 TC 89 Z9 89 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2000 VL 118 IS 2 SU S BP S2 EP S8 DI 10.1016/S0016-5085(00)70003-5 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 284GF UT WOS:000085322600002 PM 10868895 ER PT J AU Wolfe, MM Sachs, G AF Wolfe, MM Sachs, G TI Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome SO GASTROENTEROLOGY LA English DT Review ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CRITICALLY ILL PATIENTS; HELICOBACTER-PYLORI INFECTION; PROTON PUMP INHIBITORS; INTENSIVE-CARE UNIT; ANTI-INFLAMMATORY DRUGS; ZOLLINGER-ELLISON SYNDROME; PLACEBO-CONTROLLED TRIAL; ACTIVE DUODENAL-ULCER; CANINE PARIETAL-CELLS C1 Bostn Med Ctr, Gastroenterol Sect, Sch Med, Boston, MA 02118 USA. Boston Med Ctr, Boston, MA USA. Univ Calif Los Angeles, Sch Med, Div Gastroenterol, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Bostn Med Ctr, Gastroenterol Sect, Sch Med, 88 E Newton St, Boston, MA 02118 USA. EM michael.wolfe@bmc.org NR 185 TC 135 Z9 138 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2000 VL 118 IS 2 SU S BP S9 EP S31 DI 10.1016/S0016-5085(00)70004-7 PG 23 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 284GF UT WOS:000085322600003 PM 10868896 ER PT J AU Kuver, R Klinkspoor, JH Osborne, WRA Lee, SP AF Kuver, R Klinkspoor, JH Osborne, WRA Lee, SP TI Mucous granule exocytosis and CFTR expression in gallbladder epithelium SO GLYCOBIOLOGY LA English DT Article DE calcium; chloride channel; cystic fibrosis; mucin ID X-RAY-MICROANALYSIS; MUCIN SECRETION; CYSTIC-FIBROSIS; CHLORIDE TRANSPORT; ZYMOGEN GRANULES; CELLS; MEMBRANE; CALCIUM; GLAND; BILE AB A mechanistic model of mucous granule exocytosis by columnar epithelial cells must take into account the unique physical-chemical properties of mucin glycoproteins and the resultant mucus gel. In particular, any model must explain the intracellular packaging and the kinetics of release of these large, heavily charged species. We studied mucous granule exocytosis in gallbladder epithelium, a model system for mucus secretion by columnar epithelial cells. Mucous granules released mucus by merocrine exocytosis in mouse gallbladder epithelium when examined by transmission electron microscopy. Spherules of secreted mucus larger than intracellular granules were noted on scanning electron microscopy. Electron probe microanalysis demonstrated increased calcium concentrations within mucous granules. Immunofluorescence microscopic studies revealed intracellular colocalization of mucins and the cystic fibrosis transmembrane conductance regulator (CFTR), Confocal laser immunofluorescence microscopy confirmed colocalization, These observations suggest that calcium in mucous secretory granules provides cationic shielding to keep mucus tightly packed. The data also suggests CFTR chloride channels are present in granule membranes. These observations support a model in which influx of chloride ions into the granule disrupts cationic shielding, leading to rapid swelling, exocytosis and hydration of mucus. Such a model explains the physical-chemical mechanisms involved in mucous granule exocytosis. C1 Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. RP Kuver, R (reprint author), Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA. RI Lee, Sum Ping/C-4333-2009 FU NIDDK NIH HHS [DK47754, R01DK50246] NR 43 TC 31 Z9 33 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0959-6658 J9 GLYCOBIOLOGY JI Glycobiology PD FEB PY 2000 VL 10 IS 2 BP 149 EP 157 DI 10.1093/glycob/10.2.149 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 281DY UT WOS:000085143700004 PM 10642606 ER PT J AU Contreras, MA Khan, M Smith, BT Cimini, AM Gilg, AG Orak, J Singh, I Singh, AK AF Contreras, MA Khan, M Smith, BT Cimini, AM Gilg, AG Orak, J Singh, I Singh, AK TI Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators SO HEPATOLOGY LA English DT Article ID TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; BETA-OXIDATION; FACTOR-ALPHA; BACTERIAL-ENDOTOXIN; LIPID-COMPOSITION; GENE-EXPRESSION; FATTY-ACIDS; CACHECTIN; DEGRADATION AB We report that endotoxin treatment results in decreased amounts of peroxisomes as well as changes in structure and function of peroxisomal membranes. Peroxisomes isolated from the liver of control and treated animals showed a marked decrease in total protein, but no significant alteration in the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) protein profile. However, the Western blot study of the peroxisomal beta-oxidation enzymes and catalase showed an increase in those enzymes in the peroxisomal peak of normal density in endotoxin-treated rats. Disintegration of peroxisomal membranes by carbonate treatment from endotoxin-treated liver and change in the fluidity of peroxisomal membranes suggests alterations in peroxisomal membrane structure. No such alterations were found in mitochondrial or microsomal membranes of endotoxin-treated livers. The lipid analysis of these organelles showed that the only organelle affected was the peroxisome, with a significant decrease in the phospholipid and cholesterol concentrations. To understand the mechanism of endotoxin-mediated alterations in peroxisomes, we studied the possible role of Kupffer cell secreted soluble factors (tumor necrosis factor alpha [TNF-alpha]) on the peroxisomal structure/function. Inactivation/elimination of Kupffer cells by gadolinium chloride before endotoxin treatment did not normalize the overall peroxisomal protein amount and the lipid composition of isolated peroxisomes, However, the levels of individual protein amount in remaining peroxisomes were normalized. Endotoxin also decreased peroxisomal beta-oxidation, and this was partially restored with gadolinium treatment. These results clearly show that peroxisomes are severely affected by endotoxin treatment and suggest that the damage to this organelle may contribute, at least in part, to endotoxin-induced 'hepatic cytotoxicity. C1 Ralph H Johnson Vet Adm Med Ctr, Dept Lab Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Ralph H Johnson Vet Adm Med Ctr, Dept Lab Med, 109 Bee St, Charleston, SC 29401 USA. RI Cimini, Annamaria/C-3688-2011 OI Cimini, Annamaria/0000-0002-2737-7970 FU NINDS NIH HHS [NS-37766, NS-22576, NS-34741] NR 59 TC 18 Z9 18 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD FEB PY 2000 VL 31 IS 2 BP 446 EP 455 DI 10.1002/hep.510310226 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 281EB UT WOS:000085144000026 PM 10655269 ER PT J AU Komers, R Oyama, TT Chapman, JG Allison, KM Anderson, S AF Komers, R Oyama, TT Chapman, JG Allison, KM Anderson, S TI Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats SO HYPERTENSION LA English DT Article DE blood pressure; diabetes; S-methyl-L-thiocitrulline; nitric oxide; nitric oxide synthase ID GLOMERULAR CAPILLARY-PRESSURE; ANGIOTENSIN-II; MACULA DENSA; BLOOD-PRESSURE; RENAL HEMODYNAMICS; RESPONSES; HYPERTENSION; EXPRESSION; FEEDBACK; ARGININE AB Diabetes is associated with alterations in nitric oxide-mediated vasomotor function. The role of nitric oxide generated via the neuronal nitric oxide synthase pathway in the control of systemic and renal hemodynamics in diabetes has not been studied. To explore the hypothesis that diabetic vascular dysfunction is in part caused by altered neuronal nitric oxide synthase activity, systemic and renal hemodynamics were assessed before and after acute inhibition of this enzyme with a specific inhibitor, S-methyl-L-thiocitruIline, in control and diabetic rats. The interaction of this pathway and the renin-angiotensin system was studied in separate groups of rats pretreated with the angiotensin II receptor blocker losartan; these rats were compared with rats treated with losartan alone. Diabetic animals demonstrated higher baseline glomerular filtration rates and filtration fractions. At a low dose, the neuronal nitric oxide synthase inhibitor induced similar dose-dependent presser responses in control and diabetic rats. Losartan abolished the presser response in both groups. No changes in renal plasma flow or renal vascular resistance occurred in control rats. In contrast, diabetic rats responded with significant renal vasoconstriction. At a high dose, the renal vasoconstriction was similar in both groups and was not affected by losartan. In conclusion, neuronal nitric oxide synthase-derived nitric oxide plays a role in the control of systemic and renal hemodynamics in normal and diabetic rats. Diabetic rats are more sensitive to the inhibitor, suggesting increased activity of this pathway in the diabetic kidney. Furthermore, renal responses in diabetic rats were attenuated by angiotensin II receptor blockade, whereas losartan alone induced hemodynamic changes that were opposite those seen with neuronal nitric oxide synthase inhibition. This observation implicates angiotensin II as an important modulator of this nitric oxide pathway in diabetes. C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Anderson, S (reprint author), Oregon Hlth Sci Univ, Div Nephrol, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. FU NIA NIH HHS [AG-14699] NR 48 TC 46 Z9 46 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD FEB PY 2000 VL 35 IS 2 BP 655 EP 661 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 285YA UT WOS:000085414900022 PM 10679513 ER PT J AU Radd, II Hanna, HA Hachem, RY Darouiche, RO AF Radd, II Hanna, HA Hachem, RY Darouiche, RO TI Diagnosis of catheter-related bloodstream infection: Is it necessary to culture the subcutaneous segment? SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Meeting Abstract C1 Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD FEB PY 2000 VL 21 IS 2 BP 97 EP 97 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 285XM UT WOS:000085413700077 ER PT J AU Naliboff, BD AF Naliboff, BD TI Regional brain activity during visceral stimulation in IBS patients SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2000 VL 35 IS 1 BP 35 EP 35 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 273UY UT WOS:000084727300092 ER PT J AU Wemple, MA Starkebaum, G AF Wemple, MA Starkebaum, G TI Simultaneous pseudogout and gout after intra-articular injection of hylan gel fluid 20 SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Letter ID ACUTE LOCAL REACTIONS; INTRAARTICULAR INJECTION; OSTEOARTHRITIS; HYALURONAN; KNEE C1 Univ Washington, Med Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Serv, Seattle, WA USA. RP Wemple, MA (reprint author), Univ Washington, Med Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 6 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD FEB PY 2000 VL 6 IS 1 BP 58 EP 59 PG 2 WC Rheumatology SC Rheumatology GA 290KQ UT WOS:000085675800014 ER PT J AU Menaa, C Barsony, J Reddy, SV Cornish, J Cundy, T Roodman, GD AF Menaa, C Barsony, J Reddy, SV Cornish, J Cundy, T Roodman, GD TI 1,25-dihydroxyvitamin D-3 hypersensitivity of osteoclast precursors from patients with Paget's disease SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE Paget's disease; osteoclasts; precursors; 1,25-(OH)(2)D-3; vitamin D receptor ID VITAMIN-D-RECEPTOR; MARROW CULTURES; IMMUNOCYTOCHEMICAL LOCALIZATION; MULTINUCLEATED CELLS; GENE-EXPRESSION; PHORBOL ESTER; BONE-MARROW; HORMONE; BINDING; LIGAND AB Our previous studies suggested that increased osteoclast formation and activity in Paget's disease may be related in part to increased responsiveness of highly purified osteoclast precursors to 1,25-dihydroxyvitamin D-3 [1,25-(OH)(2)D-3]. However, the basis for this enhanced sensitivity to 1,25-(OH),D3 is unclear To address this question, we examined 24-hydroxylase and 1,25-(OH)(2)D-3 receptor (VDR) messenger RNA (mRNA) expression during human osteoclast differentiation from normal subjects and patients with Paget's disease in response to 1,25-(OH)(2)D-3 as well as VDR content and affinity, Reverse-transcription polymerase chain reaction (RT-PCR) analysis of granulocyte-macrophage colony-forming unit (GM-CFU), the earliest identifiable osteoclast precursor, derived from patients with Paget's disease demonstrated 24-hydroxylase mRNA expression in response to 1,25-(OH)(2)D-3 was induced at concentrations of 1,25-(OH)(2)D-3 that were at least one log less than that required for normal GM-CFU, VDR mRNA and VDR protein were detected in both immature and more differentiated osteoclast precursors, as well as in osteoclast-like multinucleated cells (MNCs), However, VDR expression was lower in MNCs than the mononuclear precursor cells, Osteoclast precursors and MNCs from patients with Paget's disease had levels of VDR expression similar to those of normal subjects but showed increased VDR affinity for 1,25-(OH)(2)D-3. Because the effects of 1,25-(OH)(2)D-3 are in part mediated by induction of expression of RANK ligand on marrow stromal cells, which in turn stimulates osteoclast formation, we examined expression of RANK ligand mRNA by marrow stromal cell lines derived from patients with Paget's disease and normal subjects in response to 1,25-(OH)(2)D-3. RT-PCR analysis showed no difference in sensitivity of marrow stromal cells to 1,25-(OH)(2)D-3 from normal subjects or patients with Paget's disease although the Paget's stromal cells expressed increased basal levels of RANK ligand mRNA, These results show that VDR protein is expressed in early and more differentiated osteoclast precursors, that expression levels of VDR decline with osteoclast differentiation, and that 1,25-(OH)(2)D-3 has direct effects on osteoclast precursors, The enhanced sensitivity to 1,25-(OH)(2)D-3 is an intrinsic property of osteoclast precursors from patients with Paget's disease that distinguishes them from normal osteoclast precursors, Furthermore, our results suggest that an increased affinity of VDR for 1,25-(OH)(2)D-3 may be responsible for the enhanced 1,25-(OH)(2)D-3 sensitivity of osteoclast precursors in patients with Paget's disease compared with normal subjects. C1 Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78284 USA. NIH, Bethesda, MD 20892 USA. Univ Auckland, Auckland 1, New Zealand. Audie Murphy Vet Adm Hosp, San Antonio, TX USA. RP Roodman, GD (reprint author), Res Hematol 151, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG13625]; NIAMS NIH HHS [AR44603, AR41336] NR 27 TC 52 Z9 54 U1 0 U2 3 PU AMER SOC BONE & MINERAL RES PI DURHAM PA PO BOX 2759, DURHAM, NC 27715-2759 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2000 VL 15 IS 2 BP 228 EP 236 DI 10.1359/jbmr.2000.15.2.228 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282HR UT WOS:000085212800006 PM 10703924 ER PT J AU Hinkin, CH Castellon, SA Hardy, DJ AF Hinkin, CH Castellon, SA Hardy, DJ TI Dual task performance in HIV-1 infection SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article; Proceedings Paper CT 25th Meeting of the International-Neuropsychological-Society CY FEB 05-08, 1997 CL ORLANDO, FLORIDA SP Int Neuropsychol Soc ID IMMUNODEFICIENCY-VIRUS-INFECTION; WORKING-MEMORY; REACTION-TIME; HIV-1-INFECTED INDIVIDUALS; QUINOLINIC ACID; ATTENTION; DEMENTIA; DEFICITS; DISEASE AB Fifty HIV-infected individuals and 20 uninfected controls participated in an investigation of dual task performance in HIV-1 infection. Participants first engaged in a simple auditory reaction time (RT) task followed by a visual choice RT task (single task condition), and then they simultaneously engaged in both tasks (dual task condition). Under single task conditions, the HIV+ participants did not significantly differ from controls on either simple or choice RT (though a trend was evident on single task choice RT). In contrast, under dual task conditions the HIV+ group's performance decrement, relative to controls, was significantly greater on both simple and choice RT. This dual task decrement was also significantly associated with slower performance on the interference condition of the Stroop. Patients with AIDS tended to have greater dual task decrements than did the pre-AIDS group, though this fell short of statistical significance. These results suggest that HIV-1 infection leads to deficits in divided attention and the simultaneous processing of competing stimuli, deficits which have been linked to disruption of the anterior attentional system. C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, ABPP, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Hinkin, CH (reprint author), Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, ABPP, 760 Westwood Plaza,Room C8-747, Los Angeles, CA 90024 USA. FU NIMH NIH HHS [R03MH54465] NR 32 TC 28 Z9 29 U1 2 U2 5 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD FEB PY 2000 VL 22 IS 1 BP 16 EP 24 DI 10.1076/1380-3395(200002)22:1;1-8;FT016 PG 9 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 287BE UT WOS:000085484000002 PM 10649542 ER PT J AU Kirkpatrick, WR Lopez-Ribot, JL Mcatee, RK Patterson, TF AF Kirkpatrick, WR Lopez-Ribot, JL Mcatee, RK Patterson, TF TI Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VIRUS-INFECTED PATIENTS; CELL-SURFACE HYDROPHOBICITY; DENTURE ACRYLIC SURFACES; FLUCONAZOLE RESISTANCE; IN-VITRO; OROPHARYNGEAL CANDIDIASIS; IDENTIFICATION; SUSCEPTIBILITY; EXPRESSION; MACRODILUTION AB Seven isolates each of Candida albicans and Candida dubliniensis were paired (11 pairs) and examined for competitive interaction. Equal numbers of CFU of each competitor Here inoculated into Sabouraud dextrose broth and incubated at 37 degrees C with vigorous shaking under conditions favorable to either broth or biofilm growth. Surviving proportions of each competitor were calculated from the broth culture at 24 and 96 h and the biofilm culture at 96 h, with species differentiation done on CHROMagar Candida medium. C. albicans had a competitive advantage ol er C. dubliniensis in broth culture and under biofilm growing conditions; however, with the presence of a supporting structure for biofilm formation, C. dubliniensis was able to better withstand the competitive pressures from C. albicans. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. RP Kirkpatrick, WR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. RI Lopez-Ribot, Jose/D-2048-2010 FU NCRR NIH HHS [M01RR01346, M01 RR001346]; NIAID NIH HHS [1R29AI42401]; NIDCR NIH HHS [R01 DE011381, 5RO1DE11381] NR 30 TC 25 Z9 26 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2000 VL 38 IS 2 BP 902 EP 904 PG 3 WC Microbiology SC Microbiology GA 281XR UT WOS:000085187200083 PM 10655413 ER PT J AU Raskind, MA Dobie, DJ Kanter, ED Petrie, EC Thompson, CE Peskind, ER AF Raskind, MA Dobie, DJ Kanter, ED Petrie, EC Thompson, CE Peskind, ER TI The alpha(1)-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: A report of 4 cases SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ADRENERGIC-RECEPTORS; HUMAN-BRAIN; SLEEP; PTSD; ALPHA-1-ADRENOCEPTORS; PHARMACOLOGY; MECHANISMS; MANAGEMENT; SECRETION; NEURONS AB Background: Central nervous system (CNS) adrenergic hyperresponsiveness may be involved in the pathophysiology of posttraumatic stress disorder (PTSD). Two Vietnam combat veterans with PTSD prescribed the centrally active alpha(1)-adrenergic antagonist prazosin for symptoms of benign prostatic hypertrophy unexpectedly reported elimination of combat trauma nightmares. This observation prompted an open-label feasibility trial of prazosin for combat trauma nightmares in chronic combat-induced PTSD. Method: Four consecutively identified combat veterans with chronic DSM-IV PTSD and severe intractable combat trauma nightmares participated in an 8-week open trial of escalating-dose prazosin. Nightmare severity response was rated using the nightmare item of the Clinician Administered PTSD Scale and the Clinical Global Impressions-Change scale. Results: The 2 patients who achieved a daily prazosin dose of at lease 5 mg were markedly improved, with complete elimination of trauma nightmares and resumption of normal dreaming. The 2 subjects limited to 2 mg of prazosin to avoid excessive blood pressure reduction were moderately improved with at least 50% reduction in nightmare severity. Conclusion: These clinical observations, together with neurobiological evidence for alpha(1)-adrenergic regulation of CNS neurobiological systems relevant to PTSD, provide rationale for placebo-controlled trials of prazosin for PTSD combat trauma nightmares. C1 Vet Affairs NW Network Mental Illness Res Educ &, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Raskind, MA (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv 116, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 32 TC 77 Z9 79 U1 1 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2000 VL 61 IS 2 BP 129 EP 133 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 293BC UT WOS:000085830800008 PM 10732660 ER PT J AU McDermott, PA Alterman, AI Cacciola, JS Rutherford, MJ Newman, JP Mulholland, EM AF McDermott, PA Alterman, AI Cacciola, JS Rutherford, MJ Newman, JP Mulholland, EM TI Generality of Psychopathy Checklist - Revised factors over prisoners and substance-dependent patients SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article ID ANTISOCIAL PERSONALITY-DISORDER; REFINEMENT; ALCOHOLISM; ROTATION; ABUSE AB The Psychopathy Checklist-Revised (PCL-R; R. D. Hare, 1991) is an often-used device for assessment of adult antisociality. This research examined generalizability by replicating the 2-factor model for a sample of 326 male prisoners and assessing its congruence and relative reliability and specificity among 620 substance-dependent patients. Generality was assessed also across addiction subtypes (opioid, cocaine, and alcohol), age, gender, and ethnicity. The 2-factor model was found inappropriate for the substance-dependent samples, whereas a unidimensional model represented by the PCL-R total score was found generalizable across prison and substance-dependent samples. C1 Univ Penn, Grad Sch Educ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Washington, Alcohol & Drug Inst, Seattle, WA 98195 USA. Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA. RP McDermott, PA (reprint author), Univ Penn, Grad Sch Educ, 3700 Walnut St, Philadelphia, PA 19104 USA. NR 33 TC 28 Z9 29 U1 2 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2000 VL 68 IS 1 BP 181 EP 186 DI 10.1037//0022-006X.68.1.181 PG 6 WC Psychology, Clinical SC Psychology GA 287FJ UT WOS:000085495600021 PM 10710854 ER PT J AU Kiertscher, SM Luo, J Dubinett, SM Roth, MD AF Kiertscher, SM Luo, J Dubinett, SM Roth, MD TI Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; ANTIGEN-PRESENTING FUNCTION; T-HELPER CELLS; HUMAN BLOOD; DOWN-REGULATION; UP-REGULATION; CUTTING EDGE; IN-VIVO; CANCER; ACTIVATION AB Tumors produce a number of immunosuppressive factors that block the maturation of CD34(+) stem cells into dendritic cells (DC), We hypothesized that tumors might also interfere with the maturation and/or function of human monocyte-derived DC. In contrast to stem cells, we found that CD14(+) cells responded to tumor culture supernatant (TSN) by increasing expression of APC surface markers, up-regulating nuclear translocation of RelB, and developing allostimulatory activity. Although displaying these characteristics of mature DC, TSN-exposed DC lacked the capacity to produce IL-12, did not acquire full allostimulatory activity, and rapidly underwent apoptosis. The effects of TSN appeared to be specific for maturing DC, and were not reversed by Abs against known DC regulatory factors including IL-10, vascular endothelial growth factor, TGF-beta, or PGE(2). Supernatants collected from nonmalignant cell sources had no effect on DC maturation. The altered maturation and early apoptosis of monocyte-derived DC may represent another mechanism by which tumors evade immune detection. C1 Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Kiertscher, SM (reprint author), Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, 37-131 CHS, Los Angeles, CA 90095 USA. FU NCI NIH HHS [R01 CA71818] NR 50 TC 172 Z9 192 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 1 PY 2000 VL 164 IS 3 BP 1269 EP 1276 PG 8 WC Immunology SC Immunology GA 277AJ UT WOS:000084910300018 PM 10640740 ER PT J AU Reilly, CM Oates, JC Cook, JA Morrow, JD Halushka, PV Gilkeson, GS AF Reilly, CM Oates, JC Cook, JA Morrow, JD Halushka, PV Gilkeson, GS TI Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J(2) and proliferator activation receptor-gamma agonists SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MURINE LUPUS NEPHRITIS; RENAL THROMBOXANE PRODUCTION; SQUAMOUS CARCINOMA-CELLS; MRL/MP-LPR/LPR MICE; DELTA(12)-PROSTAGLANDIN J(2); PERITONEAL-MACROPHAGES; AUTOIMMUNE-DISEASE; INDUCTION; SYNTHASE; EXPRESSION AB MRL/Mp-lpr/lpr (MRL/lpr) mice develop immune complex glomerulonephritis similar to human lupus, Glomerular mesangial cells are key modulators of the inflammatory response in lupus nephritis, When activated, these cells secrete inflammatory mediators including NO and products of cyclooxygenase perpetuating the local inflammatory response. P6J(2), a product of cyclooxygenase, is a potent in vitro inhibitor of macrophage inflammatory functions and is postulated to function as an in vivo inhibitor of macrophage-mediated inflammatory responses, We hypothesized that in lupus, a defect in PGJ(2), production allows the inflammatory response to continue unchecked. To test this hypothesis, mesangial cells were isolated from MRL/lpr and BALB/c mice and stimulated with IL-1 beta or LPS plus IFN-gamma, In contrast to the 2.- to 3-fold increase in PGJ(2) production by stimulated BALB/c mesangial cells, supernatant PGJ(2) did not increase in MRL/lpr mesangial cell cultures. NO production in stimulated MRL/lpr and BALB/c mesangial cells, was blocked by PGJ(2) and pioglitazone, These studies suggest that abnormalities in PGJ(2) production are present in MRL/lpr mice and may be linked to the heightened activation state of mesangial cells in these mice. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Physiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Dept Med, 912 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA. FU NIAMS NIH HHS [K08 AR002193]; NIDDK NIH HHS [DK 48831]; NIGMS NIH HHS [GM 15431, GM 42056] NR 44 TC 60 Z9 64 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 1 PY 2000 VL 164 IS 3 BP 1498 EP 1504 PG 7 WC Immunology SC Immunology GA 277AJ UT WOS:000084910300045 PM 10640767 ER PT J AU Clark, RSB Kochanek, PM Watkins, SC Chen, MZ Dixon, CE Seidberg, NA Melick, J Loeffert, JE Nathaniel, PD Jin, KL Graham, SH AF Clark, RSB Kochanek, PM Watkins, SC Chen, MZ Dixon, CE Seidberg, NA Melick, J Loeffert, JE Nathaniel, PD Jin, KL Graham, SH TI Caspase-3 mediated neuronal death after traumatic brain injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE apoptosis; cysteine protease; N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone; programmed cell death ID CONTROLLED CORTICAL IMPACT; APOPTOTIC CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION; INHIBITION; PROTEIN AB During programmed cell death, activation of caspase-3 leads to proteolysis of DNA repair proteins, cytoskeletal proteins, and the inhibitor of caspase-activated deoxyribonuclease, culminating in morphologic changes and DNA damage defining apoptosis, The participation of caspase-3 activation in the evolution of neuronal death after traumatic brain injury in rats was examined. Cleavage of pro-caspase-3 in cytosolic cellular fractions and an increase in caspase-3-like enzyme activity were seen in injured brain versus control. Cleavage of the caspase-3 substrates DNA-dependent protein kinase and inhibitor of caspase-activated deoxyribonuclease and co-localization of cytosolic caspase-3 in neurons with evidence of DNA fragmentation were also identified. Intracerebral administration of the caspase-3 inhibitor N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluomethyl ketone (480 ng) after trauma reduced caspase-3-like activity and DNA fragmentation in injured brain versus vehicle at 24 h. Treatment with N-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone for 72 h (480 ng/day) reduced contusion size and ipsilateral dorsal hippocampal tissue loss at 3 weeks but had no effect on functional outcome versus vehicle. These data demonstrate that caspase-3 activation contributes to brain tissue loss and downstream biochemical events that execute programmed cell death after traumatic brain injury. Caspase inhibition may prove efficacious in the treatment of certain types of brain injury where programmed cell death occurs. C1 Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Clark, RSB (reprint author), Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA. RI Kochanek, Patrick/D-2371-2015 OI Kochanek, Patrick/0000-0002-2627-913X FU NINDS NIH HHS [KO8 NS01946, P50 NS30318, R01 NS38620] NR 53 TC 233 Z9 246 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD FEB PY 2000 VL 74 IS 2 BP 740 EP 753 DI 10.1046/j.1471-4159.2000.740740.x PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 274KU UT WOS:000084765700032 PM 10646526 ER PT J AU Leon, RL AF Leon, RL TI Theoretical contributions SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Letter C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Leon, RL (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD FEB PY 2000 VL 39 IS 2 BP 136 EP 136 DI 10.1097/00004583-200002000-00002 PG 1 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 279ER UT WOS:000085031900002 ER PT J AU Shapiro, M Jimenez, S Werth, VP AF Shapiro, M Jimenez, S Werth, VP TI Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID DRUG-INDUCED PEMPHIGUS; AUTOANTIBODIES AB D-Penicillamine-induced pemphigus occurs infrequently, typically in patients with rheumatoid arthritis. We describe a patient with systemic sclerosis who experienced this complication 3 months after starting D-penicillamine therapy. Nikolsky's sign, histopathologic findings, and direct immunofluorescence all confirmed the diagnosis. Termination of disease progression required intravenous pulse glucocorticoids, azathioprine, and 3 courses of plasmapheresis. The presentation, treatment, and etiology of D-penicillamine-induced pemphigus are reviewed, and the incidence of this complication in scleroderma patients is examined. C1 Univ Penn, Med Ctr, Dept Dermatol & Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Penn Hosp, Dept Med, Philadelphia, PA 19107 USA. Thomas Jefferson Univ, Dept Rheumatol, Philadelphia, PA 19107 USA. RP Werth, VP (reprint author), Univ Penn, Med Ctr, Dept Dermatol & Med, 36th & Spruce, Philadelphia, PA 19104 USA. NR 19 TC 19 Z9 19 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2000 VL 42 IS 2 BP 297 EP 299 DI 10.1016/S0190-9622(00)90146-4 PN 1 PG 3 WC Dermatology SC Dermatology GA 281ER UT WOS:000085145400026 PM 10642693 ER PT J AU Sun, W Chen, F Sarma, JSM Singh, BN AF Sun, W Chen, F Sarma, JSM Singh, BN TI Acute effects of dronedarone on potassium currents in isolated rabbit ventricular myocytes. Comparison with amiodarone SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, Sect Cardiol,Cardiovasc Res Labs, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB PY 2000 VL 35 IS 2 SU A BP 98A EP 98A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 282GL UT WOS:000085209700374 ER PT J AU Prabhu, SD Chandrasekar, B Murray, DR Freeman, GL AF Prabhu, SD Chandrasekar, B Murray, DR Freeman, GL TI beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB PY 2000 VL 35 IS 2 SU A BP 231A EP 231A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 282GL UT WOS:000085209700891 ER PT J AU Prabhu, SD Freeman, GL AF Prabhu, SD Freeman, GL TI Altered left ventricular inotropic reserve and mechanoenergetics early in the development of heart failure SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB PY 2000 VL 35 IS 2 SU A BP 233A EP 233A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 282GL UT WOS:000085209700900 ER PT J AU Law, AV Lapuerta, P Asch, SM AF Law, AV Lapuerta, P Asch, SM TI Development and testing of a clinically-detailed tool to assess quality of care in hypertension SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract C1 RAND Hlth, Santa Monica, CA USA. Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA. W Los Angeles Vet Adm, W Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB PY 2000 VL 35 IS 2 SU A BP 558A EP 558A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 282GL UT WOS:000085209702116 ER PT J AU Saliba, D Kington, R Buchanan, J Bell, R Wang, MM Lee, M Herbst, M Lee, D Sur, D Rubenstein, L AF Saliba, D Kington, R Buchanan, J Bell, R Wang, MM Lee, M Herbst, M Lee, D Sur, D Rubenstein, L TI Appropriateness of the decision to transfer nursing facility residents to the hospital SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE appropriateness; transfers; hospitalization; emergency department; nursing facility ID PROSPECTIVE PAYMENT SYSTEM; ACUTE-CARE FACILITIES; LONG-TERM; HOME RESIDENTS; EVALUATION PROTOCOL; MEDICAL-CARE; ADVANCE DIRECTIVES; INAPPROPRIATE USE; PATIENT TRANSFER; HEALTH-CARE AB OBJECTIVES: To develop and test a standardized instrument, the purpose of which is to assess (1) whether skilled nursing facilities (SNFs) transfer residents to emergency departments (ED) inappropriately, (2) whether residents are admitted to hospitals inappropriately, (3) and factors associated with inappropriate transfers. DESIGN: A structured implicit review (SIR) of medical records. SETTING AND PARTICIPANTS: Using nested random sampling in eight community SNFs, we identified SNF and hospital records of 100 unscheduled transfers to one of 10 hospitals. MEASUREMENTS: Seven trained physician reviewers assessed appropriateness using a SIR form designed for this study (2 independent reviews per record, 200 total reviews). We measured interrater reliability with kappa statistics and used bivariate analysis to identify factors associated with assessment that transfer was inappropriate. RESULTS: In 36% of ED transfers and 40% of hospital admissions, both reviewers agreed that transfer/admit was inappropriate, meaning the resident could have been cared for safely at a lower level of care. Agreement was high for both ED (percent agreement 84%, kappa .678) and hospital (percent agreement 89%, kappa .779). When advance directives were considered, both reviewers rated 44% of ED transfers and 45% of admissions inappropriate. Factors associated with inappropriateness included the perceptions that: (1) poor quality of care contributed to transfer need, (2) needed services would typically be available in outpatient settings, and (3) the chief complaint did not warrant hospitalization. CONCLUSIONS: Inappropriate transfers are a potentially large problem. Some inappropriate transfers may be associated with poor quality of care in SNFs. This study demonstrates that structured implicit review meets criteria for reliable assessment of inappropriate transfer rates. Structured implicit review may be a valuable tool for identifying inappropriate transfers from SNFs to EDs and hospitals. C1 RAND Corp, Santa Monica, CA 90407 USA. VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. AT&T Labs, Murray Hill, NJ 07974 USA. Univ Calif Los Angeles, Family Practice Residency Program, Santa Monica, CA USA. RP Saliba, D (reprint author), RAND Corp, 1700 Main St, Santa Monica, CA 90407 USA. FU NIA NIH HHS [AG10415] NR 76 TC 178 Z9 178 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2000 VL 48 IS 2 BP 154 EP 163 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 284BT UT WOS:000085311400006 PM 10682944 ER PT J AU Abou-Zamzam, AM Moneta, GL Edwards, JM Yeager, RA Taylor, LM Porter, JM AF Abou-Zamzam, AM Moneta, GL Edwards, JM Yeager, RA Taylor, LM Porter, JM TI Is a single preoperative duplex scan sufficient for planning bilateral carotid endarterectomy? SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the Society-for-Vascular-Surgery CY JUN 06-09, 1999 CL WASHINGTON, D.C. SP Soc Vasc Surg ID ARTERY STENOSIS; FOLLOW-UP; ARTERIOGRAPHY; OCCLUSION; CRITERIA; OVERESTIMATION; 60-PERCENT; SYMPTOMS; FLOW AB Purpose: Duplex scanning is often the sole imaging study before carotid endarterectomy (CEA). Patients with bilateral severe internal carotid artery (ICA) stenosis may be considered for bilateral CEA. High-grade ICA stenosis, however, may artifactually elevate velocity measurements used to quantify stenosis in the contralateral ICA. It is unknown whether ipsilateral CEA will influence duplex determination of the presence of a contralateral 60% to 99% ICA stenosis. This study was performed to determine whether a single preoperative duplex scan is sufficient to plan bilateral CEA. Methods: Preoperative and early postoperative carotid duplex scans in patients with bilateral ICA stenosis who underwent unilateral CEA were reviewed. Changes in duplex scans that determined stenosis in the ICA contralateral to the CEA were analyzed. Previously validated criteria used to determine 60% to 99% ICA stenosis were a peak systolic velocity (PSV) of 260 cm/sec or more combined with an end diastolic velocity (EDV) of 70 cm/sec or more. Results: Over an 8-year period, 460 patients underwent CEA; 107 patients (23.3%) had an asymptomatic 50% to 99% contralateral ICA stenosis by standard criteria (PSV, >125 cm/sec) and an early postoperative duplex scan examination. Of these 107 patients, 38 patients (35.5%) had duplex scan criteria for 60% to 99% contralateral ICA stenosis. In these 38 patients, there was a mean postoperative PSV decrease of 47.7 cm/sec (10.1%) and a mean EDV decrease of 36.0 cm/sec (19.3%) in the ICA contralateral to the CEA. Eight of 38 (21.1%) preoperative contralateral 60% to 99% ICA lesions were reclassified as less than 60% on postoperative duplex scanning. Six of 69 (8.7%) preoperative lesions of less than 60% were reclassified as 60% to 99% on postoperative duplex scan. These six preoperative examinations were all close to the criteria for 60% to 99% stenosis (mean PSV, 232.5 cm/sec; mean EDV, 62.5 cm/sec). Conclusion: One-fifth of patients with apparent 60% to 99% contralateral ICA lesions before the operation have less than 60% stenosis when restudied with duplex scan after unilateral CEA. Lesions below but near the cutoff for 60% to 99% may be reclassified as 60% to 99% on the postoperative duplex scan. These findings mandate that when duplex scanning is used as the sole imaging modality before CEA, patients with severe bilateral carotid stenosis must have an additional carotid duplex examination before operation on the second side. C1 Oregon Hlth Sci Univ, Div Vasc Surg, Dept Surg, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Moneta, GL (reprint author), Oregon Hlth Sci Univ, Div Vasc Surg, Dept Surg, OP-11,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. NR 19 TC 15 Z9 16 U1 0 U2 1 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD FEB PY 2000 VL 31 IS 2 BP 282 EP 287 DI 10.1016/S0741-5214(00)90159-9 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 283VE UT WOS:000085296100014 PM 10664497 ER PT J AU Stehman-Breen, CO Sherrard, DJ Gillen, D Caps, M AF Stehman-Breen, CO Sherrard, DJ Gillen, D Caps, M TI Determinants of type and timing of initial permanent hemodialysis vascular access SO KIDNEY INTERNATIONAL LA English DT Article DE arteriovenous fistula; PTFE graft; veins for dialysis; hemodialysis AB Background. We undertook a population-based study of hemodialysis (HD) patients to determine which factors are important in predicting the type of permanent access initially placed and if a functional permanent access is in place at the start of HD. Methods. Selected characteristics were abstracted from the United States Renal Data System (USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave 2. Logistic regression was used to estimate the independent contribution of specific characteristics in predicting whether the initial permanent access placed was an arteriovenous (AV) fistula compared with a polytetrafluoroethylene (PTFE) graft, and in predicting whether permanent access (fistula or graft) was in place at the initiation of dialysis. Results. Sixty seven percent of the patients had an AV graft placed as their first permanent access. Characteristics important in predicting if a fistula was initially placed included age (per decade; aOR = 0.84, P < 0.001), female gender (aOR = 0.52, P < 0.001), body mass index (per standard deviation; aOR = 0.70, P = 0.09), avoiding blood draws (aOR = 1.96, P < 0.001), ability to ambulate (aOR = 2.24, P = 0.008), underlying renal disease (glomerular compared with diabetes, aOR = 2.19, P = 0.009), college education (aOR = 1.72, P = 0.002), and sharing in decision making (aOR = 1.50, P = 0.02). Thirty-four percent of patients (34.4%) had functional permanent access at the start of HD. Characteristics important in predicting which patients had functional permanent access included serum albumin (per 1 mg/dL increase, aOR = 1.55, P = 0.003), erythropoietin prior to starting HD (aOR = 1.79, P = 0.002), fewer predialysis nephrologist visits (aOR = 0.21, P < 0.001), and when the patient was told they had renal disease (aOR = 0.33, P = 0.002). Conclusions. PTFE grafts were the most common initial permanent access. The majority of patients did not have permanent access at the start of dialysis. Factors that are thought to compromise identification of adequate veins were important predictors of PTFE graft placement. Permanent access at the start of HD was largely a function of early patient education and early referral to a nephrologist. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Dept Med, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. RP Stehman-Breen, CO (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Dept Med, 1660 S Columbian Way,Mailstop 111A, Seattle, WA 98108 USA. NR 11 TC 158 Z9 167 U1 0 U2 2 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2000 VL 57 IS 2 BP 639 EP 645 DI 10.1046/j.1523-1755.2000.00885.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 282WG UT WOS:000085243000029 PM 10652042 ER PT J AU Landefeld, CS AF Landefeld, CS TI Different strokes for different folks - Are differences in physician practices good for older persons with diabetes? SO MEDICAL CARE LA English DT Editorial Material C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. Univ Calif San Francisco, Ctr Excellence Acad Geriatr, San Francisco, CA 94118 USA. Univ Calif San Francisco, Ctr Aging, San Francisco, CA 94118 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, Box 1265,3333 Calif St,Suite 380, San Francisco, CA 94118 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2000 VL 38 IS 2 BP 125 EP 127 DI 10.1097/00005650-200002000-00001 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 280ZH UT WOS:000085133300001 PM 10659685 ER PT J AU Dobashi, K Ghosh, B Orak, JK Singh, I Singh, AK AF Dobashi, K Ghosh, B Orak, JK Singh, I Singh, AK TI Kidney ischemia-reperfusion: Modulation of antioxidant defenses SO MOLECULAR AND CELLULAR BIOCHEMISTRY LA English DT Article DE kidney; ischemia-reperfusion injury; free radicals; reactive oxygen species; gene expression; antioxidant enzymes ID ACUTE-RENAL-FAILURE; RAT-LIVER PEROXISOMES; SUPEROXIDE-DISMUTASE; PROXIMAL TUBULE; TISSUE-INJURY; FREE-RADICALS; OXYGEN; ENZYMES; ACTIVATION; CATALASE AB Reactive oxygen species (ROS; O-2-, H2O2, and OH.), normal by-products of cellular metabolic processes, are kept in control by antioxidant enzymes, such as catalase, glutathione peroxidase (GPX) and superoxide dismutases (SODs). To understand the role of antioxidant enzymatic defenses against ROS injury following ischemia-reperfusion, we examined the effect on kidney exposed to varying periods (30, 60 or 90 min) of ischemia followed by different periods of reperfusion. The enzymatic activities and protein levels of catalase, GPX, CuZnSOD and MnSOD were relatively unaffected at 30 min of ischemia followed by 0, 2 or 24 h reperfusion. However, 60 or 90 min of ischemia followed by 0, 2 or 24 h of reperfusion resulted in a decrease in activities and protein levels which paralleled the duration of ischemic injury. MnSOD activity tended to recover towards normal during reperfusion. Examination of the mRNA levels of these antioxidant enzymes demonstrated a severe decrease in mRNA levels of catalase and GPX at a time point of minimal ischemic injury (30 min of ischemia followed by reperfusion) suggesting that loss of mRNA of catalase and GPX may be the first markers of alterations in cellular redox in ischemia-reperfusion injury. Greater loss of mRNA for catalase, GPX and CuZnSOD were observed following longer periods (60 or 90 min) of ischemia. The mRNA for MnSOD was upregulated at all time points of ischemia-reperfusion injury. Actually, the greater decrease in mRNAs for catalase, GPX and CuZnSOD in the acute phase (within 24 h) subsequently showed a further decrease in these enzyme activities in the subacute phase (72 or 120 h after ischemia). These enzyme activities in the 30 min ischemia group, but not in the 90 min group, already showed tendencies for normalization at 120 h after ischemia. To understand the molecular basis of the loss of mRNA of these antioxidant enzymes during ischemia-reperfusion injury, we examined the rate of transcription by nuclear run-on assays. The similar rates of transcription in control and kidney exposed to ischemia-reperfusion indicates that the loss of mRNA for catalase, GPX and CuZnSOD are possibly due to the increased rate of turnover of their mRNAs. These studies suggest that expression of antioxidant genes during ischemia-reperfusion are not coordinately expressed and the differential loss of antioxidant enzymes may be the contributing factor(s) towards the heterogeneous renal tissue damage as a result of ischemia-reperfusion induced oxidative stress. C1 Ralph Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Ralph Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC 29425 USA. FU NINDS NIH HHS [NS-34741, NS-22576, NS-37766] NR 38 TC 119 Z9 128 U1 0 U2 4 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0300-8177 J9 MOL CELL BIOCHEM JI Mol. Cell. Biochem. PD FEB PY 2000 VL 205 IS 1-2 BP 1 EP 11 DI 10.1023/A:1007047505107 PG 11 WC Cell Biology SC Cell Biology GA 288QU UT WOS:000085575400001 PM 10821417 ER PT J AU Chang, L Mayer, EA Johnson, T FitzGerald, LZ Naliboff, B AF Chang, L Mayer, EA Johnson, T FitzGerald, LZ Naliboff, B TI Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia SO PAIN LA English DT Article DE irritable bowel syndrome; fibromyalgia; female; somatic perception ID LONGITUDINAL DATA-ANALYSIS; CONVERGENT NEURONS; PAIN; HYPERSENSITIVITY; CLASSIFICATION; HYPERALGESIA; DYSFUNCTION; STIMULATION; DISTENSION; AFFERENTS AB Background: Irritable bowel syndrome (IBS) and fibromyalgia (FM) an considered chronic syndromes of altered visceral and somatic perception, respectively. Because there is a significant overlap of IBS and FM, shared pathophysiological mechanisms have been suggested. Although visceral perception has been well studied in IBS, somatic perception has npt. Aims: To compare hypervigilance and altered sensory perception in response to somatic stimuli in patients with IBS, IBS + FM, and healthy controls. Methods: Eleven IBS females (mean age 40), 11 IBS + FM females (mean age 46), and ten healthy female controls (mean age 39) rated pain perception in response to pressure stimuli administered to active somatic tender points, non-render control points and the T-12 dermatome, delivered in a predictable ascending series, and delivered in an unpredictable randomized fashion (fixed stimulus). Results. Although IBS patients had similar pain thresholds during the ascending series compared with controls, they were found to have somatic hypoalgesia with higher pain thresholds and lower pain frequency and severity during fixed stimulus series compared with IBS + FM patients and controls (P < 0.05), Patients with IBS + FM were more bothered by the somatic stimuli and had somatic hyperalgesia with lower pain thresholds and higher pain frequency and severity. Conclusions: Both hypervigilance and somatic hypoalgesia contribute to the altered somatic perception in IBS patients. Co-morbidity with FM results in somatic hyperalgesia in IBS patients. (C) 2000 International Association for the Study of Pain. Published by Elsevier Science B.V. C1 Univ Calif Los Angeles, Sch Med, Dept Med, CURE Neuroenter Dis Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Biostat & Biomath, Los Angeles, CA 90024 USA. RP Chang, L (reprint author), Univ Calif Los Angeles, CURE Neuroenter Dis Program, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Bldg 115,Room 223, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [M01RR00425-27S2] NR 43 TC 125 Z9 127 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD FEB PY 2000 VL 84 IS 2-3 BP 297 EP 307 DI 10.1016/S0304-3959(99)00215-8 PG 11 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 282ZP UT WOS:000085251900021 PM 10666535 ER PT J AU Lan, AJ Colford, JM AF Lan, AJ Colford, JM TI The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis SO PEDIATRICS LA English DT Article DE amoxicillin; group A streptococcal; penicillin; pharyngitis; streptococcal infections; Streptococcus pyogenes ID V THERAPY; ANTIBIOTIC-THERAPY; PHARYNGITIS; PHARYNGOTONSILLITIS; CHILDREN; TRIAL AB Objective. The recommended dosing frequency of oral penicillin for the treatment of acute streptococcal tonsillopharyngitis has long been 3 to 4 times daily. In 1994, treatment guidelines included twice-daily (BID) dosing for the first time, a recommendation that could significantly increase the ease of compliance. This meta-analysis was performed to determine whether overall cure rates differed between BID or once-daily (QD) versus more frequent dosing schedules in the treatment of streptococcal tonsillopharyngitis. Data Sources. Candidate studies for this meta-analysis included all clinical trials of therapy for streptococcal tonsillopharyngitis published through August 1998 and identified using Medline, Dissertation Abstracts, conference proceedings, and bibliographies of all retrieved articles. Study Selection. A study was eligible for inclusion if it was a randomized clinical trial that compared the efficacies of different dosing frequencies of 10-day penicillin or amoxicillin in the treatment of streptococcal tonsillopharyngitis. Of the 30 articles initially identified, 6 studies met eligibility criteria. Outcome Measure. The measure of interest was the difference in proportion cured between the BID or QD dosing group and the comparison group with more frequent dosing. Results. The results of this analysis suggest that BID dosing of 10-day penicillin is as efficacious as more frequent dosing regimens in the treatment of streptococcal tonsillopharyngitis. This result also holds true in a subgroup analysis confined to pediatric cases and does not vary with total daily dose of the regimen. QD dosing of penicillin is associated with a cure rate that is 12 percentage points lower than more frequent dosing (95% confidence interval: 3-21). In contrast, this decreased efficacy is not found with QD dosing of amoxicillin. Conclusions. This meta-analysis supports current recommendations for BID dosing of penicillin in treating streptococcal tonsillopharyngitis. QD penicillin is associated with decreased efficacy and should not be used. Simplified regimens of amoxicillin of shorter duration or of less frequent dosing should be further investigated. C1 Univ Calif Berkeley, Sch Publ Hlth, Dept Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA. Univ Calif San Diego, San Diego, CA 92103 USA. San Francisco Vet Affairs Med Ctr, Infect Dis Sect, San Francisco, CA USA. RP Colford, JM (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Dept Publ Hlth Biol & Epidemiol, 113 Haviland Hall 7360, Berkeley, CA 94720 USA. NR 37 TC 22 Z9 22 U1 0 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2000 VL 105 IS 2 BP art. no. EP e19 DI 10.1542/peds.105.2.e19 PG 8 WC Pediatrics SC Pediatrics GA 280ML UT WOS:000085106500002 PM 10654979 ER PT J AU Pahlavani, MA Vargas, DM AF Pahlavani, MA Vargas, DM TI Influence of aging and caloric restriction on activation of Ras/MAPK, calcineurin, and CaMK-IV activities in rat T cells SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article ID DEPENDENT PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXPRESSION; TRANSCRIPTION; STIMULATION; GROWTH; LYMPHOCYTES; LONGEVITY AB The signaling cascade mediated by Ras (p21(ras)) and MAPK (mitogen-activated protein kinase) and calcium/calmodulin regulating enzymes, calcineurin (CaN) and CaMK-IV, are considered to be essential for T-cell growth and function. In the present study, the effect of aging and caloric restriction (CR) on the induction of Has and MAPK activation by concanavalin A (ConA) was studied. Splenic T cells were isolated from young (4-6 months) and old (22-24 months) rats that had free access to food (control group), and from caloric restricted old (22-24 months) rats that beginning at 6 weeks of age were fed 60%(40% caloric restriction) of the diet consumed by the control rats. We found that the induction of Has activity in T cells isolated from control old rats was lower (P < 0.001) than that in control young rats. However, the levels of Has activity in T cells isolated from CR old rats were similar to the levels in the age-matched control rats. The induction of MAPK activity in T cells isolated from control old rats and CR old rats was significantly less than in T cells isolated from control young rats, and caloric restriction significantly (P < 0.05) reduced the age-related decline in MAPK activation. We also measured the induction of CaN and CaMK-IV activities by ConA in T cells from control young and old and CR old rats. The induction of both CaN and CaMK-IV activity decreased with age. Caloric restriction significantly (P < 0.05) reduced the age-related decline in CaN activity, but had no significant effect on CaMK-IV activity, The changes in Ras/MAPK activation and in CaN and CaMK-IV activity with age or with CR were not associated with alterations in their corresponding protein levels, Thus, caloric restriction has a differential effect on the activation of the upstream signaling molecules that are altered with age. C1 Audie L Murphy Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr GRECC182, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. RP Pahlavani, MA (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr GRECC182, S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM Pahlavani@uthscsa.edu FU NIA NIH HHS [AG00677, AG14088] NR 43 TC 26 Z9 26 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0037-9727 J9 P SOC EXP BIOL MED JI Proc. Soc. Exp. Biol. Med. PD FEB PY 2000 VL 223 IS 2 BP 163 EP 169 DI 10.1046/j.1525-1373.2000.22322.x PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 278KP UT WOS:000084989200008 PM 10654619 ER PT J AU Goldstein, G Shemansky, WJ AF Goldstein, G Shemansky, WJ TI Length and number of hospitalizations in two cohorts of veterans with chronic schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article AB Two cohorts of male veteran patients with schizophrenia were compared on several clinical and demographic measures. The first cohort, hospitalized in one of two Veterans Affairs hospitals between 1965 and 1975, consisted largely of Korean-era veterans. The second cohort, hospitalized between 1991 and 1994, were largely Vietnam-era veterans. Although treatment and management of patients with schizophrenia differed during the two eras and the second cohort had a significantly higher mean number of hospitalizations than the first, the two cohorts did not differ in total time hospitalized. The finding suggests the need to improve methods for relapse prevention. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. NR 10 TC 6 Z9 6 U1 0 U2 0 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 1075-2730 J9 PSYCHIATR SERV JI Psychiatr. Serv. PD FEB PY 2000 VL 51 IS 2 BP 245 EP 247 DI 10.1176/appi.ps.51.2.245 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 280AL UT WOS:000085079500020 PM 10655012 ER PT J AU Kuna, ST AF Kuna, ST TI Respiratory-related activation and mechanical effects of the pharyngeal constrictor muscles SO RESPIRATION PHYSIOLOGY LA English DT Article; Proceedings Paper CT 6th International Symposium on Sleep and Respiration CY MAR 27-31, 1999 CL ALBERTA, CANADA DE mammals, humans; mammals, cat; muscle, pharyngeal constrictor; sleep, apnea, obstructive; upper airways, patency, sleep ID OBSTRUCTIVE SLEEP-APNEA; NORMAL ADULT HUMANS; WAKEFULNESS; CAT AB We have examined the respiratory-related activation of pharyngeal constrictor (PC) muscles in decerebrate cats, normal adult humans and patients with obstructive sleep apnea. In decerebrate cats and awake normal adult humans, phasic expiratory PC activity is uniformly present under hypercapnic and hypoxic conditions. While the PC muscles are electrically silent during quiet breathing in normal adult humans in NREM sleep, an activation pattern very similar to that of other upper airway dilators, such as the genioglossus muscle, is present during spontaneous and induced apneas in patients with obstructive sleep apnea. Experiments using an isolated, sealed upper airway preparation in decerebrate cat show that selective activation of the PC muscles stiffens the pharyngeal airway. The results also show that activation of the PC muscles constricts the airway at relatively high airway volumes but dilates the airway at relatively low airway volumes. These results suggest that PC muscle activation at the end of an apneic episode, when airway volume is relatively low, may help restore airway patency in patients with obstructive sleep apnea. (C) 2000 Elsevier Science B.V. All rights reserved. C1 Univ Penn, Pulm Crit Care & Sleep Sect, Dept Internal Med, Philadelphia Vet Affairs Med Ctr 111P, Philadelphia, PA 19104 USA. RP Kuna, ST (reprint author), Univ Penn, Pulm Crit Care & Sleep Sect, Dept Internal Med, Philadelphia Vet Affairs Med Ctr 111P, Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NHLBI NIH HHS [HL 27520] NR 20 TC 30 Z9 30 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0034-5687 J9 RESP PHYSIOL JI Respir. Physiol. PD FEB PY 2000 VL 119 IS 2-3 BP 155 EP 161 DI 10.1016/S0034-5687(99)00110-3 PG 7 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 299BQ UT WOS:000086176300007 PM 10722858 ER PT J AU Krieger, JN Jacobs, R Ross, SO AF Krieger, JN Jacobs, R Ross, SO TI Detecting urethral and prostatic inflammation in patients with chronic prostatitis SO UROLOGY LA English DT Article ID POLYMERASE CHAIN-REACTION; CHRONIC IDIOPATHIC PROSTATITIS; FIRST-VOID URINE; CHLAMYDIA-TRACHOMATIS; GENITAL MYCOPLASMAS; REACTION ASSAY; MEN; DIAGNOSIS; HERPES; MALES AB Objectives. Diagnosis of urethral and prostatic inflammation can represent a challenge, We compare the accuracy of diagnostic methods for detecting inflammation in lower urinary specimens/samples. Methods. A standardized protocol was used to evaluate urethral smear, first-void urine (VB1), midstream urine (VB2), expressed prostatic secretions (EPS), and postmassage urine (VB3) in urologic patients with no symptoms or signs of urethritis who were attending our prostatitis clinic. Results. Of 235 subjects, 60 (26%) had leukocytes detected by the Gram-stained urethral smear, 44 (18%) by the VB1, and only 14 (6%) by the VB2. Compared with the urethral swab, VB1 had 0% to 22% sensitivity and 81% to 98% specificity, and VB2 had 8% to 11% sensitivity. Of 83 subjects with prostatic inflammation, the EPS detected 65 (76%) and the VB3 detected 68 (82%). Conclusions. VB1 or VB2 examinations had low sensitivity for detecting urethral inflammation. Examining; both the EPS and VB3 proved best for detecting prostatic fluid inflammation. Combining the urethral smear with lower urinary tract localization ("four-glass test") represents an optimal approach for detecting urethral and prostatic inflammation. (C) 2000, Elsevier Science Inc. C1 Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. RP Krieger, JN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Urol Sect, 112UR,1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [R01-DK38955] NR 34 TC 18 Z9 18 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD FEB PY 2000 VL 55 IS 2 BP 186 EP 191 DI 10.1016/S0090-4295(99)00437-9 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 281TT UT WOS:000085177400007 PM 10688076 ER PT J AU Kawakubo, K Yang, H Tache, Y AF Kawakubo, K Yang, H Tache, Y TI Intracisternal PYY inhibits gastric lesions induced by ethanol in rats: role of PYY-preferring receptors? SO BRAIN RESEARCH LA English DT Article DE PYY; [Pro(34)]PYY; gastric protection; RX 77368; ethanol; gastric lesion ID DORSAL VAGAL COMPLEX; THYROTROPIN-RELEASING-HORMONE; NEUROPEPTIDE-Y; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CLONED RAT; BINDING; PROJECTIONS; STIMULATION; SUBTYPES AB We previously reported that intracisternal (i.c.) injection of peptide YY (PYY) and low doses of thyrotropin-releasing hormone (TRH) or TRH analog, RX 77368, increased the resistance of the gastric mucosa to ethanol injury through vagal pathways in rats. The gastroprotective effect of i.c. injection of PYY/neuropeptide NPY (NPY) agonists with differential in vitro affinity to the Y receptor subtypes was examined in urethane-anesthetized rats. Intragastric administration of ethanol (45%, 5 ml/kg) results in mucosal lesions covering 23 +/- 2% of the gastric corpus in 1 h. PW (500 ng, i.c.) significantly reduced ethanol-induced gastric lesions by 52%. [Pro(34)]PYY (PYY-preferring/Y-1/Y-5/Y-4 subtypes) injected i.c. at 50, 100, 200 or 500 ng, reduced dose dependently gastric lesions to 15.4 +/- 2.2%, 11.4 +/- 3.1%, 8.6 +/- 2.9% and 5.4 +/- 2.2%, respectively. PYY3-36, (Y-2/Y-4 subtypes), [Leu(31), Pro(34)]NPY (Y-1/Y-5), NPY (Y-3/Y-1/Y-5/Y-2) and pancreatic polypeptide (PP, Y-4) injected i.c. at 500 ng did not influence significantly ethanol-induced gastric lesions. Combined i.c. injection of RX 77368 (1 ng) and Pro(34)PYY (25 ng), at sub-threshold doses given singly, reduced ethanol-induced gastric injury to 12.9 +/- 2.3% while RX 77368 (1 ng) plus PYY3-36 (500 ng) or [Leu(31), Pro(34)]NPY (25 ng) had no effect. These findings indicate that i.c. PYY-induced gastric protection against 45% ethanol is mediated by a Y receptor subtype which bears similarity with the putative PYY-preferring receptor and distinct from the currently defined Y-1/Y-5; in addition, there is a synergistic interaction between activation of this PYY-preferring receptor and i.c. TRH to increase the resistance of the gastric mucosa to injury caused by 45% ethanol. (C) 2000 Elsevier Science B.V. All rights reserved. C1 Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Bldg 115,Rm 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-30110, DK 41301] NR 31 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JAN 31 PY 2000 VL 854 IS 1-2 BP 30 EP 34 DI 10.1016/S0006-8993(99)02293-3 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 280UN UT WOS:000085122300005 PM 10784103 ER PT J AU Menaa, C Kurihara, N Roodman, GD AF Menaa, C Kurihara, N Roodman, GD TI CFU-GM-derived cells form osteoclasts at a very high efficiency SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE osteoclasts; CFU-GM; precursors; bone resorption ID BONE-MARROW CULTURES; MULTINUCLEATED CELLS; PRECURSORS; ANTIGEN AB The granulocyte-macrophage progenitor (CFU-GM) is a multipotent cell that can differentiate to osteoclasts (OCLs), macrophages, or granulocytes, However, the relative potential of CFU-GM to efficiently form OCLs is unknown. In this report we demonstrate that granulocyte-macrophage colony-forming unit (CFU-GM)-derived cells represent an easily obtainable highly purified source of human OCL precursors that form OCLs at very high efficiency (greater than 90%) when cultured with RANK ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and dexamethasone, The OCLs that formed have high bone-resorbing activity and form multiple resorption lacunae per OCL on dentin slices. Similarly, murine marrow-derived CFU-GM also formed OCLs at a high efficiency (>80%) when treated with RANKL, M-CSF, and dexamethasone. In contrast, more committed macrophage colony-forming unit (CFU-M)-derived cells form few OCLs under these conditions, (C) 2000 Academic Press. C1 Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78229 USA. RP Roodman, GD (reprint author), Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG13625]; NIAMS NIH HHS [AR41336, AR44603] NR 18 TC 43 Z9 47 U1 0 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 27 PY 2000 VL 267 IS 3 BP 943 EP 946 DI 10.1006/bbrc.1999.2042 PG 4 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 280YR UT WOS:000085131800046 PM 10673396 ER PT J AU Minassian, BA Ianzano, L Delgado-Escueta, AV Scherer, SW AF Minassian, BA Ianzano, L Delgado-Escueta, AV Scherer, SW TI Identification of new and common mutations in the EPM2A gene in Lafora disease SO NEUROLOGY LA English DT Article DE Lafora disease; EPM2A; Laforin; epilepsy; mutation; EPM2B ID PROGRESSIVE MYOCLONUS EPILEPSY; BIOPSY AB Lafora disease is a teenage onset progressive myoclonus epilepsy caused by mutations in the EPM2A gene. in this report, we describe new mutations within EPM2A, review the known mutations to date to identify the most common, and describe three simple tests for prenatal and carrier screening. C1 Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada. Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada. Univ Toronto, Toronto, ON M5G 1X8, Canada. Univ Calif Los Angeles, Sch Med, Dept Neurol, Comprehens Epilepsy Program, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. W Los Angeles DVA Med Ctr, Los Angeles, CA USA. RP Scherer, SW (reprint author), Hosp Sick Children, Dept Genet, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. RI Howe, Jennifer/I-9013-2012; Scherer, Stephen /B-3785-2013 OI Scherer, Stephen /0000-0002-8326-1999 FU NINDS NIH HHS [5P01-NS21908] NR 10 TC 34 Z9 34 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN 25 PY 2000 VL 54 IS 2 BP 488 EP 490 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 279KW UT WOS:000085043800041 PM 10668720 ER PT J AU Weeks, DL Eskandari, S Scott, DR Sachs, G AF Weeks, DL Eskandari, S Scott, DR Sachs, G TI A H+-gated urea channel: The link between Helicobacter pylori urease and gastric colonization SO SCIENCE LA English DT Article ID PROTEIN; PH; TRANSPORTER; METABOLISM; MEMBRANES; ACID AB Acidic media trigger cytoplasmic urease activity of the unique human gastric pathogen Helicobacter pylori. Deletion of urel prevents this activation of cytoplasmic urease that is essential for bacterial acid resistance. Urel is an inner membrane protein with six transmembrane segments as shown by in vitro transcription/translation and membrane separation. Expression of Urel in Xenopus oocytes results in acid-stimulated urea uptake, with a pH profile similar to activation of cytoplasmic urease, Mutation of periplasmic histidine 123 abolishes stimulation. Urel-mediated transport is urea specific, passive, nonsaturable, nonelectrogenic, and temperature independent. Urel functions as a H+-gated urea channel regulating cytoplasmic urease that is essential for gastric survival and colonization. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Sachs, G (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK41301, DK43462, DK46917] NR 22 TC 257 Z9 278 U1 3 U2 16 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD JAN 21 PY 2000 VL 287 IS 5452 BP 482 EP 485 DI 10.1126/science.287.5452.482 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 277JF UT WOS:000084929900047 PM 10642549 ER PT J AU Furukawa, K D'Souza, I Crudder, CH Onodera, H Itoyama, Y Poorkaj, P Bird, TD Schellenberg, GD AF Furukawa, K D'Souza, I Crudder, CH Onodera, H Itoyama, Y Poorkaj, P Bird, TD Schellenberg, GD TI Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism SO NEUROREPORT LA English DT Article DE apoptosis; calcium; frontotemporal dementia and parkinsonism; mutation; tau ID PROTECTS HIPPOCAMPAL-NEURONS; EXCITOTOXICITY; FTDP-17; GENE AB It was recently discovered that mutations of tau cause hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Here we repels that cultured SH-SY5Y human neuroblastoma cells transfected with mutated tau genes are more vulnerable to apoptotic stimulus. Two kinds of mutations of tau causing FTDP-17 were examined in the present study: one was in exon 10 (N279K) and the other was in exon 12 (V337M). SH-SY5Y cells transfected with either mutated tau were more vulnerable to serum withdrawal, whereas cells transfected with the wild-type tau or vector alone showed no significant change in apoptotic vulnerability. The increase in the intracellular calcium concentration by the serum withdrawal was significantly greater in the SH-SY5Y cells transfected with mutated tau genes than in cells transfected with the wild-type tau or vector alone. These results suggest that mutations of tau might cause FTDP-17 by these proapoptotic functions by disrupting the intracellular calcium homeostasis. NeuroReport 11:57-60 (C) 2000 Lippincott Williams & Wilkins. C1 Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Neurol & Pharmacol, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Tohoku Univ, Sch Med, Dept Neurol, Aoba Ku, Sendai, Miyagi 9808574, Japan. RP Furukawa, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. NR 8 TC 22 Z9 25 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD JAN 17 PY 2000 VL 11 IS 1 BP 57 EP 60 DI 10.1097/00001756-200001170-00011 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 274YA UT WOS:000084791600012 PM 10683829 ER PT J AU Watanabe, H Garnier, G Circolo, A Wetsel, RA Ruiz, P Holers, VM Boackle, SA Colten, HR Gilkeson, GS AF Watanabe, H Garnier, G Circolo, A Wetsel, RA Ruiz, P Holers, VM Boackle, SA Colten, HR Gilkeson, GS TI Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC LUPUS-ERYTHEMATOSUS; WIRE-LOOP LESIONS; RHEUMATOID-FACTOR; IMMUNE-COMPLEXES; BLOOD MONOCYTES; GLOMERULONEPHRITIS; INDUCTION; PROTEINS; CELLS; SOLUBILIZATION AB In systemic lupus erythematosus, the renal deposition of complement-containing immune complexes initiates an inflammatory cascade resulting in glomerulonephritis. Activation of the classical complement pathway with deposition of C3 is pathogenic in lupus nephritis, Although the alternative complement pathway is activated in lupus nephritis, its role in disease pathogenesis is unknown. To determine the role of the alternative pathway in lupus nephritis, complement factor B-deficient mice were backcrossed to MRL/lpr mice. MRL/lpr mice develop a spontaneous lupus-like disease characterized by immune complex glomerulonephritis, We derived complement factor B wild-type (B+/+), homozygous knockout (B-/-), and heterozygous (B+/-) MRL/lpr mice, Compared with B+/- or B+/+ mice, MRL/lpr B-/- mice developed significantly less proteinuria, less glomerular IgG deposition, and decreased renal scores as well as lower IgG3 cryoglobulin production and vasculitis. Serum C3 levels were normal in the B-/- mice compared with significantly decreased levels in the other two groups. These results suggest that: 1) factor B plays an important role in the pathogenesis of glomerulonephritis and vasculitis in MRL/lpr mice; and 2) activation of the alternative pathway, either by the amplification loop or by IgA immune complexes, has a prominent effect on serum C3 levels in this lupus model. C1 Med Univ S Carolina, Div Rheumatol Immunol, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC 29425 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Northwestern Univ, Sch Med, Chicago, IL 60611 USA. Univ Miami, Sch Med, Dept Pathol, Miami, FL 33125 USA. Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. RP Gilkeson, GS (reprint author), Med Univ S Carolina, Div Rheumatol Immunol, Dept Med, Charleston, SC 29425 USA. FU NIAID NIH HHS [R01 AI31105, R01 AI25011, R01 AI24739] NR 48 TC 120 Z9 121 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 15 PY 2000 VL 164 IS 2 BP 786 EP 794 PG 9 WC Immunology SC Immunology GA 273LF UT WOS:000084708600033 PM 10623824 ER PT J AU Wells, KB Sherbourne, C Schoenbaum, M Duan, N Meredith, L Unutzer, J Miranda, J Carney, MF Rubenstein, LV AF Wells, KB Sherbourne, C Schoenbaum, M Duan, N Meredith, L Unutzer, J Miranda, J Carney, MF Rubenstein, LV TI Impact of disseminating quality improvement programs for depression in managed primary care - A randomized controlled trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID MAJOR DEPRESSION; MAPROTILINE; OUTPATIENTS; PAROXETINE; OUTCOMES AB Context Care of patients with depression in managed primary care settings often fails to meet guideline standards, but the long-term impact of quality improvement (QI) programs for depression care in such settings is unknown. Objective To determine if QI programs in managed care practices for depressed primary care patients improve quality of care, health outcomes, and employment. Design Randomized controlled trial initiated from June 1996 to March 1997. Setting Forty-six primary care clinics in 6 US managed care organizations. Participants Of 27 332 consecutively screened patients, 1356 with current depressive symptoms and either 12-month, lifetime, or no depressive disorder were enrolled. Interventions Matched clinics were randomized to usual care (mailing of practice guidelines) or to 1 of 2 QI programs that involved institutional commitment to QI, training local experts and nurse specialists to provide clinician and patient education, identification of a pool of potentially depressed patients, and either nurses for medication follow-up or access to trained psychotherapists. Main Outcome Measures Process of care (use of antidepressant medication, mental health specialty counseling visits, medical visits for mental health problems, any medical visits), health outcomes (probable depression and health-related quality of life [HRQOL]), and employment at baseline and at 6- and 12-month follow-up. Results Patients in QI (n = 913) and control (n = 443) clinics did not differ significantly at baseline in service use, HRQOL, or employment after nonresponse weighting. At 6 months, 50.9% of QI patients and 39.7% of controls had counseling or used antidepressant medication at an appropriate dosage (P<.001), with a similar pattern at 12 months (59.2% vs 50.1%; P = .006). There were no differences in probability of having any medical visit at any point teach P greater than or equal to.21). At 6 months, 47.5% of QI patients and 36.6% of controls had a medical visit for mental health problems (P = .001), and QI patients were more likely to see a mental health specialist at 6 months (39.8% vs 27.2%; P<.001) and at 12 months (29.1% vs 22.7%; P = .03). At 6 months, 39.9% of QI patients and 49.9% of controls still met criteria for probable depressive disorder (P = .001), with a similar pattern at 12 months (41.6% vs 51.2%; P = .005). Initially employed QI patients were more likely to be working at 12 months relative to controls (P = .05). Conclusions When these managed primary care practices implemented QI programs that improve opportunities for depression treatment without mandating it, quality of care, mental health outcomes, and retention of employment of depressed patients improved over a year, while medical visits did not increase overall. C1 RAND Corp, Hlth Program, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Georgetown Univ, Med Ctr, Dept Psychiat, Washington, DC 20007 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Wells, KB (reprint author), RAND Corp, Hlth Program, 1700 Main St, Santa Monica, CA 90407 USA. FU AHRQ HHS [R01-HS08349]; NIMH NIH HHS [MH01170-05, P50 MH54623] NR 45 TC 746 Z9 748 U1 6 U2 34 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 12 PY 2000 VL 283 IS 2 BP 212 EP 220 DI 10.1001/jama.283.2.212 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 272QA UT WOS:000084661400027 PM 10634337 ER PT J AU Tapp, A Wood, AE Chandran, M Secrest, L AF Tapp, A Wood, AE Chandran, M Secrest, L TI Combination antipsychotic therapy in clinical practice SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Amer Lake Div, Mental Illness Res Educ & Clin Ctr, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN 3 PY 2000 VL 41 IS 1 SI SI MA B114 BP 216 EP 217 DI 10.1016/S0920-9964(00)90840-5 PG 2 WC Psychiatry SC Psychiatry GA 279PP UT WOS:000085054600526 ER PT J AU Marder, SR AF Marder, SR TI Integrating pharmacological and psychosocial treatments for schizophrenia SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article; Proceedings Paper CT 1st International Zurich Conference on Clinical and Social Psychiatry CY SEP 09-12, 1999 CL ZURICH, SWITZERLAND SP Eli Lilly Suisse DE antipsychotic drugs; schizophrenia; psychosocial treatment ID EXPRESSED EMOTION; RELAPSE; FLUPHENAZINE; AFTERCARE AB Objective: The objective of this study was to develop principles of combining pharmacological and psychosocial treatment that can be useful for clinicians who are treating patients with schizophrenia. Method: Research studies in schizophrenia that controlled both pharmacological and psychosocial treatments were reviewed. These included studies using conventional and newer antipsychotics as well as a number of psychosocial methods. Results: The interactions between the forms of treatment appear to be more than merely additive, since each can enhance the effects of the other. Drug and psychosocial treatments may affect different outcome domains. with the former affecting symptoms and the later affecting social outcomes. Recent studies using newer antipsychotics suggest that these agents improve the participation of patients in psychosocial treatments. Conclusion: Understanding the interactions between psychosocial and pharmacological treatments can be useful for clinicians who are developing treatment strategies for patients with schizophrenia. Newer agents with different side-effect profiles and broader effectiveness appear to have improved the outcomes of psychosocial treatments. C1 W Los Angeles Vet Affairs Med Ctr, Psychiat Serv 116A, VISN 22 Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Marder, SR (reprint author), W Los Angeles Vet Affairs Med Ctr, Psychiat Serv 116A, VISN 22 Mental Illness Res Educ & Clin Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 12 TC 6 Z9 6 U1 1 U2 1 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PY 2000 VL 102 SU 407 BP 87 EP 90 PG 4 WC Psychiatry SC Psychiatry GA 399BH UT WOS:000166790600018 ER PT J AU Bardone, AM Krahn, DD Goodman, BM Searles, JS AF Bardone, AM Krahn, DD Goodman, BM Searles, JS TI Using interactive voice response technology and timeline follow-back methodology in studying binge eating and drinking behavior: Different answers to different forms of the same question? SO ADDICTIVE BEHAVIORS LA English DT Article DE binge eating; alcohol; methodology; interactive voice response; timeline follow-back ID RELIABILITY; VALIDATION AB As part of a study of the relationship of binge eating, alcohol use, mood, and stressors, we compared the results of two forms of reporting on binge eating and drinking behavior. Forty-three first-year college women participated in an interactive voice response (IVR) study for 12 weeks. Participants answered computer-administered questions daily via IVR technology on number of eating binges and number of alcoholic drinks consumed. After 12 weeks, participants completed a Timeline Follow-back (TLFB) interview retrospectively for number of binges and drinks in the past 12 weeks. Results of this distally retrospective methodology (commonly used in drinking research and applied here also to binge eating) were compared to the results of daily IVR reporting, There was convergence across measures for drinking behavior, but divergence between IVR and TLFB for binge eating reports, TLFB reports underrepresented actual binge eating frequency, which calls into question the validity of applying this methodology to the assessment of binge eating. (C) 2000 Elsevier Science Ltd. C1 Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA. William S Middleton Mem Vet Hosp, Geriatr Res Educ Clin Ctr, Madison, WI USA. Univ Vermont, Vermont Alcohol Res Ctr, Burlington, VT 05405 USA. RP Bardone, AM (reprint author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA. NR 11 TC 46 Z9 46 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD JAN-FEB PY 2000 VL 25 IS 1 BP 1 EP 11 DI 10.1016/S0306-4603(99)00031-3 PG 11 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 278NF UT WOS:000084995300001 PM 10708315 ER PT J AU Abrass, CK AF Abrass, CK TI The nature of chronic progressive nephropathy in aging rats SO ADVANCES IN RENAL REPLACEMENT THERAPY LA English DT Article DE kidney; aging; structure; extracellular matrix; glomerulosclerosis ID RENAL GLOMERULUS; S-LAMININ; KIDNEY; PROTEINURIA; MECHANISMS; EXPRESSION; NEPHROSIS; LESIONS; DISEASE; MATRIX AB Increases in glomerular size and thickening of the glomerular basement membrane are constant features that accompany growth and maturation in animals. Yet, some animals have chronic progressive nephropathy characterized by glomerulosclerosis and tubulointerstitial fibrosis. In these animals, clinically significant reductions in glomerular filtration rate may compromise hearth, particularly when other renal diseases occur concomitantly. Progressive thickening of the glomerular basement membrane is accompanied by changes in its composition, which may be responsible for changes in podocyte morphology and proteinuria. Within the tubulointerstitium, generalized accumulation of fibronectin and thrombospondin are accompanied by brood vessel proliferation. Fragility of these blood vessels with intermittent bleeding may initiate an inflammatory process that leads to focal areas of tubular atrophy and scarring. The pathogenesis of these lesions is unknown. Genetic background, sex, and environmental factors influence the tempo of progressive sclerosis, although these factors are not primary determinants of this lesion. This review highlights the structural changes that occur in the kidney with aging. Because the lesions are structurally similar, information gleaned from studies of aging animals should be relevant to understanding the loss of renal function that occurs in aging humans. (C) 2000 by the National Kidney Foundation, Inc. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Abrass, CK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, MD 111A,1660 S Columbian Way, Seattle, WA 98108 USA. NR 35 TC 26 Z9 27 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 1073-4449 J9 ADV RENAL REPLACE TH JI Adv. Renal Replace. Ther. PD JAN PY 2000 VL 7 IS 1 BP 4 EP 10 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 286CT UT WOS:000085426600002 PM 10672913 ER PT J AU Bremner, WF Sothern, RB Kanabrocki, EL Ryan, M McCormick, JB Dawson, S Connors, ES Rothschild, R Third, JLHC Vahed, S Nemchausky, BM Shirazi, P Olwin, JH AF Bremner, WF Sothern, RB Kanabrocki, EL Ryan, M McCormick, JB Dawson, S Connors, ES Rothschild, R Third, JLHC Vahed, S Nemchausky, BM Shirazi, P Olwin, JH TI Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men SO AMERICAN HEART JOURNAL LA English DT Article; Proceedings Paper CT International Congress on Chronobiology CY SEP 07-11, 1997 CL PARIS, FRANCE SP Univ Pierre & Marie Curie, Paris, Hopitaux Paris, Assistance Publique, INRA, INSERM ID CORONARY HEART-DISEASE; SUDDEN CARDIAC DEATH; ACUTE MYOCARDIAL-INFARCTION; RISK FACTOR; ARTERY DISEASE; CARDIOVASCULAR-DISEASE; PLASMA-LIPOPROTEINS; LP(A) LIPOPROTEIN; HEALTHY-SUBJECTS; APOLIPOPROTEINS AB Background A correlation has been reported between lipoprotein(a) [Lp(a)] concentration and risk for coronary artery disease. High concentrations of Lp(a) might be markers for vascular or tissue injury or might be associated with other genetic or environmental factors that can cause acute myocardial infarction. Methods We measured the circadian characteristics of circulating Lp(a), fibrinogen, platelets, cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol for a group of adult male volunteers who had no clinical symptoms. We obtained samples every 3 hours around the clock to assess the normal degree of variation within a 24 hour period and to test for similarities in circadian patterns and correlations with level of Lp(a). Results Each variable displayed a highly significant circadian rhythm. Lp(a), fibrinogen, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol peaked in the morning. Cholesterol and platelets peaked in the late afternoon, and triglycerides peaked in the evening. Conclusions Although peak levels of Lp(a) and fibrinogen coincide with reported morning peak frequencies of myocardial infarction and stroke, the platelet peak appears to coincide with late afternoon peak frequencies of sudden cardiac death and fatal stroke. The data suggest that proper timing of single samples may improve the usefulness and accuracy of diagnosis, risk assessment, and therapy. C1 MacNeal Cardiol Grp, Berwyn, IL 60402 USA. Univ Minnesota, Coll Biol Sci, St Paul, MN 55108 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Nucl Med, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Spinal Cord Injury, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Nursing Res, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Dietet Serv, Hines, IL 60141 USA. Swedish Covenant Hosp, Chicago, IL USA. Rush Presbyterian St Lukes Med Ctr, Dept Surg, Chicago, IL 60612 USA. RP Bremner, WF (reprint author), MacNeal Cardiol Grp, 3231 S Euclid Ave,Suite 201, Berwyn, IL 60402 USA. NR 75 TC 48 Z9 51 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JAN PY 2000 VL 139 IS 1 BP 164 EP 173 DI 10.1016/S0002-8703(00)90324-7 PN 1 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 272BU UT WOS:000084631300024 PM 10618578 ER PT J AU Sloan, KL Kivlahan, D Saxon, AJ AF Sloan, KL Kivlahan, D Saxon, AJ TI Detecting bipolar disorder among treatment-seeking substance abusers SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article ID ADDICTION SEVERITY INDEX; PSYCHIATRIC-DISORDERS; COMORBIDITY; RELIABILITY; DEPENDENCE; ILLNESS; ALCOHOL AB Bipolar disorder is increasingly recognized to have frequent comorbidity with substance use disorders, but may be difficult to diagnose among patients with active substance use. The purpose of this paper is to describe a brief, self-report form for the efficient detection of bipolar disorder. The 19-item form was piloted in 373 consecutive applicants for substance abuse treatment at an urban Veterans Affairs (VA) medical center. Results show reasonable internal consistency (alpha = .850) and high rates of manic symptomatology (36%), previous bipolar diagnosis (30%, 51% of whom report prior psychiatric hospitalization), and exposure to mood stabilizers (20%, 66% of whom reported therapeutic benefit). Comparison of nine different scoring algorithms with chart diagnosis as the validating criterion found that self-report of bipolar diagnosis was optimally sensitive. Either self-report of bipolar diagnosis with hospitalization or self-report of exposure to mood stabilizers with therapeutic response was optimally specific. Symptom self-report items had significantly poorer sensitivity and specificity (F = 7.60, p < .01). We conclude that questions pertaining to diagnostic and treatment history (especially hospitalization or therapeutic medication response) are considerably superior to symptom-based screening for clinically diagnosed bipolar disorder. Further work using structured interview as the diagnostic criterion is under way to validate this instrument. C1 VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Sloan, KL (reprint author), Seattle VA Med Ctr 116 DDTP, 1600 S Columbian Way, Seattle, WA 98108 USA. NR 15 TC 9 Z9 9 U1 3 U2 3 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2000 VL 26 IS 1 BP 13 EP 23 DI 10.1081/ADA-100100587 PG 11 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 284LB UT WOS:000085332900002 PM 10718160 ER PT J AU Faigel, DO Magaret, N Corless, C Lieberman, DA Fennerty, MB AF Faigel, DO Magaret, N Corless, C Lieberman, DA Fennerty, MB TI Evaluation of rapid antibody tests for the diagnosis of Helicobacter pylori infection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID UREA BREATH TEST; WHOLE-BLOOD TEST; ENZYME-IMMUNOASSAY; NONINVASIVE TESTS; GOLD STANDARD; FLEXSURE HP; SEROLOGY; ACCURACY; GASTRITIS; SERUM AB OBJECTIVE: The aim of this study was to compare the performance characteristics of one serum and four whole blood rapid antibody tests for Helicobacter pylori infection. METHODS: A total of 97 outpatients referred for endoscopic evaluation of dyspepsia were included. Antral biopsies were obtained for histology and rapid urease test. Serum was tested with an enzyme-linked immunoassay (HM-CAP) and a rapid serology test (FlexSure HP). A commercially available C-13-urea breath test was performed. Capillary blood obtained by fingerstick was tested with FlexSure HP, QuickVue, Accustat, and StatSimple pylori tests. Sensitivity, specificity. and accuracy of each rapid test was calculated relative to a criterion standard of histological gastritis and at least two of the four following tests positive: identifiable organisms on specially stained slides, rapid urease test, urea breath test, or serum immunoassay. RESULTS: A total of 30 patients (31%) were infected. The FlexSure HP Serum, and FlexSure HP, QuickVue, Accustat, and StatSimple pylori whole blood tests had sensitivities of 90%, 87%, 83%, 76%, and 90%; specificities of 94%, 90%, 96%, 96%, and 98%, and accuracies of 93%, 88%, 92%, 87%, and 96%. respectively. Sensitivities were not statistically different. StatSimple pylori was more specific than FlexSure HP whole blood (p < 0.03), and more accurate than FlexSure whole blood (p < 0.024) and Accustat (p < 0.01). Serum immunoassay was significantly more sensitive (97%) than FlexSure whole blood, QuickVue, and Accustat (p < 0.01), but its specificity (95%) was not statistically different from the rapid tests. CONCLUSION: Rapid antibody testing provides an accurate diagnosis of H. pylori infection. In general, these tests are less sensitive than, but as specific as, standard serology. C1 Portland VA Med Ctr, Dept Med, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Pathol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Faigel, DO (reprint author), Portland VA Med Ctr, Dept Med, P3GI,3710 US Vet Hosp Rd, Portland, OR 97201 USA. NR 41 TC 25 Z9 26 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2000 VL 95 IS 1 BP 72 EP 77 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 273CY UT WOS:000084690800014 PM 10638562 ER PT J AU Arora, S Baraona, E Lieber, CS AF Arora, S Baraona, E Lieber, CS TI Alcohol levels are increased in social drinkers receiving ranitidine SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID BLOOD-ALCOHOL; H2-RECEPTOR ANTAGONISTS; H-2-RECEPTOR ANTAGONISTS; DEHYDROGENASE ACTIVITY; ETHANOL INGESTION; METABOLISM; BIOAVAILABILITY; CIMETIDINE; ELIMINATION; INHIBITION AB OBJECTIVE: Ranitidine increases blood alcohol concentrations by decreasing the first pass metabolism of ethanol. The effect of ranitidine on alcohol levels has been found to be variable when using large doses of alcohol or conditions in which its first pass metabolism is known to be minimal. Despite a consensus that the drug increases alcohol levels after small doses of ethanol, this effect has been considered inconsequential, because of the low alcohol levels. However, social drinking comprises repetitive consumption of small doses of alcohol and the ranitidine effect could thereby be potentiated. METHODS: To study this factor, alcohol levels were determined by breath analysis in nine men (social drinkers), after four drinks of 0.15 g/kg ethanol given postprandially every 45 min, before and after ranitidine (150 mg b.i.d. for 7 days). RESULTS: Their blood alcohol increased with repeated doses, reaching peak values of 24 +/- 3 mg/dl before ranitidine and 33 +/- 2 after ranitidine (p = 0.04). In seven of the nine subjects blood alcohol exceeded 25 mg/dl, a level at which impairment of judgment and of finely tuned skills occurs and which exceeds legal limits of driving in some European countries. Moreover, the high levels persisted for a longer time with than without the drug. These effects were associated with a 62% decrease in first pass metabolism. CONCLUSION: Under conditions mimicking social drinking, ranitidine increases blood alcohol to levels known to impair psychomotor skills needed for driving. (Am J Gastroenterol 2000;95:208-213. (C) 2000 by Am. Cell. of Gastroenterology) C1 Bronx Vet Affairs Med Ctr, Ctr Alcohol Res & Treatment, New York, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. RP Lieber, CS (reprint author), Alcohol Res Ctr, Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. FU NIAAA NIH HHS [AA 05934, AA07275] NR 24 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2000 VL 95 IS 1 BP 208 EP 213 DI 10.1016/S0002-9270(99)00745-5 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 273CY UT WOS:000084690800037 PM 10638585 ER PT J AU Daw, EW Payami, H Nemens, EJ Nochlin, D Bird, TD Schellenberg, GD Wijsman, EM AF Daw, EW Payami, H Nemens, EJ Nochlin, D Bird, TD Schellenberg, GD Wijsman, EM TI The number of trait loci in late-onset Alzheimer disease SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID APOLIPOPROTEIN-E GENOTYPE; GENE; DEMENTIA; LINKAGE; AGE; SEX; METAANALYSIS; CHROMOSOME-1; SEGREGATION; ALLELE AB Although it is clear that apoE plays an important role in the genetics of late-onset Alzheimer disease (AD), evidence exists that additional genes may play a role in AD, and estimates of the total contribution of apoE to the variance in onset of AD vary widely. Unfortunately, little information is available on the number and contribution of additional genes. We estimated the number of additional quantitative-trait loci and their contribution to the variance in age at onset of AD, as well as the contribution of apoE and sex, in an oligogenic segregation analysis of 75 families (742 individuals) ascertained for members with late-onset AD. We found evidence that four additional loci make a contribution to the variance in age at onset of late-onset AD that is similar to or greater in magnitude than that made by apoE, with one locus making a contribution several times greater than that of apoE. Additionally, we confirmed previous findings of a dose effect for the apoE epsilon 4 allele, a protective effect for the epsilon 2 allele, evidence for allelic interactions at the apoE locus, and a small protective effect for males. Furthermore, although we estimate that the apoE genotype can make a difference of less than or equal to 17 years in age at onset of AD, our estimate of the contribution of apoE (7%-9%) to total variation in onset of AD is somewhat smaller than that which has previously been reported. Our results suggest that several genes that have not yet been localized may play a larger role than does apoE in late-onset AD. C1 Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. Univ Washington, Dept Stat, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Daw, EW (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA. FU NIA NIH HHS [AG 05136, AG 08017, P30 AG008017, P50 AG005136, U24 AG021886]; NIGMS NIH HHS [GM 46255, R01 GM046255, R37 GM046255] NR 28 TC 166 Z9 171 U1 2 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD JAN PY 2000 VL 66 IS 1 BP 196 EP 204 DI 10.1086/302710 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 279FK UT WOS:000085033600022 PM 10631151 ER PT J AU Mulrow, CD Williams, JW Chiquette, E Aguilar, C Hitchcock-Noel, P Lee, S Cornell, J Stamm, K AF Mulrow, CD Williams, JW Chiquette, E Aguilar, C Hitchcock-Noel, P Lee, S Cornell, J Stamm, K TI Efficacy of newer medications for treating depression in primary care patients SO AMERICAN JOURNAL OF MEDICINE LA English DT Review ID SEROTONIN REUPTAKE INHIBITORS; GENERAL-PRACTICE; DOUBLE-BLIND; MAJOR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; DISCONTINUATION RATES; CONTROLLED TRIAL; METAANALYSIS; MULTICENTER; ANXIETY AB PURPOSE: Several medications have recently been introduced for the treatment of depression. We reviewed the literature to summarize their efficacy in the treatment of depression in adult patients in primary care settings. METHODS: We searched the literature published from 1980 to January 1998 using the Cochrane Collaboration Depression Anxiety and Neurosis Group's specialized registry of 8,451 clinical trials, references from trials and 46 pertinent meta-analyses, and consultation with experts. We included randomized controlled trials of at least 6 weeks' duration that measured clinical outcomes and compared one of 32 newer medications with another newer antidepressant, an older antidepressant, a placebo, or a psychosocial intervention for the treatment of depressed patients in primary care settings. The primary outcome was response rate, defined as the proportion of patients experiencing a 50% or greater improvement in depressive symptoms. RESULTS: There were 28 randomized controlled trials involving 5,940 adult primary care patients with major depression, depression requiring treatment, dysthymia, or mixed anxiety depression. Newer agents, including selective serotonin re-uptake inhibitors, serotonin norepinephrine inhibitors, reversible inhibitors of monoamine oxidase, and dopamine antagonists, were usually compared with tricyclic agents. Average response rates were 63% for newer agents, 35% for placebo, and 60% for tricyclic agents. Newer agents were significantly more effective than placebo [risk ratio = 1.6; 95% confidence interval (CI), 1.2 to 2.1), but similar to tricyclic agents (risk ratio = 1.0; 95% CI 0.9 to 1.1). Response rates were similar in the different types of depressive disorders, except that two small trials in frail older patients showed no significant effects of newer agents compared with placebo. Dropout rates as a result of adverse effects were 8% with newer agents and 13% with tricyclic agents (P <0.05). CONCLUSIONS: In primary care settings, newer antidepressants are more effective than placebo and have similar efficacy compared with tricyclic agents in the acute treatment of depression. Dropout rates as a result of adverse effects are lower with newer compared with tricyclic agents. Future studies should compare the effectiveness of different therapies among primary care patients with less severe depression and greater medical and psychiatric comorbidity. Am J Med. 2000;108:54-64. (C)2000 by Excerpca Medica, Inc. C1 Audie L Murphy Mem Vet Affairs Hosp, Vet Affairs Cochrane Ctr, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Evidence Based Practice Ctr, San Antonio, TX 78284 USA. RP Mulrow, CD (reprint author), Audie L Murphy Mem Vet Affairs Hosp, Vet Affairs Cochrane Ctr, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78284 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 51 TC 78 Z9 78 U1 2 U2 5 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2000 VL 108 IS 1 BP 54 EP 64 DI 10.1016/S0002-9343(99)00316-2 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 273ME UT WOS:000084710800009 PM 11059441 ER PT J AU Nagatomo, Y Carabello, BA Coker, ML McDermott, PJ Nemoto, S Hamawaki, M Spinale, FG AF Nagatomo, Y Carabello, BA Coker, ML McDermott, PJ Nemoto, S Hamawaki, M Spinale, FG TI Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE myocardial remodeling; tissue inhibitor of metalloproteinases; hypertrophy; matrix metalloproteinase; left ventricular overload ID MATRIX METALLOPROTEINASE ACTIVITY; SANDWICH ENZYME-IMMUNOASSAY; NECROSIS FACTOR-ALPHA; TISSUE INHIBITOR; IV COLLAGENASE; INTERSTITIAL COLLAGENASE; DILATED CARDIOMYOPATHY; MONOCLONAL-ANTIBODIES; SYNOVIAL FIBROBLASTS; EXTRACELLULAR-MATRIX AB Left, ventricular (LV) pressure (PO) or volume (VO) overload is accompanied by myocardial remodeling, but mechanisms that contribute to this progressive remodeling process remain unclear. The matrix metalloproteinases (MMPs) contribute to tissue remodeling in a:number of disease states. This study tested the hypothesis that increased MMP expression and activity occur after the induction of an LV overload, which is accompanied by a loss;of endogenous MMP inhibitory control. LV MMP zymographic-activity and species abundance were measured in dogs cinder the following conditions: acute PO induced by ascending aortic balloon inflation (6 h, n = 9), prolonged PO by aortic banding (10 days, n = 5), acute VO through mitral regurgitation secondary to chordal rupture (6 h, n = 6), prolonged VO due to mitral regurgitation (14 days, n = 7), and sham-controls (n = 11). MMP zymographic activity in the 92-kDa region, indicative of MMP-9 activity, increased over threefold in acute PO and VO and fell to control levels in prolonged PO and VO. The MMP-9 activity-to-abundance ratio increased by over fourfold with acute VO and twofold in acute PO, suggesting a loss of inhibitory control. Endogenous MMP inhibitor content was unchanged with either PO or VO. Interstitial collagenase (MMP-1) content decreased by 50% with acute VO but not with acute PO. Stromelysin (MMP-3) levels increased by 40% with acute VO and increased by 80% with prolonged PO. Although changes in LV myocardial MMP activity and inhibitory control occurred in both acute and prolonged PO and VO states, these changes were not identical. These results suggest that the type of overload stimulus may selectively influence myocardial MMP activity and expression, which in turn would affect the overall LV myocardial remodeling process in LV overload. C1 Med Univ S Carolina, Div Cardiothorac Surg & Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg & Cardiol, Rm 625,Strom Thurmond Res Bldg,770 MUSC Complex,1, Charleston, SC 29425 USA. FU NHLBI NIH HHS [HL-97012, P01-HL-48788, HL-45024] NR 49 TC 80 Z9 81 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN PY 2000 VL 278 IS 1 BP H151 EP H161 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 274UT UT WOS:000084784000018 PM 10644594 ER PT J AU Zhang, Z Yang, XY Soltoff, SP Cohen, DM AF Zhang, Z Yang, XY Soltoff, SP Cohen, DM TI PI3K signaling in the murine kidney inner medullary cell response to urea SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE sodium chloride; hypertonicity; mIMCD3 cells; apoptosis; stress ID P70 S6 KINASE; RENAL EPITHELIAL-CELLS; DUCT MIMCD3 CELLS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; POSITIVE REGULATION; RAT HEPATOCYTES; GENE-EXPRESSION; ACTIVATOR CREM AB Growth factors and other stimuli increase the activity of phosphatidylinositol-3 kinase (PI3K), an SH2 domain-containing lipid kinase. In the murine kidney inner medullary mIMCD3 cell line, urea (200 mM) increased PI3K activity in a time-dependent fashion as measured by immune complex kinase assay. The PI3K effector, Akt, was also activated by urea as measured by anti-phospho-Akt immunoblotting. In addition, the Akt (and PI3K) effector, p70 S6 kinase, was activated by urea treatment in a PI3K-dependent fashion. PI3K inhibition potentiated the proapoptotic effect of hypertonic and urea stress. Urea treatment also induced the tyrosine phosphorylation of Shc and the recruitment to Shc of Grb2. Coexistence of activated Shc and PI3K in a macromolecular complex was suggested by the increase in PI3K activity evident in anti-She immunoprecipitates prepared from urea-treated cells. Taken together, these data suggest that PI3K may regulate physiological events in the renal medullary cell response to urea stress and that an upstream tyrosine kinase conferring activation of both PI3K and Shc may govern urea signaling in these cells. C1 Oregon Hlth Sci Univ, Div Nephrol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Div Mol Med, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA. RP Cohen, DM (reprint author), Oregon Hlth Sci Univ, Div Nephrol, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM cohend@ohsu.edu RI Zhang, Zheng/J-2388-2014 OI Zhang, Zheng/0000-0003-2497-0362 FU NIDCR NIH HHS [DE-10877]; NIDDK NIH HHS [DK-52494] NR 61 TC 35 Z9 36 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2000 VL 278 IS 1 BP F155 EP F164 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 275KV UT WOS:000084820100017 PM 10644667 ER PT J AU Rasool, A Palevsky, PM AF Rasool, A Palevsky, PM TI Treatment of edematous disorders with diuretics SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Review DE edema; diuretics; congestive heart failure; nephrotic syndrome; sodium hemostasis ID CONGESTIVE-HEART-FAILURE; CHRONIC RENAL-INSUFFICIENCY; EXPERIMENTAL NEPHROTIC SYNDROME; ATRIAL-NATRIURETIC-PEPTIDE; GLOMERULAR-FILTRATION RATE; DRUG-PROTEIN-BINDING; HIGH-DOSE FUROSEMIDE; SODIUM RETENTION; CONTINUOUS-INFUSION; VOLUME EXPANSION AB Generalized edema results from alterations in renal sodium homeostasis that ultimately result in an expansion of extracellular fluid volume and accumulation of interstitial fluid. The common edematous disorders include congestive heart failure, cirrhosis, nephrotic syndrome, and renal insufficiency. The abnormalities of sodium homeostasis contributing edema formation in each condition are discussed. Management of volume homeostasis, with an emphasis on the role of diuretic therapy, is reviewed. C1 VA Pittsburgh Healthcare Syst, Renal Sect 111FU, Univ Dr Div, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect 111FU, Univ Dr Div, Pittsburgh, PA 15240 USA. OI Palevsky, Paul/0000-0002-7334-5400 NR 148 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2000 VL 319 IS 1 BP 25 EP 37 DI 10.1097/00000441-200001000-00003 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 276ZU UT WOS:000084908900003 PM 10653442 ER PT J AU Dagan, R Leibovitz, E Fliss, DM Leiberman, A Jacobs, MR Craig, W Yagupsky, P AF Dagan, R Leibovitz, E Fliss, DM Leiberman, A Jacobs, MR Craig, W Yagupsky, P TI Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MIDDLE-EAR FLUID; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; PEDIATRIC-PATIENTS; CLINICAL EFFICACY; SENSITIVITY TEST; ANTIBIOTICS; ERYTHROMYCIN; MULTICENTER; CEFIXIME AB A prospective, open-label, randomized study was conducted in order to determine the bacteriologic efficacies of cefaclor and azithromycin in acute otitis media (AOM). Tympanocentesis was performed on entry into the study and 3 to 4 days after initiation of treatment. Bacteriologic failure after 3 to 4 days of treatment with both drugs occurred in a high proportion of culture-positive patients, especially in those in whom AOM was caused by Haemophilus influenzae (16 of 33 [53%] of those treated with azithromycin and 13 of 34 [52%] of those treated with cefaclor). Although a clear correlation of the persistence of the pathogen with increased MICs of the respective drugs could be demonstrated for Streptococcus pneumoniae, no such correlation was found for E-I. influenzae. It is proposed that susceptibility breakpoints for H. influenzae should be considerably lower than the current ones for both cefaclor and azithromycin for AOM caused by H. influenzae. C1 Soroka Univ, Med Ctr, Pediat Infect Dis Unit, IL-84101 Beer Sheva, Israel. Soroka Univ, Med Ctr, Dept Otolaryngol, IL-84101 Beer Sheva, Israel. Soroka Univ, Med Ctr, Clin Microbiol Lab, IL-84101 Beer Sheva, Israel. Ben Gurion Univ Negev, Fac Hlth Sci, IL-84101 Beer Sheva, Israel. Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. Univ Wisconsin, Dept Med, Madison, WI USA. William S Middleton Mem Vet Hosp, Madison, WI USA. RP Dagan, R (reprint author), Soroka Univ, Med Ctr, Pediat Infect Dis Unit, POB 151, IL-84101 Beer Sheva, Israel. NR 47 TC 105 Z9 106 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2000 VL 44 IS 1 BP 43 EP 50 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 266EN UT WOS:000084287800008 PM 10602721 ER PT J AU Barchiesi, F Arzeni, D Fothergill, AW Di Francesco, LF Caselli, F Rinaldi, MG Scalise, G AF Barchiesi, F Arzeni, D Fothergill, AW Di Francesco, LF Caselli, F Rinaldi, MG Scalise, G TI In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID IN-VITRO; CRYPTOCOCCUS-NEOFORMANS; CANDIDA-ALBICANS; SCH-56592; ITRACONAZOLE; ASPERGILLOSIS; SCH56592; THERAPY AB A broth microdilution method performed in accordance with the National Committee for Clinical Laboratory Standards guidelines was used to compare the in vitro activity of the new antifungal triazole SCH 56592 (SCH) to that of fluconazole (FLC), itraconazole (ITC), and ketoconazole (KETO) against 257 clinical yeast isolates. They included 220 isolates belonging to 12 different species of Candida, 15 isolates each of Cryptococcus neoformans and Saccharomyces cerevisiae, and seven isolates of Rhodotorula rubra. The MICs of SCH at which 50% (MIC50) and 90% (MIC90) of the isolates were inhibited were 0.06 and 2.0 mu g/ml, respectively. In general, SCH was considerably more active than FLC (MIC50 and MIC90 of 1.0 and 64 mu g/ml, respectively) and slightly more active than either ITC (MIC50 and MIC90 of 0.25 and 2.0 mu g/ml, respectively) and KETO (MIC50 and MIC90 of 0.125 and 4.0 mu g/ml, respectively). Our in vitro data suggest that SCH has significant potential for clinical development. C1 Univ Ancona, Ist Malattie Infett & Med Pubbl, Ancona, Italy. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Barchiesi, F (reprint author), Univ Ancona, Ist Malattie Infect & Med Pubbl, Osped Umberto 1, Largo Cappelli 1, I-60121 Ancona, Italy. NR 14 TC 56 Z9 58 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2000 VL 44 IS 1 BP 226 EP 229 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 266EN UT WOS:000084287800044 PM 10602757 ER PT S AU Sachdev, D Chirgwin, JM AF Sachdev, D Chirgwin, JM BE Thorner, J Emr, SD Abelson, JN TI Fusions to maltose-binding protein: Control of folding and solubility in protein purification SO APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS, PT A: GENE EXPRESSION AND PROTEIN PURIFICATION SE Methods in Enzymology LA English DT Review ID GLUTATHIONE-S-TRANSFERASE; SINGLE-STEP PURIFICATION; ESCHERICHIA-COLI; INCLUSION-BODIES; IN-VITRO; ASPARTIC PROTEINASES; PROCATHEPSIN-D; EXPRESSION; POLYPEPTIDES; THIOREDOXIN C1 Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA. Univ Texas, Hlth Sci Ctr, Res Serv, Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. RP Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA. NR 38 TC 47 Z9 49 U1 0 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182227-3 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2000 VL 326 BP 312 EP 321 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BR04M UT WOS:000165500400020 PM 11036650 ER PT J AU Goldbach-Mansky, R Lee, J McCoy, A Hoxworth, J Yarboro, C Smolen, JS Steiner, G Rosen, A Zhang, C Menard, HA Zhou, ZJ Palosuo, T Van Venrooij, WJ Wilder, RL Klippel, JH Schumacher, HR El-Gabalawy, HS AF Goldbach-Mansky, R Lee, J McCoy, A Hoxworth, J Yarboro, C Smolen, JS Steiner, G Rosen, A Zhang, C Menard, HA Zhou, ZJ Palosuo, T Van Venrooij, WJ Wilder, RL Klippel, JH Schumacher, HR El-Gabalawy, HS TI Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset SO ARTHRITIS RESEARCH LA English DT Review DE autoantibodies; early synovitis; human leukocyte antigen; rheumatoid arthritis; spondylarthropathy ID HUMAN EPIDERMIS FILAGGRIN; ANTIKERATIN ANTIBODIES; ANTIFILAGGRIN AUTOANTIBODIES; ANTIPERINUCLEAR FACTOR; MARKER; PURIFICATION; DISEASE; SERA; RA33 AB An inception cohort of 238 patients having peripheral joint synovitis of less than 12 months duration was evaluated clinically and followed prospectively for 1 year to determine the clinical significance of a number of rheumatoid arthritis (RA) associated autoantibodies. Serum samples collected at the time of the initial evaluation were tested for rheumatoid factor (RF) and antibodies to Sa (anti-Sa), RA-33, (pro) filaggrin [antifilaggrin antibody (AFA)], cyclic citrullinated peptide (anti-CCP), calpastatin, and keratin [antikeratin antibody (AKA)]. RF had a sensitivity of 66% and a specificity of 87% for RA. Anti-Sa, AFA, and anti-CCP all had a specificity of more than 90%, but a sensitivity of less than 50% for this diagnosis. Overall, there was a high degree of correlation between AFA, AKA, anti-Sa or anti-CCP, this being highest between anti-Sa and anti-CCP (odds ratio, 13.3; P < 0.001). Of the 101 patients who were positive for at least one of these four autoantibodies, 57% were positive for only one. Finally, anti-Sa identified a subset of predominantly male RA patients with severe, erosive disease. Anti-Sa, AFA and anti-CCP are all specific for early RA but, overall, have little additional diagnostic value over RF alone. Although these antibodies may preferentially recognize citrullinated antigens, the modest degree of concordance between them in individual patient sera suggests that it is unlikely a single antigen is involved in generating these responses. C1 Univ Vienna, Dept Med, Div Rheumatol, Vienna, Austria. Johns Hopkins Sch Med, Dept Med, Div Rheumatol, Baltimore, MD USA. Univ Sherbrooke, Ctr Univ Sante Estrie, Div Rheumatol, Sherbrooke, PQ J1K 2R1, Canada. Natl Publ Hlth Inst, Immunobiol Lab, Helsinki, Finland. Katholieke Univ Nijmegen, Nijmegen, Netherlands. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP El-Gabalawy, HS (reprint author), NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA. OI Hoxworth, Joseph/0000-0002-7179-5846; Steiner, Guenter/0000-0002-5089-7405 NR 30 TC 248 Z9 280 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1P 6LB, ENGLAND SN 1465-9913 J9 ARTHRITIS RES JI Arthritis Res. PY 2000 VL 2 IS 3 BP 236 EP 243 DI 10.1186/ar93 PG 8 WC Rheumatology SC Rheumatology GA 408ZU UT WOS:000167357700013 PM 11056669 ER PT J AU Ratcliffe, MB Hong, J Salahieh, A Wallace, AW AF Ratcliffe, MB Hong, J Salahieh, A Wallace, AW TI The effect of diastolic stiffness on ventricular function after partial ventriculectomy: A finite element simulation SO ASAIO JOURNAL LA English DT Article ID DILATED CARDIOMYOPATHY; REDUCTION SURGERY; SARCOMERE-LENGTH; HEART; PERFORMANCE; TRABECULAE AB Partial ventriculectomy (PV) has been proposed by Batista and colleagues to improve cardiac function in patients with dilated cardiomyopathy (DCM); however, results have been mixed. We tested the hypothesis that preoperative diastolic function affects the stroke volume/end-diastolic pressure (Starling) relationship after PV. A previously described finite element simulation of DCM and PV was used. Diastole and end systole were represented by separate elastic finite element models with different unloaded shapes and nonlinear material properties. Left ventricular (LV) end-systolic elastance (E-ES), diastolic compliance (DC), and Starling relationships were calculated. DC was varied by changing Ogden material property alpha (i) from 12 (compliant) to 20 (stiff). PV was simulated at 20% LV mass reduction. The slope of the Starling relationship increased from 1.82 to 1.21 as alpha (i) increased from 12 to 20. Partial ventriculectomy increased the Starling relationship in each case from 1.34 to 1.01 respectively. However, the net result in each case is a decrement in the Starling relationship with resection, and the smallest decrement was associated with the highest diastolic stiffness (alpha (i) = 20). Partial ventriculectomy depressed the Starling relationship for all values of diastolic compliance. It is expected that patients with a higher diastolic stiffness should do better. C1 San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Div Cardiothorac Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sch Med, Dept Anesthesia, San Francisco, CA 94143 USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, 112D,4150 Clement St, San Francisco, CA 94121 USA. NR 34 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1058-2916 J9 ASAIO J JI Asaio J. PD JAN-FEB PY 2000 VL 46 IS 1 BP 111 EP 116 DI 10.1097/00002480-200001000-00026 PG 6 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 392UK UT WOS:000166430800026 PM 10667728 ER PT J AU Cooper, RA Rentschler, AJ O'Connor, TJ Ster, JF AF Cooper, RA Rentschler, AJ O'Connor, TJ Ster, JF TI Wheelchair armrest strength testing SO ASSISTIVE TECHNOLOGY LA English DT Article DE wheelehair; fatigue testing; wheclchair standards; strength testing ID MANUAL WHEELCHAIRS; UNITED-STATES; ACCIDENTS; LIFE AB There are about 1.4 million manual wheelchair users, 100,000 electric-powered wheelchair users, and 60,000 electric-powered scooter users. The current study was undertaken to determine if the fasteners of a clamp-type armrest receiver were prone to failure. The first test was used to examine the potential misalignment of the armrest receiver components that attach it to the frame. The second test was to evaluate the entire armrest using the American National Standards Institute/Rehabilitation Engineering and Assistive Technology Society of North America armrest static strength standard. Finally, we conducted three fatigue tests. The first fatigue test was performed by repeating the static stability tests multiple times. The last two tests were a modified version of the double-drum wheelchair fatigue test used to apply repeated loading and vibration simultaneously. A paired t-test showed that there is no statistically significant difference (p = 0.08), with a confidence of 95%, between critical alignment measurements. The armrest including the receiver passed the standard requirement of a force of 760 N being applied outward at 15 degrees. During fatigue testing, we found that armrests did not exhibit any visible or functional damage. Upon completion of the tests, the armrests and receivers functioned properly. At about 100,289 cycles on a double-drum test machine, three bolts failed on each armrest receiver when the screws were loosened to have only five threads engaged prior to commencing the test. The design of the armrest tested was in compliance with existing national and international standards. Currently, both International Standards Organization and American National Standards Institute/Rehabilitation Engineering and Assistive Technology Society committees are developing standards for seating systems that will include static, impact, and fatigue strength testing of devices like lateral torso supports, lateral hip support, etc. Methods similar to those explored in this study should be considered. This study may help manufacturers when designing products and purchasers or regulatory agencies when attempting to evaluate the safety and quality of armrest assemblies. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, VA Rehabil Res & Dev Ctr Wheelchairs & Related Te, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. Univ Pittsburgh, Dept Orthopaed Surg, Div Phys Med & Rehabil, Pittsburgh, PA USA. Calif State Univ Sacramento, Sch Engn & Comp Sci, Sacramento, CA 95819 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R1, VA Rehabil Res & Dev Ctr Wheelchairs & Related Te, 7180 Highland Dr, Pittsburgh, PA 15206 USA. NR 15 TC 2 Z9 2 U1 3 U2 5 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2000 VL 12 IS 2 BP 106 EP 115 PG 10 WC Rehabilitation SC Rehabilitation GA 434WV UT WOS:000168839600003 PM 11508400 ER PT J AU Bliziotes, M McLoughlin, S Gunness, M Fumagalli, F Jones, SR Caron, MG AF Bliziotes, M McLoughlin, S Gunness, M Fumagalli, F Jones, SR Caron, MG TI Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene SO BONE LA English DT Article; Proceedings Paper CT 19th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 10-14, 1997 CL CINCINNATI, OHIO SP Amer Soc Bone & Mineral Res DE dopamine transporter; osteoporosis; biomechanics; neurotransmitter; bone histomorphometry; transgenic mice ID PARATHYROID-HORMONE; BODY CONFORMATION; DEFICIENT MICE; LACKING; RUNNERS; COCAINE; TRAITS; MOUSE; RATS AB Dopamine (DA) has been reported to have effects on calcium and phosphorus metabolism. The dopamine transporter (DAT) is believed to control the temporal and spatial activity of released DA by rapid uptake of the neurotransmitter into presynaptic terminals. We have evaluated the histologic and biomechanical properties of the skeleton in mice homozygous for deletion of the DA transporter gene (DAT) to help delineate the role of DA in bone biology. We have demonstrated that DAT(-/-) mice have reduced bone mass and strength. DAT(-/-) animals had shorter femur length and dry weight. Ash calcium content of the femur was 32% lower in the DAT(-/-) mice than in the wild-type animals. Cancellous bone volume in the proximal tibial metaphysis was significantly lower in the DAT(-/-) animals (p, < 0.04). There was a 32% reduction in trabecular thickness (p = NS), For the vertebrae, cancellous bone volume was again lower in the DAT(-/-) animals compared with wild-type as a consequence of increased trabecular spacing (p < 0.05) and reduced trabecular number (p < 0.05). Cortical thickness and bone area in the femoral diaphysis were reduced in the DAT(-/-) animals. The ultimate bending load (femoral strength) for the DAT(-/-) mice was 30% lower than the wild-type mice (p = 0.004). Thus, deletion of the DAT gene results in deficiencies in skeletal structure and integrity. (C) 2000 by Elsevier Science Inc. All rights reserved. C1 Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA. RP Bliziotes, M (reprint author), Portland VA Med Ctr, P-3-ENDO, Portland, OR 97201 USA. RI Fumagalli, Fabio/E-8992-2012; Jones, Sara/K-4816-2014 OI Jones, Sara/0000-0002-3424-7576; Fumagalli, Fabio/0000-0002-8814-7706 FU NINDS NIH HHS [NS-19576] NR 33 TC 35 Z9 38 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 8756-3282 J9 BONE JI Bone PD JAN PY 2000 VL 26 IS 1 BP 15 EP 19 DI 10.1016/S8756-3282(99)00232-X PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 268CD UT WOS:000084396000003 PM 10617152 ER PT J AU McNeil, MR Doyle, PJ AF McNeil, MR Doyle, PJ TI Reconsidering the hegemony of linguistic explanations in aphasia: The challenge for the beginning of the millennium SO BRAIN AND LANGUAGE LA English DT Article C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. GRECC, VA Pittsburgh Healthcare Syst, Aphasia Rehabil Res Lab & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. NR 10 TC 9 Z9 9 U1 0 U2 2 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD JAN PY 2000 VL 71 IS 1 BP 154 EP 156 DI 10.1006/brln.1999.2238 PG 3 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 291GK UT WOS:000085725600044 PM 10716833 ER PT J AU Tonini, M De Giorgio, R De Ponti, F Sternini, C Spelta, V Dionigi, P Barbara, G Stanghellini, V Corinaldesi, R AF Tonini, M De Giorgio, R De Ponti, F Sternini, C Spelta, V Dionigi, P Barbara, G Stanghellini, V Corinaldesi, R TI Role of nitric oxide- and vasoactive intestinal polypeptide-containing neurones in human gastric fundus strip relaxations SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article DE human gastric fundus; VIP- and NOS-immunohistochemistry; NADPH-diaphorase histochemistry; NANC inhibitory nerves; electrically-induced relaxations; mechanically-induced relaxations ID NONADRENERGIC NONCHOLINERGIC RELAXATION; PIG SMALL-INTESTINE; GUINEA-PIG; CIRCULAR MUSCLE; INHIBITORY TRANSMISSION; TAENIA-COLI; L-ARGININE; CHOLINERGIC TRANSMISSION; NADPH-DIAPHORASE; MYENTERIC PLEXUS AB 1 The morphological pattern and motor correlates of nitric oxide (NO) and vasoactive intestinal polypeptide (VIP) innervation in the human isolated gastric fundus was explored. 2 By using the nicotinamide adenine dinucleotide phosphate hydrogen (NADPH)-diaphorase and specific rabbit polyclonal NO-synthase (NOS) and VIP antisera, NOS- and VIP-containing varicose nerve fibres were identified throughout the muscle layer or wrapping ganglion cell bodies of the myenteric plexus. NOS-immunoreactive (IR) neural cell bodies were more: abundant than those positive for VIP-IR. The majority of myenteric neurones containing VIP coexpressed NADPH-diaphorase. 3 Electrical stimulation of fundus strips caused frequency-dependent NANC relaxations. N-G-nitro-L-arginine (L-NOARG: 300 mu M) enhanced the basal tone, abolished relaxations to 0.3-3 Hz (5 s) and those to 1 Hz (5 min), markedly reduced (similar to 50%) those elicited by 10-50 Hz, and unmasked or potentiated excitatory cholinergic responses at frequencies greater than or equal to 1 Hz. L-NOARG-resistant relaxations were virtually abolished by VIP (100 nM) desensitization at all frequencies. 4 Relaxations to graded low mechanical distension (less than or equal to 1 g) were insensitive to tetrodotoxin (TTX: 1 mu M) and L-NOARG (300 mu M), while those to higher distensions (2 g) were slightly inhibited by both agents to the same extent (similar to 25%). 5 In the human gastric fundus, NOS- and VIP immunoreactivities are colocalized in the majority of myenteric neurones; NO and VIP mediate electrically evoked relaxations: low frequency stimulation, irrespective of the duration, caused NO release only, whereas shortlasting stimulation at high frequencies induced NO and VIP release. Relaxations to graded mechanical distension were mostly due to passive viscoelastic properties, with a slight NO-mediated neurogenic component at 2 g distension. The difference between NO and VIP release suggests that in human fundus accommodation is initiated by NO. C1 Univ Pavia, Dept Internal Med & Therapeut, Div Expt & Clin Pharmacol, I-27100 Pavia, Italy. Univ Bologna, Dept Internal Med & Gastroenterol, I-40138 Bologna, Italy. Univ Bologna, Inst Pharmacol, I-40126 Bologna, Italy. Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Pavia, Policlin San Matteo, Dept Surg, IRCCS, I-27100 Pavia, Italy. RP Tonini, M (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Div Expt & Clin Pharmacol, Piazza Botta 10, I-27100 Pavia, Italy. OI DIONIGI, PAOLO/0000-0002-0768-9395; De Giorgio, Roberto/0000-0003-0867-5873; De Ponti, Fabrizio/0000-0002-0367-9595 FU NIDDK NIH HHS [P30 DK041301, R01 DK054155, R56 DK054155] NR 56 TC 55 Z9 57 U1 0 U2 2 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD JAN PY 2000 VL 129 IS 1 BP 12 EP 20 DI 10.1038/sj.bjp.0702977 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 276UB UT WOS:000084894800002 PM 10694197 ER PT J AU Arjmandi, BH Birnbaum, RS Juma, S Barengolts, E Kukreja, SC AF Arjmandi, BH Birnbaum, RS Juma, S Barengolts, E Kukreja, SC TI The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms SO CALCIFIED TISSUE INTERNATIONAL LA English DT Article DE estrogens; isoflavones; osteoporosis; ovariectomy; rats ID OVARIECTOMIZED RAT MODEL; BREAST-CANCER CELLS; POSTMENOPAUSAL WOMEN; IN-VITRO; OSTEOPOROSIS; PROGESTERONE; DENSITY; MASS AB Ipriflavone (IP), a synthetic isoflavone has been reported to prevent bone loss in both postmenopausal women and ovariectomized (ovx) rats. The purpose of this study was to compare and contrast some of the bone protective mechanisms of TP to those of 17 beta-estradiol (E-2) in ovarian hormone deficiency. Forty-eight 95-day-old Sprague-Dawley rats were assigned to four groups: sham, ovx, ovx+IP, and ovx+E-2. The doses of IP and E-2 were 100 mg and 10 mu g/kg body weight per day, respectively. Rats were fed a diet that contained 0.4% calcium, 0.3% phosphorus, and 0.195 nmol vitamin D-3/g diet. After sacrifice, left femoral bone densities were measured and bone histomorphometry was performed on the proximal tibial metaphysis. Ipriflavone as well as E-2 treatment completely prevented the ovx-induced femoral bone density loss. How ever, in contrast to E-2, IP did not lower the ovx-induced rise in serum alkaline phosphatase (ALP) activity or insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 concentrations. On histomorphometry analysis, the ovariectomy-induced increase (P < 0.09) in bone formation rate (BFR) was significantly (P < 0.05) suppressed by E-2 treatment, whereas this higher BFR was maintained in IF-treated animals. These findings indicate that IP is effective in preventing the ovx-associated bone loss. The bone protective mechanisms of IF in ovarian hormone deficiency may be different from those of E-2 and may involve increased rates of bone formation. C1 Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. VA Puget Sound Healthcare Syst, Amer Lake Div, Tacoma, WA 98493 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. W Side Vet Adm Med Ctr, Dept Med, Chicago, IL 60612 USA. RP Arjmandi, BH (reprint author), Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. NR 32 TC 31 Z9 38 U1 1 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0171-967X J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PD JAN PY 2000 VL 66 IS 1 BP 61 EP 65 DI 10.1007/s002230050012 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 266HF UT WOS:000084294000012 PM 10602847 ER PT J AU Major, PP Lipton, A Berenson, J Hortobagyi, G AF Major, PP Lipton, A Berenson, J Hortobagyi, G TI Oral bisphosphonates - A review of clinical use in patients with bone metastases SO CANCER LA English DT Review DE bisphosphonates; metastases; bone; trials ID BREAST-CANCER; MULTIPLE-MYELOMA; DOUBLE-BLIND; DICHLOROMETHYLENE-DIPHOSPHONATE; PAGETS-DISEASE; CONTROLLED TRIAL; PROSTATE-CANCER; PHARMACOLOGICAL PROPERTIES; THERAPEUTIC EFFICACY; SKELETAL METASTASES AB BACKGROUND. This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer patients. METHODS. Available published clinical studies of oral bisphosphonates in bone metastases from 1980 to the present were identified through a MEDLINE search and from literature references. Data were reviewed for efficacy and safety, with an emphasis on double blind, placebo-controlled studies; clinically relevant endpoints; and appropriate study methodology. RESULTS. Etidronate, alendronate, pamidronate, risedronate, and tiludronate currently are available in the U.S. as either intravenous and/or oral formulations. Although newer bisphosphonates are more potent, oral bioavailability remains < 1%. Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases, Pamidronate has been found to be effective in reducing skeletal morbidity associated with bone metastases in both multiple myeloma and breast carcinoma patients when given intravenously, but is ineffective orally in multiple myeloma patients. To the authors' knowledge, there are no double blind, placebo-controlled trials of oral pamidronate in patients with breast carcinoma and bone metastases. Several clinical trials with clodronate, a bisphosphonate that is not available in the U.S., have shown mixed results in patients with myeloma and breast carcinoma bone metastases. To the authors' knowledge, there are no published trials evaluating oral alendronate, tiludronate, or risedronate in patients with metastases to bone. CONCLUSIONS. Oral bisphosphonates do not appear to be as effective as intravenous administration in reducing skeletal complications in patients with metastases to bone lesions. Low oral bioavailability is the most likely reason for this difference. Oral dosing should not be substituted for intravenous administration in the treatment of malignant osteolysis. Cancer 2000;88:6-14. (C) 2000 American Cancer Society. C1 Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada. Penn State Univ, Milton S Hershey Med Ctr, Div Hematol & Oncol, Hershey, PA 17033 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Div Hematol & Oncol, Los Angeles, CA USA. Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA. RP Major, PP (reprint author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada. NR 76 TC 78 Z9 79 U1 1 U2 5 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0008-543X J9 CANCER JI Cancer PD JAN 1 PY 2000 VL 88 IS 1 BP 6 EP 14 DI 10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D PG 9 WC Oncology SC Oncology GA 270YW UT WOS:000084565600003 PM 10618600 ER PT J AU Kroning, R Lichtenstein, AK Nagami, GT AF Kroning, R Lichtenstein, AK Nagami, GT TI Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE cisplatin; nephrotoxicity; amino acids; cytotoxicity; uptake; transport ID RATS; NEPHROTOXICITY AB Purpose: Nephrotoxicity is one of the major dose-limiting side-effects of cisplatin (DDP). The disproportionate accumulation of cisplatin in kidney tissue may play an important role; however, therapeutic measures to prevent this prime cause of nephrotoxicity are not available. Because certain amino acids (AAs) have been reported to modulate DDP nephrotoxicity in vivo, we explored the potential of all 20 protein AAs, N-acetylcysteine and DL-homocysteine to reduce DDP cytotoxicity and uptake in S-1, S-3 (proximal tubule), and DCT (distal convoluted tubule) cell lines. Methods: Immortalized but non-transformed renal tubule epithelial cell lines, derived from specific portions of the nephron of an SV40 transgenic mouse, were grown to confluency and exposed to various concentrations of DDP for 1 h with or without concurrent exposure to AAs in an otherwise AA-free Krebs-Ringer buffer (I(RB). After 1 h, cell layers were washed and replenished with medium for cytotoxicity assays, or processed immediately for the determination of DDP accumulation. Cytotoxicity was assessed 48 h later by an MTT assay, and DDP uptake after Ih was determined by atomic absorption spectroscopy. Results: In an initial screening where the cells were concurrently incubated with 0.25 mM DDP and 1 mM AA for I h in KRB, only cysteine (Cys), me-thionine (Met), N-acetylcysteine and DL-homocysteine reduced DDP toxicity. This effect was enhanced at 5 mM AA and most potent for Cys, which reduced DDP cytotoxicity by 79 +/- 3% in S3 cells, by 78 +/- 12.2% in DCT cells, and by 19 +/- 3.6% in S-1 cells (P < 0.05). Reduction of cytotoxicity was less for Met, DL-homocysteine, and N-acetylcysteine, in decreasing order. All four AAs also inhibited DDP uptake in renal cells, with Cys as the strongest inhibitor. Inhibition of DDP accumulation by 1 mM Cys after 1 h was 39% in S-3 cells, 38% in DCT cells, and 28% in S-1 cells. Again, reduction of uptake was less for the three other AAs. Pre-complexing of DDP with Cys for 16 h increased its uptake by 8- to 30-fold compared with native DDP, but markedly inhibited its toxicity. Thus, pre-complexing of DDP with Cys could not explain the reduced uptake of DDP, but could partly account for the reduction in cytotoxicity. Double-reciprocal Lineweaver-Burk plots of DDP concentration-versus-uptake rates at a constant concentration of Cys suggested that: Cys competitively inhibited DDP uptake in S-1 and DCT cells, and in a more complex fashion in S-3 cells. Conclusions: We conclude that Cys, Met, N-acetylcysteine, and DL-homocysteine differentially inhibit DDP toxicity and uptake in cultured S-1, S-3, and DCT cells, and that the inhibition of uptake, as well as the complexation of DDP with Cys within the cell, may prevent toxicity. The structural element R-CH(NH2)-[CH2](1-2)-S-R, which is common to all four molecules, may play a crucial role in blocking the transport of DDP, and could have future clinical applications. C1 Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Hematol Oncol Sect, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Nephrol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Kroning, R (reprint author), Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Bldg 304,Room E2-218,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 19 TC 54 Z9 60 U1 1 U2 7 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0344-5704 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD JAN PY 2000 VL 45 IS 1 BP 43 EP 49 DI 10.1007/PL00006741 PG 7 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 269FJ UT WOS:000084465800007 PM 10647500 ER PT J AU Paulino, AC Latona, C AF Paulino, AC Latona, C TI Unresectable adenocarcinoma of the pancreas: Patterns of failure and treatment results SO CANCER INVESTIGATION LA English DT Article ID THERAPY; RADIATION; GEMCITABINE; CARCINOMA; CANCER AB We retrospectively reviewed the outcome of 36 consecutive patients seen in our department with nonmetastatic unresectable adenocarcinoma of the pancreas. There were 28 men and 8 women with a mean age of 63.7 years (range, 43-78 years). Radiation therapy (RT) was given to all patients. 5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m(2)/day) was given to 3 patients. The median survival for all patients was 10 months. Overall survival for all patients at 1 and 3 years was 47.2% and 19.1%, respectively. The pancreas, peritoneum, liver, and lungs were components of failure in 66.7%, 33.3%, 14.8%, and 14.8%, respectively. Local control was a major problem in patients treated for unreseceptable pancreatic cancer. The results of this study confirm the dismal prognosis of these patients. C1 Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Radiotherapy, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Radiotherapy, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. RP Paulino, AC (reprint author), Univ Iowa Hosp & Clin, 200 Hawkins Dr,Room W 189Z GH, Iowa City, IA 52242 USA. NR 16 TC 11 Z9 14 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 USA SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PY 2000 VL 18 IS 4 BP 309 EP 313 DI 10.3109/07357900009012173 PG 5 WC Oncology SC Oncology GA 305PK UT WOS:000086549300003 PM 10808366 ER PT J AU Bennett, CL Schwartz, DN Parada, JP Sipler, AM Chmiel, JS DeHovitz, JA Goetz, MB Weinstein, RA AF Bennett, CL Schwartz, DN Parada, JP Sipler, AM Chmiel, JS DeHovitz, JA Goetz, MB Weinstein, RA TI Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia SO CHEST LA English DT Article; Proceedings Paper CT 2nd Annual Midwestern Health Services Research Meeting CY MAR, 1998 CL CHICAGO, IL DE nosocomial outbreak of tuberculosis; patterns of care; quality of care ID RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; HIGH-RISK; OUTBREAK; EPIDEMIOLOGY; TRANSMISSION; INFECTION AB Background: Despite awareness of HIV-related tuberculosis (TB), nosocomial outbreaks of multidrug-resistant TB among HIV-infected individuals occur. Objective: To investigate delays in TB isolation and suspicion among HIV-infected inpatients discharged with TB or Pneumocystis carinii pneumonia (PCP), common HIV-related pneumonias. Design: Cohort study during 1995 to 1997, Setting: For PCP, 1,227 persons who received care at 44 New York City, Chicago, and Los Angeles hospitals, For TB, 89 patients who reteived care at five Chicago hospitals, Measurements: Two-day rates of TB isolation/suspicion, Results: For HIV-related PCP, Los Angeles hospitals had the lon est 2-day rates of isolation/suspicion of TB (24.3%/26.6% vs 65.5%/66.4% for New York City and 62.8%/58.3% for Chicago, respectively; p < 0.001 for overall comparison by chi(2) test for each outcome measure). within cities, hospital isolation/suspicion rates varied from < 35 to > 70% (p < 0.001 for interhospital comparisons in each city). The Chicago hospital with a nosocomial outbreak of multidrug-resistant TB from 1991 to 1995 isolated 60% of HIV-infected individuals who were discharged with a diagnosis of HIV-related TB and 52% discharged with HIV-related PCP, rates that were among the lowest of all Chicago hospitals in both data sets. Conclusion: Low 2-day races of TB isolation/suspicion among HIV-related PCP patients were frequent. One Chicago hospital with low 2-day rates of TB isolation/suspicion,among persons with. HIV-related PCP also had low 2-day rates of isolation/suspicion among confirmed TB patients. That hospital experienced a nosocomial multidrug-resistant TB outbreak. Educational efforts on the benefits of early TB suspicion/isolation among HIV-infected pneumonia patients are needed. C1 Chicago VA Hlth Care Syst, Lakeside Div, Chicago, IL USA. Chicago VA Hlth Care Syst, Westside Div, Chicago, IL USA. Loyola Univ, Maywood, IL 60153 USA. Loyola Univ, Med Ctr, Maywood, IL 60153 USA. Northwestern Univ, Sch Med, Dept Prevent Med, Evanston, IL USA. Northwestern Univ, Sch Med, Dept Internal Med, Evanston, IL USA. Cook Cty Hosp, Chicago, IL 60612 USA. W Los Angeles VA, Los Angeles, CA USA. SUNY Brooklyn, Allied Program, Brooklyn, NY USA. RP Bennett, CL (reprint author), Lakeside VA, 400 E Ontariao St,Suite 205, Chicago, IL 60611 USA. EM cbenne@nwu.edu RI Bennett, Charles/C-2050-2008 OI Goetz, Matthew/0000-0003-4542-992X FU NIDA NIH HHS [5RO1DA10628-02] NR 21 TC 17 Z9 18 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2000 VL 117 IS 1 BP 110 EP 116 DI 10.1378/chest.117.1.110 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 274PN UT WOS:000084774400022 PM 10631207 ER PT J AU Hoo, GWS Hakimian, N Santiago, SM AF Hoo, GWS Hakimian, N Santiago, SM TI Hypercapnic respiratory failure in COPD patients - Response to therapy SO CHEST LA English DT Article DE COPD; hypercapnia; mechanical ventilation; respiratory failure ID OBSTRUCTIVE PULMONARY-DISEASE; POSITIVE-PRESSURE VENTILATION; ACUTE EXACERBATIONS; MECHANICAL VENTILATION; LUNG-DISEASE; SURVIVAL; REAPPRAISAL; MANAGEMENT; PROGNOSIS; MORTALITY AB Introduction: The clinical course of patients with acute exacerbations of underlying COPD presenting with hypercapnic respirator failure was reviewed. : of 138 episodes of hyercapnic respiratory failure Methods: This was a retrospective review (Paco(2) greater than or equal to 50 mm Hg and pH less than or equal to 7,35), Patients were admitted to the West Los Angeles VAMC Medical Intensive Care Unit between 1990 and 1994, Results: Of the 138 hypercapnic episodes, 74 (54%) required intubation, Comparison was made with the 64 cases in which patients responded to medical therapy, Patients requiring intubation had a greater severity of illness, with a higher APACHE II (Acute Physiology and Chronic Health Evaluation II) score (18 +/- 5 vs 16 +/- 4; p < 0,01), higher W'BC, higher serum BUN, and greater acidosis (pH, 7.26 +/- 0.07 vs 7.28 +/- 0.06; p = 0,08), Those with the most severe acidosis (pH < 7,20) had the highest intubation rate (70%) and shortest time to intubation (2 +/- 2 h), and they required the longest period of time to respond to medical therapy (69 +/- 60 h). With an initial pH of < 7.25, there was a consistently higher intubation rate. Conversely, those with an initial pH of 7.31 to 7.35 were less likely to be intubated (45%), had a longer time to intubation (13 +/- 18 h), and had a more rapid response to medical therapy (30 +/- 18 h). Of those patients requiring intubation, most (78%) were intubated within 8 h of presentation, and the vast majority (93%) by 24 h. Of those patients responding to medical therapy, half(52%) recovered within 24 h and the vast majority (92%) recovered within 72 h, Conclusions: This study provides a better characterization of the response to therapy of COPD patients with hypercapnic respiratory failure. This should be useful in limiting or omitting medical therapy in high-risk patients, thereby avoiding delays in intubation as well as providing a framework for continued therapy in those more likely to improve. C1 W Los Angeles Vet Affairs Med Ctr, Pulm & Crit Care Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Hoo, GWS (reprint author), W Los Angeles Vet Affairs Med Ctr, Pulm & Crit Care Sect, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 25 TC 28 Z9 30 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2000 VL 117 IS 1 BP 169 EP 177 DI 10.1378/chest.117.1.169 PG 13 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 274PN UT WOS:000084774400031 PM 10631216 ER PT J AU Caruana-Montaldo, B Gleeson, K Zwillich, CW AF Caruana-Montaldo, B Gleeson, K Zwillich, CW TI The control of breathing in clinical practice SO CHEST LA English DT Review DE carotid body; chemoreceptors; control of ventilation; pulmonary receptors ID OBSTRUCTIVE PULMONARY-DISEASE; SLEEP-APNEA SYNDROME; POSITIVE AIRWAY PRESSURE; CONGESTIVE-HEART-FAILURE; NOCTURNAL NASAL VENTILATION; INSPIRATORY MUSCLE FATIGUE; CHEYNE-STOKES RESPIRATION; LUNG IRRITANT RECEPTORS; CAROTID-BODY RESECTION; EYE-MOVEMENT SLEEP AB The control of breathing results from a complex interaction involving the respiratory centers, which feed signals to a central control mechanism that, in turn, provides output to the effector muscles, In this review, we describe the individual elements of this system, and what is known about their function in man. We outline clinically relevant aspects of the integration of human ventilatory control system, and describe altered function in response to special circumstances, disorders, and medications. We emphasize the clinical relevance of this topic by employing case presentations of active patients from our practice. C1 Penn State Geisinger Hlth Syst, Pulm Allergy & Crit Care Sect, Hershey, PA 17036 USA. St Vincents Hosp, St Verona, Malta. Denver VA Med Ctr, Denver, CO USA. RP Gleeson, K (reprint author), Penn State Geisinger Hlth Syst, Pulm Allergy & Crit Care Sect, 500 Univ Dr, Hershey, PA 17036 USA. NR 126 TC 54 Z9 56 U1 0 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2000 VL 117 IS 1 BP 205 EP 225 DI 10.1378/chest.117.1.205 PG 29 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 274PN UT WOS:000084774400036 PM 10631221 ER PT J AU Schutzer, WE Watts, VJ Chapman, J Cumbay, MG Neve, KA Neve, RL Mader, SL AF Schutzer, WE Watts, VJ Chapman, J Cumbay, MG Neve, KA Neve, RL Mader, SL TI Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY LA English DT Article DE cAMP; gene transfer; G-protein; Herpes simplex virus; vascular tone; vasorelaxation ID VASCULAR SMOOTH-MUSCLE; RAT AORTA; PROTEIN; AGE; OVEREXPRESSION; EXPRESSION; DESENSITIZATION; MECHANISMS; RELAXATION; RESPONSES AB 1. Decline in beta-adrenoceptor (beta-AR)-mediated function occurs with increasing age, as well as in multiple disease conditions. The mechanisms responsible for this decline include alterations in beta-AR itself, beta-AR coupling proteins, such as G-proteins, or other beta-AR-linked proteins, such as G-protein receptor kinases and/or phosphatases. 2. The present study examines the physiological effects of n vitro transfer of constitutively activated G alpha s (G alpha s-U227L) to both cultured vascular smooth muscle cells (VSMC) and whole aortic tissue of 6-month-old (adult) animals via a replication-deficient Herpes simplex virus (HSV) vector. These studies were conducted to provide a model for future examination of the role of G alpha s in the age-related decline in beta-AR-mediated vasorelaxation. 3. Gene transfer was confirmed by western blotting for specific proteins. Aortic tissue infected with HSV-G alpha s-Q227L had reduced phenylephrine-induced contraction and enhanced isoproterenol-stimulated vasorelaxation, Infection of cultured VSMC with HSV-G alpha s-Q227L increased both basal- and isoproterenol-stimulated cAMP accumulation, whereas forskolin-stimulated cAMP production was unchanged. 4. These results implicate G alpha s as a target for further investigation in age-related changes in vascular reactivity and support the use of viral-mediated gene transfer as an effective tool to study adrenergic signal transduction and physiology in vascular tissue. C1 Portland VA Med Ctr, Res Serv, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Sch Med, Portland, OR 97201 USA. Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA. Harvard Univ, Sch Med, Dept Genet, Belmont, MA 02178 USA. RP Mader, SL (reprint author), Portland VA Med Ctr, Res Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. RI Watts, Val/A-4633-2012 OI Neve, Kim/0000-0003-0109-7345 FU NIDA NIH HHS [T32 DA07262] NR 24 TC 14 Z9 14 U1 1 U2 1 PU BLACKWELL SCIENCE ASIA PI CARLTON PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA SN 0305-1870 J9 CLIN EXP PHARMACOL P JI Clin. Exp. Pharmacol. Physiol. PD JAN-FEB PY 2000 VL 27 IS 1-2 BP 9 EP 13 DI 10.1046/j.1440-1681.2000.03210.x PG 5 WC Pharmacology & Pharmacy; Physiology SC Pharmacology & Pharmacy; Physiology GA 284WA UT WOS:000085354800002 PM 10696522 ER PT J AU Molano, ID Wloch, MK Alexander, AA Watanabe, H Gilkeson, GS AF Molano, ID Wloch, MK Alexander, AA Watanabe, H Gilkeson, GS TI Effect of a genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production by C57BL6 Fas(lpr) mice SO CLINICAL IMMUNOLOGY LA English DT Article DE terminal deoxynucleotidyl transferase; lpr; autoimmunity; autoantibodies; Ig sequence ID ANTI-DNA ANTIBODIES; HEAVY-CHAIN; AUTOIMMUNE ANTIBODIES; SOMATIC MUTATION; BACTERIAL-DNA; LPR MICE; REGION; SPECIFICITY; SEQUENCES; DIVERSITY AB Terminal deoxynucleotidyl transferase (TdT) adds nontemplate coded nucleotides (N additions) between the recombining ends of immunoglobulin and T cell receptor genes. These nucleotides add significant diversity to the Ig and TCR repertoires. Amino acids coded for by these nucleotides play a key role in the binding of self antigens by autoantibodies and autoreactive T cells. To determine the effect of a lack: of N additions on autoantibody production, we bred the TdT knockout genotype onto the autoimmune C57BL/6-Fas(lpr) background. TdT-deficient mice had significantly lower sera anti-DNA and rheumatoid factor activity than their TdT-producing littermates. C57BL/6Fas(lpr) TdT-deficient mice had shorter VH CDR3 regions and fewer VH CDR3 arginines [0.6% versus 4.7%] than their TdT-producing littermates. These data indicate that the absence of TdT limited the production of anti-DNA antibodies and rheumatoid factors in C57BL/6-Fas(lpr) mice, likely due to constraints on Ig diversity secondary to the lack of TdT-derived N additions. (C) 2000 Academic Press. C1 Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Duke Univ, Med Ctr, Durham, NC 27710 USA. RP Molano, ID (reprint author), Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC 29425 USA. NR 30 TC 10 Z9 10 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD JAN PY 2000 VL 94 IS 1 BP 24 EP 32 DI 10.1006/clim.1999.4797 PG 9 WC Immunology SC Immunology GA 273ZJ UT WOS:000084739000004 PM 10607487 ER PT J AU Gordon, LK Eggena, M Targan, SR Braun, J AF Gordon, LK Eggena, M Targan, SR Braun, J TI Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies SO CLINICAL IMMUNOLOGY LA English DT Article DE inflammatory bowel disease; pANCA; mast cell; autoimmunity ID INFLAMMATORY BOWEL-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; HLA CLASS-II; ULCERATIVE-COLITIS; CROHNS-DISEASE; NEUTROPHIL AUTOANTIBODIES; SUSCEPTIBILITY LOCUS; INCREASING PROTEIN; ANTIGEN RETRIEVAL; ANCA AB pANCA is a marker antibody expressed in most patients with ulcerative colitis, and its cognate antigen is potentially an immunologic target in this disease; This study evaluates whether pANCA detects an autoantigen that is expressed in the colonic mucosa. Immunohistochemistry of colon specimens with human pANCA monoclonal antibodies (Fab 5-2 and 5-3) revealed a minor population of immunoreactive mucosal cells bearing a cytoplasmic vesicle antigen. By distribution, morphology, and tryptase expression, these were identified as mast cells. Immunofluorescent analysis revealed similar immunoreactivity of mouse mast cell lines and human KU812. western analysis or mouse mast cell lines revealed immunoreactive proteins, and these were distinct from previously proposed pANCA antigens (histone H1, HMG 1 and 2, and neutrophil vesicle antigens). Cognate antigen for Fab 5-2 and 5-3 was also expressed in other tissue mast cells, cerebellar neurons, and pancreatic islet cells. These findings identify a novel cytoplasmic autoantigen(s) associated with UC by its presence in colonic mucosa and recognition by a disease-associated marker antibody. (C) 2000 Academic Press. C1 Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA 90099 USA. Cedars Sinai Med Ctr, Inflammatory Bowel Dis Res Ctr, Los Angeles, CA 90048 USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA. OI Braun, Jonathan/0000-0003-1646-2974 FU NCI NIH HHS [P01-CA12800]; NEI NIH HHS [K08-EY00360]; NIDDK NIH HHS [P01-DK46763] NR 57 TC 14 Z9 14 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD JAN PY 2000 VL 94 IS 1 BP 42 EP 50 DI 10.1006/clim.1999.4805 PG 9 WC Immunology SC Immunology GA 273ZJ UT WOS:000084739000006 PM 10607489 ER PT J AU Graybill, JR Sobel, J Saag, M van der Horst, C Powderly, W Cloud, G Riser, L Hamill, R Dismukes, W AF Graybill, JR Sobel, J Saag, M van der Horst, C Powderly, W Cloud, G Riser, L Hamill, R Dismukes, W CA NIAID Mycoses Study Grp AIDS Cooperative Treatment Grp TI Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TUBERCULOUS MENINGITIS; AMPHOTERICIN-B; CEREBROSPINAL-FLUID; ITRACONAZOLE; FLUCONAZOLE; THERAPY; TISSUE AB This study was undertaken to characterize the laboratory and clinical course of patients with AIDS and cryptococcal meningitis who had normal or elevated cerebrospinal fluid (CSF) pressure. Data were obtained retrospectively from a randomized multicenter quasifactorial phase III study comparing amphotericin B with or without flucytosine in primary treatment of cryptococcal meningitis. CSF pressure was measured before treatment and at 2 weeks. Repeated lumbar punctures were done to drain CSF and to reduce pressure, Patients with the highest baseline opening pressures (greater than or equal to 250 mm H2O) were distinguished by higher titers of cryptococcal capsular polysaccharide antigen in CSF; more frequently positive India ink smears of CSF; and more frequent headache, meningismus, papilledema, hearing loss, and pathological reflexes. After receiving antifungal therapy, those patients whose CSF pressure was reduced by >10 mm or did not change had more frequent clinical response at 2 weeks than did those whose pressure increased >10 mm (P <.001), Patients with pretreatment opening pressure greater than or equal to 250 mm H2O had increased short-term survival compared with those with higher pressure, We recommend that opening pressures greater than or equal to 250 mm H2O be treated with large-volume CSF drainage. C1 Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Infect Dis Sect 111F, San Antonio, TX 78284 USA. Houston Vet Adm Hosp, Houston, TX USA. Wayne State Univ, Detroit, MI USA. Univ Alabama Birmingham, Birmingham, AL USA. Univ N Carolina, Chapel Hill, NC USA. Washington Univ, St Louis, MO USA. NIAID, NIH, Bethesda, MD 20892 USA. RP Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Infect Dis Sect 111F, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM graybill@uthscsa.edu FU NIAID NIH HHS [AI-15082, AI-65296] NR 32 TC 204 Z9 221 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN PY 2000 VL 30 IS 1 BP 47 EP 54 DI 10.1086/313603 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 278TJ UT WOS:000085004800011 PM 10619732 ER PT J AU Craig, WA AF Craig, WA TI Pharmacokinetics of antibiotics with special emphasis on cephalosporins SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article; Proceedings Paper CT Cephalosporins - The Golden Jubilee, 1949-1998 CY DEC 11-13, 1998 CL CAGLIARI, ITALY ID PHARMACODYNAMICS; PENETRATION; FLUID; MODEL C1 William S Middleton Mem Vet Hosp, Dept Med, Madison, WI 53711 USA. Univ Wisconsin, Dept Med, Madison, WI USA. RP Craig, WA (reprint author), William S Middleton Mem Vet Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53711 USA. NR 18 TC 8 Z9 8 U1 0 U2 0 PU BLACKWELL SCIENCE LTD PI OXFORD PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PY 2000 VL 6 SU 3 BP 46 EP 49 PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 399LG UT WOS:000166812100011 PM 11449649 ER PT J AU Kahn, JG Becker, BJ Maclsaa, L Amory, JK Neuhaus, J Olkin, I Creinin, MD AF Kahn, JG Becker, BJ Maclsaa, L Amory, JK Neuhaus, J Olkin, I Creinin, MD TI The efficacy of medical abortion: A meta-analysis SO CONTRACEPTION LA English DT Review DE abortion; medical abortion; meta-analysis; mifepristone; methotrexate ID EARLY-PREGNANCY TERMINATION; SURGICAL VACUUM ASPIRATION; VAGINAL MISOPROSTOL; PROSTAGLANDIN ANALOG; MIFEPRISTONE RU-486; ORAL METHOTREXATE; MULTICENTER TRIAL; CLINICAL-TRIAL; UNITED-STATES; RU486 AB Multiple clinical studies demonstrate the efficacy of medical abortion with mifepristone or methotrexate followed by a prostaglandin analogue. However, assessing predictors of success, including regimen, is difficult because of regimen variability and a lack of direct comparisons. This meta-analysis estimates rates of primary clinical outcomes of medical abortion (successful abortion, incomplete abortion, and viable pregnancy) and compares them by regimen and gestational age. We identified 54 studies published from 1991 to 1998 using mifepristone with misoprostol (18), mifepristone with other prostaglandin analogues (23), and methotrexate with misoprostol (13). Data abstracted from studies included regimen details and clinical outcomes by gestational age. We found that efficacy decreases with increasing gestational age (p <0.001), and differences by regimen are not statistically significant except at gestational age greater than or equal to 57 days. For gestations less than or equal to 49 days, mean rates of complete abortion were 94-96%, incomplete abortion 2-4%, and ongoing (viable) pregnancy 1-3%. For gestations of 50-56 days, the mean rate of complete abortion was 91% (same for all regimens), incomplete abortion 5-8%, and ongoing pregnancy 3-5%. For greater than or equal to 57 days, success was lower for mifepristone/misoprostol (85%, 95% confidence interval 78-91%) than for mifepristone/other prostaglandin analogues 95% (CI 91-98%, p = 0.006). For mifepristone/misoprostol, using greater than or equal to 2 prostaglandin analogue doses seems to be better than a single dose for certain outcomes acid gestational ages. We conclude that both mifepristone and methotrexate, when administered with misoprostol, have high levels of success at less than or equal to 49 days gestation but may have lower efficacy at longer gestation. CONTRACEPTION 2000;61:29-40 (C) 2000 Elsevier Science Inc. All rights reserved. C1 Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Michigan State Univ, Coll Educ, Program Measurement & Quantitat Methods, E Lansing, MI 48824 USA. NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA. Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Stanford Univ, Dept Stat, Stanford, CA 94305 USA. Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. RP Kahn, JG (reprint author), Univ Calif San Francisco, Inst Hlth Policy Studies, Box 0936, San Francisco, CA 94143 USA. OI Becker, Betsy Jane/0000-0003-3438-560X NR 71 TC 60 Z9 67 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD JAN PY 2000 VL 61 IS 1 BP 29 EP 40 DI 10.1016/S0010-7824(99)00115-8 PG 12 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 302ND UT WOS:000086370900005 PM 10745067 ER PT J AU Chirgwin, JM Guise, TA AF Chirgwin, JM Guise, TA TI Molecular mechanisms of tumor-bone interactions in osteolytic metastases SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION LA English DT Review DE PTHrP; TGF-beta; osteolysis; bone metastasis; breast cancer ID HORMONE-RELATED PROTEIN; HUMAN BREAST-CANCER; PROSTATE-SPECIFIC ANTIGEN; GROWTH-FACTOR-BETA; CELLS IN-VIVO; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; MESSENGER-RIBONUCLEIC-ACID; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR RECEPTOR; N-TERMINAL KINASE AB In patients with advanced disease, several cancer types frequently metastasize to the skeleton, where they cause bone destruction. Osteolytic metastases are incurable and cause pain, hypercalcemia, fracture, and nerve compression syndromes. It was proposed over a century ago that certain cancers, such as that of the breast, preferentially metastasize to the favorable microenvironment provided by bone. Bone matrix is a rich store of immobilized growth factors that are released during bone resorption. Histological analysis of osteolytic bone metastases indicates that the bone destruction is mediated by the osteoclast rather than directly by the tumor cells. These observations suggest a vicious cycle driving the formation of osteolytic metastases: tumor cells secrete factors stimulating osteoclasts through adjacent bone marrow stromal cells; osteoclastic resorption in turn releases growth factors from the bone matrix; finally, locally released growth factors activate the tumor cells. This vicious cycle model has now been confirmed at the molecular level. In particular, transforming growth factor beta (TGF beta) is abundant in bone matrix and released as a consequence of osteoclastic bone resorption. Bone-derived TGF beta plays an integral role in promoting the development and progression of osteolytic bone metastases by inducing tumor production of parathyroid hormone-related protein (PTHrP), a known stimulator of osteoclastic bone resorption. In breast cancer cells TGF beta appears to stimulate PTHrP secretion by a posttranscriptional mechanism through both Smad and p38 mitogen activated protein (MAP) kinase signaling pathways. Osteolytic metastases can be suppressed in vivo by inhibition of bone resorption, blockade of TGF beta signaling in tumor cells, and by neutralization of PTHrP. Other factors released from bone matrix may also act on tumor cells in bone. which in turn may produce other factors that stimulate bone resorption, following the vicious cycle paradigm established for TGF beta and PTHrP. An understanding at the molecular level of the mechanisms of osteolytic metastasis will result in more effective therapies for this devastating complication of cancer. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol, San Antonio, TX 78229 USA. Vet Adm Med Ctr, Res Serv, San Antonio, TX 78229 USA. RP Chirgwin, JM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol, Mail Code 7877,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. FU NCI NIH HHS [CA40035, CA69158] NR 139 TC 144 Z9 152 U1 1 U2 3 PU BEGELL HOUSE INC PI NEW YORK PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892 USA SN 1045-4403 J9 CRIT REV EUKAR GENE JI Crit. Rev. Eukaryot. Gene Expr. PY 2000 VL 10 IS 2 BP 159 EP 178 PG 20 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 372HV UT WOS:000165229000005 PM 11186331 ER PT J AU Marder, SR AF Marder, SR TI Newer antipsychotics SO CURRENT OPINION IN PSYCHIATRY LA English DT Article ID TREATMENT-RESISTANT SCHIZOPHRENIA; VS. HALOPERIDOL; CLOZAPINE; OLANZAPINE AB Newer antipsychotics have been widely used in schizophrenia for the past 5 years. During this period, controlled clinical trials have improved our understanding of the effectiveness of these agents in different populations of patients with schizophrenia. Other studies have enhanced our understanding of how improvement on these agents is associated with the occupancy of central nervous system receptors, The best understood of the newer agents is clozapine, although clinically important information has become available for risperidone, olanzapine, quetiapine and amisulpride. Curr Opin Psychiatry 13:11-14. (C) 2000 Lippincott Williams & Wilkins. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, W Los Angeles Hlth Ctr, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Marder, SR (reprint author), W Los Angeles Vet Affairs Hlth Care Ctr, MIRECC-210A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 17 TC 7 Z9 7 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD JAN PY 2000 VL 13 IS 1 BP 11 EP 14 DI 10.1097/00001504-200001000-00003 PG 4 WC Psychiatry SC Psychiatry GA 273RQ UT WOS:000084721500003 ER PT J AU Wirshing, DA Erhart, SM Pierre, JM Boyd, JA AF Wirshing, DA Erhart, SM Pierre, JM Boyd, JA TI Nonextrapyramidal side effects of novel antipsychotics SO CURRENT OPINION IN PSYCHIATRY LA English DT Article ID NEUROLEPTIC MALIGNANT SYNDROME; DIABETIC-KETOACIDOSIS; CLOZAPINE TREATMENT; RISPERIDONE; OLANZAPINE; MEDICATIONS; FERTILITY; PREGNANCY; SEROTONIN; GLUCOSE AB The novel antipsychotic drugs offer significant advantages over conventional antipsychotic drugs because of their favorable extrapyramidal side-effect profiles, These medications do have some side effects that are clinically significant to our patients with psychotic disorders, however. We summarized the literature from July 1998 through September 1999 on nonextrapyramidal side effects of these medications, focusing on cardiac effects, weight gain, diabetes and impaired glucose tolerance, prolactin elevation, sexual side effects and neuroleptic malignant syndrome, Curr Opin Psychiatry 13:45-50. (C) 2000 Lippincott Williams & Wilkins. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Dept Vet Affairs, Vet Integrated Serv Network 22, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. RP Wirshing, DA (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, 11301 Wilshire Blvd,Bldg 210,Room 15 B-151H, Los Angeles, CA 90073 USA. NR 49 TC 14 Z9 15 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD JAN PY 2000 VL 13 IS 1 BP 45 EP 50 DI 10.1097/00001504-200001000-00008 PG 6 WC Psychiatry SC Psychiatry GA 273RQ UT WOS:000084721500008 ER PT J AU Haile, DJ AF Haile, DJ TI Assignment of Slc11a3 to mouse chromosome 1 band 1B and SLC11A3 to human chromosome 2q32 by in situ hybridization SO CYTOGENETICS AND CELL GENETICS LA English DT Article; Proceedings Paper CT 4th International Chromosome 6 Workshop CY JUN 10-12, 1999 CL CAMBRIDGE, ENGLAND ID INSITU HYBRIDIZATION C1 Univ Texas, Hlth Sci Ctr, Audie Murphy Vet Adm Hosp, San Antonio, TX USA. RP Haile, DJ (reprint author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 2 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0171 J9 CYTOGENET CELL GENET JI Cytogenet. Cell Genet. PY 2000 VL 88 IS 3-4 BP 328 EP 329 DI 10.1159/000015522 PG 2 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 319PV UT WOS:000087351100043 PM 10828623 ER PT J AU Nobler, MS Teneback, CC Nahas, Z Bohning, DE Shastri, A Kozel, FA George, MS AF Nobler, MS Teneback, CC Nahas, Z Bohning, DE Shastri, A Kozel, FA George, MS TI Structural and functional neuroimaging of electroconvulsive therapy and transcranial magnetic stimulation SO DEPRESSION AND ANXIETY LA English DT Article DE cerebral blood flow; cerebral metabolic rate; PET; SPECT ID CEREBRAL-BLOOD-FLOW; ELECTRICALLY-INDUCED SEIZURES; POSITRON-EMISSION-TOMOGRAPHY; BRAIN GLUCOSE-METABOLISM; MOTOR CORTEX; ANTIDEPRESSANT RESPONSE; COMPUTED-TOMOGRAPHY; EPILEPTIC SEIZURES; DEPRESSED-PATIENTS; TMS AB Neuroimaging has long been utilized to provide a measure of the effects of electroconvulsive therapy (ECT) on brain structure and function as well as to better understand its mechanisms of action. In a similar-fashion, functional neuroimaging may provide the means to elucidate both the underlying neurobiological effects and therapeutic potential of transcranial magnetic stimulation (TMS). This article will review findings of neuroimaging studies of both TMS and ECT; concentrating on how such studies may help guide treatment. (C) 2000 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. New York State Psychiat Inst & Hosp, Dept Biol Psychiat, New York, NY 10032 USA. Med Univ S Carolina, Funct Neuroimaging Res Div, Charleston, SC 29425 USA. Ralph H Johnson Vet Hosp, Charleston, SC USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Radiol, Room D297,171 Ashley Ave, Charleston, SC 29425 USA. EM georgem@musc.edu RI Kozel, Frank/I-5366-2012 FU NIMH NIH HHS [K08 MH01244] NR 69 TC 18 Z9 20 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PY 2000 VL 12 IS 3 BP 144 EP 156 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 379MA UT WOS:000165644800006 PM 11126189 ER PT J AU Schatz, J Craft, S Koby, M DeBaun, MR AF Schatz, J Craft, S Koby, M DeBaun, MR TI A lesion analysis of visual orienting performance in children with cerebral vascular injury SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID EARLY INFANCY; ATTENTION; DEFICITS; STROKE AB Anterior brain insults during development have been shown to result in visual orienting deficits; however, the type of orienting deficit has varied across studies. Performance on an orienting task was examined in relation to the location and volume of injury on magnetic resonance exams in 15 children with cerebral infarction and 32 control children. Contralateral lesions including the parietal lobe were associated with larger validity effects, suggesting difficulties disengaging attention. A similar trend was found for the middle-frontal gyrus. Basal ganglia injury contralateral to a given hemifield was associated with less facilitation of attention. Lesion volume in each hemisphere did not show a significant relation with contralateral validity effects. The data suggest that variability in the type of visual orienting deficits shown in prior studies of children with anterior brain insults may be related in part to the specific location of lesions within the frontal lobe. C1 Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Natl Inst Hlth, Bethesda, MD 20892 USA. Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. RP Schatz, J (reprint author), Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA. NR 23 TC 8 Z9 8 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 2000 VL 17 IS 1 BP 49 EP 61 DI 10.1207/S15326942DN1701_03 PG 13 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA 337CN UT WOS:000088340000003 PM 10916574 ER PT J AU Hickman, SE Howieson, DB Dame, A Sexton, G Kaye, J AF Hickman, SE Howieson, DB Dame, A Sexton, G Kaye, J TI Longitudinal analysis of the effects of the aging process on neuropsychological test performance in the healthy young-old and oldest-old SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID ALZHEIMERS-DISEASE; INTELLECTUAL-DEVELOPMENT; COGNITIVE PERFORMANCE; SENILE DEMENTIA; LATER LIFE; MEMORY; ADULTS; AGE; POPULATION; IMPAIRMENT AB A sample of 33 young-old (ages 65 to 74) and 20 oldest-old (ages 84 to 93) healthy elderly without dementia were assessed with neuropsychological tests annually over a 4-year period to examine longitudinal changes in cognitive functioning. Significant age-group differences existed at baseline in participants' performances on tests of immediate memory and visuospatial skills. There were no age-group differences in the rate of change over the 4-year interval on any neuropsychological tests. Within each age-group, the amount of change over time was minimal for most tests though some practice effects were apparent, and on some tests mild decline was observed. Results suggest that healthy old adults, including the oldest-old, do not experience measurable declines in cognitive functioning over a 4-year period. C1 Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Publ Hlth, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Prevent Med, Portland, OR 97201 USA. RP Howieson, DB (reprint author), Oregon Hlth Sci Univ, Dept Neurol, CR131,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. OI Kaye, Jeffrey/0000-0002-9971-3478 FU NIA NIH HHS [AGO8017] NR 49 TC 32 Z9 33 U1 0 U2 1 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 2000 VL 17 IS 3 BP 323 EP 337 DI 10.1207/S15326942DN1703_3 PG 15 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA 362AY UT WOS:000089757500003 PM 11056847 ER PT J AU Burgess, DS Hastings, RW Summers, KK Hardin, TC Rinaldi, MG AF Burgess, DS Hastings, RW Summers, KK Hardin, TC Rinaldi, MG TI Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article; Proceedings Paper CT Focus on Fungal Infection 7 CY MAR 13-15, 1997 CL SAN ANTONIO, TEXAS ID FUNGAL INFECTION; RISK-FACTORS; EPIDEMIOLOGY AB The objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans. Susceptibilities were determined according to the NCCLS guidelines (M27). Time-kill studies were performed using antifungal concentrations of 0.25-32 X MIC. Samples were withdrawn at predetermined timepoints, then plated using a spiral plater. Colony counts were determined after incubation at 35 degrees C for 24 h. The AUKC(0-48) was plotted against the concentration/MIC ratio. Candida isolates (95-2672, 96-15, and 95-2542) were classified as susceptible, susceptible-dose dependent, and resistant to fluconazole and itraconazole (MIC = 0.25 and 0.03 mu g/mL, 32 and 0.5 mu g/mL, 64 and 1 mu g/mL; respectively). All three isolates were susceptible to amphotericin B (MIC = 0.13 mu g/mL). Fluconazole inhibited the growth of the susceptible and S-DD isolates and was ineffective at all concentrations against the resistant isolate. Itraconazole, on the other hand, inhibited growth of the susceptible isolate, but was ineffective for the S-DD and resistant isolates. Maximal effectiveness was noted at the concentration 8 X MIC and 2 X MIC for fluconazole and itraconazole, respectively. Amphotericin B demonstrated concentration-dependent antifungal activity. The times necessary for the colony counts to fall below the limit of quantification were inversely related to increasing concentrations of amphotericin B. The maximal effect for amphotericin B was recorded at 2 X MIG. In summary, the triazoles inhibit growth of susceptible C. albicans; however, careful consideration should be given to the MIC for S-DD isolates because itraconazole may not be active if the MIC is reported in the higher susceptible-dose dependency range. In reference to amphotericin B, optimal activity may be achieved by maximizing the peak drug concentration/MIC ratio. (C) 2000 Elsevier Science Inc. All rights reserved. C1 Univ Texas, Coll Pharm, Austin, TX 78712 USA. Univ Texas, Hlth Sci Ctr, Dept Pharm, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Burgess, DS (reprint author), Univ Texas, Coll Pharm, Austin, TX 78712 USA. NR 13 TC 32 Z9 37 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JAN PY 2000 VL 36 IS 1 BP 13 EP 18 DI 10.1016/S0732-8893(99)00097-8 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 286QJ UT WOS:000085456400003 PM 10744363 ER PT J AU Anand, BS Velez, M AF Anand, BS Velez, M TI Influence of chronic alcohol abuse on hepatitis C virus replication SO DIGESTIVE DISEASES LA English DT Article DE hepatitis C; alcohol; viremia; HCV-RNA ID LIVER-DISEASE; RNA LEVELS; INFECTION; TRANSFUSION; ANTIBODY AB Background: Patients with alcoholic liver disease have a high prevalence of hepatitis C virus (HCV) infection, Several workers have shown that HCV-infected alcoholics have more severe biochemical and histological evidence of liver disease than anti-HCV-negative patients, One possible mechanism for the increased liver damage is that alcohol may have a stimulatory effect on HCV replication. The present study was carried out to examine this issue in detail. Methods: Sixty-eight HCV-infected patients, comprising of 50 chronic alcoholics, consuming 80 g or more of alcohol daily for at least 5 years, and 18 completely abstinent subjects were included in the study. Quantitative HCV-RNA was performed by the branched chain DNA (bDNA) technique. Results: There was no significant difference in the mean serum HCV titers in chronic alcoholics compared to nonalcoholic subjects. Linear regression analysis showed no correlation between the daily ethanol consumption and HCV titers. Seven of the chronic alcoholics, 4 of whom were continuing to drink and 3 who had become abstinent, were retested after 6 months. There was no definite trend in the viral titers, either in abstinent individuals or in those who continued to drink. Conclusions:These findings suggest that chronic alcohol abuse does not influence the HCV load in the serum. Therefore, the observation that alcoholics with HCV infection have more severe liver damage requires some other explanation than increased HCV viral titers. Copyright (C) 2000 S. Karger AG, Basel. C1 VA Med Ctr, Digest Dis Sect 111D, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Anand, BS (reprint author), VA Med Ctr, Digest Dis Sect 111D, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 27 TC 21 Z9 21 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 J9 DIGEST DIS JI Dig. Dis. PY 2000 VL 18 IS 3 BP 168 EP 171 DI 10.1159/000051390 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 412MM UT WOS:000167559000007 PM 11279335 ER PT J AU Dore, MP Leandro, G Realdi, G Sepulveda, AR Graham, DY AF Dore, MP Leandro, G Realdi, G Sepulveda, AR Graham, DY TI Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy - A meta-analytical approach SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE meta-analysis; metronidazole; clarithromycin; resistance; Helicobacter pylori; therapy ID LANSOPRAZOLE-QUADRUPLE THERAPY; COLLOIDAL BISMUTH SUBCITRATE; PEPTIC-ULCER DISEASE; TRIPLE THERAPY; DUODENAL-ULCER; ERADICATION THERAPY; COMBINATION THERAPY; CLINICAL RELEVANCE; DOUBLE-BLIND; INFECTION AB Our purpose was to define the effect of pretreatment Helicobacter pylori resistance to metronidazole or to clarithromycin on the success of antimicrobial therapy. We used 75 key words to perform a literature search in MEDLINE as well as manual searches to identify clinical treatment trials that provided results in relation to H, pylori susceptibility to metronidazole and clarithromycin or both during the period 1984-1997 (abstracts were not included). Meta-analysis was done with both fixed- and random-effect models; results were shown using Galbraith's radial plots. We identified 49 papers with 65 arms for metronidazole (3594 patients, 2434 harboring H. pylori strains sensitive to metronidazole and 1160 harboring resistant strains). Metronidazole resistance reduced effectiveness by an average of 37.7% (95% CI = 29.6-45.7%). The variability in the risk difference for metronidazole was 122.0 to -90.6 and the chi-square value for heterogeneity was significant (P < 0.001). Susceptibility tests for clarithromycin were performed in 12 studies (501 patients, 468 harboring H. pylori strains sensitive to clarithromycin and 33 harboring resistant strains). Clarithromycin resistance reduced effectiveness by an average of 55% (95% CI = 33-78%). We found no common factors that allowed patients to be divided into subgroups with additional factors significantly associated with resistance. In conclusion, metronidazole or clarithromycin pretreatment resistant Pi. pylori are the main factors responsible for treatment failure with regimens using these compounds. If H. pylori antibiotic resistance continues to increase, pretherapy antibiotic sensitivity testing might become necessary in many regions. C1 Univ Sassari, Ist Clin Med, Dept Internal Med, I-07100 Sassari, Italy. VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. IRCCS S De Bellis, Bari, Italy. RP Dore, MP (reprint author), Univ Sassari, Ist Clin Med, Dept Internal Med, Viale San Pietro 8, I-07100 Sassari, Italy. NR 71 TC 145 Z9 152 U1 0 U2 2 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2000 VL 45 IS 1 BP 68 EP 76 DI 10.1023/A:1005457226341 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 286WG UT WOS:000085471400012 PM 10695616 ER PT J AU Graybill, JR AF Graybill, JR TI The role of murine models in the development of antifungal therapy for systemic mycoses SO DRUG RESISTANCE UPDATES LA English DT Review ID LIPOSOMAL AMPHOTERICIN-B; EXPERIMENTAL CRYPTOCOCCAL MENINGITIS; COLONY-STIMULATING FACTOR; EXPERIMENTAL DISSEMINATED CANDIDIASIS; EXPERIMENTAL PULMONARY ASPERGILLOSIS; TUMOR-NECROSIS-FACTOR; IN-VITRO ACTIVITY; OBOVOIDEUM RAMICHLORIDIUM-MACKENZIEI; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PERSISTENTLY NEUTROPENIC RABBITS AB Animal testing is crucial to the development of new antifungal compounds. This review describes the role that murine and other animal models have played in the development of three classes of antifungal agents: the polyenes, the triazoles and the echinocandins and the ways in which these models have been either the positive link in the path from in vitro studies to the patient, or have foreclosed later clinical evaluation. Efficacy studies in particular mycoses are discussed, as well as studies designed to determine whether combinations of antifungal drugs may have value over single agents. (C) 2000 Harcourt Publishers Ltd. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. RP Graybill, JR (reprint author), Audie Murphy Vet Adm Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. NR 234 TC 17 Z9 18 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1368-7646 J9 DRUG RESIST UPDATE JI Drug Resist. Update PY 2000 VL 3 IS 6 BP 364 EP 383 DI 10.1054/drup.2000.0171 PG 20 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 397ER UT WOS:000166680800006 ER PT J AU Fujikawa, DG Shinmei, SS Cai, BY AF Fujikawa, DG Shinmei, SS Cai, BY TI Seizure-induced neuronal necrosis: Implications for programmed cell death mechanisms SO EPILEPSIA LA English DT Article; Proceedings Paper CT 5th Workshop on the Neurobiology of Epilepsy (WONOEP V) CY SEP 08-10, 1999 CL CESKY KRUMLOV, CZECH REPUBLIC SP Hoechst Marion Roussell, Parke Davis, Div Warner Lambert Co, Abbott Labs, Danippon Pharmaceut Co, Astra Charnwood, Daiichipharmaceut, Ortho McNeil Pharmaceut, UCB Pharma & Sanolfi DE apoptosis; status epilepticus; necrosis; DNA laddering; TUNEL stain ID INDUCED STATUS EPILEPTICUS; NMDA RECEPTOR ANTAGONIST; KAINIC ACID TREATMENT; RAT-BRAIN; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; CYCLIN D1; DAMAGE; APOPTOSIS; KAINATE AB Purpose: To determine definitively the morphology of neuronal death from lithium-pilocarpine (LPC)-and kainic acid (KA)-induced status epilepticus (SE), and to correlate this with markers of DNA fragmentation that have been associated with cellular apoptosis. Endogenous glutamate release is probably responsible for neuronal death in both seizure models, because neuronal death in both is N-methyl-D-aspartate receptor-mediated. Methods: SE was induced for 3 hours in adult male Wistar rats with either LPC or KA, and 24 or 72 hours later the rats were killed. One group of rats had brain sections, stained with hematoxylin and eosin and the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) technique, examined by light microscopy and by electron microscopy. A separate,group of rats had DNA extracted from the same brain regions examined by electron microscopy in the first group. The extracted DNA was electrophoresed on an agarose gel with ethidium bromide and was examined for the presence or absence of internucleosomal DNA cleavage (DNA "laddering"). Results: Twenty-four and 72 hours after 3 hours of LPC- or KA-induced SE, neuronal death in the hippocampus, amygdala, and piriform, entorhinal, and frontal cortices was morphologically necrotic, in spite of DNA laddering in these regions 24 and 72 hours after SE and positive TUNEL staining in some of the regions 72 hours after SE. Ultrastructurally, necrotic neurons were dark and shrunken, with cytoplasmic vacuoles and pyknotic nuclei with small, irregular, dispersed chromatin clumps. Conclusions: Our results, together with those of other reports, suggest that programmed cell death-promoting mechanisms are activated by SE in neurons that become necrotic rather than apoptotic and point to the possibility that such mechanisms may contribute to SE-induced neuronal necrosis. C1 VA Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. VA Greater Los Angeles Healthcare Syst, Nursing Home Care Unit, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90024 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 32 TC 54 Z9 62 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2000 VL 41 SU 6 BP S9 EP S13 DI 10.1111/j.1528-1157.2000.tb01549.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 351KN UT WOS:000089156500003 PM 10999512 ER PT J AU Sankar, R Shin, D Liu, HT Katsumori, H Wasterlain, CG AF Sankar, R Shin, D Liu, HT Katsumori, H Wasterlain, CG TI Granule cell neurogenesis after status epilepticus in the immature rat brain SO EPILEPSIA LA English DT Article; Proceedings Paper CT 5th Workshop on the Neurobiology of Epilepsy (WONOEP V) CY SEP 08-10, 1999 CL CESKY KRUMLOV, CZECH REPUBLIC SP Hoechst Marion Roussell, Parke Davis, Div Warner Lambert Co, Abbott Labs, Danippon Pharmaceut Co, Astra Charnwood, Daiichipharmaceut, Ortho McNeil Pharmaceut, UCB Pharma & Sanolfi DE hippocampus; dentate granule cells; development; neurogenesis; lithium-pilocarpine; status epilepticus; epilepsy; synaptic plasticity ID DENTATE GYRUS; SYNAPTIC REORGANIZATION; ADULT-RAT; TREATED RATS; SEIZURES; CONSEQUENCES; PROLIFERATION; HIPPOCAMPUS AB Purpose: Several experimental paradigms of seizure induction that produce epilepsy as a consequence have been shown to be associated with the proliferation of dentate granule cells. In developing animals, the acute sequela of hilar damage and the chronic sequelae of spontaneous seizures and mossy fiber synaptic reorganization, in response to status epilepticus, occur in an age-dependent manner. We investigated seizure-induced granule cell neurogenesis in developing rat pups to study the association between hilar injury, granule cell neurogenesis, and epilepsy. Methods: Rat pups of 2 and 3 weeks postnatal age were subjected to lithium-pilocarpine status epilepticus (LiPC SE). Rats were given bromodeoxyuridine (BrdU; 50 mg/kg intraperitoneal) twice daily for 4 days beginning 3 days after SE to label dividing cells. Routine immunocytochemistry and quantification of BrdU labeling image analysis were performed. Results were compared with previously reported data on cellular injury, mossy fiber sprouting, and spontaneous seizures in rat pups of these ages after LiPC SE. Results: In 3-week-old pups, which demonstrate SE-induced hilar damage and develop spontaneous seizures accompanied by mossy fiber sprouting, the BrdU-immunoreactive area (percent) in the subgranular proliferative zone increased to 10.6 +/- 2.5 compared with 1.4 +/- 0.5 in the control animals (p < 0.05). The 2-week-old animals, which show neither hilar damage nor sprouting and rarely develop spontaneous seizures, also showed a comparable extent of SE-induced neurogenesis [8.0 +/- 1.4 (LiPC SE) versus 0.4 +/- 0.2 (control), p < 0.05]. Conclusions: Seizure-induced granule cell neurogenesis does not appear to be a function of seizure-induced hilar cellular damage. Granule cell neurogenesis induced by SE does not determine epileptogenesis in the developing rat. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Sepulveda, CA USA. RP Sankar, R (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Box 951752, Los Angeles, CA 90095 USA. FU NINDS NIH HHS [NS13515, NS01792] NR 20 TC 64 Z9 73 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2000 VL 41 SU 6 BP S53 EP S56 DI 10.1111/j.1528-1157.2000.tb01557.x PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 351KN UT WOS:000089156500011 PM 10999520 ER PT J AU Wasterlain, CG Liu, H Mazarati, AM Baldwin, RA Shirasaka, Y Katsumori, H Thompson, KW Sankar, R de Vasconselos, AP Nehlig, A AF Wasterlain, CG Liu, H Mazarati, AM Baldwin, RA Shirasaka, Y Katsumori, H Thompson, KW Sankar, R de Vasconselos, AP Nehlig, A TI Self-sustaining status epilepticus: A condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators SO EPILEPSIA LA English DT Article; Proceedings Paper CT 5th Workshop on the Neurobiology of Epilepsy (WONOEP V) CY SEP 08-10, 1999 CL CESKY KRUMLOV, CZECH REPUBLIC SP Hoechst Marion Roussell, Parke Davis, Div Warner Lambert Co, Abbott Labs, Danippon Pharmaceut Co, Astra Charnwood, Daiichipharmaceut, Ortho McNeil Pharmaceut, UCB Pharma & Sanolfi DE epilepsy; status epilepticus; glutamate; NMDA receptors; substance P; tachykinins ID BRIEF ELECTRICAL-STIMULATION; PERFORANT PATH; MODEL; SEIZURES; 2-DEOXYGLUCOSE; MAINTENANCE; DRUGS; RATS AB We describe a model of self-sustaining status epilepticus (SSSE) induced by stimulation of the perforant path in free-running rats. In this model, seizures can be transiently suppressed by intrahippocampal injection of a blocker of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid/kainate synapses but return in the absence of further stimulation when the drug ceases to act. However, seizures are irreversibly abolished by blockers of N-methyl-D-aspartate receptors given locally or systemically. SSSE is enhanced by substance P and its agonists and blocked by its antagonists. SSSE induces novel expression of substance P-like immunoreactivity in hippocampal principal cells. These changes and those in other limbic peptides may contribute to the maintenance of SSSE and to the modulation of hippocampal excitability during epileptic seizures. C1 VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. INSERM, U398, Strasbourg, France. RP Wasterlain, CG (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NINDS NIH HHS [R01 NS 13515-21] NR 25 TC 27 Z9 27 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2000 VL 41 SU 6 BP S134 EP S143 DI 10.1111/j.1528-1157.2000.tb01572.x PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 351KN UT WOS:000089156500026 PM 10999535 ER PT J AU Berman, S Munakata, J Naliboff, BD Chang, L Mandelkern, M Silverman, D Kovalik, E Mayer, EA AF Berman, S Munakata, J Naliboff, BD Chang, L Mandelkern, M Silverman, D Kovalik, E Mayer, EA TI Gender differences in regional brain response to visceral pressure in IBS patients SO EUROPEAN JOURNAL OF PAIN-LONDON LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; POSITRON EMISSION TOMOGRAPHY; CHRONIC PAIN; MENSTRUAL-CYCLE; PERCEPTION; HUMANS; REPRESENTATION; STIMULATION; PATTERNS; CORTEX AB In two experiments including a total of 30 irritable bowel syndrome patients, symptom-mimicking rectal pressure stimuli elicited changes in regional neural activation as measured by positron electron tomography (PET) cerebral blood flow images. Although most stimuli were not rated as painful, rectal pressure increased regional cerebral blood flow (rCBF) in areas commonly associated with somatic pain, including the anterior cingulate, insula, prefrontal cortex, thalamus, and cerebellum. Despite similar stimulus ratings in male and female patients, regional activations were: much stronger for males. In both experiments, rectal pressure activated the insula bilaterally in males but not in females. Insula activation was associated most strongly with objective visceral pressure, whereas anterior cingulate activation was associated more with correlated ratings of subjective discomfort. The insula is discussed as a visceral sensory cortex. Several possible reasons for the insula gender effect are proposed. (C) 2000 European Federation of Chapters of the International Association for the Study of Pain. C1 W Los Angeles Vet Affairs Med Ctr, Div Nucl Med, PET Ctr, UCLA CURE Neuroenter Dis Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Div Digest Dis, UCLA CURE Neuroenter Dis Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol, Div Digest Dis, UCLA CURE Neuroenter Dis Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychol, Div Digest Dis, UCLA CURE Neuroenter Dis Program, Los Angeles, CA 90073 USA. RP Mayer, EA (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Nucl Med, PET Ctr, UCLA CURE Neuroenter Dis Program, Bldg 115,Rm 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK48351]; NINR NIH HHS [NR04881] NR 64 TC 110 Z9 114 U1 1 U2 6 PU W B SAUNDERS CO LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1090-3801 J9 EUR J PAIN-LONDON JI Eur. J. Pain-London PY 2000 VL 4 IS 2 BP 157 EP 172 DI 10.1053/eujp.2000.0167 PG 16 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 337GX UT WOS:000088350000006 PM 10957697 ER PT J AU Duerinckx, AJ Shaaban, A Lewis, A Perloff, J Laks, H AF Duerinckx, AJ Shaaban, A Lewis, A Perloff, J Laks, H TI 3D MR imaging of coronary arteriovenous fistulas SO EUROPEAN RADIOLOGY LA English DT Article DE coronary arteriovenous fistula; MRI; MR angiography; coronary artery; surgery; three-dimensional imaging ID MAGNETIC-RESONANCE ANGIOGRAPHY; ARTERY BYPASS GRAFTS; NONINVASIVE DIAGNOSIS; PATENCY; MANAGEMENT; FLOW AB Coronary arteriovenous fistula are uncommon if not rare, but represent the most prevalent hemodynamically significant congenital malformations the coronary arterial circulation. The goal of this report is to evaluate the use of 3D volume rendering from transaxial breathhold coronary MR angiograms to visualize coronary arteriovenous fistulas. Corollary MR angiography offers a new non-invasive technique that accurately defines the anatomy of these malformations, setting the stage for surgical intervention. C1 W Los Angeles Vet Affairs Med Ctr, Serv Radiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Hlth Sci, Dept Radiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Hlth Sci, Adult Congenital Heart Dis Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Hlth Sci, Div Cardiothorac Surg, Los Angeles, CA 90095 USA. RP Duerinckx, AJ (reprint author), VA N Texas Healthcare Syst, Serv Radiol, 4500 S Lancaster Rd, Dallas, TX 75216 USA. NR 27 TC 10 Z9 11 U1 1 U2 1 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0938-7994 J9 EUR RADIOL JI Eur. Radiol. PY 2000 VL 10 IS 9 BP 1459 EP 1463 DI 10.1007/s003309900273 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 352EG UT WOS:000089201100016 PM 10997437 ER PT J AU Rao, VLR Dogan, A Bowen, KK Dempsey, RJ AF Rao, VLR Dogan, A Bowen, KK Dempsey, RJ TI Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus SO EXPERIMENTAL NEUROLOGY LA English DT Article DE astrocytes; microglia; mRNA; peripheral-type benzodiazepine receptor; PK11195; quantitative autoradiography; traumatic brain injury ID TUMOR-NECROSIS-FACTOR; GLOBAL FOREBRAIN ISCHEMIA; CORTICAL IMPACT INJURY; PROTEIN MESSENGER-RNA; LIGAND H-3 PK11195; BINDING-SITES; PORTACAVAL ANASTOMOSIS; QUANTITATIVE AUTORADIOGRAPHY; CULTURED ASTROCYTES; ENHANCED EXPRESSION AB In mammalian CNS, the peripheral-type benzodiazepine receptor (PTBR) is localized on the outer mitochondrial membrane within the astrocytes and microglia. PTBR transports cholesterol to the site of neurosteroid biosynthesis. Several neurodegenerative disorders were reported to be associated with increased densities of PTBR. In the present study, we evaluated the changes in the PTBR density and gene expression in the brains of rats as a function of time (6 h to 14 days) after traumatic brain injury (TBI). Sham-operated rats served as control. Between 3 and 14 days after TBI, there was a significant increased in the binding of PTBR antagonist [H-3]PK11195 (by 106 to 185%, P < 0.01, as assessed by quantitative autoradiography and in vitro filtration binding) and PTBR mRNA expression (by 2- to 3.4-fold, P < 0.01, as assessed by RT-PCR) in the ipsilateral thalamus. At 14 days after the injury, the neuronal number decreased significantly (by 85 to 90%, P < 0.01) in the ipsilateral thalamus. At the same time point, the ipsilateral thalamus also showed increased numbers of the glial fibrillary acidic protein positive cells (astrocytes, by similar to 3.5-fold) and the ED-1 positive cells (microglia/macrophages, by similar to 36-fold), the two cell types known to be associated with PTBR, Increased PTBR expression following TBI seems to be associated with microglia/macrophages than astrocytes as PTBR density at different periods after TBI correlated better with the number of ED-1 positive cells (r(2) = 0.95) than the GFAP positive cells (r(2) = 0.56). TBI-induced increased PTBR expression is possibly an adaptive response to cellular injury and may play a role in the pathophysiology of TBI. (C) 2000 Academic Press. C1 Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Rao, VLR (reprint author), Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA. NR 62 TC 87 Z9 87 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD JAN PY 2000 VL 161 IS 1 BP 102 EP 114 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 290FU UT WOS:000085666300009 ER PT S AU Poorkaj, P D'Souza, I Bird, TD Schellenberg, GD AF Poorkaj, P D'Souza, I Bird, TD Schellenberg, GD BE Lee, VMY Trojanowski, JQ Buee, L Christen, Y TI Tau mutations: Genetics and pathogenetic mechanisms SO FATAL ATTRACTIONS: PROTEIN AGGREGATES IN NEURODEGENERATIVE DISORDERS SE RESEARCH AND PERSPECTIVES IN ALZHEIMERS DISEASE LA English DT Proceedings Paper CT Meeting on Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders CY APR 12, 1999 CL PARIS, FRANCE SP Fdn Ispen ID PROGRESSIVE SUPRANUCLEAR PALSY; MULTIPLE-SYSTEM TAUOPATHY; AUTOSOMAL-DOMINANT PARKINSONISM; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; PROTEIN-TAU; PRESENILE-DEMENTIA; ANTISENSE OLIGONUCLEOTIDES; FUNCTIONAL IMPLICATIONS AB Frontotemporal dementia with parkinsonism-chromosome 17 type is caused by mutations in the gene that encodes tau. These mutations can either be missense mutations or mutations in intronic regions immediately adjacent to exon 10 (E10). Some missense mutations cause disease by altering the biochemical properties of the tau protein produced. Other missense mutations act by altering the regulation of inclusion of the alternatively spliced E10. Some of these gene regulatory missense mutations are in an exon splicing enhancer element. Another mutation is in an exon splicing silencer element. These mutations can either increase or decrease exon 10 inclusion in processed tau transcripts. E10 inclusion is also negatively regulated by a cis element spanning the E10-intron 10 boundary. Thus there are at least three different regulatory mechanisms that control whether E10 is included in tau transcripts. In some FTDP-17 families and in progressive supranuclear palsy subjects, genetic studies predict that tau mutations or alleles are responsible for disease, yet no mutations are present in the open reading frame of the gene or in intronic sequences immediately flanking tau exons. The nature and action of these mutations remain to be elucidated. C1 Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. RP Poorkaj, P (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. NR 61 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0945-6066 BN 3-540-67172-2 J9 RES PER ALZ PY 2000 BP 53 EP 64 PG 12 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BQ75F UT WOS:000089402900005 ER PT J AU Fink, DJ DeLuca, NA Yamada, M Wolfe, DP Glorioso, JC AF Fink, DJ DeLuca, NA Yamada, M Wolfe, DP Glorioso, JC TI Design and application of HSV vectors for neuroprotection SO GENE THERAPY LA English DT Review DE herpes simplex; gene transfer; neurodegenerative disease; nerve growth factor ID HERPES-SIMPLEX VIRUS; TRIGEMINAL GANGLIA; LATENT INFECTION; TYPE-1; EXPRESSION; CELLS; TRANSCRIPTS; RECEPTOR; MUTANTS; ENTRY AB Herpes simplex virus has been extensively genetically modified for gene transfer to nerve and other tissues, to create vectors that are devoid of viral gene expression and toxicity. Recombinant vectors have been engineered to express genes which protect neurons against toxic insults resulting in cell death, including nerve growth factor (NGF) and anti-apopiotic genes (eg bcl-2). This review describes experiments using HSV vectors expressing these gene products and their potential protective role in ameliorating neurodegenerative processes in animal model systems. C1 Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. RP Glorioso, JC (reprint author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA. FU NCI NIH HHS [2R01CA66141-10A2]; NEI NIH HHS [5R01EY11528-03]; NIAMS NIH HHS [5R01AR4552603] NR 20 TC 37 Z9 37 U1 1 U2 1 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD JAN PY 2000 VL 7 IS 2 BP 115 EP 119 DI 10.1038/sj.gt.3301118 PG 5 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 281DZ UT WOS:000085143800004 PM 10673716 ER PT J AU Miller, PW Sharma, S Stolina, M Butterfield, LH Luo, J Lin, Y Dohadwala, M Batra, RK Wu, L Economou, JS Dubinett, SM AF Miller, PW Sharma, S Stolina, M Butterfield, LH Luo, J Lin, Y Dohadwala, M Batra, RK Wu, L Economou, JS Dubinett, SM TI Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication SO HUMAN GENE THERAPY LA English DT Article ID COLONY-STIMULATING FACTOR; CYTOTOXIC T-LYMPHOCYTES; IN-VIVO; LUNG-CANCER; RECOMBINANT ADENOVIRUSES; AUTOLOGOUS TUMOR; DOWN-REGULATION; MURINE TUMORS; GROWTH-FACTOR; THERAPY AB In two murine lung cancer models adenoviral interleukin 7-transdnced dendritic cells (DC-AdIL-7) were administered intratumorally, resulting in complete tumor regression. Intratumoral DC-AdIL-7 therapy was as effective as DCs pulsed with specific tumor peptide antigens, Comparison with other intratumoral therapies including recombinant IL-7, AdIL-7 vector alone, unmodified DCs, IL-7-transduced fibroblasts, or DCs pulsed with tumor lysates revealed DC-AdIL-7 therapy to be superior in achieving antitumor responses and augmenting immunogenicity, Mice with complete tumor eradication as a result of either DC-AdIL-7 or AdIL-7 therapy were rechallenged with parental tumor cells 30 days or more after complete tumor eradication, All the DC-AdIL-7-treated mice completely rejected a secondary rechallenge, whereas the AdIL-7-treated mice had sustained antitumor effects in only 20-25% of the mice, DC-AdIL-7 therapy was more effective than AdIL-7 in achieving systemic antitumor responses and enhancing immunogenicity. After complete tumor eradication, those mice treated with DC-AdIL-7 evidenced significantly greater release of splenocyte GM-CSF and IFN-gamma than did controls or AdIL-7-treated mice, After intratumoral injection, gene-modified DCs trafficked from the tumor to lymph node sites and spleen, DCs were detected in nodal tissues for up to 7 days after intratumoral injection, We report that intratumoral DC-AdIL-7 leads to significant systemic immune responses and potent antitumor effects in murine lung cancer models. C1 Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Ctr Hlth Sci 37 131,Dept Med,Wadsworth Pulm Lab, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Ctr Hlth Sci 37 131,Dept Med,Wadsworth Pulm Lab, 10833 LeConte Ave, Los Angeles, CA 90095 USA. FU NCI NIH HHS [P01 CA5926, R01 CA71818, R01 CA79976] NR 47 TC 83 Z9 89 U1 0 U2 1 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1043-0342 J9 HUM GENE THER JI Hum. Gene Ther. PD JAN 1 PY 2000 VL 11 IS 1 BP 53 EP 65 DI 10.1089/10430340050016157 PG 13 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 274PY UT WOS:000084775300006 PM 10646639 ER PT J AU Cooper, RA Widman, LM Jones, DK Robertson, RN Ster, JF AF Cooper, RA Widman, LM Jones, DK Robertson, RN Ster, JF TI Force sensing control for electric powered wheelchairs SO IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY LA English DT Article DE electric powered wheelchair; force sensing control; human-machine control; people with disabilities; tremor AB People with many types of disabilities use electric powered wheelchairs (EPW's) for mobility. Excessive intention tremor, limited range of motion, athetoid motions, and spastic rigidity can reduce or prohibit the control over an EPW. This study focused on the design and testing of a newly developed isometric joystick (IJ) for EPW control. The IJ was tested against existing performance standards and compared to a commercial position sensing joystick (PSJ), When averaged across all subjects (both controls and impaired subjects) the root-mean-square tracking error and time to complete the driving course were not significantly different when using the rule (p < 0.05), Results within a subject, however, did show significance. Across all subjects, nevertheless, the IJ was superior to the PSJ for two tasks: driving straight and driving in a circle. Further development of control algorithms, especially the implementation of digital control, could lead to greater improvement in performance with the IJ. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. Calif State Univ Sacramento, Sch Engn & Comp Sci, Biomed Engn Program, Sacramento, CA 95819 USA. Cent Michigan Univ, Dept Ind & Engn Technol, Mt Pleasant, MI 48859 USA. VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Calif State Univ Sacramento, Sch Engn Comp Sci, Sacramento, CA 95819 USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. NR 16 TC 37 Z9 37 U1 0 U2 2 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017-2394 USA SN 1063-6536 J9 IEEE T CONTR SYST T JI IEEE Trans. Control Syst. Technol. PD JAN PY 2000 VL 8 IS 1 BP 112 EP 117 DI 10.1109/87.817696 PG 6 WC Automation & Control Systems; Engineering, Electrical & Electronic SC Automation & Control Systems; Engineering GA 275FT UT WOS:000084809300011 ER PT J AU Mulsant, BH Harman, JS Kelleher, KJ Schulberg, HC Kupfer, DJ Reynolds, CF AF Mulsant, BH Harman, JS Kelleher, KJ Schulberg, HC Kupfer, DJ Reynolds, CF TI Treatment of depression in vulnerable populations: Narrowing the gap SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, Sch Med, Intervent Res Ctr Study Late Life Mood Disorders, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2000 VL 30 IS 4 BP 399 EP 400 PG 2 WC Psychiatry SC Psychiatry GA 413LU UT WOS:000167614300010 ER PT J AU Sultzer, DL AF Sultzer, DL TI Selective serotonin reuptake inhibitors and trazodone for treatment of depression, psychosis, and behavioral symptoms in patients with dementia SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article; Proceedings Paper CT Meeting of the International-Psychogeriatric-Association on Behavioral and Psychological Symptoms of Dementia CY 1999 CL LANSDOWNE, VIRGINIA SP Int Psychogeriatr Assoc ID DOUBLE-BLIND; ALZHEIMERS-DISEASE; PLACEBO; CITALOPRAM; DISTURBANCES; HALOPERIDOL; MULTICENTER; FLUOXETINE; AGITATION; EFFICACY C1 Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Mental Hlth Serv, Los Angeles, CA USA. RP Sultzer, DL (reprint author), W Los Angeles VA Med Ctr, Mental Hlth Serv, 3 South,116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 16 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PY 2000 VL 12 SU 1 BP 245 EP 251 DI 10.1017/S1041610200007109 PG 7 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 410HL UT WOS:000167434500042 ER PT J AU Pettinati, HM Volpicelli, JR Pierce, JD O'Brien, CP AF Pettinati, HM Volpicelli, JR Pierce, JD O'Brien, CP TI Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article; Proceedings Paper CT Annual Meeting of the Research-Society-of-Alcoholism CY JUN, 1996 CL WASHINGTON, D.C. SP Res Soc Alcoholism DE medication compliance; naltrexone; alcohol dependence; pharmacotherapy; compliance enhancement ID PLACEBO-CONTROLLED TRIAL; DEPRESSION; DRUG AB The effectiveness of naltrexoale, a FDA-approved medication for alcohol dependence, can be improved if we support and help patients to consistently take their medication. We illustrate how patient noncompliance with treatment negatively affects outcome, and, we describe a new intervention to enhance medication compliance. Outcome was evaluated for 196 alcohol dependent outpatients who were treated with 50 mg/day naltrexone or placebo for 12 weeks. For patients who adhered to the prescribed treatment, relapse rates were lower with naltrexone than placebo (10% vs. 38.6%, p < 0.001). I;or noncompliant patients, relapse rates were high and comparable between naltrexone-and placebo-treated patients (42.9% vs. 40%). In a second study of 100 alcohol dependent outpatients, we introduced an intervention that resulted in better medication compliance rates compared to a previous naltrexone study of patients who did not receive the intervention (77.0% vs, 60.8%, p < 0.01). This provided some support for the use of an intervention that targets medication compliance when prescribing naltrexone. [Article copies available for a fee from The Haworth Document Delivery Service: 1-800-342-9678. E-mail address: getinfo@haworthpressinc.com < Website:http://www.hwaorthpressinc.com>]. C1 Univ Penn, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. Philadelphia Med Ctr Vet Affairs, Philadelphia, PA USA. RP Pettinati, HM (reprint author), Univ Penn, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIAAA NIH HHS [AA-07517, AA-09544]; NIDA NIH HHS [DA-05186] NR 33 TC 84 Z9 87 U1 1 U2 2 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 2000 VL 19 IS 1 BP 71 EP 83 DI 10.1300/J069v19n01_06 PG 13 WC Substance Abuse SC Substance Abuse GA 302YD UT WOS:000086393300006 PM 10772604 ER PT J AU Gibbon, G Szeftel, A Klaustermeyer, W AF Gibbon, G Szeftel, A Klaustermeyer, W TI Toxic epidermal necrolysis due to itraconazole SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2000 VL 105 IS 1 SU S MA 1000 BP S339 EP S339 DI 10.1016/S0091-6749(00)91426-X PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 287WR UT WOS:000085530100994 ER PT J AU Sanchez, H Guadalupe, J Bush, RK AF Sanchez, H Guadalupe, J Bush, RK TI Humoral immunologic response of brown Norway rats to rAlt a2 sensitization and DNA vaccination SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2000 VL 105 IS 1 SU S MA 854 BP S291 EP S291 DI 10.1016/S0091-6749(00)91282-X PN 2 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 287WR UT WOS:000085530100850 ER PT J AU Kumar, R Gaerlan, MSM Burgess, T AF Kumar, R Gaerlan, MSM Burgess, T TI Carpal tunnel syndrome in the presence of wrist flexion and absence of repetitive movements SO JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION LA English DT Article DE carpal tunnel syndrome; wrist flexion; intracarpal pressure ID PRESSURES AB One of the mechanical factors associated with carpal tunnel syndrome is repeated movement of flexion and extension at the wrist. The objective of this study was to determine whether prolonged positioning of flexion at the wrist, in the absence of repetitive movement, could cause carpal tunnel syndrome. The study was performed in a group of stroke patients with prolonged flexion but poor volitional movement at the wrist. Forty-right patients who suffered stroke at least 6 months before the study were included. Patients with severe spasticity (Ashworth scale > 3) and motor strength of > 2/5 were excluded. Tinels Phalen's, Semmes-Weinstein monofilament tests, median and ulnar nerve conduction studies were performed on all patients, if both nerves showed abnormal latencies or conduction, contralateral median and ulnar nerves and peroneal nerve in one extremity were also studied, to rule out peripheral neuropathy. Patients with peripheral neuropathy were subsequently excluded from the study. Carpal tunnel syndrome was diagnosed if distal motor latency was > 4.2 m sec and/or if distal sensory latency was > 3.5 m sec. Twenty-one patients met the inclusion criteria. None of them were wearing resting hand splint. Mean age of the patients was 61.2 +/- 9.9 yr. Resting position of the wrist was flexion in all patients. Seven of the 21 hands showed cat-pal tunnel syndrome (30%). There was no significant difference in the degree of wrist flexion between those who had and those who did not have carpal tunnel syndrome, demonstrating that carpal tunnel syndrome can occur in the presence of flexion of the wrist even in the absence of repetitive movements. C1 VA Greater Los Angeles Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Multicampus Phys Med & Rehabil Residency Program, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Syst, Occupat Therapy Dept, Los Angeles, CA USA. RP Kumar, R (reprint author), VA Greater Los Angeles Hlth Care Syst, Dept Phys Med & Rehabil, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 19 TC 0 Z9 0 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8127 J9 J BACK MUSCULOSKELET JI J. Back Musculoskelet. Rehabil. PY 2000 VL 14 IS 3 BP 127 EP 131 PG 5 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 455FF UT WOS:000170016300008 ER PT J AU Schatten, H Ripple, M Balczon, R Weindruch, R Chakrabarti, A Taylor, M Hueser, CN AF Schatten, H Ripple, M Balczon, R Weindruch, R Chakrabarti, A Taylor, M Hueser, CN TI Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE cytoskeleton; mitosis; cell proliferation; cell culture; centrosomes ID SEA-URCHIN EGGS; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; NUCLEAR MATRIX; GAMMA-TUBULIN; PROTEIN; FERTILIZATION; CYCLE; MICROTUBULES; DIVISION AB We investigated the effects of androgen and taxol on the androgen-responsive LNCaP and androgen independent DU145 prostate cancer cell lines. Cells were treated for 48 and 72 h with 0.05-1 nM of the synthetic androgen R1881 and with 100 nM taxol. Treatment of LNCaP cells with 0.05 nM R1881 led to increased cell proliferation, whereas treatment with 1 nM R1881 resulted in inhibit-ed cell division, DNA cycle arrest, and altered centrosome organization. After treatment with 1 nM R1881, chromatin became clustered, nuclear envelopes convoluted, and mitochondria accumulated around the nucleus. Immunofluorescence microscopy with antibodies to centrosomes showed altered centrosome structure. Although centrosomes were closely associated with the nucleus in untreated cells, they dispersed into the cytoplasm after treatment with 1 nM R1881. Microtubules were only faintly detected in 1 nM R1881-treated LNCaP cells. The effects of taxol included microtubule bundling and altered mitochondria morphology, but not DNA organization. As expected, the androgen-independent prostate cancer cell line DU145 was not affected by R1881. Treatment with taxol resulted in bundling of microtubules in both cell lines. Additional taxol effects were seen in DU145 cells with micronucleation of DNA, an indication of apoptosis. Simultaneous treatment with R1881 and taxol had no additional effects on LNCaP or DU145 cells. These results suggest that LNCaP and DU145 prostate cancer cells show differences not only in androgen responsiveness but in sensitivity to taxol as well. (C) 2000 Wiley-Liss, inc. C1 Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA. Ctr Canc Res, Columbia, MO 65211 USA. Univ Wisconsin, Inst Aging, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Hosp, GRECC, Madison, WI 53792 USA. Univ S Alabama, Dept Cellular & Struct Biol, Mobile, AL 36688 USA. Univ Wisconsin, Ctr Comprehens Canc, Dept Med, Madison, WI 53706 USA. RP Schatten, H (reprint author), Univ Missouri, Dept Vet Pathobiol, 1600 E Rollins St, Columbia, MO 65211 USA. FU NIA NIH HHS [T32AG0002/3-06] NR 73 TC 16 Z9 16 U1 1 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PY 2000 VL 76 IS 3 BP 463 EP 477 DI 10.1002/(SICI)1097-4644(20000301)76:3<463::AID-JCB13>3.0.CO;2-S PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 281WM UT WOS:000085184500013 PM 10649443 ER PT J AU Iwen, PC Sigler, L Tarantolo, S Sutton, DA Rinaldi, MG Lackner, RP McCarthy, DI Hinrichs, SH AF Iwen, PC Sigler, L Tarantolo, S Sutton, DA Rinaldi, MG Lackner, RP McCarthy, DI Hinrichs, SH TI Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ACUTE MYELOID-LEUKEMIA; BLASTOMYCES-DERMATITIDIS; INVASIVE ASPERGILLOSIS; IMMUNOCOMPROMISED PATIENTS; AJELLOMYCES-DERMATITIDIS; COCCIDIOIDES-IMMITIS; SP-NOV; TAXONOMY; IDENTIFICATION; EXPERIENCE AB We report the first case of invasive pulmonary infection caused by the thermotolerant ascomycetous fungus Gymnascella hyalinospora in a 43-year-old female from the rural midwestern United States. The patient was diagnosed with acute myelogenous leukemia and treated with induction chemotherapy. She was discharged in stable condition with an absolute neutrophil count of 100 cells per pi. Four days after discharge, she presented to the Cancer Clinic with fever and pancytopenia. A solitary pulmonary nodule was found in the right middle lobe which was resected by video-assisted thoracoscopy (VATHS). Histopathological examination revealed septate branching hyphae, suggesting a diagnosis of invasive aspergillosis; however, occasional yeast-like cells were also present. The culture grew a mold that appeared dull white with a slight brownish tint that failed to sporulate on standard media. The mold was found to be positive by the AccuProbe Blastomyces dermatitidis Culture ID Test (Gen-Probe Inc., San Diego, Calif.), but this result appeared to be incompatible with the morphology of the structures in tissue. The patient was removed from consideration for stem cell transplant and,ias treated for 6 weeks with amphotericin B (AmB), followed by itraconazole (Itr). A VATHS with biopsy performed 6 months later showed no evidence of mold infection. In vitro, the isolate appeared to be susceptible to AmB and resistant to fluconazole and -5-fluorocytosine. Results for Itr could not be obtained for the case isolate due to its failure to grow in polyethylene glycol used to solubilize the drug; however, MICs for a second isolate appeared to be elevated. The case isolate was subsequently identified as G. hyalinospora based on its formation of oblate, smooth-walled ascospores within yellow or yellow-green tufts of aerial hyphae on sporulation media. Repeat testing with the Blastomyces probe demonstrated false-positive results with the case isolate and a reference isolate of G. hyalinospora. This case demonstrates that both histopathologic and cultural features should be considered for the proper interpretation of this molecular test and extends the list of fungi recognized as a cause of human mycosis in immunocompromised patients. C1 Univ Nebraska, Nebraska Med Ctr 986495, Dept Pathol & Microbiol, Omaha, NE 68198 USA. Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA. Univ Alberta, Devonian Bot Garden, Microfungus Collect & Herbarium, Edmonton, AB, Canada. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Long Isl Jewish Med Ctr, Dept Surg, Long Isl, NY USA. RP Iwen, PC (reprint author), Univ Nebraska, Nebraska Med Ctr 986495, Dept Pathol & Microbiol, Omaha, NE 68198 USA. NR 37 TC 19 Z9 19 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2000 VL 38 IS 1 BP 375 EP 381 PG 7 WC Microbiology SC Microbiology GA 273CN UT WOS:000084689800067 PM 10618119 ER PT J AU Schwid, HA Rooke, GA AF Schwid, HA Rooke, GA TI Systolic blood pressure at end-expiration measured by the automated systolic pressure variation monitor is equivalent to systolic blood pressure during apnea SO JOURNAL OF CLINICAL MONITORING AND COMPUTING LA English DT Article DE blood pressure; mechanical ventilation; heart function; cardiovascular function; circulatory physiology; hemodynamics ID SEPSIS-INDUCED HYPOTENSION; VENTILATED PATIENTS; HEMODYNAMIC-CHANGES; GRADED HEMORRHAGE; FLUID THERAPY; INDICATOR; VOLUME; GUIDE; DOGS AB Objective. It is necessary to define a reference systolic arterial blood pressure (RP) to calculate delta-Up (dUp) and delta-Down (dDown) for systolic pressure variation. Most studies define the reference pressure as the average systolic blood pressure during a short period of apnea. We describe an automated systolic pressure variation monitor that measures airway pressure and defines the reference pressure as the systolic blood pressure at end-expiration. The present study compares the reference systolic blood pressure measured at end-expiration by the automated systolic pressure variation monitor and the reference systolic blood pressure measured during apnea to test whether the end-expiration value is an adequate substitute for the value during apnea. Methods. After obtaining informed consent, 108 sets of measurements of systolic pressure variation (SPV) were made in 20 intubated, mechanically-ventilated, anesthetized patients by the automated SPV monitor and during apnea. Measurements were taken during periods of hemodynamic stability defined as three consecutive end-expiratory systolic blood pressures within four mmHg of each other. The three systolic pressures at end-expiration were averaged (RPmonitor). Immediately following these measurements, the ventilator was turned off and the systolic blood pressure was measured at 6, 8, 10 and 12 seconds of apnea. The reference pressure during apnea (RPapnea) was defined as the average of the systolic blood pressure at 8, 10 and 12 seconds of apnea. For each measurement set, RPmonitor and the systolic blood pressure at 6 seconds of apnea (SBP6) were compared to RPapnea using Bland-Altman analysis. Results. Bland-Altman analysis for the difference between SBP6 and RPapnea yielded a small bias of -0.3 mmHg with standard deviation of 1.3, indicating that the systolic pressure tends to continue to increase slightly after 6 seconds of apnea. Results were similar for the difference between RPmonitor and RPapnea (-0.2 +/- 3.1 mmHg). Conclusions. dUp and dDown are calculated using the reference pressure. RPmonitor is an average of 0.2 mm Hg less than RPapnea, thus dUp calculated by the automated SPV monitor is an average of 0.2 mm Hg greater than dUp measured by the reference pressure during apnea and dDown is 0.2 mm Hg less. Since the bias of -0.2 mmHg is clinically insignificant, there is acceptable agreement between the reference pressure obtained during apnea and that obtained by the automated SPV monitor at end-expiration. The mean difference between RPmonitor and RPapnea is explained by the continued rise in systolic pressure during the period of apnea as demonstrated by the difference between SBP6 and RPapnea. C1 Univ Washington, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Anesthesia Serv 112A, Seattle, WA 98108 USA. RP Schwid, HA (reprint author), Univ Washington, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Anesthesia Serv 112A, 1660 S Columbian Way, Seattle, WA 98108 USA. RI Rooke, Alec/F-8909-2013 NR 12 TC 1 Z9 1 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 1387-1307 J9 J CLIN MONITOR COMP JI J. Clin. Monitor. Comp. PY 2000 VL 16 IS 2 BP 115 EP 120 DI 10.1023/A:1009933029279 PG 6 WC Anesthesiology SC Anesthesiology GA 355ZW UT WOS:000089419300005 PM 12578068 ER PT J AU Souders, JE AF Souders, JE TI Pulmonary air embolism SO JOURNAL OF CLINICAL MONITORING AND COMPUTING LA English DT Article DE venous air embolism; surgical positioning; precordial Doppler ultrasound; end-tidal carbon dioxide ID TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; CATHETER INTRODUCER SHEATH; END-EXPIRATORY PRESSURE; DECOMPRESSION-SICKNESS; DOPPLER ULTRASOUND; CUTANEOUS O-2; GAS EMBOLISM; LUNG TRAUMA; BLOOD-FLOW; DOGS AB Pulmonary air embolism is a well-known consequence of surgery, trauma, diving, and aviation. This article reviews the physiological effects, means of detection and methods of prevention and treatment of pulmonary air embolism. The primary physiological effects are elevated pulmonary artery pressures, increased ventilation-perfusion inhomogeneity, and right ventricular failure. The degree of physiological impairment depends on the volume of gas entrained, the rate of entrainment, the type of gas entrained, and the position of the patient when the embolism occurs. Transesophageal echocardiography is the most sensitive method of detection, but it is invasive. Precordial Doppler ultrasound is almost as sensitive and poses no risk to the patient. End-tidal carbon dioxide monitoring is used on all patients and is a moderately sensitive method of detection, which is useful during surgeries that have a low incidence of air embolism. For high-risk procedures, precordial Doppler ultrasound and a multi-orifice right heart catheter should be used to detect and treat pulmonary air embolism. Prevention measures include volume expansion, careful positioning, positive end-expiratory pressure, military anti-shock trousers, and jugular venous compression. Treatment of pulmonary air embolism includes flooding the surgical site with saline, controlling sites of air entry, repositioning the patient with the surgical site below the right atrium, aspiration of air from a central venous catheter, cessation of inhaled nitrous oxide, and resuscitation with oxygen, intravenous fluids, and inotropic agents. Some hypotheses on the effects of air in the pulmonary vasculature and investigational treatment options are discussed. C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Souders, JE (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Box 358280,S-112-Anes,1660 S Columbian Way, Seattle, WA 98108 USA. NR 59 TC 35 Z9 37 U1 0 U2 3 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 1387-1307 J9 J CLIN MONITOR COMP JI J. Clin. Monitor. Comp. PY 2000 VL 16 IS 5-6 BP 375 EP 383 DI 10.1023/A:1011455701892 PG 9 WC Anesthesiology SC Anesthesiology GA 429UJ UT WOS:000168535300006 PM 12580220 ER PT J AU Arana, GW AF Arana, GW TI An overview of side effects caused by typical antipsychotics SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Planning Roundtable on Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance CY JAN 22, 1999 CL DALLAS, TEXAS ID LONG-TERM; SCHIZOPHRENIC-PATIENTS; TARDIVE-DYSKINESIA; HYPERPROLACTINEMIA; NEUROLEPTICS; MANAGEMENT; HALOPERIDOL; MEDICATIONS; AKATHISIA; DRUGS AB Typical antipsychotics often combine efficacy in treating antipsychotic illnesses with a side effect profile that can affect every system of the body and range from the annoying-photosensitivity and jaundice, for example-to the disabling-seizures and blindness, among others-to the potentially fatal-agranulocytosis and neuroleptic malignant syndrome. The side effects of conventional antipsychotics are associated with effects at CNS transmission and receptor sites and appear in relation to dose levels and potency of the drug. Characteristics of patients-including gender, age, and comorbid medical illness-can make them more or less susceptible to particular antipsychotic side effects. Side effects influence patient quality of life and affect patient compliance with medications. This article will consider the physiologic systems affected by conventional neuroleptics, the sexual and reproductive side effects of typical antipsychotics, and the central nervous side effects of the conventional neuroleptics in the light of these concerns. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Psychiat, Mental Hlth Serv, Charleston, SC 29401 USA. RP Arana, GW (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Psychiat, Mental Hlth Serv, 109 Bee St, Charleston, SC 29401 USA. NR 27 TC 71 Z9 76 U1 2 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2000 VL 61 SU 8 BP 5 EP 11 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 311ZE UT WOS:000086916500002 PM 10811237 ER PT J AU Frazer, A AF Frazer, A TI Norepinephrine involvement in antidepressant action SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Symposium on Norepinephrine: Neurotransmitter for the Millennium held in Conjunction with the 152nd Annual Meeting of the American-Psychiatric-Association CY MAY 15, 1999 CL WASHINGTON, D.C. SP Amer Psychiat Assoc ID LOCUS-COERULEUS; NORADRENERGIC MODULATION; MASSETERIC REFLEX; RAT-BRAIN; DEPRESSION; BUPROPION; SEROTONIN; METABOLITES; SYSTEM; PROJECTIONS AB Because of the introduction and popularity of the selective serotonin reuptake inhibitor (SSRI) antidepressants, much attention was centered on the indolealkylamine 5-hydroxytryptamine, or serotonin. To some extent, this focus on serotonin occurred at the expense of the catecholamine neurotransmitter norepinephrine. Nevertheless, it has been apparent for almost 40 years that selective blockers of norepinephrine reuptake may be antidepressants (e.g., desipramine). This brief review covers the acute pharmacologic effects that may be responsible for the efficacy of currently marketed antidepressants as well as that of reboxetine, a newly developed selective norepinephrine reuptake inhibitor. Also discussed is the fact that the acute pharmacologic profile of selective reuptake inhibitors often predicts effects they produce when given long term. For example, the long-term administration of SSRIs produces certain effects on serotonergic systems, but not noradrenergic ones. By contrast, selective norepinephrine reuptake inhibitors, when given long term, modify certain noradrenergic parameters, but not serotonergic indices. Finally, it is speculated how drugs that enhance central noradrenergic transmission might ameliorate the symptoms of depression. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA. RP Frazer, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Mail Code 7764,7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NIMH NIH HHS [MH57001, MH29094] NR 44 TC 69 Z9 71 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2000 VL 61 SU 10 BP 25 EP 30 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 335NU UT WOS:000088250200004 PM 10910014 ER PT J AU Suri, RA Altshuler, LL Rasgon, NL Calcagno, JL Frye, MA Gitlin, MJ Hwang, S Zuckerbrow-Miller, J AF Suri, RA Altshuler, LL Rasgon, NL Calcagno, JL Frye, MA Gitlin, MJ Hwang, S Zuckerbrow-Miller, J TI Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 153rd Annual Meeting of the American-Psychiatric-Association CY MAY 13-18, 2000 CL CHICAGO, ILLINOIS SP Amer Psychiat Assoc ID DOUBLE-BLIND AB Background: Few studies have compared the treatment efficacy of the 2 selective serotonin reuptake inhibitors sertraline and fluoxetine. Method: A randomized, single-blind, parallel group study of 10 weeks' duration comparing the efficacy of sertraline, 50 mg/day; sertraline, 100 mg/day; and fluoxetine, 20 mg/day, was conducted in 44 psychiatric outpatients with DSM-IV unipolar major depressive disorder. Anti-depressant dosages were doubled at 6 weeks for subjects who had not achieved remission. Primary outcome measurements included the 71-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of less than or equal to 7 on the HAM-D and less than or equal to 2 on the CGI-I representing a positive treatment response, i.e., remission. Results: At 4 weeks, significant differences in rate of positive treatment response were noted, with 0% for sertraline, 50 mg; 46% for sertraline, 100 mg; and 31% for fluoxetine, 20 mg (p = .023). At 6 weeks, positive treatment response rates were 21%, 43%, and 31% for subjects taking 50 mg of sertraline, those taking 100 mg of sertraline, and those taking 20 mg of fluoxetine, respectively, with treatment groups no longer differing significantly from each other. In subjects for whom antidepressant dose was doubled at week 6, response rates at week 10 (4 weeks on increased dose) were 40% for sertraline, 100 mg; 43% for sertraline, 200 mg; and 55% for fluoxetine, 40 mg. Conclusion: Subjects taking sertraline, 100 mg, and fluoxetine, 20 mg, demonstrated an earlier treatment response compared with subjects taking sertraline, 50 mg. For patients without a positive response at 6 weeks, an increased antidepressant dose resulted in remission for a substantial proportion of patients when assessed 4 weeks later. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. RP Suri, RA (reprint author), 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. NR 15 TC 27 Z9 27 U1 3 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2000 VL 61 IS 12 BP 942 EP 946 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 394QG UT WOS:000166534300009 PM 11206600 ER PT J AU Pennington, BF Filipek, PA Lefly, D Chhabildas, R Kennedy, DN Simon, JH Filley, CM Galaburda, A DeFries, JC AF Pennington, BF Filipek, PA Lefly, D Chhabildas, R Kennedy, DN Simon, JH Filley, CM Galaburda, A DeFries, JC TI A twin MRI study of size variations in the human brain SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID INTELLIGENCE; EEG; ABILITIES AB Although it is well known that there is considerable variation among individuals in the size of the human brain, the etiology of less extreme individual differences in brain size is largely unknown. We present here data from the first large twin sample (N = 132 individuals) in which the size of brain structures has been measured. As part of an ongoing project examining the brain correlates of reading disability (RD), whole brain morphometric analyses of structural magnetic response image (MRI) scans were performed on a sample of adolescent twins. Specifically, there were 25 monozygotic (MZ) and 23 dizygotic (DZ) pairs in which at least one member of each pair had RD and 9 MZ and 9 DZ pairs in which neither member had RD. We first factor-analyzed volume data for 13 individual brain structures, comprising all of the neocortex and most of the subcortex. This analysis yielded two factors ("cortical" and "subcortical") that account for 64% of the variance. We next tested whether genetic and environmental influences on brain size variations varied for these two factors or by hemisphere. We computed intraclass correlations within MZ and DZ pairs in each sample for the cortical and subcortical factor scores, for left and right neocortex, and for the total cerebral volume. All five MZ correlations were substantial (r's = .78 to .98) and significant in both samples, as well as being larger than the corresponding DZ correlations, (r's = 0.32 to 0.65) in both samples. The MZ-DZ differences was significant for 3 variables in the RD sample and for one variable in the smaller control sample. These results indicate significant genetic influences on these variables. The magnitude of genetic influence did not vary markedly either for the 2 factors or the 2 hemispheres. There was also a positive correlation between brain size and full-scale IQ, consistent with the results of earlier studies. The total cerebral volume was moderately correlated (r = .42, p < .01, two-tailed) with full-scale IQ in the RD sample; there was a similar trend in the smaller control sample (r = .31, p < .07, two-tailed). Corrections of similar magnitude were found between the subcortical factor and full-scale IQ, whereas the results for the cortical factor (r = .16 and .13) were smaller and not significant. In sum, these results provide evidence for the heritability of individual differences in brain size which do not vary markedly by hemisphere or for neocortex relative to subcortex. Since there are also correlations between brain size and full-scale IQ in this sample, it is possible that genetic influences on brain size partly contribute to individual differences in IQ. C1 Univ Denver, Dept Psychol, Denver, CO 80208 USA. Univ Calif Irvine, Irvine, CA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Colorado, Boulder, CO 80309 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Pennington, BF (reprint author), Univ Denver, Dept Psychol, 2155 S Race St, Denver, CO 80208 USA. RI Kennedy, David/H-3627-2012 FU NICHD NIH HHS [P30 HD04024, P50 HD27802]; NIMH NIH HHS [K02 MH00419] NR 39 TC 134 Z9 136 U1 0 U2 3 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD JAN PY 2000 VL 12 IS 1 BP 223 EP 232 DI 10.1162/089892900561850 PG 10 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 298MV UT WOS:000086144200015 PM 10769318 ER PT J AU Vincent, DJ Horner, MD Roberts, DR Bloomer, CW Dubno, JR Horwitz, AR AF Vincent, DJ Horner, MD Roberts, DR Bloomer, CW Dubno, JR Horwitz, AR TI Refining an fMRI language paradigm using a nonlinguistic task. SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2000 SU S MA 37B BP 49 EP 50 PG 2 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 292UQ UT WOS:000085813800184 ER PT J AU Salat, DH Kaye, JA Janowsky, JS AF Salat, DH Kaye, JA Janowsky, JS TI Relationship between age, regional prefrontal volumes, and performance on working memory tasks with healthy aging: Is working memory necessarily working memory? SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU M I T PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2000 SU S MA 103F BP 148 EP 148 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 292UQ UT WOS:000085813800705 ER PT J AU Johnson, DA Yeh, CK Saunders, MJ Dodds, MWJ AF Johnson, DA Yeh, CK Saunders, MJ Dodds, MWJ TI Salivary function in full denture wearers SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, ALMD, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 2000 VL 79 SI SI MA 627 BP 222 EP 222 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277MH UT WOS:000084937000625 ER PT J AU Lin, AL Biggs, WS Stephan, KT Carlson, KA Johnson, DA Yeh, CK AF Lin, AL Biggs, WS Stephan, KT Carlson, KA Johnson, DA Yeh, CK TI Salivary anticandidal activities in an early HIV(+) corhort. SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA. STVHCS, GRECC, Audie L Murphy Vet Hosp, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 2000 VL 79 SI SI MA 3383 BP 566 EP 566 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277MH UT WOS:000084937003372 ER PT J AU Lin, AL Guo, ZM Dang, H Wu, Y Johnson, DA Yeh, CK AF Lin, AL Guo, ZM Dang, H Wu, Y Johnson, DA Yeh, CK TI Gamma radiation-induced DNA damage in mouse salivary glands SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, GRECC, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 2000 VL 79 SI SI MA 3381 BP 566 EP 566 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277MH UT WOS:000084937003371 ER PT J AU Yeh, CK Sims, CA Wu, Y Carlson, KA Stephan, KT Johnson, DA AF Yeh, CK Sims, CA Wu, Y Carlson, KA Stephan, KT Johnson, DA TI Evaluation of salivary gland function in HIV disease SO JOURNAL OF DENTAL RESEARCH LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, GRECC, Audie L Murphy Vet Hosp,STVHCS, San Antonio, TX USA. Wilford Hall AFB Med Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC DENTAL RESEARCH PI ALEXANDRIA PA 1619 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PY 2000 VL 79 SI SI MA 3382 BP 566 EP 566 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 277MH UT WOS:000084937003375 ER PT J AU Ahroni, JH Boyko, EJ AF Ahroni, JH Boyko, EJ TI Responsiveness of the SF-36 among veterans with diabetes mellitus SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE health status; diabetes mellitus complications; reproducibility of results; quality of life ID QUALITY-OF-LIFE; HEALTH-STATUS; FUNCTIONAL STATUS; GLYCEMIC CONTROL AB To examine the responsiveness of the Medical Outcomes Study 36-Item Short Form (SF-36) to the development of diabetes complications over time. We studied a cohort of 331 diabetic veterans participating in a prospective study of risk factors for foot complications. Eight SF-36 scales [general health (GH), physical functioning (PF), social functioning (SF), mental health (MH), physical role (RP), emotional role (RE), bodily pain (BP), and vitality VT)] and 25 diabetes complications characteristics (DCC) from history and symptom questionnaires and physical exam findings were compared over a mean interval of 3.1 years. The subjects were mostly married, white males with a mean age of 63.5 years, with primarily type 2 diabetes (91%) and a mean diabetes duration of 9.7 years at baseline. There was a statistically significant interval decrease in the GH scale of 6.1 points (effect size [ES] 0.24), PF decreased 9.7 (ES 0.38), SF decreased 5.8 (ES 0.19), PR decreased 14.7 (ES 0.38), BP decreased 4.0 (ES 0.14), VT decreased 4.5 (ES 0.16), total DCC increased by 1.8 (ES 0.53), and hemoglobin Al, declined 1.3% (ES 0.48). An increase of > 1 DCC was associated with an average loss of 7.2 to 11.8 points on six SF 36 scales (GH, PF, SF, RP, BP, VT). The development of any renal complication was related to decrements in five SF-36 scales (GH, PF, SE RP, VT) while the appearance of any neuropathy complication was associated with a decline in four SF-36 scales (GH, PF, PR, VT). These results imply that six of the SF-36 scales are responsive to the development of diabetes complications over time among elderly veterans, supporting their use in longitudinal research. Renal and neuropathy complications have the greatest effects on the SF-36. (C) 2000 Elsevier Science Inc. All rights reserved. C1 Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. RP Ahroni, JH (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. OI Boyko, Edward/0000-0002-3695-192X NR 19 TC 50 Z9 50 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN-FEB PY 2000 VL 14 IS 1 BP 31 EP 39 DI 10.1016/S1056-8727(00)00066-0 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 340ED UT WOS:000088519400006 PM 10925064 ER PT J AU Silva, JA Leong, GB Weinstock, R Gonzales, CL AF Silva, JA Leong, GB Weinstock, R Gonzales, CL TI A case of Cotard's syndrome associated with self-starvation SO JOURNAL OF FORENSIC SCIENCES LA English DT Article DE forensic science; Cotard's syndrome; major depressive disorder; self-destructive behavior; self-starvation; mental disorder; forensic psychiatry ID DELUSIONAL MISIDENTIFICATION; CAPGRAS SYNDROME AB Cotard's syndrome is a psychotic condition often associated with nihilistic delusions. This syndrome can be associated with destructive behaviors directed at the self and/or others. In this report we highlight the psychiatric-legal issues involving a case of Cotard's syndrome associated with self-starvation. C1 Palo Alto Vet Hlth Care Syst, Menlo Pk Div, Palo Alto, CA USA. Western State Hosp, Tacoma, WA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Silva, JA (reprint author), POB 20928, San Jose, CA 95160 USA. NR 24 TC 8 Z9 8 U1 0 U2 5 PU AMER SOC TESTING MATERIALS PI W CONSHOHOCKEN PA 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959 USA SN 0022-1198 J9 J FORENSIC SCI JI J. Forensic Sci. PD JAN PY 2000 VL 45 IS 1 BP 188 EP 190 PG 3 WC Medicine, Legal SC Legal Medicine GA 293BB UT WOS:000085830700027 PM 10641937 ER PT J AU Abdel-Fattah, G Yoffe, B Krishnan, B Khaoustov, V Itani, K AF Abdel-Fattah, G Yoffe, B Krishnan, B Khaoustov, V Itani, K TI MDM2/p53 protein expression in the development of colorectal adenocarcinoma SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE mdm2 oncogene; p53; colorectal cancer ID TUMOR-SUPPRESSOR GENE; SOFT-TISSUE TUMORS; WILD-TYPE P53; IMMUNOHISTOCHEMICAL EXPRESSION; HUMAN SARCOMAS; AMPLIFICATION; CANCER; PRODUCT; TRANSACTIVATION; PROGRESSION AB The murine double minutes 2 (MDM2) oncoprotein inhibits p53-mediated tumor suppression. MDM2 has been shown. to be overexpressed in sarcomas and more recently was implicated in the pathogenesis of carcinomas. The purpose of this study was to determine the expression pattern of MDM2 in adenomas and colorectal adenocarcinomas and decide whether there is a correlation between MDM2 and p53 protein status. Paraffin-embedded tissues from 52 colorectal cancer (CRC) specimens and their adjacent normal tissue (N-CRC) were studied. In addition, 56 sporadic adenomas were investigated for the im munohistochemical expression of MDM2 and p53 proteins. Immunoreactivity of p53 indicating p53 gene mutation (p53 +) was significantly higher in CRC (44 %) compared to adenomas (23.2 %) (P <0.01). None of the N-CRC specimens expressed the immunoreactive p53 protein. MDM2 overexpression (MDM2 +) was similar in adenomas (30.3 %) and CRC (25 %), but only 2 (3.8 %) of 52 N-CRC specimens showed overexpression of MDM2. In most cases MDM2 expression was associated with negative p53 expression (wild-type p53) in both adenomas (r = 0.59, P <0.001) and CRC (r = 0.69, P <0.0001). No correlation was found between MDM2, p53 expression, and either the histologic grade, nodal stage or morphology of the tumors. There is greater p53 mutation in CRC compared to adenomas and N-CRC. The data indicate that MDM2 is overexpressed in CRC and is significantly associated with wild-type p53 compared to N-CRC specimens from the same patient. The MDM2 expression pattern is similar in adenomas and CRC, which may suggest that MDM2 overexpression is an early event in the progression of CRC. C1 Houston VA Med Ctr, DeBakey Dept Surg, Houston, TX USA. Houston VA Med Ctr, Dept Med, Houston, TX USA. Houston VA Med Ctr, Dept Pathol, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Itani, K (reprint author), VAMC, Dept Surg, 112A, Houston, TX 77030 USA. NR 32 TC 21 Z9 22 U1 0 U2 1 PU QUALITY MEDICAL PUBLISHING INC PI ST LOUIS PA 11970 BORMAN DR, STE 222, ST LOUIS, MO 63146 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN-FEB PY 2000 VL 4 IS 1 BP 109 EP 114 DI 10.1016/S1091-255X(00)80041-4 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 278NR UT WOS:000084996300020 PM 10631371 ER PT J AU Hermida, R Vesely, D Kanabrocki, E Bremner, F Third, J Ryan, M AF Hermida, R Vesely, D Kanabrocki, E Bremner, F Third, J Ryan, M TI Circadian pattern in serum atrial natriuretic prohormones in aging male subjects SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract C1 Univ Vigo, Bioengn & Chronobiol Labs, Vigo, Spain. Univ S Florida, Hlth Sci Ctr, Tampa, FL USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. MacNeal Card Grp, Berwyn, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PY 2000 VL 18 SU 4 BP S64 EP S64 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 366HW UT WOS:000090000800334 ER PT J AU Siri, F Dolgilevich, S Atlas, S AF Siri, F Dolgilevich, S Atlas, S TI Use of microdialysis to assess interstitial fluid angiotensin II concentration in the rat heart SO JOURNAL OF HYPERTENSION LA English DT Meeting Abstract C1 Bronx Vet Affairs Med Ctr, Hypertens Res Lab, New York, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PY 2000 VL 18 SU 4 BP S21 EP S21 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 366HW UT WOS:000090000800104 ER PT J AU Stolina, M Sharma, S Lin, Y Dohadwala, M Gardner, B Luo, J Zhu, L Kronenberg, M Miller, PW Portanova, J Lee, JC Dubinett, SM AF Stolina, M Sharma, S Lin, Y Dohadwala, M Gardner, B Luo, J Zhu, L Kronenberg, M Miller, PW Portanova, J Lee, JC Dubinett, SM TI Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CELL LUNG-CANCER; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ESTABLISHED MURINE TUMORS; IFN-GAMMA PRODUCTION; HUMAN COLON-CANCER; CLASS-I EXPRESSION; GENE-THERAPY; EFFECTIVE ERADICATION; PROSTAGLANDIN E(2); DENDRITIC CELLS AB Cyclooxygenase-2 (COX-2), the enzyme at the rate-limiting step of prostanoid production, has been found to be overexpressed in human lung cancer. To evaluate lung tumor COX-2 modulation of antitumor immunity, we studied the antitumor effect of specific genetic or pharmacological inhibition of COX-2 in a murine Lewis lung carcinoma (3LL) model. Inhibition of COX-2 led to marked lymphocytic infiltration of the tumor and reduced tumor growth. Treatment of mice with anti-PGE(2) mAb replicated the growth reduction seen in tumor-bearing mice treated with COX-2 inhibitors. COX-2 inhibition was accompanied by a significant decrement in IL-10 and a concomitant restoration of IL-12 production by APCs, Because the COX-2 metabolite PGE2 is a potent inducer of IL-10, it was hypothesized that COX-2 inhibition led to antitumor responses by down-regulating production of this potent immunosuppressive cytokine. In support of this concept, transfer of IL-10 transgenic T lymphocytes that overexpress IL-10 under control of the IL-2 promoter reversed the COX-2 inhibitor-induced antitumor response. We conclude that abrogation of COX-2 expression promotes antitumor reactivity by restoring the balance of IL-10 and IL-12 in vivo. C1 Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Dept Med,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Wadsworth Pulm Lab, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. GD Searle & Co, St Louis, MO 63167 USA. La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Dept Med,Jonsson Comprehens Canc Ctr, W111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCI NIH HHS [R01 CA71818] NR 70 TC 353 Z9 375 U1 1 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2000 VL 164 IS 1 BP 361 EP 370 PG 10 WC Immunology SC Immunology GA 266VP UT WOS:000084321200049 PM 10605031 ER PT J AU Siegel, R AF Siegel, R TI How short can courses be in lower respiratory tract infections? SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH LA English DT Article; Proceedings Paper CT 9th International Congress on Infectious Diseases (ICID) CY APR 10-13, 2000 CL BUENOS AIRES, ARGENTINA DE community-acquired pneumonia; antibiotics; short-course therapy; cefuroxime; cefuroxime axetil; switch therapy; sequential therapy; step-down therapy ID COMMUNITY-ACQUIRED PNEUMONIA; CEFUROXIME AXETIL; EARLY SWITCH; THERAPY; ANTIBIOTICS; MANAGEMENT; PENICILLIN; DISCHARGE; OUTCOMES AB Prospective clinical studies conducted over the last 10 years provide data on which to base decisions regarding the treatment of community-acquired pneumonia (CAP), including the need for hospitalization, optimal timing of the switch from intravenous to oral antibiotic therapy and the discharge of patients. Validated treatment algorithms, such as the classification of community-acquired pneumonia, now enable decisions to be made on which patients with CAP require hospitalization, as well as identifying those who will benefit from early switch therapy Generally, unstable CAP patients are suitable candidates for early switch therapy, which consists of rapid initiation of 1 - 2 days' intravenous therapy followed by 5 days' oral therapy, with early discharge from hospital after the receipt of one or two doses of oral antibiotic. Studies with intravenous cefuroxime and followed by oral cefuroxime axetil suggest this regimen is both effective and well tolerated as rapid switch therapy and has the potential to reduce overall healthcare costs and improve patient satisfaction. C1 Med ICU, Bronx Vet Affairs Med Ctr, Dept Pulm & Crit Care Med, Bronx, NY 10468 USA. RP Siegel, R (reprint author), Med ICU, Bronx Vet Affairs Med Ctr, Dept Pulm & Crit Care Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. NR 26 TC 2 Z9 3 U1 0 U2 0 PU CAMBRIDGE MED PUBL PI WORTHING PA WICKER HOUSE, HIGH ST, WORTHING BN11 1DJ, W SUSSEX, ENGLAND SN 0300-0605 J9 J INT MED RES JI J. Int. Med. Res. PY 2000 VL 28 SU 1 BP 37A EP 47A PG 11 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 371KB UT WOS:000165177200005 PM 11092228 ER PT J AU Myatkowskj, P Seeley, RJ Havel, PJ Baskin, DG Matsumoto, AM Wilkinson, CW Schwartz, MW AF Myatkowskj, P Seeley, RJ Havel, PJ Baskin, DG Matsumoto, AM Wilkinson, CW Schwartz, MW TI Hypothalamic melanin concentrating hormone is a target for the anorexic effect of estrogen. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Cincinnati, Cincinnati, OH USA. Univ Calif Davis, Davis, CA 95616 USA. RI Schwartz, Michael/H-9950-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 65 BP 12A EP 12A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600075 ER PT J AU Kletke, ML Barsness, S Drolet, G Moe, KE Schwartz, RS Vitiello, MV Merriam, GR AF Kletke, ML Barsness, S Drolet, G Moe, KE Schwartz, RS Vitiello, MV Merriam, GR TI Effects of gender and estrogen replacement status on responses to GH-releasing hormone treatment in normal aging. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound HCS, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 337 BP 62A EP 62A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600344 ER PT J AU Sohn, EH Wolden-Hanson, T Marck, BT Matsumoto, AM AF Sohn, EH Wolden-Hanson, T Marck, BT Matsumoto, AM TI Testosterone (T)-induced increase in neuropeptide-Y (NPY) gene expression is attenuated in old compared to young male Brown Norway rats: Contribution of T to age-related decline in NPY gene expression. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 336 BP 62A EP 62A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600343 ER PT J AU Ericksen, SE Craft, S Leverenz, JB Roth, RA Cook, DG AF Ericksen, SE Craft, S Leverenz, JB Roth, RA Cook, DG TI Insulin degrading enzyme levels in Alzheimer's disease. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 422 BP 77A EP 77A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600426 ER PT J AU Nowbar, S Burkart, KM Zwillich, CW AF Nowbar, S Burkart, KM Zwillich, CW TI Hypoventilation among obese inpatients: A common and under-diagnosed problem. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 445 BP 81A EP 81A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600449 ER PT J AU Smolik, S Rodriquez, A Burns, S AF Smolik, S Rodriquez, A Burns, S TI A cross-sectional study of non-radicular, mecanical neck pain and cervical strength. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 451 BP 83A EP 83A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600455 ER PT J AU Clark, RA AF Clark, RA TI Neutrophil respiratory burst oxidase in hose defenses. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 747 BP 138A EP 138A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600747 ER PT J AU deAndrade, JA Young, KR McGiffin, D Zorn, G Alexander, CB Christie, JD Jackson, R AF deAndrade, JA Young, KR McGiffin, D Zorn, G Alexander, CB Christie, JD Jackson, R TI Reactive nitrogen species correlate with airway inflammation in lung transplants. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Univ Alabama, Birmingham VAMC, Birmingham, AL USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 936 BP 174A EP 174A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600936 ER PT J AU Kurent, JE Pennypacker, L AF Kurent, JE Pennypacker, L TI Enhancement of physician education in palliative and end-of-life care. SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2000 VL 48 IS 1 SU S MA 964 BP 179A EP 179A PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 302CD UT WOS:000086346600964 ER PT J AU Yao, JK Reddy, RD van Kammen, DP AF Yao, JK Reddy, RD van Kammen, DP TI Abnormal age-related changes of plasma antioxidant proteins in patients with schizophrenia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 2000 VL 74 SU S BP S78 EP S78 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 285DB UT WOS:000085373200312 ER PT J AU Yao, JK Stanley, JA Reddy, R Keshavan, M Pettegrew, JW AF Yao, JK Stanley, JA Reddy, R Keshavan, M Pettegrew, JW TI Correlations of membrane phospholipids between peripheral and central measures SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PY 2000 VL 74 SU S BP S78 EP S78 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 285DB UT WOS:000085373200311 ER PT J AU Braun, C Schweizer, R Elbert, T Birbaumer, N Taub, E AF Braun, C Schweizer, R Elbert, T Birbaumer, N Taub, E TI Differential activation in somatosensory cortex for different discrimination tasks SO JOURNAL OF NEUROSCIENCE LA English DT Article DE cortical reorganization; plasticity; learning; somatosensory evoked potentials; dipole source analysis; tactile sensation threshold; human ID ADULT OWL MONKEYS; CORTICAL REPRESENTATION; BRAILLE READERS; AREA 3B; REORGANIZATION; PLASTICITY; AMPUTATION; HUMANS; HAND; EEG AB Maps of the body surface in somatosensory cortex have been shown to be highly plastic, altering their configuration in response to changes in use of body parts. The current study investigated alterations in the functional organization of the human somatosensory cortex resulting from massed practice. Over a period of 4 weeks, subjects were given synchronous tactile stimulation of thumb (D1) and little finger (D5) for 1 hr/d. They had to identify the orientation of the stimuli. Neuroelectric source localization based on high-resolution EEG revealed that, when subjects received passive tactile stimulation of D1 or D5, the representations of the fingers in primary somatosensory cortex were closer together after training than before. There was also an apparently correlative tendency to anomalously mislocalize near-threshold tactile stimuli equally to the distant finger costimulated during training rather than preferentially to the finger nearest to the finger stimulated in a post-training test. However, when the stimulus discrimination had to be made, neuroelectric source imaging revealed that the digital representations of D1 and D5 were further apart after training than before. Thus, the same series of prolonged repetitive stimulations produced two different opposite effects on the spatial relationship of the cortical representations of the digits, suggesting that differential activation in the same region of somatosensory cortex is specific to different tasks. C1 Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany. Univ Konstanz, Dept Psychol, D-78457 Constance, Germany. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Braun, C (reprint author), MEG Ctr, Otfried Muller Str 7, D-72076 Tubingen, Germany. RI Elbert, Thomas/C-8556-2009; Braun, Christoph/E-4561-2010; Braun, Christoph/J-4160-2014 OI Braun, Christoph/0000-0002-7836-4010; Braun, Christoph/0000-0002-7836-4010 NR 23 TC 91 Z9 92 U1 1 U2 10 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 1 PY 2000 VL 20 IS 1 BP 446 EP 450 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 271ET UT WOS:000084581800051 PM 10627620 ER PT J AU Sherwood, AM Graves, DE Priebe, MM AF Sherwood, AM Graves, DE Priebe, MM TI Altered motor control and spasticity after spinal cord injury: Subjective and objective assessment SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE classification; computer-assisted; electromyography; muscle spasticity; signal processing; spinal cord injuries ID MODIFIED ASHWORTH SCALE; INTRATHECAL BACLOFEN; SURFACE EMG; RELIABILITY; HYPERTONIA; CLASSIFICATION; RECORDINGS; STANDARDS; PLACEBO; SCI AB This study of measures of spasticity, or altered motor control, compares the clinically used Ashworth scale with a method based on surface electromyographic (sEMG) recordings called brain motor control assessment (BMCA) in a group of 97 subjects with spinal cord injury (SCI) and varying levels of motor dysfunction. In this paper, we describe how sEMG-derived scores relate to the severity of spasticity as judged clinically. When sEMG data from passive movements from the BMCA were analyzed by Ashworth category, we found that when the sEMG data were averaged for a limb, there was a significant difference between scores for those with Ashworth 0 vs. 2 and 3, and 1 vs. 2 and 3 (p<0.001), but not between 0 and 1. Analysis of the individual muscle scores improved the discrimination between Ashworth categories. Superiority of sEMG data over Ashworth category as an objective quantification of altered motor control ("spasticity") is argued. C1 VA Rehabil Res & Dev Ctr Excellence Hlth Aging Di, Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Dept Vet Affairs N Texas Hlth Care Syst, Dallas, TX 75216 USA. Univ Texas, SW Med Sch, Dept Phys Med & Rehabil, Dallas, TX 75235 USA. RP Sherwood, AM (reprint author), VA Rehabil Res & Dev Ctr Excellence Hlth Aging Di, Dept Vet Affairs Med Ctr, 2002 Holcombe Blvd,153, Houston, TX 77030 USA. OI Sherwood, Arthur/0000-0002-0110-4317 NR 61 TC 30 Z9 32 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD JAN-FEB PY 2000 VL 37 IS 1 BP 41 EP 52 PG 12 WC Rehabilitation SC Rehabilitation GA 380YM UT WOS:000165733300010 PM 10847571 ER PT J AU Shekelle, PG Morton, SC AF Shekelle, PG Morton, SC TI Principles of metaanalysis SO JOURNAL OF RHEUMATOLOGY LA English DT Article; Proceedings Paper CT OMERACT Imaging Task Force Workshop on Heterogeneity in Rheumatoid Arthritis Radiographics Trials - Issues to Consider in a Metaanalysis CY NOV 07, 1998 CL SAN DIEGO, CALIFORNIA SP Connet Corp DE metaanalysis ID SYSTEMATIC REVIEWS; TRIALS; HETEROGENEITY; QUALITY AB Metaanalysis is a relatively new tool to help make evidence based decisions. This technique involves the systematic examination of available evidence on a given clinical topic, and the summary of that evidence using statistical techniques that pool data from multiple studies to yield a single result. We briefly discuss the principal steps in a metaanalysis: identifying all the studies; assessing the studies for quality; organizing the studies into subgroups: and summarizing the results. C1 W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med, Los Angeles, CA 90073 USA. Rand Hlth Program & Stat Grp, Santa Monica, CA USA. RP Shekelle, PG (reprint author), W Los Angeles Vet Affairs Med Ctr, Div Gen Internal Med, 111G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 11 TC 9 Z9 9 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD JAN PY 2000 VL 27 IS 1 BP 251 EP 252 PG 2 WC Rheumatology SC Rheumatology GA 274RC UT WOS:000084778000043 PM 10648049 ER PT J AU Kirkish, P Sreenivasan, S Welsh, R Van Gorp, W Eth, S Shoptaw, S Ling, W AF Kirkish, P Sreenivasan, S Welsh, R Van Gorp, W Eth, S Shoptaw, S Ling, W TI The future of criminal violence: Juveniles tried as adults SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID SEXUAL HOMICIDE; OFFENDERS; DELINQUENTS; PSYCHOPATHY; CHILDREN AB Juveniles tried as adults (JTA) represent a select and small subsample of juvenile offenders. This study seeks to provide a profile of habitually violent JTAs transferred to the adult penal system and to compare them with their adult counterparts. Twenty-nine incarcerated violent male juveniles tried as adults were compared with a sample of 27 incarcerated violent male offenders across demographic, neuropsychological, criminal history, psychopathy, and substance abuse variables. The JTAs were characterized by a high rate of gang membership (96%), substance abuse (alcohol, marijuana, and phenylcyclidene), and use of guns. In the juvenile sample, 65 percent used guns in violence not leading to arrest, and 93 percent used guns in a violent crime leading to arrest. Juvenile offenders were similar to their adult counterparts in patterns of criminality, although adult offenders had higher psychopathy scores. Both groups revealed generally intact neuropsychological functioning with the exception of a higher rate of perseverative responses in the adult sample. The results are discussed in terms of the implication of the degree of violence in a young offender population. C1 Loma Linda Univ, Loma Linda, CA 92350 USA. W Los Angeles Vet Adm Med Ctr, Forens Outreach Serv, VAMC, Los Angeles, CA USA. Univ So Calif, Sch Med, Los Angeles, CA USA. Los Angeles Addict Treatment Res Consortium, Los Angeles, CA USA. Patton State Hosp, Patton, CA 92369 USA. Cornell Univ, Sch Med, Neuropsychol Lab, Ithaca, NY 14853 USA. New York Med Coll, Valhalla, NY 10595 USA. Los Angeles Addiction Treatment Res Ctr, Los Angeles, CA USA. Friends Res Inst Inc, Baltimore, MD 21285 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Loma Linda Univ, Loma Linda, CA 92350 USA. RP Kirkish, P (reprint author), DMH Forens Serv, POB 70673, Pasadena, CA 91117 USA. FU NIDA NIH HHS [5 P501 DA-09260] NR 57 TC 3 Z9 4 U1 1 U2 8 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2000 VL 28 IS 1 BP 38 EP 46 PG 9 WC Law; Psychiatry SC Government & Law; Psychiatry GA 299TL UT WOS:000086213900009 PM 10774840 ER PT J AU Leong, GB Silva, JA Weinstock, R Ganzini, L AF Leong, GB Silva, JA Weinstock, R Ganzini, L TI Survey of forensic psychiatrists on evaluation and treatment of prisoners on death row SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article AB Psychiatrists have debated their role in evaluating prisoners accused of capital crimes and in treating prisoners on death row when restoration of competence would result in execution. Despite debate, there are no previous surveys of psychiatrists' opinions on this issue. We sent an anonymous questionnaire to all board-certified forensic psychiatrists in the United States. Of the 456 forensic psychiatrists identified, 290 (64%) returned the survey. Most respondents supported a role, in at least some cases, for psychiatric evaluation of prisoners accused of capital crimes. Respondents were divided on whether or nor psychiatrists should treat incompetent death row prisoners if restoration of competence would result in execution. Attitudes about the ethical acceptability of capital punishment were associated with views about the psychiatrists' role but were not determinative in every case. C1 Western State Hosp, Ctr Forens Serv, Tacoma, WA 98498 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA USA. Palo Alto Vet Affairs Healthcare Syst, Palo Alto, CA USA. Univ Calif Los Angeles, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR USA. RP Leong, GB (reprint author), Western State Hosp, Ctr Forens Serv, MS 07-550,9601 Steilacoom Blvd, Tacoma, WA 98498 USA. NR 22 TC 8 Z9 8 U1 0 U2 0 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2000 VL 28 IS 4 BP 427 EP 432 PG 6 WC Law; Psychiatry SC Government & Law; Psychiatry GA 392LB UT WOS:000166411600006 PM 11196252 ER PT J AU Sreenivasan, S Kirkish, P Garrick, T Weinberger, LE Phenix, A AF Sreenivasan, S Kirkish, P Garrick, T Weinberger, LE Phenix, A TI Actuarial risk assessment models: A review of critical issues related to violence and sex-offender recidivism assessments SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID PSYCHIATRIC-PATIENTS; PREDICTION; METAANALYSIS AB Risk assessment in the area of identification of violence has been dichotomized by several prominent researchers as the "clinical approach" versus the "actuarial method". The proponents of the actuarial approach argue for actuarially derived decisions to replace existing clinical practice. The actuarial method requires no clinical input, just a translation of the relevant material from the records to calculate the risk score. A risk appraisal approach based upon a sole actuarial method raises several questions: those of public safety, peer-accepted standards of practice, liability issues, and concordance with evidence-based medicine practice. We conclude that the sole actuarial approach fails to satisfy these critical issues. C1 Los Angeles Vet Adm, VA Med Ctr, Forens Outreach Serv, Los Angeles, CA 90073 USA. Univ So Calif, Sch Med, Los Angeles, CA USA. Calif Dept Mental Hlth, Mentally Disordered Offender Program, Sacramento, CA USA. W Los Angeles Vet Affairs Med Ctr, Consultat & Liaison Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ So Calif, Inst Psychiat Law & Behav Sci, Los Angeles, CA USA. Univ So Calif, Sch Med, Los Angeles, CA USA. Calif Dept Mental Hlth, Sexually Violent Predator Program, San Luis Obispo, CA USA. RP Sreenivasan, S (reprint author), W Los Angeles Vet Affairs Med Ctr, 691-B116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 39 TC 20 Z9 20 U1 0 U2 2 PU AMER ACAD PSYCHIATRY LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2000 VL 28 IS 4 BP 438 EP 448 PG 11 WC Law; Psychiatry SC Government & Law; Psychiatry GA 392LB UT WOS:000166411600008 PM 11196254 ER PT J AU Muder, RR AF Muder, RR TI Management of nursing home-acquired pneumonia: Unresolved issues and priorities for future investigation SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID TERM-CARE FACILITY; RESIDENTS; HOSPITALIZATION; VALIDATION; INFECTIONS; MORTALITY; EMERGENCY; OUTCOMES; INDEX C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 23 TC 12 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2000 VL 48 IS 1 BP 95 EP 96 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 273ET UT WOS:000084695500017 PM 10642029 ER PT J AU Ferrell, BA Fine, P Dilpiaz, A Lipman, AG AF Ferrell, BA Fine, P Dilpiaz, A Lipman, AG TI Medication for chronic pain in older persons - In reply SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Utah, Sch Pharm, Dept Anesthesiol, Salt Lake City, UT 84112 USA. RP Ferrell, BA (reprint author), Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2000 VL 48 IS 1 BP 103 EP 103 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 273ET UT WOS:000084695500021 ER PT J AU Kim, CY Etemad, B Glenn, TF Mackey, HA Viator, GE Wallace, MB Mokhashi, MS Cotton, PB Hawes, RH AF Kim, CY Etemad, B Glenn, TF Mackey, HA Viator, GE Wallace, MB Mokhashi, MS Cotton, PB Hawes, RH TI Remote clinical assessment of gastrointestinal endoscopy (tele-endoscopy): An initial experience SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article; Proceedings Paper CT Annual Symposium of the American-Medical-Informatics-Association CY NOV 04-08, 2000 CL LOS ANGELES, CALIFORNIA SP Amer Med Informat Assoc AB Background: Gastrointestinal (GI) endoscopy is an effective tool to screen for cancers of the digestive tract. However, access to endoscopy is limited in many parts of South Carolina. This trial is a part of a prospective mufti part study for remote cancer screening in coastal South Carolina. This pilot study was to evaluate the quality of tele-endoscopy for cancer screening. Methods: 10 patients scheduled for endoscopic procedures were observed simultaneously by the endoscopist and a remote observer connected over a 512kbps ISDN line. Findings by both were compared for concordance on malignant or premalignant lesions: Results: The image quality was adequate to support remote diagnosis of GI cancer and abnormal lesions by an experienced observer. However, assessment of the esophagogastric junction for Barren's esophagus was equivocal. Conclusions: Overall, our tele-endoscopy setup shows great promise for remote supervision or observation of endoscopic procedures done by nurse endoscopists. Tele-endoscopy is both adequate and feasible for diagnosis of most gastrointestinal lesions. Subtle lesions still may be missed in our current setup. However, improvements are being made in our setup to address the problem with resolution prior to further evaluation. C1 Ralph H Johnson VA Med Ctr, Coastal Canc Control Program, Charleston, SC USA. Med Univ S Carolina, Ctr Digest Dis, Charleston, SC 29425 USA. RP Kim, CY (reprint author), Ralph H Johnson VA Med Ctr, Coastal Canc Control Program, Charleston, SC USA. NR 6 TC 5 Z9 5 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 2000 SU S BP 423 EP 427 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 458RC UT WOS:000170207500087 ER PT J AU Lovis, C Payne, TH AF Lovis, C Payne, TH TI Extending the VA CPRS electronic patient record order entry system using natural language processing techniques SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article; Proceedings Paper CT Annual Symposium of the American-Medical-Informatics-Association CY NOV 04-08, 2000 CL LOS ANGELES, CALIFORNIA SP Amer Med Informat Assoc ID LEGIBILITY AB An automated practitioner order entry system was recently implemented at the YA Puget Sound Health Care System. Since the introduction of this system, we have experienced various problems, among them an increase in time required for practitioners to enter orders. In order to improve usability and acceptance of the order entry, an alternate pathway was built within CPRS that allows direct natural language based order entry. Implementation of the extension in CPRS has been made possible because of the three layers CPRS architecture and its strong object oriented models. This paper discusses the advantages and needs for a natural language based order entry system and its implementation within an existing order entry system. C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lovis, C (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Lovis, Christian/D-2634-2012 OI Lovis, Christian/0000-0002-2681-8076 NR 17 TC 1 Z9 1 U1 2 U2 3 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 2000 SU S BP 517 EP 521 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 458RC UT WOS:000170207500106 ER PT J AU Payne, TH Savarino, J Marshall, R Hoey, CT AF Payne, TH Savarino, J Marshall, R Hoey, CT TI Use of a clinical event monitor to prevent and detect medication errors SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article; Proceedings Paper CT Annual Symposium of the American-Medical-Informatics-Association CY NOV 04-08, 2000 CL LOS ANGELES, CALIFORNIA SP Amer Med Informat Assoc ID ADVERSE DRUG EVENTS AB Errors in health care facilities are common and often unrecognized. We have used our clinical event monitor to prevent and detect medication errors by scrutinizing electronic messages sent to it when any medication order is written in our facility. fl growing collection of medication safety rules covering dose limit errors, laboratory monitoring, and other topics may be applied to each medication order message to provide an additional Layer of protection beyond existing order checks; reminders, and alerts available within our computer-based record system. During a typical day the event monitor receives 4802 messages, of which 4719 pertain to medication orders. We have found the clinical event monitor to be a valuable tool for clinicians and quality management groups charged with improving medication safety. C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Payne, TH (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 11 TC 3 Z9 3 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 2000 SU S BP 640 EP 644 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 458RC UT WOS:000170207500131 ER PT J AU Hill, E Hammond, KW AF Hill, E Hammond, KW TI The usability of multimedia automated psychological tests to screen for Alzheimer's disease SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 2000 SU S BP 1030 EP 1030 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 458RC UT WOS:000170207500282 ER PT J AU Mar, CM Chabal, C Jacobson, L Mariano, AJ Vore, A AF Mar, CM Chabal, C Jacobson, L Mariano, AJ Vore, A TI Interactive computerized chronic pain education program SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Meeting Abstract C1 Talaria Inc, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PY 2000 SU S BP 1077 EP 1077 PG 1 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 458RC UT WOS:000170207500328 ER PT J AU Ratcliffe, MB Wallace, AW Salahieh, A Hong, J Ruch, S Hall, TS AF Ratcliffe, MB Wallace, AW Salahieh, A Hong, J Ruch, S Hall, TS TI Ventricular volume, chamber stiffness, and function after anteroapical aneurysm plication in the sheep SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID CANINE LEFT-VENTRICLE; CONDUCTANCE CATHETER; PATCH REPAIR; SURGERY AB Objective: The success of left ventricular aneurysm plication depends on how the procedure affects both end-systolic elastance and diastolic compliance and how those changes affect ventricular function (stroke work/end-diastolic volume [PRSW] and stroke volume/end-diastolic pressure [Starling] relationships). Methods: Five male Dorsett sheep were surgically instrumented with coronary artery snares, an inferior vena caval occluder, and an ascending aortic ultrasonic flow probe. One week later an anteroapical myocardial infarction was produced by tightening the coronary snares. Ten weeks after myocardial infarction, the left ventricular aneurysm was plicated, Absolute left ventricular volume was measured by long-axis transdiaphragmatic echocardiography, and relative changes in left ventricular volume were measured with a conductance catheter. End-systolic elastance, diastolic compliance, PRSW, and Starling relationships were measured immediately before myocardial infarction, 10 weeks after myocardial infarction (immediately before plication), and immediately after and 6 weeks after aneurysm plication. Results: After plication, end-diastolic and end-systolic left ventricular volumes return to preinfarction values. The slopes of end-systolic elastance, diastolic compliance, and PRSW decrease 10 weeks after myocardial infarction, increase with aneurysm plication, and then decrease 6 weeks after aneurysm plication. The Starling relationship undergoes a downward parallel shift with aneurysm plication. Conclusion: Aneurysm plication abruptly decreases left ventricular volume and diastolic compliance, increases end-systolic elastance and PRSW, but decreases the Starling relationship. The net effect on left ventricular function is mixed. Furthermore, left ventricular remodeling 6 weeks after aneurysm plication causes left ventricular volume, end-systolic elastance, diastolic compliance, PRSW, and the Starling relationship to return to preplication values. C1 San Francisco Vet Affairs Med Ctr, VAMC Surg 112D, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Div Cardiothorac Surg, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, Dept Anesthesia, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, VAMC Surg 112D, 4150 Clement St, San Francisco, CA 94121 USA. NR 23 TC 38 Z9 39 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2000 VL 119 IS 1 BP 115 EP 124 DI 10.1016/S0022-5223(00)70225-X PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 276BZ UT WOS:000084856900023 PM 10612769 ER PT J AU Roehrborn, CG McConnell, J Bonilla, J Rosenblatt, S Hudson, PB Malek, GH Schellhammer, PF Bruskewitz, R Matsumoto, AM Harrison, LH Fuselier, HA Walsh, P Roy, J Andriole, G Resnick, M Waldstreicher, J AF Roehrborn, CG McConnell, J Bonilla, J Rosenblatt, S Hudson, PB Malek, GH Schellhammer, PF Bruskewitz, R Matsumoto, AM Harrison, LH Fuselier, HA Walsh, P Roy, J Andriole, G Resnick, M Waldstreicher, J CA Proscar Long-Term Efficacy Safety TI Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia SO JOURNAL OF UROLOGY LA English DT Article; Proceedings Paper CT 93rd Annual Meeting of the American-Urological-Association CY MAY 30-JUN 04, 1998 CL SAN DIEGO, CALIFORNIA SP Amer Urol Assoc DE prostatic hyperplasia; prostate-specific antigen; magnetic resonance imaging; prostate ID ACUTE URINARY RETENTION; FINASTERIDE; SYMPTOMS; VOLUME; FLOW; VARIABILITY; EFFICACY; INDEX; RISK AB Purpose: We analyze patterns of prostate growth in men diagnosed with benign prostatic hyperplasia (BPH) and treated with placebo during 4 years, and determine which baseline parameters were the strongest predictors of growth. Materials and Methods: A total of 3,040 men were enrolled in the 4-year randomized, placebo controlled Proscar Long-Term Efficacy and Safety study. Of these men a subgroup of 10% underwent pelvic magnetic resonance imaging prostate volume measurement at baseline and yearly thereafter. Absolute and percent volume changes during 4 years were calculated in the 164 placebo treated men in the subgroup. The ability of age, baseline prostate volume and prostate specific antigen (PSA) to predict prostate growth in placebo treated patients was assessed by multiple linear regression analyses, receiver operator characteristics curves, and evaluations of growth stratified by tertiles of baseline serum PSA and decades of life. Results: In placebo treated patients a steady increase in mean plus or minus standard deviation prostate volume from year to year was noted (2.5 +/- 6.1, 4.9 +/- 6.8, 6.4 +/- 8.5 and 7.2 +/- 8.8 ml. at years 1, 2, 3 and 4, respectively). Mean volume changes at 4 years ranged from -9 to +30 mi. Mean percent change from baseline ranged from 12.5% to 16.6% for men 50 to 59 years old to those 70 to 79 years old. Baseline serum PSA was a strong predictor of growth with 7.4% to 22.0% change at 4 years from the lowest to highest PSA tertiles. Annualized growth rates from baseline were 0.7 ml. per year for PSA 0.2 to 1.3, 2.1 for PSA 1.4 to 3.2 and 3.3 for PSA 3.3 to 9.9 ng/ml. Multiple Linear regression analysis showed that serum PSA was a stronger predictor of prostate growth than age or baseline prostate volume. All but 1 man with baseline serum PSA greater than 2.0 ng/ml. had prostate growth during 4 years, and 32.6% of men with serum PSA less than 2.0 exhibited a decrease in volume. Conclusions: Serum PSA is a stronger predictor of growth of the prostate in placebo treated patients than age or baseline prostate volume. Since prostate volume is a risk factor for acute urinary retention and the need for BPH related surgery, the ability of PSA to predict prostate growth may be an important factor when considering individual treatment options for BPH. Such use of PSA represents a shift. in paradigm away from focusing solely on symptoms of BPH toward a more comprehensive approach with consideration of predicting and preventing risk factors of BPH related outcomes. C1 Univ Texas, SW Med Ctr, Dallas, TX 75235 USA. Vet Adm Med Ctr, Dept Vet Affairs, Bay Pines, FL USA. Irvine Clin Res Ctr, Irvine, CA USA. Jackson Fdn Med Educ & Res, Madison, WI USA. Eastern Virginia Med Sch, Norfolk, VA 23501 USA. Univ Wisconsin, Madison, WI USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA. Johns Hopkins Hosp, Baltimore, MD 21287 USA. Univ Oklahoma, Oklahoma City, OK USA. Washington Univ, St Louis, MO USA. Univ Hosp Cleveland, Cleveland, OH 44106 USA. Merck Res Labs, Dept Clin Res Endocrinol & Metab, Rahway, NJ USA. RP Roehrborn, CG (reprint author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA. NR 25 TC 129 Z9 141 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2000 VL 163 IS 1 BP 13 EP 20 DI 10.1016/S0022-5347(05)67962-1 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 266XE UT WOS:000084324900004 PM 10604304 ER PT J AU Aronson, WJ Freeland, SJ AF Aronson, WJ Freeland, SJ TI Editorial: Can we lower the mortality rate of black men with prostate cancer? SO JOURNAL OF UROLOGY LA English DT Editorial Material DE prostatic neoplasms; blacks; mortality; prostate-specific antigen; prostatectomy ID WHITE MEN; REFERENCE RANGES; ANTIGEN; SURVIVAL; GENE C1 Univ Calif Los Angeles, Dept Urol, Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. RP Aronson, WJ (reprint author), Univ Calif Los Angeles, Dept Urol, Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. NR 14 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2000 VL 163 IS 1 BP 150 EP 151 DI 10.1016/S0022-5347(05)67992-X PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 266XE UT WOS:000084324900044 PM 10604334 ER PT J AU Mintorovitch, J Duerinckx, AJ Goldman, MD Meisner, HH AF Mintorovitch, J Duerinckx, AJ Goldman, MD Meisner, HH TI Breathhold cine MRI of left ventricular function in patients with obstructive sleep apnea: work-in-progress SO MAGNETIC RESONANCE IMAGING LA English DT Article DE sleep apnea; sleep disorders; cine MRI; left ventricular dysfunction; wall thickness ID MAGNETIC-RESONANCE; VOLUME; REPRODUCIBILITY; TURBOFLASH; MOTION; LONG AB Obstructive sleep apnea (OSA) is a sleep-related breathing disorder that can cause left ventricular (LV) dysfunction. In patients with OSA, the LV dysfunction is usually evaluated by echocardiography. The purpose of this study was to evaluate whether the use of breathhold cine MRI for the study of LV dysfunction would be feasible and well tolerated by patients with OSA. Six volunteers and five patients underwent a breathhold cine MRI study of the LV using a 1.5 Tesla MR imager. Cine MRI was performed using a breathhold k-space segmented TurboFLASH technique during end-expiration. Systolic thickening of the LV septal wall was 49% +/- 16% in normals vs. 25% +/- 10.5% in patients (p < 0.05). Systolic thickening of the LV free wall was 42% +/- 12% in normals vs. 22% +/- 9% in patients (p < 0.05), There was a significant difference in end-diastolic wall thickness between the two groups. All patients tolerated the procedure well. The total duration of each study was relatively short (less than 11 min). Breathhold MRI techniques can be used to study LV dysfunction in patients with respiratory disability such as OSA. (C) 2000 Elsevier Science Inc. All rights reserved. C1 VA Greater Los Angeles Healthcare Ctr Wadsworth, Serv Radiol, Los Angeles, CA 90073 USA. RP Duerinckx, AJ (reprint author), VA Greater Los Angeles Healthcare Ctr Wadsworth, Serv Radiol, Mail Route W114,MRI Bld 507,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 31 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PD JAN PY 2000 VL 18 IS 1 BP 81 EP 87 DI 10.1016/S0730-725X(99)00111-3 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 271HB UT WOS:000084587200009 PM 10642105 ER PT J AU Aron, DC Gordon, HS DiGiuseppe, DL Harper, DL Rosenthal, GE AF Aron, DC Gordon, HS DiGiuseppe, DL Harper, DL Rosenthal, GE TI Variations in risk-adjusted cesarean delivery rates according to race and health insurance SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Annual Meeting of the Midwestern Section of the Society-of-General-Internal-Medicine CY NOV, 1997 CL CHICAGO, ILLINOIS SP Soc Gen Internal Med, Midwestern Sect DE cesarean delivery; insurance; insurance; race ID ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; RACIAL ETHNIC-DIFFERENCES; BIRTH CERTIFICATE DATA; CARDIOVASCULAR PROCEDURES; WASHINGTON-STATE; BLACK-AMERICANS; SECTION RATES; NEW-YORK; CARE AB OBJECTIVE. To assess the association between race and insurance and Cesarean delivery rates after adjusting for clinical risk factors that increase the likelihood of cesarean delivery. DESIGN. Retrospective cohort study in 21 hospitals in northeast Ohio. SUBJECTS. 25,697 women without prior cesarean deliveries admitted for labor and delivery January 1993 through June 1995. METHODS. Demographic and clinical data were abstracted from patients' medical records. The risk of cesarean delivery was adjusted for 39 maternal and neonatal risk factors that were included in a previously developed risk-adjustment model using nested logistic regression analysis. MAIN OUTCOME MEASURES. Odds ratios for cesarean delivery in nonwhite patients relative to whites and for patients with government insurance or who were uninsured relative to patients with commercial insurance. RESULTS. The overall rate of cesarean delivery was similar in white and nonwhite patients (15.8% and 16.1%, respectively), but rates varied (P < 0.001) according to insurance (17.0%, 14.2%, 10.7% in patients with commercial insurance, government insurance, and without insurance, respectively). However, after adjusting for clinical factors, the adjusted odds ratio (OR) of cesarean delivery was higher in nonwhite patients (OR = 1.34; 95% CI: 1.14-1.57; P < 0.001), but similar for patients with government insurance (OR = 1.01; 95% CI: 0.90-1.14; P = 0.84) and lower for uninsured patients (OR = 0.65; 95% CI, 0.41, 1.03; P = 0.067), albeit not statistically significant. In analyses stratified according to quintiles of predicted risk of cesarean delivery, racial differences were largely limited to patients in the lower risk quintiles. However, differences in odds ratios for uninsured patients were seen across the risk quintiles, although odds ratios were not statistically significant. CONCLUSION. After adjusting for clinical factors, race and insurance status may independently influence the use of cesarean delivery. The higher rates in nonwhites and lower rates in the uninsured may reflect differences in patient preferences or expectations, differences in physician practice, or unmeasured risk factors. The lower adds of cesarean delivery in uninsured women, particularly women at high risk, may raise the issue of underutilization of services and warrants further study. C1 Louis Stokes Cleveland VA Med Ctr, Educ Off 14 W, Dept Med, Inst Hlth Care Res, Cleveland, OH 44106 USA. Louis Stokes Cleveland VA Med Ctr, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Internal Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Cleveland VA Med Ctr, Dept Med, Cleveland, OH USA. Cleveland VA Med Ctr, Inst Hlth Care Res, Cleveland, OH USA. Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. Qual Informat Management Program, Cleveland, OH USA. RP Aron, DC (reprint author), Louis Stokes Cleveland VA Med Ctr, Educ Off 14 W, Dept Med, Inst Hlth Care Res, 10701 E Blvd, Cleveland, OH 44106 USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 71 TC 30 Z9 31 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2000 VL 38 IS 1 BP 35 EP 44 DI 10.1097/00005650-200001000-00005 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 270ZG UT WOS:000084566600005 PM 10630718 ER PT J AU DeKay, ML Nickerson, CAE Ubel, PA Hershey, JC Spranca, MD Asch, DA AF DeKay, ML Nickerson, CAE Ubel, PA Hershey, JC Spranca, MD Asch, DA TI Further explorations of medical decisions for individuals and for groups SO MEDICAL DECISION MAKING LA English DT Article DE decision making; expected utility theory; practice guidelines; risk; survey research ID FREQUENCY FORMATS; ANALYTIC MODEL; PHYSICIANS; JUDGMENT; PROBABILITY; DISCREPANCY; GUIDELINES; BEDSIDE; GAMBLES AB Background. Important discrepancies between clinical practice and health policy may be related to the ways in which physicians and others make decisions about individuals and groups. Previous research has found that physicians and laypersons asked to consider an individual patient generally make different decisions than those asked to consider a group of comparable patients, but this discrepancy has not been observed in more recent studies. This study was designed to explore possible reasons for these findings. Methods. Prospective jurors (N = 1,013) each made a recommendation regarding a risky treatment for an incurable blood condition. Perspective (individual vs group) was crossed with uncertainty frame (probability vs frequency) and response wording (original vs revised) in a 2 x 2 x 2 between-participants design. Results. When the strength of participants' recommendations was considered, the effects of perspective, uncertainty frame, and response wording were not statistically significant. When recommendations were dichotomized, participants in the revised-response-wording conditions were more likely to recommend treatment to the group than to the individual. Conclusions. These results conflict with previous findings for this scenario and suggest that reported differences between decisions for individuals and decisions for groups are not robust. C1 Carnegie Mellon Univ, H John Heinz III Sch Publ Policy & Management, Pittsburgh, PA 15213 USA. Carnegie Mellon Univ, Dept Engn & Publ Policy, Pittsburgh, PA 15213 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Operat & Informat Management, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RAND Corp, Santa Monica, CA USA. RP DeKay, ML (reprint author), Carnegie Mellon Univ, H John Heinz III Sch Publ Policy & Management, Pittsburgh, PA 15213 USA. NR 35 TC 6 Z9 7 U1 1 U2 3 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JAN-MAR PY 2000 VL 20 IS 1 BP 39 EP 44 DI 10.1177/0272989X0002000105 PG 6 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 272TM UT WOS:000084667100005 PM 10638535 ER PT J AU Ali, SO Denicoff, KD Altshuler, LL Hauser, P Li, XM Conrad, AJ Mirsky, AF Smith-Jackson, EE Post, RM AF Ali, SO Denicoff, KD Altshuler, LL Hauser, P Li, XM Conrad, AJ Mirsky, AF Smith-Jackson, EE Post, RM TI A preliminary study of the relation of neuropsychological performance to neuroanatomic structures in bipolar disorder SO NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY LA English DT Article ID TEMPORAL-LOBE STRUCTURE; MAGNETIC-RESONANCE; MOOD DISORDERS; SIGNAL HYPERINTENSITIES; VENTRICULAR ENLARGEMENT; ELDERLY DEPRESSIVES; BRAIN ABNORMALITIES; COGNITIVE CHANGES; AFFECTIVE-ILLNESS; NORMATIVE DATA AB Objective: To investigate the relation between neuropsychological dysfunction and volumetric measures of neuroanatomic structures in patients with bipolar disorder; Background: Previous research suggests that neuropsychological deficits are associated with neuroanatomic changes in patients with bipolar disorder. Method: Twenty-six outpatients who met Diagnostic and Statistical Manual, Third Edition-Revised criteria for bipolar disorder were administered a battery of neuropsychological tests that assessed, memory, abstracting ability, psychomotor performance, sustained attention, and intelligence. Patients also received a magnetic resonance imaging scan, from which volumes of the temporal lobes, hippocampus, third ventricle, and areas of the lateral ventricles were calculated. Using multiple regression analyses, neuroanatomic structures were compared with neuropsychological test variables. Results: Data suggest that a larger right hippocampal volume is associated with poorer neuropsychological functioning. Conclusions: Further studies are needed to both replicate and examine the relation between potential mechanisms of neuroanatomic alterations and neuropsychological dysfunction in patients with bipolar disorder. C1 NIMH, Psychol Sect, Biol Psychiat Branch, Bethesda, MD 20892 USA. NIMH, Sect Clin & Expt Neuropsychol, Lab Brain & Cognit, Bethesda, MD 20892 USA. Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. Baltimore Vet Affairs Med Ctr, Psychiat Serv, Baltimore, MD USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Natl Inst Genet, Los Angeles, CA USA. RP Denicoff, KD (reprint author), NIMH, Psychol Sect, Biol Psychiat Branch, Bldg 10,Room 3N212,9000 Rockville Pike, Bethesda, MD 20892 USA. OI Ali, Syed/0000-0003-3131-3299 NR 66 TC 53 Z9 54 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-878X J9 NEUROPSY NEUROPSY BE JI Neuropsychiatr. Neuropsychol. Behav. Neurol. PD JAN PY 2000 VL 13 IS 1 BP 20 EP 28 PG 9 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 273BZ UT WOS:000084688500004 PM 10645733 ER PT J AU Anderson, B Mennemeier, M Chatterjee, A AF Anderson, B Mennemeier, M Chatterjee, A TI Variability not ability: another basis for performance decrements in neglect SO NEUROPSYCHOLOGIA LA English DT Article DE neglect; attention; reaction time ID UNILATERAL SPATIAL NEGLECT; SIMPLE REACTION-TIME; VISUAL NEGLECT; SUSTAINED ATTENTION; LINE BISECTION; REHABILITATION; HEMINEGLECT; SEARCH AB Objective: To determine reaction time (RT) and its variability as a function of horizontal spatial position, in subjects with neglect. Background: In neglect, performance is frequently reported a as mean and a decreased ability to perform the task inferred by comparison to control groups. Few studies have examined how consistency and optimal performance relate to spatial neglect. Methods: Ten subjects with brain damage, five with and five without spatial neglect. were assessed on a RT task. Subjects responded by pushing a computer key to the onset of a white square appearing on a black screen. The locations of stimuli were randomly varied along the horizontal meridian. Results. For three of five neglect subjects. optimal RT showed no or little relation to horizontal location. Four of five neglect subjects demonstrated an increased variability in RT that correlated with spatial position and which was not present in our brain damaged subjects without neglect. The relationship was not an artifact of left sided stimuli, in general, being processed differently. For the two neglect subjects with the most trials, a significant correlation between RT variability and spatial position existed for left-sided trials alone. Increased variability was not a consequence of simply looking left proportionately less often, nor could a model of multiple compensatory systems operating in parallel explain the enhanced variability. Neither hemianopsia alone nor brain damage per se could account for the spatial modulation of RT variability. Conclusions. That neglect subjects perform the RT task normally on some trials, even in their 'neglected field, challenges the notion that neglect must reflect an irreparably damaged cognitive system, Performance decrements in neglect call reflect an inability to consistently detect and respond. Evaluating optimal performance and variability of performance can indicate if a capacity has been lost absolutely or merely degraded such that normal performance cannot be sustained. (C) 2000 Elsevier Science Ltd. All rights reserved. C1 Univ Alabama, Dept Neurol, Birmingham, AL 35233 USA. Birmingham VA Med Ctr, Neurol Serv, Birmingham, AL USA. Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. RP Anderson, B (reprint author), Univ Alabama, Dept Neurol, Birmingham, AL 35233 USA. NR 30 TC 31 Z9 31 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PY 2000 VL 38 IS 6 BP 785 EP 796 DI 10.1016/S0028-3932(99)00137-2 PG 12 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 296YN UT WOS:000086054500007 PM 10689054 ER PT J AU Bartzokis, G Lu, PH Beckson, M Rapoport, R Grant, S Wiseman, EJ London, ED AF Bartzokis, G Lu, PH Beckson, M Rapoport, R Grant, S Wiseman, EJ London, ED TI Abstinence from cocaine reduces high-risk responses on a gambling task SO NEUROPSYCHOPHARMACOLOGY LA English DT Letter ID HUMAN PREFRONTAL CORTEX; MEMORY C1 Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. Cent Arkansas Vet Healthcare Syst, Mental Hlth Serv Line, Little Rock, AR USA. Greater Los Angeles VA Healthcare Syst, W Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. NIDA, Brain Imaging Ctr, Baltimore, MD USA. RP Bartzokis, G (reprint author), Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. RI Bartzokis, George/K-2409-2013 NR 5 TC 67 Z9 68 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2000 VL 22 IS 1 BP 102 EP 103 DI 10.1016/S0893-133X(99)00077-9 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 267YU UT WOS:000084387500014 PM 10633497 ER PT J AU O'Connor, TJ Cooper, RA Fitzgerald, SG Dvorznak, MJ Boninger, ML VanSickle, DP Glass, L AF O'Connor, TJ Cooper, RA Fitzgerald, SG Dvorznak, MJ Boninger, ML VanSickle, DP Glass, L TI Evaluation of a manual wheelchair interface to computer games SO NEUROREHABILITATION AND NEURAL REPAIR LA English DT Article DE wheelchair; exercise; computer games; fitness; design ID VIDEO-GAME; PAIN AB The sedentary lifestyle of many people with spinal cord injury (SCI) has lead to cardiovascular diseases being a major health concern. A suitable exercise program may help improve the SCI individual's cardiovascular fitness level. GAME(Wheels) is an interface between a custom wheelchair roller system and a computer that enables an individual to control computer video games by driving his or her wheelchair. The purpose of Phase 1 was to evaluate the design of the GAME(Wheels) system and to determine the type of computer video game that is likely to motivate wheelchair users to exercise. Phase 2 included physiologic testing of wheelchair users and the GAME(Wheels) system to investigate whether the system elicits an exercise training response. Thirty-five subjects were recruited to evaluate the GAME(Wheels) by Flaying three commercial computer games (Phase 1) and to identify the computer game that they would prefer to use when exercising. The feedback from Phase 1 was used with test subjects to verify that the GAME(Wheels) system elicits an exercise training effect (Phase 2). Phase 2 included 10 subjects using the GAME(Wheels) system to play Need for Speed II. During game play, physiologic data were collected and the subjects' oxygen consumption and heart rate were analyzed. Analysis showed that the GAME(Wheels) system induced nine subjects to reach their tr;training zone, defined as 50% and 60% of their maximum oxygen consumption and heart rate, respectively. This study demonstrates that the GAME(Wheels) system elicits an exercise training response. C1 VA Pitsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & TEchnol, Pittsburgh, PA 15260 USA. UPMC Hlth Syst, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP O'Connor, TJ (reprint author), VA Pitsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,151R-1, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X FU NICHD NIH HHS [P01-HD33989-0151] NR 19 TC 29 Z9 29 U1 1 U2 3 PU DEMOS MEDICAL PUBLISHING PI NEW YORK PA 386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA SN 0888-4390 J9 NEUROREHAB NEURAL RE JI Neurorehabil. Neural Repair PY 2000 VL 14 IS 1 BP 21 EP 31 DI 10.1177/154596830001400103 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 330MY UT WOS:000087966900003 PM 11228946 ER PT J AU Holschneider, DP Scremin, OU Huynh, L Chen, K Seif, I Shih, JC AF Holschneider, DP Scremin, OU Huynh, L Chen, K Seif, I Shih, JC TI Regional cerebral cortical activation in monoamine oxidase A-deficient mice: Differential effects of chronic versus acute elevations in serotonin and norepinephrine SO NEUROSCIENCE LA English DT Article DE cerebral blood flow; monoamine oxidase; serotonin; norepinephrine; fenfluramine; iodo-antipyrine ID BLOOD-FLOW; D-FENFLURAMINE; SOMATOSENSORY CORTEX; BEHAVIORAL SYNDROME; ADAPTIVE-CHANGES; AMINO-ACIDS; BRAIN; RAT; LACKING; NEURONS AB Mice deficient in monoamine oxidase A have previously been shown to demonstrate a chronic elevation of serotonin and norepinephrine in the brain. Using the autoradiographic [C-14]iodo-antipyrine method, we examined cerebral cortical blood flow in conscious, restrained four- to five-month-old knock-out and wild-type animals following the intraperitoneal administration of either saline or D-fenfluramine. Knock-out animals administered saline, compared to their wild-type counterparts, demonstrated a significantly higher regional cortical blood flow in somatosensory and barrel field neocortex, an area which previous histological studies have shown to be characterized by abnormal serotonergic projection fibers and absent barrel formation. Regional cortical blood how was significantly lower in knock-out than in wild-type mice in the entorhinal and midline motor cortex, with nonsignificant decreases noted in the olfactory, piriform and retrosplenial cortices and the amygdala. We compared the above findings to those obtained in response to D-fenfluramine which, in conjunction with its metabolite D-norfenfluramine, results in acute elevations of brain levels of serotonin and norepinephrine. Administration of D-fenfluramine (21.2 mg/kg) resulted in changes in regional cortical perfusion in most brain regions of both knock-out and wild-type mice that were opposite to the genotypic differences seen in perfusion in response to saline. Fenfluramine significantly increased regional cortical blood flow in the allocortex (olfactory, piriform, entorhinal) and the amygdala, and significantly decreased regional cortical blood flow in the somatosensory, barrel field, midline motor and retrosplenial cortices. Changes in regional perfusion in response to fenfluramine were topographically equivalent in knock-out and wild-type mice, although in knock-out mice such changes were of greater magnitude. Our study suggests that the effects on regional cortical blood how of a lifelong absence of monoamine oxidase A, and the consequent chronic increase in serotonin and norepinephrine, differ from those attributable to acute increases in these neurotransmitters following fenfluramine administration. Such a differential response may reflect neurodevelopmental abnormalities and/or effects of a chronic physiological adaptation on the regulation of cortical activation. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved. C1 USC, LAC, Ctr Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. W Los Angeles VAMC, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA. Ctr Univ Orsay, Inst Curie, F-91405 Orsay, France. Univ Calif Los Angeles, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA USA. RP Holschneider, DP (reprint author), USC, LAC, Ctr Med, Dept Psychiat & Behav Sci, 1200 N State St, Los Angeles, CA 90033 USA. FU NIA NIH HHS [K12-AG-00521, K12 AG000521]; NIMH NIH HHS [R37 MH39085, R01 MH 37020, R37 MH039085] NR 51 TC 10 Z9 10 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2000 VL 101 IS 4 BP 869 EP 877 DI 10.1016/S0306-4522(00)00436-X PG 9 WC Neurosciences SC Neurosciences & Neurology GA 385BZ UT WOS:000165982900007 PM 11113335 ER PT J AU Melone, M Brecha, NC Sternini, C Evans, C Conti, F AF Melone, M Brecha, NC Sternini, C Evans, C Conti, F TI Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex SO NEUROSCIENCE LA English DT Article DE opiate; neurons; immunocytochemistry; rats ID CENTRAL-NERVOUS-SYSTEM; IMMUNOHISTOCHEMICAL LOCALIZATION; INTERNALIZATION; RAT; MORPHINE; PROTEIN; BRAIN; ENDOCYTOSIS; ACTIVATION; MECHANISM AB Imunocytochemical techniques were used to determine whether agonist-induced activation of mu -opioid receptors alters the number and distribution of mu -opioid receptor-positive cells in the rat cerebral cortex. In untreated rats, mu -opioid receptor immunoreactivity was localized to neuronal perikarya and dendrites and to neuropilar punctate structures. mu -Opioid receptor positive neurons were mostly in layers II and III and exhibited a bipolar or bitufted morphology. In rats treated with the mu -opioid receptor agonist etorphine (0.1 mg/kg intraperitoneally) and perfused after different survival periods, there was an enhancement of immunostaining for mu -opioid receptors observed at 15 min, reaching a maximum at 60 min, and which returned to normal at 480 min. Etorphine-induced effects included an increase in the intensity of cellular and neuropil staining; statistical analysis showed that the number of mu -opioid receptor-positive cells in etorphine-treated groups was significantly higher than in controls or saline-treated rats. In animals that received both etorphine and the mu -opioid receptor antagonist naloxone, the pattern of mu -opioid receptors immunoreactivity was similar to that of untreated animals. This study shows that the number of mu -opioid receptor-positive cells is significantly increased following etorphine treatment and suggests that agonist treatment may be exploited to increased immunostaining of mu -opioid receptors and also of other G-protein coupled receptors. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved. C1 Univ Ancona, Inst Human Physiol, I-60020 Ancona, Italy. Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90037 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90037 USA. Univ Calif Los Angeles, Sch Med, CURE, Los Angeles, CA 90037 USA. Univ Calif Los Angeles, Sch Med, Opioid Res Ctr, Los Angeles, CA 90037 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90037 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90037 USA. RP Conti, F (reprint author), Univ Ancona, Inst Human Physiol, I-60020 Ancona, Italy. RI Melone, Marcello/B-3529-2011 OI Melone, Marcello/0000-0003-4173-0774 FU NEI NIH HHS [EY04067]; NIDA NIH HHS [P50 DA005010]; NIDDK NIH HHS [DK54155, P30 DK041301, DK41301] NR 24 TC 2 Z9 2 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2000 VL 100 IS 3 BP 439 EP 443 DI 10.1016/S0306-4522(00)00307-9 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 369JA UT WOS:000165061100001 PM 11098106 ER PT J AU Fujikawa, DG Shinmei, SS Cai, B AF Fujikawa, DG Shinmei, SS Cai, B TI Kainic acid-induced seizures produce necrotic, not apoptotic, neurons with internucleosomal DNA cleavage: Implications for programmed cell death mechanisms SO NEUROSCIENCE LA English DT Article DE apoptosis; DNA laddering; necrosis; programmed cell death; status epilepticus; TUNEL ID INDUCED STATUS EPILEPTICUS; NMDA RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; DEVELOPING RAT-BRAIN; ELECTRICAL-STIMULATION; HIPPOCAMPAL-NEURONS; PROTEIN-SYNTHESIS; CAUTIONARY NOTE; PERFORANT PATH; CYCLIN D1 AB Prolonged seizures (status epilepticus) induced by kainic acid activate programmed cell death mechanisms, and it is believed that kainic acid-induced status epilepticus induces neuronal apoptosis. In order to test this hypothesis, adult rats were subjected to 3-h kainic acid-induced seizures, with 24- or 72-h recovery periods. Neuronal death was assessed by light microscopy with the Hematoxylin and Eosin stain and with in situ terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL stain), by electron microscopy, and by agarose gel electrophoresis of DNA extracted from five vulnerable brain regions. Spontaneous and MK-801-induced apoptotic neurons from retrosplenial cortex of neonatal rats, evaluated by light and electron microscopy, were used as positive controls for apoptosis. Surprisingly, the large chromatin clumps of apoptotic neurons were TUNEL negative, whereas the cytoplasm showed light-to-moderate TUNEL staining, consistent with a lack of identifiable nuclear membranes ultrastructurally, and with intermingling of nuclear and cytoplasmic contents. Ultrastructurally, the acidophilic neurons produced by kainic acid-induced status epilepticus, identified with Hematoxylin and Eosin stain, were dark, shrunken and necrotic, with pyknotic nuclei containing small, dispersed chromatin clumps, and with cytoplasmic vacuoles, some of which were swollen, disrupted mitochondria. No apoptotic cells were seen. Acidophilic neurons were found in up to 20 of 23 brain regions examined and comprised 10-25% of the total number of neurons examined. A subset of these neurons (<10% of the total number of neurons in five of 23 regions) had TUNEL-positive nuclei 72 h but not 23 h after status epilepticus. Internucleosomal DNA cleavage (DNA "laddering") occurred in the four most damaged brain regions examined by electron microscopy 24 h after SE and the three most damaged regions 72 h after status epilepticus. Our results demonstrate that kainic acid-induced status epilepticus produces neuronal necrosis and not apoptosis in adult rats. The necrotic neurons show nuclear pyknosis, chromatin condensation and DNA laddering. Programmed cell death mechanisms activated by kainic acid-induced status epilepticus occur in neurons which become necrotic and could contribute to necrotic, as well as apoptotic, neuronal death. Published by Elsevier Science Ltd. C1 VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Nursing Home Care Unit, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. NR 69 TC 152 Z9 164 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2000 VL 98 IS 1 BP 41 EP 53 DI 10.1016/S0306-4522(00)00085-3 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 326NA UT WOS:000087740600005 PM 10858610 ER PT J AU Sternini, C Brecha, NC Minnis, J D'Agostino, G Balestra, B Fiori, E Tonini, M AF Sternini, C Brecha, NC Minnis, J D'Agostino, G Balestra, B Fiori, E Tonini, M TI Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors SO NEUROSCIENCE LA English DT Article DE receptor endocytosis; spare opioid receptors; enteric neurons; mu opioid receptors; opioid peptides; opiates ID GUINEA-PIG ILEUM; MYENTERIC-PLEXUS; NEUROKININ-1 RECEPTOR; MOLECULAR-BIOLOGY; MORPHINE; NEURONS; PEPTIDES; STIMULATION; ENDOCYTOSIS; RELEASE AB Organotypic cultures and ileal neuromuscular preparations were used to determine (i) whether endogenous release of opioids by electrical stimulation induces mu receptor endocytosis, and (ii) whether and under which conditions Ligand-induced mu receptor endocytosis influences the responsiveness of neurons expressing native mu receptor. In longitudinal muscle-myenteric plexus preparations, electrical stimulation at 20 Hz induced a prominent endocytosis of mu receptors in enteric neurons, indicating endogenous release of opioids. A similar massive endocytosis was triggered by exogenous application of the mu receptor agonist, [D-Ala(2),MePhe(4),Gly-ol(5)] enkephalin, whereas exogenous application of morphine was ineffective. [D-Ala(2),MePhe(4),Gly-ol(5)] enkephalin and morphine induced a concentration-dependent inhibition of neurogenic cholinergic twitch contractions to electrical stimulation at 0.1 Hz. beta-Chlornaltrexamine shifted to the right the inhibitory curve of both agonists with a concentration-dependent reduction of the maximum agonist response, which is consistent with the existence of spare mu opioid receptors. Under these conditions, the induction of mu receptor endocytosis by exogenously applied [D-Ala(2),MePhe(4),Gly-ol(5)] enkephalin diminished the inhibitory effect of this agonist on twitch contractions and tritiated acetylcholine release. In contrast, there was no reduction of the inhibitory effect of morphine, which failed to induce mu receptor endocytosis, on neurogenic cholinergic response. These results provide the first evidence for the occurrence of mu receptor endocytosis in neurons by endogenously released opioids and show that agonist-dependent mu receptor endocytosis could serve as a mechanism to regulate mu opioid receptor responsiveness to ligand stimulation when the opioid receptor reserve is reduced. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved. C1 CURE Digest Dis Res Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Div Digest Dis, Dept Med, Los Angeles, CA 90073 USA. CURE Digest Dis Res Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurobiol, Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Opioid Res Ctr, Los Angeles, CA 90095 USA. Univ Pavia, Sch Pharm, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy. Univ Pavia, Div Clin & Expt Pharmacol, Dept Internal Med & Therapeut, I-27100 Pavia, Italy. RP Sternini, C (reprint author), CURE Digest Dis Res Ctr, Vet Adm Greater Los Angeles Healthcare Syst, Div Digest Dis, Dept Med, Bldg 115,Room 224,VAGLAHS,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NEI NIH HHS [EY04067]; NIDA NIH HHS [P50 DA005010]; NIDDK NIH HHS [DK54155, DK41301] NR 43 TC 44 Z9 45 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2000 VL 98 IS 2 BP 233 EP 241 DI 10.1016/S0306-4522(00)00118-4 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 326NC UT WOS:000087740800005 PM 10854754 ER PT J AU Yang, H Yuan, PQ Wang, L Tache, Y AF Yang, H Yuan, PQ Wang, L Tache, Y TI Activation of the parapyramidal region in the ventral medulla stimulates gastric acid secretion through vagal pathways in rats SO NEUROSCIENCE LA English DT Article DE kainate; raphe pallidus; Fos; vagus; TRH mRNA; 5-HT ID THYROTROPIN-RELEASING-HORMONE; DORSAL MOTOR NUCLEUS; INTERMEDIOLATERAL CELL COLUMN; LESION FORMATION; RAPHE PALLIDUS; SUBSTANCE-P; C-FOS; BODY-TEMPERATURE; GENE-EXPRESSION; KAINIC ACID AB Neurons synthesizing thyrotropin-releasing hormone, substance P and serotonin in the medullary caudal raphe nuclei project to the dorsal vagal complex and play a role in the central vagal regulation of gastric function. Neurons in the parapyramidal region in the ventral medulla share similar biochemical coding and projections as those in the caudal raphe nuclei. The role of the parapyramidal region in the autonomic regulation of gastric acid secretion was investigated in urethane-anesthetized rats. Unilateral microinjection of kainate into the parapyramidal region at 10, 15 and 20 ng induced a dose-related stimulation of gastric acid secretion (net increases: 22.2 +/- 11.2, 40.5 +/- 8.5 and 89.8 +/- 19.4 mu mol/60 min, respectively), while injection of vehicle had no effect (net change: -0.1 +/- 1.4 mu mol/60 min). Time-course studies showed a nine-fold peak increase over basal at 30 min after parapyramidal injection of kainate (20 ng) and acid secretion returned to basal level at 70 min. Microinjections of kainate (15-20 ng) outside the parapyramidal region or into the parapyramidal region in vagotomized rats had no effect. Exposure to cold (4 degrees C) for 2 h, which is known to induce vagally mediated gastric secretory and motor responses through medullary thyrotropin-releasing hormone pathways, increased the number of Fos-positive cells in the caudal, middle and rostral parts of the parapyramidal region to 4.3 +/- 0.4, 9.4 +/- 0.9 and 18.4 +/- 1.6/section, respectively, compared with 0.1 +/- 0.1, 0.1 +/- 0.0 and 0.7 +/- 0.6/section, respectively, in rats maintained at room temperature. Most of the Fos-labeled cells co-expressed pro-thyrotropin-releasing hormone messenger RNA signal and/or were serotonin immunoreactive. These data show that chemical activation of neurons in the parapyramidal region results in a vagal-dependent stimulation of gastric acid secretion and that acute cold exposure activates parapyramidal neurons containing pro-thyrotropin-releasing hormone and/or serotonin, suggesting a potential role of the parapyramidal region, in addition to the caudal raphe nuclei, as medullary sites involved in the vagal regulation of gastric function. (C) 1999 IBRO. Published by Elsevier Science Ltd. C1 Univ Calif Los Angeles, Div Digest Dis, Dept Med,Digest Dis Res Ctr, W Los Angeles Vet Adm Med Ctr,CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Yang, H (reprint author), Univ Calif Los Angeles, Div Digest Dis, Dept Med,Digest Dis Res Ctr, W Los Angeles Vet Adm Med Ctr,CURE, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-50255, DK-30110, DK-33061] NR 44 TC 27 Z9 27 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PY 2000 VL 95 IS 3 BP 773 EP 779 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 272RE UT WOS:000084664100014 PM 10670444 ER PT J AU Orwoll, ES Bevan, L Phipps, KR AF Orwoll, ES Bevan, L Phipps, KR TI Determinants of bone mineral density in older men SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE bone density; male; osteoporosis ID OSTEOPOROTIC FRACTURES; HIP FRACTURE; ELDERLY MEN; WOMEN; MASS; RISK; WEIGHT; INDEX; LIFE; SIZE AB Although osteoporosis in men is increasingly recognized as an important health issue and bone mass appears to be a major determinant of fracture, there remain few data concerning the determinants of bone mass in men. To determine the correlates of bone density in men, we studied a large group of older subjects recruited from three rural communities in the northwestern United States. Three hundred and fifty-five men over the age of 60 years (mean 71.5 +/- 7.4 years) without known disorders of mineral metabolism were recruited by community advertising. Bone mineral density was measured at the lumbar spine, proximal femur and radius by dual-energy X-ray absorptiometry, and factors potentially related to skeletal status were assessed by direct measurements or questionnaire. In univariate analyses weight (positively) and age (negatively) were associated with bone density. After adjustment for these two factors, alcohol intake, osteoarthritis and thiazide use were associated with higher bone density, while previous fractures, gastrectomy, peptic ulcer disease, rheumatoid arthritis, glucocorticoid use, hypertension, previous hyperthyroidism, height loss since age 20 years, chronic lung disease and smoking were related to lower density. In multivariate models, only weight and a history of cancer were related to higher bone mass, and age, previous fracture, rheumatoid arthritis, gastrectomy and hypertension were associated with lower density. These data contribute to the emerging field of osteoporosis in men, and may help in the clinical identification of men at higher risk of osteopenia. C1 Oregon Hlth Sci Univ, Sch Med, Bone & Mineral Unit, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Res Serv, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Sch Dent, Portland, OR 97201 USA. RP Orwoll, ES (reprint author), Oregon Hlth Sci Univ, Sch Med, Bone & Mineral Unit, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. OI Orwoll, Eric/0000-0002-8520-7355 FU NIDCR NIH HHS [R0I DE 09883] NR 25 TC 65 Z9 67 U1 1 U2 3 PU SPRINGER-VERLAG LONDON LTD PI GODALMING PA SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PY 2000 VL 11 IS 10 BP 815 EP 821 DI 10.1007/s001980070039 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 385GT UT WOS:000165996000001 PM 11199184 ER PT J AU Brawer, MK Ferreri, LF Bankson, DD AF Brawer, MK Ferreri, LF Bankson, DD TI Long-term stability of alpha-1-antichymotrypsin complexed form of prostate specific antigen SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE prostate specific antigen; complexed stability ID PREDICTIVE VALUE; REFERENCE RANGES; SERUM; CANCER; PSA; CARCINOMA; ENHANCE; MEN; PERFORMANCE; HYPERPLASIA AB PSA complexed with alpha-1-anti-chymotrypsin (cPSA(TM)) is the moiety in greatest proportion in the serum of men with prostate cancer (CAP). The performance of this analyte has been established primarily in retrospective archival serum. Studies indicate cPSA(TM) provides the specificity enhancement of the free-to-total PSA ratio, yet obviates the need to measure two markers. In the present investigation we sought to establish the stability of cPSA(TM) with longterm storage. Serum from men undergoing: ultrasound-guided biopsy was utilized. Serum was assayed soon after collection and 18 months later. All serum was initially aliquotted and stored at -80 degreesC There was no freeze-thaw. cPSA(TM) was measured utilizing the Bayer Immune 1 method according to manufacturer's recommendations. The mean (s.d.) PSA was 5.5 (3.8) and 5.6 (3.9) ng/ml at the initial and subsequent testing, respectively. The medians were 4.3 and 4.4 ng/ml, respectively. No significant differences exist between the two determinants (r(2) = 1.0, slope = 1.01, t-test P = 0.9194). These data establish for the first time the long-term stability of cPSA(TM) Retrospective studies performed on archival material should give meaningful results. C1 NW Prostate Inst, Seattle, WA 98133 USA. NW Hosp, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Brawer, MK (reprint author), NW Prostate Inst, 1560 N 115th St,Suite 209, Seattle, WA 98133 USA. NR 34 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND SN 1365-7852 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PY 2000 VL 3 IS 3 BP 191 EP 194 DI 10.1038/sj.pcan.4500419 PG 4 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 382QQ UT WOS:000165834100009 ER PT J AU Silverman, SL AF Silverman, SL TI The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis SO QUALITY OF LIFE RESEARCH LA English DT Article; Proceedings Paper CT Conference on the 1st International State of the Art Meeting on Health Outcome Assessment for Post-Menopausal Women CY NOV 09-10, 1998 CL VENICE, ITALY DE osteoporosis; vertebral fracture; health-related quality of life; OPAQ ID OF-LIFE AB The Osteoporosis Assessment Questionnaire (OPAQ) is a reliable and valid disease-targeted self assessment questionnaire of health-related quality of life (HRQOL) in osteoporosis first developed in 1993. OPAQ has been used in two international multicenter trials. OPAQ structure includes 14-18 domains which may be grouped into four dimensions: physical function, emotional status, symptoms and social interaction. OPAQ exists in two long versions: OPAQ 1.0 (73 questions) and OPAQ 2.0 (60 questions) OPAQ also exists as a short version: OPAQ-SV (34 questions) with three dimensions: physical function, emotional status and back pain. OPAQ detects changes in HRQOL with prevalent vertebral and nonvertebral fracture. Decreases in HRQOL are seen with increasing numbers of prevalent vertebral fractures. OPAQ is sensitive to changes in HRQOL of incident vertebral fracture. C1 OMC Clin Res Ctr, OMC Res Div, Beverly Hills, CA 90211 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Silverman, SL (reprint author), OMC Clin Res Ctr, OMC Res Div, 8641 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA. NR 13 TC 25 Z9 25 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PY 2000 VL 9 IS 6 SU S BP 767 EP 774 DI 10.1023/A:1008934208764 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 401QM UT WOS:000166939800011 ER PT J AU Burruss, JW Hurley, RA Taber, KH Rauch, RA Norton, RE Hayman, LA AF Burruss, JW Hurley, RA Taber, KH Rauch, RA Norton, RE Hayman, LA TI Functional neuroanatomy of the frontal lobe circuits SO RADIOLOGY LA English DT Article DE brain, anatomy; brain, cortex; brain, function; brain, injuries; brain, MR; special reports ID SUBCORTICAL CIRCUITS; CORTEX AB This article summarizes the current theories regarding the locations and functions of the three primary frontal lobe circuits. It forms the framework for structuring functional magnetic resonance imaging investigations. It can be used to assist in (a) detecting subtle lesions of the frontal circuits and (b)applying the current theories of neuropsychiatry to assess prognosis and to plan rehabilitation. C1 Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. Baylor Coll Med, Herbert J Frensley Ctr Imaging Res, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Psychiat Serv, Houston, TX USA. Houston NW Med Ctr, Dept Radiol, Houston, TX USA. RP Hayman, LA (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, 1 Baylor Plaza, Houston, TX 77030 USA. NR 13 TC 57 Z9 57 U1 0 U2 3 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 2000 VL 214 IS 1 BP 227 EP 230 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 268LD UT WOS:000084414400037 PM 10644129 ER PT J AU Grant, EG Duerinckx, AJ El Saden, SM Melany, ML Hathout, GM Zimmerman, PT Marumoto, AK Cohen, SN Baker, JD AF Grant, EG Duerinckx, AJ El Saden, SM Melany, ML Hathout, GM Zimmerman, PT Marumoto, AK Cohen, SN Baker, JD TI Ability to use duplex US to quantify internal carotid arterial stenoses: Fact or fiction? SO RADIOLOGY LA English DT Article DE angiography, comparative studies; carotid arteries, angiography; carotid arteries, stenosis or obstruction; carotid arteries, US ID ENDARTERECTOMY TRIAL; COST-EFFECTIVENESS; CRITERIA; 70-PERCENT; ULTRASOUND; SONOGRAPHY; ULTRASONOGRAPHY; ACCURACY; DISEASE AB PURPOSE: To determine if duplex ultrasonography (US) can help predict the degree of internal carotid arterial (ICA) stenosis. MATERIALS AND METHODS: ICA peak systolic velocity (PSV) and the:ratio Of the PSV in the ICA to that in the ipsilateral common carotid artery (VICA/VCCA) were compared with the degree of arteriographically measured stenosis. ICAs were arteriographically subgrouped at 10% incremental levels' of stenosis and broader ranges. Mean PSV, VICA/VCCA, and SDs were calculated for each category Histograms showing the numbers of-stenotic ICAs in subgroups and for vessels with stenoses of greater than or equal to or less than 70% narrowing were:constructed. The number of vessels correctly subgrouped with typical Doppler US thresholds was calculated. RESULTS: Mean PSV and VICA/VCCA increased with stenosis level (P < .01); SDs were wide. Histograms showed Doppler US values in the central groups across all disease levels. Histograms differentiating at least or less than 70% stenosis showed minimal overlap. PSV and VICA/VCCA helped classify respectively, 185 and 181 of 204 vessels with stenoses of less than 50%, 15 and 21 of 46 vessels with stenoses of 50%-69%, and 73 and 67 of 84 vessels with stenoses of 70% or greater. When classifying stenoses as 69% or less or 70% or more, PSV and VICA/VCCA were correct in 90.6% and 90.3% of vessels. CONCLUSION: Doppler US is excellent for classifying stenoses as above or below a single deg ree of severity but does not function well in stenosis subclassification. C1 W Los Angeles Vet Affairs Med Ctr, Dept Radiol, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Dept Neurol, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Dept Surg, Los Angeles, CA 90073 USA. RP Grant, EG (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Radiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 29 TC 52 Z9 56 U1 1 U2 2 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 2000 VL 214 IS 1 BP 247 EP 252 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 268LD UT WOS:000084414400040 PM 10644132 ER PT J AU Rosen, HR Martin, P AF Rosen, HR Martin, P TI Hepatitis B and C in the liver transplant recipient SO SEMINARS IN LIVER DISEASE LA English DT Review DE hepatitis B; hepatitis C; viral recurrence ID VIRUS-INFECTION; INTERFERON-ALPHA; IMMUNE GLOBULIN; CHOLESTATIC HEPATITIS; ALLOGRAFT CIRRHOSIS; REJECTION EPISODES; UNITED-STATES; RECURRENCE; DISEASE; PROPHYLAXIS AB Liver disease related to chronic viral hepatitis is the leading indication for orthotopic fiver transplantation (OLT) worldwide. The evolution of our understanding of hepatitis B and C infection in the OLT recipient has been rapid in the last decade. The spontaneous risk for viral recurrence after transplantation is high but has been effectively decreased in hepatitis B infected recipients with the use of HBIG and lamivudine with dramatic improvements in patient and graft survivals, HCV recurrence as defined by histologic injury is almost universal although graft or patient outcomes for the first decade after OLT do not appear to be limited by HCV infection for most patients. However; individual patients do suffer severe graft injury and even graft loss due to recurrent HCV With longer follow up into the second decade, the prevalence of HCV-related graft failure is likely to increase. In addition, the role of different immunosuppressive protocols on disease recurrence requires further study. Thus, although hepatitis B recurrence has been effectively contained by use of HBIG with or without lamivudine, the more intractable problem of managing recurrent HCV has as yet no obvious solutions. Optimal antiviral strategies for hepatitis C post-OLT have yet to be identified. C1 Oregon Hlth Sci Univ, Div Gastroenterol Hepatol, Portland VA Med Ctr, Portland, OR 97207 USA. Portland Vet Adm, Liver Transplantat Program, Portland, OR 97207 USA. Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. Univ Calif Los Angeles, Dumont Transplant Program, Ctr Hlth Sci, Los Angeles, CA USA. RP Rosen, HR (reprint author), Oregon Hlth Sci Univ, Div Gastroenterol Hepatol, Portland VA Med Ctr, POB 1034,111-A,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. NR 122 TC 12 Z9 12 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0272-8087 J9 SEMIN LIVER DIS JI Semin. Liver Dis. PY 2000 VL 20 IS 4 BP 465 EP 480 DI 10.1055/s-2000-13156 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 392EY UT WOS:000166399100006 PM 11200416 ER PT J AU Anzueto, A AF Anzueto, A TI Treatment of acute exacerbations of chronic bronchitis: Antibiotic therapy SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE antibiotics; acute exacerbation of chronic bronchitis; marcrolides; fluoroquinolones; cephalosporins; penicillins ID OBSTRUCTIVE PULMONARY-DISEASE; STREPTOCOCCUS-PNEUMONIAE; DOUBLE-BLIND; HAEMOPHILUS-INFLUENZAE; TOPOISOMERASE-IV; PRIMARY TARGET; DNA GYRASE; FLUOROQUINOLONES; RESISTANCE; CONTROVERSIES AB Acute exacerbation of chronic bronchitis (AECB) is a condition associated with increased morbidity and mortality. Bacterial infections are the most frequent cause of exacerbations. The most common bacterial etiologies include Haemophilus influenzae, Moraxella catarrhalis, and Streptococeus pneumonia. The diagnosis of AE:CB is often based on the clinical presentation, but microbiological assessment, including Gram stain and sputum culture should be done. Antibiotic therapy should be used in patients with the following characteristics: underlying lung disease, frequent exacerbations, and comorbid conditions. Penicillins, erythromycin, beta-lactamase inhibitors, and trimethoprim-sulfamethoxazole have been the preferred antibiotics. However, because of the increasing prevalence of resistance among respiratory pathogens, mainly the production of beta-lactamase by H. influenzae and IM. catarrhalis, and the emergence of multidrug-resistant S. pneumonia, new generation macrolides and fluoroquinolones should be the first line of treatment in selected patients. These drugs have increased efficacy and safety. C1 Univ Texas, Hlth Sci Ctr, VA Med Ctr 111 E, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Anzueto, A (reprint author), Univ Texas, Hlth Sci Ctr, VA Med Ctr 111 E, 7400 Mentor Minter Blvd, San Antonio, TX 78284 USA. NR 34 TC 2 Z9 2 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PY 2000 VL 21 IS 2 BP 97 EP 106 DI 10.1055/s-2000-9843 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 336KX UT WOS:000088301400005 PM 16088723 ER PT J AU Angel, L Homma, A Levine, SM AF Angel, L Homma, A Levine, SM TI Bronchiolitis obliterans SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE bronchiolitis obliterans; constrictive bronchiolitis; lung transplantation; bone marrow transplantation; panbronchiolitis ID BONE-MARROW TRANSPLANTATION; INTERSTITIAL LUNG-DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; AIR-FLOW OBSTRUCTION; SILO-FILLERS DISEASE; TERM FOLLOW-UP; DIFFUSE PANBRONCHIOLITIS; ORGANIZING PNEUMONIA; RISK-FACTORS; SMALL AIRWAYS AB Bronchiolitis obliterans (BO) is a fibrotic lung disease involving the small conducting airways. BO may be classified by etiology and underlying disease or, more commonly, by histopathological pattern. The two major histopathological categories are (1) BO organizing pneumonia (BOOP) and proliferative bronchiolitis and (2) constrictive bronchiolitis. The former is often idiopathic in nature and may also be associated with connective tissue diseases and inhalation injury Characteristic findings on chest imaging include alveolar infiltrates and ground glass opacities and pulmonary function tests (PFTs) usually reveal restrictive dysfunction. Constrictive bronchiolitis is associated with organ transplantation, infections, connective tissue diseases, inhalation injury, and drugs and may also have an idiopathic origin. The radiographic characteristic is a mosaic pattern on high-resolution computed tomography (HRCT) and PFTs most often reveal obstructive dysfunction. This article will attempt to review constrictive BO, including histopathology, clinical presentation, radiographic appearance, and physiological findings, for both idiopathic diseases, as well as specific clinical-associated entities. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Levine, SM (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Dis Crit Care Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 100 TC 6 Z9 6 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PY 2000 VL 21 IS 2 BP 123 EP 134 DI 10.1055/s-2000-9846 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 336KX UT WOS:000088301400008 PM 16088726 ER PT J AU Fink, JB Dhand, R AF Fink, JB Dhand, R TI Aerosol therapy in mechanically ventilated patients: Recent advances and new techniques SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE aerosols; nebulizers; pulmonary mechanics; bronchodilators; beta-agonists ID METERED-DOSE INHALER; AIR-FLOW OBSTRUCTION; INSTILLED EXOGENOUS SURFACTANT; RESPIRATORY-DISTRESS-SYNDROME; BRONCHODILATOR DELIVERY; CYSTIC-FIBROSIS; LUNG INJURY; NEBULIZED ALBUTEROL; IPRATROPIUM BROMIDE; NONUNIFORM PATTERN AB Therapeutic aerosols are commonly used in mechanically ventilated patients, yet information regarding their efficacy and optimal technique of administration has been limited. The advantages of aerosol therapy include a smaller dose, efficacy comparable with that observed with systemic administration of the drug, and a rapid onset of action. Inhaled drugs are delivered directly to the respiratory tract, their systemic absorption is limited, and systemic side effects are minimized. Inhaled bronchodilators are routinely used with mechanically ventilated patients in the intensive care unit, but a variety of drugs ranging from antibiotics to surfactants has been administered. Nebulizers and metered-dose inhalers (MDIs) are commonly used aerosol generators because they produce respirable particles with a mass median aerodynamic diameter (MMAD) between 1 and 5 mu m. Due to the limitation of available formulations, MDIs are chiefly used to deliver bronchodilators and steroids, whereas nebulizers have greater versatility and can he used to administer bronchodilators, antibiotics, surfactant, mucokinetic agents, and other drugs. The delivery of inhaled drugs in mechanically ventilated patients differs from that in ambulatory patients in several respects. Until recently, the consensus of opinion was that the efficiency of aerosol delivery to the lower respiratory tract in mechanically ventilated patients was much lower that that in ambulatory patients. Data suggest that this might be overly pessimistic and that the endotracheal tube may actually facilitate greater aerosol delivery compared with the normal airway when a variety of variables effecting aerosol delivery during mechanical ventilation are optimized. C1 Aerogen, Resp Program, Sunnyvale, CA 94089 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. Loyola Univ, Chicago Stritch Sch Med, Hines, IL USA. RP Fink, JB (reprint author), Aerogen, Resp Program, 1310 Orleans Dr, Sunnyvale, CA 94089 USA. NR 84 TC 10 Z9 10 U1 0 U2 2 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PY 2000 VL 21 IS 3 BP 183 EP 201 DI 10.1055/s-2000-9854 PG 19 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 345GM UT WOS:000088808300006 PM 16088731 ER PT J AU Batra, RK Sharma, S Dubinett, SM AF Batra, RK Sharma, S Dubinett, SM TI New gene and cell-based therapies for lung cancer SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE lung cancer; gene therapy; immunotherapy ID WILD-TYPE P53; COLONY-STIMULATING FACTOR; PULSED DENDRITIC CELLS; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; IFN-GAMMA PRODUCTION; DOWN-REGULATION; TUMOR-CELLS; ADENOVIRAL VECTORS; IMMUNE-RESPONSES AB Lung cancer is the leading cause of cancer-related mortality in men and women in the United States, in part, because of the poor treatment options available. New treatment strategies that specifically target discreet steps in the molecular and cellular pathogenesis of this disease are under development. This review highlights many of the basic defects that result in the cellular transformation and subsequent progression of lung cancer, and how the understanding of those fundamental defects lead to the formulation of rational gene-based or cell-based therapies. C1 Univ Calif Los Angeles, Sch Med, Vet Adm Greater Los Angeles Hlth Care Syst, Div Pulm & Crit Care Med,Wadsworth Pulm Immunol L, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles VA Med Ctr,Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90073 USA. RP Batra, RK (reprint author), Univ Calif Los Angeles, Sch Med, Vet Adm Greater Los Angeles Hlth Care Syst, Div Pulm & Crit Care Med,Wadsworth Pulm Immunol L, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 124 TC 1 Z9 1 U1 0 U2 2 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PY 2000 VL 21 IS 5 BP 463 EP 472 DI 10.1055/s-2000-9455 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 362AJ UT WOS:000089756200011 PM 16088747 ER PT J AU Masih, S Sorenson, SM Gentili, A Seeger, LL AF Masih, S Sorenson, SM Gentili, A Seeger, LL TI Atypical adult non-calcified pilomatricoma SO SKELETAL RADIOLOGY LA English DT Article DE MRI; neoplasms, MRI; soft tissues, MRI; soft tissue neoplasms; skin, neoplasms; MRI, pilomatricoma (histology) ID CALCIFYING EPITHELIOMA; MALHERBE AB We present a rare case of a non-calcified pilomatricoma in a 67-year-old man. This tumor was extremely large in size, and its location, in the lower extremity, was very unusual. The clinical, radiographic, and histopathological features are described in detail. The role of magnetic resonance imaging (MRI) in the diagnosis of this entity is discussed. Definite internal reticulations and septations were observed. A possible explanation for this observation is that the high signal intensity reticulations may represent edematous stroma surrounding basaloid cells. C1 W Los Angeles Vet Affairs Med Ctr, Dept Radiol 114, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Masih, S (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Radiol 114, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Gentili, Amilcare/G-1238-2013 OI Gentili, Amilcare/0000-0002-5623-7512 NR 8 TC 11 Z9 11 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0364-2348 J9 SKELETAL RADIOL JI Skeletal Radiol. PD JAN PY 2000 VL 29 IS 1 BP 54 EP 56 PG 3 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA 282DC UT WOS:000085200400010 PM 10663591 ER PT J AU Cohen, SN Muthukamaran, A El-Saden, S Hathout, G AF Cohen, SN Muthukamaran, A El-Saden, S Hathout, G TI Spread of negative symptoms to contiguous body areas: A clinical marker of amyloid angiopathy? SO STROKE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 2000 VL 31 IS 1 MA P202 BP 337 EP 337 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 271HX UT WOS:000084589100367 ER PT J AU Childress, AR O'Brien, CP AF Childress, AR O'Brien, CP TI Dopamine receptor partial agonists could address the duality of cocaine craving SO TRENDS IN PHARMACOLOGICAL SCIENCES LA English DT Editorial Material ID NUCLEUS-ACCUMBENS; METHYLPHENIDATE TREATMENT; EXTRACELLULAR DOPAMINE; SQUIRREL-MONKEYS; SEEKING BEHAVIOR; MODULATION; ADDICTION; REINFORCEMENT; ABUSERS; RATS C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Behav Hlth Div, Philadelphia, PA 19104 USA. RP Childress, AR (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. NR 55 TC 44 Z9 46 U1 2 U2 4 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0165-6147 J9 TRENDS PHARMACOL SCI JI Trends Pharmacol. Sci. PD JAN PY 2000 VL 21 IS 1 BP 6 EP 9 DI 10.1016/S0165-6147(99)01422-4 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 271HZ UT WOS:000084589300001 PM 10637646 ER PT S AU Craft, S Asthana, S Schellenberg, G Baker, L Cherrier, M Boyt, AA Martins, RN Raskind, M Peskind, E Plymate, S AF Craft, S Asthana, S Schellenberg, G Baker, L Cherrier, M Boyt, AA Martins, RN Raskind, M Peskind, E Plymate, S BE Kalaria, RN Ince, P TI Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype SO VASCULAR FACTORS IN ALZHEIMER'S DISEASE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Vascular Factors in Alzheimers Disease CY MAY 25-28, 1999 CL NEWCASTLE TYNE, ENGLAND SP Bayer AG, Eisai Ltd, GJ Livanos Trust, Alzheimers Report, Hoechst Marrion Roussel, Janssen Pharmaceut, Novartis Pharma AG, Parke Davis, Pfizer Inc, SmithKline Beecham Pharmaceut, Zeneca, Med Res Council, Inst Brain & Blood Vessels, Akita, Inst Hlth Elderly, Univ Newcastle Upon Tyne ID RECEPTOR-RELATED PROTEIN; HYPERINSULINEMIA; DEGRADATION AB Higher lasting plasma Insulin levels and reduced CSF-to-plasma insulin ratios, suggestive of insulin resistance, have been observed In patients with Alzheimer's disease (AD) who do not possess an apolipoprotein E (ApoE)-epsilon 4 allele, Insulin has also been implicated in processing of beta-amyloid and amyloid precursor protein (APP), We examined the effects of intravenous insulin administration while maintaining euglycemia on insulin-mediated glucose disposal, memory, and plasma APP in patients with AD and normal adults of varying ApoE genotypes, AD subjects without an epsilon 4 allele had significantly lower insulin-mediated glucose disposal rates than did AD patients with an epsilon 4 allele (p < 0.03) or than did normal adults without an epsilon 4 allele (p < 0.02). AD subjects without an e4 allele also showed significant memory facilitation with insulin administration (p < 0.04), whereas the AD-epsilon 4 group did not, Insulin reduced APP levels for AD patients without an ApoE epsilon 4 allele, but raised APP for AD patients with an ApoE epsilon H4 allele These results document ApoE-related differences in insulin metabolism in AD that may relate to disease pathogenesis. C1 VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98108 USA. Univ Western Australia, Sir James McCusker Alzheimers Dis Res Unit, Dept Surg, Perth, WA 6009, Australia. RP Craft, S (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, 182B,1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [AG-05136, AG-10880] NR 13 TC 100 Z9 106 U1 0 U2 3 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-251-7 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2000 VL 903 BP 222 EP 228 DI 10.1111/j.1749-6632.2000.tb06371.x PG 7 WC Multidisciplinary Sciences; Clinical Neurology; Peripheral Vascular Disease SC Science & Technology - Other Topics; Neurosciences & Neurology; Cardiovascular System & Cardiology GA BQ26Z UT WOS:000087756800030 PM 10818510 ER PT S AU Pisegna, JR Lyu, RM Germano, PM AF Pisegna, JR Lyu, RM Germano, PM BE Fahrenkrug, J Said, SI TI Essential structural motif in the C-terminus of the PACAP type I receptor for signal transduction and internalization SO VIP, PACAP, GLUCAGON, AND RELATED PEPTIDES SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 4th International Symposium on VIP, PACAP, GLUCAGON, and Related Peptides CY SEP 02-04, 1999 CL ELSINORE, DENMARK SP Amersham Pharmacia Biotech, ASTRA AB, BACHEM AG, Biotechnol Ctr Cellular Commun, Clinalfa AG, Danish Canc Fdn, Eli Lilly Danmark AS, Euro Diagnost, Fujifilm Sverige AB, Interneuron Pharmaceut Inc, Novex Kem En Tec AS, Leica, Neurosci Pharmabiotec, Neosystem SA, NOVO Nordist AS, Roche Molec Biochem, Schering AG, Sigma Genosys Ltd, Danish Med Res Council, Plasmid Fdn AB The objectives of the study reported here were to identify amino acid residues of the C-terminus that are critical for intracellular signaling. A total of nine amino acid substitution and truncation mutants were constructed by PCR and confirmed by sequencing. Mutant and wildtype receptors were stably transfected into NIH/3T3 fibroblasts and studied for their ability to bind PACAP-27 and activate phospholipase C (PLC) and adenylyl cyclase (AC). Receptor affinity of I-125-PACAP-27 for the widtype and mutants were similar (K-d = 0.6-1.5 nM). However, truncation of the entire 63 amino acids of the hPAC(1) resulted in no signaling to either AC or IP. Addition of the proximal 10 amino acids of the C-terminus failed to restore AC or IP signaling, whereas addition of the proximal 27 amino acids of the C-terminus resulted in reconstitution of complete AC and IP responses, identical to the WT. Point mutations within this 17 amino acid region identified specific amino acids involved in PAC(1) signaling. These results indicate that a structural motif within the proximal region of the carboxyl terminus is critical for G protein coupling. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA 90073 USA. RP Pisegna, JR (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK 52274-0 1] NR 0 TC 3 Z9 3 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-273-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2000 VL 921 BP 195 EP 201 PG 7 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Science & Technology - Other Topics GA BT09Y UT WOS:000171939800021 PM 11193823 ER PT S AU Pisegna, JR Ohning, GV Athmann, C Zeng, NX Walsh, JH Sachs, G AF Pisegna, JR Ohning, GV Athmann, C Zeng, NX Walsh, JH Sachs, G BE Fahrenkrug, J Said, SI TI Role of PACAP, receptor in regulation of ECL cells and gastric acid secretion by pituitary adenylate cyclase activating peptide SO VIP, PACAP, GLUCAGON, AND RELATED PEPTIDES SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 4th International Symposium on VIP, PACAP, GLUCAGON, and Related Peptides CY SEP 02-04, 1999 CL ELSINORE, DENMARK SP Amersham Pharmacia Biotech, ASTRA AB, BACHEM AG, Biotechnol Ctr Cellular Commun, Clinalfa AG, Danish Canc Fdn, Eli Lilly Danmark AS, Euro Diagnost, Fujifilm Sverige AB, Interneuron Pharmaceut Inc, Novex Kem En Tec AS, Leica, Neurosci Pharmabiotec, Neosystem SA, NOVO Nordist AS, Roche Molec Biochem, Schering AG, Sigma Genosys Ltd, Danish Med Res Council, Plasmid Fdn ID VASOACTIVE-INTESTINAL-PEPTIDE; POLYPEPTIDE PACAP; RAT-BRAIN; HYPOTHALAMIC POLYPEPTIDE; I RECEPTOR; NEUROPEPTIDE; VIP; PROLIFERATION; HISTAMINE; LUNG AB We previously reported that PAC, is expressed on ECL cells resulting in stimulation of [Ca2+](i), histamine and acid secretion. The study reported here characterized the signaling by PAC, on ECL cells; determined the effects of PACAP on the gastric acid secretion if: vivo, and determined the effects of chronic administration of PACAP-27 on ECL cell proliferation. PACAP-27 dose dependently stimulated ECL cell Ca2+ and AC with detectable stimulation at 1 nM and maximal stimulation at 100 nM (six-fold). In rats PACAP-27 administration (10 pmol/kg/h) increased the rate of gastric acid secretion when an antisomatostatin antibody was co-administered. Chronic administration of PACAP (10 pmol/h for seven days) via osmotic pump resulted in a more than twofold increase in BrdU incorporation into ECL cells. PACAP acting at the PAC, results in dual signaling responses to both [Ca2+](i). AC in ECL cells stimulates gastric acid secretion via the actions of histamine acting at the parietal cell and in whole animals leads to proliferation of ECL cells when administered chronically. C1 Univ Calif Los Angeles, W LA VA Med Ctr, CURE, VA UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, 111C, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK 52274-01, DK17294, DK40615, DK41301] NR 30 TC 13 Z9 13 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 1-57331-273-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2000 VL 921 BP 233 EP 241 PG 9 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Science & Technology - Other Topics GA BT09Y UT WOS:000171939800026 PM 11193828 ER PT J AU Brown, AM Dolan, JW Willi, SM Garvey, WT Argyropoulos, G AF Brown, AM Dolan, JW Willi, SM Garvey, WT Argyropoulos, G TI Endogenous mutations in human uncoupling protein 3 alter its functional properties SO FEBS LETTERS LA English DT Article DE mitochondrion; obesity; membrane potential; UCP3 ID THYROID-HORMONE; GENE-EXPRESSION; OBESITY; ORGANIZATION; MEMBER; FAMILY; TISSUE; LEPTIN; MUSCLE; UCP3 AB Human uncoupling protein 3 (UCP3) is a mitochondrial transmembrane carrier that uncouples oxidative phosphorylation and is a candidate gene for obesity. Expression of native human UCP3 mutations in yeast showed complete loss (R70W), significant reduction (R143X), or no effect (V102I and IVS6+1G>A) on the uncoupling activity of UCP3, It is concluded that certain mutations in UCP3 alter its functional impact on membrane potential (Delta Psi), possibly conferring susceptibility to develop metabolic diseases, (C) 1999 Federation of European Biochemical Societies. C1 Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Med Univ S Carolina, Dept Med, Div Endocrinol, 114 Doughty St, Charleston, SC 29425 USA. EM argyrog@musc.edu FU NHLBI NIH HHS [HL 07260]; NIDDK NIH HHS [DK-47461] NR 26 TC 14 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 EI 1873-3468 J9 FEBS LETT JI FEBS Lett. PD DEC 31 PY 1999 VL 464 IS 3 BP 189 EP 193 DI 10.1016/S0014-5793(99)01708-1 PG 5 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 272MR UT WOS:000084654800018 PM 10618503 ER PT J AU Schwartz, MW Kahn, SE AF Schwartz, MW Kahn, SE TI Diabetes - Insulin resistance and obesity SO NATURE LA English DT Editorial Material ID PPAR-GAMMA; SENSITIVITY C1 Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Schwartz, MW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98108 USA. RI Schwartz, Michael/H-9950-2012 NR 10 TC 27 Z9 27 U1 0 U2 4 PU MACMILLAN PUBLISHERS LTD PI LONDON PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD DEC 23 PY 1999 VL 402 IS 6764 BP 860 EP 861 DI 10.1038/47209 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 269ML UT WOS:000084482000024 PM 10622250 ER PT J AU Braddock, CH Edwards, KA Hasenberg, NM Laidley, TL Levinson, W AF Braddock, CH Edwards, KA Hasenberg, NM Laidley, TL Levinson, W TI Informed decision making in outpatient practice - Time to get back to basics SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CLINICAL DECISIONS; PRIMARY-CARE; CONSENT; DISCLOSURE; PHYSICIANS AB Context Many clinicians have called for an increased emphasis on the patient's role in clinical decision making. However, little is known about the extent to which physicians foster patient involvement in decision making, particularly in routine office practice. Objective To characterize the nature and completeness of informed decision making in routine office visits of both primary care physicians and surgeons. Design Cross-sectional descriptive evaluation of audiotaped office visits during 1993, Setting and Participants A total of 1057 encounters among 59 primary care physicians (general internists and family practitioners) and 65 general and orthopedic surgeons; 2 to 12 patients were recruited from each physician's community-based private office. Main Outcome Measures Analysis of audiotaped patient-physician discussions for elements of informed decision making, using criteria that varied with the level of decision complexity: basic (eg, laboratory test), intermediate (eg, new medication), or complex (eg, procedure), Criteria for basic decisions included discussion of the nature of the decision and asking the patient to voice a preference; other categories had criteria that were progressively more stringent, Results The 1057 audiotaped encounters contained 3552 clinical decisions. Overall, 9.0% of decisions met our definition of completeness for informed decision making, Basic decisions were most often completely informed (17.2%), while no intermediate decisions were completely informed, and only 1 (0.5%) complex decision was completely informed. Among the elements of informed decision making, discussion of the nature of the intervention occurred most frequently (71%) and assessment of patient understanding least frequently (1.5%). Conclusions Informed decision making among this group of primary care physicians and surgeons was often incomplete. This deficit was present even when criteria for informed decision making were tailored to expect less extensive discussion for decisions of lower complexity. These findings signal the need for efforts to encourage informed decision making in clinical practice. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Hlth Serv Res & Dev Field Program, Seattle, WA 98108 USA. Cascade Physicians, Portland, OR USA. Univ Chicago, Div Gen Internal Med & Geriatr, Chicago, IL 60637 USA. RP Braddock, CH (reprint author), VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Hlth Serv Res & Dev Field Program, 1660 S Columbian Way, Seattle, WA 98108 USA. FU AHRQ HHS [R01-HS0728 9] NR 26 TC 644 Z9 650 U1 4 U2 28 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 22 PY 1999 VL 282 IS 24 BP 2313 EP 2320 DI 10.1001/jama.282.24.2313 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 265TK UT WOS:000084261700024 PM 10612318 ER PT J AU McAlister, FA Clark, HD van Walraven, C Straus, SE Lawson, FME Moher, D Mulrow, CD AF McAlister, FA Clark, HD van Walraven, C Straus, SE Lawson, FME Moher, D Mulrow, CD TI The medical review article revisited: Has the science improved? SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROL TRIALS; METAANALYSES; QUALITY; BIAS AB Background: The validity of a review depends on its methodologic quality. Objective: To determine the methodologic quality of recently published review articles. Design: Critical appraisal. Setting: All reviews of clinical topics published in six general medical journals in 1996. Measurements: Explicit criteria that have been published and validated were used. Results: Of 158 review articles, only 2 satisfied all 10 methodologic criteria (median number of criteria satisfied, 1), Less than a quarter of the articles described how evidence was identified, evaluated, or integrated; 34% addressed a focused clinical question; and 39% identified gaps in existing knowledge. Of the 111 reviews that made treatment recommendations, 48% provided an estimate of the magnitude of potential benefits (and 34%, the potential adverse effects) of the treatment options, 45% cited randomized clinical trials to support their recommendations, and only 6% made any reference to costs. Conclusions: The methodologic quality of clinical review articles is highly variable, and many of these articles do not specify systematic methods. C1 Univ Oxford, Oxford, England. Univ Alberta, Edmonton, AB, Canada. Univ Ottawa, Loeb Hlth Res Inst, Ottawa, ON, Canada. Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON K1H 8L1, Canada. Univ Toronto, Toronto, ON, Canada. Audie L Murphy Vet Affairs Hosp, San Antonio, TX USA. RP McAlister, FA (reprint author), Univ Alberta Hosp, 2E3-24 WMC,8440 112 St, Edmonton, AB T6G 2R7, Canada. RI McAlister, Finlay/C-4151-2013 OI Moher , David /0000-0003-2434-4206 NR 20 TC 87 Z9 89 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 21 PY 1999 VL 131 IS 12 BP 947 EP 951 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 267TB UT WOS:000084374400006 PM 10610646 ER PT J AU Goldstein, G Allen, DN Weiner, CL AF Goldstein, G Allen, DN Weiner, CL TI Lateralized brain dysfunction in schizophrenia: a comparison with patients with lateralized structural lesions SO SCHIZOPHRENIA RESEARCH LA English DT Article DE cognitive function; laterality; neuropsychology AB A comparison was made among participants with schizophrenia and those with structural lateralized or diffuse brain damage in order to determine the extent to which the cognitive profile of the schizophrenia sample resembled the profiles obtained from patients with left-hemisphere, right-hemisphere, and diffuse brain damage. The Halstead-Reitan Neuropsychological Battery was used as the testing procedure. The data were subjected to discriminant analysis in order to obtain frequencies of predicted classification of the participants with schizophrenia into schizophrenia, left-hemisphere, right-hemisphere, and diffuse groups. Half of the participants with schizophrenia were classified into the schizophrenia group. The other half was evenly distributed across the left-hemisphere, right-hemisphere, and diffuse brain damage groups. There was not a disproportionately large number of participants classified into the left-hemisphere group. Comparisons among these four predicted groups were accomplished for each of the Halstead-Reitan Battery measures using one-way analysis of variance. The comparison of the subtest scores among the predicted groups indicated that the patients classified into the left-hemisphere group were characterized by a pattern of language dysfunction thought to be developmental in nature, and an abnormal lack of asymmetry in tapping speed favoring the right hand. (C) 1999 Elsevier Science B.V. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Highland Dr Div, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Pittsburgh, PA 15213 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Highland Dr Div, 7180 Highland Dr, Pittsburgh, PA 15206 USA. NR 23 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC 21 PY 1999 VL 40 IS 3 BP 179 EP 187 DI 10.1016/S0920-9964(99)00050-X PG 9 WC Psychiatry SC Psychiatry GA 261RP UT WOS:000084023000002 PM 10638856 ER PT J AU Keire, DA Solomon, TE Reeve, JR AF Keire, DA Solomon, TE Reeve, JR TI Identical primary sequence but different conformations of the bioactive regions of canine CCK-8 and CCK-58 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article ID FLUORESCENCE-TRANSFER MEASUREMENTS; H-1-NMR SPECTROSCOPY; CHOLECYSTOKININ; FRAGMENTS; BRAIN; BLOOD AB The C-terminal bioactive regions of CCK-8 and CCK-58 are identical (DY*MGWMDF-NH2, Y* denotes a sulfated tyrosine residue), but these peptides have different patterns of bioactivity. Specifically, CCK-58 binds more avidly to the CCKA receptor while CCK-8 is more potent for stimulation of amylase secretion from pancreatic acini. We postulate that these seemingly contradictory observations reflect a stable conformational change in CCK-58 that enhances binding, but diminishes activation of second messenger. We used CD and NMR spectra to evaluate postulated structural differences between CCK-8 and the carboxy-terminus of synthetic CCK-58. The CD spectra indicate the presence of turns in CCK-8 but a mixture of helical and random coil structures for CCK-58. Comparisons of partial NMR chemical shift assignments of CCK-58 and full assignments for CCK-8 also indicate differences in the backbone conformations for these residues. The data support the hypothesis that these peptides have different, stable, carboxy-terminal structures that may influence bioactivity. (C) 1999 Academic Press. C1 Greater Los Angeles Vet Hlth Care Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90023 USA. RP Reeve, JR (reprint author), Greater Los Angeles Vet Hlth Care Syst, CURE, Digest Dis Res Ctr, Room 115,Bldg 115, Los Angeles, CA 90073 USA. NR 20 TC 15 Z9 15 U1 0 U2 2 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD DEC 20 PY 1999 VL 266 IS 2 BP 400 EP 404 DI 10.1006/bbrc.1999.1825 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 271FG UT WOS:000084583100021 PM 10600515 ER PT J AU Kohen, R AF Kohen, R TI Technology transfer SO SCIENCE LA English DT Article C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, GRECC 182B, Seattle, WA 98108 USA. RP Kohen, R (reprint author), Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 3 U2 4 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD DEC 17 PY 1999 VL 286 IS 5448 BP 2296 EP 2298 DI 10.1126/science.286.5448.2296 PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 266UK UT WOS:000084318500046 ER PT J AU Zhang, HJ Yan, T Oberley, TD Oberley, LW AF Zhang, HJ Yan, T Oberley, TD Oberley, LW TI Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype SO CANCER RESEARCH LA English DT Article ID MALIGNANT PHENOTYPE; LUNG FIBROBLASTS; OVEREXPRESSION; SUPPRESSION; EXPRESSION; CARCINOGENESIS; MUTATION; RADICALS; GENE AB Two polymorphic variants of manganese superoxide dismutase (MnSOD), vMh either lie or Thr at amino acid 58, (Ile(58)MnSOD or Thr(58)MnSOD), have been found in the human population. The MnSOD activity of these two variants and their effects on the malignant phenotype of human breast cancer MCF-7 cells were compared. It,vas demonstrated that MnSOD-overexpressing: clones obtained from transfection of the two MnSOD cDNAs into MCF-7 cells had increased MnSOD immunoreactive protein and increased MnSOD activity. Cells overexpressing Ile(58)MnSOD had 3-fold higher MnSOD activity than cells overexpressing Thr(58)MnSOD irt vivo at an equal MnSOD protein level Tumor-suppressive effects of MnSOD-overexpressing cells were indicated by: (a) decreased plating efficiency; (b) elongated cell population doubling time; (c) lower clonogenic fraction in soft agar; and (d) complete inhibition or delayed onset of tumor formation in nude mice. When compared on the same activity basis, the suppressive effects of Ile(58)MnSOD were similar to those of Thr(58)MnSOD, However, far more Thr(58)MnSOD protein was required to obtain the same amount of MnSOD activity, making the Thr(58)MnSOD far less effective, A dose-response suppressive effect was observed when the increase of MnSOD activity was moderate. We conclude that MnSOD is a tumor suppressor in human breast cancer, but the Thr(58) form of the protein is a much less effective tumor suppressor than the Ile(58) form of the protein. C1 Univ Iowa, Coll Med, Radiat Res Lab, Med Labs B180, Iowa City, IA 52242 USA. William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA. RP Oberley, LW (reprint author), Univ Iowa, Coll Med, Radiat Res Lab, Med Labs B180, Iowa City, IA 52242 USA. FU NCI NIH HHS [CA66081] NR 35 TC 72 Z9 76 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 1999 VL 59 IS 24 BP 6276 EP 6283 PG 8 WC Oncology SC Oncology GA 270HT UT WOS:000084530400042 PM 10626823 ER PT J AU Peterfy, M Phan, J Oswell, GM Xu, P Reue, K AF Peterfy, M Phan, J Oswell, GM Xu, P Reue, K TI Genetic, physical, and transcript map of the fld region on mouse chromosome 12 SO GENOMICS LA English DT Article ID MUTANT MOUSE; E2F FAMILY; MUTATION; MICE; AMPLIFICATION; METABOLISM; REPRESSOR; MEMBER AB The fatty liver dystrophy (fld) mutation is manifested in abnormalities of lipid and glucose metabolism and peripheral neuropathy, To identify the gene affected by this mutation, we generated a genetic map of the fld region on chromosome 12 by the analysis of F2 offspring from an intersubspecific cross between strains BALB/cByJ-fld and CAST/EiJ, The results localize fld to the 0.42-cM interval between the microsatellite markers D12Mit170 and D12Mit184. A contig of YACs and BACs covering the nonrecombinant genomic region has been constructed and used for the identification of genes. Expressed sequence tag mapping and exon trapping identified three transcripts within the critical interval: Ctla2b, which encodes a cysteine protease inhibitor, and mouse homologs of KIAA0188 and KIAA0575, two long human transcripts of unknown function. Expression analysis revealed that Kiaa0188 is expressed in wildtype but not in fld liver, implicating this gene as a candidate for harboring the fld mutation. (C) 1999 Academic Press. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Lipid Res Lab, Los Angeles, CA 90073 USA. RP Reue, K (reprint author), VA Greater Los Angeles Healthcare Ctr, Bldg 113,Room 312,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NHLBI NIH HHS [HL58627, HL28481] NR 26 TC 13 Z9 15 U1 1 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 J9 GENOMICS JI Genomics PD DEC 15 PY 1999 VL 62 IS 3 BP 436 EP 444 DI 10.1006/geno.1999.6023 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 280EN UT WOS:000085089400013 PM 10644441 ER PT J AU Miller, LG Simon, PA Miller, ME Long, A Yu, EI Asch, SM AF Miller, LG Simon, PA Miller, ME Long, A Yu, EI Asch, SM TI High-risk sexual behavior in Los Angeles: Who receives testing for HIV? SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV testing; high-risk sexual behavior ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; AIDS; PREDICTORS; TRENDS AB No recent population-based data on HN testing in people with high-risk sexual behavior are available. We sought predictors of testing using data from the 1997 Los Angeles County Health Survey, a random-digit telephone survey of 8004 county households. An estimated 2.3 million (35.5%) adults were tested for HIV in the past 2 years and approximately 370,000 (5.6%) engaged in high-risk sexual behavior (defined as having greater than or equal to 2 partners in the past 12 months and not always using condoms). Among high-risk persons, an estimated 46% of heterosexual men, 56% of heterosexual women, and 72% of men who had sex with men (MSM) were tested for HIV. In a multivariable model of high-risk people, both heterosexual men (odds ratio [OR], 0.31; 95% confidence interval [CI], 0.16-0.61) and women (OR, 0.41; 95% CI, 0.19-0.87) had significantly lower proportions of testing than MSM. Although African Americans and Hispanics had significantly higher testing proportions than whites overall among all county residents, those reporting high-risk sexual behavior did not test at higher proportions. We conclude that the proportion of adults with high-risk sexual behavior tested for HIV is higher than almost a decade ago. However, testing among this group remains suboptimal. Future public health campaigns should intensify efforts to encourage HIV testing among this population. C1 Univ Calif Los Angeles, Med Ctr, Div Infect Dis, VA Greater Los Angeles Healthcare Syst, Torrance, CA 90509 USA. Univ Calif Los Angeles, AIDS Inst, Torrance, CA 90509 USA. Los Angeles Cty Dept Hlth Serv, Off AIDS Programs & Policy, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA. RP Miller, LG (reprint author), Univ Calif Los Angeles, Harbor Med Ctr, Div Infect Dis, 1124 W Carson St,Box 466, Torrance, CA 90509 USA. NR 25 TC 12 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 J ACQ IMMUN DEF SYND JI J. Acquir. Immune Defic. Syndr. PD DEC 15 PY 1999 VL 22 IS 5 BP 490 EP 497 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 284MR UT WOS:000085336600010 PM 10961611 ER PT J AU Alam, MN Szymusiak, R Gong, H King, J McGinty, D AF Alam, MN Szymusiak, R Gong, H King, J McGinty, D TI Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; NUCLEUS BASALIS; ACETYLCHOLINE-RELEASE; SUBSTANTIA INNOMINATA; POSSIBLE INVOLVEMENT; CHOLINERGIC NEURONS; CEREBRAL-CORTEX; DIAGONAL BAND; STIMULATION; WAKEFULNESS AB 1. The cholinergic system of the basal forebrain (BF) is hypothesized to play an important role in behavioural and electrocortical arousal. Adenosine has been proposed as a sleep-promoting substance that induces sleep by inhibiting cholinergic neurons of the BF and brainstem. However, adenosinergic influences on the activity of BF neurons in naturally awake and sleeping animals have not been demonstrated. 2. We recorded the sleep-make discharge profile of BF neurons and simultaneously assessed adenosinergic influences on wake- and sleep-related activity of these neurons by delivering adenosinergic agents adjacent to the recorded neurons with a microdialysis probe. Discharge rates of BF neurons were recorded through two to three sleep-wake episodes during baseline (artificial cerebrospinal fluid perfusion), and after delivering an adenosine transport inhibitor (s-(p-nitrobenzyl)-6-thioinosine; NBTI), or exogenous adenosine, or a selective adenosine A1. receptor antagonist (8-cyclopentyl-1,3-dimethylxanthine; CPDX). 3. NBTI and adenosine decreased the discharge rate of BF neurons during both waking and non-rapid eye movement (NREM) sleep. In contrast, CPDX increased the discharge rate of BF neurons during both waking and NREM sleep. These results suggest that in naturally awake and sleeping animals, adenosine exerts tonic inhibitory influences on BF neurons, supporting the hypothesized role of adenosine in sleep regulation. 4. However, in the presence of exogenous adenosine, NBTI or CPDX, BF neurons retained their wake- and sleep-related discharge patterns, i.e. still exhibited changes in discharge rate during transitions between waking and NREM sleep. This suggests that other neuro transmitters/neuromodulators also contribute to the sleep-wake discharge modulation of BF neurons. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90033 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90033 USA. RP McGinty, D (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, 16111 Plummer St, North Hills, CA 91343 USA. EM dmcginty@ucla.edu FU NHLBI NIH HHS [HC 60296]; NIMH NIH HHS [MH 47480, R01 MH047480] NR 54 TC 114 Z9 120 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD DEC 15 PY 1999 VL 521 IS 3 BP 679 EP 690 DI 10.1111/j.1469-7793.1999.00679.x PG 12 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 273DB UT WOS:000084691200011 PM 10601498 ER PT J AU Alexander, M Tekawa, I Hunkeler, E Fireman, B Rowell, R Selby, JV Massie, BM Cooper, W AF Alexander, M Tekawa, I Hunkeler, E Fireman, B Rowell, R Selby, JV Massie, BM Cooper, W TI Evaluating hypertension control in a managed care setting SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID BLOOD-PRESSURE AB Background: We conducted a retrospective cohort study on a random sample of adult patients with hypertension in a large health maintenance organization to assess the feasibility of documenting blood pressure (BP) control and to compare different measures for defining BP control. Methods: Three criteria for BP control were assessed: systolic BP less than 140 mm Hg; diastolic BP less than 90 mm Hg; and combined BP control, with systolic BP less than 140 mm Hg and diastolic BP less than 90 mm Hg. Four methods of assessing hypertension control by the above criteria were examined: proportion of patients with BP under control at 75% and 50% or more of their office visits; the mean of all pressures during the study period; and the BP from the last visit during the study period. Results: The proportion of patients meeting each criterion for control was similar whether we used the mean BP for all visits, the last recorded BP, or control at 50% or more of visits. Control rates were substantially lower when the more stringent assessment, 75% of visits, was used. The proportion of patients with combined BP control at 75% or more of their visits was half that of the other methods. Conclusions: In this health maintenance organization population, results with the use of the simplest approach, the last BP measurement recorded, were similar to results with the mean BP. Our findings indicate that evaluation of BP control in a large health maintenance organization will find substantial room for improvement, and clinicians should be encouraged to be more aggressive in their management of hypertension, especially with regard to the systolic BP, which until recent years has been underemphasized. C1 Kaiser Permanente, Div Res, Med Care Program, Oakland, CA 94611 USA. Univ Calif San Francisco, Med Effectiveness Res Ctr, Ctr Aging Diverse Communities, Div Gen Internal Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Astra Pharmaceut LP, Wayne, PA USA. RP Alexander, M (reprint author), Kaiser Permanente, Div Res, Med Care Program, 3505 Broadway,No Calif Reg, Oakland, CA 94611 USA. FU AHRQ HHS [HS07373]; NIA NIH HHS [1 P30 AG15272] NR 13 TC 76 Z9 77 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 13 PY 1999 VL 159 IS 22 BP 2673 EP 2677 DI 10.1001/archinte.159.22.2673 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 262EM UT WOS:000084052700007 PM 10597757 ER PT J AU Aylward, EH Minshew, NJ Goldstein, G Honeycutt, NA Augustine, AM Yates, KO Barta, PE Pearlson, GD AF Aylward, EH Minshew, NJ Goldstein, G Honeycutt, NA Augustine, AM Yates, KO Barta, PE Pearlson, GD TI MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults SO NEUROLOGY LA English DT Article DE limbic; hippocampus; amygdala; autism; brain volume; neuroimaging; MRI ID PERVASIVE DEVELOPMENTAL DISORDERS; DIAGNOSTIC INTERVIEW; FACIAL EXPRESSIONS; INFANTILE-AUTISM; BRAIN; ABNORMALITIES; INDIVIDUALS; DEFICITS AB Objective: To determine whether volumes of hippocampus and amygdala are abnormal in people with autism. Background: Neuropathologic studies of the limbic system in autism have found decreased neuronal size, increased neuronal packing density, and decreased complexity of dendritic arbors in hippocampus, amygdala, and other limbic structures. These findings are suggestive of a developmental curtailment in the maturation of the neurons and neuropil. Methods: Measurement of hippocampus, amygdala, and total brain volumes from 1.5-mm coronal, spoiled gradient-recalled echo MRI scans in 14 non-mentally retarded autistic male adolescents and young adults and 14 individually matched, healthy community volunteers. Results: Amygdala volume was significantly smaller in the autistic subjects, both with (p = 0.006) and without (p = 0.01) correcting for total brain volume. Total brain volume and absolute hippocampal volume did not differ significantly between groups, but hippocampal volume, when corrected for total brain volume, was significantly reduced (p = 0.04) in the autistic subjects. Conclusions: There is a reduction in the volume of amygdala and hippocampus in people with autism, particularly in relation to total brain volume. The histopathology of autism suggests that these volume reductions are related to a reduction in dendritic tree and neuropil development, and likely reflect the underdevelopment of the neural connections of limbic structures with other parts of the brain, particularly cerebral cortex. C1 Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Psychiat Neuroimaging, Baltimore, MD 21205 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Highland Dr Div, Pittsburgh, PA USA. RP Aylward, EH (reprint author), Univ Washington, Sch Med, Dept Radiol, Box 357115, Seattle, WA 98195 USA. FU NICHD NIH HHS [HD 35469]; NINDS NIH HHS [NS 33355] NR 34 TC 294 Z9 300 U1 5 U2 26 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD DEC 10 PY 1999 VL 53 IS 9 BP 2145 EP 2150 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 265QR UT WOS:000084255300042 PM 10599796 ER PT J AU Yuan, PQ Yang, H AF Yuan, PQ Yang, H TI Hyperthyroidism decreases thyrotropin-releasing hormone gene expression in the caudal raphe nuclei and the parapyramidal regions in rats SO NEUROSCIENCE LETTERS LA English DT Article DE autonomic disorders; hypothyroid; substance P; in situ hybridization; thyroid hormones; feedback regulation ID PROJECTIONS; BRAIN AB Altered thyroid statuses are associated with autonomic disorders. Medullary thyrotropin-releasing hormone (TRH) and substance P (SP) regulate autonomic nervous activity. The influences of thyroid statuses on TRH and SP gene expressions in the caudal raphe nuclei and the parapyramidal regions were studied using quantitative in situ hybridization histochemistry. In male rats thyroidectomized (Tx) for 30 days, the serum T-4 levels decreased by 64% and the medullary pro-TRH mRNA signals (silver grains per neuron) significantly increased by 32-45%. These changes were prevented by daily i.p. T-4 (2 mu g/100 g) injection in Tx rats. In sham operated/T-4 (20 mu g/100 g, daily) injected rats, T-4 levels significantly increased by 88% and the silver g rains decreased by 38-40%. Medullary SP mRNA signals were not significantly:changed by altering thyroid status. These results support the concept that thyroid hormone regulates medullary TRH gene expression by negative feedback. (C) 1999 Elsevier Science Ireland Ltd. Ail rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Brain Res Inst, Los Angeles, CA 90073 USA. Dept Med, Div Digest Dis, Los Angeles, CA 90073 USA. RP Yang, H (reprint author), W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Room 203,Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-41301, DK-50255] NR 19 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD DEC 10 PY 1999 VL 276 IS 3 BP 189 EP 192 DI 10.1016/S0304-3940(99)00830-7 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 264GA UT WOS:000084171200013 PM 10612637 ER PT J AU Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME Kaplan, JE AF Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME Kaplan, JE CA USPHS IDSA Prevention Oportunisti TI 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; PLACEBO-CONTROLLED TRIAL; ACTIVE ANTIRETROVIRAL THERAPY; TRIMETHOPRIM-SULFAMETHOXAZOLE; CYTOMEGALOVIRUS RETINITIS; RANDOMIZED TRIAL; TOXOPLASMIC ENCEPHALITIS; AEROSOLIZED PENTAMIDINE; MAINTENANCE THERAPY C1 NIH, Bethesda, MD 20892 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Univ Washington, Seattle, WA 98195 USA. Univ Arizona, Tucson, AZ USA. Johns Hopkins Univ, Baltimore, MD USA. Natl Assoc People AIDS, Washington, DC USA. Forum Collaborat HIV Res, Washington, DC USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Calif San Diego, La Jolla, CA 92093 USA. Harvard Univ, Med Ctr, Boston, MA 02115 USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. US Dept Vet Affairs, Washington, DC USA. Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94120 USA. Harlem Hosp, New York, NY USA. Holmes Hosp, Cincinnati, OH USA. Boston Univ, Sch Med, Boston, MA 02118 USA. Univ Hosp Bern, CH-3010 Bern, Switzerland. Univ Alabama, Birmingham, AL USA. US FDA, Rockville, MD 20857 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. US Dept Hlth & Human Serv, Washington, DC USA. Hackensack Med Ctr, Hackensack, NJ 07604 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. Vet Adm Med Ctr, Minneapolis, MN 55417 USA. Univ Washington, Seattle, WA 98195 USA. Hop Bichat Claude Bernard, F-75877 Paris 18, France. Hosp Univ Gregorio Maranon, Madrid, Spain. Treatment Act Grp, New York, NY USA. Henry Ford Hosp, Detroit, MI 48202 USA. Kaiser Permanente, Springfield, VA USA. St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada. Univ Minnesota, Minneapolis, MN USA. US Hlth Resources & Serv Adm, Rockville, MD 20857 USA. Northwestern Univ, Chicago, IL 60611 USA. Johns Hopkins Hosp, Baltimore, MD 21287 USA. Univ Amsterdam, Amsterdam, Netherlands. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Natl Fdn Infect Dis, Indianapolis, IN USA. Tulane Univ, Sch Med, New Orleans, LA 70112 USA. Indiana Univ, Sch Med, Indianapolis, IN USA. Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. RP Masur, H (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA. RI Furrer, Hansjakob/G-6768-2013 OI Furrer, Hansjakob/0000-0002-1375-3146 NR 90 TC 19 Z9 19 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 7 PY 1999 VL 131 IS 11 BP 873 EP 908 PG 36 WC Medicine, General & Internal SC General & Internal Medicine GA 262ET UT WOS:000084053200019 ER PT J AU Pahlavani, MA Vargas, DM AF Pahlavani, MA Vargas, DM TI Age-related decline in activation of calcium/calmodulin-dependent phosphatase calcineurin and kinase CaMK-IV in rat T cells SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE aging; rat; T cell; calcineurin; CaMK-IV ID CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR NFAT; SIGNAL TRANSDUCTION; IMMUNE FUNCTION; DNA-BINDING; KAPPA-B; EXPRESSION; CALMODULIN; CALCIUM; PHOSPHORYLATION AB We have previously shown that the DNA binding activity of the transcription factor NFAT which plays a predominant role in IL-2 transcription decreases with age. Because the transactivation (dephosphorylation and nuclear translocation) of the NFAT-c (cytoplasmic component of the NFAT complex) is mediated by the calcium/calmodulin-dependent phosphatase, calcineurin (CaN), and because Ca2+ /calmodulin-dependent kinases (CaMK-II and IV/Gr) have been shown to play a critical role in calcium signaling in T cells, it was of interest to determine what effect aging has on the activation and the levels of these calcium regulating enzymes. The induction of calcineurin phosphatase activity, and CaMK-II and IV/Gr activities, were studied in splenic T cells isolated from Fischer 344 rats at 6, 15, and 24 months of age. In addition, the changes in the protein levels of these enzymes were measured by Western blot. The calcineurin phosphatase activity and CaMK-II and IV kinase activities were at a maximum after the cells were incubated with anti-CD3 antibody for 5-10 minutes. The induction of calcineurin activity by anti-CD3 and by calcium ionophore (A23187) declined 65 and 55%, respectively, between 6 and 24 months of age. The induction of CaMK-IV activity, but not CaMK-II activity by anti-CD3, was significantly less (by 54%) in T cells from old rats compared to T cells from young rats. The decline in the activation of these enzymes with age was not associated with changes in their corresponding protein levels. These results demonstrate that alterations in calcineurin phosphatase activity and CaMK-IV activity may contribute to the well-documented age-related decline in T cell function. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Vet Hosp, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. RP Pahlavani, MA (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Vet Hosp, Ctr Geriatr Res Educ & Clin, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. FU NIA NIH HHS [AG00677, AG14088] NR 53 TC 21 Z9 21 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing. Dev. PD DEC 7 PY 1999 VL 112 IS 1 BP 59 EP 74 DI 10.1016/S0047-6374(99)00077-9 PG 16 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 269ZX UT WOS:000084511700005 PM 10656183 ER PT J AU Buckman, JF Meshul, CK AF Buckman, JF Meshul, CK TI Glial differences between naive withdrawal seizure-prone and -resistant mice SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE immunocytochemistry; glutamate; glial fibrillary acidic protein; cytochrome oxidase; excitatory amino acid transporters ID GLUTAMATE-ASPARTATE TRANSPORTER; QUANTITATIVE EM ANALYSIS; CYTOCHROME OXIDASE-RICH; MACAQUE STRIATE CORTEX; CENTRAL-NERVOUS-SYSTEM; ETHANOL-WITHDRAWAL; RAT-BRAIN; INDUCED CONVULSIONS; CNS TRANSMITTER; GABA AB Background: Withdrawal seizure-prone (WSP) and withdrawal seizure-resistant (WSR) mice were bred in replicate (i.e., WSP-1 and WSP-2) to exhibit differences in handling-induced convulsion severity during ethanol withdrawal. Methods: We examined the role of the glutamatergic system in susceptibility to ethanol-withdrawal convulsions in naive mice by measuring the density of immunolabeling for several glutamate transporters and the glutamate-metabolizing enzyme, glutamine synthetase. The density of glial fibrillary acidic protein immunolabeling (a marker of glial structure) and cytochrome oxidase activity (a marker of neuronal activity) were also characterized in naive mice. Results: We observed a significantly greater density of immunolabeling for the glial transporter, glutamate/aspartate transporter, in CA1 subfield of the hippocampus (CA1) of naive WSP-2 mice as compared to WSR-2 mice. No other significant differences were observed. However, as compared to WSR mice, naive WSP mice exhibited a trend toward (a) greater immunolabeling for the glial glutamate transporter, glutamate transporter-1, in CA3, (b) greater immunolabeling for glial-specific glutamate-metabolizing enzyme, glutamine synthetase, in CA1 (replicate-2 only), and (c) less immunolabeling for the glial structural protein, glial fibrillary acidic protein, in all brain regions tested. In contrast, ng trends or significant differences in the labeling density for the neuronal transporter, excitatory amino acid carrier 1, or the neuronal activity marker, cytochrome oxidase, were observed between the selected lines. Conclusions: These data suggest that the glutamatergic system and glia may play a pivotal role in the increased susceptibility to handling-induced convulsions observed in WSP mice. C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Meshul, CK (reprint author), Portland VA Med Ctr, Mail Code RD-29,3710 SW Vet Hosp Rd, Portland, OR 97201 USA. FU NIAAA NIH HHS [AA07468, AA05507-01, P60 AA010760]; NIDA NIH HHS [DA07262-06] NR 48 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD DEC PY 1999 VL 23 IS 12 BP 1905 EP 1913 PG 9 WC Substance Abuse SC Substance Abuse GA 271GE UT WOS:000084585200008 PM 10630609 ER PT J AU Roman, GC AF Roman, GC TI A historical review of the concept of vascular dementia: Lessons from the past for the future SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article; Proceedings Paper CT 1st International Conference on Development of Drug Treatment for Vascular Dementia CY OCT 07-09, 1998 CL OSAKA, JAPAN DE history of medicine; history of neurology; Thomas Willis; Alois Alzheimer; Otto Binswanger; Emil Kraepelin; senile dementia; vascular dementia ID ALZHEIMERS-DISEASE; BINSWANGER,OTTO AB The history of senile dementia begins in the Greco-Roman period with basic concepts of senility by Pythagoras and Hippocrates. During the Middle Ages, the main contribution was by Roger Bacon in 1290. The first textbook of neurology, De cerebri morbis, by Jaso de Pratis (1549), included a chapter on dementia ("De memoriae detrimento'). Tn the 17th century, Thomas Willis recognized intellectual loss with aging. In the 19th century, Philippe Pinel removed chains from the mentally ill; his student Esquirol wrote the first modem classification of mental disease, including senile dementia. In 1860, Morel recognized brain atrophy with aging. The modem history of vascular dementia began in 1896, when Emil Kraepelin in his textbook Psychiatrie included "arteriosclerotic dementia" among the senile dementias, following the ideas of Otto Binswanger and Alois Alzheimer, who had differentiated clinically and pathologically arteriosclerotic brain lesions from senile dementia and from neurosyphilitic general paresis of the insane. Binswanger's and Alzheimer's contributions are reviewed in detail. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Roman, GC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 20 TC 22 Z9 27 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD DEC PY 1999 VL 13 SU 3 BP S4 EP S8 PG 5 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 269HZ UT WOS:000084471900002 PM 10609675 ER PT J AU Roman, GC Royall, DR AF Roman, GC Royall, DR TI Executive control function: A rational basis for the diagnosis of vascular dementia SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article; Proceedings Paper CT 1st International Conference on Development of Drug Treatment for Vascular Dementia CY OCT 07-09, 1998 CL OSAKA, JAPAN DE Alzheimer disease; Binswanger disease; dementia; diagnostic criteria; executive control functions; vascular dementia; controlled clinical trials ID POSITRON EMISSION TOMOGRAPHY; ENCEPHALOPATHY BINSWANGER DISEASE; FRONTAL-SUBCORTICAL CIRCUITS; ANTERIOR CINGULATE CORTEX; WHITE-MATTER CHANGES; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; HUNTINGTONS-DISEASE; CARDIOVASCULAR HEALTH; BEDSIDE ASSESSMENT AB Problems with diagnostic criteria for vascular dementia (VaD) stem from the inadequacy of the current dementia concept, a paradigm based on amnestic and other cortical deficits typical of Alzheimer disease (AD). However, most cases of VaD are due to subcortical lesions such as Binswanger-type periventricular white matter ischemia, or strokes causing decreased frontal activation and diaschisis-mediated cerebral hypoperfusion. Wie propose a new definition of dementia based on executive dysfunction and a formal assessment of executive control functions (ECF) for the diagnosis of VaD. The instruments proposed are the rapid screening executive clock-drawing task (CLOX; Royall et al. J Neurol Neurosurg Psychiatry 1998;64.588-94), and the more comprehensive Executive Interview Test (EXIT25; Royall et al. J Am Geriatr Soc 1992;40:1221-6). Extensive application of these tests in elderly subjects in retirement communities has shown that both are brief, simple to administer, and more sensitive case-finding tools for cognitively impaired individuals than the Mini-Mental State Examination (MMSE). These three tests (CLOX, EXIT25, MMSE) accurately separate nondemented subjects from those with cortical or subcortical (frontal system) dementias. In addition, for controlled clinical trials of VaD, formal evaluation of motor and frontal sphincter functions-usually not considered part of the dementia syndrome-should also be included. Evaluation of gait and falls, timed-walk, manual dexterity, timed finger-lapping, and frontal bladder control (urge incontinence and nocturia) should improve determination of functional status and disability, and more accurately measure the effects of potential therapies. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Roman, GC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 152 TC 89 Z9 96 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD DEC PY 1999 VL 13 SU 3 BP S69 EP S80 PG 12 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 269HZ UT WOS:000084471900012 PM 10609685 ER PT J AU Lehmann, KG Heath-Lange, SJ Ferris, ST AF Lehmann, KG Heath-Lange, SJ Ferris, ST TI Randomized comparison of hemostasis techniques after invasive cardiovascular procedures SO AMERICAN HEART JOURNAL LA English DT Article ID CONVENTIONAL MANUAL COMPRESSION; ARTERIAL PUNCTURE SITES; CARDIAC-CATHETERIZATION; CORONARY ANGIOGRAPHY; OUTPATIENT CATHETERIZATION; STENT IMPLANTATION; GUIDING CATHETERS; BRACHIAL APPROACH; TRIAL; ANGIOPLASTY AB Background The arterial access required during most invasive vascular procedures provides a common source of complications and morbidity. This problem has been made worse by recent trends in earlier ambulation and more aggressive antihemostatic drug regimens. Despite these trends, no randomized trials have been reported comparing the 3 most commonly used techniques in achieving hemostasis at the arterial puncture site. Methods A cohort of 400 patients undergoing catheterization laboratory procedures were randomly assigned to 1 of 3 groups of arterial compression:manual compression, mechanical clamp, and pneumatic compression device. Standard requirements of the trial included uniformity in initial compression times, patient instructions, nursing follow-up, and timing of ambulation as well as a structured interview and physical examination at 24 hours. Results Prolonged compression was required in 13% of the manual group, 20% of the clamp group, and 35% of the pneumatic group (P < .0001). In-lab bleeding was more common in the pneumatic group (3%, 4%, and 16%, respectively, P < .0001), as was the need for an alternate compression technique (1%, 1%, and 27%, P < .0001). The groups also differed in respect to mean hematoma size (3.9 cm(2), 7.8 cm(2), and 19.8 cm(2), P = .036) and level of discomfort during compression (1.9, 2.2, and 3.1 on a 1- to 10-point scale, P < .0001). Comparable findings were observed in the subgroup of patients eligible for outpatient procedures. Conclusions Use of the pneumatic compression device leads to longer compression times, greater discomfort, more bleeding,, and larger hematomas. Differences between manual compression and the mechanical clamp were more subtle but tend to favor use of the manual technique. C1 Vet Affairs Puget Sound Hlth Care Syst, Sect Cardiol 111C, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Lehmann, KG (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Sect Cardiol 111C, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 24 TC 26 Z9 29 U1 0 U2 1 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD DEC PY 1999 VL 138 IS 6 BP 1118 EP 1125 DI 10.1016/S0002-8703(99)70078-5 PN 1 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 262EU UT WOS:000084053300022 PM 10577443 ER PT J AU El-Serag, HB AF El-Serag, HB TI Barrett's esophagus, hiatal hernia, and logistic regression analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID MODELS C1 Houston Vet Affairs Med Ctr, Dept Gastroenterol, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Dept Hlth Serv Res, Houston, TX USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. NR 11 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 1999 VL 94 IS 12 BP 3395 EP 3396 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 263PL UT WOS:000084134400001 PM 10606286 ER PT J AU Nagatomo, Y Carabello, BA Hamawaki, M Nemoto, S Matsuo, T McDermott, PJ AF Nagatomo, Y Carabello, BA Hamawaki, M Nemoto, S Matsuo, T McDermott, PJ TI Translational mechanisms accelerate the rate of protein synthesis during canine pressure-overload hypertrophy SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE pressure overload; translation; eukaryotic initiation factor 4E ID MYOSIN HEAVY-CHAIN; LEFT-VENTRICULAR HYPERTROPHY; INITIATION-FACTOR EIF-4E; RIBOSOMAL-RNA SYNTHESIS; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; VOLUME OVERLOAD; TRANSCRIPTIONAL REGULATION; GROWTH; HEART AB This study examined how translational mechanisms regulate the rate of cardiac protein synthesis during canine pressure overload in vivo. Acute aortic stenosis (AS) was produced by inflating a balloon catheter in the ascending aorta for 6 h; sustained AS was created by controlled banding of the ascending aorta. AS caused significant hypertrophy as reflected by increased left ventricular (LV) mass after 5 and 10 days. To monitor LV protein synthesis in vivo, myosin heavy chain (MHC) synthesis was measured by continuous infusion of radiolabeled leucine. Acute AS accelerated the rate of myosin synthesis without a corresponding increase in ribosomal RNA, indicating an increase in translational efficiency. Total MHC synthesis (mg MHC/LV per day) was significantly increased at 5 and 10 days of sustained AS. Total MHC degradation was not significantly altered at 5 days of AS but increased at 10 days of AS in concordance with a new steady state with respect to growth. Translational capacity (mg total RNA/LV) was significantly increased after 5 and 10 days of AS and was preceded by an increase in the rate of ribosome formation. MHC mRNA levels remained unchanged during AS. These findings demonstrate that cardiac protein synthesis is accelerated in response to pressure overload by an initial increase in translational efficiency, followed by an adaptive increase in translational capacity during sustained hypertrophic growth. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Rm 303,Strom Thurmond Biomed Res Bldg,114 Doughty, Charleston, SC 29403 USA. FU NHLBI NIH HHS [P01-HL-48788] NR 41 TC 27 Z9 27 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD DEC PY 1999 VL 277 IS 6 BP H2176 EP H2184 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 263UE UT WOS:000084143000009 PM 10600835 ER PT J AU Norton, JA AF Norton, JA TI The role of surgery in adrenal cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Editorial Material ID ADRENOCORTICAL CARCINOMA; RESECTION; DISEASE C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Norton, JA (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 clement St, San Francisco, CA 94121 USA. NR 7 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD DEC PY 1999 VL 6 IS 8 BP 713 EP 714 DI 10.1007/s10434-999-0713-0 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 268FA UT WOS:000084402600001 PM 10622495 ER PT J AU Koletar, SL Berry, AJ Cynamon, MH Jacobson, J Currier, JS MacGregor, RR Dunne, MW Williams, DJ AF Koletar, SL Berry, AJ Cynamon, MH Jacobson, J Currier, JS MacGregor, RR Dunne, MW Williams, DJ TI Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VIRUS INFECTION; CLARITHROMYCIN; THERAPY; ETHAMBUTOL; BACTEREMIA; RESISTANT; DISEASE; INVITRO; INVIVO AB This multicenter, randomized, dose-ranging study was performed to determine the safety and efficacy of two different doses of azithromycin for treating disseminated Mycobacterium avium complex (MAC) in patients with AIDS. Eighty-eight AIDS patients with symptoms and blood cultures consistent with disseminated MAC were treated with 600 or 1,200 mg of azithromycin daily for 6 weeks; 62 patients completed the entire 6 weeks of study, Of note, this study was done prior to the time when combination antiretroviral or anti-MAC regimens were the standard of care. Over the 6-week study period, symptomatic improvement was noted in both dose groups, Microbiological responses were comparable, with mean decreases of 1.5 and 2.0 log CFU/ml in the high- and low-dose groups, respectively, Sterilization of blood cultures occurred in 54% of samples; patients with lower baseline colony counts were more likely to achieve culture negativity, Resistance developed in one patient. Gastrointestinal symptoms were the most common side effects and were more frequent in patients receiving 1,200 mg. Azithromycin is a useful alternative treatment for disseminated MAC infection in AIDS patients. Symptomatic improvement correlates with measurable decreases in mycobacterial load. C1 Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. SUNY, Syracuse, NY USA. Dept Vet Affairs Med Ctr, Bronx, NY USA. Beth Israel Hosp, Boston, MA 02215 USA. Univ Penn, Philadelphia, PA 19104 USA. Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA. RP Koletar, SL (reprint author), N-1135 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA. EM koletar.1@osu.edu NR 22 TC 18 Z9 21 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 1999 VL 43 IS 12 BP 2869 EP 2872 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 261YE UT WOS:000084037900007 PM 10582873 ER PT J AU Al-Abdely, HM Graybill, JR Loebenberg, D Melby, PC AF Al-Abdely, HM Graybill, JR Loebenberg, D Melby, PC TI Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID KETOCONAZOLE; ITRACONAZOLE; STIBOGLUCONATE; PANCREATITIS; AMPHOTERICIN; COINFECTION AB Current therapy for leishmaniasis is unsatisfactory. Efficacious and safe oral therapy would be ideal. We examined the efficacy of SCH 56592, an investigational triazole antifungal agent, against cutaneous infection with Leishmania amazonensis and visceral infection with Leishmania donovani in BALB/c mice. Mice were infected in the ear pinna and tail with L, amazonensis promastigotes and were treated with oral SCI-I 56592 or intraperitoneal amphotericin B for 21 days. At doses of 60 and 30 mg/kg/day, SCH 56592 was highly efficacious in treating cutaneous disease, and at a dose of 60 mg/kg/day, it was superior to amphotericin B at a dose of 1 mg/kg/day, The means of tail lesion sizes were 0.32 +/- 0.12, 0.11 +/- 0.06, 0.17 +/- 0.07, and 0.19 +/- 0.08 mm for controls, SCH 56592 at 60 and 30 mg/kg/day, and amphotericin B recipients, respectively (P = 0.00113, 0.005, and 0.01, respectively). Parasite burden in draining lymph nodes confirmed these efficacy findings. In visceral leishmaniasis due to L. donovani infection, mice treated with SCH 56592 showed a 0.5- to 1-log-unit reduction in parasite burdens in the liver and the spleen compared to untreated mice. Amphotericin B at 1 mg/kg/day was superior to SCH 56592 in the treatment of visceral infection, with a 2-log-unit reduction in parasite burdens in both the liver and spleen. These studies indicate very good activity of SCH 56592 against cutaneous leishmaniasis due to L, amazonensis infection and, to a lesser degree, against visceral leishmaniasis due to L. donovani infection in susceptible BALB/c mice. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA. Audie Murphy Vet Adm Hosp, Med Serv, San Antonio, TX 78284 USA. Schering Plough Res Inst, Kenilworth, NJ 07833 USA. RP Al-Abdely, HM (reprint author), King Faisal Specialist Hosp & Res Ctr, Dept Med MBC 46, Div Infect Dis, POB 3354, Riyadh 11211, Saudi Arabia. NR 15 TC 54 Z9 55 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD DEC PY 1999 VL 43 IS 12 BP 2910 EP 2914 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 261YE UT WOS:000084037900015 PM 10582881 ER PT J AU Tompkins, CA Spencer, KA Schulz, R AF Tompkins, CA Spencer, KA Schulz, R TI Evaluating stresses and interventions for informal carers of aphasic adults: taking a broader perspective. A commentary on Servaes, Draper, Conroy, and Bowing (1999) SO APHASIOLOGY LA English DT Article ID CARDIOVASCULAR HEALTH; STROKE; CAREGIVERS; OUTCOMES; SUPPORT; PEOPLE C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Ctr Social & Urban Res, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Aphasia Rehabil Res Lab & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. RP Tompkins, CA (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI LONDON PA ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD DEC PY 1999 VL 13 IS 12 BP 902 EP 907 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 267CX UT WOS:000084338400003 ER PT J AU Craft, S Asthana, S Newcomer, JW Wilkinson, CW Matos, IT Baker, LD Cherrier, M Lofgreen, C Latendresse, S Petrova, A Plymate, S Raskind, M Grimwood, K Veith, RC AF Craft, S Asthana, S Newcomer, JW Wilkinson, CW Matos, IT Baker, LD Cherrier, M Lofgreen, C Latendresse, S Petrova, A Plymate, S Raskind, M Grimwood, K Veith, RC TI Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID MILD SENILE DEMENTIA; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; RECEPTOR; BRAIN; METABOLISM; DEFICITS; HYPERINSULINEMIA; RESPONSES; PITUITARY AB Background: Increasing plasma glucose levels improves memory in patients with Alzheimer disease (AD). Increasing plasma glucose levels also increases endogenous insulin levels, raising the question of whether memory improvement is due to changes in insulin, independent of hyperglycemia. We address this question by examining memory and counterregulatory hormone response during hyperglycemia when endogenous insulin was suppressed by concomitant infusion of the somatostatin analogue octreotide (Sandostatin). Methods: Twenty-three patients with AD and 14 similarly aged healthy adults participated in 4 metabolic conditions on separate days: (1) hyperinsulinemia (538 pmol/L) with fasting glucose (5.6 mmol/L [100 mg/dL]), achieved by insulin and variable dextrose infusion; (2) hyperglycemia (12.5 mmol/L [225 mg/dL]) with fasting insulin (57 pmol/L), achieved by dextrose and somatostatin (octreotide) infusion (150 mg/h); (3) placebo with isotonic sodium chloride solution (saline) infusion (fasting insulin and glucose); and (4) an active control condition in which somatostatin alone was infused (150 mg/h). Declarative memory (story recall) and selective attention (Stroop interference test) were measured during steady metabolic states. Results: Patients with AD showed improved memory during hyperinsulinemia relative to placebo (P = .05) and relative to hyperglycemia (P<.005). Memory did not improve during hyperglycemia when insulin was suppressed. Somatostatin analogue infusion alone also improved memory for patients with AD (P<.05). Hyperinsulinemia increased cortisol levels in subjects with AD, whereas somatostatin alone lowered cortisol concentrations. Conclusions: These results confirm that elevated insulin without hyperglycemia enhances memory in adults with AD, and indicate that insulin is essential for hyperglycemic memory facilitation. These results also suggest a potential therapeutic role for somatostatin in AD. C1 Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Craft, S (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182B, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [R01-AG-10880] NR 39 TC 196 Z9 211 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD DEC PY 1999 VL 56 IS 12 BP 1135 EP 1140 DI 10.1001/archpsyc.56.12.1135 PG 6 WC Psychiatry SC Psychiatry GA 262ER UT WOS:000084053100009 PM 10591291 ER PT J AU Tsuang, D Larson, EB Bowen, J McCormick, W Teri, L Nochlin, D Leverenz, JB Peskind, ER Lim, A Raskind, MA Thompson, ML Mirra, SS Gearing, M Schellenberg, GD Kukull, W AF Tsuang, D Larson, EB Bowen, J McCormick, W Teri, L Nochlin, D Leverenz, JB Peskind, ER Lim, A Raskind, MA Thompson, ML Mirra, SS Gearing, M Schellenberg, GD Kukull, W TI The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series SO ARCHIVES OF NEUROLOGY LA English DT Article ID CLINICAL-DIAGNOSIS; DEMENTIA; ALLELE; ASSOCIATION; SENSITIVITY; SPECIFICITY; CONSORTIUM; ESTABLISH; EPSILON-4; REGISTRY AB Context: A recent collaborative study found that apolipoprotein E (APOE) genotype, in conjunction with the clinical diagnosis of Alzheimer disease (AD), was useful in improving diagnostic specificity (correctly not diagnosing AD) relative to the clinical diagnosis alone. Since these samples are particularly enriched with patients with AD and the APOE epsilon 4 allele, results may not be generalizable to patients seen in the general medical community. Objective: To evaluate the diagnostic utility of the APOE genotype in diagnosing AD in a community-based case series from the largest health maintenance organization in an urban area. Design: We examined the effect of including APOE genotype on the diagnosis of AD in a community-based case series of patients presenting with memory complaints. Patients: Clinical and neuropathologic diagnoses and APOE genotype were obtained from 132 patients who underwent evaluation for dementia and subsequent autopsy. Main Outcome Measures: Sensitivity, specificity, and positive and negative predictive values given various combinations of clinical diagnoses and the presence of an APOE epsilon 4 allele. Results: Of the 132 patients, 94 had neuropathologically confirmed AD, yielding a prevalence of 71%. The clinical diagnosis alone yielded a sensitivity of 84%, an estimated specificity of 50%, and positive and negative predictive values of 81% and 56%, respectively. The presence of an epsilon 4 allele alone was associated with an estimated sensitivity of 59%, specificity of 71%, and positive and negative predictive values of 83% and 41%, respectively. Using the presence of clinical AD and an epsilon 4 allele decreased the sensitivity to 49% and increased the specificity to 84%. The positive and negative predictive values were 88% and 40%, respectively. Alternatively, the clinical diagnosis of AD or the presence of an epsilon 4 allele in individuals not meeting clinical criteria for AD increases the estimated sensitivity to 94% but decreases the specificity to 37%. The positive and negative predictive values were 79% and 70%, respectively. The changes in the sensitivity and specificity for the combined tests relative to clinical diagnosis alone offset each other. For lower prevalence communities, the positive predictive value will be much lower than those observed herein. Conclusions: Our findings do not support the use of APOE gene typing alone in the diagnosis of AD in the general medical community. Although the presence of an epsilon 4 allele in older persons with clinical AD increased the probability of having AD and the absence of an epsilon 4 allele in this group decreased the probability of having AD, the association is not strong enough in the differential diagnosis of non-Alzheimer dementia and AD. C1 Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Neuropathol Lab, Seattle, WA 98195 USA. Talbert Med Grp, Phoenix, AZ USA. SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA. Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. RP Tsuang, D (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Mail Stop 116 MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [R01-AG10845, U01AG06781, U01AG10130] NR 38 TC 28 Z9 28 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD DEC PY 1999 VL 56 IS 12 BP 1489 EP 1495 DI 10.1001/archneur.56.12.1489 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 262LD UT WOS:000084068000009 PM 10593304 ER PT J AU Anderson, CA Sandberg, E Filley, CM Harris, SL Tyler, KL AF Anderson, CA Sandberg, E Filley, CM Harris, SL Tyler, KL TI One and one-half syndrome with supranuclear facial weakness - Magnetic resonance imaging localization SO ARCHIVES OF NEUROLOGY LA English DT Article ID PALSY; INFARCTION AB Objective: To provide clinicoanatomical correlation for a small pontine tegmental ischemic stroke producing the one and one-half syndrome associated with supranuclear facial weakness. Design: Case report. Setting: Tertiary care center. Patients: A 70-year-old man developed left-sided facial weakness sparing the forehead, a left internuclear ophthalmoplegia, and a complete left horizontal gaze palsy immediately after percutaneous transluminal coronary angioplasty. Magnetic resonance imaging demonstrated a small lesion in the left paramedian aspect of the dorsal pontine tegmentum. Main Outcome and Results: Electromyographic findings were consistent with supranuclear facial involvement. The patient had nearly complete recovery after 1 year. Conclusions: To our knowledge, this is the first report of supranuclear facial weakness in association with the one and one-half syndrome. The location of the lesion provides evidence of the existence of corticofugal fibers that extend to the facial nucleus in the dorsal paramedian pontine tegmentum. C1 Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Surg, Div Emergency Med, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Radiol, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Immunol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Anderson, CA (reprint author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Neurol, Neurol B-182,4200 E 9th Ave, Denver, CO 80262 USA. OI Tyler, Kenneth/0000-0003-3294-5888 NR 11 TC 4 Z9 6 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD DEC PY 1999 VL 56 IS 12 BP 1509 EP 1511 DI 10.1001/archneur.56.12.1509 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 262LD UT WOS:000084068000013 PM 10593308 ER PT J AU Scremin, AME Kurta, L Gentili, A Wiseman, B Perell, K Kunkel, C Scremin, OU AF Scremin, AME Kurta, L Gentili, A Wiseman, B Perell, K Kunkel, C Scremin, OU TI Increasing muscle mass in spinal cord injured persons with a functional electrical stimulation exercise program SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article ID CROSS-SECTIONAL AREA; SKELETAL-MUSCLE; RESISTANCE EXERCISE; FIBER AREA; STRENGTH; CAPILLARIZATION; HYPERTROPHY; TOMOGRAPHY; PATIENT; RATS AB Objective: To determine the magnitude of changes in muscle mass and lower extremity body composition that could be induced with a regular regimen of functional electrical stimulation (FES)-induced lower-extremity cycling, as well as the distribution of changes in muscle mass among the thigh muscles in persons with spinal cord injury (SCI). Study Design: Thirteen men with neurologically complete motor sensory SCI underwent a 3-phase, FES-induced, ergometry exercise program: phase 1, quadriceps strengthening; phase 2, progressive sequential stimulation to achieve a rhythmic pedaling motion (surface electrodes placed over the quadriceps, hamstrings, and gluteal muscles); phase 3, FES-induced cycling for 30 minutes. Participants moved from one phase to the next when they met the objectives for the current phase. Measures: Computed tomography of legs to assess muscle cross-sectional area and proportion of muscle and adipose tissue. Scans were done at baseline (before subjects started the program), at first follow-up, typically after 65.4 +/- 5.6 (SD) weekly sessions, and at second follow-up, typically after 98.1 +/- 9.1 sessions. Results: Increases in cross-sectional areas were found in the following muscles: rectus femoris (31%, p < .001), sartorius (22%, p < .025), adductor magnus-hamstrings (26%, p < .001), vastus lateralis (39%, p = .001), vastus medialis-intermedius (31%, p = .025). Cross-sectional area of adductor longus and gracilis muscles did not change. The ratio of muscle to adipose tissue increased significantly in thighs and calves. There was no correlation among the total number of exercise sessions and the magnitude of muscle hypertrophy. Conclusions: Muscle cross-sectional area and the muscle to adipose tissue ratio of the lower extremities increased during a regular regimen of 2.3 FES-induced lower extremity cycling sessions weekly. The distribution of changes was related to the proximity of muscles to the stimulating electrodes. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. C1 W Los Angeles Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Res Dept, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. Albuquerque Vet Affairs Med Ctr, Albuquerque, NM USA. RP Scremin, AME (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Bldg 115,Room 319,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Winstein, Carolee/A-8375-2008; Gentili, Amilcare/G-1238-2013 OI Gentili, Amilcare/0000-0002-5623-7512 NR 36 TC 71 Z9 73 U1 2 U2 13 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 1999 VL 80 IS 12 BP 1531 EP 1536 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 262WZ UT WOS:000084092400002 PM 10597802 ER PT J AU Murray, DR Prabhu, SD Freeman, GL AF Murray, DR Prabhu, SD Freeman, GL TI Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-alpha-induced myodepression SO CARDIOVASCULAR RESEARCH LA English DT Article DE cytokines; hemodynamics; nitric oxide; ventricular function; angiotensin ID PRESSURE-VOLUME RELATION; CLOSED-CHEST DOGS; CONSCIOUS DOGS; CELL-FUNCTION; SEPTIC SHOCK; HEART; ENDOTOXIN; INDUCTION; HUMANS; CONTRACTILITY AB Objective: Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression. Methods: Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a l-h rhTNF alpha infusion (40 mu g/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either N-G-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg). Results: L-NAME, under control conditions or following recombinant human (rh)TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. Regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dt(max)-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dt(max)-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure. Conclusions: Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload. (C) 1999 Elsevier Science B.V. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. RP Murray, DR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. RI Prabhu, Sumanth/D-5223-2009 NR 36 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD DEC PY 1999 VL 44 IS 3 BP 527 EP 535 DI 10.1016/S0008-6363(99)00226-6 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 262HA UT WOS:000084060100012 PM 10690284 ER PT J AU Goetz, MB AF Goetz, MB TI Editorial response: Discordance between virological, immunologic, and clinical outcomes of therapy with protease inhibitors among human immunodeficiency virus-infected patients SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID ACTIVE ANTIRETROVIRAL THERAPY; T-CELL RESPONSES; HIV-1 INFECTION; GENETIC RESTRICTION; DISEASE PROGRESSION; VIRAL-LOAD; AIDS; PATHOGENESIS; LYMPHOCYTES; VARIANT C1 Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Goetz, MB (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, 111-F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI Goetz, Matthew/0000-0003-4542-992X NR 46 TC 6 Z9 6 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC PY 1999 VL 29 IS 6 BP 1431 EP 1434 DI 10.1086/313563 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 273DW UT WOS:000084693400020 PM 10585791 ER PT J AU Fausti, SA Henry, JA Helt, WJ Phillips, DS Frey, RH Noffsinger, D Larson, VD Fowler, CG AF Fausti, SA Henry, JA Helt, WJ Phillips, DS Frey, RH Noffsinger, D Larson, VD Fowler, CG TI An individualized, sensitive frequency range for early detection of ototoxicity SO EAR AND HEARING LA English DT Article ID CISPLATIN OTOTOXICITY; GUINEA-PIG AB Objective: The aim of this study was to identify auditory frequencies at which serial threshold testing would provide the greatest sensitivity for early detection of ototoxicity. The overall objective is to develop a more time-efficient ototoxicity monitoring protocol. Design: Threshold data were analyzed from 370 hospitalized patients treated with aminoglycoside antibiotics (AMGs) or cisplatin (CDDP) who received serial auditory monitoring before, during, and after treatment at conventional (0.25 to 8 kHz) and high (9 to 20 kHz) frequencies. Results: For patients showing hearing changes due to ototoxicity, a frequency range was identified for its apparent high sensitivity to initial ototoxicity. This sensitive range is identified according to an individual's hearing threshold configuration, and is, therefore, unique for each patient. The range consists of five frequencies, generally separated by 1/6 octave, e.g., 8, 9, 10, 11.2, and 12.5 kHz. To determine frequencies and combinations of frequencies that were most often involved in ototoxicity detection, threshold data in the sensitive range were analyzed in detail. This analysis suggests that patients receiving treatment with AMG or CDDP can be monitored for hearing thresholds at only five frequencies, resulting in an 84% detection rate for AMG and 94% for CDDP compared with monitoring at all conventional and high frequencies. Conclusions: This comprehensive analysis supports earlier observations that a sensitive, limited frequency range exists in which serial threshold monitoring will provide early warning of ototoxicity before effects in the speech frequency range. This finding is now being evaluated in a prospective investigation. C1 Natl Ctr Rehabil Auditory Res, Dept Vet Affairs Med Ctr, VA RR&D, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. George Washington Univ, Washington, DC USA. Univ Wisconsin, Madison, WI USA. RP Henry, JA (reprint author), Natl Ctr Rehabil Auditory Res, Dept Vet Affairs Med Ctr, VA RR&D, POB 1034,R&D NCAR, Portland, OR 97207 USA. NR 24 TC 56 Z9 60 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD DEC PY 1999 VL 20 IS 6 BP 497 EP 505 DI 10.1097/00003446-199912000-00005 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 266UH UT WOS:000084318300005 PM 10613387 ER PT J AU Figlewicz, DP AF Figlewicz, DP TI Endocrine regulation of neurotransmitter transporters SO EPILEPSY RESEARCH LA English DT Article; Proceedings Paper CT Workshop on the Ketogenic Diet - Mechanisms and Models CY SEP 18-19, 1998 CL SEATTLE, WASHINGTON SP Parke Davis, Ortho McNeil Pharmaceut Inc, Glaxo Wellcome Inc, Novartis Pharmaceut Corp DE insulin; glucocorticoids; transporters; dopamine ID HUMAN DOPAMINE TRANSPORTER; BRAIN GABA TRANSPORTER; MESSENGER-RNA; RAT-BRAIN; SEROTONIN TRANSPORTERS; NOREPINEPHRINE UPTAKE; FUNCTIONAL REGULATION; TYROSINE-HYDROXYLASE; EXPRESSION CLONING; NEURONAL CULTURES AB Aminergic signalling in the CNS is terminated by clearance of neurotransmitters from the synapse via high affinity transporter molecules in the presynaptic membrane. Relatively recent sequence identification of these molecules has now permitted the initiation of studies of regulation of transporter function at the cellular and systems levels. In vitro studies provide evidence that the transporters for dopamine, serotonin, and gamma-aminobutyric acid (GABA) may be substrates for regulation by protein kinase C and protein kinase A signalling. Changes in energy balance and metabolic status, such as starvation, result in major shifts in hormonal output. It is now recognized that metabolic hormones such as insulin or the adrenal steroids can have significant acute and chronic effects on several aspects of CNS function. Data from this laboratory and others now provide evidence that insulin and adrenal and gonadal steroid hormones may regulate the synthesis and activity of the transporters. Future studies should permit elucidation of the cellular basis for endocrine regulation of neurotransmitter clearance, and thus, the role of endocrines in the maintenance of normal CNS aminergic signalling. The potential relevance of transporter regulation for the ketogenic diet is discussed. (C) 1999 Published by Elsevier Science B.V. All rights reserved. C1 Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Dept Metab Endocrinol, 151,1660 So Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [R01-DK40963] NR 55 TC 36 Z9 36 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD DEC PY 1999 VL 37 IS 3 BP 203 EP 210 DI 10.1016/S0920-1211(99)00072-8 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 251YK UT WOS:000083473800005 PM 10584970 ER PT J AU Lipsky, BA AF Lipsky, BA TI Evidence-based antibiotic therapy of diabetic foot infections SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY LA English DT Article DE diabetes mellitus; foot infection; antibiotic therapy; evidence-based treatment ID LOWER-EXTREMITY INFECTIONS; PERIPHERAL VASCULAR-DISEASE; TISSUE CONCENTRATIONS; CIPROFLOXACIN; AMPICILLIN/SULBACTAM; CLINDAMYCIN; OFLOXACIN; MELLITUS; COST AB In addition to proper cleansing, debridement and local wound care, foot infections in diabetic patients require carefully selected antibiotic therapy. Serious infections necessitate hospitalization for initial parenteral broad-spectrum antibiotic therapy. Appropriately selected patients with mild infections can be treated as outpatients with oral (or even topical) therapy. Initial antibiotic selection is usually empirical, but definitive therapy may be modified based on culture results and the clinical response. Therapy should nearly always be active against staphylococci and streptococci, with broader-spectrum agents indicated if Gram-negative or anaerobic organisms are likely. In infected foot tissues levels of most antibiotics, except fluoroquinolones. ale often subtherapeutic. The duration of therapy ranges fi om a week (for mild soft tissue infections) to over 6 weeks (for osteomyelitis). Recent antibiotic trials have shown that several intravenously or orally administered agents are effective in treating these infections, with no one agent or combination emerging as optimal. Suggested regimens based on the severity of infection are provided. (C) 1999 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved. C1 Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98108 USA. RP Lipsky, BA (reprint author), Univ Washington, Sch Med, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 40 TC 72 Z9 73 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0928-8244 J9 FEMS IMMUNOL MED MIC JI FEMS Immunol. Med. Microbiol. PD DEC PY 1999 VL 26 IS 3-4 BP 267 EP 276 DI 10.1016/S0928-8244(99)00143-1 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 260WQ UT WOS:000083976800012 PM 10575138 ER PT J AU Sjak-Shie, NN Vescio, RA Berenson, JR AF Sjak-Shie, NN Vescio, RA Berenson, JR TI The role of human herpesvirus-8 in the pathogenesis of multiple myeloma SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; PROTEIN-COUPLED RECEPTOR; HIV-INFECTED INDIVIDUALS; KAPOSIS-SARCOMA; DENDRITIC CELLS; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8; KSHV; GROWTH; HHV-8 AB Human herpesvirus-8 (HHV-8), a new gammaherpesvirus, was recently detected in long-term stromal cultures derived from fresh bone marrow aspirates from myeloma patients. The association between HHV-8 and multiple myeloma and the question whether HHV-8 is of pathophysiologic significance in myeloma, remains controversial. Evidence supporting an association between this virus and multiple myeloma is, however, accumulating. It seems that the strain of HHV-8 found in myeloma harbors sequence variations within ORF65 unique to myeloma. HHV-8 encodes several genes homologous to eukaryotic genes involved in cellular proliferation, apoptosis, cell migration, and intercellular signaling, through which it may induce abnormal cellular proliferation and tumor formation in its hosts. C1 Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. RP Berenson, JR (reprint author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90024 USA. NR 56 TC 6 Z9 7 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD DEC PY 1999 VL 13 IS 6 BP 1159 EP + DI 10.1016/S0889-8588(05)70118-0 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA 270YH UT WOS:000084564400005 PM 10626142 ER PT J AU Haake, DA Mazel, MK McCoy, AM Milward, F Chao, G Matsunaga, J Wagar, EA AF Haake, DA Mazel, MK McCoy, AM Milward, F Chao, G Matsunaga, J Wagar, EA TI Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection SO INFECTION AND IMMUNITY LA English DT Article ID HARDJO-BOVIS INFECTION; BORRELIA-BURGDORFERI; TREPONEMA-PALLIDUM; PATHOGENIC LEPTOSPIRA; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; NEISSERIA-MENINGITIDIS; PSEUDOMONAS-AERUGINOSA; PROTECTIVE CAPACITY; ESCHERICHIA-COLI AB New vaccine strategies are needed for prevention of leptospirosis. a widespread human and veterinary disease caused by invasive spirochetes belonging to the genus Leptospira, We have examined the immunoprotective capacity of the leptospiral porin OmpL1 and the leptospiral outer membrane Lipoprotein LipL41 in the Golden Syrian hamster model of leptospirosis, Specialized expression plasmids were developed to facilitate expression of leptospiral proteins in Escherichia coli as the membrane-associated proteins OmpL1-M and LipL41-M. Although OmpL1-M expression is highly toxic in E. coli, this was accomplished by using plasmid pMMB66-OmpL1, which has undetectable background expression without induction. LipL41-M expression and processing were enhanced by altering its lipoprotein signal peptidase cleavage site to mimic that of the murein lipoprotein. Active immunization of hamsters with E, coli membrane fractions containing a combination of OmpL1-M and LipL41-M was found to provide significant protection against homologous challenge with Leptospira kirschneri serovar grippotyphosa. At 28 days after intraperitoneal inoculation, survival in animals vaccinated dth both proteins was 71% (95% confidence interval [CI], 53 to 89%), compared with only 25% (95% CII 8 to 42%) in the control group (P < 0.001). On the basis of serological, histological, and microbiological assays, no evidence of infection was found in the vaccinated survivors. The protective effects of immunization with OmpL1-M and Lip41-M sere synergistic, since significant levels of protection Here not observed in animals immunized with either OmpL1-M or LipL41-M alone. In contrast to immunization with the membrane-associated farms of leptospiral proteins, hamsters immunized with His(6)-OmpL1 and His(6)-LipL41 fusion proteins, either alone or in combination, were not protected, These data indicate that the manner in which OmpL1 and LipL41 associates with membranes is an important determinant of immunoprotection. C1 VA Greater LA Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. Predev, Merial Biodiv, F-69342 Lyon 07, France. RP Haake, DA (reprint author), VA Greater LA Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [R01 AI034431, AI34431, R21 AI034431, R29 AI034431, R29 AI034431-04] NR 56 TC 146 Z9 165 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD DEC PY 1999 VL 67 IS 12 BP 6572 EP 6582 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 257DW UT WOS:000083768000047 PM 10569777 ER PT J AU Duerinckx, AJ Laughrun, D Lewis, BS AF Duerinckx, AJ Laughrun, D Lewis, BS TI Usefulness of coronary MR angiography prior to angioplasty SO INTERNATIONAL JOURNAL OF CARDIAC IMAGING LA English DT Article DE coronary arteries; coronary stenosis; heart; MR angiography; PTCA ID ARTERIES AB The range of indications for percutaneous transluminal coronary angioplasty (PTCA) has increased greatly since the procedure was initially introduced. The success rate depends on the anatomy and length of the occlusion and on the state of the distal vessel. We present a case where the use of magnetic resonance angiography (MRA) allowed to evaluate the length of a subtotal occlusion prior to PTCA, and thus could have had an impact on therapeutic decisions. Coronary MR angiography is one of the many applications of breathhold MRI, where breathholding and segmented k-space acquisition are combined to provide anatomical images of coronary vessels. Coronary MR angiography allows reproducible visualization of coronary vessels. Even under adverse circumstances (poor cardiac triggering) the images are sometimes of sufficient quality to help make a diagnosis. This capability may increase the as yet limited clinical use of MR technology in the practice of cardiology. C1 VA Greater Los Angeles Healthcare Ctr, Serv Radiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90053 USA. VA Greater Los Angeles Healthcare Ctr, Cardiol Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. Lady Davies Carmel Med Ctr, Dept Cardiol, IL-34362 Haifa, Israel. RP Duerinckx, AJ (reprint author), VA Greater Los Angeles Healthcare Ctr, Serv Radiol, Mail Route W114,MRI,Bld 507,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 18 TC 1 Z9 1 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0167-9899 J9 INT J CARDIAC IMAG JI Int. J. Card. Imaging PD DEC PY 1999 VL 15 IS 6 BP 533 EP 540 DI 10.1023/A:1006331628682 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 288TF UT WOS:000085580000011 PM 10768747 ER PT J AU Frazer, A Gerhardt, GA Daws, LC AF Frazer, A Gerhardt, GA Daws, LC TI New views of biogenic amine transporter function: implications for neuropsychopharmacology SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Review DE dopamine transporter; norepinephrine transporter; serotonin transporter ID HUMAN NOREPINEPHRINE TRANSPORTER; HUMAN SEROTONIN TRANSPORTER; HUMAN DOPAMINE TRANSPORTER; RECEPTOR-LIKE IMMUNOREACTIVITY; VOLTAGE-DEPENDENT UPTAKE; CENTRAL-NERVOUS-SYSTEM; RAT NUCLEUS-ACCUMBENS; MESSENGER-RNA LEVELS; IN-VIVO; EXTRACELLULAR DOPAMINE AB Biogenic amine transporters, namely the dopamine (DA), norepinephrine (NE) and 5-hydroxytryptamine (serotonin 5-HT) transporters (DAT, NET and 5-HTT, respectively) appear to be the key elements in regulating biogenic amine neurotransmission. These proteins therefore represent a primary target for therapeutic intervention in the treatment of numerous psychiatric disorders, such as depression, anxiety and perhaps even schizophrenia as well as drug abuse. The cloning of DAT, NET and 5-HTT and development of selective radioligands for them over the last decade has dramatically increased our understanding of their location, structure and function. These breakthroughs have also enabled remarkable progress in determining how biogenic amine transporters are regulated under not only normal conditions but also when confronted with acute or chronic exposure to a variety of stimuli including psychotherapeutic drugs. Because of the important therapeutic consequences of a better understanding of these transporters, the present review discusses recent advances in defining their mechanism of action, location and regulation and the implications of the newer data for neurupsychopharmacology. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA. Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA. RP Daws, LC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM daws@uthscsa.edu NR 126 TC 16 Z9 17 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD DEC PY 1999 VL 2 IS 4 BP 305 EP 320 DI 10.1017/S1461145799001625 PG 16 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 273VW UT WOS:000084729400008 PM 11285147 ER PT J AU Heckman, JD Ehler, W Brooks, BP Aufdemorte, TB Lohmann, CH Morgan, T Boyan, BD AF Heckman, JD Ehler, W Brooks, BP Aufdemorte, TB Lohmann, CH Morgan, T Boyan, BD TI Bone morphogenetic protein but not transforming growth factor-beta enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID SKULL DEFECTS; CARTILAGE; TISSUE; REPAIR; CHROMATOGRAPHY; OSTEOGENESIS; INVITRO; MUSCLE; DOGS AB Background: The purpose of the present study was to create an effective bone-graft substitute for the treatment of a diaphyseal nonunion. Methods: A standardized nonunion was established in the midportion of the radial diaphysis in thirty mongrel dogs by creating a three-millimeter segmental bone defect (at least 2 percent of the total length of the bone). The nonunion was treated with implantation of a carrier comprised of poly(DL-lactic acid) and polyglycolic acid copolymer (50:50 polglactic acid-polyglycolic acid [PLG50]) containing canine purified bone morphogenetic protein (BMP) or recombinant human transforming growth factor-beta (TGF-beta 1), or both, or the carrier without BMP or TGF-beta 1, Five groups, consisting of sis dogs each, were treated with implantation of the carrier alone, implantation of the carrier with fifteen milligrams of BR IP, implantation of the carrier with 1.5 milligrams of BR IP, implantation of the carrier with fifteen milligrams of BMP and ten nanograms of TGF-beta 1, or implantation of the carrier,vith ten nanograms of TGF-beta 1, At twelve weeks after implantation, the radii were examined radiographically and the sites of nonunion were examined histomorphometrically. Results: We found that implantation of the polylactic acid-polyglycolic acid carrier alone or in combination with ten nanograms of TGF-beta 1 failed to induce significant radiographic or histomorphometric evidence of healing at the site of the nonunion. The radii treated with the carrier enriched,vith either 1.5 or fifteen milligrams of BMP showed significantly increased periosteal and endosteal bone formation on histomorphometric (p < 0.05) and radiographic (p < 0.02) analysis. Conclusions: Bone formation in a persistent osseous defect that is similar to an ununited diaphyseal fracture is increased when species-specific BMP incorporated into a polylactic acid-polyglycolic acid carrier is implanted at the site of the nonunion. TGF-beta 1 at a dose of ten nanograms per implant did not induce a similar degree of bone formation or potentiate the effect of BMP in this model. Clinical Relevance: The biodegradable implant containing BMP that was used in the present study to treat diaphyseal nonunion is an effective bone-graft substitute. C1 Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Hosp, San Antonio, TX 78284 USA. Wilford Hall USAF Med Ctr, Lackland AFB, TX USA. RP Heckman, JD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Orthopaed, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NIDCR NIH HHS [DE08603] NR 60 TC 77 Z9 87 U1 0 U2 1 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD DEC PY 1999 VL 81A IS 12 BP 1717 EP 1729 PG 13 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 264WM UT WOS:000084206000009 PM 10608383 ER PT J AU Chen, YM Lee, WH Chew, HK AF Chen, YM Lee, WH Chew, HK TI Emerging roles of BRCA1 in transcriptional regulation and DNA repair SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Review ID CANCER SUSCEPTIBILITY GENE; EARLY EMBRYONIC LETHALITY; POLYMERASE-II HOLOENZYME; C-TERMINAL REGION; BREAST-CANCER; CELL-CYCLE; FAMILIAL BREAST; OVARIAN-CANCER; PROTEIN; DAMAGE AB BRCA1 was the first breast cancer susceptibility gene to be identified and cloned. In individuals from high-risk families, mutations in BRCA1 increase the lifetime risk of developing breast cancer eight to tenfold, compared to the general population. How the BRCA1 protein product normally functions to suppress tumor formation and how defects in the gene can ultimately lead to breast cancer have been the focus of intense scrutiny by the scientific and medical communities. BRCA1 has intrinsic transactivation activity and is able to activate the p21 promoter. In addition, BRCA1 is linked to a number of genes involved in transcriptional regulation, including CtlP, c-Myc, the RNA holoenzyme complex, and the histone deacetylase complex. Moreover, BRCA1 is essential for cellular response to DNA damage repair. Inactivation of Brca1 in mouse embryonic stem and fibroblast cells results in increased cell sensitivity to DNA-damaging agents. In human cells, BRCA1 binds to both Rad50 and Rad51 and colocalizes with these proteins at repair foci. Part of BRCA1's response to DNA damage may in fact be corroborated through transcriptional regulation. The expression of GADD45, a DNA damage-responsive gene, is increased immediately after induction of BRCA1. Recently, BRCA1 was shown to repress estradiol (E2)-responsive ER-alpha-mediated transcriptional activity, potentially linking the multiple functions of BRCA1 to specific tissue targets. These recent developments in BRCA1 function are an encouraging step toward understanding the role of BRCA1 in breast cancer formation. (C) 1999 Wiley-Liss, Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Med Oncol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Div Med Res, San Antonio, TX USA. RP Chew, HK (reprint author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. NR 49 TC 54 Z9 56 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD DEC PY 1999 VL 181 IS 3 BP 385 EP 392 DI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4 PG 8 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 252UT UT WOS:000083521200002 PM 10528224 ER PT J AU Kitten, AM Kreisberg, JI Olson, MS AF Kitten, AM Kreisberg, JI Olson, MS TI Expression of osteogenic protein-1 mRNA in cultured kidney cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID BONE MORPHOGENETIC PROTEIN-7; MESSENGER-RNA; I RECEPTORS; RAT; ACTIVIN; REGULATORS; INDUCTION; INJURY; BMP-7; EYE AB Osteogenic protein-1 (OP-1 or BMP-7) is a multifunctional cytokine that regulates the development of several tissues during embryogenesis, including the skeleton, eye, and kidney. In postnatal life, OP-1 expression is most abundant in the kidney, although the cellular localization of this expression has not been described. In this study, we utilized a cell culture approach to localize OP-1 mRNA expression in various renal cell types and to determine potential target cells for OP-1 effects. OP-1 mRNA expression was demonstrated in several glomerular cell types, such as mesangial, epithelial, and endothelial cells. Distal tubule MDCK cells also expressed OP-1 mRNA but human proximal tubule HK-2 cells did not. Multiple OP-1 transcripts, which ranged in size from 1.6 to 3.8 kb, were observed in both glomerular and tubule cells. Interestingly, the pattern of expression varied among the different cell types, suggesting cell-specific expression of OP-1 mRNA. Analysis of OP-1 receptor expression revealed transcripts for BMP receptors type IA and IB in HK-2 cells and transcripts for BMPR-IA and ALK-2 in mesangial cells. Treatment of HK-2 cells with OP-1 (300 ng/ml) for 24-48 hr increased cellular proliferation whereas treatment of cells with transforming growth factor-beta had no effect. Mesangial cell proliferation was not affected by OP-1. The results suggest that OP-1 is produced in the renal glomerulus and then travels to the proximal tubule to regulate the proliferation of cells in this region of the nephron. (C) 1999 Wiley-Liss, Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Hosp, Res & Dev Serv, San Antonio, TX 78284 USA. RP Olson, MS (reprint author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. OI Kitten, Allison/0000-0002-6047-1379 FU NIA NIH HHS [AG-14384]; NIDDK NIH HHS [DK-19473] NR 33 TC 24 Z9 29 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD DEC PY 1999 VL 181 IS 3 BP 410 EP 415 DI 10.1002/(SICI)1097-4652(199912)181:3<410::AID-JCP4>3.0.CO;2-H PG 6 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 252UT UT WOS:000083521200004 PM 10528226 ER PT J AU Simon, JA Hudes, ES AF Simon, JA Hudes, ES TI Serum ascorbic acid and other correlates of self-reported cataract among older Americans SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE age-related; antioxidants; ascorbic acid; cataract; vitamin C ID AGE-RELATED CATARACTS; BEAVER DAM EYE; CIGARETTE-SMOKING; LENS OPACITIES; RISK-FACTORS; VITAMIN-C; NUCLEAR; ANTIOXIDANTS; SUNLIGHT; WOMEN AB The purpose of this study was to examine the correlates of self-reported cataract among older Americans, and specifically, to determine whether serum ascorbic acid levels are associated with a decreased prevalence of cataract. A national probability survey of Americans, the Second National Health and Nutrition Examination Survey (NHANES II), was conducted between 1976 and 1980. A total of 4001 participants were included between the ages of 60 and 74 years with data on serum ascorbic acid level and other variables of interest. A total of 252 women (12%) and 164 men (9%) reported a history of cataract. Serum ascorbic acid level was inversely associated with prevalence of cataract in multiple logistic regression analyses; each 1 mg/dl increase was independently associated with a 26% decrease in cataract (P = 0.03). Other independent correlates of cataract included increasing age, female sex, smoking, and diabetes mellitus (all P < 0.01). We identified four correlates of cataract among older Americans: serum ascorbic acid level, increasing age, smoking, and diabetes mellitus. Ascorbic acid, a water-soluble antioxidant found in high concentrations in the lens, may be of importance for the prevention of cataract among older Americans. Published by Elsevier Science Inc. C1 San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA. RP San Francisco VA Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA. EM jasimon@itsa.ucsf.edu FU NHLBI NIH HHS [HL53479] NR 36 TC 38 Z9 39 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD DEC PY 1999 VL 52 IS 12 BP 1207 EP 1211 DI 10.1016/S0895-4356(99)00110-9 PG 5 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 258AZ UT WOS:000083817000011 PM 10580784 ER PT J AU Barker, JH Musher, DM Silberman, R Phan, HM Watson, DA AF Barker, JH Musher, DM Silberman, R Phan, HM Watson, DA TI Genetic relatedness among nontypeable pneumococci implicated in sporadic cases of conjunctivitis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE; PHASE VARIATION; SEROTYPES; VIRULENCE AB Nontypeable Streptococcus pneumoniae is a common cause of epidemic conjunctivitis, A previous molecular fingerprinting study identified a clone of nontypeable pneumococcus that was responsible for a recent outbreak of conjunctivitis. In the present study, we examined the extent to which pneumococci that cause sporadic cases of conjunctivitis are related to this epidemic strain, Using arbitrarily primed BOX-PCR, we have determined that, of 10 nontypeable pneumococci causing sporadic conjunctivitis, 5 were clonal and closely related to a previous outbreak strain, whereas 5 others were genetically diverse. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Vet Affairs Med Ctr, Infect Dis Labs, Houston, TX 77030 USA. Louisiana State Univ, Med Ctr, Dept Pathol, Shreveport, LA USA. Informat Dynam Inc, Washington, DC USA. RP Musher, DM (reprint author), Infect Dis Sect, Dept Vet Affairs Med Ctr, 2002 Holcombe Blvd,Room 4B-370, Houston, TX 77030 USA. NR 16 TC 18 Z9 18 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 1999 VL 37 IS 12 BP 4039 EP 4041 PG 3 WC Microbiology SC Microbiology GA 259CY UT WOS:000083877400042 PM 10565927 ER PT J AU Saha, S Saint, S Christakis, DA Simon, SR Fihn, SD AF Saha, S Saint, S Christakis, DA Simon, SR Fihn, SD TI A survival guide for generalist physicians in academic fellowships - Part 2: Preparing for the transition to junior faculty SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article ID INTERNAL-MEDICINE; RESEARCH CAREER C1 Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Gen Internal Med Sect, Dept Med,Med Serv P3MED, Portland, OR 97207 USA. Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA. Univ Washington, Dept Pediat, Seattle, WA 98195 USA. Univ Washington, Inst Child Hlth, Seattle, WA 98195 USA. Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA. Univ Washington, NW Hlth Serv Res & Dev Field Program, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Saha, S (reprint author), Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Gen Internal Med Sect, Dept Med,Med Serv P3MED, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. NR 12 TC 4 Z9 4 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 1999 VL 14 IS 12 BP 750 EP 755 DI 10.1046/j.1525-1497.1999.12148.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 267LG UT WOS:000084359000006 PM 10632820 ER PT J AU Helander, KG AF Helander, KG TI Formaldehyde binding in brain and kidney: A kinetic study of fixation SO JOURNAL OF HISTOTECHNOLOGY LA English DT Article DE C-14-formaldehyde; lipids; proteins; rats AB The aim of the study was to estimate the time needed for fixation of tissues with formaldehyde. For this purpose, rat brains and kidneys were cut in half and put into 4% buffered formaldehyde containing C-14-formaldehyde. The specimens measured about 1.5 cm(3) in size, and the distance from the surface to the center was about 4 mm. At regular intervals, specimens were removed from the fixative for determination of bound C-14-formaldehyde. Maximal binding was reached after about 50 hr; half-maximal binding was reached after 3 hr in kidney and 5 hr in brain. Maximal binding was slightly higher in kidney than in brain, possibly because of a higher protein content in the kidney than in the brain. It is concluded that formaldehyde fixation is complete only after prolonged immersion of the tissues: in this study, the rate of fixation was about 80 mu m/hr. C1 Univ Calif Los Angeles, Lab Membrane Biol, Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Univ Gothenburg, Dept med Lab Sci, Gothenburg, Sweden. RP Helander, KG (reprint author), Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden. NR 5 TC 8 Z9 8 U1 1 U2 3 PU NATL SOC HISTOTECHNOLOGY PI BOWIE PA 4201 NORTHVIEW DR, STE 502, BOWIE, MD 20716-1073 USA SN 0147-8885 J9 J HISTOTECHNOL JI J. Histotechnol. PD DEC PY 1999 VL 22 IS 4 BP 317 EP 318 PG 2 WC Cell Biology SC Cell Biology GA 264ND UT WOS:000084187600008 ER PT J AU Bales, ES Dietrich, C Bandyopadhyay, D Schwahn, DJ Xu, WD Didenko, V Leiss, P Conrad, N Pereira-Smith, O Orengo, I Medrano, EE AF Bales, ES Dietrich, C Bandyopadhyay, D Schwahn, DJ Xu, WD Didenko, V Leiss, P Conrad, N Pereira-Smith, O Orengo, I Medrano, EE TI High levels of expression of p27(KIP1) and cyclin E in invasive primary malignant melanomas SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; INHIBITOR P27(KIP1); FREE SURVIVAL; PROTEIN; P21(WAF1/CIP1); PROGRESSION; DIFFERENTIATION; GENE; P53; P21 AB Cancer cells have abnormal cell cycle regulation which favors accelerated proliferation, chromosomal instability, and resistance to the senescence response. Although the p16(INK5n) locus is the most prominent susceptibility locus for familial melanomas, the low frequency of p16 mutations in sporadic melanomas suggests additional alterations in other cell cycle regulatory genes. Here we used primary melanoma tumors to reveal early cell cycle alterations that could be masked in advanced metastatic lesions due to their inherently high genetic instability. Unexpectedly, the cyclin-dependent kinase inhibitors p27(KIP1) and/or p21(Waf-1/SDI-1) were found to be expressed in 13 of 18 (72%) of the primary melanomas with a Breslow thickness greater than 0.076 mm, In general, p27 and/or p21 staining in the primary tumors correlated with low Ki-67 index, Importantly, most of the p21- and p27-positive tumors expressed high levels of cyclin D1 and cyclin E, In proliferating cells p27 is predominantly associated with cyclin D-CDK4 complexes, but does not inhibit the kinase activity, whereas in quiescent cells p27 is found associated with inactive CDK2 complexes, p27 was also expressed at high levels in proliferating primary melanomas in culture, and found to be associated with active cyclin E-CDK2 complexes containing high levels of cyclin E, It is thus Likely that accumulation of cyclin E overcomes the potent inhibitory activity of p27 and p21 in CDK2 complexes. Of the primary melanomas with no indication of invasiveness, only three of 15 (20%) were positive for p27 and/or p21, We propose that high levels of p27 and p21 may confer upon melanoma tumors their characteristic resistance to conventional therapies. In turn, high levels of cyclins E and D1 may contribute to unlimited proliferation in primary melanomas that express the tumor suppressor p16(INK4). C1 Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. RP Medrano, EE (reprint author), Baylor Coll Med, VAMC, Res Serv, Bld 110, Houston, TX 77030 USA. FU NIA NIH HHS [AG00594, AG3663] NR 45 TC 57 Z9 59 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD DEC PY 1999 VL 113 IS 6 BP 1039 EP 1046 DI 10.1046/j.1523-1747.1999.00812.x PG 8 WC Dermatology SC Dermatology GA 268VE UT WOS:000084436600027 PM 10594749 ER PT J AU Cariski, D Rosenbek, J AF Cariski, D Rosenbek, J TI The effectiveness of the Speech Enhancer (TM) SO JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY LA English DT Article ID PARKINSONS-DISEASE AB The influence of the Speech Enhancer(TM) on sentence intelligibility was measured for two males with severe hypokinetic dysarthria under a variety of environmental settings. Comparisons of speech intelligibility were made between sentences read aloud with and without the Speech Enhancer. Additional measures of speech intelligibility were made for one of the subjects, including a comparison between the Speech Enhancer and another amplifier and the combined effect of treatment with the Speech Enhancer. The treatment effects on speech intelligibility were appreciable. Clinical implications are discussed. C1 William S Middleton Mem Vet Hosp, Speech Pathol Serv, Madison, WI 53705 USA. RP Cariski, D (reprint author), William S Middleton Mem Vet Hosp, Audiol & Speech Pathol Serv, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 16 TC 7 Z9 7 U1 1 U2 3 PU SINGULAR PUBLISHING GROUP INC PI SAN DIEGO PA 401 WEST A ST, STE 325, SAN DIEGO, CA 92101-7904 USA SN 1065-1438 J9 J MED SPEECH-LANG PA JI J. Med. Speech-Lang. Pathol. PD DEC PY 1999 VL 7 IS 4 BP 315 EP 322 PG 8 WC Audiology & Speech-Language Pathology; Clinical Neurology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology GA 264LL UT WOS:000084183700007 ER PT J AU Prabhu, SD Azimi, A Frosto, T AF Prabhu, SD Azimi, A Frosto, T TI Nitric oxide effects on myocardial function and force-interval relations: Regulation of twitch duration SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE nitric oxide; myocardial contraction; force-interval relaion; systole e-c coupling; sarcoplasmic reticulum; rat ID RAT VENTRICULAR MYOCYTES; CARDIAC-MUSCLE; FREQUENCY-RELATIONSHIP; CONTRACTILE RESPONSE; ACTIVATION; SYNTHASE; RELEASE; HUMANS; FERRET; CGMP AB As the precise role of nitric oxide (NO) as a modulator of myocardial contraction and the force-interval relationship remains unclear, the objective of this study was to examine the effect of the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) on baseline myocardial contraction, and the impact of both SNAP and the NO synthase (NOS) inhibitor N-G-nitro-L-arginine methyl ester (L-NAME) on the force interval relation, Studies were performed using isolated rat papillary muscles. In the presence of baseline NOS blockade, nanomolar to micromolar concentrations of SNAP exerted a modest positive inotropic effect with a small but significant increase in twitch isometric tension (P<0.007). Nanomolar concentrations of SNAP also reduced overall twitch duration (P<0.007). These effects were not seen in control experiments using N-acetyl-penicillamine instead of SNAP The force-frequency response (FFR) and post-rest contractile potentiation, mechanical correlates of sarcoplasmic reticulum ISR) Ca2+ handling, were also examined. Neither L-NAME, nor SNAP had any effect on post-rest potentiation following rest intervals as long as 6 min, or on the negative FFR at stimulation frequencies between 0.3 to 1.7 Hz, However, L-NAME significantly blunted the net reduction in twitch duration between 0.3 Hz and 1.7 Wt compared to control (P = 0.006), an effect reversed by 100 nM SNAP. These results indicate that low concentrations of NO can modulate myocardial function by influencing myocardial inotropy and the time course of myofilament interaction, but do not impact significantly on the force interval relation and, by inference, SR Ca2+ handling. Moreover, modulation of twitch duration occurs over a of stimulation frequencies, suggesting a mechanistic role for NO in the changes range ol simulation frequencies. suggesting a mechanist: relaxation time intervals seen during changes in heart rate. (C) in contraction and (C) 1399 Academic Press. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. RP Prabhu, SD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM Prabhu@uthscsa.edu RI Prabhu, Sumanth/D-5223-2009 NR 28 TC 19 Z9 20 U1 3 U2 5 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD DEC PY 1999 VL 31 IS 12 BP 2077 EP 2085 DI 10.1006/jmcc.1999.1038 PG 9 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 274UB UT WOS:000084782500001 PM 10640437 ER PT J AU Fitten, LJ Ortiz, F Siembieda, DW O'Neill, J Halgren, E Fisher, A AF Fitten, LJ Ortiz, F Siembieda, DW O'Neill, J Halgren, E Fisher, A TI Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID ALZHEIMERS-DISEASE; AGED MONKEYS; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; CHOLINERGIC HYPOTHESIS; PRIMATE MODELS; DEMENTIA; PATIENT; MEMORY; TETRAHYDROAMINOACRIDINE AB The cholinesterase inhibitor tacrine (THA) and the M(1) muscarinic agonist AF102B (cevimeline), both reported to enhance cognition in animals and humans, were tested in 5 macaques for reduction of spontaneous, random movements. Monkeys were videotaped 1 hour after administration of normal saline vehicle, after low- and high-dose intramuscular AF102B, and after low- and high-dose oral THA. Two independent blind judges counted numbers of spontaneous movements made by each monkey over 12 consecutive 15-second segments for each drug condition. Both THA and AF102B reduced movement significantly at high doses without overt side effects, warranting further research on the agitation-reducing potential of cognition-enhancing cholinomimetic drugs. C1 US Dept Vet Affairs, Supulveda Med Ctr, Los Angeles, CA USA. RP Fitten, LJ (reprint author), Vet Adm Med Ctr, 116A-9,16111 Plummer St, Sepulveda, CA 91343 USA. NR 47 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 1999 VL 11 IS 1 BP 79 EP 85 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 162PC UT WOS:000078354800012 PM 9990560 ER PT J AU Benmansour, S Cecchi, M Morilak, DA Gerhardt, GA Javors, MA Gould, GG Frazer, A AF Benmansour, S Cecchi, M Morilak, DA Gerhardt, GA Javors, MA Gould, GG Frazer, A TI Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level SO JOURNAL OF NEUROSCIENCE LA English DT Article DE serotonin transporter; antidepressants; in vivo electrochemistry; [H-3]CN-IMI binding; mRNA for the SERT; dorsal hippocampus ID DORSAL RAPHE NUCLEUS; MESSENGER-RNA LEVELS; LONG-TERM TREATMENT; RAT-BRAIN; 5-HT UPTAKE; QUANTITATIVE AUTORADIOGRAPHY; UPTAKE SITES; FLUOXETINE TREATMENT; IN-VIVO; PAROXETINE AB To investigate functional changes in the brain serotonin transporter (SERT) after chronic antidepressant treatment, several techniques were used to assess SERT activity, density, or its mRNA content. Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake inhibitors (SSRIs) paroxetine or sertraline, the selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine. High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats. Fluvoxamine decreased the clearance of serotonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of serotonin in SSRI-treated rats. SERT density in the CA3 region of the hippocampus of the same rats, assessed by quantitative autoradiography with tritiated cyanoimipramine ([H-3]CN-IMI), was decreased by 80-90% in SSRI-treated rats but not in those treated with phenelzine or DMI. The serotonin content of the hippocampus was unaffected by paroxetine or sertraline treatment, ruling out neurotoxicity as a possible explanation for the SSRI-induced decrease in SERT binding and alteration in 5-HT clearance. Levels of mRNA for the SERT in the raphe nucleus were also unaltered by chronic paroxetine treatment. Based on these results, it appears that the SERT is downregulated by chronic administration of SSRIs but not other types of antidepressants; furthermore, the downregulation is not caused by decreases in SERT gene expression. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Kentucky, Dept Anat, Lexington, KY 40536 USA. Univ Kentucky, Dept Neurobiol, Lexington, KY 40536 USA. RP Benmansour, S (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. OI Gould, Georgianna/0000-0002-5470-8763 FU NIMH NIH HHS [MH01245, MH53851, MH57001] NR 42 TC 202 Z9 204 U1 4 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD DEC 1 PY 1999 VL 19 IS 23 BP 10494 EP 10501 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 258YN UT WOS:000083867400030 PM 10575045 ER PT J AU Wong, AL Wong, WK Harker, J Sterz, M Bulpitt, K Park, G Ramos, B Clements, P Paulus, H AF Wong, AL Wong, WK Harker, J Sterz, M Bulpitt, K Park, G Ramos, B Clements, P Paulus, H CA Western Consortium Practicing Rheu TI Patient self-report tender and swollen joint counts in early rheumatoid arthritis SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE rheumatoid arthritis; self-report articular scores; joint count ID DISEASE-ACTIVITY MEASURES; REPORT ARTICULAR INDEX; VALIDITY; QUESTIONNAIRE; RELIABILITY; SENSITIVITY; SCORES; MOOD AB Objective. To determine the correlation between patient self-report joint counts and standard physician joint counts, and to compare pictorial (Mannequin) and text (Rapid Assessment of Disease Activity in Rheumatology, RADAR) formats for obtaining patient self-reports, Methods. Baseline patient self-report joint counts were mailed and completed by 60 patients with early rheumatoid arthritis (RA) one day before and one day after being examined by a physician. Twenty-seven were randomized to the Mannequin tender and Mannequin swollen joint counts; 33 were randomized to the RADAR tender and swollen joint counts. Agreement between patient and physician self-report joint counts, diagnostic characteristics, and lest-retest reliability of patient self-report joint counts was computed. Stepwise regression analyses were performed to identify predictors of patient-physician differences in total joint count. Results, Means and standard deviations of paired patient and physician total joint counts were not different for Mannequin or RADAR forms. Spearman correlations were moderate (0.58 to 0.69 for Mannequin, 0.37 to 0.58 for RADAR). Agreement (intraclass correlations) was 0.65 for the Mannequin and 0.56 for the RADAR forms. Patient test-retest reproducibility was moderate for RADAR tenderness (0.58) and high (r > 0.90) for RADAR swollen and both Mannequin forms, Level of patient education predicted patient-physician differences on the RADAR swollen joint counts (p = 0,003), but was not significant in Mannequin forms, suggesting that education was not a factor in accurate completion of Mannequin forms, Conclusion, Both pictorial and text format patient self-report joint counts are significantly correlated with physician joint counts, In addition to moderately high patient test-retest reproducibility, this suggests that patient self-reports in both formats may yield accurate measures of improvement in disease activity. C1 Olive View UCLA Med Ctr, Dept Rheumatol, Sylmar, CA 91326 USA. Vet Adm Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Med, Dept Rheumatol, Los Angeles, CA USA. RP Wong, AL (reprint author), Olive View UCLA Med Ctr, Dept Rheumatol, 14445 Olive view Dr,2B182, Sylmar, CA 91326 USA. NR 30 TC 40 Z9 41 U1 1 U2 2 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 1999 VL 26 IS 12 BP 2551 EP 2561 PG 11 WC Rheumatology SC Rheumatology GA 262ZP UT WOS:000084098400011 PM 10606362 ER PT J AU Mertens, PR Alfonso-Jaume, MA Steinmann, K Lovett, DH AF Mertens, PR Alfonso-Jaume, MA Steinmann, K Lovett, DH TI YB-1 regulation of the human and rat gelatinase A genes via similar enhancer elements SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID MATRIX METALLOPROTEINASE-2; CELL-PROLIFERATION; IV COLLAGENASE; EXPRESSION; TRANSCRIPTION; PROMOTER; GLOMERULONEPHRITIS; DIFFERENTIATION; IDENTIFICATION; PROTEIN AB Experimental and clinical studies strongly suggest that gelatinase a plays a central role in the evolution of glomerular injury and sclerosis. The sequences of the 5' flanking regions of the human and rat gelatinase A genes do not share similarities with other members of the matrix metalloproteinase gene family and are regulated in a distinctive manner. The human and rat gelatinase A genes include regions of significant homology (r2 human; RE-1 rat), which have been shown to act as potent cis-activators of transcription. The rat RE-1 sequence interacts specifically with the developmentally regulated transcription factors AP2 and YB-1, resulting in a synergistic activation of gelatinase A transcription. Although the human r2 sequence specifically interacts with AP2 (Mol Cell Biol 10: 6524-6532, 1990), there is no clear evidence for the presence of a canonical YB-1 binding site (Y-box) within this sequence. This study demonstrates, despite the absence of a canonical Y-box sequence in the r2 element, that YB-1 and AP2. specifically interact with r2, yielding synergistic transactivation of the human gelatinase A gene. It is concluded that the r2 element is the conserved functional analog of the RE-1 element, and that interactions of AP2 and YB-1 govern human gelatinase A gene expression. C1 Rhein Westfal TH Aachen, Med Klin 2, D-52057 Aachen, Germany. Univ Calif San Francisco, San Francisco VAMC, Dept Med, San Francisco, CA 94143 USA. RP Mertens, PR (reprint author), Rhein Westfal TH Aachen, Med Klin 2, Pauwelsstr 30, D-52057 Aachen, Germany. FU NIDDK NIH HHS [DK 39776] NR 18 TC 39 Z9 39 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 1999 VL 10 IS 12 BP 2480 EP 2487 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 259CH UT WOS:000083876000003 PM 10589685 ER PT J AU Kennefick, TM Al-Nimri, MA Oyama, TT Thompson, MM Kelly, FJ Chapman, JG Anderson, S AF Kennefick, TM Al-Nimri, MA Oyama, TT Thompson, MM Kelly, FJ Chapman, JG Anderson, S TI Hypertension and renal injury in experimental polycystic kidney disease SO KIDNEY INTERNATIONAL LA English DT Article DE angiotensin; hydralazine; interstitial fibrosis; progressive renal disease ID CONVERTING-ENZYME-INHIBITION; EPIDERMAL GROWTH-FACTOR; RENIN-ANGIOTENSIN SYSTEM; CYCLOSPORINE NEPHROPATHY; FAMILY MEMBERS; ACE-INHIBITION; II BLOCKADE; RAT; ENDOTHELIN; SODIUM AB Background. Hypertension accelerates renal failure in autosomal dominant polycystic kidney disease (ADPKD), and evidence suggests a role for the renin-angiotensin system (RAS) in the functional and structural changes. To explore the hypothesis that RAS adaptations contribute to disease progression, we examined RAS activity and the long-term consequences of antihypertensive drugs, which suppress (enalapril) or stimulate (hydralazine) the RAS, in experimental polycystic kidney disease. Methods. Studies were conducted in male heterozygous cystic Han:SPRD rats (Cy/+) and in unaffected littermates (controls). In protocol 1, either angiotensin II (Ang II), enalaprilat, or saline vehicle was acutely infused into cystic and control rats, which were aged 10 to 12 weeks. The mean arterial pressure (MAP), glomerular filtration rate (GFR), and renal plasma flow (RPF) were measured at baseline and after an infusion of test substances. In protocol 2, cystic rats received chronic therapy with either enalapril, hydralazine, or no therapy for 10 to 12 weeks of age and then underwent renal function and RAS studies. In protocol 3, similar cohorts were followed for 40 weeks to assess the effects of therapy on blood pressure, proteinuria, serum creatinine, RAS parameters, and renal morphology. Results. In protocol 1, cystic rats had massive kidneys, slightly elevated blood pressure, and profound renal vasoconstriction and reduced GFR. Ang II induced similar changes in MAP and renal function in control and cystic rats. Enalaprilat induced little effect on MAP but more striking increases in GFR and RPF in cystic rats. In protocol 2, at 10 weeks of age, enalapril was superior in preserving renal function, but neither drug limited the expansion of the tubulointerstitium. In protocol 3, at 40 weeks of age, both drugs ameliorated the increase in serum creatinine, although only enalapril reduced proteinuria and kidney size. Conclusions. In polycystic rats, acute RAS suppression markedly ameliorates renal dysfunction. However, although chronic enalapril and hydralazine protect against the loss of renal function, only enalapril limits renal growth and proteinuria, and neither significantly limits tubulointerstitial fibrosis. The long-term studies give clear support to the importance of blood pressure control, per se, but only partial support to the importance of the particular agent used. As in clinical studies, angiotensin-converting enzyme inhibition may be less beneficial in ADPKD than in renal diseases characterized by predominant glomerular injury. C1 Oregon Hlth Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA. Portland VA Med Ctr, Med Serv, Portland, OR USA. RP Anderson, S (reprint author), Oregon Hlth Sci Univ, Div Nephrol, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. NR 51 TC 28 Z9 31 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 1999 VL 56 IS 6 BP 2181 EP 2190 DI 10.1046/j.1523-1755.1999.00783.x PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 263CK UT WOS:000084104900019 PM 10594794 ER EF